{
  "doc_id": "2018_nicu_guide_full__052655",
  "original_filename": "2018 NICU Guide Full.pdf",
  "md_path": "data/parsed/2018 NICU Guide Full/2018 NICU Guide Full.md",
  "rmd_path": "data/parsed/2018 NICU Guide Full/2018 NICU Guide Full.rmd",
  "blocks": [
    {
      "type": "heading",
      "level": 1,
      "section": "Nursery Guide 2018",
      "line": 0
    },
    {
      "type": "image",
      "section": "Nursery Guide 2018",
      "line": 2,
      "content": "![img-0.jpeg](images/7fe048f8ec8c62bc.png)"
    },
    {
      "type": "image",
      "section": "Nursery Guide 2018",
      "line": 4,
      "content": "![img-1.jpeg](images/eb725fd5eb98b4b8.png)"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 6,
      "preview": "Editors: Alexis Davis, M.D., Ashley Forester, N.N.P., Bailey White"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 7,
      "preview": "Photos by: Erin Lubin"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 9,
      "preview": "--- page 1 ---"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 11,
      "preview": "."
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 13,
      "preview": "--- page 2 ---"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 15,
      "preview": "Copyright \u00a9 Board of Trustees of the Leland Stanford Junior University 2017. This document is intend"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 17,
      "preview": "The NICU Guide is intended to provide general guidelines for care that are representative of the usu"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 19,
      "preview": "--- page 3 ---"
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 21,
      "preview": "."
    },
    {
      "type": "text",
      "section": "Nursery Guide 2018",
      "line": 23,
      "preview": "--- page 4 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Table of Contents",
      "line": 25
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 27,
      "preview": "Part I: Administrative"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 28,
      "preview": "A. Developmental \\& Family-centered Care"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 29,
      "preview": "Developmental Care in the NICU ..... 2"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 30,
      "preview": "Melissa Scala, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 31,
      "preview": "Family Involvement ..... 6"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 32,
      "preview": "William Rhine, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 33,
      "preview": "Developmental-Behavioral Pediatric Programs ..... 9"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 34,
      "preview": "Anne DeBattista, R.N., M.S., C-P.N.P., C-P.M.H.S."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 35,
      "preview": "B. Delivery and Admission"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 36,
      "preview": "Prenatal Counseling ..... 15"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 37,
      "preview": "Christine Johnson, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 38,
      "preview": "The Delivery Room ..... 21"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 39,
      "preview": "Kristine Boyle, N.N.P.-B.C. and Arun Gupta, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 40,
      "preview": "Respiratory Management of the Preterm Infant ..... 28"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 41,
      "preview": "Christine Johnson, M.D., Katherine McCallie, M.D., and Ronald S. Cohen, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 42,
      "preview": "The NEST: Guidelines for the Care of Micropreemies ..... 35"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 43,
      "preview": "Melissa Scala, M.D., Katie Hunt, N.N.P., Jessica Matei, B.S.N., R.N.C.-N.I.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 44,
      "preview": "Toward Optimally Timed Cord Clamping ..... 40"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 45,
      "preview": "Brittany Weldon, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 46,
      "preview": "Non-Immune Fetal Hydrops ..... 44"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 47,
      "preview": "Anna-Kaisa Niemi, M.D., Ph.D. and Janene Fuerch, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 48,
      "preview": "Complex Coordinated Deliveries ..... 50"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 49,
      "preview": "Beth Fluharty, N.N.P., Valerie Chock, M.D., M.S. Epi, Alexis Davis, M.D., M.S. Epi, Susan Hintz, M.D"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 50,
      "preview": "M.S. Epi"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 51,
      "preview": "When to Notify an Attending in the NICU ..... 54"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 52,
      "preview": "Alexis Davis, M.D., M.S. Epi"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 53,
      "preview": "C. Discharging \\& Transferring Patients"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 54,
      "preview": "Packard Nursery Transfer Guidelines ..... 58"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 55,
      "preview": "Arun Gupta, M.D., and Ronald S. Cohen, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 56,
      "preview": "Process for Basic and Complex Discharges ..... 59"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 57,
      "preview": "Audrey Moore, N.N.P-B.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 58,
      "preview": "Comfort Care in the NICU ..... 66"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 59,
      "preview": "Diana Kobayashi, N.N.P."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 60,
      "preview": "Part II: Clinical Management"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 61,
      "preview": "A. Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 62,
      "preview": "Management of IV Fluids and TPN ..... 77"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 63,
      "preview": "Kari McCallie, M.D., Olivia Mayer, R.D. CSP, I.B.C.L.C, Alexis Davis, M.D., M.S. Epi, and Ronald S."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 64,
      "preview": "Cohen, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 65,
      "preview": "Enteral Feeding ..... 93"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 66,
      "preview": "Kari McCallie, M.D., Olivia Mayer, R.D. CSP, I.B.C.L.C, and Ronald S. Cohen, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 67,
      "preview": "Vitamin and Mineral Requirements for Enterally Fed Neonates ..... 105"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 68,
      "preview": "Olivia Mayer, R.D., CSP, I.B.C.L.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 69,
      "preview": "Formula Selection, Description, and Indications ..... 110"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 70,
      "preview": "Olivia Mayer, R.D., CSP, I.B.C.L.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 72,
      "preview": "--- page 5 ---"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 74,
      "preview": "Hyperkalemia ..... 115"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 75,
      "preview": "Arlene Sheehan, RN, N.N.P., MS-B.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 76,
      "preview": "Hypokalemia ..... 119"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 77,
      "preview": "Arlene Sheehan, RN, N.N.P., MS-B.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 78,
      "preview": "Hyponatremia ..... 121"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 79,
      "preview": "Arlene Sheehan, RN, N.N.P., MS-B.C. and Matthew Wallenstein, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 80,
      "preview": "B. Respiratory"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 81,
      "preview": "Mechanical Ventilation ..... 126"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 82,
      "preview": "Ronald S. Cohen, M.D., and William Benitz, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 83,
      "preview": "High Frequency Ventilation ..... 136"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 84,
      "preview": "Ronald S. Cohen, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 85,
      "preview": "Nasal Cannula Oxygen Delivery - High Flow and Low Flow ..... 142"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 86,
      "preview": "Arlene Sheehan, N.N.P-B.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 87,
      "preview": "Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 88,
      "preview": "Sonia Bonifacio, M.D., and Krisa Van Meurs, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 89,
      "preview": "Management of Congenital Diaphragmatic Hernia ..... 152"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 90,
      "preview": "Krisa Van Meurs, M.D., and Sonia Bonifacio, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 91,
      "preview": "Extracorporeal Membrane Oxygenation (ECMO) ..... 159"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 92,
      "preview": "Krisa Van Meurs, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 93,
      "preview": "Apnea ..... 162"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 94,
      "preview": "Ronald S. Cohen, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 95,
      "preview": "Oxygen Saturation Guidelines ..... 167"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 96,
      "preview": "Ronald S. Cohen, M.D., and Diana Kobayashi, N.N.P.-B.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 97,
      "preview": "Bronchopulmonary Dysplasia ..... 171"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 98,
      "preview": "Ronald S. Cohen, M.D., and Richard Bland, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 99,
      "preview": "Cystic Fibrosis ..... 179"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 100,
      "preview": "Carol Conrad, M.D., and Bill Callas, R.R.T."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 101,
      "preview": "Aerosolized Medications ..... 186"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 102,
      "preview": "Carol Contrad, M.D., and Bill Callas, R.R.T."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 103,
      "preview": "C. Cardiac"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 104,
      "preview": "Diagnostic Evaluation of Suspected Congenital Heart Disease - CHD ..... 192"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 105,
      "preview": "Gail Wright, M.D., Megan Tracey, N.N.P., and Shazia Bhombal, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 106,
      "preview": "Cardiac Resuscitation and Initial Management of CHD ..... 197"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 107,
      "preview": "Shazia Bhombal, M.D., and Kathleen Ryan, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 108,
      "preview": "Cardiovascular Pharamcologic Agents ..... 204"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 109,
      "preview": "Shabnam Gaskar, Pharm. D"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 110,
      "preview": "Arythmia in the Neonate. ..... 211"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 111,
      "preview": "Shazia Bhombal, M.D., and Kathleen Ryan, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 112,
      "preview": "Patent Ductus Arteriosus Management ..... 216"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 113,
      "preview": "Valerie Chock, M.D., M.S. Epi"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 114,
      "preview": "Evaluation and Management of Pulmonary Hypertension in BPD Patients ..... 220"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 115,
      "preview": "Christine Johnson, M.D., Shazia Bhombal, M.D., Michelle Ogawa, C.P.N.P., and Jeffrey Feinstein, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 116,
      "preview": "D. Hematology"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 117,
      "preview": "Blood Product Ordering and Transfusion Practices ..... 226"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 118,
      "preview": "Jennifer Andrews, M.D., M.Sc"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 119,
      "preview": "Clinical Approach to Unconjugated Hyperbilirubinemia ..... 231"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 120,
      "preview": "Vinod K. Bhutani, M.D., and Ronald J. Wong"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 121,
      "preview": "Neonatal Thrombosis Work-up ..... 241"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 122,
      "preview": "Clara Lo, M.D., Bertil Glader, M.D., and Susan Hintz, M.D., M.S. Epi"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 124,
      "preview": "--- page 6 ---"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 126,
      "preview": "Thrombocytopenia ..... 245"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 127,
      "preview": "Janene Fuerch, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 128,
      "preview": "E. Infection"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 129,
      "preview": "NICU Infection/Hand Hygeine Policy ..... 249"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 130,
      "preview": "Kari McCallie, M.D., and Amy Valencia, C.H.S.P., C.I.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 131,
      "preview": "Suspected Sepsis in Newborn Infants ..... 253"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 132,
      "preview": "William Benitz, M.D., and Arun Gupta, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 133,
      "preview": "Immunizations ..... 266"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 134,
      "preview": "Sruti Nadimpalli, M.D., M.P.H."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 135,
      "preview": "RSV Prophylaxis ..... 273"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 136,
      "preview": "Hayden Schwenk, M.D., M.P.H."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 137,
      "preview": "Suspected HSV Infection ..... 276"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 138,
      "preview": "Hayden Schwenk, M.D., M.P.H."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 139,
      "preview": "F. Gastrointestinal"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 140,
      "preview": "Gastroesophageal Reflux Disease ..... 283"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 141,
      "preview": "William Berquist, M.D., and Carol K. Conrad, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 142,
      "preview": "Necrotizing Entercolitis ..... 289"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 143,
      "preview": "Susan Hintz, M.D., M.S. Epi"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 144,
      "preview": "Abdominal Wall Defects ..... 294"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 145,
      "preview": "Claire Abrajano, P.N.P., and Matias Bruzoni, M.D., F.A.C.S."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 146,
      "preview": "Clinical Approach to Conjugated Hyperbilirubinemia (Neonatal Cholestasis) ..... 301"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 147,
      "preview": "Vinod K. Bhutani, M.D., and Ronald J. Wong"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 148,
      "preview": "G. Renal and Genitourinary"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 149,
      "preview": "Management of Hypertension ..... 308"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 150,
      "preview": "Abanti Chaudhuri, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 151,
      "preview": "Neonatal Acute Kidney Injury (AKI) ..... 314"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 152,
      "preview": "Scott Sutherland, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 153,
      "preview": "H. Endocrine"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 154,
      "preview": "Hyperglycemia ..... 321"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 155,
      "preview": "Tandy Aye, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 156,
      "preview": "Hypoglycemia ..... 324"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 157,
      "preview": "Tandy Aye, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 158,
      "preview": "Management of Hypotension with Suspected Adrenal Insufficiency ..... 329"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 159,
      "preview": "Susan Hintz, M.D., M.S. Epi"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 160,
      "preview": "Thyroid Function in VLBW Infants ..... 335"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 161,
      "preview": "Susan Hintz, M.D., M.S. Epi, and Laura K. Bachrach, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 162,
      "preview": "Disorders of Sexual Differentiation ..... 339"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 163,
      "preview": "Caroline Buckway, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 164,
      "preview": "I. Neurology"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 165,
      "preview": "Neonatal Seizures ..... 345"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 166,
      "preview": "Courtney Wustoff, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 167,
      "preview": "Intraventricular and Periventricular Hemorrhage ..... 353"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 168,
      "preview": "Alexis Davis, M.D., M.S. Epi, and Valerie Chock"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 169,
      "preview": "Retinopathy of Prematurity ..... 356"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 170,
      "preview": "Lisa Charo Bain, M.D., and Rachael Small, N.N.P."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 171,
      "preview": "Hydrocephalus and External Ventricular Drains ..... 361"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 172,
      "preview": "Mary Casazza, C.P.N.P.-A.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 174,
      "preview": "--- page 7 ---"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 176,
      "preview": "Hypothermia Therapy for Hypoxic Ischemic Encephalopathy in Term and Near Term Neonates ..... 367"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 177,
      "preview": "Krisa Van Meurs, M.D., and Celia Glennon, N.N.P."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 178,
      "preview": "Pain Assessment and Management In Neonates ..... 373"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 179,
      "preview": "Julie Good, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 180,
      "preview": "Brain Monitoring Using aEEG and NIRS ..... 382"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 181,
      "preview": "Alexis Davis, M.D., M.S. Epi, and Valerie Chock, M.D., M.S. Epi"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 182,
      "preview": "The LPCH Neuro NICU ..... 390"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 183,
      "preview": "Krisa Van Meurs, M.D., and Celia Glennon, N.N.P.-B.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 184,
      "preview": "Moderate Sedation - Physician and Nurse Practitioner Responsibilities ..... 394"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 185,
      "preview": "Arlene Sheehan, N.N.P.-B.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 186,
      "preview": "Guidelines for Asymptomatic Subgaleal Hemorrhage ..... 399"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 187,
      "preview": "Adam Frymoyer, M.D., Ronald Cohen, M.D., and Arun Gupta, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 188,
      "preview": "Approach to Neonatal Hypotonia ..... 402"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 189,
      "preview": "Anna-Kaisa Niemi, M.D., Ph.D., and Caroline Tesi-Rocha. M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 190,
      "preview": "Neonatal Abstinence Syndrome Due to In-utero Opiod Exposure ..... 408"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 191,
      "preview": "Krista Birnie, M.D., Sarah Dubner, M.D., and Adam Frymoyer, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 192,
      "preview": "J. Genetics"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 193,
      "preview": "Management of Hyperammonemia and Urea Cycle Defects. ..... 416"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 194,
      "preview": "Greg Enns, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 195,
      "preview": "Genetic Testing in the NICU ..... 420"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 196,
      "preview": "Melanie Manning, M.D., and Athena Cherry, Ph.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 197,
      "preview": "22q11 Deletion Syndrome ..... 424"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 198,
      "preview": "Susan Hintz, M.D., M.S. Epi, Jon Bernstein, M.D., David Lewis, M.D., and Inger Olson, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 199,
      "preview": "Trisomy 21 - Down Syndrome ..... 429"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 200,
      "preview": "Melanie Manning, M.D., and Gary Dahl, M.D."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 201,
      "preview": "Newborn Screening ..... 432"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 202,
      "preview": "Joan Luthra, R.N., Joann Matouk, R.N., and Marianne Varley, R.N."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 203,
      "preview": "Pierre Robin Syndrome/Sequence ..... 436"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 204,
      "preview": "Elena Hopkins, R.N., M.S., P.N.P."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 205,
      "preview": "Part III: Research"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 206,
      "preview": "Neonatal/Perinatal Clinical Research ..... 440"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 207,
      "preview": "Bethany Ball, B.S., C.C.R.C."
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 208,
      "preview": "Informed Consent for Clinical Research ..... 447"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 209,
      "preview": "Bethany Ball, B.S., C.C.R.C"
    },
    {
      "type": "text",
      "section": "Table of Contents",
      "line": 211,
      "preview": "--- page 8 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part I: Administrative",
      "line": 213
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Section A: Developmental \\& Family-centered Care",
      "line": 215
    },
    {
      "type": "text",
      "section": "Section A: Developmental \\& Family-centered Care",
      "line": 217,
      "preview": "--- page 9 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Developmental Care in the NICU",
      "line": 219
    },
    {
      "type": "text",
      "section": "Developmental Care in the NICU",
      "line": 221,
      "preview": "Melissa Scala, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition and Background for Developmental Care",
      "line": 223
    },
    {
      "type": "text",
      "section": "I. Definition and Background for Developmental Care",
      "line": 225,
      "preview": "Individualized family-centered developmental care is a framework for providing care that enhances th"
    },
    {
      "type": "text",
      "section": "I. Definition and Background for Developmental Care",
      "line": 227,
      "preview": "The NICU is a much different environment from the womb, which is a warm and dark place free from hig"
    },
    {
      "type": "text",
      "section": "I. Definition and Background for Developmental Care",
      "line": 229,
      "preview": "This is an evolving field and much remains to be learned regarding best evidence based practice. Man"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. The Physical Environment",
      "line": 231
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. NICU Design",
      "line": 233
    },
    {
      "type": "text",
      "section": "A. NICU Design",
      "line": 235,
      "preview": "The physical design of the NICU is an important part of developmental care as it affects levels and "
    },
    {
      "type": "text",
      "section": "A. NICU Design",
      "line": 236,
      "preview": "B. Light"
    },
    {
      "type": "text",
      "section": "A. NICU Design",
      "line": 238,
      "preview": "Recommended light levels in the NICU are 10-600 lux but in most NICUs, levels are much higher and in"
    },
    {
      "type": "text",
      "section": "A. NICU Design",
      "line": 240,
      "preview": "--- page 10 ---"
    },
    {
      "type": "text",
      "section": "A. NICU Design",
      "line": 242,
      "preview": "C. Sound"
    },
    {
      "type": "text",
      "section": "A. NICU Design",
      "line": 244,
      "preview": "Most sound exposure in the NICU comes from alarms, background staff conversation and other noise suc"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Therapeutic Interventions",
      "line": 246
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 248,
      "preview": "These therapies may be provided by health care workers but are preferably delivered by trained paren"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 249,
      "preview": "A. Touch"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 251,
      "preview": "Most infants, even the most ill, can and should be cared for using positive touch. Use of \"hand-hugs"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 252,
      "preview": "B. Voice Exposure"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 254,
      "preview": "Preterm infants are at increased risk for cognitive and language difficulties. Development of langua"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 255,
      "preview": "C. Music Therapy"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 257,
      "preview": "Decibel appropriate, soothing music played for preterm infants increases O2 saturations, stabilizes "
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 258,
      "preview": "D. Kangaroo Care or Skin to Skin Care"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 260,
      "preview": "Holding an infant against a parent's bare chest can have both short and long term positive impacts o"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 261,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 263,
      "preview": "--- page 11 ---"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 265,
      "preview": "infants and parents. Effects include lower mortality, lower risk of sepsis, increased breast feeding"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 266,
      "preview": "E. Infant Massage"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 268,
      "preview": "Preterm infants receiving moderate pressure massage gain weight faster and have shorter lengths of s"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 269,
      "preview": "F. Therapeutic Positioning"
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 271,
      "preview": "Infants should be evaluated with each care interaction for age-appropriate postural alignment which "
    },
    {
      "type": "text",
      "section": "III. Therapeutic Interventions",
      "line": 272,
      "preview": "Therapeutic positioning facilitates infant comfort, physiologic stability, and optimal neuromotor an"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Managing Pain and Stress in the Newborn",
      "line": 274
    },
    {
      "type": "text",
      "section": "IV. Managing Pain and Stress in the Newborn",
      "line": 276,
      "preview": "A. Stress"
    },
    {
      "type": "text",
      "section": "IV. Managing Pain and Stress in the Newborn",
      "line": 278,
      "preview": "Signs of infant stress are subtle and are often misinterpreted as normal behavior. Stress signals ca"
    },
    {
      "type": "text",
      "section": "IV. Managing Pain and Stress in the Newborn",
      "line": 279,
      "preview": "B. Pain"
    },
    {
      "type": "text",
      "section": "IV. Managing Pain and Stress in the Newborn",
      "line": 281,
      "preview": "See Pain Assessment and Management in Neonates -"
    },
    {
      "type": "text",
      "section": "IV. Managing Pain and Stress in the Newborn",
      "line": 282,
      "preview": "V. Developmental care overlaps with and is central to family centered care. Developmental care progr"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 284
    },
    {
      "type": "text",
      "section": "References",
      "line": 286,
      "preview": "1. Developmental Care of Newborns and Infants, A guide for health professionals. 2nd edition. Kenner"
    },
    {
      "type": "text",
      "section": "References",
      "line": 287,
      "preview": "2. Symington AJ, Pinelli J. Developmental care for promoting development and preventing morbidity in"
    },
    {
      "type": "text",
      "section": "References",
      "line": 289,
      "preview": "--- page 12 ---"
    },
    {
      "type": "text",
      "section": "References",
      "line": 291,
      "preview": "3. Lester BM, Hawes K, Abar B, Sullivan M, Miller R, Bigsby R, Laptook A, Salisbury A, Taub M, Lagas"
    },
    {
      "type": "text",
      "section": "References",
      "line": 292,
      "preview": "4. Pineda RG, Stransky KE, Rogers C, Duncan MH, Smith GC, Neil J, Inder T. The single-patient room i"
    },
    {
      "type": "text",
      "section": "References",
      "line": 293,
      "preview": "5. Morag I, Ohisson A. Cycled light in the intensive care unit for preterm and low birth weight infa"
    },
    {
      "type": "text",
      "section": "References",
      "line": 294,
      "preview": "6. Graven SN. Sound and the developing infant in the NICU: Conclusions and recommendations for care."
    },
    {
      "type": "text",
      "section": "References",
      "line": 295,
      "preview": "7. Brown G, NICU noise and the preterm infant. Neonatal Network, 2009 3: 165-173."
    },
    {
      "type": "text",
      "section": "References",
      "line": 296,
      "preview": "8. Standley J. Music therapy research in the NICU: an updated meta-analysis. Neonatal Network 2012. "
    },
    {
      "type": "text",
      "section": "References",
      "line": 297,
      "preview": "9. Boundy EO, Dastjerdi R, Spiegelman D, Fawzi WW, Missmer SA, Lieberman E, Kajeepeta S, Wall S, Cha"
    },
    {
      "type": "text",
      "section": "References",
      "line": 298,
      "preview": "10. Preterm Infant Massage Therapy Research: A Review, Field T, Diego M, Hernandez-Reif M, Infant Be"
    },
    {
      "type": "text",
      "section": "References",
      "line": 299,
      "preview": "11. Coughlin, M (2014). Age-Appropriate Activities of Daily Living. In Transformative Nursing in the"
    },
    {
      "type": "text",
      "section": "References",
      "line": 300,
      "preview": "12. White RD. Recommended standard for newborn ICU design, eight edition. J Perinatol 2013; 33:52-16"
    },
    {
      "type": "text",
      "section": "References",
      "line": 302,
      "preview": "--- page 13 ---"
    },
    {
      "type": "text",
      "section": "References",
      "line": 304,
      "preview": "William Rhine, M.D."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "I. Philosophy",
      "line": 306
    },
    {
      "type": "text",
      "section": "I. Philosophy",
      "line": 308,
      "preview": "We recognize that parents and families are often in a state of emotional crisis when their newborn i"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Family Involvement Guidelines",
      "line": 310
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 312,
      "preview": "A. Parents are encouraged to be at their baby's bedside however long and whenever best suits their e"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 314,
      "preview": "1. When there is a procedure or emergency in the room happening to another patient, medical personne"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 315,
      "preview": "2. During nurses' changes of shift (from 7-7:30 am and 7-7:30 p.m., and 11-11:30 pm), parents may be"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 316,
      "preview": "3. During doctors' rounds, parents are allowed to remain at their baby's bedside and should be inclu"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 317,
      "preview": "B. Parents are given a plastic wrist ID band from the NICU front desk. They may be asked to show pho"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 318,
      "preview": "C. Parents may bring one guest at a time into the Nursery during visiting hours ( 8 am to 9 pm ). Th"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 319,
      "preview": "4. There is a limit of 2 persons at the bedside. Parents may list up to 4 individuals who may visit "
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 320,
      "preview": "5. No visitors, except immediate family members, may be admitted into the NICU after 9 pm for safety"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 321,
      "preview": "6. Siblings of any age can visit in the NICU, ICN, and the Maternity floors during visiting hours. N"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 322,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 324,
      "preview": "--- page 14 ---"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 326,
      "preview": "4. Visitors under the age 18 may not remain in the hospital after 9 pm unless they are the parents; "
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 327,
      "preview": "D. Sleeping arrangements can be made with the social worker. Fire codes prohibit sleeping in alcoves"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 328,
      "preview": "E. Parents, siblings, and guests must not have been exposed to chicken pox or measles, have had a co"
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 329,
      "preview": "F. Additional restrictions may be necessary during Influenza and RSV season."
    },
    {
      "type": "text",
      "section": "II. Family Involvement Guidelines",
      "line": 330,
      "preview": "G. Medical information will only be given out to the parents. The parents may, if they choose to, se"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Special Circumstances",
      "line": 332
    },
    {
      "type": "text",
      "section": "III. Special Circumstances",
      "line": 334,
      "preview": "A. Adoption: We respect the biological mother's wishes at all times and encourage her presence. The "
    },
    {
      "type": "text",
      "section": "III. Special Circumstances",
      "line": 335,
      "preview": "B. Surrogacy: All parties involved are welcome to enter the NICU. Please consult with the Social Wor"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. General Information",
      "line": 337
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 339,
      "preview": "A. Hand washing is vigorously enforced, as it is as very important and successful in controlling the"
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 340,
      "preview": "B. There are 2 Parent Rooms and 2 sleep sofas in the Family Lounge where parents can stay overnight."
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 341,
      "preview": "C. Parent Rooms are open for general use on a rotating basis between 8:30 am and 8:30 pm. These room"
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 342,
      "preview": "D. Parents are encouraged to bring family pictures to place at the bedside of their babies. Stuffed "
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 343,
      "preview": "E. We request that families and guests in the nursery patient rooms stay at their baby's bedside in "
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 344,
      "preview": "F. Flowers, plants, balloons, and electrical appliances are not allowed on the unit. No food or drin"
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 346,
      "preview": "--- page 15 ---"
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 348,
      "preview": "G. Medical procedures often require that babies are quiet, relaxed, and rested. For this reason, fam"
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 349,
      "preview": "H. Parents are asked not to bring clothes in for the baby until the infant's condition is stable."
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 350,
      "preview": "I. Cultural rituals and spiritual or religious ceremonies will be accommodated to the extent that th"
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 351,
      "preview": "J. Before moving a patient within the NICU, or before transferring a patient to another unit within "
    },
    {
      "type": "text",
      "section": "IV. General Information",
      "line": 353,
      "preview": "--- page 16 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Developmental-Pediatric Programs",
      "line": 355
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Anne De Battista, PhD, CPNP, CPMHS",
      "line": 357
    },
    {
      "type": "heading",
      "level": 3,
      "section": "Introduction",
      "line": 359
    },
    {
      "type": "text",
      "section": "Introduction",
      "line": 361,
      "preview": "Developmental and Behavioral Pediatrics at Stanford Children's Health offers clinical services for i"
    },
    {
      "type": "heading",
      "level": 3,
      "section": "I. Team Values",
      "line": 363
    },
    {
      "type": "heading",
      "level": 4,
      "section": "A. Family-centered practice",
      "line": 365
    },
    {
      "type": "text",
      "section": "A. Family-centered practice",
      "line": 366,
      "preview": "Elicit family concerns, engage families in decision-making."
    },
    {
      "type": "heading",
      "level": 4,
      "section": "B. Active interdisciplinary teaming",
      "line": 368
    },
    {
      "type": "text",
      "section": "B. Active interdisciplinary teaming",
      "line": 369,
      "preview": "Efficient sharing of information."
    },
    {
      "type": "heading",
      "level": 4,
      "section": "C. Flexible role definitions",
      "line": 371
    },
    {
      "type": "text",
      "section": "C. Flexible role definitions",
      "line": 372,
      "preview": "Willingness to assure comprehensive examination by stretching beyond conventional disciplinary bound"
    },
    {
      "type": "heading",
      "level": 4,
      "section": "D. Cultural humility",
      "line": 374
    },
    {
      "type": "text",
      "section": "D. Cultural humility",
      "line": 375,
      "preview": "Willingness to adapt recommendations depending on family culture and willingness to ask families abo"
    },
    {
      "type": "heading",
      "level": 4,
      "section": "E. Community inclusion",
      "line": 377
    },
    {
      "type": "text",
      "section": "E. Community inclusion",
      "line": 378,
      "preview": "Promoting the engagement of all children and families in their communities, regardless of abilities "
    },
    {
      "type": "heading",
      "level": 3,
      "section": "II. Programs",
      "line": 380
    },
    {
      "type": "heading",
      "level": 4,
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 382
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 384,
      "preview": "1. The Developmental Care Team is comprised of infant development specialists including an educator,"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 386,
      "preview": "2. Each baby referred for Developmental Care Team services will have a primary team member working w"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 388,
      "preview": "3. Criteria for Referral to the Developmental Care Team:"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 389,
      "preview": "- a. Birth weight <1500 gm"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 390,
      "preview": "- b. Prolonged hospital course"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 391,
      "preview": "- c. Suspected CNS abnormalities"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 392,
      "preview": "- d. Syndromes associated with developmental compromise"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 394,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 396,
      "preview": "--- page 17 ---"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 398,
      "preview": "e. Maternal drug use"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 399,
      "preview": "f. Sensory impairment"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 400,
      "preview": "g. Congenital anomalies"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 401,
      "preview": "h. S/P ECMO/PPHN"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 402,
      "preview": "i. Any baby meeting criteria for Neuro NICU"
    },
    {
      "type": "text",
      "section": "A. Inpatient Johnson Center Developmental Program",
      "line": 403,
      "preview": "j. Any baby or family who needs extra support with developmental information/reading cues"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Outpatient High Risk Infant Follow-up (HRIF) Program",
      "line": 405
    },
    {
      "type": "text",
      "section": "B. Outpatient High Risk Infant Follow-up (HRIF) Program",
      "line": 407,
      "preview": "1. As a tertiary center, Packard Children's Hospital is required by California Children Services (CC"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Purpose of HRIF Evaluations",
      "line": 409
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 411,
      "preview": "a. Follow-up of children with risk factors for developmental compromise"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 412,
      "preview": "b. Early identification of developmental delays and disorders"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 413,
      "preview": "c. Referral to appropriate community-based services"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 414,
      "preview": "d. Referral for appropriate medical interventions"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 415,
      "preview": "e. Counseling families on appropriate child rearing and management strategies"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 416,
      "preview": "f. Reassurance, when appropriate"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 417,
      "preview": "g. Reduced likelihood of vulnerable child syndrome"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 418,
      "preview": "3. California Children Services (CCS) High-Risk Infant Follow-up (HRIF) Program Eligibility"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 419,
      "preview": "a. Infant has met CCS medical eligibility criteria for NICU care in a CCS-approved NICU or PICU (reg"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 421,
      "preview": "OR"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 422,
      "preview": "b. Infant had a CCS eligible medical condition in a CCS-approved NICU (regardless of length of stay,"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 423,
      "preview": "i. The birth weight was less than or equal to 1500 grams, or the gestational age at birth was less t"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 425,
      "preview": "OR"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 426,
      "preview": "ii. The birth weight was more than 1500 grams and the gestational age at birth was 32 weeks or more "
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 427,
      "preview": "a) pH less than 7.0 on an umbilical cord blood sample or a blood gas obtained within one hour This d"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 429,
      "preview": "--- page 18 ---"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 431,
      "preview": "of life or an APGAR score of less than or equal to three at five minutes or an APGAR score of less t"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 432,
      "preview": "b) An unstable infant manifested by hypoxia, acidemia, hypoglycemia and/or hypotension requiring pre"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 433,
      "preview": "c) Persistent apnea which required caffeine or other stimulant medication for the treatment of apnea"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 434,
      "preview": "d) Required oxygen for more than 28 days of hospital stay and had radiographic findings consistent w"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 435,
      "preview": "e) Infants placed on extracorporeal membrane oxygenation (ECMO)"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 436,
      "preview": "f) Infants who received inhaled nitric oxide greater than four hours, and/or treatment during hospit"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 437,
      "preview": "g) History of observed clinical or electroencephalographic (EEG) seizure activity or receiving antie"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 438,
      "preview": "h) Evidence of intracranial pathology, including but not limited to, intracranial hemorrhage (grade "
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 439,
      "preview": "i) Other documented problems that could result in a neurologic abnormality, such as:"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 441,
      "preview": "1) history of CNS infection"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 442,
      "preview": "2) documented sepsis (e.g. positive blood culture)"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 443,
      "preview": "3) bilirubin levels that are concerning for brain injury, as determined by NICU medical staff"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 444,
      "preview": "j) history of cardiovascular instability as determined by NICU medical staff due to: sepsis, congeni"
    },
    {
      "type": "text",
      "section": "2. Purpose of HRIF Evaluations",
      "line": 445,
      "preview": "k) Clinical history and/or physical exam findings consistent with neonatal encephalopathy."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 447
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 449,
      "preview": "a. Intrauterine drug exposure"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 450,
      "preview": "b. CCS HRIF risk factors admitted to intensive care after first 28 days of life."
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 451,
      "preview": "c. At the discretion of the physician, any concerning medical condition (i.e. abnormal neurological "
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 452,
      "preview": "5. Questions about eligibility may be directed to any of the following personnel:"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 453,
      "preview": "a. HRIF Coordinator"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 455,
      "preview": "--- page 19 ---"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 457,
      "preview": "12 Part I-A: Administrative"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 458,
      "preview": "b. HRIF Manager"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 459,
      "preview": "c. HRIF Medical Director"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 461,
      "preview": "CCS supports 3 visits up to age 3 years and scheduled for 4-8 months, 12-16 months, and 18-36 months"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 462,
      "preview": "6. Written information on the follow-up program is generally provided to the parents while the infan"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 463,
      "preview": "7. HRIF visit schedule:"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 464,
      "preview": "a. 1st visit between 4-8 months corrected age"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 465,
      "preview": "b. 2nd visit between 12-16 months corrected age"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 466,
      "preview": "c. 3rd visit between 18-36 months corrected age"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 467,
      "preview": "8. Enrollment Process in High Risk Infant Follow-Up"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 468,
      "preview": "a. It is the responsibility of the discharging NICU to register the baby with CCS CPQCC for High Ris"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 469,
      "preview": "i. Babies discharged from the LPCH intensive care nurseries will be registered by the CCS HRIF Coord"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 470,
      "preview": "ii. Appointment dates and times can also be viewed in electronic medical record."
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 471,
      "preview": "b. When a baby is transported back to a CCS approved Community NICU and discharged to home, the disc"
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 472,
      "preview": "c. The discharging NICU/Hospital must submit a SAR (Service Authorization Request) to the local CCS "
    },
    {
      "type": "text",
      "section": "4. Non-CCS LPCH HRIF Eligibility",
      "line": 473,
      "preview": "d. Non-CCS referrals (see II.B. 4 above) are sent by secure email or fax to the Developmental and Be"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "9. Outpatient Preemie Graduate Services",
      "line": 475
    },
    {
      "type": "text",
      "section": "9. Outpatient Preemie Graduate Services",
      "line": 477,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "9. Outpatient Preemie Graduate Services",
      "line": 479,
      "preview": "--- page 20 ---"
    },
    {
      "type": "text",
      "section": "9. Outpatient Preemie Graduate Services",
      "line": 481,
      "preview": "Our specialized services for children who had birth-related complications, such as prematurity, exte"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "10. Outpatient Developmental Behavioral Pediatric Programs",
      "line": 483
    },
    {
      "type": "text",
      "section": "10. Outpatient Developmental Behavioral Pediatric Programs",
      "line": 485,
      "preview": "Referrals are accepted through the LPCH Referral Center for the Young Child Program (under age 7 yea"
    },
    {
      "type": "text",
      "section": "10. Outpatient Developmental Behavioral Pediatric Programs",
      "line": 487,
      "preview": "--- page 21 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part I-B: Delivery and Admission",
      "line": 489
    },
    {
      "type": "text",
      "section": "Part I-B: Delivery and Admission",
      "line": 491,
      "preview": "--- page 22 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Prenatal Counseling",
      "line": 493
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Christine Johnson, MD",
      "line": 495
    },
    {
      "type": "text",
      "section": "Christine Johnson, MD",
      "line": 497,
      "preview": "These are general guidelines for inpatient prenatal consults at LPCH. Each consult will need to be t"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Who Needs Prenatal Counseling?",
      "line": 499
    },
    {
      "type": "text",
      "section": "I. Who Needs Prenatal Counseling?",
      "line": 501,
      "preview": "A. Anyone whose infant is likely to need specialized newborn care."
    },
    {
      "type": "text",
      "section": "I. Who Needs Prenatal Counseling?",
      "line": 502,
      "preview": "B. Mothers who are delivering or are at high risk of delivering prematurely need an inpatient prenat"
    },
    {
      "type": "text",
      "section": "I. Who Needs Prenatal Counseling?",
      "line": 503,
      "preview": "C. Mothers who are carrying fetuses with known surgical or other high risk conditions will likely ha"
    },
    {
      "type": "text",
      "section": "I. Who Needs Prenatal Counseling?",
      "line": 504,
      "preview": "D. Consults may be requested by the Maternal-Fetal Medicine physicians or obstetricians. Requests fo"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Who Does Prenatal Counseling?",
      "line": 506
    },
    {
      "type": "text",
      "section": "II. Who Does Prenatal Counseling?",
      "line": 508,
      "preview": "A. Fellow: Most in-patient prenatal consults are done by the Neonatalogy Fellow. It is best to do th"
    },
    {
      "type": "text",
      "section": "II. Who Does Prenatal Counseling?",
      "line": 509,
      "preview": "B. Hospitalist: For infants who are being delivered at $>33$ wks EGA and are likely to go the ICN in"
    },
    {
      "type": "text",
      "section": "II. Who Does Prenatal Counseling?",
      "line": 510,
      "preview": "C. Housestaff: Although housestaff do not do consults, they may accompany the fellow or hospitalist "
    },
    {
      "type": "text",
      "section": "II. Who Does Prenatal Counseling?",
      "line": 511,
      "preview": "D. Attending: Outpatient prenatal consults are done through the Fetal and Pregnancy Health Program. "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 513
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 515,
      "preview": "A. The most important thing to know before doing a prenatal consult is whether a consult has already"
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 516,
      "preview": "B. Check the chart: There should be a note in the mother's chart in EPIC, under the \"Consults\" tab, "
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 517,
      "preview": "C. Ask the patient: Check with the patient to determine if they have spoken with a neonatologist, ne"
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 519,
      "preview": "--- page 23 ---"
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 521,
      "preview": "should be done (e.g., a consult was done at 24 wks EGA, but the patient is now about to deliver at 3"
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 522,
      "preview": "D. Once you have determined that a consult is needed, collect information about the patient's pregna"
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 524,
      "preview": "1. Gender, dates, estimated fetal weight and steroids: For premature deliveries, the most important "
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 525,
      "preview": "2. Patient knowledge: It is useful to find out what the mother has been told and what her reaction h"
    },
    {
      "type": "text",
      "section": "III. What Do I Need to Know Before the Consult?",
      "line": 526,
      "preview": "3. Language: If the mother is not a native English speaker, remember to request a translator and not"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. How Should I Start the Conversation?",
      "line": 528
    },
    {
      "type": "text",
      "section": "IV. How Should I Start the Conversation?",
      "line": 530,
      "preview": "A. Everyone has their own style, but there are a few useful initial questions to ask."
    },
    {
      "type": "text",
      "section": "IV. How Should I Start the Conversation?",
      "line": 532,
      "preview": "1. Who would the mother like included in the conversation? Is their partner available? If time allow"
    },
    {
      "type": "text",
      "section": "IV. How Should I Start the Conversation?",
      "line": 533,
      "preview": "2. What have the parents already been told and what is their understanding of the situation?"
    },
    {
      "type": "text",
      "section": "IV. How Should I Start the Conversation?",
      "line": 534,
      "preview": "3. Ask the parents if they have named the baby. This may help personalize what is otherwise a diffic"
    },
    {
      "type": "text",
      "section": "IV. How Should I Start the Conversation?",
      "line": 535,
      "preview": "4. Encourage them to ask questions. Reassurance that we understand that they are stressed and may no"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. What are the Major Issues to Discuss?",
      "line": 537
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 539,
      "preview": "A. Team structure: We work as a team in both the DR and the NICU, and explaining this can help to av"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 540,
      "preview": "B. Respiratory support: Briefly describe the possible types of respiratory support that we provide, "
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 541,
      "preview": "C. Cardiac support: Discuss the interventions that may be necessary in the DR or NICU, such as medic"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 543,
      "preview": "--- page 24 ---"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 545,
      "preview": "lines since many of our patients will need them. It is also a good time to mention the potential use"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 546,
      "preview": "D. Metabolic support: Almost every mother asks how her infant will be fed. If the mother plans to pr"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 547,
      "preview": "E. Infection: Many babies admitted to the NICU will undergo a septic work up, which will include imm"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 548,
      "preview": "F. Neurologic support: It is important to reassure parents that we treat pain and agitation in newbo"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 549,
      "preview": "G. Other common concerns: Parents find the idea of separation from their infant very stressful. Expl"
    },
    {
      "type": "text",
      "section": "V. What are the Major Issues to Discuss?",
      "line": 550,
      "preview": "H. Reassure mom: Most importantly, please remember to let the mother know that what is happening is "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Specific Circumstances for Discussion",
      "line": 552
    },
    {
      "type": "text",
      "section": "VI. Specific Circumstances for Discussion",
      "line": 554,
      "preview": "A. Premature birth: Most inpatient consults will be requested for impending premature delivery. Each"
    },
    {
      "type": "text",
      "section": "VI. Specific Circumstances for Discussion",
      "line": 555,
      "preview": "B. Decisions regarding viability and resuscitation: This is likely to be the most difficult part of "
    },
    {
      "type": "text",
      "section": "VI. Specific Circumstances for Discussion",
      "line": 556,
      "preview": "C. Extreme prematurity: The American Academy of Pediatrics and the American College of Obstetricians"
    },
    {
      "type": "text",
      "section": "VI. Specific Circumstances for Discussion",
      "line": 558,
      "preview": "--- page 25 ---"
    },
    {
      "type": "text",
      "section": "VI. Specific Circumstances for Discussion",
      "line": 560,
      "preview": "and Gynecologists stress adequate counseling regarding outcomes as a critical aspect of peri-viable "
    },
    {
      "type": "text",
      "section": "VI. Specific Circumstances for Discussion",
      "line": 561,
      "preview": "D. Multiples: Most parents of multiples have had counseling from their OB regarding the risks of twi"
    },
    {
      "type": "text",
      "section": "VI. Specific Circumstances for Discussion",
      "line": 562,
      "preview": "E. Hydrops: This condition requires special counseling of parents because of the increased possibili"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. What Else Do Parents Need to Know?",
      "line": 564
    },
    {
      "type": "text",
      "section": "VII. What Else Do Parents Need to Know?",
      "line": 566,
      "preview": "Every consult should also discuss the following:"
    },
    {
      "type": "text",
      "section": "VII. What Else Do Parents Need to Know?",
      "line": 567,
      "preview": "A. Research: LPCH is a university hospital and a member of the NICHD Research Network and Pediatrics"
    },
    {
      "type": "text",
      "section": "VII. What Else Do Parents Need to Know?",
      "line": 568,
      "preview": "B. LPCH has several nurseries: Let parents know that their infant may start off in the NICU, but whe"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 570
    },
    {
      "type": "text",
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 572,
      "preview": "There are many resources that parents will learn about, but a few are worth mentioning prior to deli"
    },
    {
      "type": "text",
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 573,
      "preview": "A. Tour of the NICU: The mother may not to be able to see the NICU, but her partner can be shown the"
    },
    {
      "type": "text",
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 575,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 577,
      "preview": "--- page 26 ---"
    },
    {
      "type": "text",
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 579,
      "preview": "NICU by the NICU charge RN. That way they know where the unit is located, what an incubator looks li"
    },
    {
      "type": "text",
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 580,
      "preview": "B. Lactation services: LPCH has a dedicated team of doctors and nurses who will help the mother prod"
    },
    {
      "type": "text",
      "section": "VIII. What Resources Can We Offer to Parents Beyond the Consult?",
      "line": 581,
      "preview": "C. Religious Services/Social Work Services/Parent Support Groups: There are many people to help the "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IX. What Needs to Be Done After the Consult?",
      "line": 583
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Please remember to:",
      "line": 585
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 587,
      "preview": "A. Document the consult: Place a note in the mother's EPIC chart, letting both the OB and the NICU t"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 589,
      "preview": "1. Create a consult note, then type \"prenatal consult note IP\" into the SmartText box. This will gen"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 590,
      "preview": "2. Type in the dot phrase appropriate for the EGA of the fetus to generate the details of your discu"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 591,
      "preview": "a. .prenatal24wk"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 592,
      "preview": "b. .prenatal26wk"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 593,
      "preview": "c. .prenatal28wk"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 594,
      "preview": "d. .prenatal30wk"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 595,
      "preview": "e. .prenatal32wk"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 596,
      "preview": "B. Tell the Antepartum or L\\&D Nurse: This may help prevent redundant consult requests."
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 597,
      "preview": "C. Inform the NICU team: Let the admitting NICU attending know about the consult. In the case of ext"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 598,
      "preview": "D. Speak with the OB team: Particularly in the case of extreme prematurity (i.e., <25 wks EGA), a pa"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 600,
      "preview": "--- page 27 ---"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 602,
      "preview": "References:"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 604,
      "preview": "1. Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA, Andrews WW, Wallace D, Das "
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 605,
      "preview": "2. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, "
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 606,
      "preview": "3. Patel RM, Kandefer S, Walsh MC, Bell EF, Carlo WA, Laptook AR, S\u00e1nchez PJ, Shankaran S, Van Meurs"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 607,
      "preview": "4. Hintz SR, Kendrick DE, Wilson-Costello DE, Das A, Bell EF, Vohr BR, Higgins RD; NICHD Neonatal Re"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 608,
      "preview": "5. Halamek LP. The advantages of prenatal consultation by a neonatologist. J Perinatol. 2001 Mar;21("
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 609,
      "preview": "6. Halamek LP. Prenatal consultation at the limits of viability. NeoReviews. 2003;4:e153-e156."
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 610,
      "preview": "7. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD; National Institute of Child Health and Human "
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 611,
      "preview": "8. Doyle LW, Roberts G, Anderson PJ; Victorian Infant Collaborative Study Group. Outcomes at age 2 y"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 612,
      "preview": "9. Moore T, Hennessy EM, Myles J, Johnson SJ, Draper ES, Costeloe KL, Marlow N. Neurological and dev"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 613,
      "preview": "10. Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA, Buzas JS. Mortality and neonat"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 614,
      "preview": "11. Rysavy MA, LiL, Bell EF et al. Between-Hospital Variation in Treatment and Outcomes in Extremely"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 616,
      "preview": "--- page 28 ---"
    },
    {
      "type": "text",
      "section": "Please remember to:",
      "line": 618,
      "preview": "Kristine Boyle, N.N.P.-B.C. and Arun Gupta, M.D."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "I. Which Deliveries Do We Attend?",
      "line": 620
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 622,
      "preview": "A. All high-risk pregnancies (e.g., preterm deliveries, meconium-stained amniotic fluid, or cesarean"
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 623,
      "preview": "B. Instrumented deliveries (e.g., forceps, vacuum)."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 624,
      "preview": "C. Abnormal presentations (e.g., breech)."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 625,
      "preview": "D. Polyhydramnios or oligohydramnios."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 626,
      "preview": "E. Multiple gestation."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 627,
      "preview": "F. Suspected maternal infections (e.g., chorioamnionitis)."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 628,
      "preview": "G. Prenatal diagnosis of congenital anomalies (e.g., cardiac, gastrointestinal)."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 629,
      "preview": "H. Mothers receiving sedatives or other types of medication (e.g., anti-epileptics, heroin, methadon"
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 630,
      "preview": "I. Fetal distress (e.g., meconium, decelerations, abnormal non-stress test, tachycardia, Category 2 "
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 631,
      "preview": "J. Postmaturity ( $>42$ wks)."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 632,
      "preview": "K. Intrauterine growth restriction (IUGR)."
    },
    {
      "type": "text",
      "section": "I. Which Deliveries Do We Attend?",
      "line": 633,
      "preview": "L. Maternal bleeding (e.g., placenta previa, abruption)."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Delivery Room Preparation and Resuscitation",
      "line": 635
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Delivery Room Team:",
      "line": 637
    },
    {
      "type": "text",
      "section": "A. Delivery Room Team:",
      "line": 639,
      "preview": "Our \"Standard\" Delivery Room team is comprised of at least one MD/NNP and at least one RN. Our \"Stan"
    },
    {
      "type": "text",
      "section": "A. Delivery Room Team:",
      "line": 641,
      "preview": "If, at any time, you are in the Delivery Room and realize that more support is needed, make sure to "
    },
    {
      "type": "text",
      "section": "A. Delivery Room Team:",
      "line": 643,
      "preview": "--- page 29 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Introduction into the Delivery Room:",
      "line": 645
    },
    {
      "type": "text",
      "section": "B. Introduction into the Delivery Room:",
      "line": 647,
      "preview": "When entering the Delivery Room, always make sure to introduce yourself. When going to a delivery in"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Preparing your equipment",
      "line": 649
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 651,
      "preview": "1. Make sure the radiant warmer is on, the heat is turned up to maximum, and warm blankets are avail"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 652,
      "preview": "2. Check the suction set-up."
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 653,
      "preview": "3. Check the oxygen source and make sure there is adequate flow to the anesthesia bag or T-piece (8$"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 654,
      "preview": "4. To prepare the T-piece, adjust the gas supply to desired flow rate between 8-10 lpm. Check maximu"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 655,
      "preview": "5. Check to ensure you have the proper size mask. Check the laryngoscope light and ascertain that pr"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 656,
      "preview": "6. Set out the correct size endotracheal tube (i.e., 3.5 for term or weight $>2 \\mathrm{~kg}, 3.0$ f"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 657,
      "preview": "7. If you anticipate that the infant will need resuscitation, PPV, or oxygen supplementation, set ou"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 658,
      "preview": "8. If attending the delivery of an infant $<35$ weeks or IUGR, take a warming mattress with you. If "
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 659,
      "preview": "9. If you anticipate that the infant will be admitted to the NICU, check to see if a battery pack is"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 660,
      "preview": "10. For potential codes, set up an umbilical vein catheter, flush solution, epinephrine, and have th"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 662,
      "preview": "--- page 30 ---"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 664,
      "preview": "the contents and location of the Neonatal Resuscitation Carts prior to the delivery. If code meds ar"
    },
    {
      "type": "text",
      "section": "C. Preparing your equipment",
      "line": 665,
      "preview": "11. At the time of delivery, look for nuchal cord, amount of maternal bleeding, degree of placental "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Once the infant is born",
      "line": 667
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 669,
      "preview": "1. Start the Apgar timer."
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 670,
      "preview": "2. Follow Delayed Cord Clamping Procedure (see Nursery Guide Section on Delayed Cord Clamping)."
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 671,
      "preview": "3. Place the infant on the radiant warmer with the head towards the end of the bed. If the infant is"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 672,
      "preview": "4. It is not necessary to suction all infants, only those who demonstrate respiratory distress or if"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 673,
      "preview": "5. If the infant has meconium prior to or at delivery, see section V. A on \"Meconium Staining\"."
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 674,
      "preview": "6. Dry the infant (unless NeoWrap used), especially the head and face, which represent $20 \\%$ of bo"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 675,
      "preview": "7. If resuscitation is anticipated, PPV is required, supplemental oxygen is administered, or persist"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 676,
      "preview": "8. If the infant has a heart rate $\\leq 100$ and/or has little or no respiratory effort after warmin"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 677,
      "preview": "9. The T-piece can be used to give blow-by oxygen, CPAP, and mask or endotracheal tube ventilation. "
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 678,
      "preview": "10. For infants born at term, you may use supplemental oxygen (start at $21 \\%$, the concentration c"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 679,
      "preview": "11. For preterm infants <35 weeks, use an oxygen blender and pulse oximeter during resuscitation. If"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 680,
      "preview": "12. If endotracheal (ET) intubation is required for resuscitation (except in the case of suctioning "
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 682,
      "preview": "--- page 31 ---"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 684,
      "preview": "13. Chest compressions are indicated when the heart rate remains $<60$ beats/min after at least 30 s"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 685,
      "preview": "14. If epinephrine is required during the resuscitation, use recommended dosing and concentration fo"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 686,
      "preview": "a. IV: 0.1 to $0.3 \\mathrm{~mL} / \\mathrm{kg}$ of the 1 mg in 10 mL concentration (previously labele"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 687,
      "preview": "b. ET: 0.5 to $1 \\mathrm{~mL} / \\mathrm{kg}$ of the 1 mg in 10 mL concentration (previously labeled "
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 688,
      "preview": "c. Consider ET route ONLY while IV access is being obtained"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 689,
      "preview": "15. Determine the Apgar scores as outlined in Section III.D below, \"APGAR Scoring System\". Check the"
    },
    {
      "type": "text",
      "section": "D. Once the infant is born",
      "line": 690,
      "preview": "16. If you arrive at the delivery room after the infant is greater than 1 min of age, the OB team is"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Other Resuscitation Information",
      "line": 692
    },
    {
      "type": "text",
      "section": "III. Other Resuscitation Information",
      "line": 694,
      "preview": "A. Review your Neonatal Resuscitation Program (NRP) booklet, and attend a Center for Advanced Pediat"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Clinical judgment:",
      "line": 696
    },
    {
      "type": "text",
      "section": "B. Clinical judgment:",
      "line": 698,
      "preview": "1. When assessing the newborn, do not let the Apgar score dictate disposition or appropriate resusci"
    },
    {
      "type": "text",
      "section": "B. Clinical judgment:",
      "line": 699,
      "preview": "2. If you have doubt about a baby's stability, consider admitting the baby to the NICU or the ICN fo"
    },
    {
      "type": "text",
      "section": "B. Clinical judgment:",
      "line": 700,
      "preview": "C. Always explain to the parents what you are doing and allow them to see their baby as soon as poss"
    },
    {
      "type": "text",
      "section": "B. Clinical judgment:",
      "line": 702,
      "preview": "--- page 32 ---"
    },
    {
      "type": "text",
      "section": "B. Clinical judgment:",
      "line": 704,
      "preview": "D. APGAR Scoring System: Provides a standard for describing the condition of infants at birth. Five "
    },
    {
      "type": "table",
      "section": "B. Clinical judgment:",
      "line": 706,
      "preview": "| Sign | 0 | 1 | 2 |"
    },
    {
      "type": "table",
      "section": "B. Clinical judgment:",
      "line": 707,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "B. Clinical judgment:",
      "line": 708,
      "preview": "| Color <br> (Appearance) | Blue or pale | Pink body, blue extremities | All pink |"
    },
    {
      "type": "table",
      "section": "B. Clinical judgment:",
      "line": 709,
      "preview": "| Heart rate <br> (Pulse) | Absent | $<100$ bpm | $>100$ bpm |"
    },
    {
      "type": "table",
      "section": "B. Clinical judgment:",
      "line": 710,
      "preview": "| Reflex irritability <br> (Grimace) | No response | Grimace | Cough or sneeze |"
    },
    {
      "type": "table",
      "section": "B. Clinical judgment:",
      "line": 711,
      "preview": "| Muscle tone <br> (Activity) | Limp | Some flexion of extremities | Active movements |"
    },
    {
      "type": "table",
      "section": "B. Clinical judgment:",
      "line": 712,
      "preview": "| Respiration | Absent | Slow, irregular | Good, crying |"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Admission from the Delivery Room",
      "line": 714
    },
    {
      "type": "text",
      "section": "IV. Admission from the Delivery Room",
      "line": 716,
      "preview": "A. Admissions to the NICU or Packard Intermediate Care Nursery include but are not limited to:"
    },
    {
      "type": "text",
      "section": "IV. Admission from the Delivery Room",
      "line": 718,
      "preview": "1. Premature infants born at $<35$ wks gestation."
    },
    {
      "type": "text",
      "section": "IV. Admission from the Delivery Room",
      "line": 719,
      "preview": "2. Term infants with respiratory distress not responsive to delivery room interventions."
    },
    {
      "type": "text",
      "section": "IV. Admission from the Delivery Room",
      "line": 720,
      "preview": "3. Term infants with hemodynamic instability."
    },
    {
      "type": "text",
      "section": "IV. Admission from the Delivery Room",
      "line": 721,
      "preview": "4. Infants with significant congenital anomalies."
    },
    {
      "type": "text",
      "section": "IV. Admission from the Delivery Room",
      "line": 722,
      "preview": "5. All infants with known congenital heart disease."
    },
    {
      "type": "text",
      "section": "IV. Admission from the Delivery Room",
      "line": 723,
      "preview": "B. For all infants admitted to the NICU from the Delivery Room, conduct a post-delivery debriefing w"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Special Delivery Room Circumstances",
      "line": 725
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Meconium Staining",
      "line": 727
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 729,
      "preview": "1. It is no longer necessary for the OB team to suction the mouth and nares at delivery."
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 730,
      "preview": "2. If the infant is vigorous and the heart rate is $>100$, warm, dry, and stimulate the infant and p"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 731,
      "preview": "3. If the infant is not vigorous at delivery, follow the steps listed in Section II.D for routine re"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 732,
      "preview": "4. If you have any doubts about the baby's status, admit to the NICU or ICN for observation."
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 734,
      "preview": "--- page 33 ---"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 736,
      "preview": "26 Part I-B: Delivery and Admission"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 737,
      "preview": "B. Congenital diaphragmatic hernia"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 739,
      "preview": "1. Intubate infant as soon as possible after delivery to avoid excessive air entry into GI tract, un"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 740,
      "preview": "2. Place orogastric tube to aid in gastric decompression."
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 741,
      "preview": "C. Spinal Cord Defects (Myelomeningocele)"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 742,
      "preview": "3. Keep infant in side-lying or prone position if possible during resuscitation (to keep patient off"
    },
    {
      "type": "text",
      "section": "A. Meconium Staining",
      "line": 743,
      "preview": "4. Place warm saline-soaked gauze/Telfa ${ }^{\\text {TM }}$ directly over the defect and then cover "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Abdominal Wall Defects (Gastroschisis/omphalocele)",
      "line": 745
    },
    {
      "type": "text",
      "section": "D. Abdominal Wall Defects (Gastroschisis/omphalocele)",
      "line": 747,
      "preview": "1. Open \"turkey bag\" in sterile fashion and place on radiant warmer."
    },
    {
      "type": "text",
      "section": "D. Abdominal Wall Defects (Gastroschisis/omphalocele)",
      "line": 748,
      "preview": "2. Upon delivery, place infant in \"turkey bag\" and cinch bag under infant's armpits."
    },
    {
      "type": "text",
      "section": "D. Abdominal Wall Defects (Gastroschisis/omphalocele)",
      "line": 749,
      "preview": "3. Resuscitate per NRP protocol. May need to consider intravenous or intraosseous line as route for "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 751
    },
    {
      "type": "text",
      "section": "References:",
      "line": 753,
      "preview": "1. Textbook of Neonatal Resuscitation, 7th Edition. The American Academy of Pediatrics and the Ameri"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 754,
      "preview": "2. Summary AAP/AHA: 2015 Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 756,
      "preview": "--- page 34 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "DELIVERY ROOM GUIDELINES",
      "line": 758
    },
    {
      "type": "heading",
      "level": 2,
      "section": "All Deliveries:",
      "line": 760
    },
    {
      "type": "text",
      "section": "All Deliveries:",
      "line": 762,
      "preview": "Pre-Delivery"
    },
    {
      "type": "text",
      "section": "All Deliveries:",
      "line": 763,
      "preview": "Briefing Warmer"
    },
    {
      "type": "text",
      "section": "All Deliveries:",
      "line": 764,
      "preview": "on, heat $100 \\%$"
    },
    {
      "type": "text",
      "section": "All Deliveries:",
      "line": 765,
      "preview": "$\\mathrm{FiO}_{2} 21 \\% \\bullet$ T-piece $20 / 5 \\bullet$"
    },
    {
      "type": "text",
      "section": "All Deliveries:",
      "line": 766,
      "preview": "Flow 8-10 Suction 80 mm Hg"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 768,
      "preview": "| GA < 32 Weeks |  |  | MRSORA Algorithm |  |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 769,
      "preview": "| :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 770,
      "preview": "|  | Set up intubation and pulse oximetry Plastic wrap Thermal mattress Thermal hat |  | Corrective "
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 771,
      "preview": "|  |  | M | Mask adjustment | Reapply mask. Consider 2-hand technique |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 772,
      "preview": "|  |  | R | Reposition airway | Place head neutral or slightly extended |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 773,
      "preview": "|  | GA 32-35 Weeks |  |  |  |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 774,
      "preview": "|  | Set up intubation and pulse ox, if indicated Thermal mattress Normal Hat |  | Try PPV and reass"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 775,
      "preview": "|  |  |  | S | Suction mouth/nose |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 776,
      "preview": "|  |  | 0 | Open mouth | Open mouth and lift jaw forward |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 777,
      "preview": "|  | GA $>35$ Weeks |  |  | Try PPV and reassess chest movement |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 778,
      "preview": "|  | Set up intubation and pulse ox, if indicated Normal hat |  | P | Pressure increase |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 779,
      "preview": "|  |  |  |  | 5 to 10 cm increments (max $40 \\mathrm{~cm} \\mathrm{H}_{2} \\mathrm{O}$ ) |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 780,
      "preview": "|  |  | ETT Size Recommendations |  |  |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 781,
      "preview": "|  |  | Weight | Gest Age | ETT |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 782,
      "preview": "|  |  | $<1000 \\mathrm{~g}$ | $<28$ wks | 2.5 |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 783,
      "preview": "|  |  | $1000-2000 \\mathrm{~g}$ | 28-34 wks | 3.0 |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 784,
      "preview": "|  |  | $>2000 \\mathrm{~g}$ | $>34$ wks | 3.5 |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 787,
      "preview": "| Normal SpO2 saturations |  |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 788,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 789,
      "preview": "| 1 min | 60-65\\% |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 790,
      "preview": "| 2 min | 65-70\\% |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 791,
      "preview": "| 3 min | 70-75\\% |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 792,
      "preview": "| 4 min | 75-80\\% |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 793,
      "preview": "| 5 min | 80-85\\% |"
    },
    {
      "type": "table",
      "section": "All Deliveries:",
      "line": 794,
      "preview": "| 10 min | 85-95\\% |"
    },
    {
      "type": "text",
      "section": "All Deliveries:",
      "line": 796,
      "preview": "--- page 35 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Respiratory Management of the Preterm Infant",
      "line": 798
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Christine Johnson M.D., Katherine McCallie M.D., and Ronald Cohen M.D.",
      "line": 800
    },
    {
      "type": "text",
      "section": "Christine Johnson M.D., Katherine McCallie M.D., and Ronald Cohen M.D.",
      "line": 802,
      "preview": "The arrival of an extremely preterm infant is a high-intensity event which, to be handled successful"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. The Platinum Hour",
      "line": 804
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 806,
      "preview": "A. SUPPORT Trial: This RCT comparing intubation to CPAP in the DR for babies 24-27 weeks found:"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 808,
      "preview": "1. Required intubation or postnatal corticosteroids for BPD less frequently."
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 809,
      "preview": "2. Required fewer days of mechanical ventilation."
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 810,
      "preview": "3. More likely to be alive and free from need for mechanical ventilation by day 7 ."
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 811,
      "preview": "B. COIN Trial: This RCT also compared CPAP to intubation in DR for babies 25-28 weeks gestation foun"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 812,
      "preview": "4. A trend towards lower BPD rates with the use of early NCPAP (by 5 minutes of life) that was not s"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 813,
      "preview": "5. Subgroup analysis (Germany) with follow up pulmonary function testing at 2 months of age found:"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 814,
      "preview": "a. Fewer days of mechanical ventilation."
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 815,
      "preview": "b. Fewer total respiratory support days."
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 816,
      "preview": "c. Better PFTs: lower RR, lower minute ventilation, better compliance, improved work of breathing."
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 817,
      "preview": "C. AAP Policy Statement on \"Respiratory Support in Preterm Infants at Birth\" from the Committee of F"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 818,
      "preview": "6. The recommendation was: \"Using CPAP immediately after birth with subsequent selective surfactant "
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 819,
      "preview": "D. Platinum Hour Delivery room management of Preterm infants $\\leq 28$ weeks."
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 820,
      "preview": "7. Team composition: The \"Complex\" DR team should be called for infants <28 weeks estimated gestatio"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 821,
      "preview": "a. Neonatal fellow"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 822,
      "preview": "b. NNP and/or NICU hospitalist"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 824,
      "preview": "--- page 36 ---"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 826,
      "preview": "c. NICU nursing team leader"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 827,
      "preview": "d. Repiratory therapist"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 829,
      "preview": "A pre-delivery briefing (with assignment of roles) should occur prior to delivery when possible. For"
    },
    {
      "type": "text",
      "section": "I. The Platinum Hour",
      "line": 830,
      "preview": "2. Temperature regulation: Careful attention should be paid to temperature management (pre-warmed, i"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "3. Respiratory care:",
      "line": 832
    },
    {
      "type": "text",
      "section": "3. Respiratory care:",
      "line": 834,
      "preview": "a. ALL infants $\\leq 29$ 6/7 weeks GA should receive continuous mask CPAP in the delivery room using"
    },
    {
      "type": "text",
      "section": "3. Respiratory care:",
      "line": 835,
      "preview": "b. Intubation should be reserved only for standard NRP indications (e.g. failure to respond to PPV w"
    },
    {
      "type": "text",
      "section": "3. Respiratory care:",
      "line": 836,
      "preview": "c. The oxygen saturation probe should be placed on the infant's right upper extremity (pre-ductal) i"
    },
    {
      "type": "text",
      "section": "3. Respiratory care:",
      "line": 837,
      "preview": "d. The infant should be transported to the NICU immediately following stabilization."
    },
    {
      "type": "text",
      "section": "3. Respiratory care:",
      "line": 839,
      "preview": "--- page 37 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Platinum Hour: Delivery Room \\& Initial NICU Respiratory Management",
      "line": 841
    },
    {
      "type": "image",
      "section": "Platinum Hour: Delivery Room \\& Initial NICU Respiratory Management",
      "line": 843,
      "content": "![img-2.jpeg](images/aa89b94622d7abfb.png)"
    },
    {
      "type": "text",
      "section": "Platinum Hour: Delivery Room \\& Initial NICU Respiratory Management",
      "line": 845,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "Platinum Hour: Delivery Room \\& Initial NICU Respiratory Management",
      "line": 847,
      "preview": "--- page 38 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. NICU Management",
      "line": 849
    },
    {
      "type": "text",
      "section": "II. NICU Management",
      "line": 851,
      "preview": "A. Bedside RN weighs infant and places the monitor leads."
    },
    {
      "type": "text",
      "section": "II. NICU Management",
      "line": 852,
      "preview": "B. RT places the infant on CPAP via nasal prongs or mechanical ventilation if intubated. Care should"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 854
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 856,
      "preview": "1. FiO2 $>40 \\%$ required to maintain $\\mathrm{SpO} 2 \\geq 90 \\%$ for 1 hour"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 857,
      "preview": "2. $\\mathrm{PaCO} 2>60 \\mathrm{~mm} \\mathrm{Hg}$"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 858,
      "preview": "3. Repetitive apnea requiring bag-mask ventilation"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 859,
      "preview": "4. Hemodynamic instability (low blood pressure and/or poor perfusion requiring volume or pressors fo"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 860,
      "preview": "5. Clinical shock"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 861,
      "preview": "D. Initial ventilator settings:"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 863,
      "preview": "PEEP $=4$ to 5"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 864,
      "preview": "PIP limit $=25$"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 865,
      "preview": "I-time $=0.35$ seconds"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 866,
      "preview": "rate $=40$"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 867,
      "preview": "volume guarantee, assist control mode $=4-5$"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 868,
      "preview": "$\\mathrm{ml} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 869,
      "preview": "FiO2 to maintain SpO2 90-95\\%"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 870,
      "preview": "E. Endotracheal tube position is confirmed clinically using:"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 872,
      "preview": "1. Measured depth of 6 cm + infant's weight in kilograms"
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 873,
      "preview": "2. Auscultation of equal breath sounds by two care providers."
    },
    {
      "type": "text",
      "section": "C. Intubation criteria for CPAP infants:",
      "line": 874,
      "preview": "3. Consider use of Sonarmed Airwave device to monitor ETT depth"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Indications for surfactant administration:",
      "line": 876
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 878,
      "preview": "1. Treatment of surfactant deficiency associated with Respiratory Distress Syndrome (RDS) in the pre"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 879,
      "preview": "2. Treatment of surfactant inactivation associated with severe respiratory failure (Meconium aspirat"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 880,
      "preview": "G. Surfactant dosing of Curosurf ${ }^{\\circledR}$ (Poractant Alfa). Porcine derived preparations ar"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 881,
      "preview": "3. Initial dose: $2.5 \\mathrm{ml} / \\mathrm{kg}(200 \\mathrm{mg} / \\mathrm{kg} /$ dose $)$ using birt"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 883,
      "preview": "--- page 39 ---"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 885,
      "preview": "32 Part I-B: Delivery and Admission"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 886,
      "preview": "2. Subsequent (up to 2): $1.25 \\mathrm{ml} / \\mathrm{kg}$ every 12 hours"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 887,
      "preview": "3. In the unstable infant, a test dose of $1 \\mathrm{ml} / \\mathrm{kg}$ may be given to check for to"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 888,
      "preview": "4. Maximum dosing: $5 \\mathrm{ml} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 889,
      "preview": "H. Surfactant therapy is most effective when given within the first 30-60 minutes of life and result"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 891,
      "preview": "1. Intubate"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 892,
      "preview": "2. Instill Curosurf\u00ae $2.5 \\mathrm{ml} / \\mathrm{kg}$ with 5 Fr catheter through suction port of endo"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 893,
      "preview": "3. Give 3 manual breaths with PIP 20 and PEEP 5"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 894,
      "preview": "4. Extubate and place on CPAP with PEEP of 5-7"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 895,
      "preview": "5. If the InSurE method is not used, surfactant can be administered using the traditional method:"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 896,
      "preview": "a. Intubate patient and stabilize on SIMV with volume guarantee of $4.5-5 \\mathrm{ml} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 897,
      "preview": "b. Position patient supine with neutral head position"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 898,
      "preview": "c. Administer Curosurf\u00ae $2.5 \\mathrm{ml} / \\mathrm{kg}$ with 5 Fr catheter through suction port of e"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 899,
      "preview": "d. Avoid suctioning for 1 hour post administration"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 900,
      "preview": "I. When considering surfactant therapy, remember:"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 901,
      "preview": "6. Pulmonary hemorrhage is not a contraindication to surfactant administration. On the contrary, sur"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 902,
      "preview": "7. Infants treated with surfactant may have rapid changes in pulmonary mechanics, specifically, dram"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 903,
      "preview": "J. UAC/UVC placement is performed."
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 904,
      "preview": "K. Chest radiograph and blood gas performed"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 905,
      "preview": "L. Consider HFOV when:"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 906,
      "preview": "8. Unable to ventilate at a rate of 40 and tidal volume of $6 \\mathrm{ml} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 907,
      "preview": "9. Mean airway pressure exceeds 9.5"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 908,
      "preview": "10. Evidence of PIE"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 910,
      "preview": "--- page 40 ---"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 912,
      "preview": "M. Change Agent of Respiratory Care Bundle - CLD reduction. Standardization of non-invasive ventilat"
    },
    {
      "type": "text",
      "section": "F. Indications for surfactant administration:",
      "line": 914,
      "preview": "1. Respiratory Care Preemie Extubation Algorithm- Recommended Guidelines."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Post- Extubation Respiratory Support Guidelines",
      "line": 916
    },
    {
      "type": "text",
      "section": "Post- Extubation Respiratory Support Guidelines",
      "line": 918,
      "preview": "infants $<32^{0 / 7}$ weeks EGA"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "$<1000$ grams",
      "line": 920
    },
    {
      "type": "image",
      "section": "$<1000$ grams",
      "line": 922,
      "content": "![img-3.jpeg](images/d89a1bb8f89ea8c0.png)"
    },
    {
      "type": "text",
      "section": "$<1000$ grams",
      "line": 924,
      "preview": "--- page 41 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 926
    },
    {
      "type": "text",
      "section": "References:",
      "line": 928,
      "preview": "1. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carl"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 929,
      "preview": "2. Marley CJ, Davis PG, Doyle LW, at al, Nasal CPAP or intubation at birth for very preterm infants."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 930,
      "preview": "3. Laptook AR, Salhab W, Bhaskar B., Neonatal Research Network. Admission temperature of low birth w"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 931,
      "preview": "4. Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newb"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 932,
      "preview": "5. Ramanathan R, Bhatia JJ, Sekar K, Ernst FR. Mortality in preterm infants with respiratory distres"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 933,
      "preview": "6. Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory di"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 934,
      "preview": "7. Pandit PB, Dunn MS, Calucci EA, Surfactant therapy in neonates with respiratory deterioration due"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 935,
      "preview": "8. Amizuka T, et al. Surfactant therapy in neonates with respiratory failure due to haemorrhagic pul"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 936,
      "preview": "9. Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 937,
      "preview": "10. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Fin"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 938,
      "preview": "11. Roehr CC, Proquitte H, Hammer H, Wauer RR, Morley CJ, Schmalisch G. Positive effects of early co"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 940,
      "preview": "--- page 42 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "The NEST: Guidelines for the Care of Micropreemies",
      "line": 942
    },
    {
      "type": "text",
      "section": "The NEST: Guidelines for the Care of Micropreemies",
      "line": 944,
      "preview": "Melissa Scala, M.D., Katie Hunt, N.N.P., and Jessica Matei, B.S.N., R.N.C.-N.I.C."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Rationale for the NEST",
      "line": 946
    },
    {
      "type": "text",
      "section": "I. Rationale for the NEST",
      "line": 948,
      "preview": "Survival of infants at the extreme of prematurity has increased over the last few decades but signif"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Patient Considerations",
      "line": 950
    },
    {
      "type": "text",
      "section": "II. Patient Considerations",
      "line": 952,
      "preview": "A. Gestational Age: Infants less than 29 weeks postmenstrual age should be admitted to the NEST and "
    },
    {
      "type": "text",
      "section": "II. Patient Considerations",
      "line": 953,
      "preview": "B. Location: Prior to the NICU expansion, room 4 (beds A-D, I) will be used for the NEST. Bed \"C\" sh"
    },
    {
      "type": "text",
      "section": "II. Patient Considerations",
      "line": 954,
      "preview": "C. Environment: Ambient noise levels should be 45-50 decbles with transient noise not to exceed 65 d"
    },
    {
      "type": "text",
      "section": "II. Patient Considerations",
      "line": 955,
      "preview": "D. Family centered care: Families should be included in all care activities and provided opportuniti"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Medical Management",
      "line": 957
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Delivery and Initial Stabilization",
      "line": 959
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 961,
      "preview": "1. Prior to delivery"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 962,
      "preview": "a. Pre-delivery briefing to discuss roles during resuscitation"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 963,
      "preview": "b. Order vanilla/starter TPN"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 964,
      "preview": "c. Set up lines"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 965,
      "preview": "2. In the delivery room"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 966,
      "preview": "a. Ensure optimal thermoregulation"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 967,
      "preview": "i. Operating room temperature is set to 74 degrees"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 969,
      "preview": "--- page 43 ---"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 971,
      "preview": "ii. Ensure radiant warmer is set to servo-control 37 C"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 972,
      "preview": "iii. Activate chemical warmer and place inside plastic bag"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 973,
      "preview": "iv. Place infant in polyethylene bag (turkey bag) directly, minimal drying"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 974,
      "preview": "v. Place temperature probe onto infant's chest"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 975,
      "preview": "vi. Obtain temperature prior to leaving delivery room"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 976,
      "preview": "b. Respiratory support"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 977,
      "preview": "i. Minimum respiratory support for ALL infants is CPAP $5 \\mathrm{cmH2O}$"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 978,
      "preview": "ii. If intubation is indicated, recommend minimum 2.5ETT for infants > 24 0/7 weeks"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 979,
      "preview": "3. Upon return to NICU"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 980,
      "preview": "a. Admit baby to the Nest (PCU 270 room 4 OR PCU 260 pod)"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 981,
      "preview": "b. Obtain temperature upon arrival to the NICU"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 982,
      "preview": "c. Have developmental supplies ready at the bedside to assist with positioning"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 983,
      "preview": "d. Update parents within 1 hour"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 984,
      "preview": "e. Encourage hand expression of breastmilk within 1 hour of delivery"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 985,
      "preview": "f. Obtain and document assent for use of donor breastmilk"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 986,
      "preview": "B. Early medical management considerations for extremely preterm infants"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 988,
      "preview": "1. Monitoring"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 989,
      "preview": "a. Daily weights using bed scale. While weighing, infant is inside of snggle up, and then the weight"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 990,
      "preview": "b. 2 person approach whenever possible to provide containment; provide supportive positioning"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 991,
      "preview": "c. Q6 hour touch times: coordinate assessments with RN and RT. Refer to laminated clock at bedside."
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 992,
      "preview": "d. Standard lab draw times are 0600 and 1800. Limit draws to these times unless emergent."
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 993,
      "preview": "e. UAC blood draws: withdraw and return blood slowly over 30 seconds"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 994,
      "preview": "2. Nutrition"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 995,
      "preview": "a. Initiate feeding pathway on DOL0 using expressed MBM or DBM"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 996,
      "preview": "b. Abdominal girth on admission and per patient condition"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 997,
      "preview": "c. No routine residual checks, done per patient condition"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 998,
      "preview": "d. Begin TPN on DOL0"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 999,
      "preview": "3. Fluid management/Cardiovascular"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1000,
      "preview": "a. Avoid multiple fluid boluses; low threshold for vasoactive support"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1002,
      "preview": "--- page 44 ---"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1004,
      "preview": "b. BP measured every 3-6 hours, or in the stable patient, every 12; immediately remove cuff"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1005,
      "preview": "c. Eligible infants should have hydrocortisone ordered per PREMILOC protocol"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1006,
      "preview": "4. Respiratory"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1007,
      "preview": "a. Non-invasive support"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1008,
      "preview": "i. CPAP 5-6cmH20"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1009,
      "preview": "ii. Do not escalate to NIPPV mode"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1010,
      "preview": "iii. Consider intubation if FiO2>40\\%, significant respiratory distress, PaCO2 >60, repetitive apnea"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1011,
      "preview": "b. Invasive respiratory support"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1012,
      "preview": "i. Initial conventional ventilator settings"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1013,
      "preview": "a) Assist control, volume guarantee: $4-5 \\mathrm{ml} / \\mathrm{kg}$, max PIP 25"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1014,
      "preview": "b) PEEP 5 cm H2O"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1015,
      "preview": "c) It 0.35 sec , no slope"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1016,
      "preview": "d) Rate 40 (do not wean)"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1017,
      "preview": "e) FiO2 to maintain SpO2 90-95\\%"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1018,
      "preview": "ii. Escalate to HFOV if:"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1019,
      "preview": "a) Peak inspiratory pressures $>20$ on VTs $5 \\mathrm{ml} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1020,
      "preview": "b) $\\mathrm{pCO} 2>60$"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1021,
      "preview": "c) FiO2 $>30 \\%$ on PEEP $\\leq 6$"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1022,
      "preview": "c. Other considerations"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1023,
      "preview": "i. Oral and endotracheal suctioning as needed, not scheduled"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1024,
      "preview": "ii. Review histograms daily with goal $80 \\%$ of saturations within SpO2 target 90-95\\%"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1025,
      "preview": "iii. Consider extubation when:"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1026,
      "preview": "a) FiO2 $<40 \\%$"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1027,
      "preview": "b) Conventional ventilator settings: PIPs $\\leq 16$ on VT 4-5ml/kg, PEEP $\\leq 6$"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1028,
      "preview": "5. Neurologic"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1029,
      "preview": "a. Neuroprotective measures"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1030,
      "preview": "i. Midline head positioning for the first 72 h after birth. Use of log roll when turning infant."
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1031,
      "preview": "ii. Head of bed elevated 30 degrees"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1032,
      "preview": "iii. Placement of NIRS monitor for first 7 days."
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1033,
      "preview": "iv. Placement of aEEG if intraventricular hemorrhage grade 3 or 4 diagnosed"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1035,
      "preview": "--- page 45 ---"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1037,
      "preview": "v. Incubator cover in place"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1038,
      "preview": "vi. Utilize developmental positioning devices"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1039,
      "preview": "b. Pain considerations"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1040,
      "preview": "i. Use NPASS scoring system to assess infant's pain"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1041,
      "preview": "ii. Non-pharmacologic methods should be employed first to calm an infant, such as developmentally-ap"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1042,
      "preview": "iii. When non-pharmacologic measures have been exhausted, morphine should be the first choice. Use o"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1043,
      "preview": "6. Skin considerations"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1044,
      "preview": "a. Humidity"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1045,
      "preview": "i. For infants <26 weeks' gestation, start humidity at $80 \\%$. This may be increased per provider o"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1046,
      "preview": "ii. For infants 26-28 weeks' gestation, start humidity at $75 \\%$."
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1047,
      "preview": "iii. On day 7 , wean humidity to $50 \\%$."
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1048,
      "preview": "iv. On day 14, discontinue humidification."
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1049,
      "preview": "b. Change pulse ox probe site every 6 hours"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1050,
      "preview": "c. NO chlorhexidine on infants <28 weeks, <1000 grams, and <1 week of age"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1051,
      "preview": "i. Use betadine for procedures (alcohol is acceptable for heelsticks)"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1052,
      "preview": "ii. Remove betadine with sterile water and dry with sterile gauze before breaking the skin barrier"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1053,
      "preview": "d. Aquaphor to diaper area, not routinely used elsewhere when infants are in humiditiy"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1054,
      "preview": "e. Use sterile water to remove adhesives"
    },
    {
      "type": "text",
      "section": "A. Delivery and Initial Stabilization",
      "line": 1056,
      "preview": "--- page 46 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Appendix A",
      "line": 1058
    },
    {
      "type": "image",
      "section": "Appendix A",
      "line": 1060,
      "content": "![img-4.jpeg](images/3bad71b6cbbb0d64.png)"
    },
    {
      "type": "text",
      "section": "Appendix A",
      "line": 1062,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "Appendix A",
      "line": 1064,
      "preview": "--- page 47 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Toward Optimally Timed Cord Clamping",
      "line": 1066
    },
    {
      "type": "text",
      "section": "Toward Optimally Timed Cord Clamping",
      "line": 1068,
      "preview": "Brittany Weldon, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 1070
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 1072,
      "preview": "For many years, the standard of care for most deliveries has involved immediate clamping and cutting"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 1074,
      "preview": "At the time of birth, approximately $50 \\%$ of the total feto-placental blood volume is contained wi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Mechanism",
      "line": 1076
    },
    {
      "type": "text",
      "section": "II. Mechanism",
      "line": 1078,
      "preview": "The benefits conferred on both preterm and full term infants likely stems from the increased red blo"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Preterm Infants",
      "line": 1080
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1082,
      "preview": "Multiple prospective trials and reviews have concluded that delaying the clamping and cutting of the"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1083,
      "preview": "A. Decreased risk of IVH"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1085,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1087,
      "preview": "--- page 48 ---"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1089,
      "preview": "B. Decreased need for transfusions for either anemia or hypotension"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1090,
      "preview": "C. Improved hematocrit in the first hours of life"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1091,
      "preview": "D. Possibly improved blood pressure stabilization"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1093,
      "preview": "Of course, no intervention is without risks, and placental transfusion to the newborn through delaye"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1094,
      "preview": "A. Increased peak bilirubin concentrations"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1095,
      "preview": "B. Possibly an increased risk of requiring phototherapy"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1096,
      "preview": "C. Possibly an increased risk of polycythemia, though premature infants have more of a tendency towa"
    },
    {
      "type": "text",
      "section": "III. Preterm Infants",
      "line": 1098,
      "preview": "However, given the substantial benefits and the ease with which we can, and already do, monitor for "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Term Babies",
      "line": 1100
    },
    {
      "type": "text",
      "section": "IV. Term Babies",
      "line": 1102,
      "preview": "Given their fortitude and improved reserves, the benefits of waiting for placento-fetal transfusion "
    },
    {
      "type": "text",
      "section": "IV. Term Babies",
      "line": 1104,
      "preview": "There is still concern for an increased risk of hyperbilirubinemia requiring phototherapy in babies "
    },
    {
      "type": "text",
      "section": "IV. Term Babies",
      "line": 1106,
      "preview": "Importantly, studies of delayed cord clamping in term babies have shown no increased risk to the mot"
    },
    {
      "type": "text",
      "section": "IV. Term Babies",
      "line": 1107,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Term Babies",
      "line": 1109,
      "preview": "--- page 49 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Toward Optimally Timed Cord Clamping",
      "line": 1111
    },
    {
      "type": "text",
      "section": "V. Toward Optimally Timed Cord Clamping",
      "line": 1113,
      "preview": "It is likely that the optimal moment to clamp and cut the umbilical cord is not a specific time from"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Our Practice Protocol",
      "line": 1115
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1117,
      "preview": "The standard of care at LPCH is to wait until about 1 minute following birth in vigorous infants of "
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1118,
      "preview": "A. Babies born apneic and not responding to stimulation"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1119,
      "preview": "B. Major congenital anomalies"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1120,
      "preview": "C. Congenital heart block"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1121,
      "preview": "D. Hydrops"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1122,
      "preview": "E. Abruption"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1123,
      "preview": "F. Placenta acreta"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1124,
      "preview": "G. Hemorrhage"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1125,
      "preview": "H. Any problem that concerns the pediatrician or obstetrician to the point that they feel delaying c"
    },
    {
      "type": "text",
      "section": "VI. Our Practice Protocol",
      "line": 1126,
      "preview": "I. Parental request, including for umbilical cord blood banking"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. PROCEDURE FOR OPTIMALLY TIMED CORD CLAMPING",
      "line": 1128
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Vaginal Deliveries",
      "line": 1130
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1132,
      "preview": "1. Delivered by OB"
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1133,
      "preview": "2. Baby may be placed on the abdomen for care by the pediatrician or RN, or may be held by the OB at"
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1134,
      "preview": "3. Pitocin is administered with delivery of the baby, per obstetrician's discretion."
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1135,
      "preview": "4. Caregiver will stimulate the baby to induce crying, causing expansion of the pulmonary vascular b"
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1136,
      "preview": "5. Pediatric team to announce when 60 seconds has passed, the cord is clamped and cut, and care proc"
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1138,
      "preview": "--- page 50 ---"
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1140,
      "preview": "1. Delivered by OB and placed in a convenient location as the umbilical cord and surgical field will"
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1141,
      "preview": "2. Pitocin is administered with delivery of the baby, per obstetrician's discretion."
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1142,
      "preview": "3. Stimulation to be provided by the OB or the pediatrician at the table to induce crying, causing e"
    },
    {
      "type": "text",
      "section": "A. Vaginal Deliveries",
      "line": 1143,
      "preview": "4. Pediatric team to announce when 60 seconds has passed, the cord is clamped and cut, and the baby "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 1145
    },
    {
      "type": "text",
      "section": "References",
      "line": 1147,
      "preview": "1. Andersson O, et al. \"Effect of Delayed Cord Clamping on Neurodevelopment at 4 Years of Age: A Ran"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1148,
      "preview": "2. Farrar D, et al. \"Measuring placental transfusion for term births: weighing babies with cord inta"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1149,
      "preview": "3. Yao A, Moinian M, Lind J; \"Distribution of Blood Between Infant and Placenta After Birth,\" Lancet"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1150,
      "preview": "4. Ultee CA, van der Deure J, Swart J, Lasham C, van Baar AL. Delayed cord clamping in preterm infan"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1151,
      "preview": "5. Oh W, Fanaroff AA, Carlo WA, Donovan EF, McDonald SA, Poole WK. Effects of delayed cord clamping "
    },
    {
      "type": "text",
      "section": "References",
      "line": 1152,
      "preview": "6. Baenzinger O, Stolkin F, Keel M, von Siebenthal K, Fauchere JC, Kundu SD, Dietz V, Bucher HU, Wol"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1153,
      "preview": "7. Aladangady N, et al. Infants' Blood Volume in a Controlled Trial of Placental Transfusion at Pret"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1154,
      "preview": "8. Rabe H, et al. Early versus delayed umbilical cord clamping in preterm infants (Review). The Coch"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1155,
      "preview": "9. Rabe H, et al. A Systematic Review and Meta-Analysis of a Brief Delay in Clamping the Umbilical C"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1156,
      "preview": "10. Kugelman A, Borenstein-Levin L, Riskin A, Chistyakov I, Ohel G, Gonen R, and Bader D. Immediate "
    },
    {
      "type": "text",
      "section": "References",
      "line": 1158,
      "preview": "--- page 51 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Non-Immune Fetal Hydrops",
      "line": 1160
    },
    {
      "type": "text",
      "section": "Non-Immune Fetal Hydrops",
      "line": 1162,
      "preview": "Anna-Kaisa Niemi M.D., Ph.D., Janene Fuerch M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 1164
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 1166,
      "preview": "Fetal hydrops (hydrops fetalis) is defined as abnormal fluid accumulation in at least two different "
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 1168,
      "preview": "The incidence of fetal hydrops is $\\sim 3$ in 10,000 live births but overall incidence is much highe"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 1170,
      "preview": "Factors that have been reported to be associated with high mortality include younger gestational age"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 1172,
      "preview": "Because pleural and pericardial effusions impair breathing and cardiac function, and because deliver"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1174
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1176,
      "preview": "A. The etiology of NIFH is multifactorial. There is variation in the frequency of etiologies on depe"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1177,
      "preview": "B. Overall frequencies of etiology from recent and/or large reports/reviews 1-7 are as follows:"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1179,
      "preview": "1. Cardiovascular (10-20\\%)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1180,
      "preview": "a. Structural cardiac anomalies"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1181,
      "preview": "b. Cardiac arrhythmia (fetal SVT, fetal bradyarrhythmia)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1182,
      "preview": "2. Chromosomal/syndromic (15-70\\%)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1183,
      "preview": "a. Turner, trisomies, chromosomal deletions/duplications"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1184,
      "preview": "3. Idiopathic ( $17 \\%$ )"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1185,
      "preview": "4. Hematological $(7-10 \\%)$"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1187,
      "preview": "--- page 52 ---"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1189,
      "preview": "a. Thalassemias (parental testing by OB), other hemoglobinopathies"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1190,
      "preview": "b. G6PD deficiency or other red blood cell disorders"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1191,
      "preview": "5. Infectious (4-15\\%)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1193,
      "preview": "Often associated with findings on US such as intracranial calcifications, hepatomegaly, splenomegaly"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1194,
      "preview": "a. Parvovirus B19 most frequent (fetal anemia)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1195,
      "preview": "b. Other: toxoplasmosis, CMV, varicella, syphilis, rubella"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1196,
      "preview": "6. Thoracic malformations and other structural fetal anomalies (6\\%)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1197,
      "preview": "a. Congenital pulmonary airway malformation (CPAM)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1198,
      "preview": "b. Congenital chylothorax"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1199,
      "preview": "7. Placental disorders (5\\%)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1200,
      "preview": "a. Twin-to-twin transfusion"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1201,
      "preview": "b. Placental hemangioma/anomalies"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1202,
      "preview": "8. Inborn errors of metabolism (1-2\\%)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1203,
      "preview": "a. Gaucher disease, mucopolysaccharidosis type VII, infantile galactosialidosis, some glycogen stora"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1204,
      "preview": "9. Gastrointestinal (1\\%)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1205,
      "preview": "a. CDH"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1206,
      "preview": "b. Gastrointestinal obstruction"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1207,
      "preview": "c. Meconium peritonitis"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1208,
      "preview": "10. Urinary structural anomalies (rare)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1209,
      "preview": "a. Ruptured bladder"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1210,
      "preview": "b. Congenital nephrotic syndrome"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1211,
      "preview": "11. Fetal tumors (rare)"
    },
    {
      "type": "text",
      "section": "II. Etiology of non-immune fetal hydrops (NIFH):",
      "line": 1212,
      "preview": "12. Skeletal dysplasias (rare)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Diagnostic evaluation",
      "line": 1214
    },
    {
      "type": "text",
      "section": "III. Diagnostic evaluation",
      "line": 1216,
      "preview": "A. Diagnosing or ruling out a genetic cause for NIFH is important because there is a risk of recurre"
    },
    {
      "type": "text",
      "section": "III. Diagnostic evaluation",
      "line": 1218,
      "preview": "--- page 53 ---"
    },
    {
      "type": "text",
      "section": "III. Diagnostic evaluation",
      "line": 1220,
      "preview": "(or dies shortly thereafter), giving minimal time for obtaining consultations."
    },
    {
      "type": "text",
      "section": "III. Diagnostic evaluation",
      "line": 1221,
      "preview": "B. Before delivery the obstetrician may have done detailed anatomy including US, fetal ECHO, Doppler"
    },
    {
      "type": "text",
      "section": "III. Diagnostic evaluation",
      "line": 1222,
      "preview": "C. The following examinations are recommended should the infant die soon after birth:"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "1. Echocardiogram",
      "line": 1224
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Chest XR",
      "line": 1226
    },
    {
      "type": "heading",
      "level": 2,
      "section": "3. Abdominal US",
      "line": 1228
    },
    {
      "type": "heading",
      "level": 2,
      "section": "4. Head US",
      "line": 1230
    },
    {
      "type": "text",
      "section": "4. Head US",
      "line": 1232,
      "preview": "5. CGH to Stanford Cytogenetics: 1-3ml of blood in a green-topped sodium heparinized tube. If the in"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "6. Placental pathology (OB)",
      "line": 1234
    },
    {
      "type": "heading",
      "level": 2,
      "section": "7. Autopsy",
      "line": 1236
    },
    {
      "type": "text",
      "section": "7. Autopsy",
      "line": 1238,
      "preview": "a. Skeletal survey (can be done at autopsy)"
    },
    {
      "type": "text",
      "section": "7. Autopsy",
      "line": 1239,
      "preview": "b. Photos (can be done at autopsy)"
    },
    {
      "type": "text",
      "section": "7. Autopsy",
      "line": 1240,
      "preview": "8. Skin biopsy for fibroblast culture ( $\\sim 3 \\times 3 \\mathrm{~mm}$ piece / punch biopsy, send in"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "9. Consider:",
      "line": 1242
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1244,
      "preview": "a. Aspiration of pleural fluid for cytology, protein, albumin"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1245,
      "preview": "b. CBC, transaminases, liver function tests, CK"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1246,
      "preview": "c. Hemoglobin electrophoresis (for thalassemias if fetal anemia, depending on ethnicity)"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1247,
      "preview": "10. Family history especially with regards to: ethnic background, consanguinity, fetal loss, death i"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1248,
      "preview": "D. If infant survives the following are recommended:"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1250,
      "preview": "1. Above imaging tests on all infants with fetal hydrops"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1251,
      "preview": "2. Other tests depending on initial physical/imaging/laboratory findings."
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1252,
      "preview": "3. Medical Genetics consultation: recommended in all cases of fetal hydrops, unless cause known and"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1254,
      "preview": "--- page 54 ---"
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1256,
      "preview": "non- genetic, to help in ordering the most appropriate genetic testing (karyotype, CGH, gene panel, "
    },
    {
      "type": "text",
      "section": "9. Consider:",
      "line": 1257,
      "preview": "4. Other consultations: as needed depending on physical exam and imaging findings."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Initial management of a newborn with fetal hydrops in the delivery room",
      "line": 1259
    },
    {
      "type": "text",
      "section": "IV. Initial management of a newborn with fetal hydrops in the delivery room",
      "line": 1261,
      "preview": "A. Each infant with hydrops will require different procedures and the following list must be altered"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Potential Procedures:",
      "line": 1263
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1265,
      "preview": "1. Intubation: Establishment of ventilation is a priority and prompt intubation is often necessary. "
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1266,
      "preview": "a. 4 uncuffed ETTs ( 2 - for expected gestational age; 2 - one size smaller)"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1267,
      "preview": "b. Other standard intubation supplies"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1268,
      "preview": "c. Optional: stylet for ETT"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1269,
      "preview": "d. Anesthesia bag"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1270,
      "preview": "2. Thoracentesis / Paracentesis: Discuss sequence of planned fluid removal prior to delivery (i.e. t"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1271,
      "preview": "a. 16 or 18 gauge angiocaths (6) - [NICU supply room or anesthesia cart]"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1272,
      "preview": "b. Stopcocks (4) - [NICU supply room]"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1273,
      "preview": "c. Tubing (connect stopcocks \\& syringes) - [NICU supply room]"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1274,
      "preview": "d. 20 mL syringes (multiple)"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1275,
      "preview": "e. Argyle chest tubes (2)"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1276,
      "preview": "f. Scalpel \\& Kelly clamp - [NICU supply room]"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1277,
      "preview": "3. Pericardiocentesis: Alert Cardiology to the need for a stat ECHO for cardiac function and evaluat"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1278,
      "preview": "4. Umbilical venous catheter (UVC) emergency line placement for code medication administration"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1279,
      "preview": "a. Umbilical Line Kit"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1280,
      "preview": "b. 5 Fr single lumen catheter"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1281,
      "preview": "c. 3.5 Fr single lumen catheter"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1282,
      "preview": "d. O neg pRBCs $\\rightarrow$ Draw up 3-4, 20mL syringes from blood bank or dry pack in CVICU/NICU"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1284,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1286,
      "preview": "--- page 55 ---"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1288,
      "preview": "e. Sterile NS syringes (multiple) - flush line and bolus as needed for volume"
    },
    {
      "type": "text",
      "section": "B. Potential Procedures:",
      "line": 1289,
      "preview": "f. Sterile gown and gloves for provider"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Additional Supplies:",
      "line": 1291
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Monitoring:",
      "line": 1293
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1295,
      "preview": "a. SpO2 probe"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1296,
      "preview": "b. EKG leads and portable CR monitor"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1297,
      "preview": "i. Alcohol swabs to clean skin prior to attaching EKG leads"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1298,
      "preview": "2. Medications: Consider calling pharmacy to be present in the DR."
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1299,
      "preview": "a. 1 mg in 10 mL Epinephrine (formerly labeled 1:10,000 solution) - Multiple ETT and IV doses"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1300,
      "preview": "b. Calcium chloride"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1301,
      "preview": "c. Sterile NS syringes"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1302,
      "preview": "d. Preorder UVC/UAC fluids, dopamine - Prepare on pumps in NICU"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1303,
      "preview": "D. Personnel/Roles: Assign roles prior to delivery and perform a pre-briefing in the delivery room."
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1305,
      "preview": "1. Leader (Neonatology Fellow or Attending)"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1306,
      "preview": "2. Intubation"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1307,
      "preview": "3. Bag mask ventilation (RT)"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1308,
      "preview": "4. Chest compressions (2)"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1309,
      "preview": "5. UVC placementThoracentesis (1-2)"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1310,
      "preview": "6. Paracentesis (1-2)"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1311,
      "preview": "7. Nurses $\\times 2$"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1312,
      "preview": "a. Attach monitors"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1313,
      "preview": "b. Prepare suction"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1314,
      "preview": "c. Prepare medication / packed red blood cells (pRBCs)"
    },
    {
      "type": "text",
      "section": "1. Monitoring:",
      "line": 1315,
      "preview": "d. Recorder"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Special Considerations:",
      "line": 1317
    },
    {
      "type": "text",
      "section": "E. Special Considerations:",
      "line": 1319,
      "preview": "1. Perform prenatal consult - Discuss potential procedures \\& morbidity/mortality"
    },
    {
      "type": "text",
      "section": "E. Special Considerations:",
      "line": 1321,
      "preview": "--- page 56 ---"
    },
    {
      "type": "text",
      "section": "E. Special Considerations:",
      "line": 1323,
      "preview": "2. Alert on call Neonatology attending for impending delivery."
    },
    {
      "type": "text",
      "section": "E. Special Considerations:",
      "line": 1324,
      "preview": "3. Estimate true weight to be LESS than hydropic weight. (e.g. -2.5 kg EFW - use 2 kg as actual weig"
    },
    {
      "type": "text",
      "section": "E. Special Considerations:",
      "line": 1325,
      "preview": "4. Increased pressures may be required to ensure appropriate ventilation. Use anesthesia bag in deli"
    },
    {
      "type": "text",
      "section": "E. Special Considerations:",
      "line": 1326,
      "preview": "5. Once intubated if there is a large pleural effusion and fluid removal is sluggish, consider using"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 1328
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1330,
      "preview": "1. Bellini C, Hennekam RC, Bonioli E. A diagnostic flow chart for non-immune hydrops fetalis. Am J M"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1331,
      "preview": "2. Bellini C, Hennekam RC, Fulcheri E, et al. Etiology of nonimmune hydrops fetalis: a systematic re"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1332,
      "preview": "3. D\u00e9silets V, Audibert F; Society of Obstetrician and Gynaecologists of Canada. Investigation and m"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1333,
      "preview": "4. Fukushima K, Morokuma S, Fujita Y, et al. Short-term and long-term outcomes of 214 cases of nonim"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1334,
      "preview": "5. Society for Maternal-Fetal Medicine (SMFM), Norton ME, Chauhan SP, Dashe JS. Society for Maternal"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1335,
      "preview": "6. Takci S, Gharibzadeh M, Yurdakok M, et al. Etiology and outcome of hydrops fetalis: report of 62 "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1336,
      "preview": "7. Watanabe N, Hosono T, Chiba Y et al. Outcomes of infants with nonimmune hydrops fetalis born afte"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1337,
      "preview": "8. Murphy JH. Nonimmune Hydrops Fetalis. NeoReviews. 2004 Jan;5(1):e5-14."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 1339,
      "preview": "--- page 57 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Complex Coordinated Deliveries",
      "line": 1341
    },
    {
      "type": "text",
      "section": "Complex Coordinated Deliveries",
      "line": 1343,
      "preview": "Beth Fluharty, N.N.P., Valerie Chock, MD., M.S. Epi, Alexis Davis, M.D., M.S. Epi, Susan Hintz, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. What are Complex Deliveries?",
      "line": 1345
    },
    {
      "type": "text",
      "section": "I. What are Complex Deliveries?",
      "line": 1347,
      "preview": "The Fetal and Pregnancy Health Program is a multidisciplinary program for the management of complex "
    },
    {
      "type": "text",
      "section": "I. What are Complex Deliveries?",
      "line": 1349,
      "preview": "The Fetal and Pregnancy Health team drafts a full case description and delivery checklist specific t"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Types of Complex Deliveries",
      "line": 1351
    },
    {
      "type": "text",
      "section": "II. Types of Complex Deliveries",
      "line": 1353,
      "preview": "1. EXIT procedure (Ex-Utero Intrapartum Treatment) is delivery and management of the fetus while sti"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Basic Steps",
      "line": 1355
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1357,
      "preview": "a. Mother is placed under general anesthesia."
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1358,
      "preview": "b. MFM performs a hysterotomy with careful control of bleeding."
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1359,
      "preview": "c. Pediatric Surgery and MFM teams deliver head and shoulders."
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1360,
      "preview": "d. Pediatric Anesthesiology places a pulse oximeter on fetus and administers sedation (e.g., IM fent"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1361,
      "preview": "e. In most cases, ENT or Pediatric Anesthesia will perform direct laryngoscopy and attempt intubatio"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1362,
      "preview": "f. If breath sounds are auscultated and intubation is considered successful, the umbilical cord will"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1363,
      "preview": "g. If unsuccessful, intubation with rigid bronchoscopy will be performed. If intubation cannot be ac"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1365,
      "preview": "--- page 58 ---"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1367,
      "preview": "h. In fetal cases with classic features of severe Congenital High Airway Obstruction (CHAOS), intuba"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1368,
      "preview": "i. In some clinical scenarios, such as cystic hygroma, cannulation for ECMO may be performed if trac"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1369,
      "preview": "2. Indication: Severe congenital airway anomalies including cystic hygroma, laryngeal/tracheal atres"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1370,
      "preview": "2. Side-by-Side OR is when a delivery is planned in the main LPCH OR with a separate OR on standby f"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1372,
      "preview": "1. Indication: Large bronchopulmonary malformations, which may impede the ability to adequately vent"
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1373,
      "preview": "2. OR to Cath lab is when the cath lab is on hold at the time of the scheduled delivery. Cardiology "
    },
    {
      "type": "text",
      "section": "1. Basic Steps",
      "line": 1374,
      "preview": "3. Indication: Severe Cardiac deliveries including HLHS with intact or restrictive atrial septum"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1376
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1378,
      "preview": "1. Always involved"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1379,
      "preview": "2. Maternal-Fetal Medicine (MFM)"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1380,
      "preview": "3. OB Anesthesiology"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1381,
      "preview": "4. Neonatology"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1382,
      "preview": "5. Pediatric anesthesiology"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1383,
      "preview": "6. Depending on the fetal diagnosis:"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1384,
      "preview": "7. Pediatric Surgery"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1385,
      "preview": "8. Pediatric Otolaryngology"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1386,
      "preview": "9. Pediatric Cardiology:"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1387,
      "preview": "a. Echocardiogram specialist"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1388,
      "preview": "b. Electrophysiology specialist"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1389,
      "preview": "c. Interventional cath specialist"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1391,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1393,
      "preview": "--- page 59 ---"
    },
    {
      "type": "text",
      "section": "III. Teams Involved in Complex Deliveries:",
      "line": 1395,
      "preview": "d. Pediatric Cardiovascular Surgery"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1397
    },
    {
      "type": "text",
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1399,
      "preview": "NOTE: The on-service Fellow should notify the following team members in advance so that appropriate "
    },
    {
      "type": "text",
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1401,
      "preview": "1. Attending: present and ready to direct and assist resuscitation efforts."
    },
    {
      "type": "text",
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1402,
      "preview": "2. Fellow: scrubbed for infant hand-off and assistance with resuscitation."
    },
    {
      "type": "text",
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1403,
      "preview": "3. Nurse Practitioner (1-2): assists with resuscitation and possible line placement."
    },
    {
      "type": "text",
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1404,
      "preview": "4. NICU RN: 2 RNs to assist with resuscitation, administer meds, and complete documentation."
    },
    {
      "type": "text",
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1405,
      "preview": "5. Respiratory Therapist: assists with ventilation."
    },
    {
      "type": "text",
      "section": "IV. Neonatology Personnel and Responsibilities",
      "line": 1406,
      "preview": "6. Pharmacist: assists with medication needs (may be immediately outside OR)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Equipment Checklist",
      "line": 1408
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. For use in L\\&D DR:",
      "line": 1410
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1412,
      "preview": "1. Transport hot bed with full oxygen tanks"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1413,
      "preview": "2. Intubation box/Neonatal Code Cart on standby"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1414,
      "preview": "3. Umbilical lines, set up and flushed with saline"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1415,
      "preview": "4. NS boluses (drawn up) - Six 30 ml syringes"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1416,
      "preview": "5. O2 sat monitors $\\times 2$ (pre- and post-ductal) in DR and for transport"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1417,
      "preview": "6. End-tidal CO2 detector"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1418,
      "preview": "7. Transport CR monitor"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1419,
      "preview": "8. Appropriate RT equipment for hand ventilation and/or appropriate ventilator"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1420,
      "preview": "9. Chemical warmers (for transport)"
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1421,
      "preview": "10. Syringes, tubing, IV supplies, O2 sat probes, etc."
    },
    {
      "type": "text",
      "section": "A. For use in L\\&D DR:",
      "line": 1422,
      "preview": "11. A crystalloid-primed ECMO circuit with appropriate cannulae may be set up outside the DR in cert"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. For use in OR/CVICU/NICU/Cath lab:",
      "line": 1424
    },
    {
      "type": "text",
      "section": "B. For use in OR/CVICU/NICU/Cath lab:",
      "line": 1426,
      "preview": "1. Additional umbilical lines, line tray, flush for UAC, UVC placement"
    },
    {
      "type": "text",
      "section": "B. For use in OR/CVICU/NICU/Cath lab:",
      "line": 1428,
      "preview": "--- page 60 ---"
    },
    {
      "type": "text",
      "section": "B. For use in OR/CVICU/NICU/Cath lab:",
      "line": 1430,
      "preview": "2. I-stat machine and cassettes"
    },
    {
      "type": "text",
      "section": "B. For use in OR/CVICU/NICU/Cath lab:",
      "line": 1431,
      "preview": "3. Glucose scan equipment"
    },
    {
      "type": "text",
      "section": "B. For use in OR/CVICU/NICU/Cath lab:",
      "line": 1432,
      "preview": "4. Newborn screen card $\\times 2$ (one at admit, another at 24 hours)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1434
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1436,
      "preview": "1. D10 W in bag (to correct hypoglycemia)"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1437,
      "preview": "2. Dopamine drip in syringe"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1438,
      "preview": "3. Epinephrine drip in syringe"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1439,
      "preview": "4. PGE drip in syringe (if ductal-dependent lesion prenatally diagnosed, e.g. HLHS)"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1440,
      "preview": "5. D10 W $+1 / 2$ unit/ml heparin for UVC in syringe with syringe pump"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1441,
      "preview": "6. $1 / 2 \\mathrm{NS}+1 / 2$ unit $/ \\mathrm{ml}$ heparin for UAC in a syringe with syringe pump"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1442,
      "preview": "7. Pharmacy to prepare:"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1443,
      "preview": "a. Code meds $\\times 3$ rounds, calcium chloride"
    },
    {
      "type": "text",
      "section": "C. MEDICATIONS/DRIPS",
      "line": 1444,
      "preview": "b. Morphine and/or Fentanyl, vecuronium $\\times 3$ doses"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. BLOOD PRODUCTS",
      "line": 1446
    },
    {
      "type": "text",
      "section": "D. BLOOD PRODUCTS",
      "line": 1448,
      "preview": "Notify transfusion service prior to Delivery (preferably 1 day lead time)"
    },
    {
      "type": "text",
      "section": "D. BLOOD PRODUCTS",
      "line": 1450,
      "preview": "1. Order 1 unit fresh PRBCs ( $<7$ days old) to be on hand in the OR during the procedure plus one-h"
    },
    {
      "type": "text",
      "section": "D. BLOOD PRODUCTS",
      "line": 1451,
      "preview": "2. Notify Transfusion Service that an O-negative/uncrossed matched ECMO set-up may be emergently req"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "REFERENCES:",
      "line": 1453
    },
    {
      "type": "text",
      "section": "REFERENCES:",
      "line": 1455,
      "preview": "1. Liechty KW. Ex-utero intrapartum therapy. Semin Fetal Neonatal Med. 2010; 15(1): 34-9."
    },
    {
      "type": "text",
      "section": "REFERENCES:",
      "line": 1456,
      "preview": "2. Olutoye. Exit procedure for fetal neck masses. Curr Opin Pediatr 2012; 24: 386-93."
    },
    {
      "type": "text",
      "section": "REFERENCES:",
      "line": 1457,
      "preview": "3. Donofrio MT et al. Specialized delivery room planning for fetuses with critical congenital heart "
    },
    {
      "type": "text",
      "section": "REFERENCES:",
      "line": 1459,
      "preview": "--- page 61 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "When to Notify an Attending in the NICU",
      "line": 1461
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Alexis Davis, M.D., M.S.Epi",
      "line": 1463
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1465
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1467,
      "preview": "A. All new critically ill infants: CPAP, vent, pressors, suspected seizures, or neonatal encephalopa"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1468,
      "preview": "B. All admits <34 weeks' gestational age"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1469,
      "preview": "C. Whenever census $>35$ (or short on RNs) - all admits"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1470,
      "preview": "D. If census $<35$, if $>2$ admits"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1471,
      "preview": "E. Prior to engaging a new consulting service"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1472,
      "preview": "F. Significant change in patient status including, but not limited to:"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1474,
      "preview": "1. Considering starting iNO; Change to HFOV"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1475,
      "preview": "2. Pneumothorax requiring possible intervention (or s/p intervention, if done emergently)"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1476,
      "preview": "3. Initiation of new vasoactive medication (e.g., dopamine, PGE)"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1477,
      "preview": "4. Any neonatal code"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1478,
      "preview": "5. New onset seizures"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1479,
      "preview": "6. NEC work up that includes KUB"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1480,
      "preview": "7. Possible need for exchange transfusion"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1481,
      "preview": "8. Patient expiration"
    },
    {
      "type": "text",
      "section": "I. Conditions Requiring Notification of Attending",
      "line": 1482,
      "preview": "G. Any time such notification is requested by the Charge Nurse, ANM or Nurse Manager"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1484
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1486,
      "preview": "A. New patients $\\leq 28$ weeks' gestational age"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1487,
      "preview": "B. New patients with complex congenital heart disease and requiring:"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1489,
      "preview": "1. ventilation"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1490,
      "preview": "2. pressors (except prenatal diagnosis requiring PGE)"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1491,
      "preview": "3. intervention anticipated within 24 hours OR"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1492,
      "preview": "4. prenatally-diagnosed CHD where clinical presentation different than expected"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1493,
      "preview": "C. Any infant being considered for hypothermia"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1495,
      "preview": "--- page 62 ---"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1497,
      "preview": "D. Congenital diaphragmatic hernia"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1498,
      "preview": "E. New patients with congenital anomalies that are likely to require immediate surgical intervention"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1499,
      "preview": "F. Any patients with anomalies or injuries so severe that there will be new consideration of limitin"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1500,
      "preview": "G. Hyperammonemia or severe metabolic disease"
    },
    {
      "type": "text",
      "section": "II. Conditions Requiring the Presence of the Attending Neonatologist",
      "line": 1501,
      "preview": "H. Any time such presence is requested by any of the inpatient team or nursing staff"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1503
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1505,
      "preview": "A. Clinical management concerns"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1507,
      "preview": "1. In-house NNPs and physicians"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1508,
      "preview": "2. Attending Neonatologist"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1509,
      "preview": "3. Medical Director, Dr. Alexis Davis; when Dr. Davis is out of town or unavailable, at least one ot"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1510,
      "preview": "i. Dr. Bill Rhine"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1511,
      "preview": "ii. Dr. Bill Benitz"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1512,
      "preview": "iii. Dr. David Stevenson"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1513,
      "preview": "4. LPCH Vice President of Medical Affairs (Dr. Christy Sandborg)"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1514,
      "preview": "B. NICU Staffing Concerns (DIVERT protocol)"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1515,
      "preview": "5. On call neonatologist should review ability to transfer infants to ICN, PICU, Sequoia, and other "
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1516,
      "preview": "6. Resource nurse should notify the nurse manager and/or nursing supervisor on call to review:"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1517,
      "preview": "i. Staffing assignments"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1518,
      "preview": "ii. Options to call in additional staff on short notice"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1519,
      "preview": "iii. Option to obtain staff from float pool"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1520,
      "preview": "iv. Other available nursing leadership to include in staffing count"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1521,
      "preview": "7. If these options have been exhausted, the Director of the Johnson Center (Sheryl Goldstein), the "
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1522,
      "preview": "8. Once all alternatives have been exhausted, the attending neonatologist should notify the senior p"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1524,
      "preview": "--- page 63 ---"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1526,
      "preview": "56 Part I-B: Delivery and Admission"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1527,
      "preview": "Reference:"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1528,
      "preview": "LPCH Policy: \"Perinatal/Neonatal Line of Authority\" approved February 2015"
    },
    {
      "type": "text",
      "section": "III. Medical and Hospital Chains of Command",
      "line": 1530,
      "preview": "--- page 64 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part I-C: Discharging and Transferring Patients",
      "line": 1532
    },
    {
      "type": "text",
      "section": "Part I-C: Discharging and Transferring Patients",
      "line": 1534,
      "preview": "--- page 65 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1536
    },
    {
      "type": "text",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1538,
      "preview": "Arun Gupta, M.D., and Ronald S. Cohen, M.D."
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1540,
      "preview": "| ICN-Red Team Preference (Neonatology) | Consideration | ICN-Blue Team Preference (Hospitalist) |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1541,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1542,
      "preview": "| $>2$ weeks | Projected LOS | $<2$ weeks |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1543,
      "preview": "| Complex | On-going w/u | Straight-forward |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1544,
      "preview": "| $\\leq 4$ Consultants | Consulting services | $<2$ consultants |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1545,
      "preview": "| Any | Gestational age | $>32$ wk |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1546,
      "preview": "| Moderate | Apnea/brady/desat | Mild |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1547,
      "preview": "| If long stay/complex | Initially from ICN Blue Team | Preferred |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1548,
      "preview": "| Preferred | Initially from other hospital | OK if short stay |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1549,
      "preview": "| OK | G-Tube/stoma/trach | Avoid |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1550,
      "preview": "| Progressing on pathway | Birth Wt <1000 gm | No |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1551,
      "preview": "| Tolerating initial enteral intake | Birth Wt 1000-1500 gm | Avoid |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1552,
      "preview": "| Preferred | ROP follow-up | Avoid |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1553,
      "preview": "| OK | Neonatal abstinence syndrome | OK |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1554,
      "preview": "| Long-course [PICC per NICU] | TPN/PPN | Short-course |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1555,
      "preview": "| Multiple/complex | Anomalies | Minor |"
    },
    {
      "type": "table",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1556,
      "preview": "| $>24-\\mathrm{hr} ; \\mathrm{ncO} \\leq 0.5 \\mathrm{Lpm}$ | Extubation/off CPAP/HFNC | $>24-\\mathrm{h"
    },
    {
      "type": "text",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1558,
      "preview": "These are guidelines, meant to help place patients where care can be optimized. Clinical judgment sh"
    },
    {
      "type": "text",
      "section": "Packard Nursery Transfer Guidelines",
      "line": 1560,
      "preview": "--- page 66 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Process for Basic and Complex Discharges",
      "line": 1562
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Audrey Moore, NP",
      "line": 1564
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Discharge Checklist",
      "line": 1566
    },
    {
      "type": "text",
      "section": "I. Discharge Checklist",
      "line": 1568,
      "preview": "Designed for those patient that will be hospitalized for $>2$ weeks. Open a new note and choose \"Pro"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Health Care Maintenance",
      "line": 1570
    },
    {
      "type": "text",
      "section": "II. Health Care Maintenance",
      "line": 1572,
      "preview": "When writing the first progress note on a patient, include the. HCM dot phrase at the bottom of the "
    },
    {
      "type": "text",
      "section": "II. Health Care Maintenance",
      "line": 1574,
      "preview": "As you consult services please make a note of them there and as the baby gets closer to discharge it"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Identification of the patient's PCP (at minimum 7 days before the target discharge date)",
      "line": 1576
    },
    {
      "type": "text",
      "section": "III. Identification of the patient's PCP (at minimum 7 days before the target discharge date)",
      "line": 1578,
      "preview": "A. When your patient's status changes from level 3 (critical care) to level 2 (intensive care), the "
    },
    {
      "type": "text",
      "section": "III. Identification of the patient's PCP (at minimum 7 days before the target discharge date)",
      "line": 1579,
      "preview": "B. Once the PCP is identified, that information can be input into EPIC under \"treatment team\""
    },
    {
      "type": "text",
      "section": "III. Identification of the patient's PCP (at minimum 7 days before the target discharge date)",
      "line": 1580,
      "preview": "C. The patient's parents should make the PCP appointment for 1-2 days post discharge, and let the te"
    },
    {
      "type": "text",
      "section": "III. Identification of the patient's PCP (at minimum 7 days before the target discharge date)",
      "line": 1581,
      "preview": "D. For the Gardner Clinic: Use the following link to identify Gardner Health Centers in Santa Clara "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. The Complex Primary Care Clinic (CPCC)",
      "line": 1583
    },
    {
      "type": "text",
      "section": "IV. The Complex Primary Care Clinic (CPCC)",
      "line": 1585,
      "preview": "Consideration for the CPCC should be discussed in rounds and, if possible, during multidisciplinary "
    },
    {
      "type": "text",
      "section": "IV. The Complex Primary Care Clinic (CPCC)",
      "line": 1586,
      "preview": "A. Followed by $\\geq .3$ pediatric or surgical specialists"
    },
    {
      "type": "text",
      "section": "IV. The Complex Primary Care Clinic (CPCC)",
      "line": 1587,
      "preview": "B. Children who are technology dependent"
    },
    {
      "type": "text",
      "section": "IV. The Complex Primary Care Clinic (CPCC)",
      "line": 1588,
      "preview": "C. Have frequent or prolonged hospitalization"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Consultant follow up appointments at LPCH",
      "line": 1590
    },
    {
      "type": "text",
      "section": "V. Consultant follow up appointments at LPCH",
      "line": 1592,
      "preview": "A. Identify and order outpatient follow up appointments in EPIC 1- 2 weeks prior to discharge. For a"
    },
    {
      "type": "text",
      "section": "V. Consultant follow up appointments at LPCH",
      "line": 1593,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Consultant follow up appointments at LPCH",
      "line": 1595,
      "preview": "--- page 67 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Audiology and Hearing Screening",
      "line": 1597
    },
    {
      "type": "text",
      "section": "B. Audiology and Hearing Screening",
      "line": 1599,
      "preview": "1. All patients born at LPCH must have a hearing screen prior to discharge."
    },
    {
      "type": "text",
      "section": "B. Audiology and Hearing Screening",
      "line": 1600,
      "preview": "2. Patients admitted from home or transferred from another hospital do not need a hearing screen if "
    },
    {
      "type": "text",
      "section": "B. Audiology and Hearing Screening",
      "line": 1601,
      "preview": "3. Patients born at LPCH and readmitted need a repeat ALGO if they have hyperbilirubinemia, received"
    },
    {
      "type": "text",
      "section": "B. Audiology and Hearing Screening",
      "line": 1602,
      "preview": "4. Failed ALGO: may be repeated once. If patient refers on second ALGO a referral is made to audiolo"
    },
    {
      "type": "text",
      "section": "B. Audiology and Hearing Screening",
      "line": 1603,
      "preview": "5. Newborns designated as being at increased risk of hearing loss will be identified at multidiscipl"
    },
    {
      "type": "text",
      "section": "B. Audiology and Hearing Screening",
      "line": 1604,
      "preview": "6. For more information on hearing screening please refer to LPCH policies: Newborn Hearing Screenin"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1606
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1608,
      "preview": "1. All patients going home from the NICU/ICN with GT, JT, NGT or NJT should be referred to the GI Cl"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1609,
      "preview": "2. Place referral via EPIC, mark \"Urgent\" and indicate \"pt has feeding tube, needs GI visit by wk of"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1610,
      "preview": "3. If it is known that there are no available appointments within specific time frame, please contac"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1611,
      "preview": "4. Assess family's comfort with ability to replace dislodged NG and/or GTs. If parents are not comfo"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1612,
      "preview": "5. Once patient is seen by the Peds GI Service (either inpt or outpt), family can come to Peds GI cl"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1613,
      "preview": "6. The Case Managers will indicate in EPIC under \"Snapshot\" in the field Patient Care Coordination N"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1614,
      "preview": "7. If there is a family struggling with decision over whether to go home with an NG tube vs GT place"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1615,
      "preview": "D. If PT/OT follow up is needed, the PT/OT will provide a paper order to be signed by the attending "
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1616,
      "preview": "E. If a patient meets criteria, order high risk infant follow up on EPIC if not yet scheduled. (\"Dis"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1618,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "C. Babies going home on NG or GT Feeds",
      "line": 1620,
      "preview": "--- page 68 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Consultant follow up appointments at outside facilities/practices",
      "line": 1622
    },
    {
      "type": "text",
      "section": "VI. Consultant follow up appointments at outside facilities/practices",
      "line": 1624,
      "preview": "A. The LPCH consultant should provide a referral to an appropriate outside consultant if follow up w"
    },
    {
      "type": "text",
      "section": "VI. Consultant follow up appointments at outside facilities/practices",
      "line": 1625,
      "preview": "B. The LPCH consultant should provide sign out to the follow up consultant."
    },
    {
      "type": "text",
      "section": "VI. Consultant follow up appointments at outside facilities/practices",
      "line": 1626,
      "preview": "C. The Case Manager will schedule follow up appointments with all outside consultants."
    },
    {
      "type": "text",
      "section": "VI. Consultant follow up appointments at outside facilities/practices",
      "line": 1627,
      "preview": "D. Records should be sent in a separate packet for the consultant (i.e. copies of the echocardiogram"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. ROP Follow up",
      "line": 1629
    },
    {
      "type": "text",
      "section": "VII. ROP Follow up",
      "line": 1631,
      "preview": "A. Drs. Gaynon, Moshfeghi, and Koo are the LPCH retinal specialists and must approve discharge for a"
    },
    {
      "type": "text",
      "section": "VII. ROP Follow up",
      "line": 1632,
      "preview": "B. ROP discharge follow up appointments must be made prior to discharge as this can be a high risk m"
    },
    {
      "type": "text",
      "section": "VII. ROP Follow up",
      "line": 1633,
      "preview": "C. The USA will call the ophthalmologist's office and either schedule an appointment for the patient"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. Discharge supplies and home health follow up needs",
      "line": 1635
    },
    {
      "type": "text",
      "section": "VIII. Discharge supplies and home health follow up needs",
      "line": 1637,
      "preview": "A. Notify the Case Manager of needed supplies (i.e. home oxygen, enteral feeding supplies, ostomy su"
    },
    {
      "type": "text",
      "section": "VIII. Discharge supplies and home health follow up needs",
      "line": 1638,
      "preview": "B. Notify the Case Manager of nursing care needs."
    },
    {
      "type": "text",
      "section": "VIII. Discharge supplies and home health follow up needs",
      "line": 1639,
      "preview": "C. The Case Manager will make Agency referrals."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IX. Car Seat Testing",
      "line": 1641
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Indications for Car Seat testing",
      "line": 1643
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1645,
      "preview": "Infants <37 wks gestation at birth OR who meet 1 of the following criteria:"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1647,
      "preview": "1. Weight at discharge less than 5 lbs ( 2.27 kg )"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1648,
      "preview": "2. With lung disease requiring supplemental oxygen at the time of discharge"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1649,
      "preview": "3. With reflux requiring medication or thickened feedings"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1650,
      "preview": "4. Any infant sent home on an apnea monitor"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1651,
      "preview": "5. Infants with known physical or developmental limitations who are not able to tolerate sitting pos"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1653,
      "preview": "Some infants are unable to tolerate a sitting position because of physical or developmental limitati"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1655,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1657,
      "preview": "--- page 69 ---"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1659,
      "preview": "Seats Policy"
    },
    {
      "type": "text",
      "section": "A. Indications for Car Seat testing",
      "line": 1660,
      "preview": "https://intranet.lpch.org/formsPoliciesReferences/procedures/hospitalWide/patientCare/childPassenger"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Equipment",
      "line": 1662
    },
    {
      "type": "text",
      "section": "B. Equipment",
      "line": 1664,
      "preview": "1. Pulse Oximeter"
    },
    {
      "type": "text",
      "section": "B. Equipment",
      "line": 1665,
      "preview": "2. Cardiorespiratory monitor"
    },
    {
      "type": "text",
      "section": "B. Equipment",
      "line": 1666,
      "preview": "3. Car seat that will be used to transport the infant home"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Process",
      "line": 1668
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1670,
      "preview": "1. Upon identification of an infant requiring monitoring, arrangements should be made for the parent"
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1671,
      "preview": "2. Testing should be done immediately after or between feedings."
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1672,
      "preview": "3. Place infant on cardio-respiratory and O 2 saturation monitors. If infant is going home on a moni"
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1673,
      "preview": "4. The infant must maintain parameters set on the home monitor to be considered safe"
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1674,
      "preview": "5. May utilize baseline measurements if monitors already in place."
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1675,
      "preview": "6. Place infant in car seat. Bolster with blankets to keep baby in optimal position while maintainin"
    },
    {
      "type": "image",
      "section": "C. Process",
      "line": 1676,
      "content": "![img-5.jpeg](images/12b7f39ee6b1af21.png)"
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1678,
      "preview": "There should not be anything between the baby and the car seat that did not originally come with the"
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1680,
      "preview": "--- page 70 ---"
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1682,
      "preview": "7. Monitor infant for 90 to 120 min or the duration of travel, whichever is longer."
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1683,
      "preview": "8. Assess for apnea, bradycardia, or oxygen desaturation episodes during car seat observation."
    },
    {
      "type": "text",
      "section": "C. Process",
      "line": 1684,
      "preview": "9. Child must pass the challenge in the Car Restraint (CR) they will be discharged in, even if it me"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1686
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1688,
      "preview": "Test is abnormal and considered a fail if any of the following occurs"
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1690,
      "preview": "1. $\\mathrm{HR}<80 \\mathrm{bpm}$ for $>4 \\mathrm{sec}$ with oxygen desaturation $<88 \\%$"
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1691,
      "preview": "2. $\\mathrm{HR}<80 \\mathrm{bpm}$ for 10 seconds without oxygen desaturation"
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1692,
      "preview": "3. Apnea $>20 \\mathrm{sec}$"
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1693,
      "preview": "4. Steady decline in oxygen saturation to $<88 \\%$ without spontaneous recovery. NOTE: the O2 satura"
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1694,
      "preview": "5. Persistent labored respiratory effort despite repositioning."
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1695,
      "preview": "6. If infant exhibits significant event, reposition or stimulate, document intervention and terminat"
    },
    {
      "type": "text",
      "section": "D. Criteria to determine Pass/Fail:",
      "line": 1696,
      "preview": "7. If the infant fails the initial test, one can be repeated. It is usually best to wait 24 hours."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. During re-test:",
      "line": 1698
    },
    {
      "type": "text",
      "section": "E. During re-test:",
      "line": 1700,
      "preview": "1. Closely check monitor connections"
    },
    {
      "type": "text",
      "section": "E. During re-test:",
      "line": 1701,
      "preview": "2. Check infant's position and harness to ensure proper fit and position"
    },
    {
      "type": "text",
      "section": "E. During re-test:",
      "line": 1702,
      "preview": "3. Check angle of CR is at manufacturer's recommended $45^{\\circ}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Two failed tests will require further evaluation",
      "line": 1704
    },
    {
      "type": "text",
      "section": "F. Two failed tests will require further evaluation",
      "line": 1706,
      "preview": "1. An extended stay may be required to further monitor/treat apnea, desaturations, bradycardia"
    },
    {
      "type": "text",
      "section": "F. Two failed tests will require further evaluation",
      "line": 1707,
      "preview": "2. A new car restraint system may be required. A repeat test in the car bed or alternative restraint"
    },
    {
      "type": "text",
      "section": "F. Two failed tests will require further evaluation",
      "line": 1708,
      "preview": "a. A different standard infant car seat may be utilized. Infant only car seats with smaller weight l"
    },
    {
      "type": "text",
      "section": "F. Two failed tests will require further evaluation",
      "line": 1709,
      "preview": "b. A car bed can be obtained from Distribution Supply but should only be used when upright position "
    },
    {
      "type": "text",
      "section": "F. Two failed tests will require further evaluation",
      "line": 1710,
      "preview": "G. Results are documented in the electronic record by the RN."
    },
    {
      "type": "text",
      "section": "F. Two failed tests will require further evaluation",
      "line": 1711,
      "preview": "H. Communicate any abnormal testing and needed follow up to the infant's pediatrician at time of dis"
    },
    {
      "type": "text",
      "section": "F. Two failed tests will require further evaluation",
      "line": 1713,
      "preview": "--- page 71 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "X. Discharge teaching",
      "line": 1715
    },
    {
      "type": "text",
      "section": "X. Discharge teaching",
      "line": 1717,
      "preview": "A. Notify the RN to initiate more assertive discharge teaching when patient is within 7 days of disc"
    },
    {
      "type": "text",
      "section": "X. Discharge teaching",
      "line": 1718,
      "preview": "B. The Case Manager will coordinate family teaching for home health/durable medical equipment."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1720
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1722,
      "preview": "A. Contact your patient's PCP to provide a detailed sign out and discuss timing of follow up. Docume"
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1723,
      "preview": "B. Reconcile the medications and place order to outpatient pharmacy as needed."
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1724,
      "preview": "C. Complete the health care maintenance checklist."
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1725,
      "preview": "D. Complete the remaining relevant items on the \"Discharge Checklist\""
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1726,
      "preview": "E. Update problem list on EPIC."
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1727,
      "preview": "F. Fill out the Brief Hospital section in the ADT Navigator"
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1728,
      "preview": "G. Fill out the discharge Instructions in the ADT Navigator."
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1730,
      "preview": "1. Click on \"Using Additional DC Instructions Only\" at the top of the screen. Scroll to the bottom t"
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1731,
      "preview": "2. Use the. ADT dot phrases for the follow up appointments (. ADTneuro for example)."
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1732,
      "preview": "3. The dot phrases contain info for all of the clinics and should be used for all scheduled/ordered "
    },
    {
      "type": "text",
      "section": "XI. Things to do 48-72 hours prior to discharge",
      "line": 1733,
      "preview": "4. Do not use the \"Follow Up Appointment\" section because of the word limit."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XII. Things to do the day of discharge",
      "line": 1735
    },
    {
      "type": "text",
      "section": "XII. Things to do the day of discharge",
      "line": 1737,
      "preview": "A. Discharge exam"
    },
    {
      "type": "text",
      "section": "XII. Things to do the day of discharge",
      "line": 1738,
      "preview": "B. Complete the Discharge Summary on EPIC and forward it to the PCP using the routing tab on EPIC. E"
    },
    {
      "type": "text",
      "section": "XII. Things to do the day of discharge",
      "line": 1739,
      "preview": "C. Use the ADT navigator to place the discharge order."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XIII. Tips and Tricks",
      "line": 1741
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1743,
      "preview": "A. To access the smart phrases, click on the Epic tab-->Tools-->Smart Phrase Manager-->type in \"Audr"
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1744,
      "preview": "B. If discharge is to CRC or George Mark, along with the Health Care Maintenance chart, please use t"
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1746,
      "preview": "--- page 72 ---"
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1748,
      "preview": "C. Order outpatient follow up as soon as it is finalized by the consulting team."
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1749,
      "preview": "D. If a patient had PDA on last ECHO they should follow up with cardiology $\\sim 1$ month after disc"
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1750,
      "preview": "E. If a patient has a G-tube, they will need follow up with Surgery 3 months after discharge"
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1751,
      "preview": "F. Non-English speaking families: after placing the discharge order, ask the USA to request to have "
    },
    {
      "type": "text",
      "section": "XIII. Tips and Tricks",
      "line": 1753,
      "preview": "--- page 73 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Comfort Care in the NICU",
      "line": 1755
    },
    {
      "type": "text",
      "section": "Comfort Care in the NICU",
      "line": 1757,
      "preview": "Diana Kobayashi, N.N.P.-B.C."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. General",
      "line": 1759
    },
    {
      "type": "text",
      "section": "I. General",
      "line": 1761,
      "preview": "In our culture, the death of an infant is a rare event. Most parents have limited experience with de"
    },
    {
      "type": "text",
      "section": "I. General",
      "line": 1763,
      "preview": "Two thirds of all infant deaths occur during the neonatal period. The most preterm and the smallest "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Communication",
      "line": 1765
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1767,
      "preview": "Good communication with families is essential. Families want to be included in the decision making a"
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1769,
      "preview": "When parents are experiencing emotional distress, often we want to say something to reduce or remove"
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1771,
      "preview": "Ideally decisions regarding transitioning to comfort care occur over a series of conversations. Esse"
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1773,
      "preview": "The series of conversations should include what is clearly known about their infant; what tests, ima"
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1775,
      "preview": "Sometimes the infant's condition does not give us as much time as we wish for these conversations to"
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1777,
      "preview": "--- page 74 ---"
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1779,
      "preview": "Our goal is to provide the same information, but in a tighter timeframe. Whenever possible and appro"
    },
    {
      "type": "text",
      "section": "II. Communication",
      "line": 1781,
      "preview": "Lastly, we must include in our discussions what death looks like. Many families have limited experie"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Intensive Care vs. Comfort Care",
      "line": 1783
    },
    {
      "type": "text",
      "section": "III. Intensive Care vs. Comfort Care",
      "line": 1785,
      "preview": "The goals of intensive care and comfort care are very different. These goals need to be clarified fo"
    },
    {
      "type": "text",
      "section": "III. Intensive Care vs. Comfort Care",
      "line": 1787,
      "preview": "When the parents and medical team decide to pursue comfort care, the comfort care order set, \"Neonat"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Palliative Care vs. End-of-Life Care",
      "line": 1789
    },
    {
      "type": "text",
      "section": "IV. Palliative Care vs. End-of-Life Care",
      "line": 1791,
      "preview": "Unfortunately, many parents and health care providers assume that palliative care and end-of-life/ho"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. When Will the Infant Die?",
      "line": 1793
    },
    {
      "type": "text",
      "section": "V. When Will the Infant Die?",
      "line": 1795,
      "preview": "No one can ever predict the length of time until death. Even in the seemingly \"easy case\" one should"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Religious and Cultural Issues",
      "line": 1797
    },
    {
      "type": "text",
      "section": "VI. Religious and Cultural Issues",
      "line": 1799,
      "preview": "It is important to ask parents if they have any religious or cultural practices we can facilitate. S"
    },
    {
      "type": "text",
      "section": "VI. Religious and Cultural Issues",
      "line": 1801,
      "preview": "--- page 75 ---"
    },
    {
      "type": "text",
      "section": "VI. Religious and Cultural Issues",
      "line": 1803,
      "preview": "ask for a special blessing, anointment, or prayer. If the parents have a religious person they wish "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. Pain Management",
      "line": 1805
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1807,
      "preview": "Comfort measures often include swaddling and being held by family members or staff, when the parents"
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1809,
      "preview": "Prior to transitioning to comfort care, a plan for pain control should be made. There are several co"
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1811,
      "preview": "There are several routes that can be used for pain control. Each route has advantages and disadvanta"
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1813,
      "preview": "To determine the appropriate dosing, the first issue to consider is whether the infant is opiate na\u00ef"
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1815,
      "preview": "The fear of hastening death is NOT a reason to deny escalating narcotic dosing to treat pain and/or "
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1816,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1818,
      "preview": "--- page 76 ---"
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1820,
      "preview": "dyspnea is an equivalent process."
    },
    {
      "type": "text",
      "section": "VII. Pain Management",
      "line": 1821,
      "preview": "In Palliative Care, the standard of care for escalation of dosing is by a percentage increase. In ge"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VIII. Nutrition",
      "line": 1823
    },
    {
      "type": "text",
      "section": "VIII. Nutrition",
      "line": 1825,
      "preview": "Not providing nutrition is an emotional topic that may need to be discussed with the parents dependi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IX. Siblings and Grandparents",
      "line": 1827
    },
    {
      "type": "text",
      "section": "IX. Siblings and Grandparents",
      "line": 1829,
      "preview": "Siblings and grandparents are an important part of the family, however their needs and grief are oft"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "X. Location of Death",
      "line": 1831
    },
    {
      "type": "text",
      "section": "X. Location of Death",
      "line": 1833,
      "preview": "Some parents would prefer the infant to die in the hospital and others that the infant die at home. "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XI. Comfort Care of the Infant on The Postpartum Unit",
      "line": 1835
    },
    {
      "type": "text",
      "section": "XI. Comfort Care of the Infant on The Postpartum Unit",
      "line": 1837,
      "preview": "Some families have decided on comfort care prior to birth. Other families make this decision while t"
    },
    {
      "type": "text",
      "section": "XI. Comfort Care of the Infant on The Postpartum Unit",
      "line": 1839,
      "preview": "--- page 77 ---"
    },
    {
      "type": "text",
      "section": "XI. Comfort Care of the Infant on The Postpartum Unit",
      "line": 1841,
      "preview": "NICU medical and nursing teams will care for the infant receiving comfort care in the postpartum uni"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "XII. Pediatric Palliative Care Program",
      "line": 1843
    },
    {
      "type": "text",
      "section": "XII. Pediatric Palliative Care Program",
      "line": 1845,
      "preview": "For the majority of NICU infants who die, the NICU multidisciplinary team is able to skillfully assi"
    },
    {
      "type": "text",
      "section": "XII. Pediatric Palliative Care Program",
      "line": 1847,
      "preview": "The goal of the Pediatric Palliative Care Program is to plan and provide comprehensive care for chil"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Pediatric Palliative Care Team (24/7 availability)",
      "line": 1849
    },
    {
      "type": "text",
      "section": "A. Pediatric Palliative Care Team (24/7 availability)",
      "line": 1851,
      "preview": "1. Phone (voicemail): 497-8963, Pager: \\#19474"
    },
    {
      "type": "text",
      "section": "A. Pediatric Palliative Care Team (24/7 availability)",
      "line": 1852,
      "preview": "2. Nancy Contro, MSW (Bereavement and Family Guidance Director) 497-8304, pager \\#18628"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XIII. Social Work",
      "line": 1854
    },
    {
      "type": "text",
      "section": "XIII. Social Work",
      "line": 1856,
      "preview": "When the death of an infant is anticipated, notify the social worker assigned to the infant. If a de"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XIV. Nursing",
      "line": 1858
    },
    {
      "type": "text",
      "section": "XIV. Nursing",
      "line": 1860,
      "preview": "The Bedside Nurse is an integral part of support for the family and should be included in family con"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XV. Family Room",
      "line": 1862
    },
    {
      "type": "text",
      "section": "XV. Family Room",
      "line": 1864,
      "preview": "The NICU has a room available where the family can spend private, quiet time with their infant. They"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XVI. Chaplain",
      "line": 1866
    },
    {
      "type": "text",
      "section": "XVI. Chaplain",
      "line": 1868,
      "preview": "A chaplain is available 24 hours a day for support, comfort, baptisms, and blessings. They are avail"
    },
    {
      "type": "text",
      "section": "XVI. Chaplain",
      "line": 1869,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "XVI. Chaplain",
      "line": 1871,
      "preview": "--- page 78 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "XVII. Pronouncing Death",
      "line": 1873
    },
    {
      "type": "text",
      "section": "XVII. Pronouncing Death",
      "line": 1875,
      "preview": "A physician or nurse practitioner with a California license is called to pronounce the time of death"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XVIII. Paperwork",
      "line": 1877
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1879,
      "preview": "A. Death paperwork is completed using the ADT navigator and selecting \"Discharge as deceased.\" The d"
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1880,
      "preview": "B. The MD is responsible for the following:"
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1882,
      "preview": "1. Calling the Coroner, if it is a coroner's case (review the checklist on the back of the Death Cer"
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1883,
      "preview": "2. Calling the California Transplant Donor Network (CTDN) at 800-553-6667 to inform of all deaths of"
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1884,
      "preview": "3. If autopsy is to be performed, complete the \"Consent for Autopsy\" form, signed by the next of kin"
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1885,
      "preview": "4. Complete the \"Death Certificate Worksheet\". All questions should be answered with no blanks left."
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1886,
      "preview": "5. Once completed, the front desk will submit all of the paperwork to the Nursing Supervisor, who wi"
    },
    {
      "type": "text",
      "section": "XVIII. Paperwork",
      "line": 1887,
      "preview": "6. The MD should prepare a Death Summary in Epic called \"IP Discharge Summary\" (Death Note). All pro"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1889
    },
    {
      "type": "text",
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1891,
      "preview": "A. The immediate cause of death is the disease, abnormality or injury that led directly to the death"
    },
    {
      "type": "text",
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1893,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1895,
      "preview": "--- page 79 ---"
    },
    {
      "type": "text",
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1897,
      "preview": "order and must be supported by etiological sequence. [e.g., unacceptable would be: cardiac arrest, s"
    },
    {
      "type": "text",
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1898,
      "preview": "B. The underlying causes must have a plausible causal relationship to the next-higher item on the li"
    },
    {
      "type": "text",
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1899,
      "preview": "C. The initial condition that starts the sequence on the form must be specific so that it does not l"
    },
    {
      "type": "text",
      "section": "XIX. Helpful Hints in Determining the Cause of Death",
      "line": 1900,
      "preview": "D. If prematurity is specified as a cause, the Medical Examiner may request clarity as to whether or"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1902
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1904,
      "preview": "A. Stillborn Infants"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1906,
      "preview": "1. Stillborn infants are infants who are born with no signs of life. For stillborn infants born afte"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1907,
      "preview": "2. If documentation by the peds team on delivery room activities related to a stillborn infant (feta"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1908,
      "preview": "B. Infants born alive"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1909,
      "preview": "3. Any baby who is born with signs of life (a heart rate or any spontaneous breathing movement, incl"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1910,
      "preview": "a. Completion of the Birth Certificate by the Birth Recorder"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1911,
      "preview": "b. Creation of a medical record by Admitting"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1912,
      "preview": "c. Entering of admission orders. Use the order set called Neonatal Comfort Care Supplemental Orders."
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1913,
      "preview": "The infant is admitted to the NICU, even if the infant does not physically move to the NICU."
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1914,
      "preview": "d. Documentation of a medical evaluation in an Admission Note (see template below)"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1915,
      "preview": "e. Completion of initial nursing assessment by RN"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1916,
      "preview": "4. Extremely premature infants (<24 weeks estimated gestational age) - management may consist of:"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1917,
      "preview": "a. Attempted resuscitation and/or stabilization for initiation of intensive care, if requested by th"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1918,
      "preview": "i. Resuscitation and stabilization of infants < 23 weeks' gestation or < 500 grams will generally be"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1919,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1921,
      "preview": "--- page 80 ---"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1923,
      "preview": "b. Evaluation to confirm that the infant is extremely premature and therefore unlikely to benefit fr"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1924,
      "preview": "c. Documentation includes:"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1925,
      "preview": "i. An admission evaluation, confirming the estimated gestational age (see template below)"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1926,
      "preview": "ii. A written medical assessment that intensive care measures will not be beneficial and are not ind"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1927,
      "preview": "iii. Neonatal Comfort Care Supplemental Orders."
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1928,
      "preview": "3. If there has been an antepartum decision not to initiate intensive care, based on the estimated g"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1929,
      "preview": "a. Evaluation to confirm the findings that form the basis for the decision to limit interventions, f"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1930,
      "preview": "b. Attendance of the birth by a minimal pediatric team and respect for the parents' wishes for priva"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1931,
      "preview": "c. Documentation includes:"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1932,
      "preview": "i. An admission note confirming the findings that provided the basis for the decision not to interve"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1933,
      "preview": "ii. Neonatal Comfort Care Supplementation Orders."
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1934,
      "preview": "4. If an infant is born alive and expires in the delivery room, the pediatric team completes the fol"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1935,
      "preview": "a. A Draft Death Certificate and subsequently a Death Certificate. If \"extreme prematurity\" is liste"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1936,
      "preview": "b. Notify the Santa Clara County Coroner of the infant's demise. (Expect the coroner's investigator "
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1937,
      "preview": "c. Notify the California Transport Donor Network of the infant's demise."
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1938,
      "preview": "d. Complete a discharge summary. See template below for extremely immature infants (<24 weeks gestat"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1939,
      "preview": "5. If an infant who is expected to expire in the delivery room remains alive."
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1940,
      "preview": "a. The infant can be taken to the mother's room on Maternity or to the NICU for ongoing comfort care"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1941,
      "preview": "b. The infant remains the responsibility of the NICU medical and nursing teams."
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1942,
      "preview": "c. Documentation should be completed as described in Section XIX.B.3. If the infant survives through"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1944,
      "preview": "--- page 81 ---"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1946,
      "preview": "74 Part I-C: Delivery and Admission"
    },
    {
      "type": "text",
      "section": "XX. Stillbirth vs. Baby Born Alive",
      "line": 1947,
      "preview": "a following day, the fellow should perform an assessment and complete a progress note."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "XXI. Templates",
      "line": 1949
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1951,
      "preview": "These templates can be used for documenting in Epic by cutting and pasting. These are formatted for "
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1952,
      "preview": "A. Admission Note"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1954,
      "preview": "I was called by Dr."
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1955,
      "preview": "$\\qquad$ to"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1956,
      "preview": "$\\qquad$ attend the birth of"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1957,
      "preview": "$\\qquad$ evaluate following the birth of"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1958,
      "preview": "this infant who was born at an estimated gestational age of $\\qquad$ weeks."
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1960,
      "preview": "The infant demonstrated the following signs of life:"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1961,
      "preview": "cry $\\qquad$ respiratory effort $\\qquad$ heart rate by auscultation/palpation"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1962,
      "preview": "$\\qquad$ spontaneous movement"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1964,
      "preview": "My examination confirms the gestational age estimate. Because of his/her extreme immaturity, intensi"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1966,
      "preview": "The parents, $\\qquad$ and $\\qquad$ , have been informed of these findings and recommendations for ca"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1967,
      "preview": "B. Expiration/Discharge Note"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1969,
      "preview": "This infant expired from extreme prematurity resulting in $\\qquad$ respiratory and/or $\\qquad$ circu"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1970,
      "preview": "$\\qquad$ hours and was pronounced dead by $\\qquad$ me, Dr. $\\qquad$ , MD/NP."
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1972,
      "preview": "The following parties have been notified of the infant's expiration:"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1973,
      "preview": "$\\qquad$ Parents"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1974,
      "preview": "$\\qquad$ Coroner"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1975,
      "preview": "$\\qquad$ CTDN"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1976,
      "preview": "$\\qquad$ Nursing Supervisor"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1978,
      "preview": "--- page 82 ---"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1980,
      "preview": "1. Catlin, A, Carter, B. Creation of a Neonatal End-of-Life Palliative Care Protocol. J Perinatol. 2"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1981,
      "preview": "2. Engelder, S, Zeillinger, T. A Model Program for Perinatal Palliative Services. Adv Neonatal Care."
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1982,
      "preview": "3. Gale, G, Brooks, A. Implementing a Palliative Care Program in a Newborn Intensive Care Unit. Adv "
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1983,
      "preview": "4. Kobler, K, Limbo, R. Making a Case: Creating a Perinatal Palliative Care Service Using a Perinata"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1984,
      "preview": "5. Workman, E. Guiding Parents Through the Death of Their Infant. JOGNN. 2001; 30: 569-573."
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1985,
      "preview": "6. Born-Alive Infants Protection Act of 2002, HR 2175."
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1986,
      "preview": "http://www.gpo.gov/fdsys/pkg/BILLS- 107hr2175enr/pdf/BILLS-107hr2175enr.pdf"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1987,
      "preview": "7. Benitz, W E. A Paradigm for Making Difficult Choices in the Intensive Care Nursery. Cambridge Qua"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1988,
      "preview": "8. Wolfe, J, Hinds, P. S, Sourkes, B. M. Textbook of Interdisciplinary Pediatric Palliative Care. El"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1989,
      "preview": "9. Ferrell, B. R, Coyle, N. Oxford Textbook of Palliative Care Nursing. 3rd Edition. Oxford Universi"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1990,
      "preview": "10. Weissman, D. E. Fast Facts and Concepts \\#20 Opioid Dose Escalation. Palliative Care Network of "
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1991,
      "preview": "11. HPNA Position Statement: The Ethics of Opioid Use at End of Life. Hospice \\& Palliative Nurses A"
    },
    {
      "type": "text",
      "section": "XXI. Templates",
      "line": 1993,
      "preview": "--- page 83 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II: Clinical Management",
      "line": 1995
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Section A: Fluids and Nutrition",
      "line": 1997
    },
    {
      "type": "text",
      "section": "Section A: Fluids and Nutrition",
      "line": 1999,
      "preview": "--- page 84 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Management of IV Fluids and TPN",
      "line": 2001
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 2003
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2005,
      "preview": "Newborn infants typically lose up to $10 \\%$ of their body weight over the first 7-14 days of life. "
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2007,
      "preview": "At birth, neonates are fluid overloaded and need to diurese and lose weight. Though they don't need "
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2009,
      "preview": "Extra-uterine growth restriction is an ongoing issue in the NICU. Neonates, particularly premature o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Rationale for Fluid Management",
      "line": 2011
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2013,
      "preview": "A. Very Low Birth Weight (VLBW) Infants (<1500 gm): Infants have increased fluid needs due to a vari"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2015,
      "preview": "1. Immature skin integrity results in increased transcutaneous water losses."
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2016,
      "preview": "2. Kidneys have decreased ability to concentrate urine."
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2017,
      "preview": "3. Capillaries are more prone to leak fluid, resulting in extravascular edema."
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2018,
      "preview": "4. Both skin integrity and renal concentrating ability improve significantly over the first week of "
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2019,
      "preview": "B. Micro-preemies ( $<28$ weeks or 1000 gm ): These infants may need $200 \\mathrm{~mL} / \\mathrm{kg}"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2020,
      "preview": "5. Indications for increasing fluids include weight loss $>15 \\%$ of birth weight, urine output $>6 "
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2021,
      "preview": "6. Babies $<28$ weeks should be in a humidified isolette after initial stabilization. Humidity is ro"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2022,
      "preview": "7. Electrolytes, calcium, and hematocrit should be checked every 12 hours if the patient demonstrate"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2023,
      "preview": "C. Both term and pre-term infants with capillary leak problems (e.g., associated with asphyxia, sept"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2025,
      "preview": "--- page 85 ---"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2027,
      "preview": "shock, etc) are best managed by providing a relatively restricted baseline crystalloid infusion and "
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2028,
      "preview": "D. The goal of IV fluid therapy during the first few days of life is to:"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2030,
      "preview": "1. Prevent excessive weight loss and dehydration, which can result in hypotension, cell damage, hype"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2031,
      "preview": "2. Allow the premature infant to lose 1-2\\% body weight per day, not to exceed a total of $15 \\%$ ov"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2032,
      "preview": "3. Provide adequate glucose and amino acid delivery."
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2033,
      "preview": "4. Meet electrolyte needs."
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2034,
      "preview": "5. Keep indwelling catheters patent."
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2035,
      "preview": "6. Avoid fluid overload, which can lead to pulmonary edema, PDA, and an increased incidence of Chron"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2036,
      "preview": "E. Typical fluid volume ( $\\mathrm{mL} / \\mathrm{kg} /$ day): This will vary with the gestational ag"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2037,
      "preview": "7. $>1500 \\mathrm{gm}: 60-80 \\mathrm{~mL} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2038,
      "preview": "8. $1000-1500 \\mathrm{gm}: 80 \\mathrm{~mL} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2039,
      "preview": "9. $<1000 \\mathrm{gm}: 80-100 \\mathrm{~mL} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2040,
      "preview": "10. Advance over next 5 days depending upon labs, weights, and urine output, generally by $10-20 \\ma"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2041,
      "preview": "F. Adjustments in maintenance fluids are needed as follows:"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2042,
      "preview": "11. Increase maintenance fluids for:"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2043,
      "preview": "12. Excessive weight loss"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2044,
      "preview": "13. Gastroschisis/omphalocele"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2045,
      "preview": "14. Immature, sticky, translucent skin"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2046,
      "preview": "15. Polyuria, hypernatremia, hyperkalemia"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2047,
      "preview": "16. Decrease maintenance fluids for:"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2048,
      "preview": "17. Asphyxia/cerebral edema"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2049,
      "preview": "18. Generalized body edema"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2050,
      "preview": "19. Oliguria (e.g., renal failure, SIADH, indomethacin)"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2051,
      "preview": "20. Heart failure or PDA"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2053,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2055,
      "preview": "--- page 86 ---"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2057,
      "preview": "5. Pulmonary edema"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2058,
      "preview": "6. Excessive weight gain"
    },
    {
      "type": "text",
      "section": "II. Rationale for Fluid Management",
      "line": 2059,
      "preview": "7. Hyponatremia"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Electrolyte Requirements",
      "line": 2061
    },
    {
      "type": "text",
      "section": "III. Electrolyte Requirements",
      "line": 2063,
      "preview": "A. Hemodynamically stable term infants usually need no sodium or potassium during the first day of l"
    },
    {
      "type": "text",
      "section": "III. Electrolyte Requirements",
      "line": 2064,
      "preview": "B. Patients with hypotension or cardiac disease, requiring blood product transfusion (calcium is bou"
    },
    {
      "type": "text",
      "section": "III. Electrolyte Requirements",
      "line": 2066,
      "preview": "1. Calcium maintenance requirements are provided by calcium gluconate, $200-400 \\mathrm{mg} / \\mathr"
    },
    {
      "type": "text",
      "section": "III. Electrolyte Requirements",
      "line": 2067,
      "preview": "2. When boluses are required for severe hypocalcemia (ionized levels $<0.8$ ) and poor cardiac funct"
    },
    {
      "type": "text",
      "section": "III. Electrolyte Requirements",
      "line": 2068,
      "preview": "3. Calcium is incompatible with many medications, especially bicarbonate; don't add calcium to any l"
    },
    {
      "type": "text",
      "section": "III. Electrolyte Requirements",
      "line": 2069,
      "preview": "C. When the patient demonstrates a need for sodium, either by falling sodium levels or to support ti"
    },
    {
      "type": "text",
      "section": "III. Electrolyte Requirements",
      "line": 2070,
      "preview": "D. Potassium requirement is usually $2 \\mathrm{mEq} / \\mathrm{kg} /$ day initially, and is added whe"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Glucose Requirements",
      "line": 2072
    },
    {
      "type": "text",
      "section": "IV. Glucose Requirements",
      "line": 2074,
      "preview": "A. Newborn infants have a basal requirement of about $4-6 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ "
    },
    {
      "type": "text",
      "section": "IV. Glucose Requirements",
      "line": 2075,
      "preview": "B. Healthy term infants can meet this need through glycolysis and gluconeogenesis and do not necessa"
    },
    {
      "type": "text",
      "section": "IV. Glucose Requirements",
      "line": 2076,
      "preview": "C. Pre-term infants and IUGR term infants have decreased supply of substrate and decreased ability t"
    },
    {
      "type": "text",
      "section": "IV. Glucose Requirements",
      "line": 2078,
      "preview": "--- page 87 ---"
    },
    {
      "type": "text",
      "section": "IV. Glucose Requirements",
      "line": 2080,
      "preview": "D. Infants of Diabetic Mothers (IDMs) are exposed to higher than normal glucose levels in utero that"
    },
    {
      "type": "text",
      "section": "IV. Glucose Requirements",
      "line": 2081,
      "preview": "E. Typical IV infusion is dextrose $10 \\%$ in water (D10W) which contains 10 gm of dextrose monohydr"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Hypoglycemia",
      "line": 2083
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2085,
      "preview": "1. Initial levels are checked by a glucometer. Levels $<40$ need to be verified by a serum glucose d"
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2086,
      "preview": "2. Blood for glucose levels needs to be checked via heel-stick, venipuncture or drawn through an ind"
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2087,
      "preview": "3. IV dextrose concentration and delivery rate should be adjusted to keep the glucose level $>40$ an"
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2088,
      "preview": "4. After an intervention for hypoglycemia repeat glucose determinations should be done every 30 min "
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2089,
      "preview": "5. IV dextrose is the appropriate therapy for levels $<25 \\mathrm{mg} / \\mathrm{dL}$ regardless of g"
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2090,
      "preview": "6. Know the glucose delivery being supplied to any patient. For example, a patient on D12.5W at 80 $"
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2091,
      "preview": "7. Hypoglycemia is treated with IV pushes of dextrose ( $2 \\mathrm{~mL} / \\mathrm{kg}$ of D10W). All"
    },
    {
      "type": "text",
      "section": "F. Hypoglycemia",
      "line": 2092,
      "preview": "8. For persistent hypoglycemia, please see Section II:H. 2 \"Hypoglycemia\"."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Parenteral Nutrition (PN)",
      "line": 2094
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Goals",
      "line": 2096
    },
    {
      "type": "text",
      "section": "A. Goals",
      "line": 2098,
      "preview": "The goals of PN are to meet the patient's fluid, calorie, fat, protein, electrolyte, vitamin, and tr"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Calories",
      "line": 2100
    },
    {
      "type": "text",
      "section": "B. Calories",
      "line": 2102,
      "preview": "Most of the calories to support growth, generally around $60 \\%$, should come from dextrose monohydr"
    },
    {
      "type": "text",
      "section": "B. Calories",
      "line": 2104,
      "preview": "--- page 88 ---"
    },
    {
      "type": "text",
      "section": "B. Calories",
      "line": 2106,
      "preview": "1. Maintenance: $60-80 \\mathrm{kcal} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "B. Calories",
      "line": 2107,
      "preview": "2. Growth: $70-100 \\mathrm{kcal} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "B. Calories",
      "line": 2108,
      "preview": "3. Pulmonary/heart disease: $100-120 \\mathrm{kcal} / \\mathrm{kg} /$ day"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Protein",
      "line": 2110
    },
    {
      "type": "text",
      "section": "C. Protein",
      "line": 2112,
      "preview": "Babies need protein initially to prevent tissue break-down (catabolism), and then for new tissue gro"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Initial",
      "line": 2114
    },
    {
      "type": "text",
      "section": "1. Initial",
      "line": 2116,
      "preview": "The neonate loses about 1.2 gm of protein $/ \\mathrm{kg} /$ day if not supplemented. All infants sho"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Growth",
      "line": 2118
    },
    {
      "type": "text",
      "section": "2. Growth",
      "line": 2120,
      "preview": "Amino acids can gradually be increased until $3.5 \\mathrm{gm} / \\mathrm{kg} /$ day is reached for te"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Lipid",
      "line": 2122
    },
    {
      "type": "text",
      "section": "D. Lipid",
      "line": 2124,
      "preview": "Fats are needed to meet essential fatty acid requirements ( $\\sim 0.5 \\mathrm{gm} / \\mathrm{kg} /$ d"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Initial",
      "line": 2126
    },
    {
      "type": "text",
      "section": "1. Initial",
      "line": 2128,
      "preview": "Most neonates will tolerate 1.2 gm of protein $/ \\mathrm{kg} /$ day if not supplemented. All infants"
    },
    {
      "type": "text",
      "section": "1. Initial",
      "line": 2130,
      "preview": "--- page 89 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "2. Growth",
      "line": 2132
    },
    {
      "type": "text",
      "section": "2. Growth",
      "line": 2134,
      "preview": "Lipids can be advanced by $0.5-1 \\mathrm{gm} / \\mathrm{kg}$ daily up to a maximum of $3 \\mathrm{gm} "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2136
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2138,
      "preview": "A. PN must be ordered daily and custom-formulated for each patient. The custom program is accessible"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2139,
      "preview": "B. Neonatal vs. Premie Day1 Protocol. Premie Day1 Protocol is used to write the initial, \"starter\" o"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2140,
      "preview": "C. Central vs. Peripheral. Catheters ending in a large vessel (inferior/superior vena cava or aorta)"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2141,
      "preview": "D. Fluid Volume. By indicating what other IV fluids are running, the Pharmacy can adjust the Parente"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2142,
      "preview": "E. Enteral Feeds. If the infant on PN is feeding and the feeding volume is included in the total flu"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2143,
      "preview": "F. Dextrose. The goal is to provide about $60 \\%$ of total calories as carbohydrate, which provides "
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2145,
      "preview": "--- page 90 ---"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2147,
      "preview": "glucose at $60 \\mathrm{~mL} / \\mathrm{kg} /$ day, and $5.1 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2148,
      "preview": "G. Lipids. IntraLipid\u00ae 20\\% (IL-20) is used in the LPCH NICU. It is ordered in $\\mathrm{g} / \\mathrm"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2149,
      "preview": "H. Protein. Patients should be started on TrophAmine ${ }^{\\circledR}$ of $2-3 \\mathrm{~g} / \\mathrm"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2150,
      "preview": "I. Trace elements. $0.2 \\mathrm{~mL} / \\mathrm{kg}$ of Pediatric Trace Element Solution (PTES) is th"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2151,
      "preview": "J. Zinc. Preemies need $400 \\mathrm{mcg} / \\mathrm{kg} /$ day of Zinc in PN. Term infants need a tot"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2152,
      "preview": "K. Vitamins. For our preemie population (weight $<2.5 \\mathrm{~kg}$ ) $2 \\mathrm{~mL} / \\mathrm{kg} "
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2153,
      "preview": "L. Sodium. Usual maintenance is $3 \\mathrm{mEq} / \\mathrm{kg} /$ day. VLBW infants do not usually ne"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2154,
      "preview": "M. Potassium. Usual maintenance is $2 \\mathrm{mEq} / \\mathrm{kg} /$ day. Potassium is difficult to m"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2155,
      "preview": "N. Acetate/chloride. Cations ( $\\mathrm{Na}, \\mathrm{K}$ ) are balanced with either acetate or chlor"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2157,
      "preview": "--- page 91 ---"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2159,
      "preview": "minimizing acetate, increasing the potassium in the PN will also help. In patients with chronic meta"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2160,
      "preview": "O. Magnesium. Maintenance magnesium $(\\mathrm{Mg})$ of $0.2-0.3 \\mathrm{mEq} / \\mathrm{kg} /$ day is"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2161,
      "preview": "P. Calcium/Phosphorus. Both elements are vital to bone deposition. The body will compensate for hypo"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2162,
      "preview": "Q. Heparin. Total heparin delivery should not exceed 5 units $/ \\mathrm{kg} / \\mathrm{hr}$."
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2164,
      "preview": "1. PIV (peripheral IV): no heparin."
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2165,
      "preview": "2. Arterial Lines (i.e., UAC, PAL): 1 unit heparin $/ \\mathrm{mL}$"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2166,
      "preview": "3. Central Venous Lines (i.e., UVC, PICC, Hickman/Broviac): 0.5 unit heparin/mL. Make sure to add TK"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2167,
      "preview": "R. Ranitidine. Ranitidine should NOT be ordered routinely for stress ulcer prophylaxis for patients "
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2168,
      "preview": "S. Selenium. After an infant has been on PN for 1 month, selenium should be added to the daily PN so"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2169,
      "preview": "T. Copper. The dose is $20 \\mathrm{mcg} / \\mathrm{kg} /$ day. If direct bilirubin levels are $>2$, t"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2170,
      "preview": "U. PN Labs. Order the \"Clinical Pathway for TPN\" in Epic. After 1 month of PN, zinc, copper, and sel"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2171,
      "preview": "V. Carnitine. Should be added in cases of very high serum triglyceride levels, as it helps process l"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2172,
      "preview": "W. PN Cholestasis. In patients with PN cholestasis (conjugated bilirubin $\\geq 2$ ), if the Pediatri"
    },
    {
      "type": "text",
      "section": "VI. Ordering Parenteral Nutrition",
      "line": 2174,
      "preview": "--- page 92 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. Important Notes Regarding PN",
      "line": 2176
    },
    {
      "type": "text",
      "section": "VII. Important Notes Regarding PN",
      "line": 2178,
      "preview": "A. Initiation of PN is recommended immediately on admission of VLBW infants unless significant fluid"
    },
    {
      "type": "text",
      "section": "VII. Important Notes Regarding PN",
      "line": 2179,
      "preview": "B. PN rate should never be increased to make-up additional fluid requirements unless PN has specific"
    },
    {
      "type": "text",
      "section": "VII. Important Notes Regarding PN",
      "line": 2180,
      "preview": "C. Central PN should never be run in a peripheral line (even if calcium and dextrose concentration l"
    },
    {
      "type": "text",
      "section": "VII. Important Notes Regarding PN",
      "line": 2181,
      "preview": "D. The UAC catheter is used as a non-contaminated site for lab sampling. Standard solution is $1 / 2"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. Peripheral vs. Central Line Concentration Limits",
      "line": 2183
    },
    {
      "type": "text",
      "section": "VIII. Peripheral vs. Central Line Concentration Limits",
      "line": 2185,
      "preview": "There are both solubility and osmolality limits to what can be placed in parenteral solutions. The \""
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Amino Acids",
      "line": 2187
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2189,
      "preview": "1. Peripheral IV: $2 \\%$ of PN volume"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2190,
      "preview": "2. Central IV: $3 \\%$ of PN volume"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2191,
      "preview": "B. Dextrose"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2192,
      "preview": "3. Peripheral IV: $12.5 \\%$"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2193,
      "preview": "4. Central IV: $30 \\%$"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2194,
      "preview": "C. Potassium"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2195,
      "preview": "5. Peripheral IV: $60 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2196,
      "preview": "6. Central IV: $120 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2197,
      "preview": "D. Calcium Gluconate"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2198,
      "preview": "7. Peripheral IV: maximum $3 \\mathrm{~g} / \\mathrm{L}$ in PN , consider lower concentration in PN if"
    },
    {
      "type": "text",
      "section": "A. Amino Acids",
      "line": 2199,
      "preview": "8. Central IV: $8 \\mathrm{~g} / \\mathrm{L}$ or as per calcium/phosphate solubility curves"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IX. Basic Calculations",
      "line": 2201
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2203,
      "preview": "A. Glucose Delivery: Calculating glucose delivery or Glucose Infusion Rate (GIR) requires converting"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2205,
      "preview": "1. GIR mg/kg/min = (D\\%)(10/11)(\\# mL/kg/day)(1/144). Example -"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2207,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2209,
      "preview": "--- page 93 ---"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2211,
      "preview": "D12.5\\% @ $80 \\mathrm{~mL} / \\mathrm{kg} /$ day $=(12.5)(10 / 11)(80)(1 / 144)=6.3 \\mathrm{mg} / \\ma"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2212,
      "preview": "i. Most neonates require $4-8 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ initially."
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2213,
      "preview": "ii. Advance by $1-2.5 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ daily as tolerated"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2214,
      "preview": "iii. Target is $10-12 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$."
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2215,
      "preview": "2. GIR g/kg/day = (D\\%)(10/11)(\\# mL/kg/day)(1/100). Example --"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2217,
      "preview": "D12.5\\% @ $120 \\mathrm{~mL} / \\mathrm{kg} /$ day $=(12.5)(10 / 11)(120)(1 / 100)=13.6 \\mathrm{~g} / "
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2218,
      "preview": "i. Most neonates need $13-18 \\mathrm{~g} / \\mathrm{kg} /$ day; avoid $>18 \\mathrm{~g} / \\mathrm{kg} "
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2219,
      "preview": "3. To convert $\\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ to $\\mathrm{g} / \\mathrm{kg} /$ day, multip"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2220,
      "preview": "B. Calories Provided: Calories from PN can be calculated from the amounts of fats and carbohydrates "
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2222,
      "preview": "1. Carbohydrate - calculate either from dextrose monohydrate concentration ( $3.4 \\mathrm{kcal} / \\m"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2223,
      "preview": "i. GIR: (Glucose gm/kg/day)(3.8 kcal/gm) = kcal/kg/day, or,"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2224,
      "preview": "ii. GIR: (Glucose mg/kg/min)(1.44)(3.8 kcal/g) = kcal/kg/day."
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2225,
      "preview": "2. Lipids - calculate either from:"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2226,
      "preview": "i. $\\mathrm{g} / \\mathrm{kg} /$ day: $(\\mathrm{g} / \\mathrm{kg} /$ day $)(10 \\mathrm{kcal} / \\mathrm"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2227,
      "preview": "ii. $\\mathrm{mL} / \\mathrm{kg} /$ day: $(\\mathrm{mL} / \\mathrm{kg} /$ day $)(2 \\mathrm{kcal} / \\math"
    },
    {
      "type": "text",
      "section": "IX. Basic Calculations",
      "line": 2228,
      "preview": "3. Protein $-\\mathrm{Kcal} / \\mathrm{kg}=(\\mathrm{g}$ amino acid $/ \\mathrm{kg} /$ day $)(4 \\mathrm{"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Calcium Calculations:",
      "line": 2230
    },
    {
      "type": "text",
      "section": "C. Calcium Calculations:",
      "line": 2232,
      "preview": "Calcium gluconate mg per 250 mL bag $=(\\mathrm{mg}$ calcium $/ \\mathrm{kg} /$ day $) /(\\mathrm{mL} /"
    },
    {
      "type": "text",
      "section": "C. Calcium Calculations:",
      "line": 2234,
      "preview": "1. Remember maximum safe concentrations -- calcium IV infiltrates can cause severe injury resulting "
    },
    {
      "type": "text",
      "section": "C. Calcium Calculations:",
      "line": 2235,
      "preview": "i. Central: $8 \\mathrm{~g} / \\mathrm{L}=800 \\mathrm{mg} / 100 \\mathrm{~mL}$"
    },
    {
      "type": "text",
      "section": "C. Calcium Calculations:",
      "line": 2236,
      "preview": "ii. Peripheral: $3 \\mathrm{~g} / \\mathrm{L}=300 \\mathrm{mg} / 100 \\mathrm{~mL}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 2238
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2240,
      "preview": "1. American Academy of Pediatrics Committee on Nutrition (2009). Parenteral Nutrition. In R.E. Klein"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2241,
      "preview": "2. te Braake FW, van den Akker CH, Riedijk MA, van Goudoever JB. Parenteral amino acid and energy"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2243,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2245,
      "preview": "--- page 94 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2247,
      "preview": "3. Ehrenkranz RA. Early nutritional support and outcomes in ELBW infants. Early Hum Dev. 2010 July; "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2248,
      "preview": "4. Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK et al. Growth in the neonatal in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2249,
      "preview": "5. Stephens BE et al. First-week protein and energy intakes are associated with 18-month development"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2250,
      "preview": "6. Uthaya S, Modi N. Practical preterm parenteral nutrition: Systematic literature review and recomm"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2251,
      "preview": "7. Vlaardingerbroek H, van Goudoever J. Intravenous Lipids in Preterm Infants: Impact on Laboratory "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2253,
      "preview": "--- page 95 ---"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2255,
      "preview": "| Nutrient | Initial | Advance | Comments |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2256,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2257,
      "preview": "| Dextrose | $<1500 \\mathrm{gm}: 4-6$ <br> $\\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ <br> All other"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2258,
      "preview": "| Fat/ IL 20\\% | $<1500 \\mathrm{gm}: 0.5$ <br> $\\mathrm{g} / \\mathrm{kg} /$ day <br> All others, min"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2259,
      "preview": "| Protein/AA <br> (TrophAmine) | $<1500 \\mathrm{gm}$ : max <br> allowed, up to 3 <br> $\\mathrm{gm} /"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2260,
      "preview": "| Trace <br> elements | $\\underline{Z n}$ : <br> Pre-term infant: <br> $400 \\mathrm{mcg} / \\mathrm{k"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2262,
      "preview": "--- page 96 ---"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2264,
      "preview": "| Nutrient | Initial | Advance | Comments |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2265,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2266,
      "preview": "| $\\mathrm{Ca} /$ Phos | Calcium gluconate: up to 300 $\\mathrm{mg} / \\mathrm{kg} /$ day <br> Phospho"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2267,
      "preview": "| Na | 1st DOL: no additional needed (i.e., min allowed) DOL 2-3: 0-2 mEq/kg/day Older: maintenance "
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2268,
      "preview": "| $\\mathrm{K+}$ | 1st DOL: no additional needed (i.e., min allowed) DOL 2-3: 0-2 mEq/kg/day Older: M"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2269,
      "preview": "| Acetate | 0-1 mEq/kg/day | As needed per labs (<1500 gm may need max allowed) | Watch labs closely"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2270,
      "preview": "| Mg | Do not give if elevated Mg Otherwise: 0.2-0.3 mEq/kg/d | Usual dose: 0.3 mEq/kg/d, once Mg le"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2272,
      "preview": "--- page 97 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2274
    },
    {
      "type": "image",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2276,
      "content": "![img-6.jpeg](images/dfe3081e1f15ca26.png)"
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2278,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2280,
      "preview": "--- page 98 ---"
    },
    {
      "type": "image",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2282,
      "content": "![img-7.jpeg](images/56dbb7cdcb32694a.png)"
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2284,
      "preview": "1. Enter weight"
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2285,
      "preview": "2. Enter IV access type."
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2286,
      "preview": "3. Total Fluid Intake defaults to 80 $\\mathrm{mL} / \\mathrm{kg}$. You may enter a range of $80 \\math"
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2287,
      "preview": "4. Amino Acids defaults to $3 \\mathrm{~g} / \\mathrm{kg} / \\mathrm{d}$."
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2288,
      "preview": "5. Dextrose defaults to $10 \\%$. You may enter a range of $5-10 \\%$."
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2290,
      "preview": "--- page 99 ---"
    },
    {
      "type": "image",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2292,
      "content": "![img-8.jpeg](images/f58fa3d1dfd1f01d.png)"
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2294,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "Appendix 1: Ordering Vanilla TPN via PremieDay1 Protocol in TPN Link Software",
      "line": 2296,
      "preview": "--- page 100 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Enteral Feeding",
      "line": 2298
    },
    {
      "type": "text",
      "section": "Enteral Feeding",
      "line": 2300,
      "preview": "Kari McCallie, M.D., Olivia Mayer, R.D., CSP, I.B.C.L.C., Alexis Davis, M.D. and Ronald S. Cohen, M."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 2302
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2304,
      "preview": "A. Goals for the premature infant"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2306,
      "preview": "1. Simulate intrauterine growth"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2307,
      "preview": "a. Weight gain: $1-2 \\%$ of body weight/day"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2308,
      "preview": "b. OFC increase by $0.5-1.0 \\mathrm{~cm} / \\mathrm{wk}$"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2309,
      "preview": "c. Length increase by $1-1.5 \\mathrm{~cm} / \\mathrm{wk}$"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 2310,
      "preview": "2. Stimulate fetal intestinal function: The fetal gut absorbs 500 mL of amniotic fluid/day near term"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "3. Avoid complications of TPN",
      "line": 2312
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. When to start enteral feeding?",
      "line": 2314
    },
    {
      "type": "text",
      "section": "B. When to start enteral feeding?",
      "line": 2316,
      "preview": "As soon as there are no contraindications, such as:"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Hemodynamic instability",
      "line": 2318
    },
    {
      "type": "text",
      "section": "1. Hemodynamic instability",
      "line": 2320,
      "preview": "a. Need for volume resuscitation"
    },
    {
      "type": "text",
      "section": "1. Hemodynamic instability",
      "line": 2321,
      "preview": "b. Dopamine $>5 \\mathrm{mcg} / \\mathrm{kg} / \\mathrm{min}$"
    },
    {
      "type": "text",
      "section": "1. Hemodynamic instability",
      "line": 2322,
      "preview": "c. Initiation of hydrocortisone (can feed if stable on maintenance or weaning doses)"
    },
    {
      "type": "text",
      "section": "1. Hemodynamic instability",
      "line": 2323,
      "preview": "d. Significant PDA or $\\leq 48$ hrs after closure with indomethacin"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Abnormal abdomen",
      "line": 2325
    },
    {
      "type": "text",
      "section": "2. Abnormal abdomen",
      "line": 2327,
      "preview": "a. Abdominal distention, discoloration, \"surgical\" abdomen"
    },
    {
      "type": "text",
      "section": "2. Abnormal abdomen",
      "line": 2328,
      "preview": "b. Suspected GI anomaly"
    },
    {
      "type": "text",
      "section": "2. Abnormal abdomen",
      "line": 2329,
      "preview": "c. Large volume or bloody gastric residual."
    },
    {
      "type": "text",
      "section": "2. Abnormal abdomen",
      "line": 2330,
      "preview": "d. After GI Surgery - per discussion with Surgical Team."
    },
    {
      "type": "text",
      "section": "2. Abnormal abdomen",
      "line": 2331,
      "preview": "3. Perinatal depression (e.g., low Apgars, metabolic acidosis, hypoxic-ischemic encephalopathy, Ther"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "4. Respiratory instability",
      "line": 2333
    },
    {
      "type": "text",
      "section": "4. Respiratory instability",
      "line": 2335,
      "preview": "a. Impending ECMO"
    },
    {
      "type": "text",
      "section": "4. Respiratory instability",
      "line": 2337,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "4. Respiratory instability",
      "line": 2339,
      "preview": "--- page 101 ---"
    },
    {
      "type": "text",
      "section": "4. Respiratory instability",
      "line": 2341,
      "preview": "b. Prolonged episodes of hypoxemia/desaturation."
    },
    {
      "type": "text",
      "section": "4. Respiratory instability",
      "line": 2342,
      "preview": "c. Mechanical ventilation and/or UAC are not in and of themselves contraindications to enteral feedi"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. What to Feed",
      "line": 2344
    },
    {
      "type": "text",
      "section": "II. What to Feed",
      "line": 2346,
      "preview": "A. Maternal milk (MM): Every effort should be made before and after delivery to encourage maternal p"
    },
    {
      "type": "text",
      "section": "II. What to Feed",
      "line": 2348,
      "preview": "1. The volume of expressed milk at 2 wks post-partum is usually predictive of successful lactation; "
    },
    {
      "type": "text",
      "section": "II. What to Feed",
      "line": 2349,
      "preview": "2. Lactation Services are available to consult and assist our mothers. Early intervention is best."
    },
    {
      "type": "text",
      "section": "II. What to Feed",
      "line": 2350,
      "preview": "3. It is not necessary however to delay enteral nutrition until maternal milk supply is available."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Donor milk (DM)",
      "line": 2352
    },
    {
      "type": "text",
      "section": "B. Donor milk (DM)",
      "line": 2354,
      "preview": "1. For VLBW infants at risk for NEC, Human Donor Milk (DM) from the Milk Bank is available to supple"
    },
    {
      "type": "text",
      "section": "B. Donor milk (DM)",
      "line": 2355,
      "preview": "2. Pasteurization does kill the white cells in DM, and thus, it is not as good as fresh MM. However,"
    },
    {
      "type": "text",
      "section": "B. Donor milk (DM)",
      "line": 2356,
      "preview": "3. DM is available in small-volume containers for use in trophic feeds in even the smallest infants,"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Advantages of human milk",
      "line": 2358
    },
    {
      "type": "text",
      "section": "C. Advantages of human milk",
      "line": 2360,
      "preview": "1. Presence of numerous hormones and growth factors, including epidermal growth factor; as well as b"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Limitations of human milk",
      "line": 2362
    },
    {
      "type": "text",
      "section": "D. Limitations of human milk",
      "line": 2364,
      "preview": "1. Additional protein, sodium, Vitamin D, calcium, and phosphorus may be necessary to meet premature"
    },
    {
      "type": "text",
      "section": "D. Limitations of human milk",
      "line": 2365,
      "preview": "2. Human milk has a range of caloric content and it is occasionally inadequate to support adequate w"
    },
    {
      "type": "text",
      "section": "D. Limitations of human milk",
      "line": 2366,
      "preview": "3. Maternal milk can be a source of bacterial infection if not collected carefully. MM may transmit "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. \"Fortifying\" human milk",
      "line": 2368
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2370,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2372,
      "preview": "--- page 102 ---"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2374,
      "preview": "Human Milk Fortifiers (HMF) or formula can be added to breast milk to increase caloric density, prot"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2376,
      "preview": "1. Human-Milk Based Human Milk Fortifier (H2MF) from Prolacta is used for infants less than 1250 gra"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2377,
      "preview": "a. Prolact+4 ( 10 mL fortifier added to 40 mL human milk ) adds $4 \\mathrm{kcal} / \\mathrm{oz}$ to h"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2378,
      "preview": "b. Prolact+6 ( 30 mL fortifier added to 70 mL human milk$) \\approx 26 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2379,
      "preview": "c. Prolact+8 ( 40 mL fortifier added to 60 mL human milk$) \\approx 28 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2380,
      "preview": "d. Prolact+10 ( 50 mL fortifier added to 50 mL human milk$) \\approx 30 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2381,
      "preview": "e. See Figure 1 for guidelines for transitioning off of Prolacta products at $\\sim 34$ weeks PMA"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2382,
      "preview": "2. Similac\u00ae Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid (Liquid HMF) is a cow's milk"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2383,
      "preview": "a. 1 packet added to 50 mL of Human Milk $\\approx 22 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2384,
      "preview": "b. 1 packet added to 25 mL of Human Milk $\\approx 24 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2385,
      "preview": "3. Liquid Protein Fortifier- Abbott Liquid Protein Fortifier ${ }^{\\circledR}$ (ALPF) is an extensiv"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2386,
      "preview": "4. Liquid Formula- There are concerns about sterility with powdered formulas, so liquid concentrates"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2387,
      "preview": "a. Similac Special Care $30^{\\circledR}$ (SSC30)"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2388,
      "preview": "i. Human Milk: SSC30 mixed 2:1 $\\approx 23 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2389,
      "preview": "ii. Human Milk: SSC30 mixed 1:1 $\\approx 25 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2390,
      "preview": "iii. Human Milk: SSC30 mixed 1:2 $\\approx 27 \\mathrm{kcal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2391,
      "preview": "b. Term Formula Concentrate (typically $40 \\mathrm{cal} / \\mathrm{oz}$ )"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2393,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2395,
      "preview": "--- page 103 ---"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2397,
      "preview": "i. Human Milk: Term Formula Concentrate mixed 9:1 22 kcal/oz"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2398,
      "preview": "ii. Human Milk: Term Formula Concentrate mixed 4:1 24 kcal/oz"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2399,
      "preview": "iii. Human Milk: Term Formula Concentrate mixed 2.3:1 26 kcal/oz"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2400,
      "preview": "iv. Human Milk: Term Formula Concentrate mixed 1.5:1 28 kcal/oz"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2401,
      "preview": "v. Human Milk: Term Formula Concentrate mixed 1:1 30 kcal/oz"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2402,
      "preview": "5. Fat - very concentrated caloric source, though not optimum nutrition and large doses can cause lo"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2403,
      "preview": "a. MCT oil (medium-chain triglycerides) - $7.6 \\mathrm{kcal} / \\mathrm{mL}$ readily absorbed; useful"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2404,
      "preview": "b. MicroLipid $-4.5 \\mathrm{kcal} / \\mathrm{mL}$ includes essential long-chain fatty acids"
    },
    {
      "type": "text",
      "section": "E. \"Fortifying\" human milk",
      "line": 2405,
      "preview": "6. Formula Powder, e.g., NeoSure\u00ae, Enfamil\u00ae, EnfaCare\u00ae, Similac\u00ae, Pregestimil\u00ae, Nutramigen\u00ae, Aliment"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Formula feedings",
      "line": 2407
    },
    {
      "type": "text",
      "section": "F. Formula feedings",
      "line": 2409,
      "preview": "On (hopefully) rare occasions, mothers may not provide their own milk and refuse donor milk. In this"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "G. Osmolality Guidelines",
      "line": 2411
    },
    {
      "type": "text",
      "section": "G. Osmolality Guidelines",
      "line": 2413,
      "preview": "1. AAP suggests that formulas for normal infants not exceed $400 \\mathrm{mOsm} / \\mathrm{L}(450 \\mat"
    },
    {
      "type": "text",
      "section": "G. Osmolality Guidelines",
      "line": 2414,
      "preview": "a. Osmolality of most feeds, including formula are $<370 \\mathrm{mOsm} / \\mathrm{kg}$, except for wh"
    },
    {
      "type": "text",
      "section": "G. Osmolality Guidelines",
      "line": 2415,
      "preview": "b. Human Milk +Similac Hydrolyzed Protein Liquid HMF (24 cal/oz) $=450 \\mathrm{mOsm} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "G. Osmolality Guidelines",
      "line": 2416,
      "preview": "c. Do NOT fortify MM/DM with the LHMF beyond $24 \\mathrm{cal} / \\mathrm{oz}$"
    },
    {
      "type": "text",
      "section": "G. Osmolality Guidelines",
      "line": 2417,
      "preview": "d. IF you think the patient needs more kcals, STOP the HMF and fortify MM with Similac Special Care "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Fluid Volume",
      "line": 2419
    },
    {
      "type": "text",
      "section": "III. Fluid Volume",
      "line": 2421,
      "preview": "A. Our main goals for enteral feeds are to provide calories for growth and to meet all the other nut"
    },
    {
      "type": "text",
      "section": "III. Fluid Volume",
      "line": 2423,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Fluid Volume",
      "line": 2425,
      "preview": "--- page 104 ---"
    },
    {
      "type": "text",
      "section": "III. Fluid Volume",
      "line": 2427,
      "preview": "1. If your goal calories are $100-120 \\mathrm{kcal} / \\mathrm{kg} /$ day. This will require $150 \\ma"
    },
    {
      "type": "text",
      "section": "III. Fluid Volume",
      "line": 2428,
      "preview": "2. Premature infants with chronic lung disease or heart disease may require $120-150 \\mathrm{kcal} /"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Feeding Guidelines for Preterm Infants",
      "line": 2430
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Route",
      "line": 2432
    },
    {
      "type": "text",
      "section": "A. Route",
      "line": 2434,
      "preview": "1. Asymptomatic infants who can suck/swallow (usually $\\geq 33$ wks EGA) may attempt nipple feeds."
    },
    {
      "type": "text",
      "section": "A. Route",
      "line": 2435,
      "preview": "2. Most premature infants <34 EGA weeks are fed via gavage tube, either nasogastric (NG) or orogastr"
    },
    {
      "type": "text",
      "section": "A. Route",
      "line": 2436,
      "preview": "3. Premature infants who don't tolerate gastric feeding due to poor gastric emptying or small preemi"
    },
    {
      "type": "text",
      "section": "A. Route",
      "line": 2437,
      "preview": "a. NJ tubes require an x-ray to verify placement."
    },
    {
      "type": "text",
      "section": "A. Route",
      "line": 2438,
      "preview": "b. Transpyloric feeds must be by \"continuous drip\" using a pump."
    },
    {
      "type": "text",
      "section": "A. Route",
      "line": 2439,
      "preview": "c. Enteral medications should be checked to verify that they can be given via transpyloric route."
    },
    {
      "type": "text",
      "section": "A. Route",
      "line": 2440,
      "preview": "d. Note that any form of drip feeding will result in loss of calories due from nutrients sticking to"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Trophic feeds",
      "line": 2442
    },
    {
      "type": "text",
      "section": "B. Trophic feeds",
      "line": 2444,
      "preview": "Early enteral nutrition has been demonstrated to have a beneficial effect on maturation of the intes"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Colostrum",
      "line": 2446
    },
    {
      "type": "text",
      "section": "C. Colostrum",
      "line": 2448,
      "preview": "Colostrum, the initial milk produced in the first several days of lactation, has very important immu"
    },
    {
      "type": "text",
      "section": "C. Colostrum",
      "line": 2450,
      "preview": "1. If the infant is ready to begin feeds, colostrum should be used according to the appropriate feed"
    },
    {
      "type": "text",
      "section": "C. Colostrum",
      "line": 2451,
      "preview": "2. If feeds are still contraindicated, colostrum should be delivered to the buccal pouch (i.e. insid"
    },
    {
      "type": "text",
      "section": "C. Colostrum",
      "line": 2453,
      "preview": "--- page 105 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Feeding pathways",
      "line": 2455
    },
    {
      "type": "text",
      "section": "D. Feeding pathways",
      "line": 2457,
      "preview": "1. See the pathways below for details of feeding babies with birth weights $\\leq 1000 \\mathrm{~g}, 1"
    },
    {
      "type": "text",
      "section": "D. Feeding pathways",
      "line": 2458,
      "preview": "2. Feedings should be rounded to nearest mL (i.e., 2 mL not 2.2 mL )."
    },
    {
      "type": "text",
      "section": "D. Feeding pathways",
      "line": 2459,
      "preview": "3. The goal is to initiate feedings on the first day of life, using donor milk until maternal milk i"
    },
    {
      "type": "text",
      "section": "D. Feeding pathways",
      "line": 2460,
      "preview": "4. For infants $\\leq 14$ days old, use birth weight until the baby regains above this. Thereafter, y"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Monitoring",
      "line": 2462
    },
    {
      "type": "text",
      "section": "E. Monitoring",
      "line": 2464,
      "preview": "Tolerance to feeds must be monitored continuously. Infants should be clinically evaluated/examined a"
    },
    {
      "type": "text",
      "section": "E. Monitoring",
      "line": 2466,
      "preview": "1. Abdominal distention, visible loops or abdominal discoloration"
    },
    {
      "type": "text",
      "section": "E. Monitoring",
      "line": 2467,
      "preview": "2. Worsening clinical status, e.g.:"
    },
    {
      "type": "text",
      "section": "E. Monitoring",
      "line": 2468,
      "preview": "a. Hemodynamic/respiratory instability"
    },
    {
      "type": "text",
      "section": "E. Monitoring",
      "line": 2469,
      "preview": "b. Hypo- or hyperglycemia"
    },
    {
      "type": "text",
      "section": "E. Monitoring",
      "line": 2470,
      "preview": "3. Bloody stools NOT related to anal fissure"
    },
    {
      "type": "text",
      "section": "E. Monitoring",
      "line": 2471,
      "preview": "4. Bloody gastric residual or emesis"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Constipation",
      "line": 2473
    },
    {
      "type": "text",
      "section": "F. Constipation",
      "line": 2475,
      "preview": "Premature infants may go more than 24 hrs without a stool, but constipation may result in feeding in"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "G. Vitamins, Iron, and Minerals",
      "line": 2477
    },
    {
      "type": "text",
      "section": "G. Vitamins, Iron, and Minerals",
      "line": 2479,
      "preview": "See Vitamin and Mineral Chapter"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "H. Nutrition laboratory studies",
      "line": 2481
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2483,
      "preview": "We check labs periodically on \"feeding and growing\" premature infants for signs of vitamin/mineral, "
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2485,
      "preview": "1. Hematocrit q week; if low ( $<30 \\%$ ) and decreasing, then add reticulocyte count."
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2486,
      "preview": "2. For patients on chronic diuretics:"
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2487,
      "preview": "a. Renal Function Panel x 1-2/wk to follow electrolytes, Ca, \\& P."
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2489,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2491,
      "preview": "--- page 106 ---"
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2493,
      "preview": "b. Watch for hypochloremia, an indication of intracellular K-depletion; correct with KCl ."
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2494,
      "preview": "c. Consider Alkaline Phosphatase q 1-2 wks to watch for metabolic bone disease."
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2495,
      "preview": "3. Once off of PN, TPN labs can be discontinued if they have been benign. Labs that may need to be f"
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2496,
      "preview": "a. BUN: assesses protein utilization and renal function. A high BUN in the presence of normal renal "
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2497,
      "preview": "b. Ca/Phos: assesses dietary intake \\& Ca:P ratio. Severe rickets can develop in the presence of a n"
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2498,
      "preview": "c. Alkaline phosphatase (AlkP): normally increased with bone formation in premature infants, but if "
    },
    {
      "type": "text",
      "section": "H. Nutrition laboratory studies",
      "line": 2499,
      "preview": "d. Albumin: assesses protein intake/anabolism. Usually a low ALB and low BUN indicates inadequate Pr"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "I. Growth monitoring",
      "line": 2501
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2503,
      "preview": "1. Weight is measured daily, unless it is unsafe"
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2504,
      "preview": "a. Goal Weight Gain"
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2505,
      "preview": "2. Re-gain Birthweight by Day of Life 14"
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2506,
      "preview": "3. Premature Goals: $18 \\mathrm{~g} / \\mathrm{kg} /$ day for optimal neurodevelopmental outcomes"
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2507,
      "preview": "4. Term Goals: $25+\\mathrm{g} /$ day"
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2508,
      "preview": "5. Length and Head Circumference are measured weekly"
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2509,
      "preview": "a. Length Growth Goals $>0.9 \\mathrm{~cm} /$ week"
    },
    {
      "type": "text",
      "section": "I. Growth monitoring",
      "line": 2510,
      "preview": "b. Head Circumference Goals: $>0.9 \\mathrm{~cm} /$ week"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Post-discharge diet",
      "line": 2512
    },
    {
      "type": "text",
      "section": "V. Post-discharge diet",
      "line": 2514,
      "preview": "Though many NICU Grads will grow well and meet their nutritional needs on unfortified maternal milk,"
    },
    {
      "type": "text",
      "section": "V. Post-discharge diet",
      "line": 2515,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Post-discharge diet",
      "line": 2517,
      "preview": "--- page 107 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2519
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2521,
      "preview": "A. Post op: Assess when to initiate enteral feeding based on surgical repair"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2522,
      "preview": "B. Criteria for starting pathway:"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2524,
      "preview": "1. Adjusted gestational age/PMA $\\geq 34+0 / 7$ weeks"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2525,
      "preview": "2. Hemodynamically stable"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2526,
      "preview": "3. Evidence of return of bowel function as documented by stool and/or clearing of color or decrease "
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2527,
      "preview": "4. No evidence of GI obstruction (no abdominal distension, emesis)"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2528,
      "preview": "5. NICU and Surgery agree on starting pathway and any deviation is discussed during rounds"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2529,
      "preview": "C. Guidelines for which pathway to start based on surgical repair (ultimate decision is at the discr"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2530,
      "preview": "6. Pathway A - Slow: aspiration on barium swallow, documented aspiration pneumonia, ENT issue, duode"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2531,
      "preview": "7. Pathway B - Medium: CDH, omphalocele/gastroschisis, volvulus"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2532,
      "preview": "8. Pathway C - Fast: no vocal cord issues, low risk repair (LADD's procedure, pyloric stenosis after"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2533,
      "preview": "9. For G-tube placement: Wait 24 hours, then start half of previously tolerated gastric feeding regi"
    },
    {
      "type": "table",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2535,
      "preview": "| Pathway A - Slow | Pathway B - Medium | Pathway C - Fast |"
    },
    {
      "type": "table",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2536,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2537,
      "preview": "| Slow Continuous via NG or NJ tube | Continuous via NG tube | Bolus PO |"
    },
    {
      "type": "table",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2538,
      "preview": "| $\\square$ Start continuous at $1 \\mathrm{~mL} / \\mathrm{hr}$ <br> $\\square$ Advance 1 mL q 12 hr <"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2540,
      "preview": "D. Criteria to advance feedings:"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2542,
      "preview": "1. No emesis (more than a few mL of spit-up)"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2543,
      "preview": "2. Abdominal girth stable"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2545,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2547,
      "preview": "--- page 108 ---"
    },
    {
      "type": "text",
      "section": "VI. Pediatric Surgery Feeding Algorithm for NICU Patients",
      "line": 2549,
      "preview": "3. Normal bowel function"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "E. If unable to advance",
      "line": 2551
    },
    {
      "type": "heading",
      "level": 2,
      "section": "feedings",
      "line": 2553
    },
    {
      "type": "text",
      "section": "feedings",
      "line": 2555,
      "preview": "1. Return to previous rate and attempt again"
    },
    {
      "type": "text",
      "section": "feedings",
      "line": 2556,
      "preview": "2. Move to next slower pathway after failing to advance 3 times"
    },
    {
      "type": "text",
      "section": "feedings",
      "line": 2557,
      "preview": "3. Consider adding pro-motility agent. Consider adding anti-reflux medication (if emesis thought to "
    },
    {
      "type": "text",
      "section": "feedings",
      "line": 2558,
      "preview": "4. If unable to advance on slowest pathway, may need more extensive work up (x-rays, contrast study,"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 2560
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2562,
      "preview": "1. Cohen RS, McCallie KR. Feeding Premature Infants: Why, When, and What to Add to Human Milk. JPEN "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2563,
      "preview": "2. Fogleman AD, Cohen RS, Sakamoto P, Allen JC. Effect of added calcium, phosphorus, and infant form"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2564,
      "preview": "3. McCallie KR, Lee HC, Mayer O, Cohen RS, Hintz SR, Rhine WD. Improved outcomes with a standardized"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2565,
      "preview": "4. Morton J, Hall JY, Wong RJ, Thairu L, Benitz WE, Rhine WD. Combining hand techniques with electri"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2566,
      "preview": "5. Quigley MA, Henderson G, Anthony MY, McGuire W. Formula milk versus donor breast milk for feeding"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2567,
      "preview": "6. Cohen RS, Mayer O, Fogleman AD. Managing the Human-Milk-Fed, Preterm, VLBW Infant at NICU Dischar"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2569,
      "preview": "--- page 109 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2571,
      "preview": "Figure 1: Guidelines for transitioning off Prolacta products at 34 weeks PMA"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2573,
      "preview": "A: Maternal Milk Supply Adequate"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2575,
      "preview": "| Low risk VLBW | Medium risk VLBW | High risk VLBW |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2576,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2577,
      "preview": "| Routine feeders \\& growers; Wt gain adequate; Labs WNL | SGA; <br> Wt gain inadequate; <br> Labs m"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2578,
      "preview": "| Unfortified MBM up to $180-200+\\mathrm{mL} / \\mathrm{kg} / \\mathrm{d}$ | MBM + Liquid HMF 1 pack/ "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2580,
      "preview": "B: Maternal Milk Supply Inadequate"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2582,
      "preview": "| Low risk VLBW | Medium risk VLBW | High risk VLBW |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2583,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2584,
      "preview": "| Routine feeders \\& growers; Wt gain adequate; Labs WNL | SGA; <br> Wt gain inadequate; <br> Labs m"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2585,
      "preview": "| MBM:SSC ${ }^{30}$ 2:1 or PDF $22 \\mathrm{kcal} / \\mathrm{oz}$ up to $180-200+\\mathrm{mL} / \\mathr"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2587,
      "preview": "Abbreviations: SGA = small for gestational age, EUGR = extra-uterine growth restriction, MBM = mater"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2589,
      "preview": "--- page 110 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2591,
      "preview": "Table 1: Enteral Feeding Pathway: Birth Weight $\\leq 1000 \\mathrm{~g}$"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2593,
      "preview": "| Day | Total Feed $\\mathrm{mL} / \\mathrm{kg} / \\mathrm{d}$ | Frequency | Comments |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2594,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2595,
      "preview": "| Day 1 | 10 | q 6 h | Use DM if MM unavailable |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2596,
      "preview": "| Day 2 | 10 | q 6 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2597,
      "preview": "| Day 3 | 10 | q 6 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2598,
      "preview": "| Day 4 | 20 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2599,
      "preview": "| Day 5 | 20 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2600,
      "preview": "| Day 6 | 20 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2601,
      "preview": "| Day 7 | 40 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2602,
      "preview": "| Day 8 | 60 | q 3 h | add Prolact +6 |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2603,
      "preview": "| Day 9 | 80 | q 3 h | Run IL $1 \\mathrm{~g} / \\mathrm{kg}$ max |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2604,
      "preview": "| Day 10 | 100 | q 3 h | Discontinue central line |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2605,
      "preview": "| Day 11 | 120 | q 3 h | Increase to Prolact +8 |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2606,
      "preview": "| Day 12 | 140 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2607,
      "preview": "| Day 13 | 160 | q 3 h |  |"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2609,
      "preview": "Table 2: Enteral Feeding Pathway: Birth Weight 1001-1250 g"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2611,
      "preview": "| Day | Total Feed $\\mathrm{mL} / \\mathrm{kg} / \\mathrm{d}$ | Frequency | Comments |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2612,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2613,
      "preview": "| Day 1 | 20 | q 3 h | Use DM if MM unavailable |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2614,
      "preview": "| Day 2 | 20 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2615,
      "preview": "| Day 3 | 20 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2616,
      "preview": "| Day 4 | 20 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2617,
      "preview": "| Day 5 | 40 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2618,
      "preview": "| Day 6 | 60 | q 3 h | add Prolact +6 |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2619,
      "preview": "| Day 7 | 80 | q 3 h | Run IL at $1 \\mathrm{~g} / \\mathrm{kg}$ max |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2620,
      "preview": "| Day 8 | 100 | q 3 h | Discontinue central line |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2621,
      "preview": "| Day 9 | 120 | q 3 h | Increase to Prolact +8 |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2622,
      "preview": "| Day 10 | 140 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2623,
      "preview": "| Day 11 | 160 | q 3 h |  |"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2625,
      "preview": "Table 3: Enteral Feeding Pathway: Birth Weight 1251-1500 g"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2627,
      "preview": "| Day | Total Feed $\\mathrm{mL} / \\mathrm{kg} / \\mathrm{d}$ | Frequency | Comments |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2628,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2629,
      "preview": "| Day 1 | 20 | q 3 h | Use DM if MM unavailable |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2630,
      "preview": "| Day 2 | 20 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2631,
      "preview": "| Day 3 | 40 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2632,
      "preview": "| Day 4 | 40 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2633,
      "preview": "| Day 5 | 60 | q 3 h | add 1 packet Liquid HMF to <br> 25 mL |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2634,
      "preview": "| Day 6 | 80 | q 3 h | Run IL at $1 \\mathrm{~g} / \\mathrm{kg}$ max |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2635,
      "preview": "| Day 7 | 100 | q 3 h | Discontinue central line |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2636,
      "preview": "| Day 8 | 120 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2637,
      "preview": "| Day 9 | 140 | q 3 h |  |"
    },
    {
      "type": "table",
      "section": "References:",
      "line": 2638,
      "preview": "| Day 10 | 160 | q 3 h |  |"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2640,
      "preview": "$\\mathrm{DM}=$ donor milk; MM = maternal milk; IL = Intralipid; Liquid HMF = Similac ${ }^{\\circledR"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2642,
      "preview": "Figure 2: Post-discharge diet regimens"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2643,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2645,
      "preview": "--- page 111 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Post-Discharge Feeding Regimens",
      "line": 2647
    },
    {
      "type": "table",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2649,
      "preview": "| Adequate Maternal Milk Supply |  |  |"
    },
    {
      "type": "table",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2650,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2651,
      "preview": "| Appropriate Growth \\& Benign Labs | Slow Growth \\& Benign Labs | Slow Growth \\&/or Abnormal Bone L"
    },
    {
      "type": "table",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2652,
      "preview": "| Maternal Milk ad lib <br> PO Vitamin \\& Iron Drops | Maternal Milk ad lib \\& <br> PDF-22 x 2 feedi"
    },
    {
      "type": "table",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2653,
      "preview": "| Inadequate Maternal Milk Supply |  |  |"
    },
    {
      "type": "table",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2654,
      "preview": "| Adequate Growth \\& Benign Labs | Slow Growth \\& Benign Labs | Slow Growth \\&/or Abnormal Bone Labs"
    },
    {
      "type": "table",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2655,
      "preview": "| Maternal Milk ad lib \\& <br> PDF-22 as needed <br> PO Vitamin \\& Iron Drops | Maternal Milk ad lib"
    },
    {
      "type": "text",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2657,
      "preview": "From: Cohen RS, Mayer O, Fogleman AD. Managing the Human-Milk-Fed, Preterm, VLBW Infant at NICU Disc"
    },
    {
      "type": "text",
      "section": "Post-Discharge Feeding Regimens",
      "line": 2659,
      "preview": "--- page 112 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Vitamin and Mineral Requirements for Enterally Fed Newborns",
      "line": 2661
    },
    {
      "type": "text",
      "section": "Vitamin and Mineral Requirements for Enterally Fed Newborns",
      "line": 2663,
      "preview": "Olivia Mayer RD, CSP, IBCLC"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Vitamin Requirements",
      "line": 2665
    },
    {
      "type": "text",
      "section": "I. Vitamin Requirements",
      "line": 2667,
      "preview": "A. Vitamin $A$"
    },
    {
      "type": "text",
      "section": "I. Vitamin Requirements",
      "line": 2669,
      "preview": "As of 2/26/2015, the LPCH pharmacy does not routinely carry Vitamin A due to limited availability an"
    },
    {
      "type": "text",
      "section": "I. Vitamin Requirements",
      "line": 2670,
      "preview": "B. Vitamin E"
    },
    {
      "type": "text",
      "section": "I. Vitamin Requirements",
      "line": 2672,
      "preview": "5-25 IU/kg/d. Minimum needs are met by fortified human milk or preterm formula; Poly-vi-sol\u00ae ( $1 \\m"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Vitamin D",
      "line": 2674
    },
    {
      "type": "text",
      "section": "C. Vitamin D",
      "line": 2676,
      "preview": "1. $400-600 \\mathrm{IU} / \\mathrm{kg} / \\mathrm{d}$; met by pre-term formula or fortified human milk"
    },
    {
      "type": "text",
      "section": "C. Vitamin D",
      "line": 2677,
      "preview": "a. Not always met by full formula feeds, as Vitamin D content varies widely between formulations"
    },
    {
      "type": "text",
      "section": "C. Vitamin D",
      "line": 2678,
      "preview": "2. If found to be Vitamin D deficient, need at least 1000 IU Vitamin D/day."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Other Vitamins",
      "line": 2680
    },
    {
      "type": "text",
      "section": "D. Other Vitamins",
      "line": 2682,
      "preview": "Fortified human milk or pre-term formula, in combination with multivitamins, is an important dietary"
    },
    {
      "type": "text",
      "section": "D. Other Vitamins",
      "line": 2684,
      "preview": "--- page 113 ---"
    },
    {
      "type": "text",
      "section": "D. Other Vitamins",
      "line": 2686,
      "preview": "106 Part II-A: Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "D. Other Vitamins",
      "line": 2687,
      "preview": "E. Vitamin Requirements for Pre-Term Infants Receiving Enteral Nutrition"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2689,
      "preview": "| Vitamin and <br> unit of measure | Human milk content <br> (unit/100 kcal) | Suggested target <br>"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2690,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2691,
      "preview": "| Vitamin A, IU | 465 | $1,300-3,663$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2692,
      "preview": "| Vitamin E, IU | 0.48 | $2.2-11$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2693,
      "preview": "| Vitamin D, IU | 3.2 | $400-1000$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2694,
      "preview": "| Vitamin C, mg | 5.6 | $20-55$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2695,
      "preview": "| Folate, mcg | 6.9 | $35-100$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2696,
      "preview": "| Thiamine (B1), mcg | 29 | $140-300$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2697,
      "preview": "| Riboflavin (B2), mcg | 49 | $200-400$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2698,
      "preview": "| Pyridoxine (B6), mcg | 28 | $50-300$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2699,
      "preview": "| Niacin (B3), mg | 0.21 | $1-5.5$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2700,
      "preview": "| Cobalamin (B12), mcg | 0.07 | $0.1-0.8$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2701,
      "preview": "| Biotin, mcg | 0.56 | $1.7-16.5$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2702,
      "preview": "| Pantothenate, mg | 0.25 | $0.5-2.1$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2703,
      "preview": "| Choline, mg | $115-225$ (mcmol) | $8-55$ |"
    },
    {
      "type": "table",
      "section": "D. Other Vitamins",
      "line": 2704,
      "preview": "| Vitamin K, mcg | 0.29 | $4.4-28$ |"
    },
    {
      "type": "text",
      "section": "D. Other Vitamins",
      "line": 2706,
      "preview": "Fortified human milk and most formulas in combination with Poly-Vi-Sol\u00ae (or other pediatric multivit"
    },
    {
      "type": "text",
      "section": "D. Other Vitamins",
      "line": 2707,
      "preview": "*Human milk content varies widely, these values are estimated based"
    },
    {
      "type": "text",
      "section": "D. Other Vitamins",
      "line": 2709,
      "preview": "--- page 114 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Multivitamin Supplement",
      "line": 2711
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2713,
      "preview": "1. Typical dose recommended: 1 mL daily for those babies $>1.5 \\mathrm{~kg}$; and 0.5 mL given in di"
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2714,
      "preview": "2. For LPCH Pharmacy Product Information: http://online.lexi.com/lco/action/doc/retrieve/docid/chist"
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2715,
      "preview": "3. For most current formulation of Poly-Vi-Sol\u00ae, manufacturer site:"
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2716,
      "preview": "https://www.meadjohnson.com/pediatric/us-"
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2717,
      "preview": "en/productinformation/products/vitamins/enfamil-poly-vi-sol-drops\\#nutrients"
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2718,
      "preview": "G. AquADEKs ${ }^{\\text {TM }}$ Pediatric Drops: recommended for babies on enteral feeds with chroni"
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2720,
      "preview": "For most current formulation, see LPCH House Staff Manual:"
    },
    {
      "type": "text",
      "section": "F. Multivitamin Supplement",
      "line": 2721,
      "preview": "http://online.lexi.com/lco/action/doc/retrieve/docid/chistn f/67894"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Mineral Requirements",
      "line": 2723
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Iron",
      "line": 2725
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Term infants",
      "line": 2727
    },
    {
      "type": "text",
      "section": "1. Term infants",
      "line": 2729,
      "preview": "a. Breast-fed: no supplemental iron until 4-6 months of life"
    },
    {
      "type": "text",
      "section": "1. Term infants",
      "line": 2730,
      "preview": "b. Formula-fed: use iron fortified formula per AAP Guidelines"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Preterm Infants",
      "line": 2732
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2734,
      "preview": "Begin after the infant has been advanced to full feeds. Ferrous sulfate oral drops (elemental Fe 15 "
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2735,
      "preview": "a. If on breast milk:"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2736,
      "preview": "i. For $<1500 \\mathrm{~g}$ birthweight: $2-4 \\mathrm{mg}$ elemental $\\mathrm{Fe} / \\mathrm{kg} /$"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2737,
      "preview": "ii. For $>1500 \\mathrm{gm}$ birthweight: $0-2 \\mathrm{mg}$ elemental $\\mathrm{Fe} / \\mathrm{kg} / \\m"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2738,
      "preview": "b. If on iron-fortified formula: $1-2 \\mathrm{mg}$ elemental $\\mathrm{Fe} / \\mathrm{kg} / \\mathrm{d}"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2739,
      "preview": "c. For those treated with recombinant erythropoietin: $4-6 \\mathrm{mg}$ elemental $\\mathrm{Fe} / \\ma"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2741,
      "preview": "Order Ferrous sulfate oral drops ( $15 \\mathrm{mg} / \\mathrm{mL}$ ) so that the dose given is an inc"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2743,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2744,
      "preview": "\\begin{aligned}"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2745,
      "preview": "1.5 \\mathrm{mg} & =0.1 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2746,
      "preview": "3 \\mathrm{mg} & =0.2 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2747,
      "preview": "4.5 \\mathrm{mg} & =0.3 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2748,
      "preview": "6 \\mathrm{ml} & =0.4 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2749,
      "preview": "7.5 \\mathrm{ml} & =0.5 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2750,
      "preview": "9 \\mathrm{mg} & =0.6 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2751,
      "preview": "10.5 \\mathrm{mg} & =0.7 \\mathrm{~mL}"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2752,
      "preview": "\\end{aligned}"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2753,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2755,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2757,
      "preview": "--- page 115 ---"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2759,
      "preview": "108 Part II-A: Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2761,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2762,
      "preview": "\\begin{aligned}"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2763,
      "preview": "& 12 \\mathrm{mg}=0.8 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2764,
      "preview": "& 13.5 \\mathrm{mg}=0.9 \\mathrm{~mL} \\\\"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2765,
      "preview": "& 15 \\mathrm{mg}=1 \\mathrm{~mL}"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2766,
      "preview": "\\end{aligned}"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2767,
      "preview": "$$"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Calcium",
      "line": 2769
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Term infants",
      "line": 2771
    },
    {
      "type": "text",
      "section": "1. Term infants",
      "line": 2773,
      "preview": "a. AAP Guidelines: $0-6$ months $=210 \\mathrm{mg} /$ day. Met by breast milk or formula"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Preterm infants",
      "line": 2775
    },
    {
      "type": "text",
      "section": "2. Preterm infants",
      "line": 2777,
      "preview": "a. Maintenance: $120-220 \\mathrm{mg} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "2. Preterm infants",
      "line": 2778,
      "preview": "b. Therapeutic: in setting of Alk Phos $>500$ when on full feeds and MVI for at least 1 week, start "
    },
    {
      "type": "text",
      "section": "2. Preterm infants",
      "line": 2779,
      "preview": "i. Supplementation should be $\\approx 220-250 \\mathrm{mg} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "2. Preterm infants",
      "line": 2780,
      "preview": "ii. Calcium Glubionate (NeoCalGlucon) $\\approx 23 \\mathrm{mg}$ elemental calcium/mL or Calcium Carbo"
    },
    {
      "type": "text",
      "section": "2. Preterm infants",
      "line": 2781,
      "preview": "iii. Ca: Phos ratio=1.8-2:1 for optimal bone mineralization (using mg:mg)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Phosphorus",
      "line": 2783
    },
    {
      "type": "text",
      "section": "C. Phosphorus",
      "line": 2785,
      "preview": "1. Term Infants $100 \\mathrm{mg} /$ day. Met by breast milk or formula."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Preterm Infants",
      "line": 2787
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2789,
      "preview": "a. Maintenance $60-140 \\mathrm{mg} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2790,
      "preview": "b. Therapeutic; in setting of Alk Phos $>500$ when on full feeds and MVI for at least 1 wk , start s"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2791,
      "preview": "i. Request a Nutrition Consult for recommendations and assistance in determining appropriate dose."
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2792,
      "preview": "ii. Supplementation should be about $120-150 \\mathrm{mg} / \\mathrm{kg} /$ day, use $\\mathrm{Na} / \\m"
    },
    {
      "type": "text",
      "section": "2. Preterm Infants",
      "line": 2793,
      "preview": "iii. Ca:Phos ratio=1.8-2:1 for optimal bone mineralization (using mg:mg)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Carnitine",
      "line": 2795
    },
    {
      "type": "text",
      "section": "D. Carnitine",
      "line": 2797,
      "preview": "1. Estimated need of $2.9 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{d}$ is typically met by breast milk or"
    },
    {
      "type": "text",
      "section": "D. Carnitine",
      "line": 2798,
      "preview": "2. If deficient, supplemental carnitine oral dose is $100 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{d}$ gi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Sodium",
      "line": 2800
    },
    {
      "type": "text",
      "section": "E. Sodium",
      "line": 2802,
      "preview": "1. Term Infants: $120 \\mathrm{mg} /$ day. Met by breast milk or formula."
    },
    {
      "type": "text",
      "section": "E. Sodium",
      "line": 2803,
      "preview": "2. Preterm Infants: $3-5 \\mathrm{mEq} / \\mathrm{kg} /$ day. May need oral supplement of sodium chlor"
    },
    {
      "type": "text",
      "section": "E. Sodium",
      "line": 2805,
      "preview": "--- page 116 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Potassium",
      "line": 2807
    },
    {
      "type": "text",
      "section": "F. Potassium",
      "line": 2809,
      "preview": "1. Term Infants: $400 \\mathrm{mg} /$ day. Met by breast milk or formula."
    },
    {
      "type": "text",
      "section": "F. Potassium",
      "line": 2810,
      "preview": "2. Preterm Infants: 2-3 mEq/kg. May need oral supplement of potassium chloride. Start oral KCl 2 $\\m"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "G. Chloride",
      "line": 2812
    },
    {
      "type": "text",
      "section": "G. Chloride",
      "line": 2814,
      "preview": "1. Term Infants $180 \\mathrm{mg} /$ day. Met by breast milk or formula."
    },
    {
      "type": "text",
      "section": "G. Chloride",
      "line": 2815,
      "preview": "2. Preterm Infants: 3-7 mEq/kg. Can be supplemented orally as NaCl or KCl ."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 2817
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2819,
      "preview": "1. Koletzko B, Poindexter B, Uauy R (eds): Nutritional Care of Preterm Infants: Scientific Basis and"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2820,
      "preview": "2. Sj\u00f6str\u00f6m et al. Intakes of Micronutrients Are Associated With Early Growth in Extremely Preterm I"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2821,
      "preview": "3. Bhatia J, et. al. Selected Macro/Micronutrient Needs of the Routine Preterm Infant . J Pediatr 20"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2822,
      "preview": "4. Steven A. Abrams and the COMMITTEE ON NUTRITION. Calcium and Vitamin D Requirements of Enterally "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2823,
      "preview": "5. M. Hermoso et al. Nutritional requirements of infants. Maternal and Child Nutrition (2010), 6 (Su"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2824,
      "preview": "6. Tyson JE et al. Vitamin A supplementation for extremely low birth weight infants. N Engl J Med 19"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2825,
      "preview": "7. Tolia VN et al. The effect of the national shortage of vitamin A on the death or chronic lung dis"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2826,
      "preview": "8. Bhatia J, Griffin I, Anderson D, Kler N, Domellof M. Selected Macro/Micronutrient needs of the ro"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2827,
      "preview": "9. Policy on Use of Flouride. American Academy of Pediatric Dentistry. Revised 2012. http://www.aapd"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2828,
      "preview": "10. Groh-Wargo, S; Thompson M, Cox J (eds.) ADA pocket guide to neonatal nutrition. 2009, pg 78."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2829,
      "preview": "11. Tudehope, et al. Nutritional needs of the micropreterm infant. (Table II). J Peds 2013; 162:S72-"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2830,
      "preview": "12. Abrams, et, al. Micronutrient Requirements of High-Risk Infants. Clin Perinatol 41 (2014) 347-36"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 2832,
      "preview": "--- page 117 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Formula Selection, Description, and Indications",
      "line": 2834
    },
    {
      "type": "text",
      "section": "Formula Selection, Description, and Indications",
      "line": 2836,
      "preview": "Olivia Mayer, RD, CSP, IBCLC"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Milk Types",
      "line": 2838
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2840,
      "preview": "A. Mother's milk"
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2842,
      "preview": "1. Nutrients are readily absorbed."
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2843,
      "preview": "2. Anti-infective factors present."
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2844,
      "preview": "3. Nutrient composition is unique."
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2845,
      "preview": "4. With the addition of human milk fortifier, can meet growth needs of pre-term infants."
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2846,
      "preview": "B. Banked Donor Milk (DM)"
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2847,
      "preview": "5. For use with high-risk VLBW infants when mom is unable or unwilling to provide sufficient breast "
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2848,
      "preview": "6. Must obtain parental/guardian assent, document in progress note"
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2849,
      "preview": "7. Slight nutrient degradation due to the pasteurization and freezing process."
    },
    {
      "type": "text",
      "section": "I. Milk Types",
      "line": 2850,
      "preview": "8. Maintains immune-enhancing properties unable to be duplicated in formula"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Formula Types",
      "line": 2852
    },
    {
      "type": "text",
      "section": "II. Formula Types",
      "line": 2854,
      "preview": "The AAP recommends all infants who are not breast-fed be given iron-fortified formula."
    },
    {
      "type": "text",
      "section": "II. Formula Types",
      "line": 2855,
      "preview": "The CDC and FDA recommend that powdered infant formulas not be used in neonatal intensive care setti"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Cow's Milk Based",
      "line": 2857
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2859,
      "preview": "1. Term: (e.g., Enfamil Premium\u00ae Newborn (birth-3 mo.), Enfamil Premium\u00ae Infant (3mo.-12mo.), Simila"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2860,
      "preview": "2. Pre-term: (e.g., Premature Enfamil\u00ae, Similac Special Care\u00ae) for infants with birth weight $<2 \\ma"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2861,
      "preview": "a. All available in a $24 \\mathrm{cal} / \\mathrm{oz}$, High Protein formulation, and a $30 \\mathrm{c"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2862,
      "preview": "b. $30 \\mathrm{cal} / \\mathrm{oz}$ Preterm formulas can be mixed with MBM"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2863,
      "preview": "3. Transitional/Post-Discharge: (e.g., Similac Neosure\u00ae, Enfamil Enfacare\u00ae) for pre-terms once they "
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2864,
      "preview": "B. Soy Protein Based: (e.g., Enfamil Prosobee\u00ae, Similac Soy Isomil\u00ae)"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2865,
      "preview": "4. Do NOT use in pre-term infants, as it results in poor bone mineralization."
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2866,
      "preview": "5. Not always appropriate when infant shows an allergy to milk products, as they may also be allergi"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2867,
      "preview": "6. Only medically indicated in infants diagnosed with Galactosemia."
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2869,
      "preview": "--- page 118 ---"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2871,
      "preview": "C. Partially Hydrolyzed Proteins (e.g., Similac Alimentum\u00ae, Enfamil Nutramigen\u00ae, Enfamil Pregestimil"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2873,
      "preview": "1. In a setting of compromised Gl tract, possible cow's milk protein allergy, or malabsorption."
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2874,
      "preview": "2. Similac Alimentum ${ }^{\\circledR}-33 \\%$ of fat is MCT"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2875,
      "preview": "3. Enfamil Pregestimil\u00ae - 55\\% of fat from MCT; typically used in babies with fat malabsorption, liv"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2876,
      "preview": "D. Free Amino Acid (e.g., Neocate\u00ae, Elecare\u00ae, Alfamino\u00ae Infant)"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2877,
      "preview": "4. Used if an infant does not tolerate partially hydrolyzed protein formula, and/or shows multiple p"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2878,
      "preview": "5. $33 \\%$ of fat from MCT, except for Alfamino\u00ae Infant, which has $43 \\%$ of fat from MCT"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2879,
      "preview": "E. Low-Fat Formulas (e.g., Monogen\u00ae, Enfaport ${ }^{\\text {TM }}$ )"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2880,
      "preview": "6. For Chylothorax, LCHAD Deficiency, or in some cases of severe liver failure"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2881,
      "preview": "7. Enfaport ${ }^{\\text {TM }}$ is designed to meet the nutritional needs of infants, contains Enfam"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2882,
      "preview": "8. Monogen\u00ae recommended for children $>1$ year of age by the manufacturer"
    },
    {
      "type": "text",
      "section": "A. Cow's Milk Based",
      "line": 2883,
      "preview": "III. Additives"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2885
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2887,
      "preview": "1. ONLY added to human breast milk for premature infants."
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2888,
      "preview": "2. Prolacta Bioscience Products - Human milk based fortifiers; used in infants $<1.25 \\mathrm{~kg}$ "
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2889,
      "preview": "a. Prolacta Fortifiers available as $+4,+6,+8,+10$, when added to MBM/BBM, the assumed final concent"
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2890,
      "preview": "b. Start with Prolacta+6\u00ae added breastmilk, for an assumed final concentration of $\\sim 26 \\mathrm{c"
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2891,
      "preview": "c. Prolact CR, Prolacta \"Cream\" - contains $2.5 \\mathrm{kcal} / \\mathrm{mL}$, and is added to human "
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2892,
      "preview": "d. Transition off of Prolacta products when infant reaches 34 weeks PMA, though use may be extended "
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2893,
      "preview": "3. Similac\u00ae Liquid HMF"
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2894,
      "preview": "a. Hydrolyzed Protein, Concentrated Liquid - same protein as found in Alimentum\u00ae formula, and higher"
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2895,
      "preview": "b. 1 packet per 25 mL of MBM will make $24 \\mathrm{cal} / \\mathrm{oz}$ feeding; no iron added"
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2896,
      "preview": "c. Do not use to concentrate MBM $>24 \\mathrm{cal} / \\mathrm{oz}$, as the osmolality will then be ab"
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2898,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Human Milk Fortifier (HMF)",
      "line": 2900,
      "preview": "--- page 119 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Carbohydrate",
      "line": 2902
    },
    {
      "type": "text",
      "section": "B. Carbohydrate",
      "line": 2904,
      "preview": "1. Sol Carb: glucose polymers (powder $=3.8 \\mathrm{kcal} / \\mathrm{gm}$ )."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Protein",
      "line": 2906
    },
    {
      "type": "text",
      "section": "C. Protein",
      "line": 2908,
      "preview": "1. Abbott Liquid Protein Fortifier; same casein hydrolysate protein as found in Similac Expert Care\u00ae"
    },
    {
      "type": "text",
      "section": "C. Protein",
      "line": 2909,
      "preview": "2. BeneProtein\u00ae: 100\\% hydrolyzed whey ( $3.4 \\mathrm{kcal} / \\mathrm{gm}$ ), only available as a po"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Fat",
      "line": 2911
    },
    {
      "type": "text",
      "section": "D. Fat",
      "line": 2913,
      "preview": "1. Microlipid: safflower oil $(4.5 \\mathrm{kcal} / \\mathrm{mL})$."
    },
    {
      "type": "text",
      "section": "D. Fat",
      "line": 2914,
      "preview": "2. MCT oil: fractionated coconut oil $(7.7 \\mathrm{kcal} / \\mathrm{mL}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2916
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2918,
      "preview": "--- page 120 ---"
    },
    {
      "type": "image",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2920,
      "content": "![img-9.jpeg](images/3e85841d5c9db5bf.png)"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2922,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2924,
      "preview": "--- page 121 ---"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2926,
      "preview": "114 Part II-A: Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2928,
      "preview": "**References:**"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2930,
      "preview": "1. http://www.prolacta.com/human-milk-fortifier/"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2931,
      "preview": "2. http://abbottnutrition.com/brands/similac"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2932,
      "preview": "3. http://www.min.com/app/iwp/hcp2/content2.do?dm=mj&id=/HCP_Home2/ProductInformation/hcpProducts&iw"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2933,
      "preview": "pst=HCP&ls=0&csred=1&r=3546121656"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2934,
      "preview": "4. http://medical.gerber.com/products/formulas/good-start-gentle#NutritionProfile"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2935,
      "preview": "5. Lapillonne et al. Nutritional Recommendations for the Late-Preterm Infant and the Preterm Infant "
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2936,
      "preview": "Discharge. J Pediatr 2013;162:S90-100"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2937,
      "preview": "6. Tudehope D. Human Milk and the Nutritional Needs of Preterm Infants. J Pediatr 2013;162:S17-25"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2938,
      "preview": "7. Vandenplas Y, et. al. Practical algorithms for managing common gastrointestinal symptoms in infan"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2939,
      "preview": "(2013) 184\u2013194"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2940,
      "preview": "8. http://www.fda.gov/Food/RecallsOutbreaksEmergencies/SafetyAlertsAdvisories/ucm111299.htm (Accesse"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2941,
      "preview": "5/20/2013)"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2942,
      "preview": "9. Jason J. Prevention of invasive cronobacter infections in young infants fed powdered infant formu"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2943,
      "preview": "2012;130;e1076; DOI: 10.1542/peds.2011-3855"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2944,
      "preview": "10. M Prahl et al. Lactobezoar formation in two premature infants receiving medium-chain triglycerid"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2945,
      "preview": "of Perinatology (2014) 34, 634\u2013635; doi:10.1038/jp.2014.78"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2947,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2948,
      "preview": "representations or warranties are made for outside use. Not for outside reproduction or publication "
    },
    {
      "type": "text",
      "section": "IV. Basic Infant Feeding Algorithm: (See next page)",
      "line": 2950,
      "preview": "--- page 122 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hyperkalemia",
      "line": 2952
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Arlene Sheehan, N.N.P.-B.C",
      "line": 2954
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 2956
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 2958,
      "preview": "A. Central K+ $>6.5 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 2959,
      "preview": "B. Serum $\\mathrm{K}+>7 \\mathrm{mEq} / \\mathrm{L}$, or hyperkalemia with EKG changes should be consi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Considerations",
      "line": 2961
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 2963,
      "preview": "A. About $98 \\%$ of total body potassium is intracellular, mostly in skeletal muscle."
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 2964,
      "preview": "B. About $90 \\%$ of potassium excretion from the body occurs in the urine, with approximately $10 \\%"
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 2966,
      "preview": "1. Hyperkalemia usually occurs when renal excretion is impaired"
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 2967,
      "preview": "2. Premature infants have impaired renal excretion of potassium."
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 2968,
      "preview": "C. Potassium shifts readily between the intracellular and extracellular spaces. Movement of potassiu"
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 2969,
      "preview": "3. Medications that can increase serum K: digitalis, indomethacin, spironolactone, heparin, beta blo"
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 2970,
      "preview": "4. Medications that can decrease serum K: loop diuretics (Lasix ${ }^{\\circledR}$ ), insulin, caffei"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Etiology",
      "line": 2972
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2974,
      "preview": "A. Laboratory error or hemolyzed specimen caused by phlebotomy (most common)."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2975,
      "preview": "B. Impaired renal excretion"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2977,
      "preview": "1. Acute renal failure"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2978,
      "preview": "2. Low GFR in the VLBW infant"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2979,
      "preview": "C. Acidosis (metabolic or respiratory) causing potassium shift from intracellular to extracellular s"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2980,
      "preview": "D. Tissue death with release of intracellular potassium."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2981,
      "preview": "E. Exchange transfusion with old banked blood or massive transfusion."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2982,
      "preview": "F. Excessive administration of $\\mathrm{K}+$"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2983,
      "preview": "G. Pathologic hemolysis of red blood cells"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2984,
      "preview": "3. Intraventricular hemorrhage."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2985,
      "preview": "4. Use of hypotonic glucose solution (i.e., $<3 \\%$ Dextrose)."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2987,
      "preview": "--- page 123 ---"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2989,
      "preview": "116 Part II-A: Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2990,
      "preview": "3. Pseudomonas sepsis."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2991,
      "preview": "4. Rh incompatibility."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2992,
      "preview": "H. Decreased activity of the renin-angiotensin-aldosterone system"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2994,
      "preview": "1. Congenital Adrenal Hyperplasia (patients also present with ambiguous genitalia (females), hyponat"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2995,
      "preview": "2. Adrenal hemorrhage."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2996,
      "preview": "3. Adrenal insufficiency."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2997,
      "preview": "I. Pseudohypoaldosteronism type I (PHA-1) caused by renal resistance to aldosterone - patients prese"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2998,
      "preview": "J. Digoxin therapy."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 2999,
      "preview": "K. Severe leukocytosis or thrombocytosis"
    },
    {
      "type": "image",
      "section": "III. Etiology",
      "line": 3000,
      "content": "![img-10.jpeg](images/8ddee5e40012ee2c.png)"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3001,
      "preview": "(Table from Liu, Lin, Sung and Lin, Pediatric Nephrology, Jan. 2017.)"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3003,
      "preview": "--- page 124 ---"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3005,
      "preview": "A. Repeat STAT measurement by central route. Avoid drawing blood proximal to an intravenous site tha"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3006,
      "preview": "B. Stop administration of potassium in intravenous fluids and any medications containing potassium."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3007,
      "preview": "C. EKG: Do a Lead II strip to check for peaked (tall or tented) T-waves, wide flat P waves, widening"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3009,
      "preview": "1. If EKG changes are present give calcium chloride $20 \\mathrm{mg} / \\mathrm{kg}$ IV to decrease my"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3010,
      "preview": "D. Stop all (gentamicin, vancomycin, etc.) renally toxic meds"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3011,
      "preview": "E. Determine whether cause is impaired elimination or excess administration: calculate the Fractiona"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3012,
      "preview": "2. Link: http://www.scymed.com/en/smnxps/pshfb358.htm"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3013,
      "preview": "3. Excess administration- FEK high"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3014,
      "preview": "4. Impaired elimination- FEK low"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3015,
      "preview": "F. Correct hypovolemia- normal saline bolus to increase renal perfusion and potassium excretion (if "
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3016,
      "preview": "G. Furosemide (Lasix\u00ae) $1 \\mathrm{mg} / \\mathrm{kg} /$ dose- if renal function is adequate to promot"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3017,
      "preview": "H. Correct respiratory acidosis with adequate ventilation"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3018,
      "preview": "I. Correct metabolic acidosis with bicarbonate $1 \\mathrm{mEq} / \\mathrm{kg}$ over 30 min (moves pot"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3019,
      "preview": "5. Avoid bicarbonate in the VLBW infant."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3020,
      "preview": "6. Correct respiratory acidosis first before giving bicarbonate."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3021,
      "preview": "J. Glucose and insulin may be given to drive potassium intracellularly."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3022,
      "preview": "7. If infant is normoglycemic give bolus of insulin and glucose together: 0.05 units $/ \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3023,
      "preview": "8. Start continuous infusions of dextrose and insulin"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3024,
      "preview": "a. Start dextrose infusion first using D10 at a rate of $5-10 \\mathrm{~mL} / \\mathrm{kg} / \\mathrm{h"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3025,
      "preview": "b. Once serum glucose is $>150 \\mathrm{mg} / \\mathrm{dl}$ start insulin by continuous infusion at 0."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3026,
      "preview": "c. Check serum glucose levels q 30 minutes until stable in the $100-200 \\mathrm{mg} / \\mathrm{dl}$ r"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3027,
      "preview": "d. Stop insulin infusion if serum glucose $<100 \\mathrm{mg} / \\mathrm{dl}$."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3028,
      "preview": "K. Nebulized albuterol moves potassium into cells."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3030,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3032,
      "preview": "--- page 125 ---"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3034,
      "preview": "L. Kayexalate ${ }^{\\circledR}$ (sodium polystyrene sulfonate resin) orally or by retention enema. C"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3035,
      "preview": "M. If potassium does not correct or if the infant is anuric consider other measures such as exchange"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Differential Diagnosis",
      "line": 3037
    },
    {
      "type": "text",
      "section": "V. Differential Diagnosis",
      "line": 3039,
      "preview": "A. Laboratory Studies: (monitor every 4-6 hrs.)"
    },
    {
      "type": "text",
      "section": "V. Differential Diagnosis",
      "line": 3041,
      "preview": "1. Electrolyte panel to detect other abnormalities such as metabolic acidosis."
    },
    {
      "type": "text",
      "section": "V. Differential Diagnosis",
      "line": 3042,
      "preview": "2. CK to detect muscle injury, lactate to assess tissue death"
    },
    {
      "type": "text",
      "section": "V. Differential Diagnosis",
      "line": 3043,
      "preview": "3. BUN, creatinine and urinalysis to evaluate kidney function"
    },
    {
      "type": "text",
      "section": "V. Differential Diagnosis",
      "line": 3044,
      "preview": "4. CBC to evaluate for hemolysis"
    },
    {
      "type": "text",
      "section": "V. Differential Diagnosis",
      "line": 3045,
      "preview": "5. If endocrine etiology is suspected consult Endocrine service and send serum aldosterone and plasm"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 3047
    },
    {
      "type": "text",
      "section": "References",
      "line": 3049,
      "preview": "1. Somers MJ. Causes, diagnosis, and evaluation of hyperkalemia in children. Up to Date. 2013. -http"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3050,
      "preview": "2. Profit J. Fluid and Electrolyte Therapy in Newborns. Up to Date. 2013. http://www.uptodate.com/co"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3051,
      "preview": "3. Gomela TL. Neonatology. Management, Procedures, On-Call Problems, Diseases, and Drugs. McGraw-Hil"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3052,
      "preview": "4. Sopfe J, Simmons, JH. Failure to thrive, hyponatremia, and hyperkalemia in a neonate. Pediatric A"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3053,
      "preview": "5. Bockenhauer D, Zieg J. Electrolyte Disorders. Clinics in Perinatology, 2014; 41: (3): 575-590"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3054,
      "preview": "6. Cohen, R.S. Management of Hyperkalemia. In Neonatology, Clinical Practice and Procedures. Editors"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3055,
      "preview": "7. Liu, C-C, Lin, S-H, Lung, C-C, Lin, C-M. A neonate with poor weight gain and hyperkalemia: Answer"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3056,
      "preview": "8. Bonilla-F\u00e9lix, M. Potassium regulation in the neonate, Pediatr Nephrol Epub 2017 Apr 04: 1-13"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3058,
      "preview": "--- page 126 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypokalemia",
      "line": 3060
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 3062,
      "preview": "Arlene M Sheehan, R.N., M.S., N.N.P.-B.C."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 3064
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 3066,
      "preview": "A. Normal neonatal serum potassium: 4-6.5 mEq/L"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 3067,
      "preview": "B. Mild hypokalemia: $3.5-3.9 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 3068,
      "preview": "C. Moderate hypokalemia: $2.5-3.5 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 3069,
      "preview": "D. Severe hypokalemia: $<2.5 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Principles",
      "line": 3071
    },
    {
      "type": "text",
      "section": "II. Principles",
      "line": 3073,
      "preview": "A. Serum K value obtained by heel-stick may be spuriously higher due to hemolysis associated with he"
    },
    {
      "type": "text",
      "section": "II. Principles",
      "line": 3074,
      "preview": "B. Infants rarely manifest symptoms until hypokalemia is severe (unless on digoxin)"
    },
    {
      "type": "text",
      "section": "II. Principles",
      "line": 3075,
      "preview": "C. Symptoms: EKG changes include flattened T waves, prolonged QT interval, appearance of $U$ waves. "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Etiology",
      "line": 3077
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3079,
      "preview": "A. Inadequate intake: normal maintenance is $1-2 \\mathrm{mEq} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3080,
      "preview": "B. Losses associated with medication administration: lasix ${ }^{\\circledR}$, aldactazide ${ }^{\\cir"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3081,
      "preview": "C. Losses associated with GI dysfunction: diarrhea, NG drainage, vomiting (pyloric stenosis)"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3082,
      "preview": "D. Renal loss: polyuria, RTA."
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3083,
      "preview": "E. Hyperaldosteronism"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3084,
      "preview": "F. Bartter Syndrome: renal salt wasting with hypokalemia and metabolic alkalosis"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3085,
      "preview": "G. Metabolic or respiratory alkalosis (potassium moves into cells)"
    },
    {
      "type": "text",
      "section": "III. Etiology",
      "line": 3086,
      "preview": "H. Insulin or albuterol administration (potassium moves into cells)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Diagnosis",
      "line": 3088
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3090,
      "preview": "A. Repeat STAT serum K level by central draw"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3091,
      "preview": "B. Renal function panel to assess renal status"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3092,
      "preview": "C. Calculate Fractional Excretion of Potassium (FEK). An FEK > 15\\% suggests renal losses."
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3094,
      "preview": "1. Link: http://www.scymed.com/en/smnxps/pshfb358.htm"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3096,
      "preview": "--- page 127 ---"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3098,
      "preview": "120 Part II-A: Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3099,
      "preview": "D. Urine electrolytes if renal loss is suspected"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3100,
      "preview": "E. Blood gas to assess acid/base status"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3101,
      "preview": "F. EKG if infant unstable"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3102,
      "preview": "G. Determine how much potassium the infant is receiving"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3103,
      "preview": "H. Is the infant receiving medications that waste potassium or drive potassium into the cells?"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3104,
      "preview": "I. Is the infant on digitalis? Hypokalemia in patients on digoxin can cause arrhythmia"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis",
      "line": 3105,
      "preview": "J. Is the infant experiencing high potassium loss from GI tract or kidneys?"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Treatment",
      "line": 3107
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 3109,
      "preview": "A. Treat the cause: decrease diuretic dose, stop other meds that may be causing potassium shift, cor"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 3110,
      "preview": "B. Avoid rapid replacement. Goal is to replete potassium stores over a 24 -hour period. Rapid admini"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 3111,
      "preview": "C. Mild hypokalemia can be corrected by adding or increasing maintenance potassium in the IV infusio"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 3112,
      "preview": "D. Moderate hypokalemia. Replete with slow infusion of IV potassium $0.5 \\mathrm{mEq} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 3113,
      "preview": "E. Severe hypokalemia. Replete with slow infusion of IV potassium $1 \\mathrm{mEq} / \\mathrm{kg}$ giv"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 3114,
      "preview": "F. If infant has severe GI losses consider starting replacement fluids of $1 / 2$ normal saline with"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 3116
    },
    {
      "type": "text",
      "section": "References",
      "line": 3118,
      "preview": "1. Bockenhauer, D, Zieg, J. Electrolyte Disorders. Clinics in Perinatology.2014; 41(3): 575-590."
    },
    {
      "type": "text",
      "section": "References",
      "line": 3119,
      "preview": "2. Gomella, LT. Neonatology. Management, Procedures, On-Call Problems, Diseases and Drugs. 6th Editi"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3121,
      "preview": "--- page 128 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hyponatremia",
      "line": 3123
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Arlene M Sheehan NNP and Matthew Wallenstein MD",
      "line": 3125
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 3127
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 3129,
      "preview": "Serum sodium $<135 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Signs and Symptoms",
      "line": 3131
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 3133,
      "preview": "Usually asymptomatic but may include irritability, lethargy, apnea, tremors, poor weight gain. Seizu"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Considerations",
      "line": 3135
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3137,
      "preview": "A. Newborn kidney has low GFR and poor concentrating abilities"
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3138,
      "preview": "B. Premature infants have immature skin with high transepidermal water losses"
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3139,
      "preview": "C. Normal serum sodium in the VLBW infant can range from 125-150."
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3140,
      "preview": "D. Maintenance sodium requirements $=2-4 \\mathrm{mEq} / \\mathrm{kg} /$ day. Higher in preterm after "
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3141,
      "preview": "E. Normal newborn urine output $=1-4 \\mathrm{~mL} / \\mathrm{kg} / \\mathrm{hr}$"
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3142,
      "preview": "F. Normal newborn specific gravity $=1.005$ to 1.012"
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3143,
      "preview": "G. Normal newborn serum osmolality $=280-300 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "III. Considerations",
      "line": 3144,
      "preview": "H. Normal newborn urine osmolality $=100-400 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3146
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3148,
      "preview": "A. Volume overload (usually presents with weight gain)"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3150,
      "preview": "1. Excessive free water administration"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3151,
      "preview": "2. Indomethacin - reduces free water clearance"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3152,
      "preview": "3. Sepsis with decreasing cardiac output"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3153,
      "preview": "4. Renal failure"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3154,
      "preview": "5. Congestive heart failure"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3155,
      "preview": "6. Paralytic ileus"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3156,
      "preview": "B. Sodium deficit (usually presents with weight loss)"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3157,
      "preview": "7. Prematurity with high renal Na losses"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3158,
      "preview": "8. Inadequate Na intake"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3160,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3162,
      "preview": "--- page 129 ---"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3164,
      "preview": "122 Part II-A: Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3165,
      "preview": "3. Diuretic therapy (especially Lasix)"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3166,
      "preview": "4. Renal failure with excess tubular Na excretion"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3167,
      "preview": "5. Na loss from diarrhea, gastric losses, ascites, pleural fluid"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3168,
      "preview": "6. Mineralocorticoid deficiency"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3169,
      "preview": "C. SIADH (weight usually unchanged)"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3171,
      "preview": "1. Central nervous system disorders (IVH, hydrocephalus, asphyxia, meningitis)"
    },
    {
      "type": "text",
      "section": "IV. Common Causes of Hyponatremia",
      "line": 3172,
      "preview": "2. Pulmonary disorders (pneumothorax)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Diagnosis",
      "line": 3174
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3176,
      "preview": "Determine whether low sodium is due to sodium deficit, volume overload or SIADH"
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3178,
      "preview": "Increasing sodium administration in newborns with water excess may correct the hyponatremia but may "
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3179,
      "preview": "A. For isolated low Na value- send repeat stat sample to rule out lab error."
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3180,
      "preview": "B. Calculate intake and output to determine is renal compromise/fluid overload is contributing to lo"
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3181,
      "preview": "C. Check weight trend. Hyponatremia with weight loss suggests sodium depletion. Hyponatremia with we"
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3182,
      "preview": "D. Evaluate renal function- send serum BUN/Creatinine"
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3183,
      "preview": "E. Consider sending urine sodium and osmolality and serum osmolality to evaluate for SIADH and renal"
    },
    {
      "type": "text",
      "section": "V. Diagnosis",
      "line": 3185,
      "preview": "--- page 130 ---"
    },
    {
      "type": "image",
      "section": "V. Diagnosis",
      "line": 3187,
      "content": "![img-11.jpeg](images/66e11eae536aebfd.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3189
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3191,
      "preview": "A. Sodium Deficit: treat with sodium administration"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3193,
      "preview": "1. Mild hyponatremia ( $\\mathrm{Na} 126-135$ ): correct over $24-48$ hrs by increasing sodium admini"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3194,
      "preview": "2. Moderate hyponatremia ( $\\mathrm{Na} 120-125$ ): calculate the sodium deficit using the following"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3195,
      "preview": "$\\mathrm{Na}+$ deficit $(\\mathrm{mEq} / \\mathrm{L})=[\\text { normal } \\mathrm{Na}+(\\mathrm{mEq} / \\m"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3196,
      "preview": "Give half replacement over 12-24 hrs."
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3197,
      "preview": "For replacement fluids use Normal Saline or 3\\% NaCL"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3198,
      "preview": "Try to avoid 3\\% NaCl for moderate or asymptomatic hyponatremia."
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3199,
      "preview": "$\\mathrm{NS}=154 \\mathrm{mEq} / \\mathrm{L}(0.154 \\mathrm{mEq} / \\mathrm{ml})$"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3200,
      "preview": "$3 \\% \\mathrm{NaCl}=513 \\mathrm{mEq} / \\mathrm{L}(0.5 \\mathrm{mEq} / \\mathrm{ml})$"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3202,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3204,
      "preview": "--- page 131 ---"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3206,
      "preview": "124 Part II-A: Fluids and Nutrition"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3207,
      "preview": "EXAMPLE: 1 kg preterm infant with serum sodium of 120 and evidence of sodium deficit."
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3208,
      "preview": "$\\mathrm{Na}+$ deficit $=(135-120)(1)(0.6)=9 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3209,
      "preview": "Using NS: $9 / 0.154=58 \\mathrm{ml}$"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3210,
      "preview": "Give 29 ml of NS over 12-24 hrs. Check serum sodium q 4 hrs stat during replacement."
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3211,
      "preview": "3. Severe symptomatic hyponatremia ( $\\mathrm{Na}<120 \\mathrm{mEq} / \\mathrm{L}$ and infant is seizi"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3212,
      "preview": "B. Volume overload: Hyponatremia with weight gain suggests water excess - treat with fluid restricti"
    },
    {
      "type": "text",
      "section": "VI. Treatment of Sodium Depletion",
      "line": 3213,
      "preview": "C. SIADH: Hyponatremia with no edema, decreased urine output, increased urine sodium excretion, high"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 3215
    },
    {
      "type": "text",
      "section": "References",
      "line": 3217,
      "preview": "1. Marcialis MA, Dessi A, Pintus MC, Irmesi R, Fanos V. Neonatal hyponatremia: differential diagnosi"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3218,
      "preview": "2. Moritz ML, Ayus JC. Hyponatremia in preterm neonates: not a benign condition. Pediatrics. 2009 No"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3219,
      "preview": "3. Bhatty SB, Tsirka A, Quinn PB, LaGamma EF, DeCristoforo JD. Rapid correction of hyponatremia in e"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3220,
      "preview": "4. Detlef Bockenhauer MD, PhD and Jakub Zieg MD, PhD. Electrolyte Disorders. Clinics in Perinatology"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3222,
      "preview": "--- page 132 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-B: Respiratory",
      "line": 3224
    },
    {
      "type": "text",
      "section": "Part II-B: Respiratory",
      "line": 3226,
      "preview": "--- page 133 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Mechanical Ventilation",
      "line": 3228
    },
    {
      "type": "text",
      "section": "Mechanical Ventilation",
      "line": 3230,
      "preview": "Ron Cohen, M.D. and William Benitz, M.D."
    },
    {
      "type": "text",
      "section": "Mechanical Ventilation",
      "line": 3231,
      "preview": "Background: Caring for a mechanically ventilated neonate continues to unnecessarily strike fear in t"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Indications for Mechanical Ventilation",
      "line": 3233
    },
    {
      "type": "text",
      "section": "I. Indications for Mechanical Ventilation",
      "line": 3235,
      "preview": "One, or a combination, of these may result in the need for mechanical ventilation:"
    },
    {
      "type": "text",
      "section": "I. Indications for Mechanical Ventilation",
      "line": 3236,
      "preview": "A. Apnea"
    },
    {
      "type": "text",
      "section": "I. Indications for Mechanical Ventilation",
      "line": 3237,
      "preview": "B. Hypoxemia"
    },
    {
      "type": "text",
      "section": "I. Indications for Mechanical Ventilation",
      "line": 3238,
      "preview": "C. Hypercapnea or Hypoventilation"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Types of Mechanical Ventilators",
      "line": 3240
    },
    {
      "type": "text",
      "section": "II. Types of Mechanical Ventilators",
      "line": 3242,
      "preview": "Simplistically, there are 3 types:"
    },
    {
      "type": "text",
      "section": "II. Types of Mechanical Ventilators",
      "line": 3243,
      "preview": "A. Volume Ventilators. These create breaths by inflating the lung with a prescribed tidal volume."
    },
    {
      "type": "text",
      "section": "II. Types of Mechanical Ventilators",
      "line": 3244,
      "preview": "B. Pressure Control (PC). These create breaths by inflating the lung with a prescribed amount of pre"
    },
    {
      "type": "text",
      "section": "II. Types of Mechanical Ventilators",
      "line": 3245,
      "preview": "C. High Frequency Venilators. These will be covered in Chapter II.B, High Frequency Ventilation."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3247
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3249,
      "preview": "In order to understand ventilators, we need to discuss how mechanical breaths are described and cont"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3250,
      "preview": "A. Time Paramaters"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3252,
      "preview": "1. Rate, or frequency: the number of breaths per unit time."
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3253,
      "preview": "2. Cycle time: this is the inverse of rate, or the unit of time for each breathing cycle, and is the"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3254,
      "preview": "3. Inspiratory Time (Ti): the time spent during lung inflation."
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3255,
      "preview": "4. Expiratory Time (Te): the time during which the ventilator is not trying to inflate the lung and "
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3256,
      "preview": "5. I:E Ratio: the ratio of Ti to Te ."
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3257,
      "preview": "6. When ordering mechanical breaths, only 2 parameters must be specified, since by simple math, sett"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3259,
      "preview": "--- page 134 ---"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3261,
      "preview": "rate of $30 / \\mathrm{min}$ and a Ti of 0.3 sec , then by definition the cycle time is 2 sec , the T"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3263,
      "preview": "Figure 1: Pressure \\& Time Parameters of Mechanical Breath"
    },
    {
      "type": "image",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3264,
      "content": "![img-12.jpeg](images/855df62a9e81b0bf.png)"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3265,
      "preview": "B. Pressure. Since a mechanical breath is divided into 2 parts, inspiration and expiration, the vent"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3267,
      "preview": "1. Peak Inspiratory Pressure (PIP): The peak pressure reached during inspiration. PIP is used to exp"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3268,
      "preview": "2. Positive End-Expiratory Pressure (PEEP): The minimal pressure allowed by the ventilator during ex"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3270,
      "preview": "Figure 2: Compliance"
    },
    {
      "type": "image",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3271,
      "content": "![img-13.jpeg](images/c700bad89c991d61.png)"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3272,
      "preview": "C. Volume. When using a pressure ventilator, the volume of gas delivered is measured; with volume ve"
    },
    {
      "type": "text",
      "section": "III. Definitions of Mechanical Breaths",
      "line": 3273,
      "preview": "D. Flow. With current ventilators, flow is determined automatically by the machine but can be displa"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Non-invasive Ventilatory Support",
      "line": 3275
    },
    {
      "type": "text",
      "section": "IV. Non-invasive Ventilatory Support",
      "line": 3277,
      "preview": "A. Continuous Positive Airway Pressure (CPAP). This is the least invasive type of ventilatory suppor"
    },
    {
      "type": "text",
      "section": "IV. Non-invasive Ventilatory Support",
      "line": 3279,
      "preview": "--- page 135 ---"
    },
    {
      "type": "text",
      "section": "IV. Non-invasive Ventilatory Support",
      "line": 3281,
      "preview": "lungs prone to collapse, such as babies with stiff lungs due to RDS or pneumonia. By keeping the lun"
    },
    {
      "type": "text",
      "section": "IV. Non-invasive Ventilatory Support",
      "line": 3282,
      "preview": "B. Non-invasive Positive Pressure Ventilation (NIPPV). Sometimes referred to as CPAP with a rate, th"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3284
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3286,
      "preview": "This is where is gets tricky, as there are several different modes of mechanical ventilation that ca"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3287,
      "preview": "A. Synchronized Intermittent Mandatory Ventilation (SIMV) . See Figure 3. This is the simplest of th"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3289,
      "preview": "1. Rate"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3290,
      "preview": "2. Ti"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3291,
      "preview": "3. PIP"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3292,
      "preview": "4. PEEP"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3294,
      "preview": "Figure 3: SIMV"
    },
    {
      "type": "image",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3295,
      "content": "![img-14.jpeg](images/a37d624794826046.png)"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3296,
      "preview": "B. Assist/Control (AC). See Figure 4. This mode is similar to SIMV in that there is a set minimum nu"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3298,
      "preview": "1. Rate (is the minimum)"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3300,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3302,
      "preview": "--- page 136 ---"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3304,
      "preview": "2. Ti"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3305,
      "preview": "3. PIP"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3306,
      "preview": "4. PEEP"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3308,
      "preview": "Figure 4: Assist Control"
    },
    {
      "type": "image",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3309,
      "content": "![img-15.jpeg](images/75be13901ce6d8c4.png)"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3310,
      "preview": "C. Volume Guarantee (VG). See Figure 5. This is a method of adding a safety limit to PC ventilation "
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3312,
      "preview": "1. This is a nice mode to use initially with a sick baby requiring high PIP, since it allows the wea"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3313,
      "preview": "2. Because the ventilator uses data from the last breath to set the pressure for the next one, which"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3314,
      "preview": "3. This mode may produce ventilator behaviors that appear anomalous to the uninitiated. The ventilat"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3316,
      "preview": "Figure 5: Volume Guarantee"
    },
    {
      "type": "image",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3317,
      "content": "![img-16.jpeg](images/90edfcbb7142ff21.png)"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3319,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3321,
      "preview": "--- page 137 ---"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3323,
      "preview": "A. Pressure Support (PS). See Figure 6. This mode is a variant of A/C that almost always is used in "
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3325,
      "preview": "1. The duration of the pressure support (the PS Ti if you will) is determined by patient effort. The"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3326,
      "preview": "2. The pressure ordered for PS is actually the pressure added to the PEEP. Thus, if you order a PS o"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3327,
      "preview": "3. Since PS allows the patient to determine rate and Ti , this is a very comfortable mode for the pa"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3328,
      "preview": "4. Conversely, for very sick patients, PS may not provide adequate support."
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3329,
      "preview": "5. Note, too, that when used in conjunction with SIMV, the patient may experience 2 very different k"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3330,
      "preview": "6. Thus, PS is usually reserved for more stable chronic patients in conjunction with SIMV delivering"
    },
    {
      "type": "text",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3332,
      "preview": "Figure 6: SIMV with Pressure Support"
    },
    {
      "type": "image",
      "section": "V. Modes on Endotracheal Tube Mechanical Ventilation",
      "line": 3333,
      "content": "![img-17.jpeg](images/3b9dfc8e7b5f6c2c.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Adjusting the Ventilator",
      "line": 3335
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3337,
      "preview": "A. PEEP. As discussed above, PEEP determines FRC, and has a major impact on compliance and oxygenati"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3339,
      "preview": "1. Starting PEEP is usually in the $4-6 \\mathrm{cmH} 2 \\mathrm{O}$ range."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3340,
      "preview": "2. A sicker, less compliant lung will need more PEEP to keep open."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3341,
      "preview": "3. As lung function improves, PEEP will need to be lowered to avoid \"gas trapping\" and hyperinflatio"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3342,
      "preview": "4. Increasing PEEP recruits more lung surface area for gas exchange, and is a common first maneuver "
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3343,
      "preview": "B. PIP. This is the major determinant of tidal volume in PC mode. Initially, PIP is adjusted based u"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3345,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3347,
      "preview": "--- page 138 ---"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3349,
      "preview": "movement and listening for gas exchange."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3351,
      "preview": "1. Starting PIP is usually in the $15-20 \\mathrm{cmH2O}$ range."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3352,
      "preview": "2. Sicker, less compliant lungs will need more PIP to create an adequate tidal volume."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3353,
      "preview": "3. As lung function improves, PIP will need to be lowered to avoid over-distention, volutrauma, and "
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3354,
      "preview": "4. Increasing PIP generally increases tidal volume, and is a common first maneuver to improve ventil"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3355,
      "preview": "C. Tidal Volume. If using VG, target tidal volumes need to be set."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3356,
      "preview": "5. VLBW infants: $4-5 \\mathrm{~mL} / \\mathrm{kg}$ initially."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3357,
      "preview": "6. Larger Premies infants: $5-6 \\mathrm{~mL} / \\mathrm{kg}$."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3358,
      "preview": "7. Sick Term infants: $6-8 \\mathrm{~mL} / \\mathrm{kg}$."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3359,
      "preview": "8. Note that over time the necessary setting for VLBW infants will increase slowly; by 3 -4 weeks of"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3360,
      "preview": "D. Rate. Using AC allows patients to set their own rate. Neonates with RDS tend to be tachypneic, an"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3361,
      "preview": "9. Starting rate are usually around 40 with either AC or SIMV."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3362,
      "preview": "10. With SIMV, increasing the rate is a good way to increase minute ventilation and thus improve ven"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3363,
      "preview": "11. Once patients start improving, the rate can be lowered."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3364,
      "preview": "12. In SIMV, a low level of PS allows patients to breath between PC breaths with less work of breath"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3365,
      "preview": "E. Ti. At LPCH, we usually start with a Ti of 0.35 seconds. This is long enough to provide a short i"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3366,
      "preview": "13. Longer Ti's have been associated with an increased incidence of air-leaks."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3367,
      "preview": "14. Spontaneous breaths, such as PS, will commonly use even shorter Ti's, frequently in the 0.20 sec"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3368,
      "preview": "15. With severe acute lung disease, or chronic lung disease complicated by increased airway resistan"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3369,
      "preview": "16. Increasing Ti thus is another method for improving oxygenation, but is reserved for these specia"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3370,
      "preview": "F. Oxygenation. Maneuvers to increase PaO 2 or SpO 2 include:"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3371,
      "preview": "17. Increase FiO2."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3372,
      "preview": "18. Increase PEEP."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3374,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3376,
      "preview": "--- page 139 ---"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3378,
      "preview": "3. Increase PIP."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3379,
      "preview": "4. Increase Rate"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3380,
      "preview": "5. Increase Ti."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3381,
      "preview": "G. Ventilation. Maneuvers to lower PaCO2 include:"
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3382,
      "preview": "6. Increase rate."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3383,
      "preview": "7. Increase PIP or VG."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3384,
      "preview": "8. Decrease PEEP (thus increasing the difference between PIP and PEEP)."
    },
    {
      "type": "text",
      "section": "VI. Adjusting the Ventilator",
      "line": 3385,
      "preview": "9. Increase Ti (this may increase tidal volume, but can also cause air trapping"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3387
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3389,
      "preview": "A. So, you've got a lousy blood gas:"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3391,
      "preview": "1. Figure out what's going on (oxygenation, ventilation or acid-base problem)"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3392,
      "preview": "2. Evaluate the baby"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3393,
      "preview": "3. Call for help if confused or unsure"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3394,
      "preview": "4. Make an intervention if necessary"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3395,
      "preview": "B. As far as what's going on..."
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3396,
      "preview": "5. Is there acidosis, and if so is it metabolic or respiratory?"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3397,
      "preview": "6. Look at the baby. Comfortable? Upset? Agitation is common in babies whose ventilation is sub-opti"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3398,
      "preview": "C. If you have a metabolic acidosis (i.e., base deficit with normal PaCO2)"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3399,
      "preview": "7. Is baby dry? If so, consider a bolus."
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3400,
      "preview": "8. Does baby need base? Some little babies may, as their kidneys aren't very good at retaining base "
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3401,
      "preview": "9. Could baby be septic?"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3402,
      "preview": "10. You can make a ventilator change as respiratory compensation is faster than metabolic compensati"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3403,
      "preview": "D. If you're dealing with a respiratory problem, troubleshoot first."
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3404,
      "preview": "11. Tube's out"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3405,
      "preview": "12. Tube's too low"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3407,
      "preview": "--- page 140 ---"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3409,
      "preview": "3. Tube's occluded or needs suctioning"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3410,
      "preview": "4. Recent vent change-if you make a vent change and get a bad gas, undo that change!"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3411,
      "preview": "5. Atelectasis"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3412,
      "preview": "6. Pneumothorax - these kids will be sick:"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3413,
      "preview": "a. Listen for decreased breath sounds"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3414,
      "preview": "b. Consider transillumination"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3415,
      "preview": "7. Pulmonary intestinal emphysema (PIE)"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3417,
      "preview": "--- page 141 ---"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3419,
      "preview": "Appendix:"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3420,
      "preview": "Troubleshooting some common waveform interpretation"
    },
    {
      "type": "image",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3421,
      "content": "![img-18.jpeg](images/3f91a3158a1c5951.png)"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3423,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3425,
      "preview": "--- page 142 ---"
    },
    {
      "type": "image",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3427,
      "content": "![img-19.jpeg](images/2e22abc6567f1825.png)"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3429,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VII. How to Handle a Bad Blood gas (a systematic approach):",
      "line": 3431,
      "preview": "--- page 143 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "High Frequency Ventilation",
      "line": 3433
    },
    {
      "type": "text",
      "section": "High Frequency Ventilation",
      "line": 3435,
      "preview": "Ron Cohen, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 3437
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3439,
      "preview": "A. Definition: High Frequency Ventilation [HFV] is defined by:"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3441,
      "preview": "1. Ventilator rates generally greater than 120 breaths per minute [bpm], or 2 breaths per second $[\\"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3442,
      "preview": "2. Tidal volumes [VT] less than dead space."
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3443,
      "preview": "B. The use of such small tidal volumes generally requires maintaining higher mean airway pressures ["
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3444,
      "preview": "C. For conventional ventilation:"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3446,
      "preview": "Minute Ventilation $\\mu(\\mathrm{VT}) \\times($ Rate $)$"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3447,
      "preview": "D. However, HFV minute ventilation is more dependent upon rate:"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3449,
      "preview": "Minute Ventilation $\\mu(\\mathrm{VT}) \\times($ Rate $)^{2}$"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3450,
      "preview": "E. Types of HFV"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3452,
      "preview": "1. High Frequency Jet Ventilation [HFJV]: This is a type of HFV that is characterized by the injecti"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3453,
      "preview": "2. High Frequency Oscillatory Ventilation [HFOV]: This type of HFV operates using oscillatory moveme"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3454,
      "preview": "a. Rigid ventilator circuit is needed to avoid volume loss due to tubing expansion between the baby "
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3455,
      "preview": "b. The active expiratory phase allows HFOV to run at somewhat higher frequencies than HFJV, but make"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Indications",
      "line": 3457
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3459,
      "preview": "A. HFV was originally developed as a \"rescue\" treatment for pulmonary air leak situations."
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3460,
      "preview": "B. Subsequent studies indicated it could be useful for \"rescue\" of severe pulmonary hypertension and"
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3461,
      "preview": "C. Recent trials have demonstrated efficacy for treatment of RDS."
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3462,
      "preview": "D. Studies have shown that iNO may be more effective when used in conjunction with HFV."
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3463,
      "preview": "E. Improvements in conventional ventilators and their management have tended to obscure the differen"
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3465,
      "preview": "1. Have persistent hypoventilation despite increased pressures"
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3467,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3469,
      "preview": "--- page 144 ---"
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3471,
      "preview": "2. Have pulmonary interstitial emphysema or pneumothoraces while requiring mechanical ventilation at"
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3472,
      "preview": "3. Have persistent hypoxemia on high FiO2 despite high Paw"
    },
    {
      "type": "text",
      "section": "II. Indications",
      "line": 3473,
      "preview": "4. Are approaching criteria for iNO or ECMO."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Transition to HFV [See Table]",
      "line": 3475
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3477,
      "preview": "A. Baseline preparations"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3479,
      "preview": "1. Chest $x$-Rays $[C x R]$"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3480,
      "preview": "a. Determine expansion"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3481,
      "preview": "b. Check for interstitial emphysema or pneumothorax"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3482,
      "preview": "2. Blood gases $[\\mathrm{ABG}]$"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3483,
      "preview": "3. Final conventional settings"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3484,
      "preview": "4. Nurse, Respiratory Care Practitioner[s], MD/NNP all prepared and present as rapid adjustments may"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3485,
      "preview": "B. Make sure HFOV is calibrated and ready to take over respiratory support before discontinuing conv"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3486,
      "preview": "C. Starting settings when converting to HFV"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3487,
      "preview": "5. PEEP or Paw"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3488,
      "preview": "a. The tiny VT used for HFV makes atelectasis a risk"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3489,
      "preview": "b. PEEP or Paw is increased 1-2 cmH 20 above conventional"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3490,
      "preview": "c. Too low a PEEP or Paw increases risk of hyperventilation"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3491,
      "preview": "d. The exception is when treating \"air leak\"; in this situation, the PEEP or Paw is generally NOT in"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3492,
      "preview": "6. PIP or Amplitude [DP]:"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3493,
      "preview": "a. Usually start about the same as conventional"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3494,
      "preview": "b. Adjust by watching abdominal \"jiggle\"."
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3495,
      "preview": "7. Rate or Frequency $[f]$"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3496,
      "preview": "a. Oscillator runs in the $8-12 \\mathrm{~Hz}$ range"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3497,
      "preview": "8. Second determinant of rate or $f$ is patient size:"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3498,
      "preview": "a. Size is a major contributor to time constant"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3500,
      "preview": "--- page 145 ---"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3502,
      "preview": "b. Smaller patients = shorter time constant"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3503,
      "preview": "c. Start smaller patients at higher end of range"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3504,
      "preview": "5. Third determinant of rate or $f$ is disease state:"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3505,
      "preview": "a. Diseases with low compliance [e.g., RDS] have shorter time constant and thus use rate or $f$ at t"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3506,
      "preview": "b. Airways diseases [e.g., MAS, PIE] have longer time constants and thus are best at the lower end o"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3507,
      "preview": "c. As RDS improves and compliance increases, you may need to decrease the rate to avoid \"gas trappin"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3508,
      "preview": "6. The risk of too high a rate or $f$ is \"gas trapping\" - when in doubt and there is CO 2 retention,"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3509,
      "preview": "a. Increases Ti resulting in a larger VT"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3510,
      "preview": "b. Increases Te allowing better exhalation"
    },
    {
      "type": "text",
      "section": "III. Transition to HFV [See Table]",
      "line": 3511,
      "preview": "7. In general, changing rate or $f$ significantly means moving by 1 Hz or by 60 bpm ; smaller change"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3513
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3515,
      "preview": "A. Oxygenation: As with any ventilator, the major determinants of Oxygenation are FiO2 and Paw. As w"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3517,
      "preview": "1. Paw is set directly with HFOV and can adjusted in increments of 0.5 cmH 2 O"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3518,
      "preview": "2. Remember that increasing Paw results in an increased PIP but also an increase in PEEP"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3519,
      "preview": "3. Thus, after several increases in Paw, consider increasing amplitude to avoid having a Paw that is"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3520,
      "preview": "4. Similarly, after several decreases in Paw, consider decreasing amplitude to avoid having a Paw th"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3521,
      "preview": "5. After significant Paw changes, follow-up CxR is needed to monitor for hyperexpansion or atelectas"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3522,
      "preview": "B. Ventilation: As with any ventilator, the major determinant of PaCO 2 is minute ventilation [see e"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3523,
      "preview": "6. Increasing DP at a set Paw results in increased PIP but also decreased PEEP"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3524,
      "preview": "7. Thus, after several increases in DP, consider increasing Paw to avoid having a PEEP that is too l"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3525,
      "preview": "8. Conversely, several decreases in permit weaning of Paw to avoid over inflation."
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3526,
      "preview": "9. The worst way to ventilate is to compensate for too little PEEP [atelectasis] by using too much P"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3528,
      "preview": "--- page 146 ---"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3530,
      "preview": "a. Consider above points \\& make sure PEEP not too low"
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3531,
      "preview": "b. Frequent CxR are needed to assess lung volumes. If hyperexpanded, considered decreasing the rate "
    },
    {
      "type": "text",
      "section": "IV. Adjusting HFV in Clinical Use [See Figures 1 - 4]",
      "line": 3532,
      "preview": "5. Remember that prolonged hyperventilation with any mode of ventilation increases the risk of cereb"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3534
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3536,
      "preview": "A. Some NICUs will extubate directly from HFV."
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3537,
      "preview": "B. If transition to conventional ventilation is desired, most NICU have criteria for HFV settings pr"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3539,
      "preview": "1. FiO2 generally $\\sim 40 \\%$"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3540,
      "preview": "2. Paw generally $\\sim 12 \\mathrm{cmH} 2 \\mathrm{O}$."
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3541,
      "preview": "3. Conventional setting can be chosen by reversing the process for choosing initial HFV settings:"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3542,
      "preview": "a. Same PIP or DP \\& adjust per chest excursion"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3543,
      "preview": "b. Paw about the same as HFV if oxygenating well"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3544,
      "preview": "c. Rate about 40 bpm"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3545,
      "preview": "d. Check ABG \\& CxR shortly after transition [15-30 min"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3547,
      "preview": "TABLE: Transition to HFV from conventional ventilator"
    },
    {
      "type": "table",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3549,
      "preview": "| Setting | HFOV | HFJV |"
    },
    {
      "type": "table",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3550,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3551,
      "preview": "| Rate | $8-12 \\mathrm{~Hz}[540-720 / \\mathrm{min}]$ | $300-480 / \\mathrm{min}[5-7 \\mathrm{~Hz}]$ |"
    },
    {
      "type": "table",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3552,
      "preview": "| PEEP | ---- | Increase by $\\sim 2 \\#$ |"
    },
    {
      "type": "table",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3553,
      "preview": "| Paw | Increase by $\\sim 2 \\#$ | ---- |"
    },
    {
      "type": "table",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3554,
      "preview": "| PIP | ---- | Same* |"
    },
    {
      "type": "table",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3555,
      "preview": "| DP | Same* |  |"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3557,
      "preview": "VI. Laws of High Frequency Ventilation"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3558,
      "preview": "A. Frequency Based on Machine and Weight:"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3560,
      "preview": "1. Range determined by device"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3561,
      "preview": "2. Within the device range, $f$ determined by size"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3562,
      "preview": "a. Mice breathe faster than elephants"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3563,
      "preview": "3. Changing $f$ has little effect on ventilation"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3564,
      "preview": "a. Think $T_{1}$"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3565,
      "preview": "b. $\\mathrm{V}_{\\text {min }}=\\left(f_{1} \\times(\\mathrm{Vt})^{2}\\right.$"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3566,
      "preview": "4. When in doubt, SLOW DOWN"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3568,
      "preview": "--- page 147 ---"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3570,
      "preview": "140 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3571,
      "preview": "a. Think $\\mathrm{K}_{\\mathrm{t}}$"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3572,
      "preview": "b. Slow down when $\\mathrm{C}_{\\mathrm{L}}$ improves"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3573,
      "preview": "c. Slow down when $R_{\\text {aw }}$ increased (e.g., MAS, BPD, PIE)"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3574,
      "preview": "B. Ventilation Controlled with $\\Delta P$ or PIP:"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3576,
      "preview": "1. Set initial PIP or $\\Delta P$ by observing jiggle"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3577,
      "preview": "a. Usual start at setting close to conventional"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3578,
      "preview": "2. Increase to lower $\\mathrm{pCO}_{2}$"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3579,
      "preview": "a. HFOV $-\\uparrow \\Delta \\mathrm{P}$ causes $\\downarrow$ PEEP and $\\uparrow$ PIP"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3580,
      "preview": "3. Decrease to avoid hyperventilation"
    },
    {
      "type": "text",
      "section": "V. Transitioning off HFV to Conventional Ventilation.",
      "line": 3581,
      "preview": "a. HFJV $-\\uparrow$ PEEP causes $\\downarrow \\Delta P$ and $\\uparrow P_{\\text {aw }}$"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3583
    },
    {
      "type": "text",
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3585,
      "preview": "1. Start $\\sim 2$ higher than conventional"
    },
    {
      "type": "text",
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3586,
      "preview": "a. Need to prevent atelectasis"
    },
    {
      "type": "text",
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3587,
      "preview": "b. Exception in cases of air-leak"
    },
    {
      "type": "text",
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3588,
      "preview": "2. Increase to improve oxygenation"
    },
    {
      "type": "text",
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3589,
      "preview": "a. HFOV $-\\uparrow P_{\\text {aw }}$ causes $\\uparrow$ PEEP and $\\uparrow$ PIP"
    },
    {
      "type": "text",
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3590,
      "preview": "b. HFJV $-\\uparrow$ PEEP causes $\\uparrow P_{\\text {aw, }}$ but $\\downarrow \\Delta P$"
    },
    {
      "type": "text",
      "section": "C. Oxygenation Controlled with PEEP or PAW",
      "line": 3591,
      "preview": "3. Gas trapping risk especially at higher $f$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. FRC Monitored with Chest X-Rays",
      "line": 3593
    },
    {
      "type": "text",
      "section": "D. FRC Monitored with Chest X-Rays",
      "line": 3595,
      "preview": "1. Need to get frequent Chest X-Rays!"
    },
    {
      "type": "text",
      "section": "D. FRC Monitored with Chest X-Rays",
      "line": 3596,
      "preview": "a. Watch for Atelectasis"
    },
    {
      "type": "text",
      "section": "D. FRC Monitored with Chest X-Rays",
      "line": 3597,
      "preview": "b. Watch for Hyper-expansion"
    },
    {
      "type": "text",
      "section": "D. FRC Monitored with Chest X-Rays",
      "line": 3598,
      "preview": "2. Used to adjust PEEP or $P_{\\text {aw }}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 3600
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3602,
      "preview": "1. Keszler M, Modanlou HD, Brudno DS, et al. Multicenter controlled clinical trial of high-frequency"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3603,
      "preview": "2. Courtney SE, Durand DJ, Asselin JM, et al. High-frequency oscillatory ventilation versus conventi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3605,
      "preview": "--- page 148 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3607,
      "preview": "3. Baumgart S, Hirschl RB, Butler SZ, et al. Diagnosis-related criteria in the consideration of extr"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3608,
      "preview": "4. Clark RH, Yoder BA, Sell MS. Prospective, randomized comparison of high-frequency oscillation and"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3609,
      "preview": "5. Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3610,
      "preview": "6. Coates EW, Klinepeter ME, O'Shea TM. Neonatal pulmonary hypertension treated with inhaled nitric "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3611,
      "preview": "7. Froese AB, Kinsella JP. High-frequency oscillatory ventilation: Lessons from the neonatal/pediatr"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3612,
      "preview": "8. Dani C, Bertini G, Pezzati M, et al. Effects of pressure support ventilation plus volume guarante"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3613,
      "preview": "9. Plavka R, Dokoupilova M, Pazderova L, et al. High-frequency jet ventilation improves gas exchange"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3614,
      "preview": "10. Henderson-Smart DJ, De Paoli AG, Clark RH, Bhuta T. High frequency oscillatory ventilation versu"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3615,
      "preview": "11. Zivanovic S, Peacock J, Alcazar-Paris M, et al. Late outcomes of a randomized trial of high-freq"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 3617,
      "preview": "--- page 149 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nasal Cannula Oxygen Delivery - High Flow and Low Flow",
      "line": 3619
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Arlene Sheehan, N.N.P-B.C",
      "line": 3621
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. NICU Definitions",
      "line": 3623
    },
    {
      "type": "text",
      "section": "I. NICU Definitions",
      "line": 3625,
      "preview": "A. High Flow Nasal Cannula (HFNC): $\\geq 2$ LPM (max 8 LPM) delivered with high flow nasal prongs us"
    },
    {
      "type": "text",
      "section": "I. NICU Definitions",
      "line": 3626,
      "preview": "B. Low Flow Nasal Cannula (LFNC): 0.1-1 LPM delivered via a humidifcation system using standard nasa"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Considerations",
      "line": 3628
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 3630,
      "preview": "A. High flow nasal cannula MUST BE non-occlusive (defined as $\\mathbf{5 0 - 8 0 \\%}$ of nares diamet"
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 3631,
      "preview": "B. Pressure generated by HFNC differs from CPAP because it is not set or measured. Evidence shows th"
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 3632,
      "preview": "C. LFNC delivery systems are not heated and humidified and should be limited to gas flow ranges of 0"
    },
    {
      "type": "text",
      "section": "II. Considerations",
      "line": 3633,
      "preview": "D. HFNC used only in NICU. Wean to standard nasal cannula flow of $\\leq 0.5$ LPM to go to ICN 1 or 2"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Indications",
      "line": 3635
    },
    {
      "type": "text",
      "section": "III. Indications",
      "line": 3637,
      "preview": "A. As initial support mode for the term infant with respiratory distress."
    },
    {
      "type": "text",
      "section": "III. Indications",
      "line": 3639,
      "preview": "1. Should not be used as a initial support mode for the preterm infant with RDS. A multi-center tria"
    },
    {
      "type": "text",
      "section": "III. Indications",
      "line": 3640,
      "preview": "B. Post extubation for term or near term infants (see Respiratory Care Bundle for extubation guideli"
    },
    {
      "type": "text",
      "section": "III. Indications",
      "line": 3641,
      "preview": "C. Weaning from CPAP"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Initiation",
      "line": 3643
    },
    {
      "type": "text",
      "section": "IV. Initiation",
      "line": 3645,
      "preview": "A. HFNC: flow 3-8 LPM"
    },
    {
      "type": "table",
      "section": "IV. Initiation",
      "line": 3647,
      "preview": "| Patient size | INITIAL FLOW | MAX FLOW |"
    },
    {
      "type": "table",
      "section": "IV. Initiation",
      "line": 3648,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "IV. Initiation",
      "line": 3649,
      "preview": "| $<2 \\mathrm{~kg}$ | 3 LPM | 6 LPM |"
    },
    {
      "type": "table",
      "section": "IV. Initiation",
      "line": 3650,
      "preview": "| $2-3 \\mathrm{~kg}$ | 4 LPM | 7 LPM |"
    },
    {
      "type": "table",
      "section": "IV. Initiation",
      "line": 3651,
      "preview": "| $>3 \\mathrm{~kg}$ | 5 LPM | 8 LPM |"
    },
    {
      "type": "text",
      "section": "IV. Initiation",
      "line": 3653,
      "preview": "1. FiO2 delivery range is $21-40 \\%$. If patient is requiring more than $40 \\%$ FiO2, consider CPAP "
    },
    {
      "type": "text",
      "section": "IV. Initiation",
      "line": 3654,
      "preview": "2. FiO2 delivery range is $21-40 \\%$. If patient is requiring more than $40 \\%$, consider CPAP or in"
    },
    {
      "type": "text",
      "section": "IV. Initiation",
      "line": 3655,
      "preview": "B. LFNC: flow 0.1 to 0.5 LPM"
    },
    {
      "type": "text",
      "section": "IV. Initiation",
      "line": 3657,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Initiation",
      "line": 3659,
      "preview": "--- page 150 ---"
    },
    {
      "type": "text",
      "section": "IV. Initiation",
      "line": 3661,
      "preview": "1. Start at 100\\$ FiO2. Actual oxygen delivery to the infant with vary depending on flow and mixing "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "3. Weaning of Nasal Cannula",
      "line": 3663
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3665,
      "preview": "A. HFNC"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3667,
      "preview": "1. Wean FiO2 first. When FiO2 < 30\\%, wean flow"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3668,
      "preview": "2. Wean by 1-2 LPM increments when FiO2 < 30\\%, SpO2 > 90\\%, pC02 in recommended range and no signif"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3669,
      "preview": "3. Wean from HFNC to LFNC at flows of 2-3 LPM (there is no evidence that flows <4 LPM are efficaciou"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3670,
      "preview": "B. LFNC"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3671,
      "preview": "4. Wean flow as tolerated per oximetry parameters and clinical work of breathing."
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3672,
      "preview": "5. Wean flow first before weaning FiO2 to avoid confusion."
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3673,
      "preview": "6. Decrease flow from 0.5 to 0.1 LPM"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3674,
      "preview": "7. If an infant needs more than 0.5 LPM with $100 \\% \\mathrm{FiO} 2$, consider HFNC or CPAP"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3675,
      "preview": "8. When infants are discharged on LFNC, flow can be set at 0.1-0.25 LPM, 100\\% FiO2"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3676,
      "preview": "C. Weaning example: Infant on HFNC, 3 LPM, 25\\% FiO2."
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3677,
      "preview": "9. Infant on HFNC, 3 LPM, 25\\% FiO2."
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3678,
      "preview": "10. Wean to LFNC, $100 \\% \\mathrm{FiO} 2$ and adjust flow from $0.1-0.5 \\mathrm{LPM}$ to meet satura"
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3679,
      "preview": "11. At flow 0.1 LPM, wean FiO2 to meet sat goals."
    },
    {
      "type": "text",
      "section": "3. Weaning of Nasal Cannula",
      "line": 3680,
      "preview": "12. Wean to room air"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Patient Care Considerations",
      "line": 3682
    },
    {
      "type": "text",
      "section": "V. Patient Care Considerations",
      "line": 3684,
      "preview": "A. When starting HFNC feed with OG tube"
    },
    {
      "type": "text",
      "section": "V. Patient Care Considerations",
      "line": 3685,
      "preview": "B. Patient can nipple feed when flow is $<3$ LPM and respiratory status is stable"
    },
    {
      "type": "text",
      "section": "V. Patient Care Considerations",
      "line": 3686,
      "preview": "C. Do not need a second OG tube for pop-off as HFNC prongs are non-occlusive"
    },
    {
      "type": "text",
      "section": "V. Patient Care Considerations",
      "line": 3687,
      "preview": "D. Once infant is stable for $24-48 \\mathrm{hrs}$ and flow is $\\leq 3$ may change to 5 Fr NG tube"
    },
    {
      "type": "text",
      "section": "V. Patient Care Considerations",
      "line": 3689,
      "preview": "--- page 151 ---"
    },
    {
      "type": "text",
      "section": "V. Patient Care Considerations",
      "line": 3691,
      "preview": "144 Part II-B: Respiratory"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 3693
    },
    {
      "type": "text",
      "section": "References",
      "line": 3695,
      "preview": "1. Manley, B.J. and Owen, L.S.. High-flow nasal cannula: mechanisms, evidence and recommendations. S"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3696,
      "preview": "2. Robert CT, Owen LS, Manley BJ, Froisland DH, Donath MA, Dlaziel K, Pritchard MA, Cartwright DW, C"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3697,
      "preview": "3. Yoder BA, Manley B, Collins C, Ives K, Kugelman, A, Lavizzari A and McQueen M. Consensus approach"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3699,
      "preview": "--- page 152 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide 145 Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn and Inhaled Nitric Oxide",
      "line": 3701
    },
    {
      "type": "text",
      "section": "Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide 145 Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn and Inhaled Nitric Oxide",
      "line": 3703,
      "preview": "Sonia Lomeli Bonifacio, M.D. and Krisa Van Meurs, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definitions",
      "line": 3705
    },
    {
      "type": "text",
      "section": "I. Definitions",
      "line": 3707,
      "preview": "Hypoxemic respiratory failure (HRF) frequently occurs in association with persistent pulmonary hyper"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. PPHN Occurs in Several Settings",
      "line": 3709
    },
    {
      "type": "text",
      "section": "II. PPHN Occurs in Several Settings",
      "line": 3711,
      "preview": "A. Idiopathic: Idiopathic PPHN occurs when there is abnormally constricted pulmonary vasculature wit"
    },
    {
      "type": "text",
      "section": "II. PPHN Occurs in Several Settings",
      "line": 3712,
      "preview": "B. Parenchymal lung disease: PPHN frequently accompanies meconium aspiration syndrome, respiratory d"
    },
    {
      "type": "text",
      "section": "II. PPHN Occurs in Several Settings",
      "line": 3713,
      "preview": "C. Lung hypoplasia: Lung hypoplasia can be seen with congenital diaphragmatic hernia and in infants "
    },
    {
      "type": "text",
      "section": "II. PPHN Occurs in Several Settings",
      "line": 3714,
      "preview": "D. Rare, fatal conditions: Respiratory failure and PPHN can be the presenting features in Surfactant"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Treatment",
      "line": 3716
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3718,
      "preview": "A. Identify infants at risk for PPHN: Infants with meconium in the amniotic fluid should be monitore"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3719,
      "preview": "B. Promptly treat hypoxemia and acidosis: Hypoxemia and acidosis increase pulmonary vascular resista"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3720,
      "preview": "C. Assure adequate cardiac output by maintaining a mean arterial pressure $>45$ in a term or near-te"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3721,
      "preview": "D. Maintain adequate oxygen carrying capacity by keeping the hematocrit between 40 and 50. Hematocri"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3723,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3725,
      "preview": "--- page 153 ---"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3727,
      "preview": "146 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3728,
      "preview": "excess of 50 may result in increased pulmonary vascular resistance."
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3729,
      "preview": "E. Intubation and mechanical ventilation for infants with continued instability of oxygenation: Both"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3730,
      "preview": "F. If there is evidence of pulmonary hypertension clinically or on ECHO, the suggested target ABGs a"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3731,
      "preview": "G. Minimize stress by reducing unnecessary handling and noise."
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3732,
      "preview": "H. Assure appropriate sedation and analgesia. The drugs of choice are morphine and versed given as c"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3733,
      "preview": "I. Calculate the oxygenation index (OI) for all infants with oxygen requirement $\\geq 60 \\%$ :"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3735,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3736,
      "preview": "\\mathrm{OI}=\\frac{\\mathrm{MAP} \\times 100 \\times \\mathrm{FiO} 2}{\\mathrm{~PaO} 2}"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 3737,
      "preview": "$$"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Maximal Medical Therapy Alternatives",
      "line": 3739
    },
    {
      "type": "text",
      "section": "IV. Maximal Medical Therapy Alternatives",
      "line": 3741,
      "preview": "A. High frequency oscillatory ventilation (HFOV): HFOV should be considered when PIP is $>25-28$ or "
    },
    {
      "type": "text",
      "section": "IV. Maximal Medical Therapy Alternatives",
      "line": 3742,
      "preview": "B. Surfactant therapy: Surfactant should be considered in patients with parenchymal lung disease and"
    },
    {
      "type": "text",
      "section": "IV. Maximal Medical Therapy Alternatives",
      "line": 3743,
      "preview": "C. Inhaled nitric oxide therapy (iNO): See section V"
    },
    {
      "type": "text",
      "section": "IV. Maximal Medical Therapy Alternatives",
      "line": 3744,
      "preview": "D. ECMO: See NICU Guide Section II:B"
    },
    {
      "type": "text",
      "section": "IV. Maximal Medical Therapy Alternatives",
      "line": 3745,
      "preview": "E. Milrinone: Milrinone increases cardiac output and lowers systemic vascular resistance as well as "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Inhaled Nitric Oxide",
      "line": 3747
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Background",
      "line": 3749
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 3751,
      "preview": "1. Nitric oxide is a regulator of vascular tone, endogenously produced by the vascular endothelium. "
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 3753,
      "preview": "--- page 154 ---"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 3755,
      "preview": "Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Indications",
      "line": 3757
    },
    {
      "type": "text",
      "section": "B. Indications",
      "line": 3759,
      "preview": "1. Gestational age $\\geq 34$ wks."
    },
    {
      "type": "text",
      "section": "B. Indications",
      "line": 3760,
      "preview": "2. Mechanical ventilation with an $\\mathrm{OI} \\geq 25$ on 2 ABGs at least 15 min apart. Use of iNO "
    },
    {
      "type": "text",
      "section": "B. Indications",
      "line": 3761,
      "preview": "3. There is some recent literature suggesting that iNO initiation with an $\\mathrm{OI} \\geq 15-25$ r"
    },
    {
      "type": "text",
      "section": "B. Indications",
      "line": 3762,
      "preview": "4. Attending physician approval."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3764
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3766,
      "preview": "1. Nitric Oxide Dosing Strategy - Refer to algorithm (see figure)."
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3767,
      "preview": "2. Acute Deterioration During Initial Dosing - If the patient experiences a significant deterioratio"
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3768,
      "preview": "3. Exit Criteria"
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3769,
      "preview": "a. NO2 levels $>5 \\mathrm{ppm}$."
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3770,
      "preview": "b. Methemoglobin levels $>10 \\%$."
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3771,
      "preview": "c. Deterioration in patient's condition felt to be related to iNO therapy."
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3772,
      "preview": "4. Toxicity - Toxicity related to nitrogen dioxide (NO2) formation and methemoglobinemia (metHb) is "
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3773,
      "preview": "a. If NO2 $\\geq 3 \\mathrm{ppm}$, wean by $50 \\%$ (if $\\leq 5 \\mathrm{ppm}$ iNO then decrease by 1 pp"
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3774,
      "preview": "b. If NO2 levels $>5 \\mathrm{ppm}$, discontinue iNO therapy. If metHb $\\geq 5 \\%$, wean by $50 \\%$ ("
    },
    {
      "type": "text",
      "section": "C. Administration, Dosing, and Weaning Strategies for iNO in the Term Infant",
      "line": 3775,
      "preview": "c. If metHb levels $>10 \\%$, discontinue iNO therapy."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Weaning",
      "line": 3777
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3779,
      "preview": "1. Baseline refers to pre-wean ABG drawn $<15 \\mathrm{~min}$ before change."
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3780,
      "preview": "2. First wean performed $6 \\pm 2$ hrs following initiation."
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3781,
      "preview": "3. Subsequent weans every $4 \\pm 2$ hrs if $\\mathrm{OI} \\leq 10$ or every $6 \\pm 2$ hrs if $\\mathrm{"
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3783,
      "preview": "--- page 155 ---"
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3785,
      "preview": "4. Nitric oxide is weaned as follows: $20 \\rightarrow 10 \\rightarrow 5 \\rightarrow 4 \\rightarrow 3 \\"
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3786,
      "preview": "5. ABG timing: baseline before wean, then 30 min after. No vent/FiO2 changes during wean attempt."
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3787,
      "preview": "6. If pre-wean $\\mathrm{PaO} 2 \\geq 100$, wean successful if PaO 2 falls by $\\leq 35 \\%$ and $\\mathr"
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3788,
      "preview": "7. If pre-wean $\\mathrm{PaO} 2<100$, wean successful if PaO 2 falls by $\\leq 20 \\%$ and $\\mathrm{PaO"
    },
    {
      "type": "text",
      "section": "D. Weaning",
      "line": 3789,
      "preview": "8. If pre-wean $\\mathrm{PaO} 2<60$, wean successful if decrease in $\\mathrm{PaO} 2 \\leq 10 \\%$ from "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "E. Escalation",
      "line": 3791
    },
    {
      "type": "text",
      "section": "E. Escalation",
      "line": 3793,
      "preview": "1. Recommended maximum iNO dose is 20 ppm ."
    },
    {
      "type": "text",
      "section": "E. Escalation",
      "line": 3794,
      "preview": "2. Deterioration in oxygenation is defined as $\\mathrm{PaO} 2<50$ and/or decrease in $\\mathrm{PaO} 2"
    },
    {
      "type": "text",
      "section": "E. Escalation",
      "line": 3795,
      "preview": "3. Escalation continues until a full response ( $>20$ Torr) is achieved."
    },
    {
      "type": "text",
      "section": "E. Escalation",
      "line": 3796,
      "preview": "4. If only a partial response (10-20 Torr), then return to the lowest iNO dose that resulted in a pa"
    },
    {
      "type": "text",
      "section": "E. Escalation",
      "line": 3797,
      "preview": "5. If less than a partial response is achieved, then return to pre-escalation iNO dose."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Re-Initiation",
      "line": 3799
    },
    {
      "type": "text",
      "section": "F. Re-Initiation",
      "line": 3801,
      "preview": "1. Recommended cumulative iNO administration is 336 hrs (14 days)."
    },
    {
      "type": "text",
      "section": "F. Re-Initiation",
      "line": 3802,
      "preview": "2. Reinitiation is possible if patient meets original eligibility requirements again, after a succes"
    },
    {
      "type": "text",
      "section": "F. Re-Initiation",
      "line": 3803,
      "preview": "3. iNO is restarted at 1 ppm (ABG after 30 min ) looking for a full response."
    },
    {
      "type": "text",
      "section": "F. Re-Initiation",
      "line": 3804,
      "preview": "4. If there is not a full response, then return to the iNO initiation flow algorithm using the pre-i"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "G. Methemoglobin Levels",
      "line": 3806
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3808,
      "preview": "1. Within 3 hrs after starting iNO."
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3809,
      "preview": "2. Every 24 hrs if dose $>5 \\mathrm{ppm}$."
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3810,
      "preview": "3. Every 48 hrs if dose $\\leq 5 \\mathrm{ppm}$"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3812,
      "preview": "--- page 156 ---"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3814,
      "preview": "Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide "
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3815,
      "preview": "Recommended Initiation Algorithm for Inhaled Nitric Oxide Therapy in Term and Near-term Neonatal Res"
    },
    {
      "type": "image",
      "section": "G. Methemoglobin Levels",
      "line": 3817,
      "content": "![img-20.jpeg](images/7cb6920b7514df6a.png)"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3819,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3820,
      "preview": "representations or warranties are made for outside use. Not for outside reproduction or publication "
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3822,
      "preview": "--- page 157 ---"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3824,
      "preview": "1. Congenital Diaphragmatic Hernia (CDH): Prospective randomized controlled trials of iNO for CDH ha"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3825,
      "preview": "2. Cardiac indications: iNO has been used for pulmonary hypertension related to cardiac anomalies, p"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3826,
      "preview": "3. iNO for preterm infants: Trials in premature infants have been categorized as follows: Early resc"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3827,
      "preview": "a. Early Rescue use: There were several trials in critically ill infants after birth and the Cochran"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3828,
      "preview": "i. No benefit to survival or in reduction of rate of physiologic BPD in infants with severe RDS."
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3829,
      "preview": "ii. Subgroup analysis suggested that infants $>1000 \\mathrm{gm}$ may benefit in terms of the outcome"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3830,
      "preview": "iii. However, neurodevelopment follow-up from this trial showed no benefit from iNO exposure on deat"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3831,
      "preview": "b. Early prophylactic use: Three large trials were completed in this subgroup. A single center study"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3832,
      "preview": "c. Later use for BPD prevention: One large RCT enrolled newborns between 7 and 21 days of life if th"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3833,
      "preview": "d. An individual patient data meta-analysis, NIH Consensus Conference statement and AAP Committee on"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3834,
      "preview": "e. Of note, the NIH Consensus Conference statement recognized that there are specific clinical situa"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3836,
      "preview": "--- page 158 ---"
    },
    {
      "type": "text",
      "section": "G. Methemoglobin Levels",
      "line": 3838,
      "preview": "Hypoxic Respiratory Failure, Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 3840
    },
    {
      "type": "text",
      "section": "References",
      "line": 3842,
      "preview": "1. Konduri GG and Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertens"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3843,
      "preview": "2. Lakshminrusimha S and Keszler M. Persistent Pulmonary Hypertension of the Newborn. Neoreviews 201"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3844,
      "preview": "3. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Funkel JH. Multicenter study of surfactant "
    },
    {
      "type": "text",
      "section": "References",
      "line": 3845,
      "preview": "4. Neonatal Inhaled Nitric Oxide Study Group, Inhaled Nitric Oxide in full-term infants and nearly f"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3846,
      "preview": "5. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella J"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3847,
      "preview": "6. Kinsella J, Parker TA, Ivy DD, Abman SH. Noninvasive delivery of inhaled nitric oxide therapy for"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3848,
      "preview": "7. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respirato"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3849,
      "preview": "8. Barrington K, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane "
    },
    {
      "type": "text",
      "section": "References",
      "line": 3850,
      "preview": "9. Askie LM, Ballard RA, Cutler GR, Dani C, Elbourne D, Field D, Hascoet JM, Hibbs AM, Kinsella JP, "
    },
    {
      "type": "text",
      "section": "References",
      "line": 3851,
      "preview": "10. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3852,
      "preview": "11. Kumar P, Committee on Fetus and Newborn. Use of inhaled nitric oxide in preterm infants. Pediatr"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3853,
      "preview": "12. Chock VY, Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Kendrick D, Stevenson DK, for the Pr"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3854,
      "preview": "13. Kinsella JP, Steinhorn RH, Krishnan US, Feinstein JA, Adatia I, Austin ED, Rosenzweig EB, Everet"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3856,
      "preview": "--- page 159 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Management of Congenital Diaphragmatic Hernia",
      "line": 3858
    },
    {
      "type": "text",
      "section": "Management of Congenital Diaphragmatic Hernia",
      "line": 3860,
      "preview": "Krisa Van Meurs, M.D. and Sonia Lomeli Bonifacio, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 3862
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3864,
      "preview": "A. Infants with Congenital Diaphragmatic Hernia (CDH) who have respiratory distress from birth often"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3865,
      "preview": "B. The past approach to the patient with CDH utilized hyperventilation, alkalinization, and high mea"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3866,
      "preview": "C. Severity of CDH can be estimated using antenatal US and MRI. Lung-to-Head Ratio (LHR) and Observe"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 3868,
      "preview": "Gestational age (GA) and is most predictive at 24-34 weeks. An LHR < 1 carries a poor prognosis and "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Current Management of Congenital Diaphragmatic Hernia",
      "line": 3870
    },
    {
      "type": "text",
      "section": "II. Current Management of Congenital Diaphragmatic Hernia",
      "line": 3872,
      "preview": "Since first suggested by Wung, et al, many centers have used \"gentle\" ventilation strategies with pe"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Delivery Room Management",
      "line": 3874
    },
    {
      "type": "text",
      "section": "III. Delivery Room Management",
      "line": 3876,
      "preview": "A. Intubate immediately. Initiate resuscitation with FiO2 of $50 \\%$; ventilate with a PIP 20-24, PE"
    },
    {
      "type": "text",
      "section": "III. Delivery Room Management",
      "line": 3877,
      "preview": "B. Avoid bag mask ventilation to minimize air entry and dilation of intra-thoracic bowel."
    },
    {
      "type": "text",
      "section": "III. Delivery Room Management",
      "line": 3878,
      "preview": "C. Place OG/replogle tube."
    },
    {
      "type": "text",
      "section": "III. Delivery Room Management",
      "line": 3879,
      "preview": "D. Transfer to NICU once stablilized in the DR."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Initial NICU Management",
      "line": 3881
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3883,
      "preview": "A. Place pre-ductal saturation monitor."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3885,
      "preview": "1. Respiratory management is to be guided by the pre-ductal saturations."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3887,
      "preview": "--- page 160 ---"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3889,
      "preview": "2. Goal pre-ductal saturation is $>70 \\%$ in first hour of life and $>85-95 \\%$ thereafter."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3890,
      "preview": "B. Place UAC or right radial arterial line and UVC or double lumen PICC."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3891,
      "preview": "C. Place Replogle tube to suction."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3892,
      "preview": "D. Obtain CXR to help guide respiratory management."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3893,
      "preview": "E. Respiratory Management"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3894,
      "preview": "3. Conventional Ventilation (PC/SIMV) should be used before HFOV. Initial management with convention"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3895,
      "preview": "4. Blood Gas Goals: $\\mathrm{pH}>7.20$, PaCO2 50-70, PaO2 $>30$; Lactic acid $<3$."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3896,
      "preview": "5. Ventilate with lowest PIP (usually $20-24 \\mathrm{mmHg}$ ) to provide adequate BS, PEEP of $3-5 \\"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3897,
      "preview": "6. Surfactant should not be routinely used in term or preterm neonates with CDH. In preterm neonates"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3898,
      "preview": "F. High frequency oscillatory ventilation should be considered in infants who fail conventional vent"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3899,
      "preview": "7. Failure of conventional ventilation = inability to control CO2 with a max PIP of 25 and rate of 6"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3900,
      "preview": "8. Initial Paw should be 2 above that on conventional ventilation but not $>15$; Amplitude may be $2"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3901,
      "preview": "G. Blood Pressure Management"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3903,
      "preview": "Goal is to maintain the arterial blood pressure at normal level for gestational age and appropriate "
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3905,
      "preview": "1. NS bolus of $10-20 \\mathrm{ml} / \\mathrm{kg}$ for hypotension or poor perfusion. May be repeated "
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3906,
      "preview": "2. Initiate Dopamine at $3 \\mathrm{mcg} / \\mathrm{kg} / \\mathrm{min}$ following crystalloid boluses."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3907,
      "preview": "3. Consider Hydrocortisone if blood pressure does not improve with appropriate doses of Dopamine."
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3908,
      "preview": "H. Sedatives or analgesics should be initiated either in DR (during a prolonged resuscitation) or up"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3909,
      "preview": "4. Provide pain relief with Morphine $0.05-0.1 \\mathrm{mg} / \\mathrm{kg}$ q 6 hrs and lightly sedate"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3910,
      "preview": "I. Place NIRS monitor (cerebral and renal)"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3911,
      "preview": "J. Obtain ECHO within 24 hours after birth. ECHO will evaluate for cardiac anomalies (present in abo"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3913,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Initial NICU Management",
      "line": 3915,
      "preview": "--- page 161 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "K. Obtain HUS",
      "line": 3917
    },
    {
      "type": "text",
      "section": "K. Obtain HUS",
      "line": 3919,
      "preview": "L. Consult the following services: Pediatric Surgery, Cardiology and Genetics (additional congenital"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3921
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3923,
      "preview": "A. The focus is to tolerate marginal pulmonary gas exchange and maintain adequate cerebral oxygen de"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3925,
      "preview": "1. Post-ductal saturations as low as $60 \\%$ are acceptable as long as pre-ductal saturations remain"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3926,
      "preview": "B. Use of inhaled Nitric Oxide (iNO) and ECMO"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3927,
      "preview": "2. Consider iNO in patients who cannot maintain pre-ductal saturations $>85 \\%$ or post-ductal PaO2 "
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3928,
      "preview": "3. Small studies and meta-analyses have concluded that ECMO use improves survival in this patient po"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3930,
      "preview": "The following are indications for ECMO:"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3931,
      "preview": "a. Inability to maintain pre-ductal saturations despite initiation of HFOV and iNO"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3932,
      "preview": "b. PIP $>24$ or Paw $>15 \\mathrm{~cm} \\mathrm{H} 2 \\mathrm{O}$ to achieve pre-ductal saturation $>85"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3933,
      "preview": "c. $\\mathrm{OI} \\geq 40$ for at least 3 hours"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3934,
      "preview": "d. Inadequate oxygen delivery with resultant metabolic acidosis: lactate $\\geq 5 \\mathrm{mmol} / \\ma"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3935,
      "preview": "e. $\\mathrm{pCO} 2>70$ resulting in a respiratory acidosis with $\\mathrm{pH}<7.15$, despite optimiza"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3936,
      "preview": "f. Hypotension resistant to fluid resuscitation and adequate inotropic support resulting in a urine "
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3938,
      "preview": "--- page 162 ---"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3940,
      "preview": "g. Either VV or VA ECMO can be used and there is no evidence of superiority for one modality over th"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3941,
      "preview": "3. Second ECMO runs have been used in this patient population with success rates varying from $36 \\%"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3942,
      "preview": "C. Pulmonary Hypertension Management and Use of Other Vasoactive Medications"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3944,
      "preview": "Pulmonary hypertension in CDH is related to a decreased cross-sectional area of the pulmonary vascul"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3946,
      "preview": "When there is abnormal left ventricular function and signs of RV dependent systemic circulation demo"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3948,
      "preview": "1. Milrinone, a Phosphodiesterase-3 inhibitor, has been used in CDH associated with elevated PVR and"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3949,
      "preview": "2. Prostaglandin E1: PGE, has been used in several small studies to maintain ductal patency and stab"
    },
    {
      "type": "text",
      "section": "V. Management of the Critically-III CDH Infant",
      "line": 3950,
      "preview": "3. Sildenafil: Sildenafil, a phosphodiesterase-5 inhibitor, has primarily been used in the managemen"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Timing of Surgical Repair",
      "line": 3952
    },
    {
      "type": "text",
      "section": "VI. Timing of Surgical Repair",
      "line": 3954,
      "preview": "Timing of CDH repair has varied over the last 3 decades. Initially patients were operated on soon af"
    },
    {
      "type": "text",
      "section": "VI. Timing of Surgical Repair",
      "line": 3956,
      "preview": "--- page 163 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "156 Part II-B: Respiratory",
      "line": 3958
    },
    {
      "type": "text",
      "section": "156 Part II-B: Respiratory",
      "line": 3960,
      "preview": "(LHR, O/E LHR, Lung volume as measured by MRI). Physiologic parameters after birth may also predict "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3962
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3964,
      "preview": "A. FiO2 Weaning"
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3966,
      "preview": "1. Goal is to maintain a pre-ductal saturation $85-95 \\%$ or PaO2 60-90 mmHg. Start weaning when pre"
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3967,
      "preview": "B. Conventional Ventilator"
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3968,
      "preview": "2. Wean PIP/PC before rate depending on tidal volume to keep goal PaCO2 as described above."
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3969,
      "preview": "3. Adjust FiO2 as needed to maintain pre-ductal SaO2 as described above."
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3970,
      "preview": "C. High Frequency Ventilation"
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3971,
      "preview": "4. Wean FiO2 to achieve goal pre-ductal saturations."
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3972,
      "preview": "5. Wean Paw only if the infant is on less than $60 \\%$ oxygen and lung expansion is greater than 8 r"
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3973,
      "preview": "6. Adjust amplitude or frequency to maintain target PaCO 2 . Increase frequency before amplitude if "
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3974,
      "preview": "D. Weaning Inhaled Nitric Oxide"
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3975,
      "preview": "7. iNO should be weaned only after the infant is stable on $<60 \\%$ oxygen and is on reasonable Paw "
    },
    {
      "type": "text",
      "section": "VII. Guidelines for Weaning Respiratory Support",
      "line": 3976,
      "preview": "8. iNO should be weaned slowly over 24 hours."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3978
    },
    {
      "type": "text",
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3980,
      "preview": "A. Brain MRI should be obtained prior to discharge in any patient with a severe neonatal course (pro"
    },
    {
      "type": "text",
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3981,
      "preview": "B. Due to the risk of neurocognitive delay, all patients should be referred for follow-up in the Hig"
    },
    {
      "type": "text",
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3982,
      "preview": "C. Late-onset hearing loss occurs in up to $30 \\%$ of CDH patients. Newborn hearing screen results a"
    },
    {
      "type": "text",
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3984,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3986,
      "preview": "--- page 164 ---"
    },
    {
      "type": "text",
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3988,
      "preview": "D. OT follow-up after discharge is important, as many neonates with CDH will develop feeding difficu"
    },
    {
      "type": "text",
      "section": "VIII. Considerations Prior to Discharge",
      "line": 3989,
      "preview": "E. RSV prophylaxis should be given to all patients with CDH prior to discharge during the RSV season"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IX. LPCH CDH Survival Results",
      "line": 3991
    },
    {
      "type": "text",
      "section": "IX. LPCH CDH Survival Results",
      "line": 3993,
      "preview": "We have submitted data to the CDH Study Group since 1995. The most recent report includes babies bor"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 3995
    },
    {
      "type": "text",
      "section": "References",
      "line": 3997,
      "preview": "1. Akinkuotu AC, Cruz SM, Abbas PI, Lee TC, Welty SE, Olutoye OO, et al. Risk-stratification of seve"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3998,
      "preview": "2. Knox E, Lissauer D, Khan K, Kilby M. Prenatal detection of pulmonary hypoplasia in fetuses with c"
    },
    {
      "type": "text",
      "section": "References",
      "line": 3999,
      "preview": "3. Deprest J, De Coppi P. Antenatal management of isolated congenital diaphragmatic hernia today and"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4000,
      "preview": "4. Kays DW, Langham MR, Ledbetter DJ, Talbert JL. Detrimental effects of standard medical therapy in"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4001,
      "preview": "5. Langham MR, Kays DW, Beierle EA, Chen MK, Mullet TC, Rieger K, et al. Twenty years of progress in"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4002,
      "preview": "6. Bagolan P, Casaccia G, Crescenzi F, Nahom A, Trucchi A, Giorlandino C. Impact of a current treatm"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4003,
      "preview": "7. Logan JW, Rice HE, Goldberg RN, Cotten CM. Congenital diaphragmatic hernia: a systematic review a"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4004,
      "preview": "8. Snoek KG, Reiss IK, Greenough A, Capolupo I, Urlesberger B, Wessel L, et al. Standardized Postnat"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4005,
      "preview": "9. Tracy ET, Mears SE, Smith PB, Danko ME, Diesen DL, Fisher KA, et al. Protocolized approach to the"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4006,
      "preview": "10. Puligandla PS, Grabowski J, Austin M, Hedrick H, Renaud E, Arnold M, et al. Management of congen"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4007,
      "preview": "11. Snoek KG, Capolupo I, van Rosmalen J, Hout Lde J, Vijfhuize S, Greenough A, et al. Conventional "
    },
    {
      "type": "text",
      "section": "References",
      "line": 4009,
      "preview": "--- page 165 ---"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4011,
      "preview": "158 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4012,
      "preview": "Clinical Trial (The VICI-trial). Ann Surg. 2016;263(5):867-74."
    },
    {
      "type": "text",
      "section": "References",
      "line": 4013,
      "preview": "12. Gien J, Kinsella JP. Management of pulmonary hypertension in infants with congenital diaphragmat"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4014,
      "preview": "13. Morini F, Goldman A, Pierro A. Extracorporeal membrane oxygenation in infants with congenital di"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4015,
      "preview": "14. Kays DW, Islam S, Richards DS, Larson SD, Perkins JM, Talbert JL. Extracorporeal life support in"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4016,
      "preview": "15. Meehan JJ, Haney BM, Snyder CL, Sharp RJ, Acosta JM, Holcomb GW, 3rd. Outcome after recannulatio"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4017,
      "preview": "16. Patel N. Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension se"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4018,
      "preview": "17. Inamura N, Kubota A, Nakajima T, Kayatani F, Okuyama H, Oue T, et al. A proposal of new therapeu"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4019,
      "preview": "18. Kays DW, Islam S, Larson SD, Perkins J, Talbert JL. Long-term maturation of congenital diaphragm"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4020,
      "preview": "19. Kays DW, Talbert JL, Islam S, Larson SD, Taylor JA, Perkins J. Improved Survival in Left Liver-U"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4021,
      "preview": "20. American Academy of Pediatrics Section on S, American Academy of Pediatrics Committee on F, Newb"
    },
    {
      "type": "text",
      "section": "References",
      "line": 4022,
      "preview": "21. Chandrasekharan PK, Rawat M, Madappa R, Rothstein DH, Lakshminrusimha S. Matern Health Neonatol "
    },
    {
      "type": "text",
      "section": "References",
      "line": 4024,
      "preview": "--- page 166 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Extracoporeal Membrane Oxygenation (ECMO)",
      "line": 4026
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Sonia Lomeli Bonifacio, M.D., and Krisa Van Meurs, M.D.",
      "line": 4028
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. General",
      "line": 4030
    },
    {
      "type": "text",
      "section": "I. General",
      "line": 4032,
      "preview": "A. ECMO is the use of prolonged extracorporeal circulation and gas exchange via a modified heart-lun"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. ECMO Criteria",
      "line": 4034
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4036,
      "preview": "1. The neonatal ECMO criteria at LPCH are the following:"
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4037,
      "preview": "2. Gestational age $\\geq 34$ wks and weight $\\geq 2.0 \\mathrm{~kg}$."
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4038,
      "preview": "3. No intracranial hemorrhage $>$ grade II."
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4039,
      "preview": "4. No lethal congenital anomalies."
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4040,
      "preview": "5. Infant has not required mechanical ventilation for a prolonged period of time."
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4041,
      "preview": "6. Cardiac or respiratory failure despite maximal medical therapy with a mortality estimated to be a"
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4043,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4044,
      "preview": "\\mathrm{OI}=(\\text { Mean Airway Pressure) }(\\mathrm{FiO} 2)(100) / \\mathrm{PaO} 2"
    },
    {
      "type": "text",
      "section": "II. ECMO Criteria",
      "line": 4045,
      "preview": "$$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Pre-ECMO Procedures",
      "line": 4047
    },
    {
      "type": "text",
      "section": "III. Pre-ECMO Procedures",
      "line": 4049,
      "preview": "Infants who are being considered for ECMO should receive:"
    },
    {
      "type": "text",
      "section": "III. Pre-ECMO Procedures",
      "line": 4050,
      "preview": "A. Echocardiogram: The echocardiogram is to exclude congenital heart disease, look for pulmonary hyp"
    },
    {
      "type": "text",
      "section": "III. Pre-ECMO Procedures",
      "line": 4051,
      "preview": "B. Head Ultrasound: This is done to check for significant intracranial hemorrhage, which could exten"
    },
    {
      "type": "text",
      "section": "III. Pre-ECMO Procedures",
      "line": 4052,
      "preview": "C. Coagulation Studies: A PT, PTT, fibrinogen, and platelet count should be sent on patients being c"
    },
    {
      "type": "text",
      "section": "III. Pre-ECMO Procedures",
      "line": 4053,
      "preview": "D. ECMO Consent: The ECMO attending and NICU fellow will take obtain the consent and notify the ECMO"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Blood Product Ordering:",
      "line": 4055
    },
    {
      "type": "text",
      "section": "E. Blood Product Ordering:",
      "line": 4057,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "E. Blood Product Ordering:",
      "line": 4059,
      "preview": "--- page 167 ---"
    },
    {
      "type": "text",
      "section": "E. Blood Product Ordering:",
      "line": 4061,
      "preview": "1. For emergency ECMO when there is no $\\mathrm{ABO} / \\mathrm{Rh}$ type, use order set in EPIC \"ECM"
    },
    {
      "type": "text",
      "section": "E. Blood Product Ordering:",
      "line": 4062,
      "preview": "2. For non-emergency ECMO 2 units dry packed RBCs and 50 ml FFP for priming are ordered. This order "
    },
    {
      "type": "text",
      "section": "E. Blood Product Ordering:",
      "line": 4063,
      "preview": "3. Give $10 \\mathrm{~mL} / \\mathrm{kg}$ unpacked platelets ASAP once on bypass."
    },
    {
      "type": "text",
      "section": "E. Blood Product Ordering:",
      "line": 4064,
      "preview": "4. Whenever ECMO is being performed in the NICU, an emergency RBC unit will be kept in the NICU."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. ECMO Orders:",
      "line": 4066
    },
    {
      "type": "text",
      "section": "F. ECMO Orders:",
      "line": 4068,
      "preview": "1. There are specific order sets which should be completed for any patient to be placed on ECMO, the"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Post-ECMO Procedures",
      "line": 4070
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4072,
      "preview": "After the patient is decannulated, you will again assume responsibility for their care. You will rec"
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4073,
      "preview": "A. Respiratory: In general, patients weaned off ECMO no longer have PPHN physiology. The respiratory"
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4074,
      "preview": "B. Fluids, Electrolytes, and Nutrition: The fluid and electrolyte requirements on ECMO are different"
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4075,
      "preview": "C. Hematologic: ECMO patients receive frequent platelet transfusions while on ECMO to keep their pla"
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4076,
      "preview": "D. Neurologic: ECMO patients receive a daily HUS during the first week on bypass; less frequent exam"
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4077,
      "preview": "E. Follow-up: ECMO patients are seen in the Developmental and Behavioral Clinic at 4 mos, 12 mos, an"
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4079,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Post-ECMO Procedures",
      "line": 4081,
      "preview": "--- page 168 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 4083
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4085,
      "preview": "1. Bahrami KR, Van Meurs KP. ECMO for neonatal respiratory failure. Sem Perinatol. 2005;29:15-23."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4086,
      "preview": "2. Knight GR, Dudell GG, Evans ML, Grimm PS. A comparison of venovenous and venoarterial extracorpor"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4087,
      "preview": "3. Dimmit RA, Moss RL, Rhine WD, Benitz WE, Henry MC, Van Meurs KP. Venoarterial versus venovenous e"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4088,
      "preview": "4. Bulas D, Glass P. Neonatal ECMO: neuroimaging and neurodevelopmental outcome. Sem Perinatol 2005;"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4089,
      "preview": "5. Downard CD, Betit P, Chang RW, Garza JJ, Arnold JH, Wilson JM. Impact of AMICAR on hemorrhagic co"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4090,
      "preview": "6. Glass P, Wagner AE, Papero PH, Rajasingham SR, Civitello LA, Kjaer MS, Coffman CE, Getson PR, Sho"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4092,
      "preview": "--- page 169 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Apnea",
      "line": 4094
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Ronald S. Cohen, M.D.",
      "line": 4096
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Clinical Assessment of Apnea or Cardio-Respiratory Insufficiency",
      "line": 4098
    },
    {
      "type": "text",
      "section": "I. Clinical Assessment of Apnea or Cardio-Respiratory Insufficiency",
      "line": 4100,
      "preview": "A. Mild: duration of apnea $<20 \\mathrm{sec}$, heart rate (HR) 80-100, oxygen saturation (sat) $85-9"
    },
    {
      "type": "text",
      "section": "I. Clinical Assessment of Apnea or Cardio-Respiratory Insufficiency",
      "line": 4101,
      "preview": "B. Moderate: duration of apnea $>20 \\mathrm{sec}, \\mathrm{HR} 60-80$, sat $75-85 \\%$, requires vigor"
    },
    {
      "type": "text",
      "section": "I. Clinical Assessment of Apnea or Cardio-Respiratory Insufficiency",
      "line": 4102,
      "preview": "C. Severe: duration of apnea $>20 \\mathrm{sec}, \\mathrm{HR}<60$, sat $<75 \\%$, requires oxygen and p"
    },
    {
      "type": "text",
      "section": "I. Clinical Assessment of Apnea or Cardio-Respiratory Insufficiency",
      "line": 4103,
      "preview": "D. Periodic breathing: Recurrent respiratory pauses of 5 to 10 sec , followed by 10 to 15 sec of rap"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Apnea types:",
      "line": 4105
    },
    {
      "type": "text",
      "section": "E. Apnea types:",
      "line": 4107,
      "preview": "1. Central: breathing pause without respiratory effort."
    },
    {
      "type": "text",
      "section": "E. Apnea types:",
      "line": 4108,
      "preview": "2. Obstructive: e.g., respiratory effort without effective ventilation and airflow; may be associate"
    },
    {
      "type": "text",
      "section": "E. Apnea types:",
      "line": 4109,
      "preview": "3. Mixed: Usually a central respiratory pause preceded or followed by airway obstruction."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4111
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4113,
      "preview": "A. Infection: especially with history of prolonged rupture of membranes, maternal fever, central lin"
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4114,
      "preview": "B. Impaired oxygenation: pallor, shock, L-to-R shunt through PDA, anemia, pulmonary edema, and heart"
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4115,
      "preview": "C. Metabolic disorders: hypoglycemia, electrolyte imbalance, lactic acidosis."
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4116,
      "preview": "D. Drugs: maternal opiates, anti-convulsants, prostaglandin, magnesium."
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4117,
      "preview": "E. Neurologic: seizures, asphyxia, intracranial hemorrhage, brain malformation, increased intracrani"
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4118,
      "preview": "F. Feeding-related: Association with gastroesophageal reflux \"GER\" in the full-term infant and pre-t"
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4119,
      "preview": "G. Thermal instability: Both hyper- and hypothermia can cause apnea."
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4120,
      "preview": "H. Idiopathic: apnea of prematurity, respiratory drive instability."
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4121,
      "preview": "I. Pulmonary disease: decreased lung compliance (e.g., RDS, pneumonia), increased work-of-breathing."
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4122,
      "preview": "J. Airway obstruction: anatomic, malposition of trachea associated with neck flexion, excessive oral"
    },
    {
      "type": "text",
      "section": "II. Differential Diagnosis of Apnea",
      "line": 4124,
      "preview": "--- page 170 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Pathogenesis",
      "line": 4126
    },
    {
      "type": "text",
      "section": "III. Pathogenesis",
      "line": 4128,
      "preview": "A. Chemoreceptor function: Preterm infants have a biphasic response to hypoxemia, with a transient i"
    },
    {
      "type": "text",
      "section": "III. Pathogenesis",
      "line": 4129,
      "preview": "B. Respiratory center depression: The frequency of apnea decreases as the brainstem function improve"
    },
    {
      "type": "text",
      "section": "III. Pathogenesis",
      "line": 4130,
      "preview": "C. Sleep state: Apnea occurs predominantly during active (REM) sleep and indeterminate (transitional"
    },
    {
      "type": "text",
      "section": "III. Pathogenesis",
      "line": 4131,
      "preview": "D. Obstruction: Airway obstruction may occur spontaneously with infant-initiated neck flexion or pas"
    },
    {
      "type": "text",
      "section": "III. Pathogenesis",
      "line": 4132,
      "preview": "E. Reflexes: Active reflexes caused by stimulation of the posterior pharynx (with a suction catheter"
    },
    {
      "type": "text",
      "section": "III. Pathogenesis",
      "line": 4133,
      "preview": "F. Pulmonary insufficiency of prematurity: when pulmonary function is insufficient for metabolic nee"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4135
    },
    {
      "type": "text",
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4137,
      "preview": "A. Incidence is inversely related to PMA."
    },
    {
      "type": "text",
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4138,
      "preview": "B. Generally begins at 1-2 days of age but can start any time during the hospitalization."
    },
    {
      "type": "text",
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4139,
      "preview": "C. Persists for variable length of time. Usually decreases by 37 wks PMA;"
    },
    {
      "type": "text",
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4141,
      "preview": "1. May last longer for infants $<28$ wks gestation at birth."
    },
    {
      "type": "text",
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4142,
      "preview": "2. May persist beyond 40 wks PMA, either as mild events during sleep, or with feeds."
    },
    {
      "type": "text",
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4143,
      "preview": "D. Abnormal for term or near-term infants, look for identifiable cause."
    },
    {
      "type": "text",
      "section": "IV. Incidence of Apnea of Prematurity",
      "line": 4144,
      "preview": "E. No relationship between apnea of prematurity and later SIDS."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4146
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4148,
      "preview": "A. Complete history and physical examination: assess frequency, duration, and temporal association o"
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4149,
      "preview": "B. Respiratory evaluation:"
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4151,
      "preview": "1. ABG (look for hypoxia, acidosis, hypercarbia)"
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4152,
      "preview": "2. CXR (look for pulmonary problem e.g., atelectasis, pulmonary edema or infiltrates)"
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4153,
      "preview": "C. Infectious disease:"
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4154,
      "preview": "3. CBC with manual differential."
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4156,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4158,
      "preview": "--- page 171 ---"
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4160,
      "preview": "2. CRP (C-reactive protein)."
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4161,
      "preview": "3. NP swab for viral pathogens if indicated by symptoms."
    },
    {
      "type": "text",
      "section": "V. Evaluation of the Apneic Infant",
      "line": 4162,
      "preview": "4. If sepsis is suspected, obtain appropriate cultures (blood, urine, CSF) and begin empiric antibio"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Metabolic:",
      "line": 4164
    },
    {
      "type": "text",
      "section": "D. Metabolic:",
      "line": 4166,
      "preview": "1. Electrolytes, calcium, magnesium, glucose."
    },
    {
      "type": "text",
      "section": "D. Metabolic:",
      "line": 4167,
      "preview": "2. Drug levels (if on methylxanthine or CNS depressant)."
    },
    {
      "type": "text",
      "section": "D. Metabolic:",
      "line": 4168,
      "preview": "3. Consider inborn error of metabolism."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Neurologic:",
      "line": 4170
    },
    {
      "type": "text",
      "section": "E. Neurologic:",
      "line": 4172,
      "preview": "1. Head ultrasound (if intracranial hemorrhage or post-hemmorhagic hydocephalus suspected)."
    },
    {
      "type": "text",
      "section": "E. Neurologic:",
      "line": 4173,
      "preview": "2. MRI (if brain abnormality suspected)."
    },
    {
      "type": "text",
      "section": "E. Neurologic:",
      "line": 4174,
      "preview": "3. If seizures suspected, obtain an aEEG; consider anticonvulsants, request neurology consult."
    },
    {
      "type": "text",
      "section": "E. Neurologic:",
      "line": 4175,
      "preview": "4. Sleep/apnea study (to clarify type of apnea, frequency, duration, and associated events)."
    },
    {
      "type": "text",
      "section": "E. Neurologic:",
      "line": 4176,
      "preview": "F. Cardiac: Consider PDA in preterms."
    },
    {
      "type": "text",
      "section": "E. Neurologic:",
      "line": 4177,
      "preview": "G. Gastrointestinal: Gastroesophageal Reflux (GER) on a pH probe study is found commonly and may be "
    },
    {
      "type": "text",
      "section": "E. Neurologic:",
      "line": 4178,
      "preview": "H. Hematologic: The association between anemia and apnea is weak and our ability to predict which pa"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Treatment",
      "line": 4180
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4182
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4184,
      "preview": "1. Treat hypoxemia/hypercarbia with supplemental oxygen to keep pO2 60-80; avoid reflexes that may t"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4185,
      "preview": "2. Nasal Cannula O2, or CPAP may help if obstructive process or pulmonary insufficiency of prematuri"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4186,
      "preview": "3. Consider blood transfusion depending on level of anemia and hypoxemia."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4187,
      "preview": "4. Mechanical ventilation, if above interventions fail."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4189,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4191,
      "preview": "--- page 172 ---"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4193,
      "preview": "B. Caffeine citrate: Methylxanthines act mainly on brainstem respiratory neurons, producing a centra"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4195,
      "preview": "1. Loading dose: $20 \\mathrm{mg} / \\mathrm{kg}$ IV or PO."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4196,
      "preview": "2. Maintenance: $5 \\mathrm{mg} / \\mathrm{kg}$ daily IV or PO."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4197,
      "preview": "3. Caffeine for prophylaxis of apnea of prematurity may be effective for ELBW infants."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4198,
      "preview": "4. Caffeine has been associated with a decreased incidence of both BPD and Cerebral Palsy in infants"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4199,
      "preview": "5. Caffeine has been used to prevent post-operative apnea/brady/desats in growing preterm infants."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4200,
      "preview": "6. Caffeine should be stopped at 34-35 wks PMA or 5-days without significant apnea, whichever comes "
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4201,
      "preview": "a. Monitor for $\\geq 5$ days off caffeine while serum levels drop below therapeutic."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4202,
      "preview": "b. Apnea beyond 38 wks PMA suggests an etiology other than prematurity."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4203,
      "preview": "c. Recent literature suggests that longer treatment with Caffeine might be helpful for preterm infan"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4204,
      "preview": "7. Insignificant events, not requiring intervention, home monitoring, resumption of caffeine, or del"
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4205,
      "preview": "a. Isolated bradycardia with pulse $>60$ and no desaturation, that resolve in 20 sec ."
    },
    {
      "type": "text",
      "section": "A. Treat any underlying causes, if identified.",
      "line": 4206,
      "preview": "b. Self-limited desaturation not below SpO2 of $80 \\%$"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. Home Apnea Monitoring",
      "line": 4208
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Indications:",
      "line": 4210
    },
    {
      "type": "text",
      "section": "A. Indications:",
      "line": 4212,
      "preview": "1. Infants with symptomatic apnea, without a treatable cause or with inadequate response to therapy."
    },
    {
      "type": "text",
      "section": "A. Indications:",
      "line": 4213,
      "preview": "2. VLBW infant with clinically significant apnea within 5 days of discharge, usually at more than 43"
    },
    {
      "type": "text",
      "section": "A. Indications:",
      "line": 4214,
      "preview": "3. Potential airway obstruction (e.g., tracheostomy)."
    },
    {
      "type": "text",
      "section": "A. Indications:",
      "line": 4215,
      "preview": "4. Acute life-threatening event requiring CPR or vigorous stimulation."
    },
    {
      "type": "text",
      "section": "A. Indications:",
      "line": 4216,
      "preview": "5. Infants with continuous NG feedings per GI recommendations."
    },
    {
      "type": "text",
      "section": "A. Indications:",
      "line": 4217,
      "preview": "B. Alarm settings: HR >200 or $<80$, apnea $>20 \\mathrm{sec}$; memory monitor indicated to assess ap"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Discontinuation of monitor:",
      "line": 4219
    },
    {
      "type": "text",
      "section": "C. Discontinuation of monitor:",
      "line": 4221,
      "preview": "1. No significant apnea (i.e., \"real\" apnea requiring stimulation or intervention) for 2 months base"
    },
    {
      "type": "text",
      "section": "C. Discontinuation of monitor:",
      "line": 4223,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "C. Discontinuation of monitor:",
      "line": 4225,
      "preview": "--- page 173 ---"
    },
    {
      "type": "text",
      "section": "C. Discontinuation of monitor:",
      "line": 4227,
      "preview": "166 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "C. Discontinuation of monitor:",
      "line": 4228,
      "preview": "memory monitor record and history."
    },
    {
      "type": "text",
      "section": "C. Discontinuation of monitor:",
      "line": 4229,
      "preview": "2. Off-drug therapy for one month."
    },
    {
      "type": "text",
      "section": "C. Discontinuation of monitor:",
      "line": 4230,
      "preview": "3. Parents refusing to use the monitor."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 4232
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4234,
      "preview": "1. Fairchild K, Mohr M, Paget-Brown A, et al. Clinical associations of immature breathing in preterm"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4235,
      "preview": "2. Patel M, Mohr M, Lake D, et al. Clinical associations with immature breathing in preterm infants:"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4236,
      "preview": "3. Doyle J, Davidson D, Katz S, et al. Apnea of prematurity and caffeine pharmacokinetics: potential"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4237,
      "preview": "4. Di Fiore JM, Poets CF, Gauda E, et al. Cardiorespiratory events in preterm infants: interventions"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4238,
      "preview": "5. Hoppenbrouwers T, Hodgman JE, Ramanathan A, Dorey F. Extreme and conventional cardiorespiratory e"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4239,
      "preview": "6. Zupancic JAF, Richardson DK, O'Brien BJ, et al. Cost-effectiveness analysis of predischarge monit"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4240,
      "preview": "7. Poets CF, Brockmann PE. Myth: Gastroesophageal reflux is a pathologic entity in the preterm infan"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4241,
      "preview": "8. Dobson NR, Rhein LM, Darnall RA, Corwin MJ, Heeren TC, Eichenwald E, et al. Caffeine decreases in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4243,
      "preview": "--- page 174 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Oxygen Saturation Guidelines",
      "line": 4245
    },
    {
      "type": "text",
      "section": "Oxygen Saturation Guidelines",
      "line": 4247,
      "preview": "Ron Cohen, M.D. and Diana Kobayashi, N.N.P.-B.C."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 4249
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4251,
      "preview": "A. Oxygen is a drug; it is probably the most widely used drug in the intensive care setting. Althoug"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4253,
      "preview": "1. Use of $100 \\%$ oxygen in incubators during the 1940s and 1950s was linked to a very high inciden"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4254,
      "preview": "2. Evidence shows that reactive oxygen species, like superoxide, in combination with other factors, "
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4255,
      "preview": "3. Antioxidant defense systems are likely to be decreased and impaired in premature infants, so our "
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4256,
      "preview": "4. A number of studies led to the recognition that an optimal range for oxygen saturation and PaO 2 "
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4257,
      "preview": "a. Several trials from 1950s to 1970s compared unrestricted oxygen supplementation (FiO2>50\\%) for 2"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4258,
      "preview": "i. The practice of \"restricted\" oxygen was NOT associated with an increase in mortality."
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4259,
      "preview": "ii. A meta-analysis of 5 trials showed that oxygen restriction decreased the incidence and severity "
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4260,
      "preview": "b. A retrospective study reviewing different oxygenation policies in England for infants born less t"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4261,
      "preview": "c. Another retrospective study of 7 United States NICUs reported that in infants 500-1000 g, a polic"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4262,
      "preview": "d. A study comparing resuscitation at birth with room air vs. $100 \\%$ oxygen in term infants follow"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4263,
      "preview": "e. The AAP and ACOG Guidelines for Perinatal Care is the official publication that sets standards of"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4265,
      "preview": "--- page 175 ---"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4267,
      "preview": "168 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 4268,
      "preview": "optimal range for oxygen saturation and PaO 2 that balances tissue metabolism, growth and developmen"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "5. Recent Randomized Controlled Trials",
      "line": 4270
    },
    {
      "type": "text",
      "section": "5. Recent Randomized Controlled Trials",
      "line": 4272,
      "preview": "a. The SUPPORT trial of the NICHD Neonatal Research Network was a $2 \\times 2$ factorial, multi-cent"
    },
    {
      "type": "text",
      "section": "5. Recent Randomized Controlled Trials",
      "line": 4273,
      "preview": "b. The BOOST II trial (UK, Australia, New Zealand) also compared the same 2 oxygen saturation ranges"
    },
    {
      "type": "text",
      "section": "5. Recent Randomized Controlled Trials",
      "line": 4274,
      "preview": "c. The COT trial (Canada, US, Argentina, Finland, Germany, Israel) showed differing results. In extr"
    },
    {
      "type": "text",
      "section": "5. Recent Randomized Controlled Trials",
      "line": 4275,
      "preview": "d. A recent meta-analysis of these major international studies6 reported \"no significant differences"
    },
    {
      "type": "text",
      "section": "5. Recent Randomized Controlled Trials",
      "line": 4276,
      "preview": "e. However, one recent paper did seem to show a decrease in severe ROP \\& laser treatment with incre"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Oxygen Therapy for Pre-threshold ROP",
      "line": 4278
    },
    {
      "type": "text",
      "section": "II. Oxygen Therapy for Pre-threshold ROP",
      "line": 4280,
      "preview": "A. The STOP-ROP study investigated the possibility that supplemental oxygen might reduce the progres"
    },
    {
      "type": "text",
      "section": "II. Oxygen Therapy for Pre-threshold ROP",
      "line": 4281,
      "preview": "B. There is ongoing debate about the best way to treat prethreshold ROP, but supplemental oxygen may"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Guidelines for Oxygen Saturations and Alarm Limits",
      "line": 4283
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Infants <35 weeks PMA",
      "line": 4285
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. In oxygen",
      "line": 4287
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4289,
      "preview": "a. Target oxygen saturations: $90-95 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4290,
      "preview": "b. Pulse oximeter alarm limits: $88 \\%$ and $95 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4292,
      "preview": "--- page 176 ---"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4294,
      "preview": "2. In room air"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4295,
      "preview": "a. Target oxygen saturations: $90-95 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4296,
      "preview": "b. Pulse oximeter alarm limits: $88 \\%$ and $100 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4297,
      "preview": "B. Infants $\\geq 35$ weeks PMA"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4298,
      "preview": "3. In oxygen"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4299,
      "preview": "a. Target oxygen saturations: $92-97 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4300,
      "preview": "b. Pulse oximeter alarm limits: $88 \\%$ and $97 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4301,
      "preview": "4. In room air"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4302,
      "preview": "a. Target oxygen saturations: $92-97 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4303,
      "preview": "b. Pulse oximeter alarm limits: $88 \\%$ and $100 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4304,
      "preview": "C. Pre-Threshold ROP (when diagnosed by Ophthalmology). At the time of detection of prethreshold ROP"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "1. In oxygen",
      "line": 4306
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4308,
      "preview": "a. Target oxygen saturations: $97-99 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4309,
      "preview": "b. Pulse oximeter alarm limits: $95 \\%$ and $99 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4310,
      "preview": "2. In room air"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4311,
      "preview": "a. Target oxygen saturations: $97-100 \\%$"
    },
    {
      "type": "text",
      "section": "1. In oxygen",
      "line": 4312,
      "preview": "b. Pulse oximeter alarm limits: $95 \\%$ and $100 \\%$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Congenital Heart Disease",
      "line": 4314
    },
    {
      "type": "text",
      "section": "D. Congenital Heart Disease",
      "line": 4316,
      "preview": "Discuss each individual case with our Pediatric Cardiology colleagues. Targets will be determined ba"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 4318
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4320,
      "preview": "1. Askie LM, Henderson-Smart DJ, Ko H. Restricted versus liberal oxygen exposure for preventing morb"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4321,
      "preview": "2. The Guidelines for Perinatal Care 6th Edition (2007). Most recent version ( $8^{\\text {th }}$ edi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4322,
      "preview": "3. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Fine"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4324,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4326,
      "preview": "--- page 177 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4328,
      "preview": "170 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4329,
      "preview": "CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Ehrenkranz RA, Watterberg KL, H"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4330,
      "preview": "4. BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4331,
      "preview": "5. Schmidt B, Whyte RK, Asztalos EV, Moddemann D, Poets C, Rabi Y, Solimano A, Roberts RS; Canadian "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4332,
      "preview": "6. Manja V, Lakshminrusimha S, Cook DJ. Oxygen saturation target range for extremely premature infan"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4333,
      "preview": "7. Cayabyab R, Arora V, Wertheimer F, Durand M, Ramanathan R. Graded oxygen saturation targets and r"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4335,
      "preview": "--- page 178 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Broncopulmonary Dysplasia",
      "line": 4337
    },
    {
      "type": "text",
      "section": "Broncopulmonary Dysplasia",
      "line": 4339,
      "preview": "Ronald S. Cohen, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 4341
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4343,
      "preview": "A. Bronchopulmonary Dysplasia (BPD) is the most common chronic lung disease (CLD) of early infancy. "
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4344,
      "preview": "B. In 1989, the Bureau of Maternal and Child Health and Resources Development proposed the following"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4346,
      "preview": "1. Requirement for positive pressure ventilation during the first 2 weeks of life. Minimum requireme"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4347,
      "preview": "2. Clinical signs of respiratory compromise persisting beyond 28 days of age."
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4348,
      "preview": "3. Requirement for supplemental oxygen beyond 28 days of age in order to maintain a PaO2 of greater "
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4349,
      "preview": "4. Chest radiographs showing characteristic lung abnormalities (diffuse bilateral densities, often a"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4350,
      "preview": "C. The definition has been modified to specify a need for supplemental oxygen for greater than 28 da"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4351,
      "preview": "D. An NIH-sponsored workshop on BPD reached a consensus to refer to this disease as BPD instead of C"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4352,
      "preview": "E. Most recently, it has been reported that surviving very low gestational age infants may be at ris"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Incidence",
      "line": 4354
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4356,
      "preview": "A. The incidence of BPD is variable between newborn care centers, reflecting not only differences in"
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4357,
      "preview": "B. Recent reports indicate that the incidence of BPD varies from 15-50\\% in infants whose birth weig"
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4358,
      "preview": "C. The incidence of BPD is inversely related to gestational age, varying from $80 \\%$ or more among "
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4360,
      "preview": "--- page 179 ---"
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4362,
      "preview": "A. The initiating event in BPD is considered to be inflammation of the incompletely developed newbor"
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4363,
      "preview": "B. Deficiency of anti-oxidant enzymes and inhibitors of proteolytic enzymes renders the very immatur"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Conditions that are associated with BPD:",
      "line": 4365
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4367,
      "preview": "1. Prematurity (especially extreme lung immaturity)."
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4368,
      "preview": "2. Repetitive stretch and overinflation of the lungs (\"volutrauma\") associated with prolonged mechan"
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4369,
      "preview": "3. Oxygen toxicity (related to the magnitude and duration of exposure to supplemental oxygen, and ow"
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4370,
      "preview": "4. Development of pulmonary air leaks, notably interstitial emphysema, and pneumothoraces."
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4371,
      "preview": "5. Lung edema: excessive fluid and salt intake, persistence of a patent ductus arteriosus, myocardia"
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4372,
      "preview": "6. Infection and associated inflammation, sometimes with chorioamnionitis before birth, sepsis or pn"
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4373,
      "preview": "7. Conditions that may contribute to acute lung injury and non-uniform lung expansion: aspiration of"
    },
    {
      "type": "text",
      "section": "C. Conditions that are associated with BPD:",
      "line": 4374,
      "preview": "8. Other factors: poor nutritional support, genetic predisposition to reactive airways disease, vita"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Pulmonary Dysfunction in BPD:",
      "line": 4376
    },
    {
      "type": "text",
      "section": "D. Pulmonary Dysfunction in BPD:",
      "line": 4378,
      "preview": "1. Increased lung vascular resistance, typically associated with impaired responsiveness to inhaled "
    },
    {
      "type": "text",
      "section": "D. Pulmonary Dysfunction in BPD:",
      "line": 4379,
      "preview": "2. Increased respiratory tract resistance and hyper-reactive airways leading to episodic bronchocons"
    },
    {
      "type": "text",
      "section": "D. Pulmonary Dysfunction in BPD:",
      "line": 4380,
      "preview": "3. Impaired respiratory gas exchange (hypoxemia with need for supplemental oxygen, alveolar hypovent"
    },
    {
      "type": "text",
      "section": "D. Pulmonary Dysfunction in BPD:",
      "line": 4381,
      "preview": "4. Diminished lung compliance, tachypnea, and increased minute ventilation and work of breathing."
    },
    {
      "type": "text",
      "section": "D. Pulmonary Dysfunction in BPD:",
      "line": 4382,
      "preview": "5. Increased lung microvascular filtration pressure that leads to interstitial pulmonary edema."
    },
    {
      "type": "text",
      "section": "D. Pulmonary Dysfunction in BPD:",
      "line": 4384,
      "preview": "--- page 180 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4386
    },
    {
      "type": "text",
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4388,
      "preview": "1. Increased smooth muscle in small pulmonary arteries and airways."
    },
    {
      "type": "text",
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4389,
      "preview": "2. Decreased numbers of terminal respiratory units (alveoli and secondary crests); increased alveola"
    },
    {
      "type": "text",
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4390,
      "preview": "3. Decreased numbers of microvessels, with reduced pulmonary expression of vascular endothelial grow"
    },
    {
      "type": "text",
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4391,
      "preview": "4. Increased abundance and abnormal distribution of elastin in the lung parenchyma and circulation w"
    },
    {
      "type": "text",
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4392,
      "preview": "5. Interstitial pulmonary edema."
    },
    {
      "type": "text",
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4393,
      "preview": "6. Diminished endothelial nitric oxide synthase (eNOS) and soluble guanylate cyclase (sGC) in lung b"
    },
    {
      "type": "text",
      "section": "E. Structural and molecular abnormalities of the lung in BPD:",
      "line": 4394,
      "preview": "7. Increased numbers of neutrophils early in course with increased numbers of macrophages later in t"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Treatment",
      "line": 4396
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4398,
      "preview": "A. The best approach for preventing or reducing the severity of BPD is to adopt strategies that mini"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4400,
      "preview": "1. Antenatal glucocorticoids and postnatal surfactant replacement may not prevent BPD, but they are "
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4401,
      "preview": "2. Early application of Nasal Continuous Positive Airway Pressure (NCPAP) may help to maintain stabi"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4402,
      "preview": "3. Treatment with a respiratory stimulant, specifically caffeine, reduces the risk of apnea, and has"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4403,
      "preview": "4. Restricting fluid and salt intake in the first week, so that the infant does not exceed fluid and"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4404,
      "preview": "5. Assisted ventilation: \"Permissive hypercapnia,\" with use of low peak-inflation pressures (PIP), r"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4405,
      "preview": "becomemore compliant, weaning from mechanical ventilation should focus on reducing PIP and tidal vol"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4407,
      "preview": "--- page 181 ---"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4409,
      "preview": "6. Early closure of the ductus arteriosus, either by pharmacologic intervention or surgical ligation"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4410,
      "preview": "7. Careful and frequent evaluations to detect early signs of infection, meticulous monitoring of ase"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4411,
      "preview": "8. Although it is important to reduce the inspired oxygen concentration quickly if the oxygen satura"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4412,
      "preview": "9. Other studies have shown that Dopamine, when delivered intravenously at low doses to support syst"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4413,
      "preview": "B. Careful attention to fluid and salt balance is important to help reduce the risk of pulmonary ede"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4414,
      "preview": "10. Fluid and heat losses in the very immature infant ( $<26$ wks gestation) during the first few da"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4415,
      "preview": "11. Fluid balance can be monitored effectively by keeping the infant on a bed scale and measuring bo"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4416,
      "preview": "12. Frequent measurements of serum electrolytes (every 6 hrs for the very immature infant, every 12 "
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4417,
      "preview": "13. In a suitably humidified environment, appropriate initial rates of IV fluid intake for the prema"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4418,
      "preview": "$>28$ wks gestation: $60-80 \\mathrm{~mL} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4419,
      "preview": "$26-28$ wks gestation: $80-100 \\mathrm{~mL} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4420,
      "preview": "$<26$ wks gestation: $100-120 \\mathrm{~mL} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4421,
      "preview": "14. These guidelines assume close monitoring of body weight, intake/output measurements, and serum s"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4422,
      "preview": "15. After the brisk diuresis that usually occurs during the first 3-7 days, urine output generally d"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4423,
      "preview": "16. Once on full enteral nutrition, infants without evidence of CHF or renal dysfunction can almost "
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4425,
      "preview": "--- page 182 ---"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4427,
      "preview": "C. Nutritional needs of the infant with BPD depend on environmental conditions (goal should be a neu"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4429,
      "preview": "1. Early delivery of parenteral nutrition, including protein and lipid, through a peripherally place"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4430,
      "preview": "2. Caloric, protein, and mineral needs usually can be met with fortification of mother's breast milk"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4431,
      "preview": "3. Premature infants with BPD require nutritional supplements of calcium and phosphorus, in addition"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4432,
      "preview": "D. Diuretics: Diuretics must be used with caution because of their potential complications, which in"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4433,
      "preview": "4. Furosemide is a potent diuretic that reduces pulmonary blood flow and lung vascular filtration pr"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4434,
      "preview": "5. Hydrochlorothiazide ( $1 \\mathrm{mg} / \\mathrm{kg} /$ dose q12h) and spironolactone ( $1-2 \\mathr"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4435,
      "preview": "6. Prolonged use of diuretics can cause contraction alkalosis with associated potassium and chloride"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 4436,
      "preview": "E. Retinol (Vitamin A): Vitamin A has been found to decrease the incidence and severity of BPD in ex"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Glucocorticoids:",
      "line": 4438
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4440,
      "preview": "1. Because immature infants often have very low plasma cortisol levels and do not always respond app"
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4441,
      "preview": "2. Dexamethasone (Decadron) is not recommended because of its serious side effects: an increased inc"
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4442,
      "preview": "3. Inhaled steroids have not been shown to be beneficial in reducing the incidence or severity of BP"
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4444,
      "preview": "--- page 183 ---"
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4446,
      "preview": "176 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4447,
      "preview": "G. Bronchodilators: because infants with BPD have increased respiratory tract resistance and airway "
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4449,
      "preview": "1. $\\beta 2$-adrenergic agonists may be beneficial in BPD by relaxing smooth muscle constriction and"
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4450,
      "preview": "2. In unusual circumstances, aerosolized bronchodilators, such as albuterol or atrovent, may induce "
    },
    {
      "type": "text",
      "section": "F. Glucocorticoids:",
      "line": 4451,
      "preview": "3. Methylxanthines, while helpful in relieving bronchospasm in selected infants with BPD, have signi"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "H. Ventilation:",
      "line": 4453
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4455,
      "preview": "1. Over the first few weeks of life, the tidal volume of ventilated neonates increases from $4-5 \\ma"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4456,
      "preview": "2. With the development of BPD, there can be an increase in both airways resistance and compliance r"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4457,
      "preview": "3. To manage this in intubated babies with BPD, we usually recommend a strategy involving higher tid"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4458,
      "preview": "4. This strategy must be individualized, and should be discussed with the Attending on rounds to gui"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4459,
      "preview": "I. Inhaled Nitric Oxide (iNO): There is considerable experimental evidence that iNO can improve resp"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4460,
      "preview": "5. Recent studies of iNO treatment in animal models of BPD have indicated that this treatment strate"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4461,
      "preview": "6. Selection of appropriate candidates for iNO treatment, as well as timing and dosing of treatment "
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4462,
      "preview": "7. Potential toxicities of iNO therapy include oxidant lung injury and loss of surfactant function f"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4464,
      "preview": "--- page 184 ---"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4466,
      "preview": "1. If suspected, an esophageal pH study should be done to test for the presence of reflux and possib"
    },
    {
      "type": "text",
      "section": "H. Ventilation:",
      "line": 4467,
      "preview": "2. If significant reflux is documented, drugs that might contribute to the problem should be discont"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "K. Assessment for vocal cord injury:",
      "line": 4469
    },
    {
      "type": "text",
      "section": "K. Assessment for vocal cord injury:",
      "line": 4471,
      "preview": "1. Stridor or persistent respiratory distress may be a sign of vocal cord injury, which sometimes oc"
    },
    {
      "type": "text",
      "section": "K. Assessment for vocal cord injury:",
      "line": 4472,
      "preview": "2. This condition can contribute to respiratory symptoms associated with BPD and also prolong weanin"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 4474
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4476,
      "preview": "1. Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respiratory therapy of hyaline m"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4477,
      "preview": "2. Ehrenkranz RA, Walsh, MC, Vohr BR, et al. Validation of the National Institutes of Health consens"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4478,
      "preview": "3. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD National Research Network. Early CPAP ver"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4479,
      "preview": "4. Miller JD, Carlo WA. Safety and effectiveness of permissive hypercapnia in the preterm infant. Cu"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4480,
      "preview": "5. Manja V, Lakshminrusimha S, Cook DJ. Oxygen Saturation Target Range for Extremely Preterm Infants"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4481,
      "preview": "6. Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4482,
      "preview": "7. Tolia VN, Murthy K, McKinley PS, et al. The Effect of the National Shortage of Vitamin A on Death"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4483,
      "preview": "8. Baud O, Maury L, Lebail F, et al. Effect of early low- dose hydrocortisone on survival without br"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4484,
      "preview": "9. Onland W, Offringa M, van Kaam A. Late ( $\\geq 7$ days) inhalation corticosteroids to reduce bron"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4485,
      "preview": "10. Finer NN, Evans N. Inhaled nitric oxide for the preterm infant: Evidence versus practice. Pediat"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4486,
      "preview": "11. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4488,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4490,
      "preview": "--- page 185 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4492,
      "preview": "178 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4493,
      "preview": "MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson W, Rowitch DH. NIH Consens State Sci Statement"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4494,
      "preview": "12. Nobile S, Noviello C, Cobellis G, Carnielli VP. Are Infants with Bronchopulmonary Dysplasia Pron"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4496,
      "preview": "--- page 186 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Cystic Fibrosis",
      "line": 4498
    },
    {
      "type": "text",
      "section": "Cystic Fibrosis",
      "line": 4500,
      "preview": "Carol Conrad, M.D. and Bill Callas, R.R.T."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 4502
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4504,
      "preview": "A. Cystic fibrosis (CF) is a chronic, multisystem, lethal recessive disorder that results from defec"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4505,
      "preview": "B. The primary morbidity in CF is from progression of obstructive lung disease. A very large percent"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 4506,
      "preview": "C. The prognosis used to be quite grave and most infants and children did not survive past the age o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Incidence",
      "line": 4508
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4510,
      "preview": "A. CF is inherited in an autosomal recessive pattern, and both parents are usually asymptomatic carr"
    },
    {
      "type": "text",
      "section": "II. Incidence",
      "line": 4511,
      "preview": "B. The gene that encodes for the chloride channel affected in CF is located on chromosome 7. Over 2,"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Pathophysiology",
      "line": 4513
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4515,
      "preview": "A. CF involves several organ systems, including the lungs, pancreas, intestines, hepatobiliary tract"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4516,
      "preview": "B. The CF defect is characterized by a reduced ability of epithelial cells in the airways and pancre"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4518,
      "preview": "--- page 187 ---"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4520,
      "preview": "180 Part II-B: Respiratory"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4521,
      "preview": "intestinal) secretions, abnormal mucociliary clearance, and finally, the lung disease characteristic"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4522,
      "preview": "C. The earliest evidence of airway obstruction occurs at the level of the bronchioles with mucus plu"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4523,
      "preview": "D. Mucociliary clearance is also greatly impaired in patients with CF. This process is manifest in m"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4524,
      "preview": "E. As mentioned above, patients with CF eventually become colonized with certain types of bacteria, "
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 4525,
      "preview": "F. Another classic pathologic feature of the CF airway is the infiltration of inflammatory cells int"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Diagnosis",
      "line": 4527
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. The \"Sweat Test \"",
      "line": 4529
    },
    {
      "type": "text",
      "section": "A. The \"Sweat Test \"",
      "line": 4531,
      "preview": "1. The gold-standard test to diagnose CF is the \"sweat test\" or the pilocarpine iontophoresis test. "
    },
    {
      "type": "text",
      "section": "A. The \"Sweat Test \"",
      "line": 4532,
      "preview": "a. The possibility of a false positive sweat test exists. The causes include: adrenal insufficiency,"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4534
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4536,
      "preview": "a. Screening for cystic fibrosis at the time of birth has led to early identification of CF with a r"
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4537,
      "preview": "b. Beginning in August 2007, the California legislature mandated the addition of testing for cystic "
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4538,
      "preview": "i. 4-step screening algorithm:"
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4539,
      "preview": "a) Serum IRT measuring $\\geq$ the upper $2.2 \\%$ of IRT measured on that day in newborn infants."
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4541,
      "preview": "--- page 188 ---"
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4543,
      "preview": "b) CF DNA mutation panel sent to detect 38 most common CF DNA gene mutations in CA."
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4544,
      "preview": "c) If 1 mutation is positive, the baby is likely a carrier, but a more extensive CF DNA mutation pan"
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4545,
      "preview": "d) If 2 mutations are positive, the baby's pediatrician and parents will be notified of the result, "
    },
    {
      "type": "text",
      "section": "2. Newborn Screening for Cystic Fibrosis",
      "line": 4546,
      "preview": "ii. By this algorithm and the cut-off for elevated IRT, it is calculated that of the 78 new CF cases"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "3. Cystic Fibrosis Metabolic Syndrome",
      "line": 4548
    },
    {
      "type": "text",
      "section": "3. Cystic Fibrosis Metabolic Syndrome",
      "line": 4550,
      "preview": "a. CF metabolic syndrome (CRMS) is used in the United States to describe infants with elevated level"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Adjunctive Testing for Newborns",
      "line": 4552
    },
    {
      "type": "text",
      "section": "B. Adjunctive Testing for Newborns",
      "line": 4554,
      "preview": "1. Serum for CF DNA - as stated above, in general, this is a less sensitive test than the sweat test"
    },
    {
      "type": "text",
      "section": "B. Adjunctive Testing for Newborns",
      "line": 4555,
      "preview": "2. Many more mutations exist - and it is not uncommon to receive a result that identifies only one C"
    },
    {
      "type": "text",
      "section": "B. Adjunctive Testing for Newborns",
      "line": 4556,
      "preview": "3. Stool elastase quantification - A small amount of stool may be obtained and sent for elastase qua"
    },
    {
      "type": "image",
      "section": "B. Adjunctive Testing for Newborns",
      "line": 4557,
      "content": "![img-21.jpeg](images/6fa00f2306dcb1b7.png)"
    },
    {
      "type": "text",
      "section": "B. Adjunctive Testing for Newborns",
      "line": 4559,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "B. Adjunctive Testing for Newborns",
      "line": 4561,
      "preview": "--- page 189 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Clinical Manifestations",
      "line": 4563
    },
    {
      "type": "text",
      "section": "V. Clinical Manifestations",
      "line": 4565,
      "preview": "A. Intestinal obstruction is common in CF patients. Meconium ileus occurring in utero or immediately"
    },
    {
      "type": "text",
      "section": "V. Clinical Manifestations",
      "line": 4566,
      "preview": "B. The most common clinical manifestation for infants with CF is respiratory. Infants frequently pre"
    },
    {
      "type": "text",
      "section": "V. Clinical Manifestations",
      "line": 4567,
      "preview": "C. The pathophysiology for most of the other organs affected in CF is similar to that of the lungs. "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Management",
      "line": 4569
    },
    {
      "type": "text",
      "section": "VI. Management",
      "line": 4571,
      "preview": "A. The management of CF can be very complicated due to multi-system involvement and a high frequency"
    },
    {
      "type": "text",
      "section": "VI. Management",
      "line": 4572,
      "preview": "B. Pulmonary Treatment of CF begins early and occurs on a daily basis. While newborn infants with CF"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Antibiotics",
      "line": 4574
    },
    {
      "type": "text",
      "section": "C. Antibiotics",
      "line": 4576,
      "preview": "1. Treatment is generally reserved for acute exacerbations. When possible, antibiotic therapy is gui"
    },
    {
      "type": "text",
      "section": "C. Antibiotics",
      "line": 4577,
      "preview": "2. If a patient requires hospitalization for CF pneumonia, when treating a gram-negative, lactose no"
    },
    {
      "type": "text",
      "section": "C. Antibiotics",
      "line": 4578,
      "preview": "3. CF patients require very high doses of most medications to achieve therapeutic serum levels. Amin"
    },
    {
      "type": "text",
      "section": "C. Antibiotics",
      "line": 4580,
      "preview": "--- page 190 ---"
    },
    {
      "type": "text",
      "section": "C. Antibiotics",
      "line": 4582,
      "preview": "dosing in an infant with CF is commonly $5 \\mathrm{mg} / \\mathrm{kg} /$ dose given every 8 hrs . Pre"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Corticosteroid Therapy",
      "line": 4584
    },
    {
      "type": "text",
      "section": "D. Corticosteroid Therapy",
      "line": 4586,
      "preview": "Additions to the CF pharmaceutical regime intended to diminish the chronic inflammation of the airwa"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Recombinant Human DNase (rhDNase)",
      "line": 4588
    },
    {
      "type": "text",
      "section": "E. Recombinant Human DNase (rhDNase)",
      "line": 4590,
      "preview": "The sputum in CF is more abundant and has increased viscosity because of increased glycoprotein sulf"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Hypertonic Saline nebulization (7\\% solution)",
      "line": 4592
    },
    {
      "type": "text",
      "section": "F. Hypertonic Saline nebulization (7\\% solution)",
      "line": 4594,
      "preview": "This treatment is a relatively recent addition to the potential regimen for CF patients to maintain "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "G. Gastrointestinal",
      "line": 4596
    },
    {
      "type": "text",
      "section": "G. Gastrointestinal",
      "line": 4598,
      "preview": "1. GI symptoms are typical for patients with CF, but treatment with oral pancreatic enzyme replaceme"
    },
    {
      "type": "text",
      "section": "G. Gastrointestinal",
      "line": 4599,
      "preview": "2. Pancreatic enzymes are obtained primarily from porcine pancreas and available in powder or capsul"
    },
    {
      "type": "text",
      "section": "G. Gastrointestinal",
      "line": 4600,
      "preview": "3. For infants, the capsule is opened, and the tiny beads are either poured directly into the infant"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4602
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4604,
      "preview": "1. Several classes of dysfunction related to CFTR gene mutations have been described."
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4606,
      "preview": "Class I - Defective protein production. This defect is usually caused by nonsense, frameshift, or sp"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4608,
      "preview": "--- page 191 ---"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4610,
      "preview": "Class II - Defective protein processing. This causes abnormal post-translational processing of the C"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4611,
      "preview": "Class III - Defective regulation. These lead to diminished channel activity in response to ATP. The "
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4613,
      "preview": "Class IV - Defective conduction - the protein is correctly localized to the apical surface of the ce"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4615,
      "preview": "Class V - Reduced amounts of functional CFTR protein."
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4616,
      "preview": "Class VI - Altered stability of the mature CFTR protein in the cell membrane."
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4617,
      "preview": "2. While there is no drug developed yet that targets the most common mutations, there has been devel"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4618,
      "preview": "3. Orkambi is another product approved for use in CF patients who are homozygous for the F508del mut"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4619,
      "preview": "a. Patients six years and older - Two tablets (each containing lumacaftor 200 mg -ivacaftor 125 mg )"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4620,
      "preview": "b. It has not yet been approved for younger children with CF. Safety and efficacy trials are ongoing"
    },
    {
      "type": "text",
      "section": "H. CFTR Protein Correctors and Potentiators",
      "line": 4621,
      "preview": "4. Intensive research is being conducted for other compounds that can affect CFTR function and clini"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. Complications",
      "line": 4623
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4625,
      "preview": "A. In the newborn, the most frequent and serious complication is that of meconium ileus with intesti"
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4626,
      "preview": "B. Older children and adults can suffer other types of complications that are a result of the scarri"
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4628,
      "preview": "1. Hemoptysis: Patients often experience blood streaking of their sputum. This is probably due to ru"
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4629,
      "preview": "2. Pneumothorax occurs in $8-23 \\%$ of older CF patients but can occur in children with severe disea"
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4631,
      "preview": "--- page 192 ---"
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4633,
      "preview": "unknown. It occurs rarely in CF infants."
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4634,
      "preview": "2. Cirrhosis of the liver, portal hypertension, splenomegaly, and hypersplenism."
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4635,
      "preview": "3. Recurrent pancreatitis: Interestingly, this occurs more commonly in the small subset of CF patien"
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4636,
      "preview": "4. Intussusception: There is an increased incidence of intussusception in children with CF. It is th"
    },
    {
      "type": "text",
      "section": "VII. Complications",
      "line": 4638,
      "preview": "--- page 193 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Aerosolized Medications",
      "line": 4640
    },
    {
      "type": "text",
      "section": "Aerosolized Medications",
      "line": 4642,
      "preview": "Bill Callas, R.R.T. and Carol Conrad, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Table of Respiratory Care Medications",
      "line": 4644
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4646,
      "preview": "| Medication | Description |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4647,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4648,
      "preview": "| Acetylcysteine (Mucomyst\u00ae) | Mucolytic |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4649,
      "preview": "| Albuterol (Proventil\u00ae/Ventolin\u00ae) | Sympathomimetic |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4650,
      "preview": "| Albuterol/ipratropium combined (Duoneb\u00ae) | Sympathomimetic and anti-cholinergic combination in hal"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4651,
      "preview": "| Beclovent\u00ae (Beclomethasone) | Corticosteroid |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4652,
      "preview": "| Budesonide (Pulmicort\u00ae) | Corticosteroid |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4653,
      "preview": "| Fluticasone (Flovent\u00ae) | Corticosteroid |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4654,
      "preview": "| Ipratropium Bromide (Atrovent\u00ae) | Anticholinergic bronchodilator |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4655,
      "preview": "| Levalbuterol (Xopenex\u00ae) | $\\beta$-2 Specific, L-isomer only |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4656,
      "preview": "| Racemic epinephrine (Vaponefrin\u00ae) | $\\alpha / \\beta$ Stimulation bronchodilator vasoconstrictor |"
    },
    {
      "type": "table",
      "section": "I. Table of Respiratory Care Medications",
      "line": 4657,
      "preview": "| Recombinant Human DNase (Pulmozyme\u00ae) | Mucolytic (purulent secretions) |"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Methods of Delivering Aerosolized Medications to Neonates",
      "line": 4659
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Hand-held Nebulizer (HHN):",
      "line": 4661
    },
    {
      "type": "text",
      "section": "A. Hand-held Nebulizer (HHN):",
      "line": 4663,
      "preview": "1. Use: Medications are diluted with normal saline to a volume of $2-3 \\mathrm{ml}$ and administered"
    },
    {
      "type": "text",
      "section": "A. Hand-held Nebulizer (HHN):",
      "line": 4664,
      "preview": "2. Ordering: by milligram or strength of solution (e.g., Albuterol 2.5 mg every 4 hrs )."
    },
    {
      "type": "text",
      "section": "A. Hand-held Nebulizer (HHN):",
      "line": 4665,
      "preview": "B. Metered Dose Inhalers (MDI):"
    },
    {
      "type": "text",
      "section": "A. Hand-held Nebulizer (HHN):",
      "line": 4666,
      "preview": "3. Use: MDIs are given to neonates using mask and spacer or in-line for ventilated patients. The adv"
    },
    {
      "type": "text",
      "section": "A. Hand-held Nebulizer (HHN):",
      "line": 4667,
      "preview": "4. Ordering: These medications are ordered by the \"puff.\" For ventilated patients the dose should be"
    },
    {
      "type": "text",
      "section": "A. Hand-held Nebulizer (HHN):",
      "line": 4669,
      "preview": "--- page 194 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Continuous Aerosolized Medications:",
      "line": 4671
    },
    {
      "type": "text",
      "section": "C. Continuous Aerosolized Medications:",
      "line": 4673,
      "preview": "1. Use: Patients requiring aerosolized medication every 2 hrs or more frequently may benefit from co"
    },
    {
      "type": "text",
      "section": "C. Continuous Aerosolized Medications:",
      "line": 4674,
      "preview": "2. Ordering: these medications are usually ordered milligram per hr (e.g., Albuterol $5 \\mathrm{mg} "
    },
    {
      "type": "text",
      "section": "C. Continuous Aerosolized Medications:",
      "line": 4675,
      "preview": "D. Medications via ETTs:"
    },
    {
      "type": "text",
      "section": "C. Continuous Aerosolized Medications:",
      "line": 4677,
      "preview": "Deposition of aerosolized medications may be reduced due to resistance of the ETT. Intubated patient"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Respiratory Care Medications Administered by Inhalation",
      "line": 4679
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Anticholinergics (parasympatholytic) Bronchodilators",
      "line": 4681
    },
    {
      "type": "text",
      "section": "A. Anticholinergics (parasympatholytic) Bronchodilators",
      "line": 4683,
      "preview": "The potential for bronchodilation by parasympatholytic agents is based on the premise that the paras"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Ipratropium Bromide (Atrovent\u00ae):",
      "line": 4685
    },
    {
      "type": "text",
      "section": "1. Ipratropium Bromide (Atrovent\u00ae):",
      "line": 4687,
      "preview": "a. Use: Ipratropium bromide is an anticholinergic agent that has a local, site-specific effect, not "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "i. How supplied:",
      "line": 4689
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4691,
      "preview": "a) Ipratropium MDI: CFC free $17 \\mathrm{mcg} / \\mathrm{inh}$"
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4693,
      "preview": "Dose: The pediatric ( $<12$ yrs old) dose is 2 puffs given every 4-6 hrs, the total 24-hr dose shoul"
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4694,
      "preview": "b) Ipratropium bromide $0.02 \\%$ solution: 500 mcg in 2.5 ml normal saline unit dose"
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4696,
      "preview": "Dose: The adult dose is 500 mcg ( 1 unit dose vial) administered 3-4 times per day by oral nebulizat"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Alpha and Beta Adrenergic stimulation",
      "line": 4698
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Racemic epinephrine (Vaponefrin\u00ae, Micronefrin):",
      "line": 4700
    },
    {
      "type": "text",
      "section": "1. Racemic epinephrine (Vaponefrin\u00ae, Micronefrin):",
      "line": 4702,
      "preview": "i. Use: In contrast to other sympathomimetics, racemic epinephrine is administered for its effect on"
    },
    {
      "type": "text",
      "section": "1. Racemic epinephrine (Vaponefrin\u00ae, Micronefrin):",
      "line": 4704,
      "preview": "--- page 195 ---"
    },
    {
      "type": "text",
      "section": "1. Racemic epinephrine (Vaponefrin\u00ae, Micronefrin):",
      "line": 4706,
      "preview": "i. How supplied: Racemic epinephrine $2.25 \\%: 22.5 \\mathrm{mg} / \\mathrm{mL}$."
    },
    {
      "type": "text",
      "section": "1. Racemic epinephrine (Vaponefrin\u00ae, Micronefrin):",
      "line": 4708,
      "preview": "Dose: Weight $<10 \\mathrm{~kg}$ : 2 mL of 1:8 dilution nebulized every 1-4 hrs."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Sympathomimetic Bronchodilators",
      "line": 4710
    },
    {
      "type": "text",
      "section": "C. Sympathomimetic Bronchodilators",
      "line": 4712,
      "preview": "1. Use: Sympathomimetic bronchodilators act by stimulating the beta-2 receptors of the sympathetic n"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "a. Albuterol (Proventil\u00ae, Ventolin\u00ae)",
      "line": 4714
    },
    {
      "type": "text",
      "section": "a. Albuterol (Proventil\u00ae, Ventolin\u00ae)",
      "line": 4716,
      "preview": "Albuterol has very little beta-1 adrenergic effect and can be utilized in relatively large doses at "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "i. How supplied:",
      "line": 4718
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4720,
      "preview": "a) Albuterol solution $0.5 \\%: 5 \\mathrm{mg} / \\mathrm{ml}$ (average treatment-2.5 mg every 4 hrs )."
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4722,
      "preview": "Dilute: $0.1-0.5 \\mathrm{ml}$ every $4-6 \\mathrm{hrs}$ prn in 2 ml dilution."
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4723,
      "preview": "b) Pre-mixed ( $0.083 \\%$ ): $0.5-1$ unit dose neb every $4-6 \\mathrm{hrs}$ prn"
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4724,
      "preview": "c) Albuterol MDI: CFC free $90 \\mathrm{mcg} / \\mathrm{inh}$"
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4726,
      "preview": "Dose: 1-2 inhalations 4 times/day."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "b. Levalbuterol (Xopenex\u00ae)",
      "line": 4728
    },
    {
      "type": "text",
      "section": "b. Levalbuterol (Xopenex\u00ae)",
      "line": 4730,
      "preview": "Little to no beta-1 adrenergic effect."
    },
    {
      "type": "text",
      "section": "b. Levalbuterol (Xopenex\u00ae)",
      "line": 4731,
      "preview": "i. How supplied: $(0.31 \\mathrm{mg} / 3 \\mathrm{ml}),(0.63 / 3 \\mathrm{ml})$ and $(1.25 \\mathrm{mg} "
    },
    {
      "type": "text",
      "section": "b. Levalbuterol (Xopenex\u00ae)",
      "line": 4733,
      "preview": "Dose: Give 1 unit dose no more than every 6 hrs. Generally, every 8 hrs is sufficient for stable pat"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Corticosteroids",
      "line": 4735
    },
    {
      "type": "text",
      "section": "D. Corticosteroids",
      "line": 4737,
      "preview": "The primary purposes of inhaled corticosteroids are to treat asthma through the anti-inflammatory ef"
    },
    {
      "type": "text",
      "section": "D. Corticosteroids",
      "line": 4739,
      "preview": "--- page 196 ---"
    },
    {
      "type": "text",
      "section": "D. Corticosteroids",
      "line": 4741,
      "preview": "1. Fluticasone (Flovent\u00ae):"
    },
    {
      "type": "text",
      "section": "D. Corticosteroids",
      "line": 4742,
      "preview": "a. Use: Reduces inflammation and airway hyperreactivity, good topical effect, may reduce need for br"
    },
    {
      "type": "text",
      "section": "D. Corticosteroids",
      "line": 4743,
      "preview": "i. How supplied: Available as MDI 3 strengths: $44 \\mathrm{mcg} /$ puff, $110 \\mathrm{mcg} /$ puff, "
    },
    {
      "type": "text",
      "section": "D. Corticosteroids",
      "line": 4745,
      "preview": "Dose: Refer to package for complete dosing guidelines."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "2 Beclomethasone (QVAR\u00ae):",
      "line": 4747
    },
    {
      "type": "text",
      "section": "2 Beclomethasone (QVAR\u00ae):",
      "line": 4749,
      "preview": "a. Use: QVAR\u00ae has anti-inflammatory effects and can help control severe asthma or upper airway edema"
    },
    {
      "type": "text",
      "section": "2 Beclomethasone (QVAR\u00ae):",
      "line": 4750,
      "preview": "i. How supplied: Beclomethasone MDI, $80 \\mathrm{mcg} / \\mathrm{inh}$"
    },
    {
      "type": "text",
      "section": "2 Beclomethasone (QVAR\u00ae):",
      "line": 4752,
      "preview": "Dose: Children (6-12) 1-2 inhalations 3-4/day. The maximum dose should not exceed 10 inhalations, 40"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "3. Budesonide (Pulmicort\u00ae):",
      "line": 4754
    },
    {
      "type": "text",
      "section": "3. Budesonide (Pulmicort\u00ae):",
      "line": 4756,
      "preview": "a. Use: Has anti-inflammatory effects, reduces airway edema, hyperreactivity, and may reduce need fo"
    },
    {
      "type": "text",
      "section": "3. Budesonide (Pulmicort\u00ae):",
      "line": 4757,
      "preview": "i. How supplied: Available as nebulized solution ( $0.25 \\mathrm{mg} / 2 \\mathrm{ml}$ and $0.5 \\math"
    },
    {
      "type": "text",
      "section": "3. Budesonide (Pulmicort\u00ae):",
      "line": 4759,
      "preview": "Dose: Neb 0.5-1 unit dose neb daily or Q12hrs, and DPI is 1-2 puffs daily or Q12hrs."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Mucolytics",
      "line": 4761
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Acetylcysteine (Mucomyst\u00ae, Mucosil\u00ae)",
      "line": 4763
    },
    {
      "type": "text",
      "section": "1. Acetylcysteine (Mucomyst\u00ae, Mucosil\u00ae)",
      "line": 4765,
      "preview": "a. Use: Acetylcysteine contains a free sulfhydryl group that breaks down the disulfide bonds of muco"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "i. How supplied:",
      "line": 4767
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4769,
      "preview": "a) Acetylcysteine $10 \\%: 100 \\mathrm{mg} / \\mathrm{mL}$."
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4770,
      "preview": "b) Acetylcysteine $20 \\%: 200 \\mathrm{mg} / \\mathrm{mL}$."
    },
    {
      "type": "text",
      "section": "i. How supplied:",
      "line": 4772,
      "preview": "Dose: Infants - 2 ml of $5 \\%$ solution 2-4/day."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Dornase Alpha, rhDNase (Pulmozyme\u00ae)",
      "line": 4774
    },
    {
      "type": "text",
      "section": "2. Dornase Alpha, rhDNase (Pulmozyme\u00ae)",
      "line": 4776,
      "preview": "a. Use: Pulmozyme\u00ae hydrolyzes the DNA in sputum of cystic fibrosis patients and reduces sputum visco"
    },
    {
      "type": "text",
      "section": "2. Dornase Alpha, rhDNase (Pulmozyme\u00ae)",
      "line": 4778,
      "preview": "--- page 197 ---"
    },
    {
      "type": "text",
      "section": "2. Dornase Alpha, rhDNase (Pulmozyme\u00ae)",
      "line": 4780,
      "preview": "i. How supplied: unit dose of Pulmozyme\u00ae containing rhDNase 2.5 mg ."
    },
    {
      "type": "text",
      "section": "2. Dornase Alpha, rhDNase (Pulmozyme\u00ae)",
      "line": 4782,
      "preview": "Dose: 2.5 mg may be nebulized."
    },
    {
      "type": "text",
      "section": "2. Dornase Alpha, rhDNase (Pulmozyme\u00ae)",
      "line": 4783,
      "preview": "Contraindications: Patients with known hypersensitivity to this drug."
    },
    {
      "type": "text",
      "section": "2. Dornase Alpha, rhDNase (Pulmozyme\u00ae)",
      "line": 4784,
      "preview": "Adverse reactions: voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Inhaled Antibiotics",
      "line": 4786
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Tobramycin (TOBI)",
      "line": 4788
    },
    {
      "type": "text",
      "section": "1. Tobramycin (TOBI)",
      "line": 4790,
      "preview": "a. Use: Tobramycin is an aminoglycoside that inhibits cell wall synthesis of gram-negative organisms"
    },
    {
      "type": "text",
      "section": "1. Tobramycin (TOBI)",
      "line": 4791,
      "preview": "i. How supplied: $300 \\mathrm{mg} / 5 \\mathrm{~mL}$, preservative-free."
    },
    {
      "type": "text",
      "section": "1. Tobramycin (TOBI)",
      "line": 4793,
      "preview": "Dose: one vial nebulized Q12."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Aztreonam (Cayston)",
      "line": 4795
    },
    {
      "type": "text",
      "section": "2. Aztreonam (Cayston)",
      "line": 4797,
      "preview": "a. Use: aztreonam is a synthetic monocyclic b-lactam that inhibits cell wall synthesis of gram-negat"
    },
    {
      "type": "text",
      "section": "2. Aztreonam (Cayston)",
      "line": 4798,
      "preview": "i. How supplied: $75 \\mathrm{mg} / 2 \\mathrm{~mL}$, preservative free"
    },
    {
      "type": "text",
      "section": "2. Aztreonam (Cayston)",
      "line": 4800,
      "preview": "Dose: one vial nebulized TID for 28-day cycles, given every other month"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "3. Colistimethate (Colistin)",
      "line": 4802
    },
    {
      "type": "text",
      "section": "3. Colistimethate (Colistin)",
      "line": 4804,
      "preview": "a. Use: colistimethate is a polycationic and has both hydrophilic and lipophilic moieties. These pol"
    },
    {
      "type": "text",
      "section": "3. Colistimethate (Colistin)",
      "line": 4805,
      "preview": "i. How supplied: $150 \\mathrm{mg} / 2 \\mathrm{~mL}$, preservative free"
    },
    {
      "type": "text",
      "section": "3. Colistimethate (Colistin)",
      "line": 4807,
      "preview": "Dose: one vial nebulized BID for 28-day cycles, given every other month"
    },
    {
      "type": "text",
      "section": "3. Colistimethate (Colistin)",
      "line": 4809,
      "preview": "--- page 198 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-C: Cardiac",
      "line": 4811
    },
    {
      "type": "text",
      "section": "Part II-C: Cardiac",
      "line": 4813,
      "preview": "--- page 199 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Diagnostic Evaluation of Suspected CHD",
      "line": 4815
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Gail Wright, M.D. and Megan Tracey, P.N.P., and Shazia Bhombal, M.D.",
      "line": 4817
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Physical Examination",
      "line": 4819
    },
    {
      "type": "text",
      "section": "I. Physical Examination",
      "line": 4821,
      "preview": "A. Color: cyanotic vs. acyanotic"
    },
    {
      "type": "text",
      "section": "I. Physical Examination",
      "line": 4822,
      "preview": "B. Activity: lethargic vs. active"
    },
    {
      "type": "text",
      "section": "I. Physical Examination",
      "line": 4823,
      "preview": "C. Perfusion: poor capillary refill time and/or difference between upper/lower extremities:"
    },
    {
      "type": "text",
      "section": "I. Physical Examination",
      "line": 4825,
      "preview": "1. Patients with low cardiac output or congestive heart failure may have peripheral vasoconstriction"
    },
    {
      "type": "text",
      "section": "I. Physical Examination",
      "line": 4826,
      "preview": "2. Neonates with left heart obstructive lesions become symtomatic when the PDA begins to close. Once"
    },
    {
      "type": "text",
      "section": "I. Physical Examination",
      "line": 4827,
      "preview": "3. Infants with low cardiac output usually have weak pulses; however, those with systemic artery-top"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Liver:",
      "line": 4829
    },
    {
      "type": "text",
      "section": "D. Liver:",
      "line": 4831,
      "preview": "Usually found at 1-2 fingers width below the right costal margin. If lower than that, one must consi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Respiratory Pattern:",
      "line": 4833
    },
    {
      "type": "text",
      "section": "E. Respiratory Pattern:",
      "line": 4835,
      "preview": "Infants with CHD may present with signs of respiratory distress, especially in cases of pulmonary ov"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Dysmorphic Features:",
      "line": 4837
    },
    {
      "type": "text",
      "section": "F. Dysmorphic Features:",
      "line": 4839,
      "preview": "1. Unusual features possibly related to a genetic syndrome should prompt a Genetics consult and chro"
    },
    {
      "type": "text",
      "section": "F. Dysmorphic Features:",
      "line": 4840,
      "preview": "2. If the heart lesion is a conotruncal heart malformation (e.g., truncus arteriosus, Tetralogy of F"
    },
    {
      "type": "text",
      "section": "F. Dysmorphic Features:",
      "line": 4841,
      "preview": "3. Chromosomal anomalies causing both cardiac and non-cardiac defects also include Trisomy 13, Triso"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "G. Heart Auscultation:",
      "line": 4843
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4845,
      "preview": "1. Soft systolic murmurs heard at the right lower sternal border are often tricuspid regurgitation t"
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4847,
      "preview": "--- page 200 ---"
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4849,
      "preview": "2. Systolic ejection murmurs present in the delivery room are usually pathologic and may be related "
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4850,
      "preview": "3. Systolic regurgitant murmurs begin with S1, with no interval between S1 and the beginning of the "
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4851,
      "preview": "4. Diastolic murmurs are classified by the timing of the murmur:"
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4852,
      "preview": "a. Early diastolic murmurs occur right after S2 and are related to incompetence of the aortic or pul"
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4853,
      "preview": "b. Mid-diastolic murmurs result from abnormal ventricular filling. These are low pitched and may be "
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4854,
      "preview": "c. Late diastolic murmurs result from flow through AV valves during ventricular diastole and are low"
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4855,
      "preview": "5. Murmurs due to left-to-right shunt lesions may not be heard until the 2nd to 4th week of life, wh"
    },
    {
      "type": "text",
      "section": "G. Heart Auscultation:",
      "line": 4856,
      "preview": "6. Ejection clicks can be normal in the first 24 hrs of life, but after that are considered patholog"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "H. Blood Pressure:",
      "line": 4858
    },
    {
      "type": "text",
      "section": "H. Blood Pressure:",
      "line": 4860,
      "preview": "Four extremity blood pressures may be helpful in identifying an aortic arch lesion. A systolic press"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Pulse ox screen:",
      "line": 4862
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4864,
      "preview": "Utilized to detect critical CHD that requires intervention in the first year of life. Up to 25-30\\% "
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4866,
      "preview": "1. There are 7 primary targets of pulse ox screening: hypoplastic left heart syndrome, pulmonary atr"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4867,
      "preview": "2. Screening recommended between $24-48$ hours"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4868,
      "preview": "a. Right hand (pre-ductal) and one foot (post-ductal)"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4870,
      "preview": "--- page 201 ---"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4872,
      "preview": "b. Pass screen if O 2 sat $>/=95 \\%$ in both probes AND there is $</=3 \\%$ difference between the tw"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4873,
      "preview": "c. LPCH Policy on failed screen:"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4874,
      "preview": "i. Critically failed screen if $<90 \\%$ in either probe, notify MD immediately"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4875,
      "preview": "ii. Failed screen if $90-94 \\%$ on both extremities OR $>3 \\%$ difference between both extremities r"
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4876,
      "preview": "d. The timing of pulse ox screening in ill infants is not well established."
    },
    {
      "type": "text",
      "section": "I. Pulse ox screen:",
      "line": 4877,
      "preview": "3. Physical exam important - pulse ox not perfect, particularly in left sided lesions such as coarct"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. Diagnostic Studies",
      "line": 4879
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Chest x-ray (frontal and lateral views):",
      "line": 4881
    },
    {
      "type": "text",
      "section": "A. Chest x-ray (frontal and lateral views):",
      "line": 4883,
      "preview": "Evaluate the heart size and shape, location of the aortic arch (right vs. left), and cardiac situs. "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Electrocardiogram (ECG):",
      "line": 4885
    },
    {
      "type": "text",
      "section": "B. Electrocardiogram (ECG):",
      "line": 4887,
      "preview": "1. Because it reflects the hemodynamic relationships that existed in utero, a normal newborn ECG is "
    },
    {
      "type": "text",
      "section": "B. Electrocardiogram (ECG):",
      "line": 4888,
      "preview": "2. Evaluation should include duration of the $P$ wave, QRS complex, QT interval (corrected for rate)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Echocardiology:",
      "line": 4890
    },
    {
      "type": "text",
      "section": "C. Echocardiology:",
      "line": 4892,
      "preview": "An echocardiogram should be obtained if there is a concern for CHD. This will be a 2-dimensional stu"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Cardiac Catheterization:",
      "line": 4894
    },
    {
      "type": "text",
      "section": "D. Cardiac Catheterization:",
      "line": 4896,
      "preview": "May be utilized for anatomic definition if not demonstrated adequately by echocardiography. Indicati"
    },
    {
      "type": "text",
      "section": "D. Cardiac Catheterization:",
      "line": 4898,
      "preview": "1. Therapeutic: balloon atrial septostomy, balloon pulmonary valvuloplasty, balloon aortic valvulopl"
    },
    {
      "type": "text",
      "section": "D. Cardiac Catheterization:",
      "line": 4899,
      "preview": "2. Diagnostic: to provide further anatomic definition (e.g., coronary artery anatomy in pulmonary at"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. CT Angiography",
      "line": 4901
    },
    {
      "type": "text",
      "section": "E. CT Angiography",
      "line": 4903,
      "preview": "May be utilized for diagnostic purposes to provide further anatomic delineation, e.g. aortopulmonary"
    },
    {
      "type": "text",
      "section": "E. CT Angiography",
      "line": 4905,
      "preview": "--- page 202 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 4907
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4909,
      "preview": "1. Spitzer, A.R. Medical Management of the neonate with congenital heart disease. In: Intensive Care"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4910,
      "preview": "2. Park, MK. The Pediatric Cardiology Handbook. 5th Edition. Philadelphia: Mosby Elsevier; 2014"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4911,
      "preview": "3. Cassidy, Steven C, Hugh D. Allen, John R. Phillips . Diagnostic and Therapeutic Methods. In : Mos"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4912,
      "preview": "4. de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C, Ingan\u00e4s L et al. Impact of p"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4913,
      "preview": "5. CCS Guidelines for Critical Congenital Heart Disease Screening Services, March 11, 2014."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4914,
      "preview": "(http://www.dhcs.ca.gov/services/ccs/Documents/ccsnl040314.pdf)"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4916,
      "preview": "--- page 203 ---"
    },
    {
      "type": "image",
      "section": "References:",
      "line": 4918,
      "content": "![img-22.jpeg](images/c3c4ab497cabe80c.png)"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4920,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 4922,
      "preview": "--- page 204 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Cardiac Resuscitation and Initial Management of CHD",
      "line": 4924
    },
    {
      "type": "text",
      "section": "Cardiac Resuscitation and Initial Management of CHD",
      "line": 4926,
      "preview": "Shazia Bhombal, M.D. and Kathleen Ryan, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Resuscitation",
      "line": 4928
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Initial Stabilization",
      "line": 4930
    },
    {
      "type": "text",
      "section": "A. Initial Stabilization",
      "line": 4932,
      "preview": "Delivery room resuscitation and/or stabilization is the same for all neonates presenting with cyanos"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. ER and NICU Admissions",
      "line": 4934
    },
    {
      "type": "text",
      "section": "B. ER and NICU Admissions",
      "line": 4936,
      "preview": "Infants admitted from the ER in shock need immediate correction of metabolic acidosis with volume ex"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Pre-op Management",
      "line": 4938
    },
    {
      "type": "text",
      "section": "II. Pre-op Management",
      "line": 4940,
      "preview": "Once the initial resuscitation is completed, there are several key points to keep in mind:"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Cardiovascular Management",
      "line": 4942
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management",
      "line": 4944,
      "preview": "Consult Cardiology (CV3 team - pager\\# 2HART) for all infants with CHD and notify them of any change"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Management",
      "line": 4946
    },
    {
      "type": "text",
      "section": "1. Management",
      "line": 4948,
      "preview": "a. PGE1 administration should begin immediately following delivery if there is suspicion of ductalde"
    },
    {
      "type": "text",
      "section": "1. Management",
      "line": 4949,
      "preview": "i. Ductal-dependent pulmonary flow lesions include: severe Tetralogy of Fallot, (blue \"Tet\", TET/PA)"
    },
    {
      "type": "text",
      "section": "1. Management",
      "line": 4950,
      "preview": "ii. Ductal-dependent systemic flow lesions include: hypoplastic left heart syndrome, mitral atresia,"
    },
    {
      "type": "text",
      "section": "1. Management",
      "line": 4951,
      "preview": "b. Consider SVR manipulation by using vasoactive support such as milrinone to decrease afterload in "
    },
    {
      "type": "text",
      "section": "1. Management",
      "line": 4953,
      "preview": "--- page 205 ---"
    },
    {
      "type": "text",
      "section": "1. Management",
      "line": 4955,
      "preview": "c. Correction of significant metabolic acidosis with either volume expanders or bicarbonate. May nee"
    },
    {
      "type": "text",
      "section": "1. Management",
      "line": 4956,
      "preview": "d. Palliative, staged or complete surgical repair depending on the lesion."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "2. Monitoring",
      "line": 4958
    },
    {
      "type": "text",
      "section": "2. Monitoring",
      "line": 4960,
      "preview": "a. Continuous evaluation of blood pressure. Normal mean arterial BP is approximately equivalent to t"
    },
    {
      "type": "text",
      "section": "2. Monitoring",
      "line": 4961,
      "preview": "b. Continuous monitoring of heart rate is necessary to identify any dysrhythmias. Tachycardic infant"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Respiratory Management",
      "line": 4963
    },
    {
      "type": "text",
      "section": "B. Respiratory Management",
      "line": 4965,
      "preview": "Infants with cardiac defects that place them at risk for increased pulmonary blood flow require clos"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Management Options:",
      "line": 4967
    },
    {
      "type": "text",
      "section": "1. Management Options:",
      "line": 4969,
      "preview": "a. If a patient with single ventricle physiology decompensates and requires intubation, this is like"
    },
    {
      "type": "text",
      "section": "1. Management Options:",
      "line": 4970,
      "preview": "b. Decrease respiratory drive with sedation in infants who are intubated. Paralysis may be used in c"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Monitoring:",
      "line": 4972
    },
    {
      "type": "text",
      "section": "2. Monitoring:",
      "line": 4974,
      "preview": "Infants with mixing lesions have an oxygen saturation goal of $75-85 \\%$ and/or a PaO2 in the high 3"
    },
    {
      "type": "text",
      "section": "2. Monitoring:",
      "line": 4976,
      "preview": "--- page 206 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Hematologic Management",
      "line": 4978
    },
    {
      "type": "text",
      "section": "C. Hematologic Management",
      "line": 4980,
      "preview": "1. Transfuse to maintain hematocrit $\\geq 40 \\%$. In patients with single ventricle physiology, a he"
    },
    {
      "type": "text",
      "section": "C. Hematologic Management",
      "line": 4981,
      "preview": "2. If the coagulation panel is abnormal, correction is usually indicated. Coagulopathies must be cor"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Infectious Disease Management",
      "line": 4983
    },
    {
      "type": "text",
      "section": "D. Infectious Disease Management",
      "line": 4985,
      "preview": "1. CBC and CRP/procalcitonin as clinically indicated if infection is suspected."
    },
    {
      "type": "text",
      "section": "D. Infectious Disease Management",
      "line": 4986,
      "preview": "2. Antibiotics prior to surgery are not routinely indicated in infants with cardiac anomalies. Howev"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4988
    },
    {
      "type": "text",
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4990,
      "preview": "1. Pre-operative fluids are usually maintained at $60-80 \\mathrm{ml} / \\mathrm{kg} /$ day. Volume ex"
    },
    {
      "type": "text",
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4991,
      "preview": "2. Monitoring of electrolytes is important to prevent dysrhythmias and maintain optimal cardiac func"
    },
    {
      "type": "text",
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4992,
      "preview": "3. In general, electrolytes, ABGs, and lactate levels are monitored every 6-12 hrs for the first 48 "
    },
    {
      "type": "text",
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4993,
      "preview": "4. Start on TPN as soon as stable, advancing AA, IL, and dextrose to optimize caloric intake."
    },
    {
      "type": "text",
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4994,
      "preview": "5. Furosemide or other diuretics may be indicated, particularly in lesions with left to right shunti"
    },
    {
      "type": "text",
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4995,
      "preview": "6. Consider starting feeds if surgery is not imminent and the infant is stable."
    },
    {
      "type": "text",
      "section": "E. Fluids, Electrolytes, and Nutrition Management",
      "line": 4996,
      "preview": "7. Avoid upper extremity PICC lines in patients on the single ventricle pathway. The SVC will be uti"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Renal Management",
      "line": 4998
    },
    {
      "type": "text",
      "section": "F. Renal Management",
      "line": 5000,
      "preview": "1. Renal ultrasound is done pre-operatively to evaluate the kidneys as part of a genetic/dysmorpholo"
    },
    {
      "type": "text",
      "section": "F. Renal Management",
      "line": 5001,
      "preview": "2. Urine output should be closely monitored to evaluate the need for fluid and/or evaluation of syst"
    },
    {
      "type": "text",
      "section": "F. Renal Management",
      "line": 5003,
      "preview": "--- page 207 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "G. Neurological Management",
      "line": 5005
    },
    {
      "type": "text",
      "section": "G. Neurological Management",
      "line": 5007,
      "preview": "1. A head ultrasound should be done prior to surgery to evaluate for anomalies of the brain and to d"
    },
    {
      "type": "text",
      "section": "G. Neurological Management",
      "line": 5008,
      "preview": "2. NIRS monitoring is performed in all pre-op patients with cyanotic CHD. aEEG is used for patients "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "H. Genetic Management",
      "line": 5010
    },
    {
      "type": "text",
      "section": "H. Genetic Management",
      "line": 5012,
      "preview": "1. Infants with CHD should be considered for genetic testing. Please see Genetics section for detail"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Transfer for Surgery",
      "line": 5014
    },
    {
      "type": "text",
      "section": "I. Transfer for Surgery",
      "line": 5016,
      "preview": "1. A transfer summary must accompany the patient to the OR/CVICU."
    },
    {
      "type": "text",
      "section": "I. Transfer for Surgery",
      "line": 5017,
      "preview": "2. Verbal sign out should be coordinated with the CV3 and CVICU teams."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Post-op Management",
      "line": 5019
    },
    {
      "type": "text",
      "section": "II. Post-op Management",
      "line": 5021,
      "preview": "For the initial post-operative period, all post-surgical cardiac infants are managed in the CVICU. O"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5023
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5025,
      "preview": "1. Interventions for slow heart rate"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5026,
      "preview": "a. Isuprel (rarely used): Dose: $0.05-0.5 \\mathrm{mcg} / \\mathrm{kg} / \\mathrm{min}$ IV"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5027,
      "preview": "b. Atropine: Dose: $0.01-0.03 \\mathrm{mg} / \\mathrm{kg} /$ dose with minimum dose of 0.1 mg IV"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5028,
      "preview": "c. Epinephrine: Dose: $0.01-0.03 \\mathrm{mg} / \\mathrm{kg} /$ dose IV. If infant needs an IV drip, t"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5029,
      "preview": "d. Internal pacing (pacer wires are usually left in for extended period after surgery)."
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5030,
      "preview": "2. Preload"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5031,
      "preview": "a. Volume expanders should be readily available. Infants are at risk for minimal preload/afterload r"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5032,
      "preview": "b. Volume should be given in small increments and blood pressure should be monitored closely."
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5033,
      "preview": "3. Afterload Reducing Agents (decrease SVR and PVR)"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5034,
      "preview": "a. Nipride: Dose: $0.5-2 \\mathrm{mcg} / \\mathrm{kg} / \\mathrm{min}$ IV"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5035,
      "preview": "b. Nitroglycerin: Starting dose usually $0.25-0.5 \\mathrm{mcg} / \\mathrm{kg} / \\mathrm{min}$ IV. May"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5036,
      "preview": "c. Captopril: Dose: Premature neonates receive $0.01 \\mathrm{mg} / \\mathrm{kg} /$ dose po/ng every $"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5038,
      "preview": "--- page 208 ---"
    },
    {
      "type": "text",
      "section": "A. Cardiovascular Management [should be done under guidance of Cardiology]",
      "line": 5040,
      "preview": "d. Milrinone: Dose: $0.25-1 \\mathrm{mcg} / \\mathrm{kg} / \\mathrm{min}$ IV mixed in NS or D5W, may co"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "4. Rhythm-Changing Drugs",
      "line": 5042
    },
    {
      "type": "text",
      "section": "4. Rhythm-Changing Drugs",
      "line": 5044,
      "preview": "a. Adenosine: For SVT. Dose: $100 \\mathrm{mcg} / \\mathrm{kg}$ IV push increasing at 2-min intervals "
    },
    {
      "type": "text",
      "section": "4. Rhythm-Changing Drugs",
      "line": 5045,
      "preview": "b. Amiodarone: For SVT, VT, atrial flutter, and JET. Loading dose is $5-10 \\mathrm{mg} / \\mathrm{kg}"
    },
    {
      "type": "text",
      "section": "4. Rhythm-Changing Drugs",
      "line": 5046,
      "preview": "c. Digoxin: For CHF and some tachyarrhythmias, as well as standard of care of post-op single ventric"
    },
    {
      "type": "text",
      "section": "4. Rhythm-Changing Drugs",
      "line": 5047,
      "preview": "d. Propranolol: dysrhythmias and hypertension: Dose: Oral: $0.5-1 \\mathrm{mg} / \\mathrm{kg} /$ day p"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "5. Pacer Wires",
      "line": 5049
    },
    {
      "type": "text",
      "section": "5. Pacer Wires",
      "line": 5051,
      "preview": "a. Pacer wires may remain in post-op until just prior to discharge. Discuss with CV Surgery plan for"
    },
    {
      "type": "text",
      "section": "5. Pacer Wires",
      "line": 5053,
      "preview": "Page CVICU APP to to remove wires once indicated. A cardiac ECHO post-removal is not needed. Monitor"
    },
    {
      "type": "text",
      "section": "5. Pacer Wires",
      "line": 5054,
      "preview": "b. Infants who experience a change in perfusion and blood pressure should be checked for dysrhythmia"
    },
    {
      "type": "text",
      "section": "5. Pacer Wires",
      "line": 5055,
      "preview": "c. JET and atrial tachycardia can be a problem secondary to poor AV conduction. With JET, look for c"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "6. Intravascular Line Management",
      "line": 5057
    },
    {
      "type": "text",
      "section": "6. Intravascular Line Management",
      "line": 5059,
      "preview": "a. IJ line - can be discontinued if not needed. APP or MD can de-line."
    },
    {
      "type": "text",
      "section": "6. Intravascular Line Management",
      "line": 5060,
      "preview": "b. Intracardial lines (RA, LA) - can be discontinued (by CV Surgery Fellow) if not needed. Need rece"
    },
    {
      "type": "text",
      "section": "6. Intravascular Line Management",
      "line": 5061,
      "preview": "c. Intracardiac Broviac - removal by CT surgery."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Respiratory Management",
      "line": 5063
    },
    {
      "type": "text",
      "section": "B. Respiratory Management",
      "line": 5065,
      "preview": "1. Chest tubes - can be discontinued when output is $<2-3 \\mathrm{ml} / \\mathrm{kg} /$ day. Disconti"
    },
    {
      "type": "text",
      "section": "B. Respiratory Management",
      "line": 5067,
      "preview": "--- page 209 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Fluids, Electrolytes, and Nutrition Management",
      "line": 5069
    },
    {
      "type": "text",
      "section": "C. Fluids, Electrolytes, and Nutrition Management",
      "line": 5071,
      "preview": "1. When starting feedings post-operatively, feedings may be advanced per usual practice in most card"
    },
    {
      "type": "text",
      "section": "C. Fluids, Electrolytes, and Nutrition Management",
      "line": 5073,
      "preview": "Some infants who have cardiac lesions in which blood flow to the bowel may have been compromised pre"
    },
    {
      "type": "text",
      "section": "C. Fluids, Electrolytes, and Nutrition Management",
      "line": 5074,
      "preview": "2. Other fluids should be managed similarly to the pre-op fluids mentioned above. It is important to"
    },
    {
      "type": "text",
      "section": "C. Fluids, Electrolytes, and Nutrition Management",
      "line": 5075,
      "preview": "3. Electrolytes should be monitored daily until stable, then weekly or twice a week if on diuretics."
    },
    {
      "type": "text",
      "section": "C. Fluids, Electrolytes, and Nutrition Management",
      "line": 5076,
      "preview": "4. Diuretics may need to be adjusted or changed as dictated by clinical findings such as pulmonary e"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Hematology Management",
      "line": 5078
    },
    {
      "type": "text",
      "section": "D. Hematology Management",
      "line": 5080,
      "preview": "1. Check hematocrit at least weekly. May need to check daily if infant is unstable and/or bleeding. "
    },
    {
      "type": "text",
      "section": "D. Hematology Management",
      "line": 5081,
      "preview": "2. Some infants with shunts or a patch will be on aspirin. The usual dose is $5 \\mathrm{mg} / \\mathr"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Infectious Disease Management",
      "line": 5083
    },
    {
      "type": "text",
      "section": "E. Infectious Disease Management",
      "line": 5085,
      "preview": "1. Immunizations should not be administered for at least 6 weeks post-operatively."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Neurologic Management",
      "line": 5087
    },
    {
      "type": "text",
      "section": "F. Neurologic Management",
      "line": 5089,
      "preview": "1. If infant has an abnormal neurologic exam, was on ECMO or CPB or previous imaging was abnormal, t"
    },
    {
      "type": "text",
      "section": "F. Neurologic Management",
      "line": 5090,
      "preview": "2. All infants with CHD that require surgery will be followed by LPCH Infant Development Clinic and/"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "G. Genetic Management",
      "line": 5092
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5094,
      "preview": "1. If chromosomes are pending or normal, and Genetics is concerned that the infant may have a syndro"
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5095,
      "preview": "2. If infant is diagnosed with a 22q11 microdeletion, Endocrine and Immunology must be consulted, an"
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5097,
      "preview": "--- page 210 ---"
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5099,
      "preview": "1. Plan ahead as much as possible. Appointments and pharmacy prescriptions should be set up at least"
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5100,
      "preview": "2. For discharge teaching, go to \"Micromedex\" in the computer and click on the section \"Caring for B"
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5101,
      "preview": "3. Parent teaching should be started early for these complex patients."
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5102,
      "preview": "4. Appointments with the PCP and Cardiologist should be scheduled prior to discharge. Please send a "
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5103,
      "preview": "5. Post-Op TOF/PA/MAPCAs"
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5104,
      "preview": "a. Need lung perfusion scan prior to discharge. (Place Nuclear Med Order and call 650-723-6855 to sc"
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5105,
      "preview": "b. Need discharge ECHO."
    },
    {
      "type": "text",
      "section": "G. Genetic Management",
      "line": 5106,
      "preview": "c. If future CV surgery required, discuss with CV3 team, the potential need to have outpatient cardi"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Resources:",
      "line": 5108
    },
    {
      "type": "text",
      "section": "Resources:",
      "line": 5110,
      "preview": "1. Park, MK. The Pediatric Cardiology Handbook. 4th Edition. Philadelphia: Mosby Elsevier; 2010"
    },
    {
      "type": "text",
      "section": "Resources:",
      "line": 5112,
      "preview": "--- page 211 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Cardiovascular Pharmacologic Agents",
      "line": 5114
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Shabnam Gaskari, Pharm.D.",
      "line": 5116
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Catecholamines",
      "line": 5118
    },
    {
      "type": "text",
      "section": "I. Catecholamines",
      "line": 5120,
      "preview": "Endogenous catecholamines include dopamine, epinephrine, and norepinephrine. Synthetic catecholamine"
    },
    {
      "type": "text",
      "section": "I. Catecholamines",
      "line": 5122,
      "preview": "The various receptor types, their cardiovascular actions, and catecholamine affinity are shown in Ta"
    },
    {
      "type": "text",
      "section": "I. Catecholamines",
      "line": 5124,
      "preview": "Table I. Cardiovascular actions, Location, and signal transduction pathways initiated by adrenergic "
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5126,
      "preview": "| Receptor Type | Location | Signal Pathway | Cardiovascular Actions |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5127,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5128,
      "preview": "| Alpha 1 | Peripheral vasculature | activation of phospholipase C | vasoconstriction |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5129,
      "preview": "| Beta 1 | Cardiac myocyte | activation of adenyl cyclase | increased heart rate, <br> contractility"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5130,
      "preview": "| Beta 2 | Peripheral vasculature | activation of adenyl cyclase | vasodilation |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5131,
      "preview": "| Dopamine | Peripheral vasculature | activation of adenyl cyclase | Renal vasodilation |"
    },
    {
      "type": "text",
      "section": "I. Catecholamines",
      "line": 5133,
      "preview": "--- page 212 ---"
    },
    {
      "type": "text",
      "section": "I. Catecholamines",
      "line": 5135,
      "preview": "Table II. Ability of commonly used sympathomimetic agents to stimulate adrenergic receptors."
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5137,
      "preview": "| Agent | Receptor Type |  |  |  | Comments |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5138,
      "preview": "| :--: | :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5139,
      "preview": "|  | Alpha 1 | Beta 1 | Beta 2 | Dopamine |  |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5140,
      "preview": "| Dopamine | 0 at low dose infusions <br> +++ at high dose infusions ^ | $+++$ | $+$ | +++ | Dose de"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5141,
      "preview": "| Dobutamine | $+$ | +++ | $+$ | 0 | Dobutamine is less effective compared to dopamine in raising sy"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5142,
      "preview": "| Epinephrine | +++ | +++ | +++ | 0 | $0.01-0.1 \\mathrm{mcg} / \\mathrm{kg} /$ minute increases HR an"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5143,
      "preview": "| Norepinephrine | +++ | +++ | $+$ | 0 | Similar to epinephrine in its beta 1 and alpha 1 effect but"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5144,
      "preview": "| Isoproterenol | 0 | +++ | +++ | 0 | Can cause hypotension, nausea, and flushing |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5145,
      "preview": "| Phenylephrine | +++ | 0 to + | 0 to + | 0 | Pure vasoconstrictor Can cause extravasation |"
    },
    {
      "type": "table",
      "section": "I. Catecholamines",
      "line": 5146,
      "preview": "| 0 = No effect, +: low effect, ++: Medium effect, +++: high effect |  |  |  |  |  |"
    },
    {
      "type": "text",
      "section": "I. Catecholamines",
      "line": 5148,
      "preview": "--- page 213 ---"
    },
    {
      "type": "text",
      "section": "I. Catecholamines",
      "line": 5150,
      "preview": "Phosphodiesterase (PDE) is the enzyme responsible for the breakdown of cAMP and cGMP. These inhibito"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "A. Milrinone (PGE5 inhibitor)",
      "line": 5152
    },
    {
      "type": "text",
      "section": "A. Milrinone (PGE5 inhibitor)",
      "line": 5154,
      "preview": "1. Prevents breakdown of cyclic AMP."
    },
    {
      "type": "text",
      "section": "A. Milrinone (PGE5 inhibitor)",
      "line": 5155,
      "preview": "2. Increases cardiac output without increasing myocardial oxygen demand and lowers systemic vascular"
    },
    {
      "type": "text",
      "section": "A. Milrinone (PGE5 inhibitor)",
      "line": 5156,
      "preview": "3. Not metabolized, excreted by the kidney."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Sildenafil (PGE3 inhibitor)",
      "line": 5158
    },
    {
      "type": "text",
      "section": "B. Sildenafil (PGE3 inhibitor)",
      "line": 5160,
      "preview": "1. Prevents breakdown of cyclic GMP."
    },
    {
      "type": "text",
      "section": "B. Sildenafil (PGE3 inhibitor)",
      "line": 5161,
      "preview": "2. Leads to vascular smooth muscle relaxation and research has demonstrated improvement in neonates "
    },
    {
      "type": "text",
      "section": "B. Sildenafil (PGE3 inhibitor)",
      "line": 5162,
      "preview": "3. Metabolized in the liver."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Vasodilators",
      "line": 5164
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Nitroglycerin",
      "line": 5166
    },
    {
      "type": "text",
      "section": "A. Nitroglycerin",
      "line": 5168,
      "preview": "1. A potent venous vasodilator and a less potent systemic and pulmonary artery dilator."
    },
    {
      "type": "text",
      "section": "A. Nitroglycerin",
      "line": 5169,
      "preview": "2. Metabolized by rapid hepatic and vascular conversion and excreted by the kidneys. Adverse reactio"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Sodium Nitroprusside",
      "line": 5171
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5173,
      "preview": "1. Cause smooth muscle relaxation with no direct cardiac effect."
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5174,
      "preview": "2. Causes a greater reduction in preload and afterload than nitroglycerin."
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5175,
      "preview": "3. Converted to cyanide in red blood cell. Cyanide is converted to thiocyanate in liver and is excre"
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5176,
      "preview": "a. Metabolic acidosis"
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5177,
      "preview": "b. Increased mixed venous O2 saturation"
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5178,
      "preview": "c. Decreased A-V O2 difference"
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5179,
      "preview": "d. Decreased O2 transport (Cyanmethemoglobin)"
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5180,
      "preview": "4. Adverse reactions include cyanide and thiocyanate toxicity, hypotension, and tachycardia."
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5182,
      "preview": "--- page 214 ---"
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5184,
      "preview": "1. Affects the precapillary arterioles causing vasodilation mostly in renal, coronary, cerebral, and"
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5185,
      "preview": "2. Use most frequently for hypertension."
    },
    {
      "type": "text",
      "section": "B. Sodium Nitroprusside",
      "line": 5186,
      "preview": "3. Metabolized in the liver."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Calcium Antagonists",
      "line": 5188
    },
    {
      "type": "text",
      "section": "IV. Calcium Antagonists",
      "line": 5190,
      "preview": "Reduce inward calcium flux to vascular smooth muscle to act as a vasodilator and a negative inotropi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Nifedipine",
      "line": 5192
    },
    {
      "type": "text",
      "section": "A. Nifedipine",
      "line": 5194,
      "preview": "1. Causes a decrease in systemic and pulmonary arterial blood pressure. Metabolized by the liver and"
    },
    {
      "type": "text",
      "section": "A. Nifedipine",
      "line": 5195,
      "preview": "2. Primarily used to lower pulmonary vascular resistance and increase pulmonary blood flow in childr"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Angiotensin Converting Enzyme (ACE) Inhibitors",
      "line": 5197
    },
    {
      "type": "text",
      "section": "V. Angiotensin Converting Enzyme (ACE) Inhibitors",
      "line": 5199,
      "preview": "Afterload reducing agents. Inhibit conversion of angiotensin I to angiotensin II in the liver. The e"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Captopril",
      "line": 5201
    },
    {
      "type": "text",
      "section": "A. Captopril",
      "line": 5203,
      "preview": "1. Lowers systemic vascular resistance and systemic blood pressure without an increase in heart rate"
    },
    {
      "type": "text",
      "section": "A. Captopril",
      "line": 5204,
      "preview": "2. Metabolized in the liver and excreted in bile and by the kidneys."
    },
    {
      "type": "text",
      "section": "A. Captopril",
      "line": 5205,
      "preview": "3. Hypotension is the most common side effect. Neutropenia and a persistent cough can also occur."
    },
    {
      "type": "text",
      "section": "A. Captopril",
      "line": 5206,
      "preview": "4. Hyperkalemia can occur with concomitant use of spironolactone"
    },
    {
      "type": "text",
      "section": "A. Captopril",
      "line": 5207,
      "preview": "5. Enteral dosing only: Give at least 1 hour before meals or 2 hours after meals"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Enalapril",
      "line": 5209
    },
    {
      "type": "text",
      "section": "B. Enalapril",
      "line": 5211,
      "preview": "1. Has longer elimination half-life compared to captopril, so it can be dosed daily or two times dai"
    },
    {
      "type": "text",
      "section": "B. Enalapril",
      "line": 5212,
      "preview": "2. An IV formulation of enalapril is available."
    },
    {
      "type": "text",
      "section": "B. Enalapril",
      "line": 5213,
      "preview": "3. Hyperkalemia can occur with concomitant use of spironolactone"
    },
    {
      "type": "text",
      "section": "B. Enalapril",
      "line": 5215,
      "preview": "--- page 215 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Diuretics",
      "line": 5217
    },
    {
      "type": "table",
      "section": "VI. Diuretics",
      "line": 5219,
      "preview": "| Agent | Type | Duration of Action | Mechanism of Action | Clinical Uses | Effects on Potassium | E"
    },
    {
      "type": "table",
      "section": "VI. Diuretics",
      "line": 5220,
      "preview": "| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "VI. Diuretics",
      "line": 5221,
      "preview": "| Acetazolamide | Carboni c anhydra se inhibitor | Days | Blocks carbonic anhydrase, prevents the re"
    },
    {
      "type": "table",
      "section": "VI. Diuretics",
      "line": 5222,
      "preview": "| Furosemide | Loop diuretic | Within 4 hours | Block resorption of $\\mathrm{Na}+/ \\mathrm{K}+/ \\mat"
    },
    {
      "type": "table",
      "section": "VI. Diuretics",
      "line": 5223,
      "preview": "| Hydrochlorothiazide | Thiazide diuretic | 6-12 <br> hours | Inhibits sodium chloride transport in "
    },
    {
      "type": "table",
      "section": "VI. Diuretics",
      "line": 5224,
      "preview": "| Spironolactone | Potassi um sparing diuretic | $24-72$ <br> hours | Inhibits aldosterone action re"
    },
    {
      "type": "table",
      "section": "VI. Diuretics",
      "line": 5225,
      "preview": "| Aldactazide | Combin ation diuretic |  | See hydrochlorothiazide and spironolactone MOA | Edema Hy"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. Beta Blockers",
      "line": 5227
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Esmolol",
      "line": 5229
    },
    {
      "type": "text",
      "section": "A. Esmolol",
      "line": 5231,
      "preview": "1. Short-acting beta-1 antagonist. Used to treat systemic hypertension after coarctation of the aort"
    },
    {
      "type": "text",
      "section": "A. Esmolol",
      "line": 5232,
      "preview": "2. Adverse effects include bradycardia, hypotension, and bronchospasm."
    },
    {
      "type": "text",
      "section": "A. Esmolol",
      "line": 5233,
      "preview": "3. This drug should be used with caution in patients with decreased ventricular function, when calci"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Labetalol",
      "line": 5235
    },
    {
      "type": "text",
      "section": "B. Labetalol",
      "line": 5237,
      "preview": "1. Alpha and beta blocker that is used in treatment of systemic hypertension. Adverse effects are th"
    },
    {
      "type": "text",
      "section": "B. Labetalol",
      "line": 5239,
      "preview": "--- page 216 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Propranolol",
      "line": 5241
    },
    {
      "type": "text",
      "section": "C. Propranolol",
      "line": 5243,
      "preview": "1. Used to treat arrhythmias (atrial flutter and fibrillation, A-V node re-entrant tachycardias), hy"
    },
    {
      "type": "text",
      "section": "C. Propranolol",
      "line": 5244,
      "preview": "2. Adverse effects include hypotension, impaired myocardial contractility, congestive heart failure,"
    },
    {
      "type": "text",
      "section": "C. Propranolol",
      "line": 5245,
      "preview": "3. Drug interactions include phenobarbital, rifampin, cimetidine, aluminum-containing antacids and p"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. Agents that Affect the Ductus Arteriosus",
      "line": 5247
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Prostaglandin E1 (PGE1)",
      "line": 5249
    },
    {
      "type": "text",
      "section": "A. Prostaglandin E1 (PGE1)",
      "line": 5251,
      "preview": "1. PGE1 use in certain lesions can lead to deterioration. These include obstructive Total Anomalous "
    },
    {
      "type": "text",
      "section": "A. Prostaglandin E1 (PGE1)",
      "line": 5252,
      "preview": "2. Adverse effects include apnea (dose-related), hyperthermia, cutaneous flushing, hypotension and s"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Indomethacin",
      "line": 5254
    },
    {
      "type": "text",
      "section": "B. Indomethacin",
      "line": 5256,
      "preview": "1. Inhibits cyclo-oxygenase, which is a key enzyme in prostaglandin synthesis, thus helping to close"
    },
    {
      "type": "text",
      "section": "B. Indomethacin",
      "line": 5257,
      "preview": "2. Contraindications include an elevated BUN and creatinine, and thrombocytopenia."
    },
    {
      "type": "text",
      "section": "B. Indomethacin",
      "line": 5258,
      "preview": "3. Adverse effects include reduced renal function and urine output, decreased platelet production an"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IX. Anticoagulants",
      "line": 5260
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Heparin",
      "line": 5262
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5264,
      "preview": "1. A glycosaminoglycuran that accelerates the process in which factors $X, I X, X I$, and $X I I I$ "
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5265,
      "preview": "2. Indications include prophylaxis against thrombosis (e.g., systemic-pulmonary artery shunts) and t"
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5266,
      "preview": "3. Treatment goal typically is to maintain the partial thromboplastin time (PTT) 1.5-2.5 times norma"
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5267,
      "preview": "4. Bleeding due to excessive heparin effect can be reversed by protamine sulfate ( $1 \\mathrm{mg} / "
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5269,
      "preview": "--- page 217 ---"
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5271,
      "preview": "210 Part II-C: Cardiac"
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5272,
      "preview": "B. Aspirin"
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5274,
      "preview": "1. Inhibits the enzyme cyclo-oxygenase by acetylation leading to inhibition of thromboxane A2 (a pla"
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5275,
      "preview": "2. Indications include clot prophylaxis for systemic-pulmonary shunts or cavopulmonary anastomosis a"
    },
    {
      "type": "text",
      "section": "A. Heparin",
      "line": 5276,
      "preview": "3. Adverse effects include gastritis, gastric ulcer and gastrointestinal bleeding."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "X. Thrombolytic Agents",
      "line": 5278
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Tissue-Type Plasminogen Activator (TPA)",
      "line": 5280
    },
    {
      "type": "text",
      "section": "A. Tissue-Type Plasminogen Activator (TPA)",
      "line": 5282,
      "preview": "1. Activates plasminogen to plasmin in the presence of fibrin. It is different from urokinase and st"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XI. Digoxin",
      "line": 5284
    },
    {
      "type": "text",
      "section": "XI. Digoxin",
      "line": 5286,
      "preview": "A. Increases the availability of intracellular calcium for myocardial contraction. Used for myocardi"
    },
    {
      "type": "text",
      "section": "XI. Digoxin",
      "line": 5287,
      "preview": "B. Toxicity:"
    },
    {
      "type": "text",
      "section": "XI. Digoxin",
      "line": 5289,
      "preview": "1. Digoxin toxicity can occur at serum level $>2 \\mathrm{ng} / \\mathrm{ml}$."
    },
    {
      "type": "text",
      "section": "XI. Digoxin",
      "line": 5290,
      "preview": "2. Increased incidence of toxic effects with hypokalemia and following calcium bolus dose."
    },
    {
      "type": "text",
      "section": "XI. Digoxin",
      "line": 5291,
      "preview": "3. Decrease dosing with simultaneous use of quinidine, verapamil, or amiodarone."
    },
    {
      "type": "text",
      "section": "XI. Digoxin",
      "line": 5292,
      "preview": "C. Side effects: bradycardia, atrioventricular block, ventricular arrhythmias and tachycardia."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XII. Resuscitation Meds",
      "line": 5294
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5296,
      "preview": "A. Epinephrine $1 \\mathrm{mg} / 10 \\mathrm{~mL}: 0.1-0.3 \\mathrm{ml} / \\mathrm{kg}$ IV or $0.01-0.03"
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5298,
      "preview": "Repeat every 3-5 min."
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5299,
      "preview": "B. Sodium Bicarbonate $0.5 \\mathrm{mEq} / \\mathrm{ml}: 1-2 \\mathrm{mEq} / \\mathrm{kg}$ IV"
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5301,
      "preview": "Give slowly over at least 2 min ."
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5302,
      "preview": "C. Narcan $1 \\mathrm{mg} / \\mathrm{ml}: 0.1 \\mathrm{mg} / \\mathrm{kg}$ IV, ETT, SQ or IM"
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5303,
      "preview": "D. Calcium Chloride 10\\%: 10-20 mg/kg IV"
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5305,
      "preview": "Incompatible with sodium bicarbonate. Must be infused through a central line."
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5306,
      "preview": "E. Dextrose $10 \\%: 2-4 \\mathrm{ml} / \\mathrm{kg}$ IV"
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5308,
      "preview": "Atropine ( $0.1 \\mathrm{mg} / \\mathrm{ml}): 0.01-0.03 \\mathrm{mg} / \\mathrm{kg} /$ dose with minimum"
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5309,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "XII. Resuscitation Meds",
      "line": 5311,
      "preview": "--- page 218 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Arrhythmia in the Neonate",
      "line": 5313
    },
    {
      "type": "text",
      "section": "Arrhythmia in the Neonate",
      "line": 5315,
      "preview": "Shazia Bhombal, M.D. and Kathleen Ryan, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Normal Conduction",
      "line": 5317
    },
    {
      "type": "text",
      "section": "I. Normal Conduction",
      "line": 5319,
      "preview": "A. Made up of 5 pathways"
    },
    {
      "type": "text",
      "section": "I. Normal Conduction",
      "line": 5321,
      "preview": "1. Sino-atrial (SA) node pacemaker, depolarizes right and left atria by continuous spread (Pwave)"
    },
    {
      "type": "text",
      "section": "I. Normal Conduction",
      "line": 5322,
      "preview": "2. Atrio-ventricular (AV) node once the impulse reaches the AV node, it slows considerably (decremen"
    },
    {
      "type": "text",
      "section": "I. Normal Conduction",
      "line": 5323,
      "preview": "3. Bundle of His - once signal reaches bundle of His, it speeds up through the right and left bundle"
    },
    {
      "type": "image",
      "section": "I. Normal Conduction",
      "line": 5324,
      "content": "![img-23.jpeg](images/ee52a06f5974bafc.png)"
    },
    {
      "type": "text",
      "section": "I. Normal Conduction",
      "line": 5325,
      "preview": "4. Left and right bundle branches"
    },
    {
      "type": "text",
      "section": "I. Normal Conduction",
      "line": 5326,
      "preview": "5. Purkinje fibers"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. EKG Intervals",
      "line": 5328
    },
    {
      "type": "text",
      "section": "B. EKG Intervals",
      "line": 5330,
      "preview": "1. PR Interval - time required for atrial depolarization (Pwave) + slow conduction through AV node"
    },
    {
      "type": "text",
      "section": "B. EKG Intervals",
      "line": 5331,
      "preview": "2. QT Interval - time required for ventricular depolarization (QRS) + silent period after ventricula"
    },
    {
      "type": "image",
      "section": "B. EKG Intervals",
      "line": 5332,
      "content": "![img-24.jpeg](images/f8a2243e19b6d940.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Arrhythmia",
      "line": 5334
    },
    {
      "type": "text",
      "section": "II. Arrhythmia",
      "line": 5336,
      "preview": "Overall fairly uncommon in the neonatal population other than sinus arrhythmia, isolated premature a"
    },
    {
      "type": "text",
      "section": "II. Arrhythmia",
      "line": 5338,
      "preview": "--- page 219 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5340
    },
    {
      "type": "text",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5342,
      "preview": "1. Sinus arrhythmia"
    },
    {
      "type": "text",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5344,
      "preview": "Normal vagal response and varies with respiration (faster with inspiration and slowing during exhala"
    },
    {
      "type": "image",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5345,
      "content": "![img-25.jpeg](images/002e0c020d24e9f7.png)"
    },
    {
      "type": "text",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5346,
      "preview": "2. Sinus tachycardia"
    },
    {
      "type": "text",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5348,
      "preview": "Gradual increase in HR may indicate sinus tachycardia - check telemetry. Regular normal sinus Pwaves"
    },
    {
      "type": "text",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5349,
      "preview": "3. Sinus bradycardia"
    },
    {
      "type": "text",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5350,
      "preview": "4. Sinus pause"
    },
    {
      "type": "text",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5352,
      "preview": "Pause in rhythm without an escape beat, usually related to increased vagal tone or hypoxia. Sometime"
    },
    {
      "type": "image",
      "section": "A. Normal Rhythms originating in sinus node",
      "line": 5353,
      "content": "![img-26.jpeg](images/24a82a48c3e02b07.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Normal Rhythms originating in atrium",
      "line": 5355
    },
    {
      "type": "text",
      "section": "B. Normal Rhythms originating in atrium",
      "line": 5357,
      "preview": "1. Premature atrial contraction (PAC) - focus from non-SA node in atrium with a morphology different"
    },
    {
      "type": "image",
      "section": "B. Normal Rhythms originating in atrium",
      "line": 5358,
      "content": "![img-27.jpeg](images/1ab5f5033c73f4d7.png)"
    },
    {
      "type": "text",
      "section": "B. Normal Rhythms originating in atrium",
      "line": 5359,
      "preview": "a. Blocked PAC - Nonconducted PAC, no intervention needed, if frequent PACs, may check electrolytes "
    },
    {
      "type": "image",
      "section": "B. Normal Rhythms originating in atrium",
      "line": 5360,
      "content": "![img-28.jpeg](images/f4cdd2384747b9c1.png)"
    },
    {
      "type": "text",
      "section": "B. Normal Rhythms originating in atrium",
      "line": 5362,
      "preview": "--- page 220 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Tachycardias originating in the atrium",
      "line": 5364
    },
    {
      "type": "text",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5366,
      "preview": "1. Atrial tachycardia"
    },
    {
      "type": "text",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5368,
      "preview": "Tachycardia that originates in the atria. Reentrant tachycardias are more commonly found in neonates"
    },
    {
      "type": "text",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5369,
      "preview": "a. Reentrant supraventricular tachycardia - most commonly caused by an accessory pathway, e.g. Wolff"
    },
    {
      "type": "image",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5370,
      "content": "![img-29.jpeg](images/042c88d26f6103d0.png)"
    },
    {
      "type": "text",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5371,
      "preview": "b. Ectopic atrial tachycardia - Automatic focus within the atria. Irregular, does not usually break "
    },
    {
      "type": "image",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5372,
      "content": "![img-30.jpeg](images/6f7337dca3d1ddbb.png)"
    },
    {
      "type": "text",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5373,
      "preview": "c. AV nodal reentrant tachycardia (AVNRT) - less commonly found in neonates, reentrant tachycardia w"
    },
    {
      "type": "text",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5374,
      "preview": "d. Atrial flutter - Reentrant tachycardia around the tricuspid valve, depending on how often the sig"
    },
    {
      "type": "image",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5375,
      "content": "![img-31.jpeg](images/e2f614b71d945801.png)"
    },
    {
      "type": "text",
      "section": "C. Tachycardias originating in the atrium",
      "line": 5376,
      "preview": "e. Atrial fibrillation - Mostly due to small circuits in left atrium around pulmonary veins. Irregul"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Normal rhythm originating in the ventricle",
      "line": 5378
    },
    {
      "type": "text",
      "section": "D. Normal rhythm originating in the ventricle",
      "line": 5380,
      "preview": "1. Premature ventricular contraction (PVC) - focus from ventricle, tends to be wider complex. Possib"
    },
    {
      "type": "text",
      "section": "D. Normal rhythm originating in the ventricle",
      "line": 5382,
      "preview": "--- page 221 ---"
    },
    {
      "type": "text",
      "section": "D. Normal rhythm originating in the ventricle",
      "line": 5384,
      "preview": "PAC look for a compensatory pause. The RR interval between the PVC and the next beat will be 2 RR in"
    },
    {
      "type": "image",
      "section": "D. Normal rhythm originating in the ventricle",
      "line": 5385,
      "content": "![img-32.jpeg](images/13eaee84a52a0cff.png)"
    },
    {
      "type": "text",
      "section": "D. Normal rhythm originating in the ventricle",
      "line": 5386,
      "preview": "2. Idioventricular rhythm - Benign ventricular rhythm when ventricular pacemaker is slightly faster "
    },
    {
      "type": "image",
      "section": "D. Normal rhythm originating in the ventricle",
      "line": 5387,
      "content": "![img-33.jpeg](images/62b1eeec0cc03856.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "E. Tachycardias originating in the ventricle",
      "line": 5389
    },
    {
      "type": "text",
      "section": "E. Tachycardias originating in the ventricle",
      "line": 5391,
      "preview": "1. Ventricular tachycardia/Ventricular fibrillation - tachycardia that originates from myocytes or p"
    },
    {
      "type": "image",
      "section": "E. Tachycardias originating in the ventricle",
      "line": 5392,
      "content": "![img-34.jpeg](images/70f882f1c93573a2.png)"
    },
    {
      "type": "text",
      "section": "E. Tachycardias originating in the ventricle",
      "line": 5394,
      "preview": "Monomorphic VT"
    },
    {
      "type": "text",
      "section": "E. Tachycardias originating in the ventricle",
      "line": 5395,
      "preview": "2. Torsades de pointes - specific pattern of positive and negative oscillation around an isoelectric"
    },
    {
      "type": "image",
      "section": "E. Tachycardias originating in the ventricle",
      "line": 5396,
      "content": "![img-35.jpeg](images/abffab2d050e5581.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Abnormalities of AV conduction",
      "line": 5398
    },
    {
      "type": "text",
      "section": "F. Abnormalities of AV conduction",
      "line": 5400,
      "preview": "Problem in conduction of signal from atria to ventricles. Varies in severity and need for interventi"
    },
    {
      "type": "text",
      "section": "F. Abnormalities of AV conduction",
      "line": 5402,
      "preview": "1. First degree AV block - Occurs due to disease within AV node leading to more slowing than normal "
    },
    {
      "type": "text",
      "section": "F. Abnormalities of AV conduction",
      "line": 5404,
      "preview": "--- page 222 ---"
    },
    {
      "type": "text",
      "section": "F. Abnormalities of AV conduction",
      "line": 5406,
      "preview": "2. Second degree AV block - Mobitz type I (Wenckebach) is a process within the AV node with progress"
    },
    {
      "type": "image",
      "section": "F. Abnormalities of AV conduction",
      "line": 5407,
      "content": "![img-36.jpeg](images/f5b63c4a2d1e3f87.png)"
    },
    {
      "type": "text",
      "section": "F. Abnormalities of AV conduction",
      "line": 5409,
      "preview": "Mobitz type I"
    },
    {
      "type": "text",
      "section": "F. Abnormalities of AV conduction",
      "line": 5410,
      "preview": "3. Third degree AV block - regular $P$ waves and regular QRS complex beat independently with no comm"
    },
    {
      "type": "image",
      "section": "F. Abnormalities of AV conduction",
      "line": 5411,
      "content": "![img-37.jpeg](images/2b965f569cc44de0.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "G. Long QT Syndrome",
      "line": 5413
    },
    {
      "type": "text",
      "section": "G. Long QT Syndrome",
      "line": 5415,
      "preview": "Congenital disorder or can be acquired due to medications, electrolyte abnormalities or toxins. Cong"
    },
    {
      "type": "image",
      "section": "G. Long QT Syndrome",
      "line": 5416,
      "content": "![img-38.jpeg](images/f1db9dbcf154759c.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 5418
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5420,
      "preview": "1. Park MK and Guntheroth WG. How to Read Pediatric ECGs. 4th ed. Mosby. 2006:"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5421,
      "preview": "2. Lifeinthefastlane.com - image library"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5423,
      "preview": "--- page 223 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Patent Ductus Arteriosus Management",
      "line": 5425
    },
    {
      "type": "text",
      "section": "Patent Ductus Arteriosus Management",
      "line": 5427,
      "preview": "Valerie Chock, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. General",
      "line": 5429
    },
    {
      "type": "text",
      "section": "I. General",
      "line": 5431,
      "preview": "A. The ductus is usually functionally closed within 12 hrs of life. Anatomic closure normally occurs"
    },
    {
      "type": "text",
      "section": "I. General",
      "line": 5432,
      "preview": "B. Left-to-right shunting through the ductus may contribute to increasing pulmonary edema, persisten"
    },
    {
      "type": "text",
      "section": "I. General",
      "line": 5433,
      "preview": "C. It remains unclear if treatment of a PDA results in improved long-term outcomes. Recent analyses "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Diagnosis",
      "line": 5435
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Clinical Signs and Symptoms",
      "line": 5437
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5439,
      "preview": "Suspect a hemodynamically significant PDA in premature infants when there is:"
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5441,
      "preview": "1. A systolic or continuous \"grating\" murmur heard in the LUSB."
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5442,
      "preview": "2. Bounding pulses (often palmar pulses are palpated)."
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5443,
      "preview": "3. Wide pulse pressure ( $>20 \\mathrm{mmHg}$ ) with low diastolic pressure."
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5444,
      "preview": "4. Difficulty weaning from the ventilator (above what is expected for typical RDS picture). Increase"
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5445,
      "preview": "5. CHF, cardiomegaly, and pulmonary edema visible on CXR."
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5446,
      "preview": "6. Metabolic acidosis."
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5447,
      "preview": "7. Feeding intolerance"
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5448,
      "preview": "8. Oliguria, rising creatinine levels"
    },
    {
      "type": "text",
      "section": "A. Clinical Signs and Symptoms",
      "line": 5450,
      "preview": "NOTE: Sometimes a PDA is asymptomatic"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Echocardiographic Findings",
      "line": 5452
    },
    {
      "type": "text",
      "section": "B. Echocardiographic Findings",
      "line": 5454,
      "preview": "Confirmation of clinical suspicion is by echocardiogram:"
    },
    {
      "type": "text",
      "section": "B. Echocardiographic Findings",
      "line": 5456,
      "preview": "1. ECHO characteristics to consider include size of the duct, direction of blood flow (left-to-right"
    },
    {
      "type": "text",
      "section": "B. Echocardiographic Findings",
      "line": 5457,
      "preview": "2. The ECHO will only capture a moment in time. As the PDA is dynamic, multiple ECHO studies may be "
    },
    {
      "type": "text",
      "section": "B. Echocardiographic Findings",
      "line": 5459,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "B. Echocardiographic Findings",
      "line": 5461,
      "preview": "--- page 224 ---"
    },
    {
      "type": "text",
      "section": "B. Echocardiographic Findings",
      "line": 5463,
      "preview": "3. If PDA treatment is being considered it is important to rule out a ductal dependent lesion."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Near-Infrared Spectroscopy (NIRS) Findings",
      "line": 5465
    },
    {
      "type": "text",
      "section": "C. Near-Infrared Spectroscopy (NIRS) Findings",
      "line": 5467,
      "preview": "NIRS monitoring may provide further evidence for a hemodynamically significant PDA."
    },
    {
      "type": "text",
      "section": "C. Near-Infrared Spectroscopy (NIRS) Findings",
      "line": 5469,
      "preview": "1. Renal saturation levels tend to be significantly lower with greater variability in the patient wi"
    },
    {
      "type": "text",
      "section": "C. Near-Infrared Spectroscopy (NIRS) Findings",
      "line": 5470,
      "preview": "2. Cerebral saturation levels also may be lower in the presence of a significant PDA, although autor"
    },
    {
      "type": "image",
      "section": "C. Near-Infrared Spectroscopy (NIRS) Findings",
      "line": 5471,
      "content": "![img-39.jpeg](images/f652fad210d0d1cc.png)"
    },
    {
      "type": "text",
      "section": "C. Near-Infrared Spectroscopy (NIRS) Findings",
      "line": 5473,
      "preview": "Figure 1: Before treatment of a preterm infant with a significant PDA, renal saturation levels are s"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Treatment",
      "line": 5475
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 5477,
      "preview": "A. Conservative Management: Consider awaiting spontaneous closure with conservative management."
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 5479,
      "preview": "1. Limit the fluid volume to the essential amount necessary to meet estimated needs, but still maint"
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 5480,
      "preview": "2. Diuretic therapy may be necessary to minimize pulmonary edema."
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 5481,
      "preview": "3. Treat hypotension with pressors."
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 5482,
      "preview": "4. Maintain higher positive airway distending pressures."
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 5483,
      "preview": "5. Consider blood transfusions to maintain adequate systemic oxygenation."
    },
    {
      "type": "text",
      "section": "III. Treatment",
      "line": 5484,
      "preview": "6. Feedings may need to be limited or discontinued if significant ductal steal present."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Medical Management:",
      "line": 5486
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5488,
      "preview": "1. Indomethacin $(0.2 \\mathrm{mg} / \\mathrm{kg} /$ dose $)$ every 12 hrs for 3 doses. May repeat cou"
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5489,
      "preview": "2. Pre-indocin labs: creatinine, platelets. Indocin may impair renal perfusion and decrease platelet"
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5490,
      "preview": "3. Doses contraindicated if platelets $<100 \\mathrm{~K}, \\mathrm{Cr}>1.5$, urine output $<0.5 \\mathr"
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5492,
      "preview": "--- page 225 ---"
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5494,
      "preview": "218 Part II-C: Cardiac"
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5495,
      "preview": "patient is on hydrocortisone (due to risk of spontaneous intestinal perforation). Not contraindicate"
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5496,
      "preview": "4. Closure rate is $65-75 \\%$. Some will re-open especially with increased intravenous fluid volume."
    },
    {
      "type": "text",
      "section": "B. Medical Management:",
      "line": 5497,
      "preview": "5. Other centers may use ibuprofen instead of indomethacin for PDA closure due to a similar efficacy"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Surgical Management:",
      "line": 5499
    },
    {
      "type": "text",
      "section": "C. Surgical Management:",
      "line": 5501,
      "preview": "1. For those with failed medical management or with contraindications to indomethacin, surgical liga"
    },
    {
      "type": "text",
      "section": "C. Surgical Management:",
      "line": 5502,
      "preview": "2. It is recommended that surgical ligation be delayed until the infant is at least 30 days of age. "
    },
    {
      "type": "text",
      "section": "C. Surgical Management:",
      "line": 5503,
      "preview": "3. Consider need for stress-dose hydrocortisone prior to surgery. Infants are at risk for impaired c"
    },
    {
      "type": "text",
      "section": "C. Surgical Management:",
      "line": 5504,
      "preview": "4. Complications of surgical ligation include risks of anesthesia, vocal cord paralysis, pneumothora"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Prophylactic Management for PDA:",
      "line": 5506
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5508,
      "preview": "Some centers use Indomethacin for preterm infants in the first 24 hours of life at $0.1 \\mathrm{mg} "
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5510,
      "preview": "--- page 226 ---"
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5512,
      "preview": "E. Current Recommended Approach to the PDA at LPCH"
    },
    {
      "type": "image",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5513,
      "content": "![img-40.jpeg](images/be9ae7b0028d7b86.png)"
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5515,
      "preview": "References:"
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5517,
      "preview": "1. Benitz, WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept t"
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5518,
      "preview": "2. Chock VY, Rose LA, Mante J, Punn R. Near Infrared Spectroscopy and Detection of a Hemodynamically"
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5519,
      "preview": "3. Chock VY, Ramamoorthy C, Van Meurs KP. Cerebral autoregulation in neonates with a hemodynamically"
    },
    {
      "type": "text",
      "section": "D. Prophylactic Management for PDA:",
      "line": 5521,
      "preview": "--- page 227 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Evaluation and Management of Pulmonary Hypertension in BPD Patients",
      "line": 5523
    },
    {
      "type": "text",
      "section": "Evaluation and Management of Pulmonary Hypertension in BPD Patients",
      "line": 5525,
      "preview": "Christine Johnson, M.D., Shazia Bhombal, M.D., Michelle Ogawa, C.P.N.P., and Jeffrey A. Feinstein, M"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 5527
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5529,
      "preview": "Despite changes in the nature and epidemiology of bronchopulmonary dysplasia (BPD), patients with BP"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Evaluation and Diagnosis",
      "line": 5531
    },
    {
      "type": "text",
      "section": "II. Evaluation and Diagnosis",
      "line": 5533,
      "preview": "A. Diagnosis of PH can be difficult in BPD patients given the subtle symptoms and the overlap with s"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5535
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5537,
      "preview": "1. Early screening echocardiograms can be performed as early as $7-10$ days of age in premature infa"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5538,
      "preview": "a. Severe respiratory distress syndrome (RDS)"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5539,
      "preview": "b. High levels of ventilator support and oxygen need"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5540,
      "preview": "c. Oligohydramnios"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5541,
      "preview": "d. Intrauterine growth restriction (IUGR)"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5542,
      "preview": "e. Slow rate of clinical improvement (ie, persistent or progressively increased need for respiratory"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5543,
      "preview": "2. Screening echocardiogram at 36 weeks postmenstrual age (PMA) if:"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5545,
      "preview": "--- page 228 ---"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5547,
      "preview": "a. On positive pressure ventilation"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5548,
      "preview": "b. Not consistently weaning from supplemental oxygen"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5549,
      "preview": "c. Oxygen needs disproportionate to level of lung disease"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5550,
      "preview": "d. Recurrent cyanotic episodes"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5551,
      "preview": "3. Other indications that warrant a screening echocardiogram:"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5552,
      "preview": "a. Feeding dysfunction"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5553,
      "preview": "b. Poor growth"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5554,
      "preview": "c. Recurrent hospitalizations"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5555,
      "preview": "d. Elevated PaCO2"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5556,
      "preview": "e. Persistent pulmonary edema requiring frequent use of diuretics"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5557,
      "preview": "C. If the patient is clinically stable and the echocardiogram is normal or shows subtle signs of mil"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5558,
      "preview": "D. For patients whose echocardiograms show signs of PH, the Pulmonary Hypertension team should be co"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5560,
      "preview": "1. Have persistent signs of cardiopulmonary disease or clinical deterioration not related to airway "
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5561,
      "preview": "2. Are suspected of having significant PH despite optimal management of lung disease and associated "
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5562,
      "preview": "3. Are a candidate for prolonged PH drug therapy"
    },
    {
      "type": "text",
      "section": "B. Recommendations at this time for PH screening are:",
      "line": 5563,
      "preview": "4. Have unexplained and recurrent pulmonary edema"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "E. Goals of advanced imaging:",
      "line": 5565
    },
    {
      "type": "text",
      "section": "E. Goals of advanced imaging:",
      "line": 5567,
      "preview": "1. Exclude or document the severity of associated anatomic cardiac lesions, including the presence o"
    },
    {
      "type": "text",
      "section": "E. Goals of advanced imaging:",
      "line": 5568,
      "preview": "2. Define the presence of systemic-pulmonary collateral vessels (including their size), pulmonary ve"
    },
    {
      "type": "text",
      "section": "E. Goals of advanced imaging:",
      "line": 5569,
      "preview": "3. Obtain a structural assessment of the pulmonary arterial and venous circulations by angiography"
    },
    {
      "type": "text",
      "section": "E. Goals of advanced imaging:",
      "line": 5570,
      "preview": "4. Assess the severity of PH"
    },
    {
      "type": "text",
      "section": "E. Goals of advanced imaging:",
      "line": 5571,
      "preview": "5. Assess pulmonary vascular reactivity in patients who fail to respond to oxygen therapy alone. Acu"
    },
    {
      "type": "text",
      "section": "E. Goals of advanced imaging:",
      "line": 5573,
      "preview": "--- page 229 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Management and Treatment",
      "line": 5575
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Address Underlying Lung Disease:",
      "line": 5577
    },
    {
      "type": "text",
      "section": "A. Address Underlying Lung Disease:",
      "line": 5579,
      "preview": "1. Sleep studies, flexible bronchoscopy, upper gastrointestinal series, pH probe/impedance studies, "
    },
    {
      "type": "text",
      "section": "A. Address Underlying Lung Disease:",
      "line": 5580,
      "preview": "2. Oxygen saturations should be in the target range of $92-95 \\%$."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Inhaled Nitric Oxide (iNO)",
      "line": 5582
    },
    {
      "type": "text",
      "section": "B. Inhaled Nitric Oxide (iNO)",
      "line": 5584,
      "preview": "1. Causes selective pulmonary vasodilation"
    },
    {
      "type": "text",
      "section": "B. Inhaled Nitric Oxide (iNO)",
      "line": 5585,
      "preview": "2. Acute improvement in pulmonary hemodynamics has been demonstrated during cardiac catheterization."
    },
    {
      "type": "text",
      "section": "B. Inhaled Nitric Oxide (iNO)",
      "line": 5586,
      "preview": "3. Starting dose: $10-20 \\mathrm{ppm}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Sildenafil",
      "line": 5588
    },
    {
      "type": "text",
      "section": "C. Sildenafil",
      "line": 5590,
      "preview": "1. Highly selective phosphodiesterase type 5 inhibitor, leading to increased cyclic GMP contents in "
    },
    {
      "type": "text",
      "section": "C. Sildenafil",
      "line": 5591,
      "preview": "2. Data in children are limited, but includes studies showing improvement of persistent pulmonary hy"
    },
    {
      "type": "text",
      "section": "C. Sildenafil",
      "line": 5592,
      "preview": "3. Starting dose: $0.5 \\mathrm{mg} / \\mathrm{kg} /$ dose q 8 h . If no systemic hypotension develops"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Endothelin-Receptor Antagonists (Bosentan)",
      "line": 5594
    },
    {
      "type": "text",
      "section": "D. Endothelin-Receptor Antagonists (Bosentan)",
      "line": 5596,
      "preview": "1. Endothelin-1 (ET-1) is a potent vasoconstrictor and smooth muscle mitogen that has been linked to"
    },
    {
      "type": "text",
      "section": "D. Endothelin-Receptor Antagonists (Bosentan)",
      "line": 5597,
      "preview": "2. Bosentan acts as an antagonist to the receptor of ET-1, thereby inhibiting vasoconstriction. It h"
    },
    {
      "type": "text",
      "section": "D. Endothelin-Receptor Antagonists (Bosentan)",
      "line": 5598,
      "preview": "3. Starting dose: $1 \\mathrm{mg} / \\mathrm{kg} /$ dose BID. Increase to $2 \\mathrm{mg} / \\mathrm{kg}"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Prostacyclin Therapy",
      "line": 5600
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5602,
      "preview": "1. Epoprostenol (Flolan)"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5604,
      "preview": "--- page 230 ---"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5606,
      "preview": "a. An intravenous $\\mathrm{PGI}_{2}$ with a short half-life ( $\\sim 6$ minutes) that must be given v"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5607,
      "preview": "b. Has been shown to be effective in older populations, but has the potential to worsen ventilationp"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5608,
      "preview": "c. Starting dose: Consult Pulmonary Hypertension team"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5609,
      "preview": "2. Treprostinil (Remodulin)"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5610,
      "preview": "a. A $\\mathrm{PGI}_{2}$ with a half-life of $\\sim 4$ hours. It can be delivered as a continuous intr"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5611,
      "preview": "b. Has been shown to be effective in older pediatric patient populations, but like epoprostenol, can"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5612,
      "preview": "c. Has been shown to be as effective as epoprostenol over 5 years (in a non-BPD population). BPD dat"
    },
    {
      "type": "text",
      "section": "E. Prostacyclin Therapy",
      "line": 5613,
      "preview": "d. Starting dose and delivery system: Consult Pulmonary Hypertension team"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5615
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5617,
      "preview": "1. Serial echocardiograms every 4 weeks during acute initiation of therapy; sooner if signs/symptoms"
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5618,
      "preview": "2. Echocardiograms every 6 months with stable disease"
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5619,
      "preview": "3. Brain natriuretic peptide levels (BNP) may be a helpful biomarker to follow during long-term ther"
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5620,
      "preview": "4. If sudden clinical deterioration, worsening of PH by echocardiogram, or when echocardiography is "
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5621,
      "preview": "G. Medications should be weaned with normal or near-normal echocardiogram findings."
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5622,
      "preview": "IV. Research in the NICU"
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5623,
      "preview": "A. RAiN (Remodulin as Add-on Therapy to iNO) Trial - Christine Johnson, M.D.:"
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5624,
      "preview": "5. \"Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary"
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5625,
      "preview": "6. An actively enrolling clinical trial studying the use of Remodulin (IV treprostinil) in infants b"
    },
    {
      "type": "text",
      "section": "F. Monitoring while on vasodilator therapy",
      "line": 5626,
      "preview": "7. The goal of this study is to determine whether Remodulin can be safely and effectively used in co"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 5628
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5630,
      "preview": "1. Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, Hanna B, Romer L, Keller RL,"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5632,
      "preview": "--- page 231 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5634,
      "preview": "224 Part II-C: Cardiac"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5635,
      "preview": "Hypertension Network (PPHNet). Evaluation and Management of Pulmonary Hypertension in Children with "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5636,
      "preview": "2. Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hyperte"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5637,
      "preview": "3. Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel DL, Steinhorn R, Adat"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5638,
      "preview": "4. Brown AT, Gillespie JV, Miquel-Verges F, Holmes K, Ravekes W, Spevak P, Brady K, Easley RB, Golde"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5639,
      "preview": "5. Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenaf"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5640,
      "preview": "6. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Groh\u00e9 C, G\u00fcnther A, Halank "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5642,
      "preview": "--- page 232 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-D: Hematology",
      "line": 5644
    },
    {
      "type": "text",
      "section": "Part II-D: Hematology",
      "line": 5646,
      "preview": "--- page 233 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Blood Product Ordering and Transfusion Practices",
      "line": 5648
    },
    {
      "type": "text",
      "section": "Blood Product Ordering and Transfusion Practices",
      "line": 5650,
      "preview": "Jennifer Andrews, MD, MSc"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. The Gann Act and Informed Consent",
      "line": 5652
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. What is the Gann Act?",
      "line": 5654
    },
    {
      "type": "text",
      "section": "A. What is the Gann Act?",
      "line": 5656,
      "preview": "1. The Paul Gann Blood Safety Act (Health and Safety Code Section 1645) requires that physicians or "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Who should be notified?",
      "line": 5658
    },
    {
      "type": "text",
      "section": "B. Who should be notified?",
      "line": 5660,
      "preview": "1. Parents whose children are in the NICU receive a general information packet upon admission from e"
    },
    {
      "type": "text",
      "section": "B. Who should be notified?",
      "line": 5661,
      "preview": "2. The Gann Act should be discussed with parents of infants with a reasonable likelihood of requirin"
    },
    {
      "type": "text",
      "section": "B. Who should be notified?",
      "line": 5662,
      "preview": "3. In the case of an emergency transfusion, the Gann Act does not apply, but if further transfusions"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Documentation of the Gann Act and Informed Consent",
      "line": 5664
    },
    {
      "type": "text",
      "section": "C. Documentation of the Gann Act and Informed Consent",
      "line": 5666,
      "preview": "1. The Physician, Nurse Practitioner or Transport Specialist who makes first contact with the parent"
    },
    {
      "type": "text",
      "section": "C. Documentation of the Gann Act and Informed Consent",
      "line": 5667,
      "preview": "2. This may not be possible in the case of infants transported in from outside hospitals with an out"
    },
    {
      "type": "text",
      "section": "C. Documentation of the Gann Act and Informed Consent",
      "line": 5668,
      "preview": "3. The provider must document in EPIC (\"Order Transfusion Consent \\& Gann Act\") the date they obtain"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Blood Product Information",
      "line": 5670
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. General information",
      "line": 5672
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5674,
      "preview": "1. Blood products must be ordered via EPIC, most commonly in the General Blood Administration Order "
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5675,
      "preview": "2. The patient's $A B O / R h$ type and antibody screen are required prior to receiving cross-matche"
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5677,
      "preview": "--- page 234 ---"
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5679,
      "preview": "order to confirm the ABO type to prevent ABO incompatible transfusion from misidentification errors."
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5680,
      "preview": "3. All cellular blood products (red blood cells and platelets) for newborn $<4$ months are irradiate"
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5681,
      "preview": "4. The patient's diagnosis should be indicated in the order. The required \"Comorbidity\" entry is typ"
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5682,
      "preview": "5. When blood products are needed within one hour of the order, place the order STAT."
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5683,
      "preview": "6. In case of an extreme emergency, providers should order uncrossmatched blood via the Emergency Re"
    },
    {
      "type": "text",
      "section": "A. General information",
      "line": 5684,
      "preview": "7. For blood ordering practices for ECMO, see NICU Guide Section II.B. 6 \"ECMO\"."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Packed red blood cells (PRBCs)",
      "line": 5686
    },
    {
      "type": "text",
      "section": "B. Packed red blood cells (PRBCs)",
      "line": 5688,
      "preview": "1. Patients typically receive $10-15 \\mathrm{~mL} / \\mathrm{kg}$ PBRCs depending on the starting and"
    },
    {
      "type": "text",
      "section": "B. Packed red blood cells (PRBCs)",
      "line": 5689,
      "preview": "2. Potassium leaks from PRBCs during storage, especially after irradiation. The amount of free potas"
    },
    {
      "type": "text",
      "section": "B. Packed red blood cells (PRBCs)",
      "line": 5690,
      "preview": "3. The hematocrit of PRBC transfusions is approximately $55-60 \\%$. Occasionally, \"dry\" PRBCs are in"
    },
    {
      "type": "text",
      "section": "B. Packed red blood cells (PRBCs)",
      "line": 5691,
      "preview": "4. Indications for PRBC transfusion are patient-specific. In general, the need for transfusion incre"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Fresh frozen plasma (FFP) and plasma frozen within 24 hrs (FP24)",
      "line": 5693
    },
    {
      "type": "text",
      "section": "C. Fresh frozen plasma (FFP) and plasma frozen within 24 hrs (FP24)",
      "line": 5695,
      "preview": "1. Fresh frozen plasma (FFP) is plasma frozen within 6-8 hrs of collection. It contains all coagulan"
    },
    {
      "type": "text",
      "section": "C. Fresh frozen plasma (FFP) and plasma frozen within 24 hrs (FP24)",
      "line": 5697,
      "preview": "--- page 235 ---"
    },
    {
      "type": "text",
      "section": "C. Fresh frozen plasma (FFP) and plasma frozen within 24 hrs (FP24)",
      "line": 5699,
      "preview": "2. FFP and FP24 are free of leukocytes, RBCs, and platelets. ABO-compatible plasma must be used. Rem"
    },
    {
      "type": "text",
      "section": "C. Fresh frozen plasma (FFP) and plasma frozen within 24 hrs (FP24)",
      "line": 5700,
      "preview": "3. The usual dose of FFP or F24 is $10-15 \\mathrm{~mL} / \\mathrm{kg}$ over 30 min , though longer in"
    },
    {
      "type": "text",
      "section": "C. Fresh frozen plasma (FFP) and plasma frozen within 24 hrs (FP24)",
      "line": 5701,
      "preview": "4. The indications for FFP include DIC, liver disease and therapeutic plasma exchange."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Platelets",
      "line": 5703
    },
    {
      "type": "text",
      "section": "D. Platelets",
      "line": 5705,
      "preview": "1. Platelets are available in \"apheresis\" units only at Stanford. Each apheresis unit is equivalent "
    },
    {
      "type": "text",
      "section": "D. Platelets",
      "line": 5706,
      "preview": "2. In some cases, only ABO-incompatible platelets will be available. If more than 15 mL of platelets"
    },
    {
      "type": "text",
      "section": "D. Platelets",
      "line": 5707,
      "preview": "3. The threshold for platelet transfusion varies according to the patient's clinical situation. Exam"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Cryoprecipitate AHF (Cryo)",
      "line": 5709
    },
    {
      "type": "text",
      "section": "E. Cryoprecipitate AHF (Cryo)",
      "line": 5711,
      "preview": "1. Cryoprecipitate AHF (anti-hemophilic factor) contains fibrinogen, factor VIII (8), von Willebrand"
    },
    {
      "type": "text",
      "section": "E. Cryoprecipitate AHF (Cryo)",
      "line": 5712,
      "preview": "2. Cryo is supplied in units of $10-15 \\mathrm{~mL}$. Neonates receive 1 unit per 10 kg of body weig"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Types of donated blood",
      "line": 5714
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Autologous donation",
      "line": 5716
    },
    {
      "type": "text",
      "section": "A. Autologous donation",
      "line": 5718,
      "preview": "Autologous donation occurs in the setting of anticipated transfusion, where an adult donates in adva"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Community donation",
      "line": 5720
    },
    {
      "type": "text",
      "section": "B. Community donation",
      "line": 5722,
      "preview": "Blood products (all blood types and components) are donated by volunteers who are not paid. All dono"
    },
    {
      "type": "text",
      "section": "B. Community donation",
      "line": 5724,
      "preview": "--- page 236 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Directed donation",
      "line": 5726
    },
    {
      "type": "text",
      "section": "C. Directed donation",
      "line": 5728,
      "preview": "1. Directed donation comes from a qualified donor who is a parent or other person chosen by the fami"
    },
    {
      "type": "text",
      "section": "C. Directed donation",
      "line": 5729,
      "preview": "2. Directed donations require a written order from a physician or nurse practitioner. A physician/NN"
    },
    {
      "type": "text",
      "section": "C. Directed donation",
      "line": 5730,
      "preview": "3. Order \"CMV negative\" (i.e., CMV antibody negative) blood for the following infants: <35 weeks ges"
    },
    {
      "type": "text",
      "section": "C. Directed donation",
      "line": 5732,
      "preview": "NOTE: Only about 50\\% of donors will be CMV antibody negative. If \"CMV negative\" is required for an "
    },
    {
      "type": "text",
      "section": "C. Directed donation",
      "line": 5734,
      "preview": "Normal full-term infants do not require CMV antibody negative blood components. All directed donatio"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "4. Considerations",
      "line": 5736
    },
    {
      "type": "text",
      "section": "4. Considerations",
      "line": 5738,
      "preview": "a. The shelf life of directed units may be shorter than units from community donors because all dire"
    },
    {
      "type": "text",
      "section": "4. Considerations",
      "line": 5739,
      "preview": "b. A mother may be permitted to donate red blood cells on behalf of her child if her hemoglobin is h"
    },
    {
      "type": "text",
      "section": "4. Considerations",
      "line": 5740,
      "preview": "c. All directed donors including the mother must be screened carefully with questions about risk fac"
    },
    {
      "type": "text",
      "section": "4. Considerations",
      "line": 5741,
      "preview": "d. Individuals with a history of pregnancy or transfusion are not permitted to donate plasma product"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Transfusion Reactions",
      "line": 5743
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5745,
      "preview": "A. Transfusion reactions are extremely rare in newborns. Symptoms of a transfusion reaction may incl"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5746,
      "preview": "B. In the event of any clinical problems during a blood transfusion, discontinue the transfusion, fi"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5748,
      "preview": "--- page 237 ---"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5750,
      "preview": "C. The On-call Physician for the Blood Center and Transfusion Service can be reached at pager 12027 "
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5751,
      "preview": "D. For other questions please contact:"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5753,
      "preview": "Jennifer Andrews, MD, MSc"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5754,
      "preview": "Clinical Assistant Professor of Pathology (Transfusion Medicine) and Pediatrics (Hematology/Oncology"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5755,
      "preview": "Stanford Hospital \\& Clinics and Lucile Packard Children's Hospital"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5756,
      "preview": "300 Pasteur Drive, H1401E"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5757,
      "preview": "Stanford, CA 94305"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5758,
      "preview": "Phone: 650-736-0788"
    },
    {
      "type": "text",
      "section": "IV. Transfusion Reactions",
      "line": 5759,
      "preview": "Email: jenandre@stanford.edu"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 5761
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5763,
      "preview": "1. Andrews J, Davis A, Fontaine M. Neonatal Anemia. In: Stevenson DL, Cohen RS, Sunshine P. Neonatol"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5764,
      "preview": "2. Roseff SD (Ed). Pediatric Transfusion: A Physician's Handbook. AABB, 2009"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5766,
      "preview": "--- page 238 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Clinical Approach to Unconjugated Hyperbilirubinemia",
      "line": 5768
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Vinod K. Bhutani and Ronald J. Wong",
      "line": 5770
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background \\& Definitions",
      "line": 5772
    },
    {
      "type": "text",
      "section": "I. Background \\& Definitions",
      "line": 5774,
      "preview": "Preterm and sick infants are at an increased risk for developing hyperbilirubinemia and long-term ne"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Clinical",
      "line": 5776
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5778,
      "preview": "1. Dependent Upon Age"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5779,
      "preview": "a. Newborns $\\geq 35$ wks gestational age (GA)"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5780,
      "preview": "i. Significant hyperbilirubinemia: TB > 95th percentile on the Bhutani nomogram"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5781,
      "preview": "ii. Severe hyperbilirubinemia: TB at level where phototherapy is recommended in the 2004 American Ac"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5782,
      "preview": "iii. Extreme hyperbilirubinemia: TB $>25 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5783,
      "preview": "b. Newborns < 35 weeks GA"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5784,
      "preview": "i. Significant hyperbilirubinemia: TB $>5 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5785,
      "preview": "ii. Severe hyperbilirubinemia: TB at level where phototherapy is recommended in the 2004 AAP Practic"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5786,
      "preview": "iii. Extreme hyperbilirubinemia: TB $>20 \\mathrm{mg} / \\mathrm{dL}$ (or at level; where exchange tra"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5787,
      "preview": "2. Clinical Risk Factors"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5788,
      "preview": "a. TB > 75th percentile ( $\\geq 35$ wks GA) on the Bhutani nomogram"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5789,
      "preview": "b. Neonatal hemolysis (intravascular or extravascular)"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5790,
      "preview": "c. Male"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5791,
      "preview": "d. Asian race"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5792,
      "preview": "e. Prematurity (increases with each early week preterm)"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5793,
      "preview": "f. Glucose-6-phosphate dehydrogenase (G6PD) deficiency (common in African-Americans, East Asians, Mi"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5794,
      "preview": "g. Sub-optimal breast milk intake or excessive weight loss ( $>6 \\%$ of BW)"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5796,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5798,
      "preview": "--- page 239 ---"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5800,
      "preview": "232 Part II-D: Hematology"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5801,
      "preview": "h. Early discharge (before age 72 hrs)"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 5802,
      "preview": "i. Family history of jaundice"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "3. Clinical Manifestations",
      "line": 5804
    },
    {
      "type": "text",
      "section": "3. Clinical Manifestations",
      "line": 5806,
      "preview": "Jaundice can be detected by using digital pressure to blanch the skin at the forehead, sternum, ilia"
    },
    {
      "type": "text",
      "section": "3. Clinical Manifestations",
      "line": 5807,
      "preview": "a. Onset of jaundice in first 24 hrs of life should be considered a sign of an excessive rate of ris"
    },
    {
      "type": "text",
      "section": "3. Clinical Manifestations",
      "line": 5808,
      "preview": "b. Jaundice is usually observed first in the face and then caudally in the trunk and extremities. It"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Testing",
      "line": 5810
    },
    {
      "type": "text",
      "section": "B. Testing",
      "line": 5812,
      "preview": "TB is measured in the serum or plasma. In term and late preterm infants, the TB level can be plotted"
    },
    {
      "type": "text",
      "section": "B. Testing",
      "line": 5814,
      "preview": "--- page 240 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5816
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5818,
      "preview": "| Biological Basis | Clinical Conditions |"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5819,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5820,
      "preview": "| $\\uparrow$ Bilirubin Production | Isoimmunization - Rh, ABO, and minor group incompatibilities <br"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5821,
      "preview": "| $\\uparrow$ Enterohepatic Circulation | Prematurity Starvation <br> Decreased Gl activity <br> Dela"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5822,
      "preview": "| $\\downarrow$ Bilirubin Elimination | Crigler-Najjar Syndrome Type 1: 2 - autosomal recessive mutat"
    },
    {
      "type": "text",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5824,
      "preview": "--- page 241 ---"
    },
    {
      "type": "text",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5826,
      "preview": "Table 2: Clinical Evaluation of the Jaundiced Infant $\\geq 35$ Wks' GA"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5828,
      "preview": "| Indication | Laboratory Assessment /Use of Clinical Toolkits |"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5829,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5830,
      "preview": "| Jaundice at age $<24$ hrs | Measure TB and/or TcB <br> Assess for neonatal hemolysis |"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5831,
      "preview": "| Jaundice excessive for infant's age | Measure TB and/or TcB |"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5832,
      "preview": "| TB $>40$ th percentile for age (18-60 hrs) | Measure TB for $\\mathrm{TcB}>12 \\mathrm{mg} / \\mathrm"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5833,
      "preview": "| Infant receiving phototherapy TB rising rapidly (such as crossing percentiles) <br> - Unexplained "
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5834,
      "preview": "| TB approaching exchange levels Failure of response to phototherapy | Reticulocyte count, G6PD, alb"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5835,
      "preview": "| Elevated direct bilirubin levels | Urinalysis and urine culture <br> Evaluate for sepsis indicated"
    },
    {
      "type": "table",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5836,
      "preview": "| Jaundice at age $>2$ wks or, a sick infant with jaundice | Total and direct (or conjugated) biliru"
    },
    {
      "type": "text",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5838,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5840,
      "preview": "--- page 242 ---"
    },
    {
      "type": "text",
      "section": "C. Table I: Differential Diagnosis of Unconjugated Hyperbilirubinemia",
      "line": 5842,
      "preview": "Strategies to rapidly reduce the bilirubin load are described in the 2004 AAP Practice Guideline, a "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "A. Interventions for TB Reduction",
      "line": 5844
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5846,
      "preview": "Interventions for TB Reduction"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5847,
      "preview": "Enteral Feeds"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5848,
      "preview": "Effective phototherapy"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5849,
      "preview": "Exchange transfusion"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5850,
      "preview": "Chemoprevention"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5852,
      "preview": "Choice of Approach"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5853,
      "preview": "Primary preventative strategy is to promote breastfeeding"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5854,
      "preview": "Requires hospitalization"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5855,
      "preview": "Assess individualized risk-benefit ratio; indicated for any clinical signs of ABE"
    },
    {
      "type": "text",
      "section": "A. Interventions for TB Reduction",
      "line": 5857,
      "preview": "Use of Intravenous Immunoglobulin (IVIG) for Rh disease and certain ABO incompatibilities"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Effective Phototherapy",
      "line": 5859
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Background Information",
      "line": 5861
    },
    {
      "type": "heading",
      "level": 2,
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5863
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5865,
      "preview": "The optimal light source is blue light within a narrow range wavelength ( $460-490 \\mathrm{~nm}$; su"
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5867,
      "preview": "--- page 243 ---"
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5869,
      "preview": "2. Table 3: Practice Considerations for Optimal Administration of Phototherapy"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5871,
      "preview": "| Parameters | Specific Interventions | Assessment |"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5872,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5873,
      "preview": "| Light source (nm) | Blue light (460 $\\pm 10 \\mathrm{~nm}$ ) | Use narrow wavelength spectral range"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5874,
      "preview": "| Light irradiance (dose) | Optimal irradiance: such as $>30$ <br> $\\mu \\mathrm{W} / \\mathrm{cm} 2 /"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5875,
      "preview": "| Body surface area <br> (BSA, cm2) | Close to the skin surface: one <br> surface (about 40\\% of BSA"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5876,
      "preview": "| Response | Assure efficacy of intervention | Degree of TB decline (1-2 mg/dL over 3 to 4 <br> hrs)"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5877,
      "preview": "| Interruption of therapy | May use intermittent <br> phototherapy (to allow breast <br> feeds) | Af"
    },
    {
      "type": "table",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5878,
      "preview": "| Duration | Discontinue at desired TB <br> threshold | Serial TB measurements defined by rate of <b"
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5880,
      "preview": "Figure 1. Guidelines for Intensive Phototherapy in Infants $>35$ wks GA"
    },
    {
      "type": "image",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5881,
      "content": "![img-41.jpeg](images/0483b55a8f601c87.png)"
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5882,
      "preview": "a. Use TB. Do not subtract direct reacting or conjugated bilirubin."
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5883,
      "preview": "b. Neurotoxicity risk factors = isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant "
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5885,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5887,
      "preview": "--- page 244 ---"
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5889,
      "preview": "c. For well infants 35 to $37^{6 / 7}$ wks, can adjust TB levels for intervention around the medium "
    },
    {
      "type": "text",
      "section": "THIS MODE OF TREATMENT DOES NOT EMIT UV LIGHT",
      "line": 5890,
      "preview": "d. It is an option to provide conventional phototherapy in hospital or at home at TB levels 2 to $3 "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5892
    },
    {
      "type": "text",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5894,
      "preview": "1. Assess for ABE (neurologic signs) regardless of the TB level"
    },
    {
      "type": "text",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5895,
      "preview": "2. Check TB/TcB and send labs (STAT)"
    },
    {
      "type": "text",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5896,
      "preview": "3. Conduct procedures while infant is under phototherapy"
    },
    {
      "type": "text",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5897,
      "preview": "4. Prepare for an exchange transfusion (look for line placement sites)"
    },
    {
      "type": "text",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5898,
      "preview": "5. Evaluate for concurrent dehydration (such as hypernatremia): IV infusions will not lower TB level"
    },
    {
      "type": "text",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5899,
      "preview": "6. Continue enteral feeds to decrease enterohepatic circulation of bilirubin. Breastfeeding can be d"
    },
    {
      "type": "text",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5901,
      "preview": "Table 4: Considerations for a \"Crash-Cart\" Approach"
    },
    {
      "type": "table",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5903,
      "preview": "| Options | Identify the most effective means to minimize brain damage |"
    },
    {
      "type": "table",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5904,
      "preview": "| :--: | :-- |"
    },
    {
      "type": "table",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5905,
      "preview": "| Risk | Weigh against the potential risk of ABE versus exchange transfusion |"
    },
    {
      "type": "table",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5906,
      "preview": "| Pre-treatment | Start total body phototherapy (while procedures are being done) <br> Consider IVIG"
    },
    {
      "type": "table",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5907,
      "preview": "| Procedure | Isovolume double volume exchange ( $170 \\mathrm{~mL} / \\mathrm{kg}$ in term, $190 \\mat"
    },
    {
      "type": "table",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5908,
      "preview": "| Duration | May be accomplished within 3 to 4 hrs (consent, labs, lines, and procedures) |"
    },
    {
      "type": "table",
      "section": "C. \"Crash-Cart\" Approach for an Infant Readmitted for Severe Hyperbilirubinemia",
      "line": 5909,
      "preview": "| Technical <br> problems | A single volume exchange transfusion may be adequate until technical pro"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5911
    },
    {
      "type": "text",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5913,
      "preview": "The primary strategy for clinical management of sick and preterm infants is prevention. Jaundice sho"
    },
    {
      "type": "text",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5915,
      "preview": "--- page 245 ---"
    },
    {
      "type": "text",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5917,
      "preview": "238 Part II-D: Hematology"
    },
    {
      "type": "text",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5918,
      "preview": "Table 5. Operational Thresholds to Manage Hyperbilirubinemia in Preterm Infants (<35 wks GA) for the"
    },
    {
      "type": "table",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5920,
      "preview": "| Stratification by GA | Operational TB Levels to Initiate <br> Phototherapy | Double Blood Volume E"
    },
    {
      "type": "table",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5921,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5922,
      "preview": "| $<28$ wks | 5 to $6 \\mathrm{mg} / \\mathrm{dL}$ | 11 to $14 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5923,
      "preview": "| 28 to 29 wks | 6 to $8 \\mathrm{mg} / \\mathrm{dL}$ | 12 to $14 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5924,
      "preview": "| 30 to 31 wks | 8 to $10 \\mathrm{mg} / \\mathrm{dL}$ | 13 to $16 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5925,
      "preview": "| 32 to 33 wks | 10 to $12 \\mathrm{mg} / \\mathrm{dL}$ | 15 to $18 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5926,
      "preview": "| $\\geq 34$ wks | 12 to $14 \\mathrm{mg} / \\mathrm{dL}$ | 17 to $19 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "text",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5928,
      "preview": "E. Use the lower range of the listed TB levels for infants at greater risk for bilirubin toxicity, e"
    },
    {
      "type": "text",
      "section": "D. Management of Hyperbilirubinemia in Sick and Preterm Infants",
      "line": 5929,
      "preview": "F. Recommendations for exchange transfusion apply to infants who are receiving intensive phototherap"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Table 6: Clinical Signs of Acute Bilirubinemia Encephalopathy",
      "line": 5931
    },
    {
      "type": "table",
      "section": "IV. Table 6: Clinical Signs of Acute Bilirubinemia Encephalopathy",
      "line": 5933,
      "preview": "| Severity of Clinical Signs | Mild | Moderate | Severe |"
    },
    {
      "type": "table",
      "section": "IV. Table 6: Clinical Signs of Acute Bilirubinemia Encephalopathy",
      "line": 5934,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "IV. Table 6: Clinical Signs of Acute Bilirubinemia Encephalopathy",
      "line": 5935,
      "preview": "| Mental Status | Sleepy <br> Poor feeding | Lethargic <br> Irritable | Stupor Seizures <br> Coma |"
    },
    {
      "type": "table",
      "section": "IV. Table 6: Clinical Signs of Acute Bilirubinemia Encephalopathy",
      "line": 5936,
      "preview": "| Muscle Tone | Neck stiffness <br> Mild hyper- or hypo-tonia | Arching neck Retrocolis <br> Arching"
    },
    {
      "type": "table",
      "section": "IV. Table 6: Clinical Signs of Acute Bilirubinemia Encephalopathy",
      "line": 5937,
      "preview": "| Cry Pattern | High pitched | Shrill | Inconsolable |"
    },
    {
      "type": "text",
      "section": "IV. Table 6: Clinical Signs of Acute Bilirubinemia Encephalopathy",
      "line": 5939,
      "preview": "--- page 246 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5941
    },
    {
      "type": "image",
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5943,
      "content": "![img-42.jpeg](images/5889c2bab708a745.png)"
    },
    {
      "type": "text",
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5945,
      "preview": "Link: Exchange Transfusion"
    },
    {
      "type": "text",
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5946,
      "preview": "VI. Post-Discharge Follow-Up is individualized to assess for rebound hyperbilirubinemia and prolonge"
    },
    {
      "type": "text",
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5948,
      "preview": "Developmental Follow-Up: Infants with TB $>25 \\mathrm{mg} / \\mathrm{dL}$ and those who receive an ex"
    },
    {
      "type": "text",
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5949,
      "preview": "A. Neurologic and neurodevelopmental evaluation: at discharge and within 3 mos"
    },
    {
      "type": "text",
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5950,
      "preview": "B. Neuroimaging with MRI at discharge."
    },
    {
      "type": "text",
      "section": "V. Figure 2: Rescue intervention: Exchange Transfusion",
      "line": 5951,
      "preview": "C. Auditory-evoked brainstem responses (ABR): at discharge and within 3 mos"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 5953
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5955,
      "preview": "1. Kramer LI. Advancement of dermal icterus in the jaundiced newborn. Am J Dis Child. 1969; 118:454-"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5956,
      "preview": "2. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilir"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5958,
      "preview": "--- page 247 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5960,
      "preview": "240 Part II-D: Hematology"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5961,
      "preview": "3. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 334:581-90."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5962,
      "preview": "4. American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. Clinical practice guideline: "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5963,
      "preview": "5. Bhutani VK, Committee on Fetus and Newborn. Technical Report: phototherapy to prevent severe neon"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5964,
      "preview": "6. Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubin"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 5966,
      "preview": "--- page 248 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Neonatal Thrombosis Work-up",
      "line": 5968
    },
    {
      "type": "text",
      "section": "Neonatal Thrombosis Work-up",
      "line": 5970,
      "preview": "Clara Lo, M.D., Bertil Glader, M.D., and Susan Hintz, M.D., M.S. Epi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 5972
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5974,
      "preview": "A. Infants are overall at lower risk for thrombosis than adults. However, severely ill neonates may "
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5976,
      "preview": "1. Indwelling central catheters and associated vascular damage"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5977,
      "preview": "2. Activation of coagulation in sepsis"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5978,
      "preview": "3. \"Low flow\" scenarios (e.g., shock, low cardiac output)"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5979,
      "preview": "4. Surgery/trauma"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5980,
      "preview": "5. Maternal diabetes mellitus"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5981,
      "preview": "6. Congenital heart disease"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5982,
      "preview": "7. Renal or hepatic function abnormalities"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5983,
      "preview": "B. Neonatal thrombosis is usually associated with line placements or attempts (umbilical, femoral/ca"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5984,
      "preview": "8. IVC, femoral veins, SVC"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5985,
      "preview": "9. CNS sinuses"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5986,
      "preview": "10. Aorta, femoral arteries, renal arteries"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5987,
      "preview": "11. Middle cerebral artery"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 5988,
      "preview": "C. Thrombosis may be multifactorial; however, a genetic/inherited thrombophilic condition may be pre"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Purpose of Suggested Guidelines for Work-up",
      "line": 5990
    },
    {
      "type": "text",
      "section": "II. Purpose of Suggested Guidelines for Work-up",
      "line": 5992,
      "preview": "To develop a strategy whereby meaningful diagnostic studies are consistently performed in infants wi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Suggested Guidelines",
      "line": 5994
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Patient identification",
      "line": 5996
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 5998,
      "preview": "1. Thrombi are most often identified in the neonatal period by an ultrasound obtained after clinical"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 5999,
      "preview": "2. There are no clear guidelines of the size, type or site of thrombus that should absolutely lead t"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 6001,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 6003,
      "preview": "--- page 249 ---"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 6005,
      "preview": "neonatal thrombophilia work-up. However, suggested scenarios that might prompt work-up include:"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 6006,
      "preview": "a. Unprovoked thromboemboli (i.e., no catheter or line attempts near the thrombus site) or is in any"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 6007,
      "preview": "b. Recurrent thromboemboli"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 6008,
      "preview": "c. A strong family history of thromboemboli (i.e., myocardial infarction or cerebrovascular accident"
    },
    {
      "type": "text",
      "section": "A. Patient identification",
      "line": 6009,
      "preview": "3. Recent literature indicates that a thrombophilia work-up is not indicated as part of the evaluati"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Approach",
      "line": 6011
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6013,
      "preview": "1. Obtain a thorough family clotting/ischemia history."
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6014,
      "preview": "2. Recommended \"special\" tests for a thrombophilia work-up include:"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6015,
      "preview": "a. Factor V Leiden: 1 ml blood/purple-top tube"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6016,
      "preview": "b. Prothrombin mutation analysis: 1 ml blood/purple-top tube"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6017,
      "preview": "c. Serum homocysteine concentration. If abnormal follow with MTHFR gene mutation analysis"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6018,
      "preview": "3. Consider a work-up on the mother:"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6019,
      "preview": "a. Lupus anticoagulant 3 ml blood/blue-top tube"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6020,
      "preview": "b. Antiphospholipid Ab 4 ml blood/red-top tube"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6021,
      "preview": "4. Protein C, Protein S, and Antithrombin III (AT III) levels in the neonate should usually be delay"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6022,
      "preview": "a. Homozygous Protein C and S deficiencies are clinically severe, usually presenting with purpura fu"
    },
    {
      "type": "text",
      "section": "B. Approach",
      "line": 6023,
      "preview": "b. Homozygous AT III deficiency is exceedingly rare since it is usually embryonic lethal."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Therapeutic Options",
      "line": 6025
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6027,
      "preview": "1. A Pediatric Hematology consult is strongly recommended when anticoagulation or thrombolytic thera"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6028,
      "preview": "2. Low molecular weight heparin (LMWH) has been used increasingly as the treatment of choice for ant"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6030,
      "preview": "--- page 250 ---"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6032,
      "preview": "a. Initial treatment dose:"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6033,
      "preview": "i. $<2$ mos: $1.5 \\mathrm{mg} / \\mathrm{kg} /$ dose $S Q$ every 12 hrs"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6034,
      "preview": "ii. $>2$ mos: $1 \\mathrm{mg} / \\mathrm{kg} /$ dose $S Q$ every 12 hrs"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6035,
      "preview": "b. Obtain first Anti-factor Xa level 4 hrs after third dose."
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6037,
      "preview": "| Anti-factor Xa <br> level | Dose Change | Repeat Anti-factor XA |"
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6038,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6039,
      "preview": "| $<0.35$ | Increase by $25 \\%$ | 4 hrs after next dose |"
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6040,
      "preview": "| $0.35-0.50$ | Increase by $10 \\%$ | 4 hrs after next dose |"
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6041,
      "preview": "| $0.50-1.00$ | No change | Next day, then weekly |"
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6042,
      "preview": "| $1.00-1.50$ | Decrease by <br> $20 \\%$ | Before next dose |"
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6043,
      "preview": "| $1.50-2.00$ | Decrease by <br> $30 \\%$ | DELAY next dose by 3 hrs; repeat level before next dose, "
    },
    {
      "type": "table",
      "section": "C. Therapeutic Options",
      "line": 6044,
      "preview": "| $>2.00$ | HOLD next dose, then repeat every 12 hrs until level $<0.50$; restart at $40 \\%$ <br> lo"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6046,
      "preview": "c. Length of enoxaparin therapy: Length of therapy should be tailored based on observation of clot r"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6047,
      "preview": "d. Local and systemic treatment with tissue plasminogen activator (tPA) has been reported in childre"
    },
    {
      "type": "text",
      "section": "C. Therapeutic Options",
      "line": 6048,
      "preview": "e. The Hospital for Sick Children in Toronto has a helpful \"hemostasis hotline\" for diagnostic and t"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 6050
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6052,
      "preview": "1. Yang, JY, Chan AK. Neonatal systemic venous thrombosis. Thromb Res. 2010 Dec;126(6)471-6."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6053,
      "preview": "2. Yang JY, Chan AK, Callen DJ, Paes BA. Neonatal cerebral sinovenous thrombosis: sifting the eviden"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6054,
      "preview": "3. Nowak-G\u00f6ttl U, Janssen V, Manner D, Kenet G. Venous thromboembolism in neonates and children-upda"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6056,
      "preview": "--- page 251 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6058,
      "preview": "244 Part II-D: Hematology"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6059,
      "preview": "4. Bhat R, Monagle P. The preterm infant with thrombosis. Arch Dis Child Fetal Neonatal Ed. 2012 Nov"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6060,
      "preview": "5. Haley K. Neonatal Venous Thromboembolism. Frontiers in Pediatrics. 2017 June; 5(136): 1-6."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6061,
      "preview": "6. Curtis C, Mineyko A, Massicotte P, Leaker M, Jian X, Floer A, and Kirston A. Thrombophilia risk i"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6063,
      "preview": "--- page 252 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Thrombocytopenia",
      "line": 6065
    },
    {
      "type": "text",
      "section": "Thrombocytopenia",
      "line": 6067,
      "preview": "Janene H. Fuerch M.D."
    },
    {
      "type": "text",
      "section": "Thrombocytopenia",
      "line": 6068,
      "preview": "I. Definition: Thrombocytopenia is defined as a platelet count under 150,000/ $\\mu$ l. It is classif"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiology:",
      "line": 6070
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6072,
      "preview": "A. If the infant is sick, preterm or has medical complications consider:"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6074,
      "preview": "1. Sepsis (bacterial, viral)"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6075,
      "preview": "2. Necrotizing Enterocolitis"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6076,
      "preview": "3. Disseminated Intravascular Coagulation (DIC)"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6077,
      "preview": "4. TORCH infections"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6078,
      "preview": "5. Birth asphyxia"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6079,
      "preview": "6. Inborn error of metabolism (e.g. propionic academia and methyl-malonic academia)"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6080,
      "preview": "B. If the infant is well appearing and has no congenital anomalies or dysmorphic features consider:"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6081,
      "preview": "7. Maternal pre-eclampsia: Evidence suggests thrombocytopenia is due to disruption of hematopoietic "
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6082,
      "preview": "8. Maternal autoimmune thrombocytopenia: The diagnosis should be considered in any infant with throm"
    },
    {
      "type": "text",
      "section": "II. Etiology:",
      "line": 6083,
      "preview": "9. Neonatal alloimmune thrombocytopenia (NAIT): Early-onset (<72 hours) marked thrombocytopenia in a"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. If the neonate has physical abnormalities or dymorphic features consider:",
      "line": 6085
    },
    {
      "type": "text",
      "section": "C. If the neonate has physical abnormalities or dymorphic features consider:",
      "line": 6087,
      "preview": "1. Kasabach-Merritt syndrome: Platelets are sequestered in a vascular malformation (hemangiomas), le"
    },
    {
      "type": "text",
      "section": "C. If the neonate has physical abnormalities or dymorphic features consider:",
      "line": 6088,
      "preview": "2. Trisomies (3, 18, 21, or Turner syndrome)."
    },
    {
      "type": "text",
      "section": "C. If the neonate has physical abnormalities or dymorphic features consider:",
      "line": 6089,
      "preview": "3. Fanconi anemia: Form of aplastic anemia associated with a variety of congenital anomalies, such a"
    },
    {
      "type": "text",
      "section": "C. If the neonate has physical abnormalities or dymorphic features consider:",
      "line": 6091,
      "preview": "--- page 253 ---"
    },
    {
      "type": "text",
      "section": "C. If the neonate has physical abnormalities or dymorphic features consider:",
      "line": 6093,
      "preview": "4. TAR (thrombocytopenia absent radius) syndrome: An autosomal recessive disorder characterized by t"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Approach",
      "line": 6095
    },
    {
      "type": "text",
      "section": "III. Approach",
      "line": 6097,
      "preview": "A. Confirm the platelet count with a repeat sample from a peripheral vein and also careful review of"
    },
    {
      "type": "text",
      "section": "III. Approach",
      "line": 6098,
      "preview": "B. Review maternal history for PIH, pre-eclampsia, HELLP syndrome, IUGR, ITP, SLE, maternal medicati"
    },
    {
      "type": "text",
      "section": "III. Approach",
      "line": 6099,
      "preview": "C. Is the neonate term, preterm or IUGR?"
    },
    {
      "type": "text",
      "section": "III. Approach",
      "line": 6100,
      "preview": "D. Is the neonate well appearing or sick? Thrombocytopenia can be the first presenting sign of a ser"
    },
    {
      "type": "text",
      "section": "III. Approach",
      "line": 6101,
      "preview": "E. Congenital anomalies or dysmorphic features?"
    },
    {
      "type": "text",
      "section": "III. Approach",
      "line": 6102,
      "preview": "F. Bruising, mucosal bleeding or petechiae?"
    },
    {
      "type": "text",
      "section": "III. Approach",
      "line": 6103,
      "preview": "G. If NAIT is suspected then blood should be collected from father and mother for confirmatory testi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Platelet transfusion guidelines",
      "line": 6105
    },
    {
      "type": "text",
      "section": "IV. Platelet transfusion guidelines",
      "line": 6107,
      "preview": "A. Transfuse platelets to preterm neonates ( $<33$ weeks) and to clinically unstable term infants du"
    },
    {
      "type": "text",
      "section": "IV. Platelet transfusion guidelines",
      "line": 6108,
      "preview": "B. After the first postnatal week, the threshold can be lowered to $30 \\times 10^{9} / \\mathrm{L}$ i"
    },
    {
      "type": "text",
      "section": "IV. Platelet transfusion guidelines",
      "line": 6110,
      "preview": "--- page 254 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 6112
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6114,
      "preview": "1. Van Der Lugt NM, van Kampen A, Walther FJ, Brand A, Lopriore E. Outcome and management in neonata"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6115,
      "preview": "2. Kiefel V, Bassler D, Kroll H, Paes B, Giers G, Ditomasso J, et al. Antigen-positive platelet tran"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6116,
      "preview": "3. Mueller-Eckhardt C, Kiefel V, Grubert A. High-dose IgG treatment for neonatal alloimmune thromboc"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6117,
      "preview": "4. Kamphuis MM, Paridaans NP, Porcelijn L, Lopriore E, Oepkes D. Incidence and consequences of neona"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6118,
      "preview": "5. Peterson JA, McFarland JG, Curtis BR, Aster RH. Neonatal alloimmune thrombocytopenia: pathogenesi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6120,
      "preview": "--- page 255 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-E: Infection",
      "line": 6122
    },
    {
      "type": "text",
      "section": "Part II-E: Infection",
      "line": 6124,
      "preview": "--- page 256 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "NICU Infection/Hand Hygiene Policy",
      "line": 6126
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Kari McCallie, M.D. and Amy Valencia, C.H.S.P, C.I.C.",
      "line": 6128
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Purpose",
      "line": 6130
    },
    {
      "type": "text",
      "section": "I. Purpose",
      "line": 6132,
      "preview": "The Johnson Center nurseries follow sound infection control policies as described in the Infection P"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Personnel Practices",
      "line": 6134
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Healthy Workforce",
      "line": 6136
    },
    {
      "type": "text",
      "section": "A. Healthy Workforce",
      "line": 6138,
      "preview": "1. All personnel shall be free of respiratory, gastrointestinal, skin or other infections. If an emp"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6140
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6142,
      "preview": "1. Wash hands with soap and water for at least 15 seconds"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6143,
      "preview": "a. When hands are visibly dirty or contaminated"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6144,
      "preview": "b. After contact with patients on Contact Plus isolation (infected with Clostridium difficile, Norov"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6145,
      "preview": "c. Before and after eating"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6146,
      "preview": "d. After using the restroom"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6147,
      "preview": "e. Procedure:"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6148,
      "preview": "i. Wet hands -- avoid using hot water, as repeated exposure to hot water may increase the risk of de"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6149,
      "preview": "ii. Apply soap to hands"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6150,
      "preview": "iii. Rub hands together vigorously for at least 15 seconds, covering all surfaces of fingers and han"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6151,
      "preview": "iv. Rinse with water"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6152,
      "preview": "v. Dry thoroughly with a disposable towel"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6153,
      "preview": "vi. Use disposable towel to turn off the faucet (if not an automatic or foot-controlled faucet)"
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6154,
      "preview": "vii. It is recommended to apply hospital-approved hand lotion to lower the risk of dermatitis."
    },
    {
      "type": "text",
      "section": "B. Personnel must observe strict hand washing/cleansing",
      "line": 6155,
      "preview": "2. Clean hands with alcohol-based hand rub for routine decontamination of hands that are not visibly"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "a. Procedure:",
      "line": 6157
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6159,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6161,
      "preview": "--- page 257 ---"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6163,
      "preview": "i. Apply the product to palm of one hand and rub hands palm to palm"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6164,
      "preview": "ii. Rub all surfaces of hands, fingers, and wrists for at least 15 seconds. See the 7 steps of handw"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6165,
      "preview": "3. 7 Steps of Handwashing"
    },
    {
      "type": "image",
      "section": "a. Procedure:",
      "line": 6166,
      "content": "![img-43.jpeg](images/a6f72b9f463fbd74.png)"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6167,
      "preview": "4. If hands are not visibly dirty, use an alcohol-based hand rub or soap and water in the following "
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6168,
      "preview": "a. Before direct contact with patients and entering the patient room or patient zone- even if you do"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6169,
      "preview": "b. Before a clean/aseptic/sterile procedure"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6170,
      "preview": "c. After contact with bodily fluids or excretions, mucous membranes, non-intact skin, and wound dres"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6171,
      "preview": "d. After touching a patient"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6172,
      "preview": "e. After contact with inanimate objects (including medical equipment and counters) in the patient su"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6173,
      "preview": "C. Personnel must wear gloves when contact could occur with blood or other potentially infectious ma"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6175,
      "preview": "1. Hand hygiene should be performed before donning gloves"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6176,
      "preview": "2. Remove and discard gloves after caring for a patient, then immediately perform hand hygiene"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6177,
      "preview": "3. Do not wear the same pair of gloves for the care of more than one patient, and do not wash gloves"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6178,
      "preview": "4. Change gloves during patient care if moving from a contaminated body site to a clean body site"
    },
    {
      "type": "text",
      "section": "a. Procedure:",
      "line": 6180,
      "preview": "--- page 258 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Jewelry and Clothing Policy",
      "line": 6182
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6184,
      "preview": "1. No artificial nails or nail enhancements including acrylics, gels, overlays, tips, nail wraps, an"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6185,
      "preview": "2. No chipped nail polish"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6186,
      "preview": "3. Long sleeves must rolled up to the elbow when performing hand hygiene and when in a patient room "
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6187,
      "preview": "a. Even if you are not going to touch a patient, if you are entering a patient care room in an ICU s"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6188,
      "preview": "b. No sweatshirts, fleeces, long-sleeve hoodies, white coats, etc. in patient care areas"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6189,
      "preview": "i. Any long sleeves over a scrub/short-sleeve top should be taken off"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6190,
      "preview": "ii. Any long sleeves under a scrub/short-sleeve top, or any street clothes, should be rolled up to t"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6191,
      "preview": "iii. If you run cold, vests are recommended, or ask the unit clerk to call to have the ambient tempe"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6192,
      "preview": "4. Any neck ties should be tucked into the shirt"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6193,
      "preview": "5. Hand, wrist, or arm jewelry and watches are not allowed during contact with patients, except one "
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6194,
      "preview": "a. If a ring is worn, the skin beneath the ring and the ring itself must be disinfected as part of t"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6195,
      "preview": "b. Safety pins are available in all patient care areas to secure rings to clothing"
    },
    {
      "type": "text",
      "section": "D. Jewelry and Clothing Policy",
      "line": 6196,
      "preview": "6. Hair that is longer than chin length must be pulled back"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Environmental Cleanliness",
      "line": 6198
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Daily Shift Cleaning",
      "line": 6200
    },
    {
      "type": "text",
      "section": "A. Daily Shift Cleaning",
      "line": 6202,
      "preview": "1. Upon start of shift and if soiled, areas in the patient room or patient zone must be disinfected "
    },
    {
      "type": "text",
      "section": "A. Daily Shift Cleaning",
      "line": 6203,
      "preview": "2. Disinfect counters and shared island counter surfaces prior to medication preparation or other cl"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 6205
    },
    {
      "type": "text",
      "section": "References",
      "line": 6207,
      "preview": "1. Guidelines on Hand Hygiene in Health Care; World Health Organization (WHO); 2009. http://whqlibdo"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6209,
      "preview": "--- page 259 ---"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6211,
      "preview": "252 Part II-E: Infection"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6212,
      "preview": "2. Guideline for Hand Hygiene in Health-Care Settings Recommendations of the Healthcare Infection Co"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6213,
      "preview": "3. LPCH Hand Hygiene Policy (IPC Manual)"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6214,
      "preview": "4. LPCH Work Restrictions for Suspected or Confirmed Contagious Infections or Conditions Policy (IPC"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6215,
      "preview": "5. LPCH Isolation- Transmission Based Precautions and Standard Precautions Policy (IPC Manual)"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6216,
      "preview": "6. LPCH Cleaning of Patient Equipment (Non-Critical Items) Policy (IPC Manual)"
    },
    {
      "type": "text",
      "section": "References",
      "line": 6218,
      "preview": "--- page 260 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Suspected Sepsis in Newborn Infants",
      "line": 6220
    },
    {
      "type": "text",
      "section": "Suspected Sepsis in Newborn Infants",
      "line": 6222,
      "preview": "William Benitz, M.D. and Arun Gupta, M.D."
    },
    {
      "type": "text",
      "section": "Suspected Sepsis in Newborn Infants",
      "line": 6224,
      "preview": "Suspected sepsis may be the most common working diagnosis in neonatal medicine. Bacterial infection "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Management Principles",
      "line": 6226
    },
    {
      "type": "text",
      "section": "I. Management Principles",
      "line": 6228,
      "preview": "Our approach to management of infants is based on three core principles:"
    },
    {
      "type": "text",
      "section": "I. Management Principles",
      "line": 6229,
      "preview": "A. Prevent infection whenever possible"
    },
    {
      "type": "text",
      "section": "I. Management Principles",
      "line": 6230,
      "preview": "B. Identify and treat bacterial infection early and consistently"
    },
    {
      "type": "text",
      "section": "I. Management Principles",
      "line": 6231,
      "preview": "C. Focus or stop antibiotic therapy as soon as possible"
    },
    {
      "type": "text",
      "section": "I. Management Principles",
      "line": 6233,
      "preview": "Strategies for pursuit of these goals are outlined below."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6235
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6237,
      "preview": "A. Early-Onset Sepsis"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6239,
      "preview": "Early-onset sepsis is defined as invasive bacterial infection occurring in the first 3 days after bi"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6241,
      "preview": "Figure 1. Bacteriology of early-onset neonatal sepsis. A. Culture-proven cases < 72 hrs of age. B. R"
    },
    {
      "type": "image",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6242,
      "content": "![img-44.jpeg](images/4772ed0e030001cb.png)"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6244,
      "preview": "--- page 261 ---"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6246,
      "preview": "254 Part II-E: Infection"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6247,
      "preview": "B. Hospital Acquired Late-Onset Sepsis"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6248,
      "preview": "a. Hospital acquired infection (HAI), including late-onset sepsis, is defined as invasive bacterial "
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6250,
      "preview": "Figure 2. The bacteriology of hospital acquired late-onset sepsis. Data from Perlman, 2007."
    },
    {
      "type": "image",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6251,
      "content": "![img-45.jpeg](images/d288713f5412a281.png)"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6252,
      "preview": "C. Community Acquired Late-Onset Sepsis"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6254,
      "preview": "Community acquired late-onset sepsis is defined as invasive bacterial infection occurring on days 4 "
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6256,
      "preview": "Figure 3. The bacteriology of community acquired late-onset sepsis. A. Culture-proven cases 3-28 day"
    },
    {
      "type": "image",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6257,
      "content": "![img-46.jpeg](images/5c70c814a0970063.png)"
    },
    {
      "type": "text",
      "section": "II. Classification of Neonatal Sepsis",
      "line": 6259,
      "preview": "--- page 262 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Prevention of Neonatal Infections",
      "line": 6261
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Early Onset Sepsis",
      "line": 6263
    },
    {
      "type": "text",
      "section": "A. Early Onset Sepsis",
      "line": 6265,
      "preview": "The landscape for Early Onset Sepsis has changed, and what was once a frequent occurrence now has an"
    },
    {
      "type": "text",
      "section": "A. Early Onset Sepsis",
      "line": 6267,
      "preview": "Figure 4. Impact of intrapartum prophylaxis on early-onset group B streptococcal sepsis."
    },
    {
      "type": "image",
      "section": "A. Early Onset Sepsis",
      "line": 6268,
      "content": "![img-47.jpeg](images/77e131f52d9bb115.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Hospital Acquired Late Onset Sepsis",
      "line": 6270
    },
    {
      "type": "text",
      "section": "B. Hospital Acquired Late Onset Sepsis",
      "line": 6272,
      "preview": "Adoption of the CLABSI prevention \"bundle\" and assiduous attention to minimizing antibiotic days in "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Community Acquired Late Onset Sepsis",
      "line": 6274
    },
    {
      "type": "text",
      "section": "C. Community Acquired Late Onset Sepsis",
      "line": 6276,
      "preview": "No strategies are known to be effective for prevention of community acquired late-onset neonatal inf"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6278
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6280,
      "preview": "A. Sepsis should be suspected in babies with the risk indicators or clinical findings listed in Tabl"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6281,
      "preview": "B. Treatment for suspected sepsis has traditionally been based on risk factors (such as those listed"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6283,
      "preview": "1. Some risk factors, such as chorioamnionitis, may warrant the need for closer monitoring after bir"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6284,
      "preview": "2. Although some risk factors may be associated with increased risk for early-onset sepsis, none hav"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6286,
      "preview": "--- page 263 ---"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6288,
      "preview": "256 Part II-E: Infection"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6289,
      "preview": "Table 1. Risk Factors and Clinical Signs of Neonatal Sepsis"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6291,
      "preview": "| Risk Factors | Clinical Signs |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6292,
      "preview": "| :-- | :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6293,
      "preview": "| Early-Onset Sepsis | Behavioral | Thermoregulatory | Cutaneous |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6294,
      "preview": "| PPROM | Lethargy | Fever | Jaundice |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6295,
      "preview": "| Preterm labor | Irritability | Hypothermia | Petechiae |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6296,
      "preview": "| Chorioamnionitis | Poor feeding |  | Purpura |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6297,
      "preview": "| Prior infant with GBS |  | Gastrointestinal | Pustules |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6298,
      "preview": "| Maternal GBS bacteruria | Respiratory | Vomiting (bilious!) | Cellulitis |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6299,
      "preview": "| Maternal GBS colonization | Apnea | Feeding intolerance | Exfoliation |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6300,
      "preview": "| PROM > 18 hours | Grunting, flaring | Distended abdomen |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6301,
      "preview": "| Intrapartum fever $>38^{\\circ} \\mathrm{C}$ | Tachypnea | Diarrhea | Metabolic |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6302,
      "preview": "| Lack of GBS-specific Ab | Retractions | Hematochezia | Hypoglycemia |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6303,
      "preview": "|  | Cyanosis | Hepatomegaly | Hyperglycemia |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6304,
      "preview": "| Hospital Acquired Sepsis |  | Splenomegaly | Hyperlipidemia |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6305,
      "preview": "| Extreme prematurity | Circulatory |  | Hyponatremia |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6306,
      "preview": "| Prolonged antibiotic use | Poor perfusion | Neurologic | Acidosis |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6307,
      "preview": "| Prolonged TPN | Congestive failure | Jitteriness |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6308,
      "preview": "| Indwelling catheters | Shock | Seizures |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6309,
      "preview": "| Postnatal steroid exposure |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6310,
      "preview": "| Gastric anti-secretory drugs |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6311,
      "preview": "| Surgical conditions |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6312,
      "preview": "| Community Acquired Sepsis |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6313,
      "preview": "| Prematurity |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6314,
      "preview": "| Maternal GBS colonization |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6315,
      "preview": "| Lack of GBS-specific Ab |  |  |  |"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6317,
      "preview": "C. The diagnostic evaluation of infants with suspected sepsis includes both indirect and definitive "
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6319,
      "preview": "Table 2: Performance of Individual Hematologic Tests for Early-Onset Sepsis"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6321,
      "preview": "| Test | Sensitivity | Specificity | PPV | NPV |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6322,
      "preview": "| :-- | :-- | :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6323,
      "preview": "| I:T $>0.15^{*}$ | $96 \\%$ | $71 \\%$ | $25 \\%$ | $99 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6324,
      "preview": "| $\\uparrow$ or $\\downarrow$ PMNs* | $96 \\%$ | $61 \\%$ | $20 \\%$ | $99 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6325,
      "preview": "| I:M $\\geq 0.3$ | $93 \\%$ | $81 \\%$ | $32 \\%$ | $99 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6326,
      "preview": "| Bands $>1500^{*}$ | $63 \\%$ | $69 \\%$ | $17 \\%$ | $95 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6327,
      "preview": "| $\\uparrow$ or $\\downarrow$ WBC $\\uparrow$ | $44 \\%$ | $92 \\%$ | $36 \\%$ | $94 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6328,
      "preview": "| WBC degenerative changes** | $33 \\%$ | $95 \\%$ | $39 \\%$ | $93 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6329,
      "preview": "| Platelets $\\leq 150,000$ | $22 \\%$ | $99 \\%$ | $60 \\%$ | $93 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6330,
      "preview": "| * based on data of Manroe, J Pediatr, 1979, as shown in Figure 6 |  |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6331,
      "preview": "| $\\uparrow$ WBC $\\leq 5 \\mathrm{~K}$ or $\\geq 25 \\mathrm{~K}, 30 \\mathrm{~K}$, or 21 K at birth, 12"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6333,
      "preview": "[^0]"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6334,
      "preview": "[^0]:    This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile "
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6336,
      "preview": "--- page 264 ---"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6338,
      "preview": "Figure 5. Normal white blood cell counts for newborn infants. From Manroe, J Pediatr, 1979."
    },
    {
      "type": "image",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6339,
      "content": "![img-48.jpeg](images/f7f02badf3396f62.png)"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6341,
      "preview": "The performance of blood counts can be improved by combining observations into a hematological score"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6343,
      "preview": "Table 3. Performance of Hematological Scoring System for Early-Onset Sepsis (Rodwell, J Pediatr, 198"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6345,
      "preview": "| Score* | Sensitivity | Specificity | PPV | NPV |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6346,
      "preview": "| :-- | :-- | :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6347,
      "preview": "| $\\geq 1$ | $100 \\%$ | $41 \\%$ | $14 \\%$ | $100 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6348,
      "preview": "| $\\geq 2$ | $100 \\%$ | $63 \\%$ | $21 \\%$ | $100 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6349,
      "preview": "| $\\geq 3$ | $96 \\%$ | $78 \\%$ | $31 \\%$ | $99 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6350,
      "preview": "| $\\geq 4$ | $89 \\%$ | $89 \\%$ | $45 \\%$ | $99 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6351,
      "preview": "| $\\geq 5$ | $41 \\%$ | $96 \\%$ | $52 \\%$ | $94 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6352,
      "preview": "| $\\geq 6$ | $22 \\%$ | $100 \\%$ | $86 \\%$ | $93 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6353,
      "preview": "| *1 point each for I:T $>0.15, \\uparrow$ or $\\downarrow$ neutrophils, I:M $\\geq 0.3$, bands $>1500 "
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6354,
      "preview": "| WBC, degenerative WBC $\\Delta$, or platelets $\\leq 150,000 ; 2$ points for no circulating |  |  | "
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6355,
      "preview": "| neutrophils (see Table 2) |  |  |  |  |"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6357,
      "preview": "If laboratory evaluation for early onset sepsis is warranted, delayed hematological testing at 12-24"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6359,
      "preview": "Table 4. Performance of Delayed Blood Counts in Early-Onset Sepsis (Greenberg, Pediatr Infect Dis J,"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6361,
      "preview": "|  | Sensitivity | Specificity | PPV | NPV |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6362,
      "preview": "| :-- | :-- | :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6363,
      "preview": "| Initial: |  |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6364,
      "preview": "| Manroe | $68 \\%$ | $45 \\%$ | $43 \\%$ | $70 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6365,
      "preview": "| Rodwell | $63 \\%$ | $55 \\%$ | $46 \\%$ | $71 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6366,
      "preview": "| At 12-24 hours: |  |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6367,
      "preview": "| Manroe | $100 \\%$ | $50 \\%$ | $56 \\%$ | $100 \\%$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6368,
      "preview": "| Rodwell | $100 \\%$ | $73 \\%$ | $73 \\%$ | $100 \\%$ |"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6370,
      "preview": "There is little evidence that screening tests add to serial examinations every 2 to 4 hours over the"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6372,
      "preview": "--- page 265 ---"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6374,
      "preview": "D. Definitive diagnosis of neonatal sepsis requires cultures, which should be obtained from each of "
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6376,
      "preview": "- blood, whenever antibiotics are initiated or changed to broaden antibacterial coverage"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6377,
      "preview": "- endotracheal aspirates, from babies with respiratory distress and a pulmonary infiltrate who are n"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6378,
      "preview": "- urine, in neonates $>72$ hours of age"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6379,
      "preview": "- cerebrospinal fluid, in neonates with clinical signs of illness or a positive blood culture"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6381,
      "preview": "1. Blood Cultures - True-positive blood cultures are very likely to be positive after incubation for"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6383,
      "preview": "Figure 6. Utility of bacterial cultures in suspected neonatal sepsis. A. Time to detection of positi"
    },
    {
      "type": "image",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6384,
      "content": "![img-49.jpeg](images/39ebd4f284dcc5c3.png)"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6385,
      "preview": "2. Tracheal cultures - Cultures of tracheal aspirates are valuable adjuncts to blood cultures in inf"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6387,
      "preview": "--- page 266 ---"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6389,
      "preview": "3. Urine cultures - Urine cultures obtained in the first 72 hours after birth are unlikely to produc"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6390,
      "preview": "4. Cerebrospinal fluid - CSF should be obtained in any infant with clinical signs of illness or posi"
    },
    {
      "type": "text",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6392,
      "preview": "Table 5. 95\\% Confidence Intervals for Cerebrospinal Fluid Analyses in Neonates (Srinivasan, J Pedia"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6394,
      "preview": "|  | Preterm Infants |  | Term Infants |  |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6395,
      "preview": "| :-- | :-- | :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6396,
      "preview": "| Analyte | $\\leq 7$ days old | $>7$ days old | $\\leq 7$ days old | $>7$ days old |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6397,
      "preview": "| White blood cell count $(\\mu \\mathrm{L})$ | $\\leq 18$ | $\\leq 12$ | $\\leq 23$ | $\\leq 32$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6398,
      "preview": "| Glucose $(\\mathrm{mg} / \\mathrm{dL})$ | $\\geq 33$ | $\\geq 33$ | $\\geq 35$ | $\\geq 38$ |"
    },
    {
      "type": "table",
      "section": "IV. Diagnosis of Neonatal Sepsis",
      "line": 6399,
      "preview": "| Protein $(\\mathrm{mg} / \\mathrm{dL})$ | $\\leq 213$ | $\\leq 203$ | $\\leq 137$ | $\\leq 158$ |"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6401
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6403,
      "preview": "A. Empiric Initial Treatment"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6405,
      "preview": "Initial antibiotic coverage should be based on the bacteriology of each category of neonatal sepsis "
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6407,
      "preview": "--- page 267 ---"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6409,
      "preview": "260 Part II-E: Infection"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6410,
      "preview": "Table 6. Empiric Initial Treatment for Suspected Neonatal Sepsis"
    },
    {
      "type": "table",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6412,
      "preview": "| Patient Category | Initial Empiric Antibiotic Choice |"
    },
    {
      "type": "table",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6413,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6414,
      "preview": "| Early-onset sepsis | Ampicillin and gentamicin |"
    },
    {
      "type": "table",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6415,
      "preview": "| Hospital acquired late-onset sepsis | Nafcillin and gentamicin (see Appendix) |"
    },
    {
      "type": "table",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6416,
      "preview": "| Community acquired late-onset sepsis | Ampicillin and gentamicin (consider cefotaxime in <br> plac"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6418,
      "preview": "Use of cefotaxime rather than gentamicin for early-onset neonatal sepsis is associated with higher m"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6420,
      "preview": "Figure 7. Empiric treatment with cefotaxime is associated with higher mortality rates in infants wit"
    },
    {
      "type": "image",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6421,
      "content": "![img-50.jpeg](images/c66094dbbf8fb840.png)"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6423,
      "preview": "Figure 8. Early-onset neonatal sepsis caused by ampicillin-resistant E. coli is more likely to occur"
    },
    {
      "type": "image",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6424,
      "content": "![img-51.jpeg](images/6afb15b72f2e97ca.png)"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6426,
      "preview": "Cefotaxime should be considered (either instead of or in addition to gentamicin) in sick preterm inf"
    },
    {
      "type": "text",
      "section": "V. Treatment of Neonatal Sepsis",
      "line": 6428,
      "preview": "Signs of skin or soft tissue infection, endocarditis, or osteomyelitis should raise concern for poss"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Adjustment of Treatment",
      "line": 6430
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6432,
      "preview": "If changes are made to antibiotic coverage because of an unsatisfactory response to empiric therapy,"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6433,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6435,
      "preview": "--- page 268 ---"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6437,
      "preview": "vancomycin). Remember that third-generation cephalosporins and carbapenems do not provide good cover"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6439,
      "preview": "Isolation of the causative organism from a nonpermissive site (see above) should prompt immediate na"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6441,
      "preview": "Table 7. Responses to Selected Positive Nonpermissive Culture Results"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6443,
      "preview": "| Bacterial Isolate Reported | Response to Consider |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6444,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6445,
      "preview": "| Gram-negative bacilli | Stop ampicillin, nafcillin or vancomycin |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6446,
      "preview": "| Gram-positive bacilli | Stop gentamicin or cefotaxime |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6447,
      "preview": "| Gram-negative cocci in pairs |  |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6448,
      "preview": "| Gram-positive cocci in pairs or chains | Stop gentamicin or cefotaxime |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6449,
      "preview": "| Gram-positive cocci in clusters | Stop gentamicin or cefotaxime, add vancomycin if not <br> clinic"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6450,
      "preview": "| Group B streptococci | Gentamicin (x 3 d), penicillin or ampicillin course |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6451,
      "preview": "| Staph. aureus, methicillin-sensitive (MSSA) | Change to cefazolin or nafcillin |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6452,
      "preview": "| Staph. aureus, methicillin-resistant (MRSA) | Change or narrow coverage to vancomycin |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6453,
      "preview": "| Coagulase- negative Staph. | Change or narrow coverage to vancomycin according to <br> sensitivity"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6454,
      "preview": "| Enterococcus, pencillin-sensitive | Change to penicillin + gentamicin |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6455,
      "preview": "| Enterococcus, vancomycin-sensitive | Change to vancomycin |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6456,
      "preview": "| Enterococcus, vancomycin-resistant (VRE) | Change to linezolid (I.D. consult required) |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6457,
      "preview": "| Escherichia coli | Stop naficillin; use ampicillin+gentamicin |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6458,
      "preview": "| Escherichia coli, ampicillin-resistant | Change to meropenem or piperacillin/tazobactam |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6459,
      "preview": "| Klebsiella | Change to ceftazidime + gentamicin |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6460,
      "preview": "| Serratia, Pseudomonas, Proteus, Acinetobacter, <br> Citrobacter, Enterobacter | Change to Meropene"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6462,
      "preview": "Coverage for anaerobic organisms is rarely necessary in neonates. Because newborn infants (preterm i"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6464,
      "preview": "When results of antimicrobial sensitivity become available, antibiotic coverage should be adjusted t"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6466,
      "preview": "Certain isolates, including coagulase-negative Staph. (in the first few days after birth), diphthero"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6467,
      "preview": "C. Duration of Treatment"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6469,
      "preview": "1. Treatment can be discontinued when:"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6471,
      "preview": "- it has been determined that the infant was not infected, or"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6472,
      "preview": "- an effective course of therapy has been completed"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6474,
      "preview": "2. Exclusion of sepsis depends upon absence of ongoing clinical signs of sepsis, negative culture re"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6476,
      "preview": "--- page 269 ---"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6478,
      "preview": "262 Part II-E: Infection"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6479,
      "preview": "Table 8. Framework for Decision to Stop or Continue Antibiotic Treatment"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6481,
      "preview": "| Infant Condition at <br> time of decision | Cultures | CRP | Management |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6482,
      "preview": "| :-- | :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6483,
      "preview": "| Well appearing | Positive | Normal <br> Elevated | Complete treatment* <br> Complete treatment |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6484,
      "preview": "|  | Negative | Normal <br> Elevated | Stop treatment <br> Stop treatment |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6485,
      "preview": "| Clinical Illness | Positive | Normal <br> Elevated | Complete treatment* <br> Complete treatment |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6486,
      "preview": "|  | Negative | Normal <br> Elevated | Stop treatment <br> Use clinical judgement |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6487,
      "preview": "| * consider spuriously positive culture, stopping antibiotics |  |  |  |"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6489,
      "preview": "Infants who are well appearing and have negative laboratory tests (including cultures) and those wit"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6491,
      "preview": "Table 9. Diagnostic Utility of C-Reactive Protein Measurements"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6493,
      "preview": "|  | Early-Onset Sepsis |  | Late-Onset Sepsis |  |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6494,
      "preview": "| :-- | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6495,
      "preview": "|  | CRP \\#1* | CRP \\#2+3* | CRP \\#1* | CRP \\#2+3* |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6496,
      "preview": "| Sensitivity | $35.0 \\%$ | $88.9 \\%$ | $61.5 \\%$ | $96.4 \\%$ |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6497,
      "preview": "| Specificity | $90.0 \\%$ | $73.8 \\%$ | $68.9 \\%$ | $71.8 \\%$ |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6498,
      "preview": "| Positive predictive value | $6.7 \\%$ | $6.0 \\%$ | $43.8 \\%$ | $45.0 \\%$ |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6499,
      "preview": "| Negative predictive value | $98.6 \\%$ | $99.7 \\%$ | $82.0 \\%$ | $98.8 \\%$ |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6500,
      "preview": "| Posterior:prior likelihood | 0.72 | 0.15 | 0.56 | 0.05 |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6501,
      "preview": "| ratio for normal results |  |  |  |  |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6502,
      "preview": "| Posterior:prior likelihood | 3.51 | 3.40 | 1.98 | 3.42 |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6503,
      "preview": "| ratio for abnormal results |  |  |  |  |"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6505,
      "preview": "* CRP \\#1 = CRP at initial evaluation, CRP \\#2+3 = delayed CRP level 24 hours apart"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6507,
      "preview": "--- page 270 ---"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6509,
      "preview": "The data provided in Table 9 support the utility of CRP levels for retrospective exclusion of sepsis"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6511,
      "preview": "Table 10. Some Nonbacterial Causes of CRP Elevation"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6513,
      "preview": "| Chorioamnionitis (without fetal <br> infection) | Renal artery or vein thrombosis <br> Necrotizing"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6514,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6515,
      "preview": "| Isoimmune hemolysis | Gastroschisis | Cephalohematoma |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6516,
      "preview": "| Myelodysplastic syndrome | Clavicular or humeral fracture | Subgaleal hematoma |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6517,
      "preview": "| Meconium aspiration | Epidermolysis bullosa | Cerebral infarction |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6518,
      "preview": "| Surgical procedures |  | Prostaglandin infusion |"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6520,
      "preview": "Figure 9. Positive predictive values of CRP levels for early- (A) and late-onset (B) proven (open ba"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6521,
      "preview": "A."
    },
    {
      "type": "image",
      "section": "B. Adjustment of Treatment",
      "line": 6522,
      "content": "![img-52.jpeg](images/c0cabee9acc3118d.png)"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6523,
      "preview": "B."
    },
    {
      "type": "image",
      "section": "B. Adjustment of Treatment",
      "line": 6524,
      "content": "![img-53.jpeg](images/8c578036276e2ca5.png)"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6526,
      "preview": "Confirmed cases of serious bacterial infection require treatment of sufficient duration to ensure co"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6528,
      "preview": "Table 11. Traditional Treatment Intervals for Neonatal Infections"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6530,
      "preview": "| Sepsis, pneumonia, cellulitis |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6531,
      "preview": "| :--: |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6532,
      "preview": "| Gram-positive: 10 days |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6533,
      "preview": "| Gram-negative: 14 days |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6534,
      "preview": "| Meningitis |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6535,
      "preview": "| Gram-positive: 14 days |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6536,
      "preview": "| Gram-negative: 21 days |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6537,
      "preview": "| Osteomyelitis or septic arthritis: 4-6 weeks |"
    },
    {
      "type": "table",
      "section": "B. Adjustment of Treatment",
      "line": 6538,
      "preview": "| Endocarditis: 4-8 weeks |"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6540,
      "preview": "Some publications have suggested treatment until CRP levels return to normal. This approach has not "
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6542,
      "preview": "--- page 271 ---"
    },
    {
      "type": "text",
      "section": "B. Adjustment of Treatment",
      "line": 6544,
      "preview": "Appendix: LPCH NICU Late Onset Sepsis Algorithm"
    },
    {
      "type": "image",
      "section": "B. Adjustment of Treatment",
      "line": 6545,
      "content": "![img-54.jpeg](images/12b268a68c68bb4c.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 6547
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6549,
      "preview": "1. Stoll BJ, Hansen NI, S\u00e1nchez PJ, Faix RG, Poindexter BB, Van Meurs KP, Bizzarro MJ, Goldberg RN, "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6551,
      "preview": "--- page 272 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6553,
      "preview": "2. Greenhow RL, Hung YY, Herz AM. Changing epidemiology of bactermia in infants aged 1 week to 3 mon"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6554,
      "preview": "3. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cie"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6555,
      "preview": "4. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization a"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6556,
      "preview": "5. Rodwell RL, Leslie AL, Tudehope DI. Early diagnosis of neonatal sepsis using a hematologic scorin"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6557,
      "preview": "6. Garcia-Prats JA, Cooper TR, Schneider VG, Stager CE, Hansen TN. Rapid dectection of microorganism"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6558,
      "preview": "7. Sherman MP, Goetzman BW, Ahlfors CE, Wennberg RP. Tracheal aspiration and its clinical correlates"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6559,
      "preview": "8. Visser VE, Hall RT. Urine culture in the evaluation of suspected neonatal sepsis. J Pediatr. 1979"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6560,
      "preview": "9. Wiswell TE, Baumgart S, Gannon CM, Spitzer AR. No lumbar puncture in the evaluation for early neo"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6561,
      "preview": "10. Srinivasan L, Shah SS, Padula MA, Abbasi S, McGowan KL, Harris MC. Cerebrospinal fluid reference"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6562,
      "preview": "11. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6563,
      "preview": "12. Terrone DA, Rinehart BK, Einstein MH, Britt LB, Martin JN Jr, Perry KG. Neonatal sepsis and deat"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6564,
      "preview": "13. Berardi A, et al. Safety of physical examination alone for managing well-appearing neonates $\\ge"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6565,
      "preview": "14. Cantoni L, et al. Physical Examination Instead of Laboratory Tests for Most Infants Born to Moth"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6566,
      "preview": "15. Benitz WE, Wynn JL, Polin RA. Reappraisal of Guidelines for Management of Neonates with Suspecte"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6568,
      "preview": "--- page 273 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Immunizations",
      "line": 6570
    },
    {
      "type": "text",
      "section": "Immunizations",
      "line": 6572,
      "preview": "Sruti Nadimpalli, M.D., M.P.H."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 6574
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6576,
      "preview": "A. All preterm infants should receive full doses of recommended vaccinations according to their chro"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6578,
      "preview": "The current recommendations from the American Academy of Pediatrics and the CDC Advisory Committee o"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6579,
      "preview": "http://aapredbook.aappublications.org/site/resources/izschedules.xhtml and at"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6580,
      "preview": "http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm."
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6581,
      "preview": "B. Hepatitis B vaccine (Engerix B or Recombivax)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. At birth",
      "line": 6583
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6585,
      "preview": "a. All newborns should receive monovalent Hepatitis B Vaccine soon after birth and before hospital d"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6586,
      "preview": "b. Infants born to Hepatitis B surface antigen (HBsAg)-positive mothers:"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6587,
      "preview": "i. All infants: administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 h"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6588,
      "preview": "ii. For preterm infants weighing $<2000 \\mathrm{~g}$, the initial vaccine dose (birth dose) should n"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6589,
      "preview": "iii. Continue vaccine series beginning at 1-2 mo of age according to recommended schedule for infant"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6590,
      "preview": "iv. Check anti-HBs and HBsAg 1-2 months after completion of vaccine series; typically around age 9-1"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6591,
      "preview": "c. Infants born to mothers whose HBsAg status is unknown:"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6592,
      "preview": "i. Test mother for HBsAg IMMEDIATELY after admission to L\\&D."
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6593,
      "preview": "ii. All infants of mothers with unknown status: administer HepB vaccine within 12 hours of birth."
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6594,
      "preview": "iii. Term infants $\\geq 2000 \\mathrm{~g}$ : if mother tests positive for HBsAg or if HBsAg status re"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6595,
      "preview": "iv. Infants $<2000 \\mathrm{~g}$ if mother tests positive for HBsAg or if HBsAg status remains unknow"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6596,
      "preview": "2. Continue vaccine series beginning at 1-2 mo of age according to recommended schedule based on mot"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6597,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "1. At birth",
      "line": 6599,
      "preview": "--- page 274 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "3. Following the birth dose",
      "line": 6601
    },
    {
      "type": "text",
      "section": "3. Following the birth dose",
      "line": 6603,
      "preview": "a. The Hepatitis B Vaccine series should be completed with either monovalent Hepatitis B or a combin"
    },
    {
      "type": "text",
      "section": "3. Following the birth dose",
      "line": 6604,
      "preview": "b. The second dose should be administered at age 1-2 mos. Monovalent HepB vaccine should be used for"
    },
    {
      "type": "text",
      "section": "3. Following the birth dose",
      "line": 6605,
      "preview": "c. Although the standard hepatitis B vaccination schedule is 3 doses, administration of a total 4 do"
    },
    {
      "type": "text",
      "section": "3. Following the birth dose",
      "line": 6606,
      "preview": "d. The minimum interval between dose 1 and dose 2 is 4 weeks, and between dose 2 and 3 is 8 weeks."
    },
    {
      "type": "text",
      "section": "3. Following the birth dose",
      "line": 6607,
      "preview": "e. The final (3rd or 4th) dose in the HepB vaccine series should not be administered before 24 weeks"
    },
    {
      "type": "text",
      "section": "3. Following the birth dose",
      "line": 6609,
      "preview": "--- page 275 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6611
    },
    {
      "type": "text",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6613,
      "preview": "a. Hepatitis B immunization management of infants weighing $<2000 \\mathrm{gm}$, by maternal Hepatiti"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6615,
      "preview": "| Maternal HBsAg status | Recommendation |"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6616,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6617,
      "preview": "| Positive | HBIG + hepatitis B vaccine (within 12 hrs of birth) <br> Continue vaccine series beginn"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6618,
      "preview": "|  | Do not count birth dose as part of the vaccine series, (i.e., 4 doses of hepatitis B vaccine sh"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6619,
      "preview": "|  | Test mother for HBsAg immediately <br> HBIG and Hepatitis B vaccine ( $\\leq 12$ hrs of birth) *"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6620,
      "preview": "| Unknown | Do not count birth dose as part of the vaccine series. Continue vaccine series beginning"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6621,
      "preview": "|  | *Redbook states that HBIG should be given if it is not possible for maternal result to be avail"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6622,
      "preview": "| Negative | Delay first dose of hepatitis B vaccine until 1 mo of age or hospital discharge, whiche"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6623,
      "preview": "|  | Continue 3-dose vaccine series beginning at 2 mo of age. See Red Book, Table 3.21 |"
    },
    {
      "type": "table",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6624,
      "preview": "|  | Follow-up anti-HBs and HBsAg testing not needed |"
    },
    {
      "type": "text",
      "section": "4. Infants weighing <2000 g (based on 2012 Red Book)",
      "line": 6626,
      "preview": "--- page 276 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Rotavirus vaccine:",
      "line": 6628
    },
    {
      "type": "text",
      "section": "D. Rotavirus vaccine:",
      "line": 6630,
      "preview": "This is an oral vaccine that consists of 5 live reassortant rotaviruses. The first dose is generally"
    },
    {
      "type": "text",
      "section": "D. Rotavirus vaccine:",
      "line": 6632,
      "preview": "1. If a recently immunized infant is hospitalized, standard precautions should be taken to prevent t"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6634
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6636,
      "preview": "1. 0.5 ml IM Pentacel (DTaP + HIB + IPV)"
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6637,
      "preview": "2. 0.5 ml IM Engerix B (HepB)"
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6638,
      "preview": "3. 0.5 ml IM Pneumococcal conjugate vaccine (Prevnar\u00ae 13)"
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6639,
      "preview": "4. Meningococcal conjugate vaccines - Menveo (MenACWY or MCV4) or Menhibrix (Hib-MenCY)"
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6640,
      "preview": "a. For children with anatomic or functional asplenia (including sickle cell disease) or persistent c"
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6641,
      "preview": "b. If Hib-MenCY vaccine (Menhibrix) is chosen to be given to high-risk infants older than 2 months o"
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6642,
      "preview": "c. Infants traveling to endemic areas for meningococcus should receive Menveo rather than Menhibrix."
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6643,
      "preview": "F. RSV Prophylaxis See NICU Guide Section II.E. 5 \"RSV Prophylaxis\"."
    },
    {
      "type": "text",
      "section": "E. Immunizations to be given at 2 months chronological age:",
      "line": 6645,
      "preview": "--- page 277 ---"
    },
    {
      "type": "heading",
      "level": 4,
      "section": "270 Part II-E: Infection",
      "line": 6647
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6649,
      "preview": "**Figure 1. Recommended immunization schedule for persons aged 0 through 18 years \u2013 2013.**"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6651,
      "preview": "(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendatio"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6653,
      "preview": "|  Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 8 mos | 12 mos | 15 mos | 18 mos | 18\u201329 mos | 2"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6654,
      "preview": "| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6655,
      "preview": "|  Hepatitis B (HepB) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 (1 dos"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6656,
      "preview": "|  Rotavirus (RV) | \u2611 (1\u20132 dose series); RV-1 (3 dose series) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 "
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6657,
      "preview": "|  Diphtheria, tetanus, & avellular pertussis (DDoP +7 yrs) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6658,
      "preview": "|  Tetanus, diphtheria, & avellular pertussis (Tdiap +2 yrs) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 ("
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6659,
      "preview": "|  Haemophilus influenzae type b (Hib) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dos"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6660,
      "preview": "|  Pneumococcal conjugate (PCV13) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6661,
      "preview": "|  Pneumococcal polyposis cheetah (PPSV20) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6662,
      "preview": "|  Inactivated Poliovirus (IPV) (HepB) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dos"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6663,
      "preview": "|  Influenza A (A1, A9) | \u2611 (1 dose for some - see footnote 3) | \u2611 (1 dose for some - see footnote 3"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6664,
      "preview": "|  Measles, mumps, rubella (MRR) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3)"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6665,
      "preview": "|  Varicella (VVPR) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 (1 dose "
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6666,
      "preview": "|  Hepatitis B (HepB) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 (1 dos"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6667,
      "preview": "|  Influenza A (A1, A9) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 (1 d"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6668,
      "preview": "|  Influenza B (A1, A9) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 (1 d"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6669,
      "preview": "|  Measles, mumps, rubella (MRR) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3)"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6670,
      "preview": "|  Varicella (VVPR) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 (1 dose "
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6671,
      "preview": "|  Hepatitis B (HepB) | \u2611 (1 dose = 0) | \u2611 (1 dose = 1) | \u2611 (1 dose = 2) | \u2611 (1 dose = 3) | \u2611 (1 dos"
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6672,
      "preview": "|  Human papillomavirus (HPV2) (Ionides only; HPV4: males and females) | \u2611 (1 dose = 0) | \u2611 (1 dose "
    },
    {
      "type": "table",
      "section": "270 Part II-E: Infection",
      "line": 6673,
      "preview": "|  Meningococcal (HepBex) (1, 2 weeks; MCV4-D, 24 mo.; MCV4-DM, 21 yrs.) | \u2611 (1 dose = 0) | \u2611 (1 dos"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6675,
      "preview": "This schedule includes recommendations in effect as of January 1, 2013. Any dose not administered at"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6677,
      "preview": "This schedule is approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/va"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6679,
      "preview": "**NOTE:** The above recommendations must be read along with the footnotes of this schedule."
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6681,
      "preview": "These recommendations must be read with the footnotes that follow. For those who fall behind or star"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6683,
      "preview": "This schedule includes recommendations in effect as of January 1, 2013. Any dose not administered at"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6685,
      "preview": "This schedule is approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/va"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6687,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "270 Part II-E: Infection",
      "line": 6689,
      "preview": "--- page 278 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hep B Vaccination Algorithm",
      "line": 6691
    },
    {
      "type": "image",
      "section": "Hep B Vaccination Algorithm",
      "line": 6693,
      "content": "![img-55.jpeg](images/3a87f9e55031bbe3.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 6695
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6697,
      "preview": "1. AAP Red Book, 2012 Edition. A Comprehensive Immunization Strategy to Eliminate Transmission of He"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6698,
      "preview": "2. CDC. Recommendations of the Advisory Committee on Immunization Practices: revised recommendations"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6699,
      "preview": "3. CDC. Prevention of Rotavirus Gastroenteritis Among Infants and Children Recommendations of the Ad"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6700,
      "preview": "4. CDC. Addition of Severe Combined Immunodeficiency as a Contraindication for Administration of Rot"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6701,
      "preview": "5. CDC. Addition of History of Intussusception as a Contraindication for Rotavirus Vaccination. MMWR"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6702,
      "preview": "6. CDC. Diphtheria, Tetanus, and Pertussis: Recommendations for Vaccine Use and Other Preventive Mea"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6703,
      "preview": "7. CDC. Prevention and Control of Haemophilus influenzae Type b Disease: Recommendations of the Advi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6705,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6707,
      "preview": "--- page 279 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6709,
      "preview": "272 Part II-E: Infection"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6710,
      "preview": "Committee on Immunization Practices (ACIP). MMWR 2014 / 63(RR01);1-14."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6711,
      "preview": "8. CDC. Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococ"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6712,
      "preview": "9. CDC. Use of MenACWY-CRM Vaccine in Children Aged 2 Through 23 Months at Increased Risk for Mening"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6714,
      "preview": "--- page 280 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "RSV Prophylaxis",
      "line": 6716
    },
    {
      "type": "text",
      "section": "RSV Prophylaxis",
      "line": 6718,
      "preview": "Hayden Schwenk, M.D., M.P.H."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 6720
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6722,
      "preview": "Respiratory syncytial virus (RSV) infection is the leading cause of lower respiratory tract infectio"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6723,
      "preview": "A. Risk Factors for Hospitalization"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6725,
      "preview": "The risk for hospitalization due to RSV infection is greatest in the following patients:"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6727,
      "preview": "1. Preterm infants born before 29 weeks gestation"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6728,
      "preview": "2. Infants and young children with chronic lung disease (CLD)"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6729,
      "preview": "3. Infants with hemodynamically significant congenital heart disease (CHD)"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6730,
      "preview": "B. Strategies for Prevention of RSV Infection"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6732,
      "preview": "Strategies to prevent RSV and other viral respiratory infections include offering breast milk feeds,"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6733,
      "preview": "C. Passive Immunoprophylaxis"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6735,
      "preview": "Data from controlled clinical trials support the efficacy of monthly $15 \\mathrm{mg} / \\mathrm{kg}$ "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Prophylaxis Recommendations",
      "line": 6737
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6739,
      "preview": "A. Who to Prophylax"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6741,
      "preview": "1. Palivizumab prophylaxis is recommended for the following patient categories during the RSV season"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6742,
      "preview": "a. Infants <12 months post-natal age AND born before 29 weeks, 0 days gestation."
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6743,
      "preview": "b. Infants <12 months post-natal age AND born before 32 weeks, 0 days gestation WITH requirement for"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6744,
      "preview": "c. Infants <12 months post-natal age AND with acyanotic heart disease on medication to control conge"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6745,
      "preview": "d. Infants <24 months post-natal age AND has a transplanted heart, is in need of cardiac transplanta"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6746,
      "preview": "e. Infants <12 months post-natal age WITH moderate to severe pulmonary hypertension."
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6747,
      "preview": "f. Infants 12-24 months post-natal age AND born before 32 weeks, 0 days gestation WITH requirement f"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6748,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6750,
      "preview": "--- page 281 ---"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6752,
      "preview": "g. Infants $\\leq 24$ months post-natal age AND listed for OR status post solid organ transplant."
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6753,
      "preview": "2. The following groups of infants with CHD are NOT at increased risk from RSV and generally should "
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6754,
      "preview": "a. Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial sept"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6755,
      "preview": "b. Infants with lesions adequately corrected by surgery, unless they continue to require medication "
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6756,
      "preview": "c. Infants with mild cardiomyopathy who are not receiving medical therapy for the condition."
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6757,
      "preview": "d. Children in the second year of life."
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6758,
      "preview": "3. Palivizumab immunoprophylaxis MAY be considered in infants $<12$ months post-natal age with neuro"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6759,
      "preview": "4. There are insufficient data to support the routine use of palivizumab in children with Down syndr"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6760,
      "preview": "5. Limited studies suggest that some patients with cystic fibrosis may be at increased risk of RSV i"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6761,
      "preview": "6. Palivizumab has not been evaluated in randomized trials in immunocompromised children. Although s"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6762,
      "preview": "7. Palivizumab is not effective in the treatment of RSV disease and is NOT approved or recommended f"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6763,
      "preview": "B. When to Prophylax"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6765,
      "preview": "1. For qualifying patients, palivizumab administration should begin in November and continue for tot"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6766,
      "preview": "a. Local respiratory virus activity is monitored weekly by the Integrated Infectious Disease Program"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6767,
      "preview": "b. The Centers for Disease Control (CDC) also monitor outbreaks of respiratory viruses and publishes"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6768,
      "preview": "2. Once a child qualifies for initiation of prophylaxis at the start of the RSV season, administrati"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6770,
      "preview": "--- page 282 ---"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6772,
      "preview": "3. Patients who qualify for prophylaxis because of CLD, prematurity, or CHD may receive the first do"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6773,
      "preview": "4. Children remaining as inpatients (in any unit) should NOT receive palivizumab, even if they meet "
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6774,
      "preview": "C. Special Considerations"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6775,
      "preview": "5. A postoperative dose of palivizumab ( $15 \\mathrm{mg} / \\mathrm{kg}$ ) should be considered after"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6776,
      "preview": "6. If an infant or child who is receiving immunoprophylaxis experiences a breakthrough RSV hospitali"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6777,
      "preview": "D. How to Order"
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6778,
      "preview": "7. Palivizumab administration on an outpatient basis should be coordinated by the patient's primary "
    },
    {
      "type": "text",
      "section": "II. Prophylaxis Recommendations",
      "line": 6779,
      "preview": "8. Palivizumab is NOT indicated for inpatient use and providers will be required to select the appro"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 6781
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6783,
      "preview": "1. American Academy of Pediatrics. Red Book: 2012 Report of the Committee on Infectious Diseases. Pi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6784,
      "preview": "2. Goothius JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related ill"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6785,
      "preview": "3. Saadah LM, Chedid FD, Sohail MR, Nazzal YM, Al Kaabi MR, Rahamani AY. Palivizumab Prophylaxis dur"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6786,
      "preview": "4. Feltes TF, et al. Cardiac Synagis Study Group. J Pediatrics 2003 143;532-40."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6787,
      "preview": "5. Committee on Infectious Diseases. Updated Guidance for Palivizumab Prophylaxis Among Infants and "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6789,
      "preview": "--- page 283 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Suspected HSV Infection",
      "line": 6791
    },
    {
      "type": "text",
      "section": "Suspected HSV Infection",
      "line": 6793,
      "preview": "Hayden Schwenk, M.D., M.P.H."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 6795
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6797,
      "preview": "A. Herpes simplex virus (HSV) belongs to the same family as cytomegalovirus (CMV), Epstein-Barr viru"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6798,
      "preview": "B. The incidence of neonatal HSV infection is estimated to be around 1:3,200 deliveries."
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6799,
      "preview": "C. HSV is most commonly transmitted from mother to infant at the time of delivery. In some cases, ba"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6800,
      "preview": "D. The risk for HSV transmission to the neonate is greatest in mothers with a primary genital infect"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 6801,
      "preview": "E. It is important to include neonatal HSV infection in the differential diagnosis of the ill neonat"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Clinical Presentation",
      "line": 6803
    },
    {
      "type": "text",
      "section": "II. Clinical Presentation",
      "line": 6805,
      "preview": "A. Neonatal HSV infection can manifest as:"
    },
    {
      "type": "text",
      "section": "II. Clinical Presentation",
      "line": 6807,
      "preview": "1. Disseminated disease involving multiple organs, most commonly liver and lungs"
    },
    {
      "type": "text",
      "section": "II. Clinical Presentation",
      "line": 6808,
      "preview": "2. Localized central nervous system (CNS) disease, with or without skin findings"
    },
    {
      "type": "text",
      "section": "II. Clinical Presentation",
      "line": 6809,
      "preview": "3. Localized skin, eye, and/or mouth (SEM) disease"
    },
    {
      "type": "text",
      "section": "II. Clinical Presentation",
      "line": 6811,
      "preview": "--- page 284 ---"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6813,
      "preview": "| Clinical <br> Characteristic | SEM Disease | CNS Disease | Disseminated Disease |"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6814,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6815,
      "preview": "| Mode of acquisition | Peripartum/ postpartum | Peripartum/ postpartum | Peripartum/ postpartum |"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6816,
      "preview": "| Frequency | $45 \\%$ | $30 \\%$ | $25 \\%$ |"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6817,
      "preview": "| Sites of involvement | Skin, eye, mucus membranes | CNS +/- skin involvement | CNS, liver, lung, a"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6818,
      "preview": "| Presentation | +/- Vesicular rash | Sz, lethargy, poor feeding, temp instability, +/- rash | Encep"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6819,
      "preview": "| Rash | $>80 \\%$ | $60-70 \\%$ | $80 \\%$ |"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6820,
      "preview": "| Timing | 10-12 days of life | 16-19 days of life | 10-12 days of life |"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6821,
      "preview": "| Mortality | -- | $4 \\%$ | $29 \\%$ |"
    },
    {
      "type": "table",
      "section": "II. Clinical Presentation",
      "line": 6822,
      "preview": "| Normal development 1yr after treatment | $100 \\%$ | $31 \\%$ | $83 \\%$ |"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Diagnosis",
      "line": 6824
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6826,
      "preview": "A. It is ESSENTIAL to ensure the appropriate diagnostic tests are obtained PRIOR to beginning acyclo"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6827,
      "preview": "B. The diagnostic evaluation for neonatal HSV includes ALL of the following"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6829,
      "preview": "1. HSV PCR, blood"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6830,
      "preview": "2. HSV PCR, CSF"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6831,
      "preview": "3. HSV PCR, conjunctivae"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6832,
      "preview": "4. HSV PCR, nasopharynx"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6833,
      "preview": "5. HSV PCR, mouth"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6834,
      "preview": "6. HSV PCR, rectum"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6835,
      "preview": "7. HSV PCR, lesion (if any lesions/vesicles/pustules concerning for HSV are present)"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6836,
      "preview": "8. CBC with differential"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6837,
      "preview": "9. ALT"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6838,
      "preview": "10. CSF protein, glucose, cell count, Gram stain, and culture"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6839,
      "preview": "11. CXR (for infants with respiratory distress)"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6840,
      "preview": "C. At LPCH, ALL HSV PCR's are orderable as \"HSV DNA PCR Qual\". Please select the specimen type and s"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6841,
      "preview": "D. Please do NOT send an HSV serology."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6842,
      "preview": "E. A flocked swab placed in viral transport media should be used for all surface site and lesion PCR"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6843,
      "preview": "F. Please contact the Virology Lab (8-5575) with any questions related to specimen collection."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6844,
      "preview": "G. Differential diagnosis includes:"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6845,
      "preview": "12. Enteroviral sepsis"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6846,
      "preview": "13. Bacterial (e.g., Listeria, GBS, S. aureus, Gram negative) infection"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6848,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6850,
      "preview": "--- page 285 ---"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6852,
      "preview": "278 Part II-E: Infection"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6853,
      "preview": "3. Varicella zoster virus infection"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6854,
      "preview": "4. Symptomatic cytomegalovirus (CMV) infection"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6855,
      "preview": "5. Noninfectious conditions"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6856,
      "preview": "a. Erythema toxicum"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6857,
      "preview": "b. Incontinentia pigmenti"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 6858,
      "preview": "c. Bednar's aphthae"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Treatment",
      "line": 6860
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6862,
      "preview": "A. Parenteral acyclovir is the treatment of choice for neonatal HSV infections."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6863,
      "preview": "B. The dose of acyclovir is $60 \\mathrm{mg} / \\mathrm{kg} /$ day given IV and divided every 8 hours,"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6864,
      "preview": "C. Duration"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6866,
      "preview": "1. Skin, eye, and mouth disease: Minimum 14 days"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6867,
      "preview": "2. Disseminated disease: Minimum 21 days"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6868,
      "preview": "3. CNS disease: Minimum 21 days"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6869,
      "preview": "a. Because the persistence of HSV DNA in the CSF is associated with poor outcome, some experts recom"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6870,
      "preview": "b. Some experts recommend continuing antiviral therapy and repeating CSF HSV DNA PCR testing weekly "
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6871,
      "preview": "D. Suppressive Therapy"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6872,
      "preview": "4. Oral suppressive therapy with acyclovir has been shown to improve neurodevelopmental outcomes and"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6873,
      "preview": "5. ALL infants with a history of neonatal HSV should be placed on oral acyclovir suppression, $300 \\"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6874,
      "preview": "6. The duration of suppressive therapy is 6 months."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6875,
      "preview": "7. At a minimum, it is recommended that an ANC is followed at 2 and 4 weeks after initiating therapy"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 6876,
      "preview": "8. Prior to discharge, outpatient Pediatric Infectious Disease follow-up should be coordinated for a"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6878
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6880,
      "preview": "--- page 286 ---"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6882,
      "preview": "A. Because the risk to infants exposed to HSV during delivery varies in different circumstances (fro"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6883,
      "preview": "B. In 2013 the AAP published a Clinical Report entitled \"Guidance on Management of Asymptomatic Neon"
    },
    {
      "type": "image",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6884,
      "content": "![img-56.jpeg](images/1b5ab79eceec80dc.png)"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6886,
      "preview": "FIGURE 2"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6887,
      "preview": "Algorithm for the evaluation of asymptomatic neonates after vaginal or cesarean delivery to women wi"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6889,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6891,
      "preview": "--- page 287 ---"
    },
    {
      "type": "image",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6893,
      "content": "![img-57.jpeg](images/1bf4b0d2541cfad1.png)"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6895,
      "preview": "FIGURE 2"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6896,
      "preview": "Algorithm for the treatment of asymptomatic neonates after vaginal or cesarean delivery to women wit"
    },
    {
      "type": "image",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6897,
      "content": "![img-58.jpeg](images/47be11605044228c.png)"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6899,
      "preview": "FIGURE 3"
    },
    {
      "type": "text",
      "section": "V. Asymptomatic, HSV Exposed Infants",
      "line": 6900,
      "preview": "Algorithm for the treatment of asymptomatic neonates after vaginal or cesarean delivery to women wit"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Isolation",
      "line": 6902
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6904,
      "preview": "A. Neonates with SEM or disseminated HSV infection"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6906,
      "preview": "1. Contact precautions until any and all lesions are dry and crusted"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6907,
      "preview": "B. Neonates with isolated CNS HSV infection"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6908,
      "preview": "2. Standard precautions"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6909,
      "preview": "C. Neonates exposed to HSV during delivery"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6910,
      "preview": "3. Contact precautions until infant HSV PCR's are negative"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6911,
      "preview": "D. Neonates born to mother with history of HSV and no lesions at time of delivery"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6913,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6915,
      "preview": "--- page 288 ---"
    },
    {
      "type": "text",
      "section": "VI. Isolation",
      "line": 6917,
      "preview": "1. No special precautions"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 6919
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6921,
      "preview": "1. Kimberlin DW, Baley JD. Committee on Infectious Diseases and Committee on Fetus and Newborn. Guid"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6922,
      "preview": "2. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Pediatr Clin N Am. 2013;(60)"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6923,
      "preview": "3. Kimberlin DW, Whitley RJ, Wan W, et. al. National Institute of Allergy and Infectious Diseases Co"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6924,
      "preview": "4. American Academy of Pediatrics. Herpes simplex. In: Red Book: 2012 Report of the Committee on Inf"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 6926,
      "preview": "--- page 289 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-F: Gastrointestinal",
      "line": 6928
    },
    {
      "type": "text",
      "section": "Part II-F: Gastrointestinal",
      "line": 6930,
      "preview": "--- page 290 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Gastroesophageal Reflux Disease",
      "line": 6932
    },
    {
      "type": "text",
      "section": "Gastroesophageal Reflux Disease",
      "line": 6934,
      "preview": "William Berquist, M.D., and Carol K. Conrad, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition of Gastroesophageal Reflux (GER)",
      "line": 6936
    },
    {
      "type": "text",
      "section": "I. Definition of Gastroesophageal Reflux (GER)",
      "line": 6938,
      "preview": "A. The important mechanism in GER is the transient relaxation of the lower esophageal sphincter, whi"
    },
    {
      "type": "text",
      "section": "I. Definition of Gastroesophageal Reflux (GER)",
      "line": 6939,
      "preview": "B. GER is common and physiologic in infants during the first 6 months of life, occurs thirty or more"
    },
    {
      "type": "text",
      "section": "I. Definition of Gastroesophageal Reflux (GER)",
      "line": 6940,
      "preview": "C. It is controversial when to consider GER pathologic, which is referred to as gastroesophageal ref"
    },
    {
      "type": "text",
      "section": "I. Definition of Gastroesophageal Reflux (GER)",
      "line": 6941,
      "preview": "D. GERD may be associated with feeding problems, such as frequent emesis or nasal-oral regurgitation"
    },
    {
      "type": "text",
      "section": "I. Definition of Gastroesophageal Reflux (GER)",
      "line": 6942,
      "preview": "E. In term infants, GERD may be associated with apnea and airway problems, such as hoarse cry and st"
    },
    {
      "type": "text",
      "section": "I. Definition of Gastroesophageal Reflux (GER)",
      "line": 6943,
      "preview": "F. Numerous carefully controlled studies have failed to demonstrate a temporal relationship or assoc"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Diagnosis of GERD",
      "line": 6945
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6947,
      "preview": "A. pH Probe/Apnea Study: Is the direct continuous measurement of intra-esophageal fluid reflux via i"
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6948,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6950,
      "preview": "--- page 291 ---"
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6952,
      "preview": "detecting GER to the level of the proximal esophagus if reflux esophagitis or aspiration of refluxed"
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6953,
      "preview": "B. Barium Swallow: Demonstrates gross reflux, but is not as sensitive as pH probe in determining ref"
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6954,
      "preview": "C. Gastric Emptying Study (Nuclear Medicine): This is used to identify prolonged emptying time and m"
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6955,
      "preview": "D. Esophageal Manometry: This is used to assess LES tone and function and is not generally available"
    },
    {
      "type": "text",
      "section": "II. Diagnosis of GERD",
      "line": 6956,
      "preview": "E. GER Impedance: Can record reflux events at multiple levels and may accompany pH (as above). It is"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6958
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6960,
      "preview": "A. Antireflux positioning: Elevate head of bed $30^{\\circ}$, position with left side down (this affe"
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6961,
      "preview": "B. Thickened feeds: There is scant evidence to support or refute efficacy of thickened feeds in infa"
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6963,
      "preview": "1. Thickeners may be used to increase the viscosity of formula, breast milk, or other thin fluids fo"
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6964,
      "preview": "2. Thickeners will not be used to thicken foods or fluids unless a swallowing evaluation has been co"
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6965,
      "preview": "3. It is recommended that patients who will discharge to home on thickened feedings receive ongoing "
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6967,
      "preview": "--- page 292 ---"
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6969,
      "preview": "Rice Cereal"
    },
    {
      "type": "table",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6971,
      "preview": "| Patient Age | Recommended Use |"
    },
    {
      "type": "table",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6972,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6973,
      "preview": "| Premature infants (no h/o <br> NEC) | Limited, recreational feedings up to 10 mL BID, if cleared b"
    },
    {
      "type": "table",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6974,
      "preview": "| FT infants 0-4 months | Limited, recreational feedings up to 10 mL BID, if cleared by primary <br>"
    },
    {
      "type": "table",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6975,
      "preview": "| 4 months and older | Full thickened oral feeds, if deemed appropriate by feeding therapist <br> an"
    },
    {
      "type": "text",
      "section": "III. Non-pharmacologic Treatment for GERD",
      "line": 6977,
      "preview": "* Rice cereal may not be used with breast milk."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Thick-It",
      "line": 6980
    },
    {
      "type": "table",
      "section": "Thick-It",
      "line": 6982,
      "preview": "| Patient Age | Recommended Use |"
    },
    {
      "type": "table",
      "section": "Thick-It",
      "line": 6983,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "Thick-It",
      "line": 6984,
      "preview": "| Premature infants (no h/o <br> NEC) | May be used for full oral feeds, if deemed appropriate by fe"
    },
    {
      "type": "table",
      "section": "Thick-It",
      "line": 6985,
      "preview": "| FT Infants 0 months | Full thickened oral feeds, if deemed appropriate by feeding therapist <br> a"
    },
    {
      "type": "text",
      "section": "Thick-It",
      "line": 6987,
      "preview": "* Thick-It may not be used with breast milk."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Simply Thick",
      "line": 6990
    },
    {
      "type": "table",
      "section": "Simply Thick",
      "line": 6992,
      "preview": "| Patient Age | Recommended Use |"
    },
    {
      "type": "table",
      "section": "Simply Thick",
      "line": 6993,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "Simply Thick",
      "line": 6994,
      "preview": "| Any infant 0-12 months | May not be used |"
    },
    {
      "type": "table",
      "section": "Simply Thick",
      "line": 6995,
      "preview": "| 12 months \\& older, <br> including premature <br> infants (no h/o NEC) | Full thickened oral feeds"
    },
    {
      "type": "table",
      "section": "Simply Thick",
      "line": 6996,
      "preview": "| Infant with h/o NEC | May be only used once child is greater than 12 years of age |"
    },
    {
      "type": "text",
      "section": "Simply Thick",
      "line": 6998,
      "preview": "* Simply Thick may be used with breast milk."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Gelmix",
      "line": 7001
    },
    {
      "type": "table",
      "section": "Gelmix",
      "line": 7003,
      "preview": "| Patient Age | Recommended Use |"
    },
    {
      "type": "table",
      "section": "Gelmix",
      "line": 7004,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "Gelmix",
      "line": 7005,
      "preview": "| Premature infants <br> (no h/o NEC) | May be used for full oral feeds, once baby is 44 weeks PMA a"
    },
    {
      "type": "table",
      "section": "Gelmix",
      "line": 7006,
      "preview": "| All other infants and <br> older children | May be used for full oral feeds, once baby is 44 weeks"
    },
    {
      "type": "text",
      "section": "Gelmix",
      "line": 7008,
      "preview": "* Gelmix may be used with breast milk."
    },
    {
      "type": "text",
      "section": "Gelmix",
      "line": 7010,
      "preview": "--- page 293 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Pharmacologic Treatment for GERD",
      "line": 7012
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Erythromycin ethylsuccinate as a prokinetic",
      "line": 7014
    },
    {
      "type": "text",
      "section": "A. Erythromycin ethylsuccinate as a prokinetic",
      "line": 7016,
      "preview": "1. Mechanism of action: may improve gastroduodenal contractility in FT and PT infant older than 33 w"
    },
    {
      "type": "text",
      "section": "A. Erythromycin ethylsuccinate as a prokinetic",
      "line": 7017,
      "preview": "2. Dose: $10-20 \\mathrm{mg} / \\mathrm{kg} /$ day PO divided q 6-8 h. Recommend starting with $5 \\mat"
    },
    {
      "type": "text",
      "section": "A. Erythromycin ethylsuccinate as a prokinetic",
      "line": 7018,
      "preview": "3. Side effects: Associated with higher incidence of acquired pyloric stenosis and prolonged QTc (se"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Ranitidine (Zantac\u00ae)",
      "line": 7020
    },
    {
      "type": "text",
      "section": "B. Ranitidine (Zantac\u00ae)",
      "line": 7022,
      "preview": "1. Mechanism of action: H 2 blocker used to decrease gastric acidity."
    },
    {
      "type": "text",
      "section": "B. Ranitidine (Zantac\u00ae)",
      "line": 7023,
      "preview": "2. Dose: $2 \\mathrm{mg} / \\mathrm{kg} /$ day twice daily PO and may increase to $2 \\mathrm{mg} / \\ma"
    },
    {
      "type": "text",
      "section": "B. Ranitidine (Zantac\u00ae)",
      "line": 7024,
      "preview": "3. Side effects: constipation, diarrhea, nausea, vomiting, and abdominal pain. It is important to ch"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Omeprazole (Prilosec\u00ae)",
      "line": 7026
    },
    {
      "type": "text",
      "section": "C. Omeprazole (Prilosec\u00ae)",
      "line": 7028,
      "preview": "1. Mechanism of action: proton-pump inhibitor (PPI). Used for severe cases of GER in which an H2 blo"
    },
    {
      "type": "text",
      "section": "C. Omeprazole (Prilosec\u00ae)",
      "line": 7029,
      "preview": "2. Dose: Start at $0.7 \\mathrm{mg} / \\mathrm{kg}$ PO once every day, then may give a 2nd dose 12 hou"
    },
    {
      "type": "text",
      "section": "C. Omeprazole (Prilosec\u00ae)",
      "line": 7030,
      "preview": "3. Side effects: Tachycardia, bradycardia, palpitations, headache, dizziness, insomnia, anxiety, ras"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Pantoprazole (Protonix\u00ae)",
      "line": 7032
    },
    {
      "type": "text",
      "section": "D. Pantoprazole (Protonix\u00ae)",
      "line": 7034,
      "preview": "1. Mechanism of action: PPI used for severe cases of GER in which H2 blockers have not effectively d"
    },
    {
      "type": "text",
      "section": "D. Pantoprazole (Protonix\u00ae)",
      "line": 7035,
      "preview": "2. Dose: $1 \\mathrm{mg} / \\mathrm{kg}$ PO every 12-24 hrs. Even less is known about pharmacokinetics"
    },
    {
      "type": "text",
      "section": "D. Pantoprazole (Protonix\u00ae)",
      "line": 7036,
      "preview": "3. Side effects: same as omeprazole."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Surgical Treatment",
      "line": 7038
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7040,
      "preview": "A. After failure of medical therapy with the following indications:"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7042,
      "preview": "1. Failure to thrive"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7044,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7046,
      "preview": "--- page 294 ---"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7048,
      "preview": "2. Recurrent aspiration pneumonia"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7049,
      "preview": "3. Persistent vomiting"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7050,
      "preview": "4. Anemia caused by esophageal bleeding"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7051,
      "preview": "5. Large hiatal hernia or para-esophageal hernia"
    },
    {
      "type": "text",
      "section": "V. Surgical Treatment",
      "line": 7052,
      "preview": "6. Esophageal stricture or ulceration"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Surgical Techniques",
      "line": 7054
    },
    {
      "type": "text",
      "section": "B. Surgical Techniques",
      "line": 7056,
      "preview": "1. Nissen fundoplication This involves placing the esophagogastric junction within the abdomen and w"
    },
    {
      "type": "text",
      "section": "B. Surgical Techniques",
      "line": 7057,
      "preview": "2. Thal repair This also mobilizes the esophagogastric junction into the abdomen and closes the esop"
    },
    {
      "type": "text",
      "section": "B. Surgical Techniques",
      "line": 7058,
      "preview": "3. Side effects of surgery Infant will have limited ability to \"burp\" to relieve gastric distension "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Summary",
      "line": 7060
    },
    {
      "type": "text",
      "section": "VI. Summary",
      "line": 7062,
      "preview": "GER/GERD has become a common diagnosis/presumed mechanism for early and late apnea, bradycardia and "
    },
    {
      "type": "text",
      "section": "VI. Summary",
      "line": 7064,
      "preview": "The most common intervention used in the NICU is an H2 blocker or PPI to decrease gastric acidity an"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 7066
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7068,
      "preview": "1. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al.: Pediatric gastroesophageal reflux, clinical pract"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7069,
      "preview": "2. Corvaglia L, Spizzichino M, Aceti, A, et al.: A thickened formula does not reduce apneas related "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7070,
      "preview": "3. Aly H, Abdel-Hady H, Khashaba M, et al.: Erythromycin and feeding intolerance in premature infant"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7072,
      "preview": "--- page 295 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7074,
      "preview": "4. Omari TI.: Apnea-associated reduction in lower esophageal sphincter tone in premature infants. J "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7075,
      "preview": "5. Di Fiore J, Arko M, Herynk B, et al.: Characterization of cardiorespiratory events following gast"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7076,
      "preview": "6. Golski CA, Rome ES, Martin RJ, et al.: Pediatric specialists' beliefs about gastroesophageal refl"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7077,
      "preview": "7. Cresi F, Locatell E, Marinaccio C, et al.: Prognostic values of multichannel intraluminal impedan"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7078,
      "preview": "8. Abu Jawdeh EG, Martin RJ.: Neonatal apnea and gastroesophageal reflux (GER): is there a problem? "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7079,
      "preview": "9. Orenstein SR, Infant GERD: Symptoms, reflux episodes \\& reflux disease, acid \\& non-acid refllux-"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7080,
      "preview": "10. Corvaglia L, Spizzichino M, Aceti A, et al: A thickened formula does not reduce apneas related t"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7081,
      "preview": "11. Beal J, Silverman B, Bellant J, et al.: Late onset necrotizing enterocolitis in infants followin"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7082,
      "preview": "12. Malcolm WF, Cotton CM.: Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7083,
      "preview": "13. Wheatley E, Kennedy KA, :Cross-over trial of treatment for bradycardia attributed to gastroesoph"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7084,
      "preview": "14. Fonkalsrud EW, Bustorff-Silva J, Perez CA, et al: Antireflux surgery in children under 3 months "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7085,
      "preview": "15. Hassall E, :Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child. 2005;"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7086,
      "preview": "16. Martin R, Hibbs AM.: Gastroesophageal reflux in premature infants. UpToDate."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7087,
      "preview": "http://www.uptodate.com/contents/gastroesophageal-reflux-in-premature-infants. 2015"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7089,
      "preview": "--- page 296 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Necrotizing Entercolitis",
      "line": 7091
    },
    {
      "type": "text",
      "section": "Necrotizing Entercolitis",
      "line": 7093,
      "preview": "Susan Hintz, M.D., M.S. Epi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. General",
      "line": 7095
    },
    {
      "type": "text",
      "section": "I. General",
      "line": 7097,
      "preview": "Necrotizing enterocolitis (NEC) is the most common acquired gastrointestinal emergency in the NICU. "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Signs and Symptoms",
      "line": 7099
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7101,
      "preview": "A. Clinical signs are variable, ranging from minor feeding intolerance and guaiac positive stools to"
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7102,
      "preview": "B. The \"Clinical Triad\" of abdominal distention, gastrointestinal bleeding, and pneumatosis intestin"
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7103,
      "preview": "C. Early symptoms include gastric residuals, lethargy, increasing apnea and bradycardia, temperature"
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7104,
      "preview": "D. Gastrointestinal symptoms range from mild distention, guarding, tenderness, abdominal discolorati"
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7105,
      "preview": "E. Radiographic evaluation may reveal distended loops of bowel with:"
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7107,
      "preview": "1. Pneumatosis intestinalis anywhere along the small or large bowel (\"bubbly\" appearance around the "
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7108,
      "preview": "2. Pneumoperitoneum which is indicative of intestinal perforation"
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7109,
      "preview": "3. Portal venous air which is considered to indicate a rapid progression."
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7110,
      "preview": "F. Perforation is a surgical emergency, yet it can be difficult to assess free air on a KUB alone. P"
    },
    {
      "type": "text",
      "section": "II. Signs and Symptoms",
      "line": 7112,
      "preview": "--- page 297 ---"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7114,
      "preview": "| Stage Classification | Systematic Signs | Intestinal <br> Signs | Radiographic <br> Signs |"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7115,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7116,
      "preview": "| IA: <br> Suspected NEC | Temperature instability, apnea, bradycardia, lethargy | Increased residua"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7117,
      "preview": "| IB: <br> Suspected NEC | As above | Bright red blood from rectum | As above |"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7118,
      "preview": "| IIA: <br> Proven NEC, mildly <br> ill | As above | As above, plus absent bowel sounds with or with"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7119,
      "preview": "| IIB: <br> Proven NEC, moderately ill | As above, plus mild metabolic acidosis and mild thrombocyto"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7120,
      "preview": "| IIIA: <br> Advanced NEC, bowel intact | As above, plus hypotension, severe apnea, combined respira"
    },
    {
      "type": "table",
      "section": "II. Signs and Symptoms",
      "line": 7121,
      "preview": "| IIIB: <br> Advanced NEC, bowel perforated | As above | As above | As above, plus free air |"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Pathogenesis and Etiology",
      "line": 7123
    },
    {
      "type": "text",
      "section": "IV. Pathogenesis and Etiology",
      "line": 7125,
      "preview": "A. Definite etiology or pathogenesis is unknown."
    },
    {
      "type": "text",
      "section": "IV. Pathogenesis and Etiology",
      "line": 7126,
      "preview": "B. It has been suggested that 3 elements contribute, but may not all be required to be present for t"
    },
    {
      "type": "text",
      "section": "IV. Pathogenesis and Etiology",
      "line": 7128,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Pathogenesis and Etiology",
      "line": 7130,
      "preview": "--- page 298 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7132
    },
    {
      "type": "text",
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7134,
      "preview": "2. Abnormal microbial colonization of the gut"
    },
    {
      "type": "text",
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7135,
      "preview": "3. Presence of substrate (feedings)"
    },
    {
      "type": "text",
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7136,
      "preview": "C. Since NEC can occur in the never-fed infant, and in previously healthy full-term infants without "
    },
    {
      "type": "text",
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7137,
      "preview": "D. Ischemia is considered to be a significant risk factor for NEC. Studies suggest that feeding lead"
    },
    {
      "type": "text",
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7138,
      "preview": "E. Abnormal bacterial proliferation is considered a likely factor in the development of NEC, especia"
    },
    {
      "type": "text",
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7139,
      "preview": "F. Feeding, and its relationship to NEC, remain important areas of discussion. Since 90-95\\% of all "
    },
    {
      "type": "text",
      "section": "1. Intestinal injury (usually ischemic)",
      "line": 7140,
      "preview": "G. Probiotics are of increasing interest and potential use in NEC prevention bundles as a way to pro"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Treatment",
      "line": 7142
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7144,
      "preview": "A. Medical: Early treatment and vigilant follow-up!"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7146,
      "preview": "1. NPO with Replogle to low intermittent suction."
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7147,
      "preview": "2. Comprehensive evaluation for sepsis including blood, urine, and CSF cultures, and CRPs."
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7149,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7151,
      "preview": "--- page 299 ---"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7153,
      "preview": "3. KUB and left lateral decubitus radiograph of the abdomen"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7154,
      "preview": "4. Begin broad-spectrum intravenous antibiotics (usually ampicillin, gentamicin, and metronidazole)."
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7155,
      "preview": "5. Correct laboratory derangements such as thrombocytopenia, anemia, hyponatremia, and acidosis. Fol"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7156,
      "preview": "6. If the infant has significant respiratory distress and is not currently intubated, intubation is "
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7157,
      "preview": "7. Frequent clinical exams focusing on change in abdominal color, abdominal girth, tenderness."
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7158,
      "preview": "8. Follow KUB and left lateral decubitus views. Frequency is dependent on level of concern, serial f"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7159,
      "preview": "9. Consult Pediatric Surgery. Should serial abdominal films reveal perforation, emergency interventi"
    },
    {
      "type": "text",
      "section": "V. Treatment",
      "line": 7160,
      "preview": "10. Assuming no surgical intervention is needed, enteral feeding is usually held for 7-14 days, depe"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Surgical:",
      "line": 7162
    },
    {
      "type": "text",
      "section": "B. Surgical:",
      "line": 7164,
      "preview": "1. Indications for surgical interventions are not absolute, differ from center to center, and among "
    },
    {
      "type": "text",
      "section": "B. Surgical:",
      "line": 7165,
      "preview": "2. The \"best\" surgical approach (drain placement or open laparotomy, or primary anastomosis vs. ente"
    },
    {
      "type": "text",
      "section": "B. Surgical:",
      "line": 7166,
      "preview": "3. The NEC Steps trial, was a randomized controlled trial of laparotomy vs. drain for initial treatm"
    },
    {
      "type": "text",
      "section": "B. Surgical:",
      "line": 7167,
      "preview": "4. It is not yet clear whether laparotomy or drain is the better approach to surgical NEC and isolat"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Surgical interventions include:",
      "line": 7169
    },
    {
      "type": "text",
      "section": "C. Surgical interventions include:",
      "line": 7171,
      "preview": "1. Placement of peritoneal drain, usually performed at the bedside."
    },
    {
      "type": "text",
      "section": "C. Surgical interventions include:",
      "line": 7173,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "C. Surgical interventions include:",
      "line": 7175,
      "preview": "--- page 300 ---"
    },
    {
      "type": "text",
      "section": "C. Surgical interventions include:",
      "line": 7177,
      "preview": "2. Laparotomy with or without resection of grossly necrotic bowel in the OR."
    },
    {
      "type": "text",
      "section": "C. Surgical interventions include:",
      "line": 7178,
      "preview": "3. Diversion enterostomy if resection is indicated."
    },
    {
      "type": "text",
      "section": "C. Surgical interventions include:",
      "line": 7179,
      "preview": "4. \"Second look\" laparotomy if entire bowel appears necrotic at time of initial laparotomy."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Outcomes",
      "line": 7181
    },
    {
      "type": "text",
      "section": "VI. Outcomes",
      "line": 7183,
      "preview": "A. Mortality estimates for VLBW infants has been reported at $\\sim 20-40 \\%$, but may be higher in s"
    },
    {
      "type": "text",
      "section": "VI. Outcomes",
      "line": 7184,
      "preview": "B. Surgery for NEC has been reported to be required in $25-60 \\%$ of cases. Subsequent stricture for"
    },
    {
      "type": "text",
      "section": "VI. Outcomes",
      "line": 7185,
      "preview": "C. Short-gut syndrome, feeding abnormalities, abscess formation, bowel obstruction, and cholestasis "
    },
    {
      "type": "text",
      "section": "VI. Outcomes",
      "line": 7186,
      "preview": "D. Multi-center, retrospective analyses of extremely low birth weight premature infant data suggest "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 7188
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7190,
      "preview": "1. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med. 2011;364(3):255-264"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7191,
      "preview": "2. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and NEC in preterm infants. Coc"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7192,
      "preview": "3. McCallie KR, Lee HC, Mayer O, Cohen RS, Hintz SR, Rhine WD. Improved outcomes with a standardized"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7193,
      "preview": "4. Quigley M, McGuire W. Formula versus donor breast milk for feeding preterm or low birth weight in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7194,
      "preview": "5. Downard CD, et al for the 2012 APSA Outcomes Clinical Trials Committee. Treatment of necrotizing "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7195,
      "preview": "6. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7196,
      "preview": "7. Embleton ND, Zalewski S, Berrington JE. Probiotics for prevention of NEC and sepsis in preterm in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7198,
      "preview": "--- page 301 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Abdominal Wall Defects",
      "line": 7200
    },
    {
      "type": "text",
      "section": "Abdominal Wall Defects",
      "line": 7202,
      "preview": "Claire Abrajano, P.N.P and Matias Bruzoni, M.D., F.A.C.S."
    },
    {
      "type": "text",
      "section": "Abdominal Wall Defects",
      "line": 7204,
      "preview": "Gastroschisis and omphaloceles are frequently encountered congenital anomalies in pediatric surgery."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Embryology",
      "line": 7206
    },
    {
      "type": "text",
      "section": "I. Embryology",
      "line": 7208,
      "preview": "A. In the trilaminar embryo, body folds (cephalic, caudal, lateral) fuse centrally, where amnion inv"
    },
    {
      "type": "text",
      "section": "I. Embryology",
      "line": 7209,
      "preview": "B. By week 6, rapid growth of midgut and herniation through umbilical ring occurs."
    },
    {
      "type": "text",
      "section": "I. Embryology",
      "line": 7210,
      "preview": "C. By week 10, abdominal cavity sufficiently enlarged to accommodate midgut."
    },
    {
      "type": "text",
      "section": "I. Embryology",
      "line": 7211,
      "preview": "D. As the intestine returns, rotation and fixation occur."
    },
    {
      "type": "text",
      "section": "I. Embryology",
      "line": 7212,
      "preview": "E. This process does not occur in babies with gastroschisis or omphalocele; hence, there is a risk o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Gastroschisis",
      "line": 7214
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Definition",
      "line": 7216
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7218,
      "preview": "1. Defect due to obstruction of the omphalomesenteric vessels during development."
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7219,
      "preview": "2. Portion of abdominal wall fails to form (i.e., full-thickness defect), causing extrusion of intes"
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7220,
      "preview": "3. Defect usually arises to the right of umbilicus; generally small ( $<2 \\mathrm{~cm}$ ) compared t"
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7221,
      "preview": "4. Umbilical cord is not involved, and parts of organs may be in the amniotic fluid, and not enclose"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Comorbidities",
      "line": 7223
    },
    {
      "type": "text",
      "section": "B. Comorbidities",
      "line": 7225,
      "preview": "1. Incidence of chromosomal anomalies $<5 \\%$."
    },
    {
      "type": "text",
      "section": "B. Comorbidities",
      "line": 7226,
      "preview": "2. GERD or Hirschsprung disease."
    },
    {
      "type": "text",
      "section": "B. Comorbidities",
      "line": 7227,
      "preview": "3. Malabsorption or motility disorder."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Considerations",
      "line": 7229
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7231,
      "preview": "1. Defect fairly uniform in size ( $3-5 \\mathrm{~cm}$ vertical opening) and location (to the right o"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7232,
      "preview": "2. If gastroschisis identified in prenatal period:"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7233,
      "preview": "a. Serial sonography to assess intestinal integrity and detect signs of intestinal injury (e.g., dec"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7235,
      "preview": "--- page 302 ---"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7237,
      "preview": "1. At delivery: Place infant into Vi-Drape\u00ae Abdominal Isolation Bag to contain bowel and promote moi"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7238,
      "preview": "2. Pediatric Surgery Service notified."
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7239,
      "preview": "3. Open abdominal wound with extruded intestine puts these patients at increased risk for hypothermi"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7240,
      "preview": "a. Parenteral nutrition"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7241,
      "preview": "b. Antibiotic coverage"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7242,
      "preview": "c. Warming bed"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7243,
      "preview": "d. Vascular access"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7244,
      "preview": "e. OG tube to LCS for abdominal decompression"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7245,
      "preview": "f. Cardiopulmonary support"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7246,
      "preview": "4. Feasibility of reduction and closure determined by:"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7247,
      "preview": "a. Amount of inflammation, edema, and intestinal turgor"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7248,
      "preview": "b. Size of abdominal cavity"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7249,
      "preview": "5. Inflammation may distort bowel appearance; therefore, it is difficult to determine if atresia is "
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7250,
      "preview": "a. Delay correction of intestinal atresia until several weeks after initial repair."
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7251,
      "preview": "6. Intestinal dysfunction may take at least 4-6 wks to normalize."
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7252,
      "preview": "a. Monitor NG/OG tube output"
    },
    {
      "type": "text",
      "section": "C. Considerations",
      "line": 7253,
      "preview": "b. Follow signs of bowel function."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7255
    },
    {
      "type": "text",
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7257,
      "preview": "1. Bowel contents easily reduced after birth."
    },
    {
      "type": "text",
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7258,
      "preview": "a. Surgeon will wrap the umbilical cord over opening, apply a pressure dressing (Tegaderm ${ }^{\\tex"
    },
    {
      "type": "text",
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7259,
      "preview": "b. Tegaderm ${ }^{\\text {TM }}$ may be removed after 7 days and wound left open to air, per surgical"
    },
    {
      "type": "text",
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7260,
      "preview": "c. Cord forms an eschar over the site as abdominal defect beneath contracts in and granulates."
    },
    {
      "type": "text",
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7261,
      "preview": "i. Wait for eschar to spontaneously fall off."
    },
    {
      "type": "text",
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7262,
      "preview": "ii. Wound care managed by Peds Surgery NP"
    },
    {
      "type": "text",
      "section": "E. Primary Reduction with Sutureless Closure of Gastroschisis",
      "line": 7264,
      "preview": "--- page 303 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7266
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7268,
      "preview": "1. When intestines are inflamed a temporary silo is needed."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7269,
      "preview": "a. Bentec\u00a9 silo 5 cm used and applied at bedside or in OR. Other available sizes, rarely used, are B"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7270,
      "preview": "b. Reduction once bowel softer, more pliable:"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7271,
      "preview": "i. At bedside, surgical team will reduce bowel in silo daily until bowel within abdominal caviy; usu"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7272,
      "preview": "ii. Administration of sucrose and/or morphine or fentanyl to aid with pain relief, sedation as neede"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7273,
      "preview": "c. Once bowel completely reduced, silo removed at bedside by Pediatric Surgery NP/Surgeon."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7274,
      "preview": "i. Pre-medicate with morphine or fentanyl to aid with pain relief, sedation as needed."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7275,
      "preview": "ii. Wound care supplies available:"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7276,
      "preview": "1) $3 \\mathrm{M}^{\\mathrm{TM}}$ No Sting Skin Barrier swabs"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7277,
      "preview": "2) Mepitel ${ }^{\\circledR}$ (non-adherent silicone barrier)"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7278,
      "preview": "3) Mepilex ${ }^{\\circledR} 4 \\times 4$ (silicone foam)"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7279,
      "preview": "4) Gauze $2 \\times 2$ and $4 \\times 4$"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7280,
      "preview": "5) Tegaderm ${ }^{\\text {TM }}$ (large) $\\times 2$"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7281,
      "preview": "2. Continue specific wound care regimen with supplies listed above to allow granulation and epitheli"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7282,
      "preview": "a. Administer sucrose for dressing changes at the bedside."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7283,
      "preview": "b. First week after silo removed, dressing changes performed by Peds Surgery NP/Surgeon."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7284,
      "preview": "c. Bedside RN may continue to apply dressing changes as directed by Peds Surgery NP/Surgeon (refer t"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7285,
      "preview": "3. The use of negative pressure wound therapy device (wound V.A.C. therapy) may be utilized at the d"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7286,
      "preview": "a. Refer to LPCH Policy \\& Procedure: Wound Care - Wound Vacuum Assisted Closure (V.A.C.) Device Man"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7287,
      "preview": "i. Pre-fill the drainage canister with water to limit the drainage collection to about 50-100 ml or "
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7288,
      "preview": "ii. The suction pressure will be determined by the pediatric surgeon/NP. (Usually pressure of 50-75 "
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7290,
      "preview": "--- page 304 ---"
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7292,
      "preview": "1. Reducible umbilical hernia is common."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7293,
      "preview": "a. Will spontaneously close over time."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7294,
      "preview": "b. If by school-age, hernia still evident, then surgical repair is an option."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7295,
      "preview": "2. Follow-up with pediatric surgery in the outpatient setting."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7296,
      "preview": "3. Epithelialized skin over abdominal defect for complete closure."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7297,
      "preview": "4. When sutures applied, closure is off-center from natural umbilicus."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7298,
      "preview": "5. Patient tolerates oral intake, growing, and developing normally."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7299,
      "preview": "6. Long-term morbidity related to intestinal dysfunction and wound problems."
    },
    {
      "type": "text",
      "section": "F. Reduction of Gastroschisis with Silo and Sutureless Closure",
      "line": 7300,
      "preview": "7. Prognosis depends on severity of associated problems (e.g. prematurity, intestinal atresia, short"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Omphalocele",
      "line": 7302
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Definition",
      "line": 7304
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7306,
      "preview": "1. Abdominal wall defect in which intestines, liver, and occasionally other organs remain outside ab"
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7307,
      "preview": "2. Sac protrudes in midline, through umbilicus, may be central, epigastric or hypogastric."
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7308,
      "preview": "3. Contained in translucent sac composed of amnion, Wharton jelly, and peritoneum; usually occurs at"
    },
    {
      "type": "text",
      "section": "A. Definition",
      "line": 7309,
      "preview": "4. Sac may be ruptured in 10-20\\% of cases and surgical primary closure or placement of Bentec silo "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Categorized as:",
      "line": 7311
    },
    {
      "type": "text",
      "section": "B. Categorized as:",
      "line": 7313,
      "preview": "1. Liver-containing (i.e., giant omphalocele, diameter of defect $>10 \\mathrm{~cm}$ )."
    },
    {
      "type": "text",
      "section": "B. Categorized as:",
      "line": 7314,
      "preview": "a. Small, undeveloped abdominal and thoracic cavities."
    },
    {
      "type": "text",
      "section": "B. Categorized as:",
      "line": 7315,
      "preview": "b. May be associated with restrictive lung disease and pulmonary hypoplasia."
    },
    {
      "type": "text",
      "section": "B. Categorized as:",
      "line": 7316,
      "preview": "c. Usually more difficult operative closures."
    },
    {
      "type": "text",
      "section": "B. Categorized as:",
      "line": 7317,
      "preview": "2. Non-liver containing (i.e. containing only bowel, diameter of defect $4-10 \\mathrm{~cm}$ )."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Comorbidities",
      "line": 7319
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7321,
      "preview": "1. Babies with omphalocele have a $35-80 \\%$ incidence of other clinical problems, such as congenita"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7322,
      "preview": "2. Incidence of associated chromosomal abnormalities is $10-40 \\%$"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7324,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7326,
      "preview": "--- page 305 ---"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7328,
      "preview": "a. Trisomies $12,13,15,18$, and 21 are seen"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7329,
      "preview": "b. Chromosomal abnormality (e.g., Trisomy 18, 21, or 13) present in 40-60\\% of fetuses with omphaloc"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7330,
      "preview": "3. Fetuses with liver-containing omphaloceles typically have normal karyotypes while smaller defects"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7331,
      "preview": "a. Aneuploidy"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7332,
      "preview": "b. Beckwith-Wiedemann syndrome"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7333,
      "preview": "i. Omphalocele, macroglossia, visceromegaly, hypoglycemia (secondary to islet-cell hyperplasia)."
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7334,
      "preview": "ii. Large, rounded facial features."
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7335,
      "preview": "iii. Genitourinary abnormalities"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7336,
      "preview": "iv. Increased risk of Wilm's tumor, hepatoblastoma, adrenocortical neoplasms."
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7337,
      "preview": "4. Pentalogy of Cantrell"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7338,
      "preview": "a. Epigastric omphalocele associated with a cleft sternum and anterior diaphragmatic hernia (Morgagn"
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7339,
      "preview": "b. Cardiac defects (e.g., ectopia cordis, VSD); absent pericardium."
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7340,
      "preview": "c. Amniotic band syndrome; schisis association."
    },
    {
      "type": "text",
      "section": "C. Comorbidities",
      "line": 7341,
      "preview": "d. OEIS syndrome (omphalocele, extrophy of the bladder, imperforate anus, spinal defects)."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Daily Nursing Considerations",
      "line": 7343
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7345,
      "preview": "1. At delivery: wrap defect with gauze/kerlix\u00ae moistened with normal saline and Saran ${ }^{\\text {T"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7346,
      "preview": "2. Notify Pediatric Surgery Service"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7347,
      "preview": "3. Open abdominal wound: extruded intestine puts these patients at increased risk for hypothermia, d"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7348,
      "preview": "a. Parenteral nutrition for patients with GI dysfunction"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7349,
      "preview": "b. Antibiotic coverage"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7350,
      "preview": "c. Vascular access"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7351,
      "preview": "d. OG/NG tube to LCS placed for abdominal decompression"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7352,
      "preview": "e. Cardiopulmonary support as needed"
    },
    {
      "type": "text",
      "section": "D. Daily Nursing Considerations",
      "line": 7353,
      "preview": "f. Assessment for associated anomalies and appropriate consults"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7355
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7357,
      "preview": "1. In the past, giant omphaloceles required multiple surgeries resulting in significant medical morb"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7359,
      "preview": "--- page 306 ---"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7361,
      "preview": "Giant omphalocele is associated with small, bell-shaped thoracic cavities and pulmonary hypoplasia. "
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7362,
      "preview": "a. Silvadene ${ }^{\\circledR}$ (silver sulfadiazine) - accepted use with no complications"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7363,
      "preview": "b. Compression with ACE\u00ae wrap"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7364,
      "preview": "c. Custom-made foam silo"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7365,
      "preview": "2. Criteria include the following:"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7366,
      "preview": "a. Meets definition for giant omphalocele"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7367,
      "preview": "b. Cardiopulmonary status is stable"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7368,
      "preview": "c. Any signs and symptoms of infection being treated"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7369,
      "preview": "3. Plan for therapy"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7370,
      "preview": "a. Consult occupational therapy (OT)."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7371,
      "preview": "b. Pediatric Surgery NP, bedside RN and OT will work with the families to teach them how to apply th"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7372,
      "preview": "c. Supplies:"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7373,
      "preview": "i. Silvadene ${ }^{\\circledR}$ cream"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7374,
      "preview": "ii. $4 \\times 4$ gauze"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7375,
      "preview": "iii. Kerlix ${ }^{\\circledR}$ gauze"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7376,
      "preview": "iv. ACE\u00ae wrap (2\" or 3\")"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7377,
      "preview": "v. Foam (blue \\& brown) to form silo/splint, Velcro\u00ae straps"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7378,
      "preview": "vi. Tape and Scissors"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7379,
      "preview": "vii. Skin barrier (if needed)"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7381,
      "preview": "1) Hydrocolloid (Duoderm\u00ae or Comfeel\u00ae)"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7382,
      "preview": "2) $3 \\mathrm{M}^{\\mathrm{TM}}$ No-Sting Skin Barrier Spray"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7383,
      "preview": "viii. Suspension (if needed), refer to OT \\& Peds Surgery NP"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7384,
      "preview": "4. Goals of therapy"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7385,
      "preview": "a. Prevent infection."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7387,
      "preview": "--- page 307 ---"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7389,
      "preview": "300 Part II-F: Gastrointestinal"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7390,
      "preview": "b. Aid with epithelialization over the sac."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7391,
      "preview": "c. Protect visceral organs."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7392,
      "preview": "i. Liver is in epigastrium, prevent trauma."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7393,
      "preview": "d. Support the abdominal lesion vertically (i.e., chimney) to allow gravity to aid with spontaneous "
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7394,
      "preview": "e. Decrease length of stay, initiate feeding, decrease complications and mortality."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7395,
      "preview": "f. Complete reduction with umbilical hernia to allow spontaneous closure over time."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7396,
      "preview": "g. By school-age, umbilical hernia may be surgically repaired."
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7397,
      "preview": "h. Discharge considerations: infants discharged with giant omphaloceles may require a special car se"
    },
    {
      "type": "text",
      "section": "E. Giant Omphalocele: Current Management",
      "line": 7399,
      "preview": "--- page 308 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Clinical Approach to Conjugated Hyperbilirubinemia (Neonatal Cholestasis)",
      "line": 7401
    },
    {
      "type": "text",
      "section": "Clinical Approach to Conjugated Hyperbilirubinemia (Neonatal Cholestasis)",
      "line": 7403,
      "preview": "Vinod K. Bhutani, M.D. and Ronald J. Wong"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Indication",
      "line": 7405
    },
    {
      "type": "text",
      "section": "I. Indication",
      "line": 7407,
      "preview": "Jaundice observed in a neonate that persists or recurs during the second week of life requires evalu"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A DIRECT BILIRUBIN LEVEL $>1 \\mathrm{mg} / \\mathrm{dL}$ SHOULD PROMPT FURTHER EVALUATION AND MANAGEMENT",
      "line": 7409
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Clinical",
      "line": 7411
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7413,
      "preview": "1. Laboratory Levels"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7414,
      "preview": "a. Direct bilirubin $>10 \\%$ of total bilirubin ( $\\mathrm{TB}<5 \\mathrm{mg} / \\mathrm{dL}$ )"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7415,
      "preview": "b. Conjugated bilirubin $>1 \\mathrm{mg} / \\mathrm{dL}(\\mathrm{TB}<5 \\mathrm{mg} / \\mathrm{dL})$"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7416,
      "preview": "c. Direct bilirubin $>20 \\%$ of TB ( $\\mathrm{TB}>5 \\mathrm{mg} / \\mathrm{dL}$ )"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7417,
      "preview": "d. Conjugated bilirubin $>2 \\mathrm{mg} / \\mathrm{dL}(\\mathrm{TB}>5 \\mathrm{mg} / \\mathrm{dL})$"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7418,
      "preview": "2. Clinical Risk Factors for Direct Hyperbilirubinemia"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7419,
      "preview": "a. An infant noted to be jaundiced at 2 wks of age should be evaluated for cholestasis with measurem"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7420,
      "preview": "3. Clinical Manifestations"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7421,
      "preview": "a. Onset of jaundice after the first week of age should be considered abnormal"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7422,
      "preview": "b. Persistence of jaundice after 2 wks of age should be considered abnormal"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7423,
      "preview": "c. Association of pale stools and/or dark urine should be an alert for cholestasis"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7424,
      "preview": "B. Testing. The most commonly-used laboratory determination (the diazo or van den Bergh method) does"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7426,
      "preview": "--- page 309 ---"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7428,
      "preview": "| CONDITION | DISORDERS |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7429,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7430,
      "preview": "| Idiopathic | Neonatal hepatitis |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7431,
      "preview": "| Viral Infections | Cytomegalovirus <br> Rubella Reovirus3 <br> Adenovirus <br> Coxsackie virus <br"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7432,
      "preview": "| Bacterial Infections | Sepsis <br> Urinary tract infection <br> Syphilis <br> Listeriosis <br> Tub"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7433,
      "preview": "| Parasitic Infections | Toxoplasmosis <br> Malaria |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7434,
      "preview": "| Bile Duct Anomalies | Biliary atresia <br> Choledochal cyst Alagille <br> syndrome <br> Non-syndro"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7435,
      "preview": "| Metabolic Disorders | a1-antitrypsin deficiency <br> Galactosemia <br> Glycogen storage disorder t"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7437,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Clinical",
      "line": 7439,
      "preview": "--- page 310 ---"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7441,
      "preview": "| Endocrine-Related Disorders | Hypothyroidism <br> Hypopituitarism (Septo-optic dysplasia) |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7442,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7443,
      "preview": "| Chromosomal Disorders | Turner's syndrome <br> Trisomy 18 <br> Trisomy 21 <br> Trisomy 13 <br> Cat"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7444,
      "preview": "| Toxic | Parenteral nutrition <br> Fetal alcohol syndrome <br> Drugs |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7445,
      "preview": "| Vascular | Budd-Chiari syndrome <br> Neonatal asphyxia <br> Congestive heart failure |"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7446,
      "preview": "| Neoplasm | Neonatal leukemia <br> Histiocytosis X <br> Neuroblastoma <br> Hepatoblastoma <br> Eryt"
    },
    {
      "type": "table",
      "section": "A. Clinical",
      "line": 7447,
      "preview": "| Miscellaneous | Neonatal lupus erythematosus <br> 'Le foie vide' (infantile hepatic non-regenerati"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Immediate Action",
      "line": 7449
    },
    {
      "type": "text",
      "section": "III. Immediate Action",
      "line": 7451,
      "preview": "If total parenteral nutrition (TPN) is being prescribed, either wean or discontinue IV lipid infusio"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Evaluation",
      "line": 7453
    },
    {
      "type": "table",
      "section": "IV. Evaluation",
      "line": 7455,
      "preview": "| STEPS | PROCESS |"
    },
    {
      "type": "table",
      "section": "IV. Evaluation",
      "line": 7456,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "IV. Evaluation",
      "line": 7457,
      "preview": "| Initial Investigations <br> Establish cholestasis and determine severity of the liver disease | $\\"
    },
    {
      "type": "table",
      "section": "IV. Evaluation",
      "line": 7458,
      "preview": "| Detect Conditions that require immediate treatment | $\\square$ Complete blood count (CBC), bacteri"
    },
    {
      "type": "text",
      "section": "IV. Evaluation",
      "line": 7460,
      "preview": "--- page 311 ---"
    },
    {
      "type": "table",
      "section": "IV. Evaluation",
      "line": 7462,
      "preview": "| Differentiate <br> extrahepatic disorders from <br> intrahepatic causes of <br> cholestasis | $\\sq"
    },
    {
      "type": "table",
      "section": "IV. Evaluation",
      "line": 7463,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "IV. Evaluation",
      "line": 7464,
      "preview": "| Establish <br> other specific diagnoses | $\\square$ Serum a1-antitrypsin levels and phenotype <br>"
    },
    {
      "type": "text",
      "section": "IV. Evaluation",
      "line": 7466,
      "preview": "PFIC: progressive familial intrahepatic cholestasis"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Bilirubin Follow-Up",
      "line": 7468
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7470,
      "preview": "A. Serial TB/direct bilirubin for progression of hyperbilirubinemia until levels decline"
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7472,
      "preview": "1. Newborns $\\geq 35$ wks gestational age (GA)"
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7473,
      "preview": "a. For onset of Jaundice: check immediately"
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7474,
      "preview": "b. Persistence: check every 1 to 2 days until levels plateau or decline"
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7475,
      "preview": "c. Aggressively investigate for etiology"
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7476,
      "preview": "2. Newborns < 35 wks GA"
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7477,
      "preview": "a. All infants: check levels every day initially"
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7478,
      "preview": "b. Serial follow-up until TB decline: 1 to 2 times/week based on rate of rise or decline of TB."
    },
    {
      "type": "text",
      "section": "V. Bilirubin Follow-Up",
      "line": 7479,
      "preview": "c. After significant decline: may track clinical resolution of jaundice"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Management",
      "line": 7481
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Nutritional Goal",
      "line": 7483
    },
    {
      "type": "text",
      "section": "A. Nutritional Goal",
      "line": 7485,
      "preview": "The goal is to discontinue parenteral feeds and transition to full enteral feeds. In infants that ar"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Medications.",
      "line": 7487
    },
    {
      "type": "text",
      "section": "B. Medications.",
      "line": 7489,
      "preview": "Pharmacologic management includes ursodeoxycholic acid to increase bile acid excretion. Cholecystoki"
    },
    {
      "type": "text",
      "section": "B. Medications.",
      "line": 7491,
      "preview": "--- page 312 ---"
    },
    {
      "type": "text",
      "section": "B. Medications.",
      "line": 7493,
      "preview": "Table: Formulary for Neonatal and Infant Cholestasis"
    },
    {
      "type": "table",
      "section": "B. Medications.",
      "line": 7495,
      "preview": "| Medication | Dose | Side Effects |"
    },
    {
      "type": "table",
      "section": "B. Medications.",
      "line": 7496,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "B. Medications.",
      "line": 7497,
      "preview": "| Ursodeoxycholic acid | 10 to $30 \\mathrm{mg} / \\mathrm{kg} /$ day | Diarrhea, hepatotoxicity |"
    },
    {
      "type": "table",
      "section": "B. Medications.",
      "line": 7498,
      "preview": "| Rifampin | $10 \\mathrm{mg} / \\mathrm{kg} /$ day | Hepatotoxicity, drug interactions |"
    },
    {
      "type": "table",
      "section": "B. Medications.",
      "line": 7499,
      "preview": "| Phenobarbital | 3 to $10 \\mathrm{mg} / \\mathrm{kg} /$ day | Sedative effects, behavioral changes |"
    },
    {
      "type": "table",
      "section": "B. Medications.",
      "line": 7500,
      "preview": "| Cholestyramine | 0.25 to 0.50 <br> $\\mathrm{gm} / \\mathrm{kg} /$ day | Constipation, steatorrhea, "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Growth Parameters and Nutrition Assessment",
      "line": 7502
    },
    {
      "type": "text",
      "section": "C. Growth Parameters and Nutrition Assessment",
      "line": 7504,
      "preview": "Height- and weight-for-age and weigh- for-height, should be closely followed by tracking growth velo"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Nutrient Choices",
      "line": 7506
    },
    {
      "type": "text",
      "section": "D. Nutrient Choices",
      "line": 7508,
      "preview": "Long chain fatty acids are not well absorbed and this leads to malnutrition and fat-soluble vitamin "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "E. Vitamins",
      "line": 7510
    },
    {
      "type": "text",
      "section": "E. Vitamins",
      "line": 7512,
      "preview": "The intestinal absorption of fat-soluble vitamins (A, D, E, and K) requires the presence of bile aci"
    },
    {
      "type": "text",
      "section": "E. Vitamins",
      "line": 7514,
      "preview": "Table: Vitamin Supplement for Neonatal and Infant Cholestasis"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7516,
      "preview": "| Vitamins | Dose | Side-effects |"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7517,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7518,
      "preview": "| Vitamin A (Aquasol A\u00ae) | 5000 to $25,000 \\mathrm{IU} /$ day | Hepatotoxicity, hypercalcemia |"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7519,
      "preview": "| Vitamin D: cholecalciferol <br> 25-OH cholecalciferol | 2500 to $5000 \\mathrm{IU} /$ day <br> 3 to"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7520,
      "preview": "| Vitamin K (Phytonadione) | 2.5 to 5.0 mg every other day | None |"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7521,
      "preview": "| Vitamin E (Aquasol E\u00ae) | 50 to $400 \\mathrm{IU} /$ day | Potentiation of coagulopathy |"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7522,
      "preview": "| TPGS (d-alpha tocopheryl <br> polyethylene glycol-succinate) | 15 to $25 \\mathrm{IU} / \\mathrm{kg}"
    },
    {
      "type": "table",
      "section": "E. Vitamins",
      "line": 7523,
      "preview": "| Water-Soluble Vitamins | Twice the recommended daily allowance |  |"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Phototherapy Use for Neonates with Cholestasis",
      "line": 7525
    },
    {
      "type": "text",
      "section": "F. Phototherapy Use for Neonates with Cholestasis",
      "line": 7527,
      "preview": "The bronze infant syndrome is the dark, grayish-brown discoloration of skin as a complication of pho"
    },
    {
      "type": "text",
      "section": "F. Phototherapy Use for Neonates with Cholestasis",
      "line": 7529,
      "preview": "--- page 313 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 7531
    },
    {
      "type": "text",
      "section": "References",
      "line": 7533,
      "preview": "1. Best C, Glenn GR, BhutaniVK. Neonatal Cholestasis-conjugated Hyperbilirubinema. Textbook of Neona"
    },
    {
      "type": "text",
      "section": "References",
      "line": 7534,
      "preview": "2. Walker WA, KR, et al, Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management."
    },
    {
      "type": "text",
      "section": "References",
      "line": 7535,
      "preview": "3. Moyer V, et al., Guideline for the evaluation of cholestatic jaundice in infants: recommendations"
    },
    {
      "type": "text",
      "section": "References",
      "line": 7536,
      "preview": "4. Venigalla S, Gourley GR, Neonatal cholestasis. Semin Perinatol, 2004; 28(5): p. 348-55."
    },
    {
      "type": "text",
      "section": "References",
      "line": 7537,
      "preview": "5. Frederick Suchy RS, Liver Disease in Children. 3rd ed. 2007, New York: Cambridge Unviversity Pres"
    },
    {
      "type": "text",
      "section": "References",
      "line": 7538,
      "preview": "6. Coakley RJ, et al., Alpha1-antitrypsin deficiency: Biological answers to clinical questions. Am J"
    },
    {
      "type": "text",
      "section": "References",
      "line": 7539,
      "preview": "7. Lomas DA, et al., The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature, 1992;"
    },
    {
      "type": "text",
      "section": "References",
      "line": 7540,
      "preview": "8. Suchy FJ, Neonatal cholestasis. Pediatr Rev, 2004; 25(11): p. 388-96."
    },
    {
      "type": "text",
      "section": "References",
      "line": 7542,
      "preview": "--- page 314 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-G: Renal and Genitourinary",
      "line": 7544
    },
    {
      "type": "text",
      "section": "Part II-G: Renal and Genitourinary",
      "line": 7546,
      "preview": "--- page 315 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Management of Hypertension",
      "line": 7548
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Abanti Chaudhuri, M.D.",
      "line": 7550
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition:",
      "line": 7552
    },
    {
      "type": "text",
      "section": "I. Definition:",
      "line": 7554,
      "preview": "A. Blood pressure (BP) elevated above the upper $95 \\%$ confidence interval for neonates/infants of "
    },
    {
      "type": "text",
      "section": "I. Definition:",
      "line": 7555,
      "preview": "B. Incidence $0.2-3 \\%$ (NICUs tend to be on the higher end of the range)."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Normative blood pressure data:",
      "line": 7557
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7559,
      "preview": "A. One challenge when diagnosing hypertension in neonates is the fact that the normative BP range is"
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7560,
      "preview": "B. The following two figures and one table are three sources of normative data:"
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7562,
      "preview": "Figure 1. Linear regression of mean systolic and diastolic blood pressures by postconceptual age (we"
    },
    {
      "type": "image",
      "section": "II. Normative blood pressure data:",
      "line": 7563,
      "content": "![img-59.jpeg](images/c26995abd64cb5d9.png)"
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7565,
      "preview": "--- page 316 ---"
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7567,
      "preview": "Figure 2. Age-specific blood pressure percentiles for boys (a) and girls (b) during the 1st 12 mos o"
    },
    {
      "type": "image",
      "section": "II. Normative blood pressure data:",
      "line": 7568,
      "content": "![img-60.jpeg](images/ef487dad352af7cd.png)"
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7570,
      "preview": "Table 1: Estimated values for blood pressures after two weeks of age in infants from 26 to 44 weeks "
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7572,
      "preview": "| Postconceptual age |  | 50th percentile | 95th percentile | 99th percentile |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7573,
      "preview": "| :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7574,
      "preview": "| 44 Weeks | SBP | 88 | 105 | 110 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7575,
      "preview": "|  | DBP | 50 | 68 | 73 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7576,
      "preview": "|  | MAP | 63 | 80 | 85 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7577,
      "preview": "| 42 Weeks | SBP | 85 | 98 | 102 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7578,
      "preview": "|  | DBP | 50 | 65 | 70 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7579,
      "preview": "|  | MAP | 62 | 76 | 81 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7580,
      "preview": "| 40 Weeks | SBP | 80 | 95 | 100 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7581,
      "preview": "|  | DBP | 50 | 65 | 70 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7582,
      "preview": "|  | MAP | 60 | 75 | 80 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7583,
      "preview": "| 38 Weeks | SBP | 77 | 92 | 97 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7584,
      "preview": "|  | DBP | 50 | 65 | 70 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7585,
      "preview": "|  | MAP | 59 | 74 | 79 |"
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7587,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Normative blood pressure data:",
      "line": 7589,
      "preview": "--- page 317 ---"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7591,
      "preview": "| 36 Weeks | SBP | 72 | 87 | 92 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7592,
      "preview": "| :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7593,
      "preview": "|  | DBP | 50 | 65 | 70 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7594,
      "preview": "|  | MAP | 57 | 72 | 71 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7595,
      "preview": "| 34 Weeks | SBP | 70 | 85 | 90 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7596,
      "preview": "|  | DBP | 40 | 55 | 60 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7597,
      "preview": "|  | MAP | 50 | 65 | 70 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7598,
      "preview": "| 32 Weeks | SBP | 68 | 83 | 88 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7599,
      "preview": "|  | DBP | 40 | 55 | 60 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7600,
      "preview": "|  | MAP | 48 | 62 | 69 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7601,
      "preview": "| 30 Weeks | SBP | 65 | 80 | 85 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7602,
      "preview": "|  | DBP | 40 | 55 | 60 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7603,
      "preview": "|  | MAP | 48 | 65 | 68 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7604,
      "preview": "| 28 Weeks | SBP | 60 | 75 | 80 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7605,
      "preview": "|  | DBP | 38 | 50 | 54 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7606,
      "preview": "|  | MAP | 45 | 58 | 63 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7607,
      "preview": "| 26 Weeks | SBP | 55 | 72 | 77 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7608,
      "preview": "|  | DBP | 30 | 50 | 56 |"
    },
    {
      "type": "table",
      "section": "II. Normative blood pressure data:",
      "line": 7609,
      "preview": "|  | MAP | 38 | 57 | 63 |"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Diagnosis of hypertension",
      "line": 7611
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7613,
      "preview": "A. Appropriate BP monitoring can be obtained using the following methods:"
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7615,
      "preview": "1. Manual oscillometry"
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7616,
      "preview": "B. Most normative BP data has been collected using measurements obtained in the right arm."
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7617,
      "preview": "C. BPs should be obtained/recorded while asleep, as increased activity, including oral feeding, can "
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7618,
      "preview": "D. If oscillometry is used:"
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7619,
      "preview": "2. Measurements should be obtained in upper extremity, as measurements in the lower extremities are "
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7620,
      "preview": "3. BPs should be obtained in the same extremity for subsequent measurements."
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7621,
      "preview": "4. The cuff bladder should be $2 / 3$ the length of the arm and 0.44 to 0.55 of the arm circumferenc"
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7622,
      "preview": "5. If choosing between a cuff that is too large and too small, use the cuff that is too large."
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7623,
      "preview": "6. Consider checking BP 10-15 min after BP cuff has been applied."
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7624,
      "preview": "E. If hypertension is suspected, the measurement should be repeated several times."
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7625,
      "preview": "F. Diagnosis of hypertension requires 2-3 appropriately measured blood pressures greater than the 95"
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7626,
      "preview": "G. Once diagnosis is made, the Pediatric Nephrology Service should be consulted."
    },
    {
      "type": "text",
      "section": "III. Diagnosis of hypertension",
      "line": 7628,
      "preview": "--- page 318 ---"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7630,
      "preview": "| Etiologic Categories of Neonatal Hypertension |  |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7631,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7632,
      "preview": "| Renovascular | Medications/Drugs |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7633,
      "preview": "| Thromboembolism (especially with umbilical artery | Maternal cocaine exposure |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7634,
      "preview": "| catheterization) | Maternal heroin exposure |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7635,
      "preview": "| Renal artery stenosis | Corticosteroids |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7636,
      "preview": "| Renal artery compression | Theophylline |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7637,
      "preview": "| Renal vein thrombosis | Caffeine |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7638,
      "preview": "| Coarctation of the aorta | Pancuronium |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7639,
      "preview": "| Idiopathic arterial calcification | Phenylephrine |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7640,
      "preview": "| Abdominal aortic aneurysm | Vitamin D intoxication |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7641,
      "preview": "|  | Adrenergic agents |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7642,
      "preview": "| Renal parenchymal disease | Pulmonary |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7643,
      "preview": "| Polycystic kidney disease (ARPKD/ADPKD) | Bronchopulmonary dysplasia |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7644,
      "preview": "| Renal dysplasia/hypoplasia | Pneumothorax |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7645,
      "preview": "| Multicystic kidney disease | Neurologic |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7646,
      "preview": "| Obstructive uropathy | Pain |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7647,
      "preview": "| Acute tubular necrosis/Cortical necrosis | Seizures |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7648,
      "preview": "| Resolving acute kidney injury | Inadequate sedation |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7649,
      "preview": "| Pyelonephritis | Intracranial hypertension |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7650,
      "preview": "| Nephrocalcinosis | Intraventricular or intracranial hemorrhage |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7651,
      "preview": "| Tuberous sclerosis | Subdural hematoma |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7652,
      "preview": "| Hemolytic uremic syndrome | Familial dysautonomia |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7653,
      "preview": "| Interstitial nephritis | Miscellaneous |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7654,
      "preview": "| Endocrine | Monogenic hypertension |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7655,
      "preview": "| Congenital adrenal hyperplasia | Hypercalcemia |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7656,
      "preview": "| Hyperaldosteronism | Fluid overload |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7657,
      "preview": "| Hyperthyroidism | Adrenal hemorrhage |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7658,
      "preview": "|  | Prolonged total parental nutrition administration |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7659,
      "preview": "| Neoplasia | Closure of an abdominal wall defect |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7660,
      "preview": "| Wilms tumor | ECMO |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7661,
      "preview": "| Neuroblastoma | Birth asphyxia |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7662,
      "preview": "| Mesoblastic nephroma |  |"
    },
    {
      "type": "table",
      "section": "III. Diagnosis of hypertension",
      "line": 7663,
      "preview": "| Pheochromocytoma |  |"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Neonatal hypertension preliminary diagnostic evaluation",
      "line": 7665
    },
    {
      "type": "text",
      "section": "V. Neonatal hypertension preliminary diagnostic evaluation",
      "line": 7667,
      "preview": "A. Review of potential iatrogenic causes (medications, volume overload, pain, sedation)"
    },
    {
      "type": "text",
      "section": "V. Neonatal hypertension preliminary diagnostic evaluation",
      "line": 7668,
      "preview": "B. Review of UAC history (UAC placed yes/no, date placed, date removed)"
    },
    {
      "type": "text",
      "section": "V. Neonatal hypertension preliminary diagnostic evaluation",
      "line": 7669,
      "preview": "C. Increased frequency of BP monitoring (Q2-4 hrs)"
    },
    {
      "type": "text",
      "section": "V. Neonatal hypertension preliminary diagnostic evaluation",
      "line": 7670,
      "preview": "D. 4 extremity BPs"
    },
    {
      "type": "text",
      "section": "V. Neonatal hypertension preliminary diagnostic evaluation",
      "line": 7671,
      "preview": "E. Chem 10 Panel, urinalysis, renin, aldosterone, CBC"
    },
    {
      "type": "text",
      "section": "V. Neonatal hypertension preliminary diagnostic evaluation",
      "line": 7672,
      "preview": "F. Renal ultrasound with Doppler evaluation"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7674
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7676,
      "preview": "A. Treatment is patient-specific."
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7677,
      "preview": "B. Drug therapy should be considered when the neonate's BP is consistently at the 99th percentile or"
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7679,
      "preview": "--- page 319 ---"
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7681,
      "preview": "312 Part II-G: Renal Genitourinary"
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7682,
      "preview": "Treatment should be started earlier if systemic symptoms exist or there is evidence of end organ dam"
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7683,
      "preview": "C. Prior to initiating therapy, all iatrogenic causes should be assessed and eliminated."
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7684,
      "preview": "D. Laboratory evaluation should be performed prior to initiating therapy."
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7685,
      "preview": "E. As soon as you begin treating an infant for hypertension, begin thinking about obtaining insuranc"
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7686,
      "preview": "Pediatric/dp/B009FOHPFU/ref=sr 11 a it?ie=UTF8\\&qid=1499973993\\&sr=8-"
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7687,
      "preview": "1\\&keywords=cms+08a+blood+pressure+pediatric"
    },
    {
      "type": "text",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7688,
      "preview": "F. Antihypertensive agents"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7690,
      "preview": "| ANTIHYPERTENSIVE THERAPUTIC AGENTS |  |  |  |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7691,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7692,
      "preview": "| Oral/Topical Antihypertensive Agents |  |  |  |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7693,
      "preview": "| Agent | Class | Dose | Comments |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7694,
      "preview": "| Isradipine | Ca++ channel blocker | - 0.05-0.15mg/kg/dose May be given up to QID | Onset 30 min <b"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7695,
      "preview": "| Amlodipine | Ca++ channel blocker | - 0.05-0.3mg/kg/dose <br> - MAX $0.6 \\mathrm{mg} / \\mathrm{kg}"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7696,
      "preview": "| Clonidine patch | Central $\\alpha 2$ agonist | - 1/8-1/4 patch to begin <br> Patch changed Q7days "
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7697,
      "preview": "| Propranolol | $\\beta$ blocker | - $0.5-1 \\mathrm{mg} / \\mathrm{kg} /$ dose <br> - MAX $8-10 \\mathr"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7698,
      "preview": "| Labetalol | $\\alpha$ and $\\beta$ blocker | - $0.5-1 \\mathrm{mg} / \\mathrm{kg} /$ dose <br> - MAX $"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7699,
      "preview": "| Hydrochlorothiazide | Thiazide diuretic | - 1-1.5mg/kg/dose Daily to BID | Monitor electrolytes |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7700,
      "preview": "| Chlorothiazide | Thiazide diuretic | - 5-15mg/kg/dose Up to BID | Monitor electrolytes |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7701,
      "preview": "| Spironolactone | Aldosterone antagonist | - 0.5-1.5mg/kg/dose Up to BID | Monitor electrolytes |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7702,
      "preview": "| Captopril | ACE Inhibitor | - (<3mo) 0.01$0.5 \\mathrm{mg} / \\mathrm{kg} /$ dose <br> - MAX $2 \\mat"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7703,
      "preview": "| Enalapril | ACE Inhibitor | - 0.05-0.1mg/kg/dose Daily to BID |  |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7704,
      "preview": "| Intravenous Antihypertensive Agents |  |  |  |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7705,
      "preview": "| Agent | Class | Dose | Comments |"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7706,
      "preview": "| Hydralazine | Vasodilator | - 0.1-0.2mg/kg/dose Up to Q4 hrs | Can cause fluid retention If used l"
    },
    {
      "type": "table",
      "section": "VI. Treatment of neonatal hypertension",
      "line": 7707,
      "preview": "| Labetalol | $\\alpha$ and $\\beta$ blocker | - 0.2-1mg/kg/dose Q4-6 hours | May cause reflex tachyca"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7709
    },
    {
      "type": "text",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7711,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7713,
      "preview": "--- page 320 ---"
    },
    {
      "type": "table",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7715,
      "preview": "| Agent | Class | Dose | Comments |"
    },
    {
      "type": "table",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7716,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7717,
      "preview": "| Esmolol | $\\beta$ blocker | - 100-500 $\\mu \\mathrm{g} / \\mathrm{kg} / \\mathrm{min}$ | Extremely sh"
    },
    {
      "type": "table",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7718,
      "preview": "| Labetalol | $\\alpha$ and $\\beta$ Blocker | - $0.25-3 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{hr}$ | Av"
    },
    {
      "type": "table",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7719,
      "preview": "| Nitroprusside | Vasodilator | - $0.5-10 \\mu \\mathrm{~g} / \\mathrm{kg} / \\mathrm{min}$ | Thiocyanat"
    },
    {
      "type": "table",
      "section": "Continuous Infusion Antihypertensive Agents",
      "line": 7720,
      "preview": "| Nicardipine | Ca++ channel blocker | - $0.5-4 \\mu \\mathrm{~g} / \\mathrm{kg} / \\mathrm{min}$ | Can "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 7722
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7724,
      "preview": "1. Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pedi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7725,
      "preview": "2. Flynn JT. Neonatal hypertension: diagnosis and management. Pediatr Nephrol 2000; 14:332."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7726,
      "preview": "3. Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7727,
      "preview": "4. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children a"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7728,
      "preview": "5. National High Blood Pressure Education Program Working Group on Hypertension Control in Children "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7730,
      "preview": "--- page 321 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Neonatal Acute Kidney Injury (AKI)",
      "line": 7732
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Scott Sutherland, M.D.",
      "line": 7734
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 7736
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 7738,
      "preview": "A. Acute Kidney Injury (AKI) has replaced the term \"Acute Renal Failure\" and is defined as an abrupt"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 7739,
      "preview": "B. Historically, AKI has been defined as \"an elevated serum creatinine\" or the onset of oliguria. Ho"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 7740,
      "preview": "C. Formal application of the below definition may not always be appropriate in the clinical setting."
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 7741,
      "preview": "D. Unlike adult onset AKI, neonatal AKI is often non-oliguric and urine output is an insensitive mar"
    },
    {
      "type": "table",
      "section": "I. Definition",
      "line": 7743,
      "preview": "| AKI <br> Stage | Creatinine Criteria for AKI Staging | Urine Output Criteria for AKI Staging |"
    },
    {
      "type": "table",
      "section": "I. Definition",
      "line": 7744,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "I. Definition",
      "line": 7745,
      "preview": "| 0 | No change in serum creatinine $\\underline{\\text { OR }}$ absolute change $<0.3 \\mathrm{mg} / \\"
    },
    {
      "type": "table",
      "section": "I. Definition",
      "line": 7746,
      "preview": "| 1 | Increase in serum creatinine of $\\geq 1.5-1.9 \\times$ baseline (previous trough) within 7 days"
    },
    {
      "type": "table",
      "section": "I. Definition",
      "line": 7747,
      "preview": "| 2 | Increase in serum creatinine $\\geq 2.0-2.9 \\times$ baseline (previous trough) within 7 days | "
    },
    {
      "type": "table",
      "section": "I. Definition",
      "line": 7748,
      "preview": "| 3 | Increase in serum creatinine $\\geq 3.0 \\times$ baseline (previous trough) within 7 days OR ser"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Determining renal function and normative GFR Data",
      "line": 7750
    },
    {
      "type": "text",
      "section": "II. Determining renal function and normative GFR Data",
      "line": 7752,
      "preview": "A. Currently, the creatinine clearance or glomerular filtration rate (GFR) is best estimated using t"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7754
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7756,
      "preview": "In this equation, \" $k$ \" represents a constant that is multiplied by the patient's height in cm and"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7758,
      "preview": "The current recommendation is to calculate the estimated GFR by both methods and report those two va"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7760,
      "preview": "--- page 322 ---"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7762,
      "preview": "B. GFR doesn't reach normal adult values ( $120 \\mathrm{~mL} / \\mathrm{min} / 1.73 \\mathrm{~m} 2)$ u"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7764,
      "preview": "1. Term neonate at birth:"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7765,
      "preview": "$25-30 \\mathrm{~mL} / \\mathrm{min} / 1.73 \\mathrm{~m} 2$"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7766,
      "preview": "2. Term neonate at 1-2 weeks of age: $40-55 \\mathrm{~mL} / \\mathrm{min} / 1.73 \\mathrm{~m} 2$"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7767,
      "preview": "3. 2-6 month old infant:"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7768,
      "preview": "$60-80 \\mathrm{~mL} / \\mathrm{min} / 1.73 \\mathrm{~m} 2$"
    },
    {
      "type": "text",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7769,
      "preview": "4. Normal GFR values for preterm neonates at $7,14,21$, and 28 days of life."
    },
    {
      "type": "table",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7771,
      "preview": "| Gestatonal Age | Post-natal Age | GFR |"
    },
    {
      "type": "table",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7772,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7773,
      "preview": "| 27 weeks | 7 days <br> 14 days <br> 21 days <br> 28 days | $\\begin{aligned} & 13.4(7.9-18.9) \\\\ & "
    },
    {
      "type": "table",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7774,
      "preview": "| 28 weeks | 7 days <br> 14 days <br> 21 days <br> 28 days | $\\begin{aligned} & 16.2(10.7-21.7) \\\\ &"
    },
    {
      "type": "table",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7775,
      "preview": "| 29 weeks | 7 days <br> 14 days <br> 21 days <br> 28 days | $\\begin{aligned} & 19.1(13.6-24.6) \\\\ &"
    },
    {
      "type": "table",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7776,
      "preview": "| 30 weeks | 7 days <br> 14 days <br> 21 days <br> 28 days | $\\begin{aligned} & 21.9(16.4-27.4) \\\\ &"
    },
    {
      "type": "table",
      "section": "(k) * (height/length in centimeters) <br> Serum creatinine",
      "line": 7777,
      "preview": "| 31 weeks | 7 days <br> 14 days <br> 21 days <br> 28 days | $\\begin{aligned} & 24.8(19.3-30.3) \\\\ &"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Incidence of AKI",
      "line": 7779
    },
    {
      "type": "text",
      "section": "III. Incidence of AKI",
      "line": 7781,
      "preview": "A. The incidence of AKI in newborns ranges from $0.4-3.5 \\%$. The incidence in the NICU, however, ma"
    },
    {
      "type": "text",
      "section": "III. Incidence of AKI",
      "line": 7782,
      "preview": "B. Incidence may be higher in at risk groups:"
    },
    {
      "type": "text",
      "section": "III. Incidence of AKI",
      "line": 7784,
      "preview": "1. $18 \\%$ in very low birthweight (VLBW) infants between $500-1500 \\mathrm{~g}$."
    },
    {
      "type": "text",
      "section": "III. Incidence of AKI",
      "line": 7785,
      "preview": "2. $52 \\%$ in infants with congenital heart disease (CHD)."
    },
    {
      "type": "text",
      "section": "III. Incidence of AKI",
      "line": 7786,
      "preview": "3. $56 \\%$ in neonates experiencing severe HIE."
    },
    {
      "type": "text",
      "section": "III. Incidence of AKI",
      "line": 7787,
      "preview": "4. $4-70 \\%$ in neonates receiving ECMO."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7789
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7791,
      "preview": "A. Renal embryogenesis/glomerulogenesis is complete by 35 weeks gestation. Injuries prior to this po"
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7792,
      "preview": "B. The perinatal period sees a transition towards increased renal blood flow. Renal blood flow is 2-"
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7794,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7796,
      "preview": "--- page 323 ---"
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7798,
      "preview": "cardiac output in the fetus, but increases to $10 \\%$ in the first post-natal week."
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7799,
      "preview": "C. Autoregulation of renal blood flow in neonates is less robust than in adults. Neonates are less c"
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7800,
      "preview": "D. Neonates have a reduced capacity to concentrate the urine and are at greater AKI risk in the sett"
    },
    {
      "type": "text",
      "section": "IV. Renal physiologic concepts relevant to neonatal AKI",
      "line": 7801,
      "preview": "E. Neonates have increased insensible water loss through the skin. Thus, they may be predisposed to "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7803
    },
    {
      "type": "text",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7805,
      "preview": "Common causes are starred."
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7807,
      "preview": "| Etiologic Categories of Neonatal AKI |  |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7808,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7809,
      "preview": "| Prerenal/Inadequate Renal Perfusion | Post-Renal/Obstruction |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7810,
      "preview": "| Dehydration/Hypovolemia* | Posterior urethral valves |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7811,
      "preview": "| Hypotension/Shock* | Obstructive uropathy (ureterocele, UVJ or UPJ |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7812,
      "preview": "| Hemorrhage | obstruction) |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7813,
      "preview": "| Sepsis* | Neurogenic bladder |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7814,
      "preview": "| Cardiac failure or congenital heart disease associated with reduced cardiac output* |  |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7815,
      "preview": "| Cardiac Surgery (post-operative)* | Medications/Drugs |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7816,
      "preview": "| Hypoalbuminemia/3rd spacing of fluid | Indomethacin* |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7817,
      "preview": "| Perinatal asphyxia* | Ibuprofen |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7818,
      "preview": "|  | Angiotensin Converting Enzyme (ACE) Inhibitors* |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7819,
      "preview": "| Intrinsic Renal or Parenchymal Disease | Aminoglycosides* |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7820,
      "preview": "| Acute tubular necrosis (ATN)* | Amphotericin |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7821,
      "preview": "| Corticomedullary necrosis | Vancomycin |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7822,
      "preview": "| Renal vein thrombosis |  |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7823,
      "preview": "| Renal artery thrombosis | Other |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7824,
      "preview": "| Pyelonephritis* | Hypoxemia |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7825,
      "preview": "| Congenital anomalies* | Polycythemia |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7826,
      "preview": "| Cystic dysplasia | Hemoglobinuria (hemolytic anemia) |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7827,
      "preview": "| Vesicoureteral reflux Resolved | Myoglobinuria (rhabdomyolysis) |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7828,
      "preview": "| in-utero obstruction | Syphilis |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7829,
      "preview": "| Polycystic kidney disease (ARPKD) | Toxoplasmosis |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7830,
      "preview": "| Diffuse mesangial sclerosis | Candidiasis |"
    },
    {
      "type": "table",
      "section": "V. Etiology/Causes of Neonatal AKI",
      "line": 7831,
      "preview": "|  | Hyperuricemia |"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7833
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7835,
      "preview": "A. Evaluate systemic and renal perfusion"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7837,
      "preview": "1. Tachycardia, hypotension, central venous pressure (CVP)"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7838,
      "preview": "2. Poor capillary/central refill, edema"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7839,
      "preview": "3. Urine output trend"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7840,
      "preview": "B. Identify potential nephrotoxins"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7841,
      "preview": "C. Renal ultrasound"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7843,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7845,
      "preview": "--- page 324 ---"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7847,
      "preview": "D. Urinalysis"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7848,
      "preview": "E. Fractional excretion of sodium (FENa)"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7850,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7851,
      "preview": "\\text { FENa, percent }=\\frac{\\text { UNa } \\times \\text { PCr }}{\\text { PNa } \\times \\text { UCr }"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7852,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7854,
      "preview": "1. The FENa is ONLY valid in OLIGURIC patients"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7855,
      "preview": "2. $\\mathrm{FENa}<2 \\%$ is usually consistent with pre-renal injury"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7856,
      "preview": "3. FENa $>3 \\%$ is usually consistent with intrinsic disease (unless receiving diuretics)"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7857,
      "preview": "4. FENa is harder to interpret in neonates since they have a reduced ability to conserve Na , especi"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7858,
      "preview": "F. Fractional excretion of urea (FEBUN)"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7860,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7861,
      "preview": "\\text { FEBUN, percent }=\\frac{\\text { UBUN } \\times \\text { PCr }}{\\text { PBUN } \\times \\text { UC"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7862,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7864,
      "preview": "1. The FEBUN is ONLY valid in OLIGURIC patients."
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7865,
      "preview": "2. FEBUN $<35 \\%$ is usually consistent with pre-renal injury."
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7866,
      "preview": "3. FEBUN results may be unreliable in the neonates, especially pre-term infants."
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7867,
      "preview": "G. CBC"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7868,
      "preview": "H. Electrolytes and serial creatinine determination"
    },
    {
      "type": "text",
      "section": "VI. Dianostic Evaluation of AKI",
      "line": 7869,
      "preview": "I. Echocardiography if heart failure is suspected"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. Treatment/Management of AKI",
      "line": 7871
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7873,
      "preview": "A. Treatment, in most cases, is determined by etiology of renal failure. Patients with AKI should un"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7874,
      "preview": "B. Fluid challenge can be considered in patients thought to be pre-renal as determined by tachycardi"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7875,
      "preview": "C. Placement of a Foley catheter should be considered to assist with more precise assessement of uri"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7876,
      "preview": "D. Hyperkalemia. For patients with an elevated serum potassium level, steps should be taken to lower"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7878,
      "preview": "1. Eliminate sources of potassium (feeds, IV fluids, TPN)"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7879,
      "preview": "2. Correction of acidosis, if present (unless concomitant hypocalcemia is present)"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7880,
      "preview": "3. Furosemide"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7882,
      "preview": "--- page 325 ---"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7884,
      "preview": "318 Part II-G: Renal Genitourinary"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7885,
      "preview": "4. Calcium gluconate/chloride infusion to stabilize cardiac membrane potential"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7886,
      "preview": "5. Albuterol"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7887,
      "preview": "6. Kayexalate"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7888,
      "preview": "7. Insulin/glucose infusion"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7889,
      "preview": "E. Furosemide can be used to convert oliguric to non-oliguric renal failure. There is no data to sug"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7890,
      "preview": "F. Fluid restriction. If fluid administration and diuretics fail to improve urine output in an oligu"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7892,
      "preview": "1. The most accurate way to assess fluid balance is daily or twice daily weights."
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7893,
      "preview": "2. When fluid restricting, it is best to administer estimated insensible water needs AND any urine o"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7894,
      "preview": "a. $>2500 \\mathrm{~g}-15$ to $25 \\mathrm{~mL} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7895,
      "preview": "b. 1500 to $2500 \\mathrm{~g}-15$ to $35 \\mathrm{~mL} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7896,
      "preview": "c. $<1500 \\mathrm{~g}-30$ to $60 \\mathrm{~mL} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7897,
      "preview": "G. Augmentation of hemodynamics/blood pressure. For patients who are septic or have either distribut"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7898,
      "preview": "H. Aminophylline can often increase urine output in patients with AKI. It can be administered interm"
    },
    {
      "type": "text",
      "section": "VII. Treatment/Management of AKI",
      "line": 7899,
      "preview": "I. Renal replacement therapy. If AKI is progressive, neonates may require renal replacement therapy."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 7901
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7903,
      "preview": "1. Selewski DT, Charlton JR, Jetton JG, et al.. Neonatal Acute Kidney Injury. Pediatrics. 2015 Aug; "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7904,
      "preview": "2. Jetton JG, Askenazi DJ. Update on acute kidney injury in the neonate. Curr Opin Pediatr. 2012 Apr"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7905,
      "preview": "3. Vieux R, Hascoet JM, Merdariu D, et al. Glomerular filtration rate reference values in very prete"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7906,
      "preview": "4. Askenazi DJ, Koralkar R, Hundley HE, Montesanti A, Patil N, Ambalavanan N. Fluid overload and mor"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7908,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7910,
      "preview": "--- page 326 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7912,
      "preview": "5. Goldstein SL. Overview of pediatric renal replacement therapy in acute kidney injury. Semin Dial."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7913,
      "preview": "6. Agras PI, Tarcan A, Baskin E, Cengiz N, G\u00fcrakan B, Saatci U. Acute renal failure in the neonatal "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 7915,
      "preview": "--- page 327 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-H: Endocrine",
      "line": 7917
    },
    {
      "type": "text",
      "section": "Part II-H: Endocrine",
      "line": 7919,
      "preview": "--- page 328 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "hyperglycemia",
      "line": 7921
    },
    {
      "type": "text",
      "section": "hyperglycemia",
      "line": 7923,
      "preview": "Tandy Aye, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 7925
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 7927,
      "preview": "Plasma glucose level $150 \\mathrm{mg} / \\mathrm{dl}>2$ hrs after the last feed."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiology",
      "line": 7929
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7931,
      "preview": "A. Excessive glucose administration (e.g., IVF)."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7932,
      "preview": "B. Medications: steroids, caffeine, phenytoin, diazoxide, epinephrine."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7933,
      "preview": "C. Very low birth weight infants ( $<1000 \\mathrm{gm}$ )."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7934,
      "preview": "D. Sepsis."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7935,
      "preview": "E. Stress."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7936,
      "preview": "F. Hypoxia."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7937,
      "preview": "G. Surgical Procedures:"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7939,
      "preview": "1. From secretion of epinephrine, glucocorticoids, and glucagon."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7940,
      "preview": "2. Excessive administration of IVF with glucose."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7941,
      "preview": "H. Transient neonatal diabetes mellitus (DM): presents before 15 days of age. Infants are usually SG"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7942,
      "preview": "I. Congenital neonatal diabetes mellitus: presents shortly after birth. Infants may be SGA or AGA."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7943,
      "preview": "J. Diabetes due to pancreatic lesion, pancreatic agenesis, Schwachman's syndrome, autoimmune diabete"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7944,
      "preview": "K. Transient, associated with ingestion of hyperosmolar formula."
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 7945,
      "preview": "L. False positive, due to drawing glucose specimen out of a central line that is infusing glucose."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Diagnosis",
      "line": 7947
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7949,
      "preview": "A. Check serum glucose level."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7950,
      "preview": "B. Send urine sample to lab to check for glucose and ketones."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7951,
      "preview": "C. Complete blood cell count with differential to screen for sepsis. Send blood and urine cultures i"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7952,
      "preview": "D. Serum electrolytes check for dehydration with osmotic diuresis."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7953,
      "preview": "E. Serum insulin level if concern for transient neonatal DM."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7954,
      "preview": "F. Tests of pancreatic exocrine function (stool fat)."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7955,
      "preview": "G. Genetic studies if congenital diabetes suspected."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7957,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7959,
      "preview": "--- page 329 ---"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7961,
      "preview": "Note: The VLBW infant often has blood glucoses $145-180 \\mathrm{mg} / \\mathrm{dL}$ due to immaturity"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7962,
      "preview": "A. Acute onset of hyperglycemia with level $>250 \\mathrm{mg} / \\mathrm{dl}$"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7964,
      "preview": "1. Consider increasing IVF to $1.5-2$ times the current IVF rate to keep infants well-hydrated durin"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7965,
      "preview": "2. This fluid should be 0.45 NS and not contain glucose."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7966,
      "preview": "3. Follow glucose every 30 min . to 1 hr and adjust IVF solution when glucose returns to normal rang"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7967,
      "preview": "B. Excess glucose administration via IVF/TPN (level 145-250 mg/dl)"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7968,
      "preview": "4. Positive urinary glucose level:"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7969,
      "preview": "a. Decrease the concentration of dextrose in IVF/TPN. If unable to provide adequate calories/weight "
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7970,
      "preview": "b. Ensure that amino acids are also being infused: the fetal pancreas releases insulin in response t"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7971,
      "preview": "c. Decrease the infusion rate."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7972,
      "preview": "d. Monitor glucose levels until stable in the normal range."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7973,
      "preview": "5. Negative urinary glucose level:"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7974,
      "preview": "a. If increasing glucose to increase caloric intake, a higher serum glucose level is acceptable as l"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7975,
      "preview": "C. Inability to metabolize glucose"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7976,
      "preview": "6. Decrease the glucose delivery ( $\\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ ) by decreasing concen"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7977,
      "preview": "7. Insulin"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7978,
      "preview": "a. Insulin infusion ( $0.01-0.05$ units $/ \\mathrm{kg} / \\mathrm{hr}$ ):"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7979,
      "preview": "i. Drip calculation:"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7980,
      "preview": "$10 \\times$ weight $(\\mathrm{kg})=$ units $/ 100 \\mathrm{ml} \\mathrm{NS}=1 \\mathrm{~mL} / \\mathrm{hr"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7981,
      "preview": "ii. Start at 0.01 units $/ \\mathrm{kg} / \\mathrm{hr}$ and titrate as needed to keep blood sugar 100-"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7982,
      "preview": "iii. Check glucose level every 60 min until stable, then every 2-4 hrs."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7983,
      "preview": "iv. Recheck 1 hr after any change in rate."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7985,
      "preview": "--- page 330 ---"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7987,
      "preview": "v. Watch for trends up or down in glucose-do not wait for hypoglycemia to occur to adjust insulin."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7988,
      "preview": "b. Lispro (Humalog\u00ae) or Aspart (Novolog\u00ae) insulin SQ (0.05-0.2 units/kg every 6 hrs):"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7989,
      "preview": "i. Check glucose level before each feed."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7990,
      "preview": "ii. Consider glargine insulin (given once every 24 hrs )."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 7991,
      "preview": "iii. Consider use of continuous glucose meter."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Medications",
      "line": 7993
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 7995,
      "preview": "A. Steroids (Decadron and Hydrocortisone)"
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 7997,
      "preview": "1. Discontinue or decrease dose of steroid."
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 7998,
      "preview": "2. Decrease glucose delivery or give insulin."
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 7999,
      "preview": "B. Diazoxide"
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 8000,
      "preview": "3. Decrease dose or discontinue diazoxide. Consult Endocrinology."
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 8001,
      "preview": "C. Caffeine"
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 8002,
      "preview": "4. Discontinue or decrease dose of caffeine."
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 8003,
      "preview": "D. Epinephrine"
    },
    {
      "type": "text",
      "section": "V. Medications",
      "line": 8004,
      "preview": "5. Decrease as tolerated clinically."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Transient Neonatal Diabetes Mellitus",
      "line": 8006
    },
    {
      "type": "text",
      "section": "VI. Transient Neonatal Diabetes Mellitus",
      "line": 8008,
      "preview": "A. IVF administration (increase depending on degree of osmotic diuresis)."
    },
    {
      "type": "text",
      "section": "VI. Transient Neonatal Diabetes Mellitus",
      "line": 8009,
      "preview": "B. Insulin (as described above)."
    },
    {
      "type": "text",
      "section": "VI. Transient Neonatal Diabetes Mellitus",
      "line": 8010,
      "preview": "C. Repeat serum insulin values (only if infant is NOT on insulin)."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. Consultation",
      "line": 8012
    },
    {
      "type": "text",
      "section": "VII. Consultation",
      "line": 8014,
      "preview": "Endocrine consultation is recommended for persistent hyperglycemia or for cases difficult to diagnos"
    },
    {
      "type": "text",
      "section": "VII. Consultation",
      "line": 8016,
      "preview": "--- page 331 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypoglycemia",
      "line": 8018
    },
    {
      "type": "text",
      "section": "Hypoglycemia",
      "line": 8020,
      "preview": "Tandy Aye, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 8022
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 8024,
      "preview": "A serum glucose level $<40 \\mathrm{mg} / \\mathrm{dL}$ in the first 48 hours of life or $<55 \\mathrm{"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiology",
      "line": 8026
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8028,
      "preview": "A. Transient hypoglycemia"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8030,
      "preview": "1. Hyperinsulinism"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8031,
      "preview": "a. Infant of a mother with gestational diabetes or diabetes mellitus (IDM) are usually LGA infants ("
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8032,
      "preview": "b. Congenital hyperinsulinism (focal or diffuse beta cell hypertrophy)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8033,
      "preview": "c. SGA"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8034,
      "preview": "d. latrogenic (from excess insulin administration)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8035,
      "preview": "2. Perinatal stress"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8036,
      "preview": "3. Sepsis (especially Gram Negative bacteremia)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8037,
      "preview": "4. Hypoxic-ischemic encephalopathy (HIE)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8038,
      "preview": "5. Hypothermia"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8039,
      "preview": "6. Polycythemia"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8040,
      "preview": "7. Insufficient delivery of glucose"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8041,
      "preview": "8. Maternal drugs (e.g., terbutaline, ritodrine or chlorpropamide)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8042,
      "preview": "9. Erythroblastosis fetalis"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8043,
      "preview": "10. Exchange transfusion"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8044,
      "preview": "11. Umbilical artery line placement near pancreas"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8045,
      "preview": "B. Decreased glycogen stores"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8046,
      "preview": "12. IUGR or SGA"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8047,
      "preview": "13. Premature or post mature infants ( $<37$ wks or $>41$ wks)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8048,
      "preview": "C. Persistent hypoglycemia"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8049,
      "preview": "14. Hormone excess hyperinsulinism"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8050,
      "preview": "a. Beckwith-Wiedemann syndrome"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8052,
      "preview": "--- page 332 ---"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8054,
      "preview": "b. Diffuse or focal beta cell hyperplasia"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8055,
      "preview": "c. SGA"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8056,
      "preview": "d. Stress-related hyperinsulinism"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8057,
      "preview": "2. Hormone deficiencies"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8058,
      "preview": "a. Growth hormone deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8059,
      "preview": "b. Adrenal insufficiency:"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8060,
      "preview": "i. ACTH deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8061,
      "preview": "ii. ACTH non-responsiveness"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8062,
      "preview": "iii. Congenital Adrenal Hyperplasia"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8063,
      "preview": "iv. Adrenal Hypoplasia"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8064,
      "preview": "v. Bilateral adrenal hemorrhage (rare)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8065,
      "preview": "c. Epinephrine deficiency (rare)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8066,
      "preview": "d. Glucagon deficiency (rare)"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8067,
      "preview": "3. Hereditary defects in carbohydrate metabolism"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8068,
      "preview": "4. Hereditary defects in amino acid metabolism"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8069,
      "preview": "5. Hereditary defects in fatty acid metabolism"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Diagnosis",
      "line": 8071
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8073,
      "preview": "A. Laboratory studies"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8075,
      "preview": "1. Routine labs"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8076,
      "preview": "a. Check serum glucose level to confirm if $<55 \\mathrm{mg} / \\mathrm{dl}$ on heel stick. Sample mus"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8077,
      "preview": "b. CBC with diff to screen for sepsis."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8078,
      "preview": "2. Persistent hypoglycemia"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8079,
      "preview": "a. Critical sample includes the following:"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8080,
      "preview": "i. Insulin*"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8081,
      "preview": "ii. Cortisol*"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8082,
      "preview": "iii. Growth hormone"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8083,
      "preview": "iv. Glucose to lab*"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 8085,
      "preview": "--- page 333 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "326 Part II-H: Endocrine",
      "line": 8087
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8089,
      "preview": "v. Urine ketones*"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8090,
      "preview": "vi. Lactic acid"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8091,
      "preview": "vii. Ammonia"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8092,
      "preview": "viii. Beta hydroxybutyrate*"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8094,
      "preview": "* Test must be performed while hypoglycemic. Others can be done at other times. If serum sample is n"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8095,
      "preview": "b. Free fatty acids"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8096,
      "preview": "c. Thyroid tests (T4 and TSH)"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8097,
      "preview": "d. Glucagon stimulation test"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8098,
      "preview": "e. Metabolic:"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8099,
      "preview": "i. Lactic acid"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8100,
      "preview": "ii. Ammonia"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8101,
      "preview": "iii. Plasma amino acids"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8102,
      "preview": "iv. Urine organic acids"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8103,
      "preview": "v. Uric acid"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8104,
      "preview": "f. Consider continuous glucose monitoring"
    },
    {
      "type": "text",
      "section": "326 Part II-H: Endocrine",
      "line": 8105,
      "preview": "g. Consider MRI and ophthalmology consult if septo-optic dysplasia or other midline abnormality is s"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Treatment",
      "line": 8108
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8110,
      "preview": "A. For infants $\\geq 35$ wks gestation with hypoglycemia"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8112,
      "preview": "1. Feed infant within $30-60 \\mathrm{~min}$ if no respiratory distress."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8113,
      "preview": "2. Check glucose $30-60 \\mathrm{~min}$ after feeding. Target for glucose should be $>60 \\mathrm{mg} "
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8114,
      "preview": "a. If glucose $>60 \\mathrm{mg} / \\mathrm{dl}$, repeat glucose 2-4 hrs after feeding. Continue feeds "
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8115,
      "preview": "b. If glucose $<55 \\mathrm{mg} / \\mathrm{dl}$, send STAT serum glucose to lab and attempt another fe"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8116,
      "preview": "c. If glucsose $<55 \\mathrm{mg} / \\mathrm{dl}$ after second feed, start IV treatment as described be"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8117,
      "preview": "B. For infants $<35$ wks gestation"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8118,
      "preview": "3. Start IV treatment as below"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8119,
      "preview": "4. Determine further treatment based on clinical findings"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8121,
      "preview": "--- page 334 ---"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8123,
      "preview": "1. Give $2 \\mathrm{ml} / \\mathrm{kg}$ of D10W slow push."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8124,
      "preview": "2. Start IVF with $6-8 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ dextrose (highest glucose in a peri"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8125,
      "preview": "3. Follow-up glucose 15 min following bolus to document resolution of hypoglycemia or need for furth"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8126,
      "preview": "4. Persistent hypoglycemia"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8127,
      "preview": "a. Increase dextrose delivery in IV incrementally."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8128,
      "preview": "b. Send lab work:"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8129,
      "preview": "i. Metabolic."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8130,
      "preview": "ii. Critical sample."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8131,
      "preview": "iii. Complete hypopituitarism work-up (e.g. free T4, cortisol post Cortrosyn, IGFBP-3, sodium)"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8132,
      "preview": "c. Medications to consider:"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8133,
      "preview": "i. Diazoxide ( $7-15 \\mathrm{mg} / \\mathrm{kg} /$ day divided every 8 hrs , orally). Consider obtain"
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8134,
      "preview": "d. Octreotide."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8135,
      "preview": "e. Human growth hormone (if GH deficient)."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8136,
      "preview": "f. Hydrocortisone (if cortisol deficient)."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8137,
      "preview": "g. Glucagon."
    },
    {
      "type": "text",
      "section": "IV. Treatment",
      "line": 8138,
      "preview": "D. Consider continuous glucose monitoring."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Consultation",
      "line": 8140
    },
    {
      "type": "text",
      "section": "V. Consultation",
      "line": 8142,
      "preview": "Endocrine consultation is recommended for persistent hypoglycemia and those cases with unclear etiol"
    },
    {
      "type": "text",
      "section": "V. Consultation",
      "line": 8144,
      "preview": "--- page 335 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8146
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8148,
      "preview": "| Container | Tests included |"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8149,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8150,
      "preview": "| 4 mint gel microtainers | Complete sample |"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8151,
      "preview": "| 3 mint gel microtainers | All priority critical tests |"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8152,
      "preview": "| 1-2 mint gel microtainers | Glucose/beta-hydroxybuterate/ammonia/lactate $+1-3$ additional tests |"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8153,
      "preview": "| Bagged urine sample 5 mL | Urine organic acids |"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8154,
      "preview": "|  | Test included |"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8155,
      "preview": "| Priority Critical Tests (MUST be done at time of hypoglycemia) (lactate/ammonia need to be transpo"
    },
    {
      "type": "table",
      "section": "Neonatal Hypoglycemia Critical Sample Obtain At Time Of Hypoglycemia",
      "line": 8156,
      "preview": "| Complete critical sample | Priority critical sample PLUS serum cortisol, growth hormone, serum fre"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 8158
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8160,
      "preview": "1. Thornton PS et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Mgmt o"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8161,
      "preview": "2. Adamkin DH and Committee on Fetus and Newborn. Clinical report - Postnatal glucose homeostasis in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8163,
      "preview": "--- page 336 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Management of Hypotension and Suspected Adrenal Insufficiency",
      "line": 8165
    },
    {
      "type": "text",
      "section": "Management of Hypotension and Suspected Adrenal Insufficiency",
      "line": 8167,
      "preview": "Susan Hintz, M.D., M.S. Epi."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8169
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8171,
      "preview": "A. Background"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8173,
      "preview": "The treatment of severe hypotension in the pre-term infant can be challenging. Fluid resuscitation a"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8174,
      "preview": "B. Guidelines for preterm hypotensive infants."
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8176,
      "preview": "1. There is significant debate about the \"definition\" of hypotension in extremely preterm infants an"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8177,
      "preview": "2. Cognizant of the limitations above, the following therapeutic approach to UNEXPLAINED severe hypo"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8178,
      "preview": "NOTE: the resuscitation of patients with ongoing fluid or blood losses such as effusions and bleedin"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8179,
      "preview": "a. Initial volume bolus $(10 \\mathrm{ml} / \\mathrm{kg})$ with isotonic saline if the patient is susp"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8180,
      "preview": "b. Consider dopamine infusion if patient is considered normovolemic with continued hypotension."
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8181,
      "preview": "c. Consider repeat volume $10 \\mathrm{ml} / \\mathrm{kg}$ for up to 3 total boluses if the patient is"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8182,
      "preview": "d. Blood product support."
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8183,
      "preview": "i. PRBC or platelet infusions may be required based on clinical presentation and/or laboratory studi"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8184,
      "preview": "ii. FFP infusion may be considered based on clinical presentation, laboratory studies and/ or respon"
    },
    {
      "type": "text",
      "section": "I. Fluid Resuscitation in The Treatment Of Neonatal Hypotension",
      "line": 8186,
      "preview": "--- page 337 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8188
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8190,
      "preview": "iii. Albumin is not recommended for the routine resuscitation of hypotensive neonates."
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8191,
      "preview": "3. Monitoring and evaluation"
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8192,
      "preview": "a. A central line should be in place for the ill neonate requiring volume boluses and inotropic supp"
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8193,
      "preview": "b. Consider an echocardiogram to evaluate cardiac anatomy and function for infants suspected of havi"
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8194,
      "preview": "4. Hypotension in the following patient categories may demand different diagnostic/therapeutic appro"
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8195,
      "preview": "a. Suspicion of congenital heart disease (e.g., presence of heart murmur, large cardiac silhouette o"
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8196,
      "preview": "b. Suspicion of coagulopathy or DIC - Check PT, PTT, fibrinogen, and d-dimer. Appropriate blood prod"
    },
    {
      "type": "text",
      "section": "However, FFP infusion as a volume expander is discouraged for routine use.",
      "line": 8197,
      "preview": "c. Suspicion of sepsis - cultures should be drawn and empiric antibiotics begun while simultaneously"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Corticosteroid Replacement for Suspected Adrenal Insufficiency in the Preterm Infant",
      "line": 8199
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Background",
      "line": 8201
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8203,
      "preview": "1. An intact hypothalamic-pituitary-adrenal (HPA) axis is crucial for the body to deal with physiolo"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8204,
      "preview": "2. Early studies suggested that extremely low birth weight infants treated prophylactically with hyd"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8205,
      "preview": "3. Since that time, the PREMILOC randomized controlled trial of routine low dose hydrocortisone init"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8207,
      "preview": "--- page 338 ---"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8209,
      "preview": "4. Which patients are likely at highest risk for adrenal insufficiency?"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8210,
      "preview": "a. Extremely low birth weight, extremely premature infants; however, premature infants of more advan"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8211,
      "preview": "b. Infants with clinical signs of adrenal insufficiency such as substantial BP instability requiring"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8212,
      "preview": "B. PREMILOC routine hydrocortisone for $<28$ week EGA infants: How does hydrocortisone for hypotensi"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8213,
      "preview": "5. The PREMILOC trial (Baud O, et al, 2016) was a double-blind, RCT done at 21 French tertiary-care "
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8214,
      "preview": "6. The Stanford Neonatology Division has determined that the risk/benefit warrants routine initiatio"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8215,
      "preview": "a. Inclusion criteria:"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8217,
      "preview": "Infants < 28 weeks in the first week of life should receive:"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8218,
      "preview": "$0.5 \\mathrm{mg} / \\mathrm{kg}$ q12 $\\times 7$ days"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8219,
      "preview": "$0.5 \\mathrm{mg} / \\mathrm{kg}$ q24 $\\times 3$ days"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8220,
      "preview": "b. Exclusion criteria:"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8222,
      "preview": "SGA (<3\\%ile weight for GA)"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8223,
      "preview": "NSAID initiated within the first 24 hours"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8224,
      "preview": "3. Given that low dose hydrocortisone will be routinely administered to extremely preterm infants wi"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8225,
      "preview": "a. If the infant is $\\geq 28+0 / 7$ weeks, and therefore not on the PREMILOC protocol."
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8226,
      "preview": "b. If the infant is already on PREMILOC hydrocortisone dosing but has hypotension unresponsive to in"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8227,
      "preview": "c. If the infant is outside the postnatal period of PREMILOC protocol (i.e., transferred in later, o"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8229,
      "preview": "--- page 339 ---"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8231,
      "preview": "332 Part II-H: Endocrine"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8232,
      "preview": "C. Suggested guidelines for hydrocortisone initiation for hypotension in setting of suspected adrena"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8234,
      "preview": "1. Once the care team has determined that hydrocortisone therapy for hypotension is clinically indic"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8236,
      "preview": "Because the \"appropriate\" or \"adequate\" adrenal response to cosyntropin or to stress in the newborn "
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8238,
      "preview": "With these points in mind, and with the concept that little data exist from which to develop treatme"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8239,
      "preview": "a. Consider a \"test dose\": Depending on the severity of the initial presentation, the care team may "
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8240,
      "preview": "b. A 5-day weaning course, beginning with $0.5 \\mathrm{mg} / \\mathrm{kg} /$ dose."
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8241,
      "preview": "i. Hydrocortisone, $0.5 \\mathrm{mg} / \\mathrm{kg}$ IV every 12 hrs $\\times 48$ hours ( 4 doses), the"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8242,
      "preview": "ii. Hydrocortisone, $0.3 \\mathrm{mg} / \\mathrm{kg}$ IV every 12 hrs $\\times 48$ hours ( 4 doses), th"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8243,
      "preview": "iii. Hydrocortisone, $0.2 \\mathrm{mg} / \\mathrm{kg}$ IV every 12 hrs $\\times 24$ hours ( 2 doses)."
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8244,
      "preview": "** The care team may implement a more aggressive hydrocortisone wean or discontinue the drug altoget"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8245,
      "preview": "**NOTE: Due to gestational age-based differences in hydrocortisone half life suggested by available "
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8246,
      "preview": "** For infants who become ill during a hydrocortisone wean or require surgery, consider increasing t"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8247,
      "preview": "2. Monitor for possible side effects:"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8248,
      "preview": "a. Check dextrose stick every 8 hrs."
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8249,
      "preview": "b. Check blood pressure every hour or continuously if arterial access (recommended)."
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8250,
      "preview": "c. Hydrocortisone dosing may need to be adjusted if hypertension or hyperglycemia is present"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8252,
      "preview": "--- page 340 ---"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8254,
      "preview": "3. A Pediatric Endocrinology consultation should be strongly considered if the patient fails to succ"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8255,
      "preview": "4. If the patient fails to successfully wean from hydrocortisone and/or requires re-initiation of hy"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8256,
      "preview": "5. The neonatal cosyntropin test is conducted as follows:"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8257,
      "preview": "a. Draw baseline cortisol level. Label this as \"baseline.\""
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8258,
      "preview": "b. Perform cosyntropin stimulation test:"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8259,
      "preview": "i. Give cosyntropin $3.5 \\mathrm{mcg} / \\mathrm{kg}$ by rapid IV infusion."
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8260,
      "preview": "ii. Draw another cortisol level 30 min after cosyntropin infusion. Label this as \"peak.\""
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8261,
      "preview": "D. Are there firm definitions of \"adrenal insufficiency\"?"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8263,
      "preview": "1. \"Adrenal insufficiency\" was defined in previous literature as a peak post-stimulation cortisol le"
    },
    {
      "type": "text",
      "section": "A. Background",
      "line": 8264,
      "preview": "2. Blood pressure has been suggested to be in \"normal\" range if the diastolic $B P \\geq 20$ and MAP "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 8266
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8268,
      "preview": "1. Barrington KJ, Janaillac M. Treating hypotension in extremely preterm infants. The pressure is mo"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8269,
      "preview": "2. Fernandez EF, Watterberg KL. Relative adrenal insufficiency in the preterm and term infant. J Per"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8270,
      "preview": "3. Faust K, Hartel C, Preuss M, et al. Short-term outcome of very-low-birthweight infants with arter"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8271,
      "preview": "4. Batton B, Lei Li, Nancy S, Newman, et al. Early blood pressure, antihypotensive therapy and outco"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8272,
      "preview": "5. Batton B, Li L, Newman NS, et al. Use of antihypotensive therapies in extremely preterm infants. "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8273,
      "preview": "6. Batton B, Li L, Newman NS, et al. Evolving blood pressure dynamics for extremely preterm infants."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8274,
      "preview": "7. Watterberg KL. Hydrocortisone dosing for hypotension in newborn infants: Less is more. J Pediatr."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8276,
      "preview": "--- page 341 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8278,
      "preview": "8. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, Couser RJ, Garland JS, Rozycki"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8279,
      "preview": "9. Ibrahim H, Sinha IP, Subhedar NV. Corticosteroids for treating hypotension in preterm infants. Co"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8280,
      "preview": "10. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, Zupan-Simunek V, Coursol A, Beuch"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8281,
      "preview": "11. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C; PREMILOC Trial Group. Association Be"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8283,
      "preview": "--- page 342 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Thyroid Function in VLBW Infants",
      "line": 8285
    },
    {
      "type": "text",
      "section": "Thyroid Function in VLBW Infants",
      "line": 8287,
      "preview": "Susan Hintz, M.D., M.S. Epi., Ronald S. Cohen, M.D., Laura K. Bachrach, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 8289
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 8291,
      "preview": "A. Appropriate thyroid function is essential for proper fetal and neonatal growth and development. C"
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 8292,
      "preview": "B. In the term infant at birth, serum TSH level rises rapidly, then falls in the first 24 hrs . T4 a"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. \"Atypical Hypothyroidism\" in VLBW and III Neonates",
      "line": 8294
    },
    {
      "type": "text",
      "section": "II. \"Atypical Hypothyroidism\" in VLBW and III Neonates",
      "line": 8296,
      "preview": "A. Several studies have reported \"atypical hypothyroidism,\" which can be seen in VLBW and extremely "
    },
    {
      "type": "text",
      "section": "II. \"Atypical Hypothyroidism\" in VLBW and III Neonates",
      "line": 8297,
      "preview": "B. The importance of these findings is that early newborn screening alone may not detect potentially"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8299
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8301,
      "preview": "A. The most important potential consequence of impaired thyroid function is later neurodevelopmental"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8302,
      "preview": "B. Den Ouden, et al. 3 found that, as expected, lower T4 levels at birth tracked closely with lower "
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8303,
      "preview": "C. Nevertheless, a systematic review of randomized controlled trials from the Cochrane Collaborative"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8304,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8306,
      "preview": "--- page 343 ---"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8308,
      "preview": "336 Part II-H: Endocrine"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8309,
      "preview": "use of thyroid hormones for treatment of preterm infants with transient hypothroxinemia result in ch"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8310,
      "preview": "D. A phase I trial of different dosing regimens has been completed. 8 Neurodevelopmental follow up o"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8311,
      "preview": "E. Although available studies attempted to adjust for multiple clinical factors, it is possible that"
    },
    {
      "type": "text",
      "section": "III. Neurodevelopmental Outcome and Low T4",
      "line": 8312,
      "preview": "F. Recent consensus guidelines and systematic reviews have underscored that repetitive re-screening "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8314
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8316,
      "preview": "The following protocol has been instituted at LPCH nurseries:"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8317,
      "preview": "A. Routine thyroid function testing"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8319,
      "preview": "1. It seems likely from reports in the literature that a phenomenon of \"delayed hypothyroidism\" can "
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8320,
      "preview": "2. Therefore, all VLBW infants (birth weight $<1500 \\mathrm{gm}$ ) disease should undergo the follow"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8321,
      "preview": "a. At 2 weeks of age, free T4 and TSH levels should be obtained."
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8322,
      "preview": "b. At 6 weeks of age, free T4 and TSH levels should be obtained."
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8323,
      "preview": "3. All patients with complex congenital heart should undergo the following testing:"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8324,
      "preview": "a. At 6 weeks of age, free T4 and TSH levels should be obtained."
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8325,
      "preview": "4. If a VLBW infant or patient with complex congenital heart disease is to be discharged or transfer"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8326,
      "preview": "5. A Pediatric Endocrinology consult should be considered in any case of abnormal thyroid function t"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8328,
      "preview": "--- page 344 ---"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8330,
      "preview": "a. If TSH is $>8$-regardless of the free T4 level\u2014call for immediate consult."
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8331,
      "preview": "b. If the TSH is 6-8 and Free T4 is $<0.9 \\mathrm{ng} / \\mathrm{dL}$, consult Endocrinology."
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8332,
      "preview": "c. If TSH is 6-8 and Free T4 is $>0.9$, repeat TSH and Free T4 in 1 wk ."
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8333,
      "preview": "B. Normal thyroid study ranges for age"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8335,
      "preview": "1. Please note that the literature reports thyroid study ranges in VARYING units! Be careful when co"
    },
    {
      "type": "text",
      "section": "IV. Routine Later Thyroid Function Testing for VLBW Infants",
      "line": 8336,
      "preview": "2. TSH surge at birth lasts 3-5 days. However, there is a $90 \\%$ probability of congenital hypothyr"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 8338
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8340,
      "preview": "1. Fisher DA, Klein AH. Thyroid development and disorders of thyroid function in the newborn. N Engl"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8341,
      "preview": "2. Biswas S, Buffery J, Enoch H, Bland JM, Walters D, Markiewicz M. A longitudinal assessment of thy"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8342,
      "preview": "3. Den Ouden AL, Kok JH, Verkerk PH, Brand R, Verloove-Vanhorick SP. The relation between neonatal t"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8343,
      "preview": "4. Reuss ML, Paneth N, Pinto-Martin JA, Lorenz JM, Susser M. The relation of transient hypothyroxine"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8344,
      "preview": "5. Delahunty C, Falconer S, Hume R, Jackson L, Midley P, Mirfield M, Ogston S, Perra O, Simpson J, W"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8345,
      "preview": "6. Osborn D, Hunt R. Prophylactic postnatal thyroid hormones for prevention of morbidity and mortali"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8346,
      "preview": "7. Osborn D, Hunt R. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8347,
      "preview": "8. La Gamma EF, van Wassenaer AG, Ares S, Golombek SG, Kok JH, Quero J, Hong T, Rahbar MH, de Escoba"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8348,
      "preview": "9. van Wassenaer-Leemhuis Aleid, Ares Susana, Golombek Sergio, Kok Joke, Paneth Nigel, Kase Jordan, "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8349,
      "preview": "10. La Gamma EF, Paneth N. Clinical importance of hypothroxinemia in the preterm infant and a discus"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8350,
      "preview": "11. L\u00e9ger J ${ }^{1}$, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8352,
      "preview": "--- page 345 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8354,
      "preview": "338 Part II-H: Endocrine"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8355,
      "preview": "Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8356,
      "preview": "12. Hashemipour M, Hovsepian S, Ansari A, Keikha M, Khalighinejad P, Niknam N. Screening of congenit"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8358,
      "preview": "--- page 346 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Disorders of Sexual Differentiation",
      "line": 8360
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Caroline Buckway M.D.",
      "line": 8362
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Key Concepts",
      "line": 8364
    },
    {
      "type": "text",
      "section": "I. Key Concepts",
      "line": 8366,
      "preview": "A. Genital formation occurs within the first 12 weeks of fetal life. Therefore, ambiguity implies se"
    },
    {
      "type": "text",
      "section": "I. Key Concepts",
      "line": 8367,
      "preview": "B. Testes must be fully functional to develop external male structures and remove internal female st"
    },
    {
      "type": "text",
      "section": "I. Key Concepts",
      "line": 8368,
      "preview": "C. During the initial evaluation, assume agreement between gender karyotype and gonads. Palpable tes"
    },
    {
      "type": "text",
      "section": "I. Key Concepts",
      "line": 8369,
      "preview": "D. Ambiguous genitalia should be addressed as a medical emergency. Appropriate initial steps include"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Main Categories",
      "line": 8371
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8373,
      "preview": "A. 46 XX DSD: Virilization of 46 XX female infant"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8375,
      "preview": "1. Etiology"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8376,
      "preview": "a. Congenital Adrenal Hyperplasia"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8377,
      "preview": "i. 21-hydroxylase deficiency ( $\\mathrm{Na}+$ wasting, most common etiology)."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8378,
      "preview": "ii. 11b-hydroxylase deficiency (possible $\\mathrm{Na}+$ wasting; may have hypertension)."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8379,
      "preview": "iii. 3b-hydroxysteroid dehydrogenase deficiency."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8380,
      "preview": "b. Adrenal virilizing tumor (fetus or mother)"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8381,
      "preview": "c. Gestational hyperandrogenism"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8382,
      "preview": "iv. Placental-fetal aromatase deficiency."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8383,
      "preview": "v. Maternal exposure synthetic androgens."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8384,
      "preview": "2. Physical exam"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8385,
      "preview": "a. Posterior labial fusion"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8386,
      "preview": "i. Most sensitive sign of virilization in the first trimester."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8387,
      "preview": "ii. Anogenital ratio - distance between the anus and posterior fourchette divided by the distance be"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8388,
      "preview": "b. Clitoromegaly - indicates virilization at any time during pregnancy."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8390,
      "preview": "--- page 347 ---"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8392,
      "preview": "i. Normal clitoral length $<6 \\mathrm{~mm}$ in term female infant."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8393,
      "preview": "c. Rugation and pigmentation of the labia majora."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8394,
      "preview": "B. 46 XY DSD: Undervirilization of 46 XY male infant"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8396,
      "preview": "1. Etiology"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8397,
      "preview": "a. Complete or partial androgen insensitivity"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8398,
      "preview": "b. 5-alpha-reductase deficiency"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8399,
      "preview": "c. Testosterone biosynthetic defects"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8400,
      "preview": "i. 3b-hydroxysteroid dehydrogenase deficiency"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8401,
      "preview": "ii. 17b-hydroxysteroid dehydrogenase deficiency"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8402,
      "preview": "iii. 17a hydroxylase/17, 20-lyase deficiency"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8403,
      "preview": "iv. StAR (Steroidogenic Acute Regulatory) protein deficiency (*21-hydroxylase and 11bhydroxylase def"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8404,
      "preview": "d. Smith-Lemli-Opitz Syndrome"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8405,
      "preview": "e. Leydig cell hypoplasia or agenesis due to LH receptor resistance"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8406,
      "preview": "f. Testicular Regression Syndrome or congenital anorchia"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8407,
      "preview": "g. Non-hormonal isolated structural defects (e.g., more common with IVF pregnancy)"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8408,
      "preview": "2. Physical exam"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8409,
      "preview": "a. Microphallus"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8410,
      "preview": "i. Normal penile length $>2.5 \\mathrm{~cm}$ in term infant."
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8411,
      "preview": "ii. Indicates insufficient testosterone production at anytime during pregnancy. For example, gonadot"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8412,
      "preview": "iii. In cases with microphallus, consider panhypopituitarism. Growth hormone is synergistic with tes"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8413,
      "preview": "b. Bifid scrotum or penoscrotal transposition"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8414,
      "preview": "c. Hypospadias"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8415,
      "preview": "i. Isolated first or second-degree hypospadias is not ambiguous if there is a normally formed penis "
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8417,
      "preview": "--- page 348 ---"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8419,
      "preview": "d. Cryptorchidism (isolated hypospadias and cryptorchidism may occur independent of virilization def"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8420,
      "preview": "C. Sex Chromosome DSD /Mixed sex chromosome patterns:"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8422,
      "preview": "1. Etiology and physical exam findings"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8423,
      "preview": "a. Sex Chromosome DSD"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8424,
      "preview": "i. Turner Syndrome (45 XO, normal external genitalia)"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8425,
      "preview": "ii. Klinefelter Syndrome (47 XXY, normal external genitalia)"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8426,
      "preview": "iii. Mixed gonadal dysgenesis"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8427,
      "preview": "a) 16 XY or $45 \\mathrm{XO} / 46 \\mathrm{XY}$ mosaic (asymmetric external genitalia with spectrum of"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8428,
      "preview": "iv. \"True hermaphroditism\""
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8429,
      "preview": "a) Ovarian and testicular tissue must be present - diagnosed on gonadal biopsy"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8430,
      "preview": "b) Generally, 46 XX karyotype"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8431,
      "preview": "b. 46 XX Male"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8432,
      "preview": "i. Sex reversal syndrome"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8433,
      "preview": "ii. SRY can be present or absent"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8434,
      "preview": "iii. Internal and external male structures"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8435,
      "preview": "c. 46 XY female"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8436,
      "preview": "i. Heterogeneous entity"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8437,
      "preview": "ii. Duplication of DAX-1 or WNT-4 gene results in sex reversal"
    },
    {
      "type": "text",
      "section": "II. Main Categories",
      "line": 8438,
      "preview": "iii. Mutation in SRY, SOX9, SF-1, WT-1 may result in complete sex reversal or spectrum of ambiguity "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8440
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8442,
      "preview": "A. Critical diagnostic labs in first 24 hrs of life"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8444,
      "preview": "1. STAT Karyotype + FISH for SRY"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8445,
      "preview": "2. Testosterone"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8446,
      "preview": "3. Pelvic ultrasound (value dependent on skill of technician, MRI of pelvis may yield better results"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8447,
      "preview": "B. Determine if gonads are palpable"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8448,
      "preview": "4. If no gonads are palpated, follow algorithm for virilized female"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8450,
      "preview": "--- page 349 ---"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8452,
      "preview": "a. Critical labs after 24 hours of life:"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8453,
      "preview": "i. STAT 17-OH Progesterone, newborn screen"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8454,
      "preview": "ii. Renin level"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8455,
      "preview": "b. Electrolytes qD (salt loss is a late phenomenon)"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8456,
      "preview": "c. Save 3 ml red top tube"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8457,
      "preview": "2. If gonads are palpated, follow algorithm for undervirilized male"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8458,
      "preview": "a. Critical labs in first 24 hours of life:"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8459,
      "preview": "i. DHT, LH, FSH"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8460,
      "preview": "b. Critical labs after 24 hours of life:"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8461,
      "preview": "i. Inhibin B and MIS to evaluate for testicular function"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8462,
      "preview": "ii. Adrenal metabolites (CAH Panel 6: includes progesterone, 17-OH pregnenolone, 17-OHprogesterone ("
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8463,
      "preview": "iii. Save 3 mL red top tube"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8464,
      "preview": "iv. Evaluation of pituitary function if appropriate based on exam (stimulated cortisol, IGFBP-3, fre"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8465,
      "preview": "c. MRI of pelvis"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8466,
      "preview": "d. Consider genetic test for androgen insensitivity and 5-alpha reductase deficiency (if testosteron"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8467,
      "preview": "e. If suspicious for gonadal dysgenesis 2nd surge of gonadotropin-dependent testosterone at 2-8 wks "
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8469,
      "preview": "--- page 350 ---"
    },
    {
      "type": "image",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8471,
      "content": "![img-61.jpeg](images/ce56d017bdd3c9ba.png)"
    },
    {
      "type": "text",
      "section": "III. Evaluation of Genital Ambiguity (see figure 1)",
      "line": 8473,
      "preview": "Figure: Preliminary diagnostic algorithm. *Adrenal steroid metabolites [progesterone, 17-OH pregneno"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 8475
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8477,
      "preview": "1. Ahmed SF, Achermann JC, Arlt W. et al. UK Guidance on the Initial Evaluation of an Infant or an A"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8478,
      "preview": "2. Lee PA, Houk CP, Ahmed SF, Hughes IA. International Consensus Conference on Intersex. Consensus S"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8479,
      "preview": "3. Murphy C, Allen L, Jamieson MA. Ambiguous Genitalia in the Newborn: An Overview and Teaching Tool"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8480,
      "preview": "4. Shah, S and Shah, AC. Ambiguous genitalia in the neonate and infant. Practical Pediatric and Adol"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8482,
      "preview": "--- page 351 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-I: Neurology",
      "line": 8484
    },
    {
      "type": "text",
      "section": "Part II-I: Neurology",
      "line": 8486,
      "preview": "--- page 352 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Neonatal Seizures",
      "line": 8488
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Courtney Wusthoff, M.D.",
      "line": 8490
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8492
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8494,
      "preview": "A. Neonates are at high risk for seizure in a number of clinical scenarios:"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8496,
      "preview": "1. HIE ( $40-60 \\%$ have seizures)"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8497,
      "preview": "2. ECMO ( $10-20 \\%$ have seizures)"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8498,
      "preview": "3. S/P certain cardiac surgeries ( $5-20 \\%$ )"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8499,
      "preview": "4. Stroke/hemorrhage/SVT ( $\\sim 80 \\%$ of neonatal stroke presents as seizure)"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8500,
      "preview": "5. CNS Infections"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8501,
      "preview": "6. Genetic/metabolic conditions"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8502,
      "preview": "B. All neonates with clinically suspected seizures should receive immediate aEEG and urgent Video EE"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8503,
      "preview": "7. $80-90 \\%$ of neonatal seizures are subclinical, with no outward signs, and can only be diagnosed"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8504,
      "preview": "8. Up to $50 \\%$ of abnormal movements suspected to be seizures in NICU babies are not seizures on E"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8505,
      "preview": "9. aEEG is initiated by the NICU team."
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8506,
      "preview": "a. aEEG is interpreted at the bedside on an ongoing basis by NICU staff"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8507,
      "preview": "b. When interpreted by experienced users, aEEG identifies about $2 / 3$ of patients with seizures, b"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8508,
      "preview": "c. aEEG is a great option for immediate monitoring to see if a baby is having any seizures, until th"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8509,
      "preview": "10. To request video EEG monitoring (including urgent vEEG at night and on weekends if available), t"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8510,
      "preview": "a. If clinically suspected seizure occurs while on video EEG, press the event button to mark the eve"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8511,
      "preview": "b. If seizures are suspected based on aEEG changes, enter in comment at bedside (if aEEG machine), o"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8512,
      "preview": "c. The neurology team should be contacted to review events as needed to confirm whether or not they "
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8514,
      "preview": "--- page 353 ---"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8516,
      "preview": "346 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8517,
      "preview": "C. A number of sudden, stereotyped clinical events raise suspicion for seizures:"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8519,
      "preview": "1. Autonomic changes"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8520,
      "preview": "a. Unexplained apnea in a term baby is a seizure until proven otherwise."
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8521,
      "preview": "b. Isolated heart rate or blood pressure changes are rarely seizures."
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8522,
      "preview": "2. Focal clonic, tonic movements"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8523,
      "preview": "a. More likely seizure if they are high amplitude, regular frequency, and cannot be suppressed"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8524,
      "preview": "b. Less likely seizure if elicited by positioning/movement, involve all extremities, and can be stop"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8525,
      "preview": "c. Benign sleep myoclonus can last for several minutes and be a close seizure mimic; it is distingui"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8526,
      "preview": "3. Forced eye/gaze deviation"
    },
    {
      "type": "text",
      "section": "I. Diagnosing Neonatal Seizures",
      "line": 8527,
      "preview": "4. Tonic stiffening"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. Seizure Types",
      "line": 8529
    },
    {
      "type": "text",
      "section": "II. Seizure Types",
      "line": 8531,
      "preview": "A. Subclinical \\& Subtle: most common type in newborns. Occur in both term and premature infants. Cl"
    },
    {
      "type": "text",
      "section": "II. Seizure Types",
      "line": 8533,
      "preview": "1. Ocular movements: conjugate horizontal deviation, repetitive blinking or fluttering of eyelids, s"
    },
    {
      "type": "text",
      "section": "II. Seizure Types",
      "line": 8534,
      "preview": "2. Oral-buccal-lingual movements: chewing, drooling, sucking, tongue thrusting"
    },
    {
      "type": "text",
      "section": "II. Seizure Types",
      "line": 8535,
      "preview": "3. Bicycling/pedaling/swimming movements of extremities"
    },
    {
      "type": "text",
      "section": "II. Seizure Types",
      "line": 8536,
      "preview": "4. Apnea"
    },
    {
      "type": "text",
      "section": "II. Seizure Types",
      "line": 8537,
      "preview": "5. Autonomic changes: combination of blood pressure changes, tachycardia, in combination with apnea/"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Multifocal/focal clonic",
      "line": 8539
    },
    {
      "type": "text",
      "section": "B. Multifocal/focal clonic",
      "line": 8541,
      "preview": "1. Most common overt clinical seizure type in newborns"
    },
    {
      "type": "text",
      "section": "B. Multifocal/focal clonic",
      "line": 8542,
      "preview": "2. Clinical manifestations include rhythmic jerking of one or more body parts"
    },
    {
      "type": "text",
      "section": "B. Multifocal/focal clonic",
      "line": 8543,
      "preview": "3. Not the same as \"generalized tonic-clonic\", which describes convulsive seizures in children/adult"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Tonic",
      "line": 8545
    },
    {
      "type": "text",
      "section": "C. Tonic",
      "line": 8547,
      "preview": "1. Clinical manifestations include tonic extension of all limbs, resembling decerebrate posturing, o"
    },
    {
      "type": "text",
      "section": "C. Tonic",
      "line": 8548,
      "preview": "2. Can be focal or generalized"
    },
    {
      "type": "text",
      "section": "C. Tonic",
      "line": 8550,
      "preview": "--- page 354 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Myoclonic",
      "line": 8552
    },
    {
      "type": "text",
      "section": "D. Myoclonic",
      "line": 8554,
      "preview": "1. Rare seizure type, occurs primarily in catastrophic epilepsy"
    },
    {
      "type": "text",
      "section": "D. Myoclonic",
      "line": 8555,
      "preview": "2. Almost always seen in conjunction with very abnormal EEG and exam"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8557
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8559,
      "preview": "A. Acute Symptomatic- About $80 \\%$ of neonatal seizures are acute symptomatic seizures, meaning the"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8561,
      "preview": "1. Hypoxic-ischemic injury: HIE is the most common cause of seizures in first few days or life (50\\%"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8562,
      "preview": "2. Stroke- $2^{\\text {nd }}$ most common cause"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8563,
      "preview": "a. Arterial Ischemic"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8564,
      "preview": "b. Intracranial hemorrhage:"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8565,
      "preview": "i. Subarachnoid: usually otherwise asymptomatic (\"well baby with seziures\")"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8566,
      "preview": "ii. Intraventricular: associated with prematurity"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8567,
      "preview": "iii. Subdural: associated with traumatic delivery"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8568,
      "preview": "c. Sinovenous thrombosis - may be evident from Doppler flow on HUS or MRV"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8569,
      "preview": "3. Hypoglycemia: occurs in association with SGA, IDM, and/or asphyxia."
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8570,
      "preview": "4. Hypocalcemia: occurs in association with prematurity, IDM, asphyxia, hypoparathyroidism, DiGeorge"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8571,
      "preview": "5. Other electrolyte abnormalities: hypomagnesemia, hypo/hypernatremia."
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8572,
      "preview": "6. CNS infection: meningitis, encephalitis, brain abscess, congenital TORCH, Zika"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8573,
      "preview": "7. Developmental defects: cortical dysgenesis"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8574,
      "preview": "B. Neonatal Onset Epilepsy- 20\\% of neonatal seizures are due to underlying chronic/congenital condi"
    },
    {
      "type": "text",
      "section": "III. Etiologies of Neonatal Seizures",
      "line": 8575,
      "preview": "8. Genetic \\& Metabolic syndromes: includes benign familial neonatal seizures due to KCNQ2 or other "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2. Brain malformation syndromes",
      "line": 8577
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Evaluation",
      "line": 8579
    },
    {
      "type": "text",
      "section": "IV. Evaluation",
      "line": 8581,
      "preview": "A. Acute diagnostic tests: check STAT electrolytes, Ca, glucose, Mg:"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Electrolytes",
      "line": 8583
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8585,
      "preview": "--- page 355 ---"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8587,
      "preview": "348 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8589,
      "preview": "1. If hypoglycemic ( $<40 \\mathrm{mg} / \\mathrm{dl}$ ), give $2-3 \\mathrm{ml} / \\mathrm{kg}$ D10W IV"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8590,
      "preview": "2. If hypocalcemic, give $10-20 \\mathrm{mg} / \\mathrm{kg}$ Calcium chloride IV push."
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8591,
      "preview": "3. If hypomagnesemic give $25-50 \\mathrm{mg} / \\mathrm{kg}$ Magnesium sulfate IV."
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8592,
      "preview": "C. First line diagnostic tests include:"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8593,
      "preview": "4. CBC"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8594,
      "preview": "5. Urine Toxic Screen"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8595,
      "preview": "6. Complete Metabolic Panel"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8596,
      "preview": "7. Lactate"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8597,
      "preview": "8. Blood culture"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8598,
      "preview": "9. Head ultrasound- Head Ultrasound is useful for excluding hemorrhage and for initial images while "
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8599,
      "preview": "D. Head imaging - Indicated as soon as possible (when baby stable and MRI available) for neonates wi"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8600,
      "preview": "E. Revisit family history after parents have checked with family; often new information comes out af"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8601,
      "preview": "F. Additional tests to consider (depending on clinical situation)"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8602,
      "preview": "10. Lumbar puncture - to rule out infection (bacterial \\& viral studies), hemorrhage. Send glucose w"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8603,
      "preview": "11. TORCH titers \\& Zika"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8604,
      "preview": "12. $A B G$"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8605,
      "preview": "13. Ammonia, lactate with paired pyruvate"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8606,
      "preview": "14. Serum amino acids, urine organic acids, acylcarnitine profile, free/total carnitine."
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8607,
      "preview": "G. Testing for Genetic/Metabolic causes Genetic testing identifies the cause of neonatal seizures in"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8608,
      "preview": "15. Serum biotinidase, uric acid, acylcarnitine panel, carnitine (free and total), very long chain f"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8609,
      "preview": "16. Urine - sulfocysteine, alpha-AASA, guanidinoacetate/creatine, pyr/pur panel"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8611,
      "preview": "--- page 356 ---"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8613,
      "preview": "3. CSF - lactate, amino acids, neurotransmitters, alpha-AASA (Amino adipic semialdehyde), glucose, 5"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8614,
      "preview": "4. Genetics - CGH, infantile epilepsy panel. Stat panel turn-around is $\\sim 2$ weeks. Standard turn"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8616,
      "preview": "| Test Type | Test Specifics |"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8617,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8618,
      "preview": "| Blood Tests | Glucose, electrolytes, calcium, magnesium, LFTs, ammonia, lactate, CBC, blood cx, me"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8619,
      "preview": "| Cerebrospinal fluid | Cell count, protein, bacterial culture <br> Glucose with paired serum glucos"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8620,
      "preview": "| Neuroimaging | Head ultrasound for screening evaluation <br> MRI for HIE, stroke, and cerebral dys"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8621,
      "preview": "| Electroencephalogram | Continuous video EEG almost always warranted; routine EEG rarely sufficient"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8622,
      "preview": "| Genetic testing | Epilepsy specific panels and/or CGH or specific genetic tests (discuss with neur"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8623,
      "preview": "| Toxicology Screen | Blood and urine |"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8624,
      "preview": "| Congenital infection screening | Serum titers in mother and child Urine for CMV <br> Zika titers m"
    },
    {
      "type": "table",
      "section": "B. Electrolytes",
      "line": 8625,
      "preview": "| Family history | Careful family history of neonatal or infantile seizures; ask parents to check wi"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8627,
      "preview": "--- page 357 ---"
    },
    {
      "type": "text",
      "section": "B. Electrolytes",
      "line": 8629,
      "preview": "Conjunctiva, skin, oropharynx Culture for HSV if HSV encephalitis is suspected"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Acute Treatment",
      "line": 8631
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8633,
      "preview": "Neonatal seizures should be treated urgently, with escalation of therapy until seizures resolve on E"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8634,
      "preview": "A. For any clinical seizure in a patient not yet on aEEG/EEG, place aEEG and call neurology to reque"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8635,
      "preview": "B. For aEEG/EEG seizures with or without clinical correlate"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8637,
      "preview": "1. Phenobarbital $20 \\mathrm{mg} / \\mathrm{kg}$ IV load"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8638,
      "preview": "a. Goal of starting infusion within 10 minutes of seizure identification"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8639,
      "preview": "b. Order STAT, available to be pulled from OMNICELL (PYXIS) in unit"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8640,
      "preview": "c. Phenobarbital infusion rate is $1 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ - infusion should be "
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8641,
      "preview": "d. NICU MD/NP to notify Neurology as soon as load is complete."
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8642,
      "preview": "e. Neuro to recheck EEG. At same time, NICU to order up additional $10 \\mathrm{mg} / \\mathrm{kg}$ ph"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8643,
      "preview": "f. Goal of EEG feedback within 15 minutes of notified infusion complete"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8644,
      "preview": "g. If still seizing, give additional $10 \\mathrm{mg} / \\mathrm{kg}$ phenobarbital, and order up drug"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8645,
      "preview": "h. NICU to notify Neurology as soon as load is complete. Neuro to recheck EEG."
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8646,
      "preview": "i. If still with seizures, move to Fosphenytoin."
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8647,
      "preview": "ii. If no longer seizing, check Phenobarbital level and start $5 \\mathrm{mg} / \\mathrm{kg} /$ day ma"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8648,
      "preview": "2. Fosphenytoin $15 \\mathrm{mg} / \\mathrm{kg}$ IV load"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8649,
      "preview": "a. To be started within 10 minutes of EEG feedback that seizures are ongoing"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8650,
      "preview": "b. Fosphenytoin infusion rate is $3 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ - infusion should be c"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8651,
      "preview": "c. NICU MD/NP to notify Neuro as soon as load is complete."
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8652,
      "preview": "d. Neuro to recheck EEG. At same time, NICU to order up drug \\#3 STAT."
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8653,
      "preview": "e. Goal of giving EEG feedback within 15 minutes of notified infusion complete"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8654,
      "preview": "i. If still seizing, go to Levetiracetam as next drug"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8655,
      "preview": "ii. If no longer seizing, check PB and PHT levels and start PB $5 \\mathrm{mg} / \\mathrm{kg} /$ day m"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8657,
      "preview": "--- page 358 ---"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8659,
      "preview": "3. Levetiracetam $40 \\mathrm{mg} / \\mathrm{kg}$ IV load"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8660,
      "preview": "a. To be started within 10 minutes of EEG feedback that seizures are ongoing"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8661,
      "preview": "b. Levetiracetam loading dose is given over 15 minutes"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8662,
      "preview": "c. NICU MD/NP to notify neuro as soon as load complete."
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8663,
      "preview": "d. Neuro to recheck EEG. At same time, order next drug STAT."
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8664,
      "preview": "e. Goal of giving EEG feedback within 15 minutes of notified infusion complete"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8665,
      "preview": "i. If still seizing, go to midazolam infusion"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8666,
      "preview": "ii. If no longer seizing, check PB and PHT level and start PB $5 \\mathrm{mg} / \\mathrm{kg} /$ day ma"
    },
    {
      "type": "text",
      "section": "V. Acute Treatment",
      "line": 8667,
      "preview": "4. Midazolam bolus and then infusion- dosing guideline per neurology"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Refractory Seizures",
      "line": 8669
    },
    {
      "type": "text",
      "section": "VI. Refractory Seizures",
      "line": 8671,
      "preview": "A. If the seizures continue, and no clear etiology has yet been found, consider empiric trials for v"
    },
    {
      "type": "text",
      "section": "VI. Refractory Seizures",
      "line": 8672,
      "preview": "B. Pyridoxine challenge: give pyridoxine 100 mg IV bolus. Mayepeat x1 if no response. CAUTION: Pyrid"
    },
    {
      "type": "text",
      "section": "VI. Refractory Seizures",
      "line": 8673,
      "preview": "C. If no response, continue $B 630 \\mathrm{mg} / \\mathrm{kg} /$ day div TID, plus PLP (below) until "
    },
    {
      "type": "text",
      "section": "VI. Refractory Seizures",
      "line": 8674,
      "preview": "D. Folinic Acid: (not folate) $-3-5 \\mathrm{mg} / \\mathrm{kg} /$ day PO for at least 5 days."
    },
    {
      "type": "text",
      "section": "VI. Refractory Seizures",
      "line": 8675,
      "preview": "E. Pyridoxal-5-phosphate: (different than pyridoxine) can be challenging to obtain. Pharmacy may req"
    },
    {
      "type": "text",
      "section": "VI. Refractory Seizures",
      "line": 8676,
      "preview": "F. Biotin: $5-10 \\mathrm{mg}$ twice daily."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. Maintenance Therapy",
      "line": 8678
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8680,
      "preview": "A. Start maintenance anti-epileptic drug dosing after acute seizures are controlled. If multiple bol"
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8682,
      "preview": "1. Phenobarbital: Maintenance dose $4-5 \\mathrm{mg} / \\mathrm{kg} /$ day given QD or BID."
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8683,
      "preview": "2. Fosphenytoin: Maintenance dose $5 \\mathrm{mg} / \\mathrm{kg} /$ day divided TID. (Therapeutic leve"
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8684,
      "preview": "3. Levetiracetam: Maintenance dose $40-80 \\mathrm{mg} / \\mathrm{kg} /$ day divided TID. Levels are n"
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8685,
      "preview": "B. Duration of maintenance therapy will depend on individual circumstances. In general, children wit"
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8686,
      "preview": "C. All patients discharged on anti-seizure medicines should have a follow-up visit with a pediatric "
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8688,
      "preview": "--- page 359 ---"
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8690,
      "preview": "352 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "VII. Maintenance Therapy",
      "line": 8691,
      "preview": "weeks after discharge to reassess response to medication. This can be with a neurologist who has see"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 8693
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8695,
      "preview": "1. Cross JH. Differential diagnosis of epileptic seizures in infancy including the neonatal period. "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8696,
      "preview": "2. Shellhaas RA, Chang T, Tsuchida T et al. The American Clinical Neurophysiology Society's Guidelin"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8697,
      "preview": "3. Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systemati"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8699,
      "preview": "--- page 360 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Intraventricular and Periventricular Hemorrhage",
      "line": 8701
    },
    {
      "type": "text",
      "section": "Intraventricular and Periventricular Hemorrhage",
      "line": 8703,
      "preview": "Alexis Davis, M.D., M.S. Epi and Valerie Chock, M.D., M.S. Epi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 8705
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 8707,
      "preview": "Together, intraventricular hemorrhage (IVH) and periventricular lesions are the most common types of"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiology",
      "line": 8709
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8711,
      "preview": "IVH in the premature infant arises from the germinal matrix (GM). This is a periventricular structur"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Classification of IVH",
      "line": 8713
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8715,
      "preview": "A. The Papile ultrasound grading system has historically been used (somewhat imperfectly) to predict"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8717,
      "preview": "1. Grade I: Bleeding limited to the subependymal or germinal matrix layer and the choroid plexus."
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8718,
      "preview": "2. Grade II: Bleeding extending into the ventricles that may fill the ventricle but not cause dilati"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8719,
      "preview": "3. Grade III: Bleeding into the ventricles that directly causes dilatation of the ventricles but no "
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8720,
      "preview": "4. Grade IV: Bleeding that extends into the brain parenchyma."
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8721,
      "preview": "B. More recently at LPCH, radiologists have chosen to describe the constellation of findings seen on"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8723,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8724,
      "preview": "\\mathrm{RI}=(\\text { Peak systolic velocity }- \\text { End diastolic velocity }) /(\\text { Peak syst"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8725,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8727,
      "preview": "RI of less than 0.5-0.6 in the neonatal period is associated with adverse neurological outcomes at 1"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8729,
      "preview": "--- page 361 ---"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8731,
      "preview": "The onset of IVH has no characteristic clinical findings. It may present asymptomatically or with se"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8732,
      "preview": "A. Post hemorrhagic hydrocephalus (PHH) occurs in up to 1/3-1/2 of patients with grade III or IV IVH"
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8733,
      "preview": "B. Periventricular leukomalacia (PVL) is a generally symmetric, non-hemorrhagic, and ischemic white "
    },
    {
      "type": "text",
      "section": "III. Classification of IVH",
      "line": 8734,
      "preview": "C. Neuromotor sequelae: Major IVH is associated strongly with neuromotor handicaps ranging from mino"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Diagnosis of IVH",
      "line": 8736
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8738,
      "preview": "A. Cranial ultrasound:"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8740,
      "preview": "1. A screening head ultrasound is indicated for infants with a birth weight $<1500$ grams and/or ges"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8741,
      "preview": "2. No follow-up is recommended for minimally abnormal head ultrasound (Grade I or II) after 1 week o"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8742,
      "preview": "3. Patients with a significant bleeding into the ventricle (i.e., grade II or III) may need at least"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8743,
      "preview": "4. Follow-up may be indicated for critically ill patients or ELBW ( $<750 \\mathrm{gm}$ ) at the disc"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8744,
      "preview": "5. Weekly measures of OFC should be performed on all patients, with more frequent measurements on th"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8745,
      "preview": "6. Infants with severe IVH (grade III or IV) are at higher risk for clinical or subclinical seizures"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8747,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8749,
      "preview": "--- page 362 ---"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8751,
      "preview": "B. Serial ultrasounds have been recommended for all patients in the past with IVH; however, serial u"
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8753,
      "preview": "1. Clinical signs of increased ICP."
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8754,
      "preview": "2. Severe IVH on initial scan."
    },
    {
      "type": "text",
      "section": "V. Diagnosis of IVH",
      "line": 8755,
      "preview": "3. Patient receiving ongoing interventions (e.g., medication, LP) to assess efficacy of therapy."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. \"Premature\" MRI Protocol",
      "line": 8757
    },
    {
      "type": "text",
      "section": "VI. \"Premature\" MRI Protocol",
      "line": 8759,
      "preview": "A. Recent developments in MR imaging (e.g., diffusion-weighted imaging and diffusion-tensor imaging "
    },
    {
      "type": "text",
      "section": "VI. \"Premature\" MRI Protocol",
      "line": 8760,
      "preview": "B. Infants needing an MRI usually are done as a \"feed and bundle\" (feed the infant just prior to and"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 8762
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8764,
      "preview": "1. Papile LA et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8765,
      "preview": "2. Ment LR et al. Practice parameter: neuroimaging of the neonate: Report of the Quality Standards S"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8766,
      "preview": "3. El-Dib M, Massaro AN, Bulas D, Aly H. Neuroimaging and neurodevelopmental outcome of premature in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8767,
      "preview": "4. van Wezel-Meijler G, Steggerda SJ, Leijser LM. Cranial ultrasonography in neonates: role and limi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8768,
      "preview": "5. Bassan H. Intracranial hemorrhage in the preterm infant: understanding it, preventing it. Clin Pe"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8769,
      "preview": "6. Adams-Chapman I, Hansen NI, Stoll BJ, et al. Neurodevelopmental outcome of extremely low birth we"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8770,
      "preview": "7. Mukerji A, Shah V, Shah PS. Periventricular/Intraventricular hemorrhage and neurodevelopmental ou"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8772,
      "preview": "--- page 363 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Retinopathy of Prematurity",
      "line": 8774
    },
    {
      "type": "text",
      "section": "Retinopathy of Prematurity",
      "line": 8776,
      "preview": "Lisa Charo Bain, M.D. and Rachael Small N.N.P."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 8778
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 8780,
      "preview": "Retinopathy of prematurity (ROP) refers to the abnormal growth of blood vessels in the retina of pre"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiology",
      "line": 8782
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 8784,
      "preview": "ROP is a multifactorial disease. The most important risk factor for developing ROP is prematurity. S"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Classification of ROP",
      "line": 8786
    },
    {
      "type": "text",
      "section": "III. Classification of ROP",
      "line": 8788,
      "preview": "Classification of ROP is based on staging of the disease (stage 1-5), location of involvement of the"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Stage",
      "line": 8790
    },
    {
      "type": "text",
      "section": "A. Stage",
      "line": 8792,
      "preview": "1. Stage 1: Flat white line demarcating the vascular and avascular retina"
    },
    {
      "type": "text",
      "section": "A. Stage",
      "line": 8793,
      "preview": "2. Stage 2: Formation of a ridge of fibrous tissue between the vascular and avascular retina"
    },
    {
      "type": "text",
      "section": "A. Stage",
      "line": 8794,
      "preview": "3. Stage 3: Growth of new blood vessels and fibrous tissue along the ridge and into the vitreous"
    },
    {
      "type": "text",
      "section": "A. Stage",
      "line": 8795,
      "preview": "4. Stage 4: Partial retinal detachment"
    },
    {
      "type": "text",
      "section": "A. Stage",
      "line": 8796,
      "preview": "5. Stage 5: Total retinal detachment"
    },
    {
      "type": "text",
      "section": "A. Stage",
      "line": 8797,
      "preview": "B. Zones"
    },
    {
      "type": "image",
      "section": "A. Stage",
      "line": 8798,
      "content": "![img-62.jpeg](images/39fce2a388790185.png)"
    },
    {
      "type": "text",
      "section": "A. Stage",
      "line": 8800,
      "preview": "--- page 364 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "C. Extent",
      "line": 8802
    },
    {
      "type": "text",
      "section": "C. Extent",
      "line": 8804,
      "preview": "Described by dividing the retinal surface into 30 degree sectors, like hours of a clock"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "D. Plus Disease",
      "line": 8806
    },
    {
      "type": "text",
      "section": "D. Plus Disease",
      "line": 8808,
      "preview": "Defined as dilated and tortuous blood vessels in the posterior pole of the eye and indicates severe "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Eligibility",
      "line": 8810
    },
    {
      "type": "text",
      "section": "IV. Eligibility",
      "line": 8812,
      "preview": "All infants born at a weight of $<1500 \\mathrm{gm}$ or gestational age of 30 weeks of less should be"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Timing",
      "line": 8814
    },
    {
      "type": "text",
      "section": "V. Timing",
      "line": 8816,
      "preview": "Infants should be screened at 4-8 weeks after birth, depending on GA at birth. Those born at 22-27 w"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Follow-up",
      "line": 8818
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8820,
      "preview": "A. Within one week"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8822,
      "preview": "1. Immature vascularization in zone I, without ROP"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8823,
      "preview": "2. Immature retina that extends into posterior zone II, near the boundary of zone I"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8824,
      "preview": "3. Stage 1 or 2 ROP in zone I"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8825,
      "preview": "4. Stage 3 ROP in zone II"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8826,
      "preview": "5. Suspected aggressive posterior ROP"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8827,
      "preview": "B. Within 1-2 weeks"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8828,
      "preview": "6. Immature vascularization in posterior zone II"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8829,
      "preview": "7. Stage 2 ROP in zone II"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8830,
      "preview": "8. Regressing ROP in zone I"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8831,
      "preview": "C. Within 2 weeks"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8832,
      "preview": "9. Stage 1 ROP in zone II"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8833,
      "preview": "10. Immature vascularization in zone II, without ROP"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8834,
      "preview": "11. Regressing ROP in zone II"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8835,
      "preview": "D. Within 2-3 weeks"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8836,
      "preview": "12. Stage 1 or 2 ROP in zone III"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8838,
      "preview": "--- page 365 ---"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8840,
      "preview": "358 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8841,
      "preview": "2. Regressing ROP in zone III"
    },
    {
      "type": "text",
      "section": "VI. Follow-up",
      "line": 8842,
      "preview": "E. Follow-up exams after discharge should be scheduled per recommendation of the Ophthalmologist."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. Prevention",
      "line": 8844
    },
    {
      "type": "text",
      "section": "VII. Prevention",
      "line": 8846,
      "preview": "Interventions to prevent ROP have been largely unsuccessful or associated with other adverse outcome"
    },
    {
      "type": "text",
      "section": "VII. Prevention",
      "line": 8847,
      "preview": "A. PaO2 $\\geq 80 \\mathrm{~mm} \\mathrm{Hg}$ in the first 2 wks of life has been shown to increase the"
    },
    {
      "type": "text",
      "section": "VII. Prevention",
      "line": 8848,
      "preview": "B. In the STOP-ROP trial infants were maintained with O2 sats either 89-94\\% (conventional) or 96-99"
    },
    {
      "type": "text",
      "section": "VII. Prevention",
      "line": 8849,
      "preview": "C. In the SUPPORT and BOOST II trials infants were maintained with O2 sats 85-89\\% (low sat arm) or "
    },
    {
      "type": "text",
      "section": "VII. Prevention",
      "line": 8850,
      "preview": "D. In the LPCH NICU, infants who reach prethreshold stage 2 or 3 ROP are managed with a combination "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8852
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8854,
      "preview": "(See NICU Guide Section II.B. 2 \"Oxygen Saturation Guidelines)"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8855,
      "preview": "A. For infants without ROP see Oxygen Saturation Guidelines chapter."
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8856,
      "preview": "B. Pre-Threshold ROP (when diagnosed by Ophthalmology). At the time of detection of prethreshold ROP"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8858,
      "preview": "1. In oxygen"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8859,
      "preview": "a. Target oxygen saturations: $97-99 \\%$"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8860,
      "preview": "b. Pulse oximeter alarm limits: $95 \\%$ and $99 \\%$"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8861,
      "preview": "2. In room air"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8862,
      "preview": "a. Target oxygen saturations: $97-100 \\%$"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8863,
      "preview": "b. Pulse oximeter alarm limites: $95 \\%$ and $100 \\%$"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8865,
      "preview": "--- page 366 ---"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8867,
      "preview": "Retinal ablative therapy is indicated for eyes with threshold ROP and eyes with high-risk pre-thresh"
    },
    {
      "type": "text",
      "section": "VIII. LPCH NICU Guidelines for O2 saturation targets and alarm limits",
      "line": 8868,
      "preview": "A. Threshold ROP: five contiguous clock hours or eight total clock hours of stage 3 and plus disease"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. High-risk pre-threshold ROP:",
      "line": 8870
    },
    {
      "type": "text",
      "section": "B. High-risk pre-threshold ROP:",
      "line": 8872,
      "preview": "Zone I: any stage ROP with plus disease"
    },
    {
      "type": "text",
      "section": "B. High-risk pre-threshold ROP:",
      "line": 8873,
      "preview": "Zone I: stage 3 ROP without plus disease"
    },
    {
      "type": "text",
      "section": "B. High-risk pre-threshold ROP:",
      "line": 8874,
      "preview": "Zone II: stage 2 or 3 ROP with plus disease"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "X. Avastin (Bevacizumab)",
      "line": 8876
    },
    {
      "type": "text",
      "section": "X. Avastin (Bevacizumab)",
      "line": 8878,
      "preview": "Intravitereal injections of anti-vascular endothelial growth factor therapy such as Avastin have bec"
    },
    {
      "type": "text",
      "section": "X. Avastin (Bevacizumab)",
      "line": 8880,
      "preview": "Recently, concerns have been raised about systemic absorption of Avastin and potential harmful effec"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XI. Ophthalmology Consultants",
      "line": 8882
    },
    {
      "type": "text",
      "section": "XI. Ophthalmology Consultants",
      "line": 8884,
      "preview": "A. Dr. Moshfeghi (dariusm@stanford.edu, pager \\#13974, cell 664-5561, Clinic 723-6995)"
    },
    {
      "type": "text",
      "section": "XI. Ophthalmology Consultants",
      "line": 8885,
      "preview": "B. Dr. Gaynon (opmed@earthlink.net, pager \\#10782)"
    },
    {
      "type": "text",
      "section": "XI. Ophthalmology Consultants",
      "line": 8886,
      "preview": "C. Dr. Euna Koo (eunakoo@stanford.edu, pager \\#23111)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "XII. ROP exam tracking",
      "line": 8888
    },
    {
      "type": "text",
      "section": "XII. ROP exam tracking",
      "line": 8890,
      "preview": "Rachael Small NNP, identifies patients weekly who meet eligibility for an ROP screen and assigns the"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References:",
      "line": 8892
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8894,
      "preview": "1. Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity. A multivariate statistical "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8895,
      "preview": "2. Hagadorn JI, Richardson DK, Schmid CH, Cole CH. Cumulative illness severity and progression from "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8897,
      "preview": "--- page 367 ---"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8899,
      "preview": "360 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8900,
      "preview": "3. Lad EM, Hernandez-Boussard R, Morton JM, Moshfeghi DM. Incidence of retinopathy or prematurity in"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8901,
      "preview": "4. Chavez-Valdez R, McGowan J, Cannon E. Lehmann CU. Contribution of early glycemic status in the de"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8902,
      "preview": "5. Kaempf JW, Kaempf AJ, Wu Y, Stawarz M, Neimeyer J, Grunkemeier G. Hyperglycemia, insulin and slow"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8903,
      "preview": "6. Flynn JT, Bancalari E, Snyder ES, Goldberg RN, Feuer W, Cassady J, et al. A cohort study of trans"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8904,
      "preview": "7. Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Target ranges of oxygen satura"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8905,
      "preview": "8. Patz A. The new international classification of retinopathy of premarturirty. Arch Ophthamlmol. 1"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8906,
      "preview": "9. Stenson BJ, Tarnow-Mordi WO, Darlow BA, Simes J, Juszczak E, Aski L, et al. Oxygen saturation and"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8907,
      "preview": "10. Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8908,
      "preview": "11. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retin"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8909,
      "preview": "12. Morin J, Luu TM, Superstein R, et al. Neurodevelopmental Outcomes Following Bevacizumab Injectio"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8910,
      "preview": "13. Policy Statement: Screening examination of premature infants for retinopathy of prematurity. Ped"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 8912,
      "preview": "--- page 368 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hydrocephalus and External Ventricular Drains",
      "line": 8914
    },
    {
      "type": "heading",
      "level": 2,
      "section": "May Casazza, CPNP-AC",
      "line": 8916
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Hydrocephalus",
      "line": 8918
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8920,
      "preview": "A. CSF pathway:"
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8922,
      "preview": "1. CSF is produced in the choroid plexus and cerebral tissue."
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8923,
      "preview": "a. Normal rate of CSF production is about $18 \\mathrm{~mL} /$ hour."
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8924,
      "preview": "2. CSF circulates through the ventricular system into the subarachnoid space."
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8926,
      "preview": "Lateral ventricles $\\rightarrow$ foramen of Monro midline $\\rightarrow 3$ rd ventricle $\\rightarrow$"
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8927,
      "preview": "3. There are large areas within the subarachnoid space called cisterns where CSF collects."
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8928,
      "preview": "a. Basal cisterns connect the intracranial and spinal subarachnoid spaces."
    },
    {
      "type": "image",
      "section": "I. Hydrocephalus",
      "line": 8929,
      "content": "![img-63.jpeg](images/191b2c9a58ff89f4.png)"
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8930,
      "preview": "B. Hydrocephalus is an abnormal accumulation of cerebrospinal fluid (CSF) within the ventricles of t"
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8932,
      "preview": "1. Non-communicating hydrocephalus or obstructive hydrocephalus: blockage within the CSF pathway or "
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8933,
      "preview": "a. Most common is aqueductal stenosis. The aqueduct of Sylvius is the narrow pathway between the 3rd"
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8934,
      "preview": "2. Communicating hydrocephalus: impaired reabsorption of CSF within the arachnoid villi, basal ciste"
    },
    {
      "type": "text",
      "section": "I. Hydrocephalus",
      "line": 8936,
      "preview": "--- page 369 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8938
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8940,
      "preview": "A. Clinical signs include:"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8942,
      "preview": "1. Rapidly increasing head circumference in a child with patent cranial sutures"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8943,
      "preview": "2. Full, bulging fontanel that can be soft or tense. It does not fluctuate with position or when the"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8944,
      "preview": "3. Disconjugate gaze or sunsetting sign of the eyes (upgaze paresis)."
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8945,
      "preview": "4. Increase sleepiness, difficult to arouse, lethargic"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8946,
      "preview": "5. Nausea/vomiting with no other associated illness or causes."
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8947,
      "preview": "6. Failure to thrive"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8948,
      "preview": "7. Slow development"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8949,
      "preview": "B. Diagnostic Studies"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8950,
      "preview": "8. Head ultrasound"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8951,
      "preview": "9. Brain MRI"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8952,
      "preview": "a. Full brain MRI without contrast often for initial study"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8953,
      "preview": "b. Full brain MRI with and without contrast if a mass is noted"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8954,
      "preview": "c. Head CT often for acute symptoms or patients with adjustable valve"
    },
    {
      "type": "text",
      "section": "II. Diagnosing Hydrocephalus",
      "line": 8955,
      "preview": "10. Follow up study: Fast brain MRI without contrast (limited sequences that can be done within minu"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8957
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8959,
      "preview": "A. Ventricular reservoir is a ventricular access device (VAD) used as a bridge to VP shunt in neonat"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8961,
      "preview": "1. A VAD can be used for serial therapeutic taps for management of hydrocephalus"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8962,
      "preview": "a. Intraventricular hemorrhage: while waiting for the CSF to clear from the hemorrhage, remove eleva"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8963,
      "preview": "b. Use as temporary management of symptoms while continuing to evaluate need for VP shunt."
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8964,
      "preview": "B. Endoscopic Third Ventriculostomy (ETV) and Choroid Plexus Cauterizaton (CPC)"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8965,
      "preview": "2. Alternative to CSF shunting in infants with hydrocephalus"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8966,
      "preview": "3. ETV: use of endoscopy to create an internal pathway for CSF diversion through the floor of the th"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8968,
      "preview": "--- page 370 ---"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8970,
      "preview": "a. About $30 \\%$ of children do not respond well to the procedure and subsequently require a shunt."
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8972,
      "preview": "Success rate is higher in children older than 1 year of age."
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8973,
      "preview": "b. Deficient CSF resorption is thought to attribute to low ETV success rate in young infants."
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8974,
      "preview": "3. CPC: endoscopic cauterization of the choroid plexus at time of ETV can augment the deficient CSF "
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8975,
      "preview": "C. Ventriculoperitoneal shunt (VP shunt):"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8977,
      "preview": "1. Components of shunt:"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8978,
      "preview": "a. Proximal catheter is radiopaque and placed in one of the lateral ventricles."
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8979,
      "preview": "b. The valve allows for unidirectional CSF flow and contains a reservoir that allows evaluation of I"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8980,
      "preview": "c. Distal catheter end is primarily placed into the peritoneum or, if clinically indicated, in other"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8981,
      "preview": "i. Ventriculoperitoneal shunt"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8982,
      "preview": "ii. Ventriculopleural shunt"
    },
    {
      "type": "text",
      "section": "III. Management of Hydrocephalus in the Neonate",
      "line": 8983,
      "preview": "iii. Ventriculo atrial shunt"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Shunt Valve Types",
      "line": 8985
    },
    {
      "type": "text",
      "section": "IV. Shunt Valve Types",
      "line": 8987,
      "preview": "A. Fixed-pressure (nonprogrammable) valve regulates the flow of CSF based on a pre-determined pressu"
    },
    {
      "type": "text",
      "section": "IV. Shunt Valve Types",
      "line": 8989,
      "preview": "1. Necessitates shunt revision when the patient's pressure/flow requirement changes"
    },
    {
      "type": "text",
      "section": "IV. Shunt Valve Types",
      "line": 8990,
      "preview": "B. Adjustable pressure (programmable) valve regulates the flow of CSF based on a pressure setting th"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Complications",
      "line": 8992
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 8994,
      "preview": "A. Shunt Failure - obstruction along any portion of the shunt system. Insufficient or over drainage "
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 8995,
      "preview": "B. Disconnection - usually neck area, often in cervical junction with longstanding shunts, should be"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 8996,
      "preview": "C. Migration - catheter migrates out of ventricle or out of peritoneal space (inguinal hernia)."
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 8997,
      "preview": "D. Infection - may require externalization of the shunt to a drain until infection is treated."
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 8999,
      "preview": "1. Meningitis - literature indicates two-thirds of cases caused by S. epidermidis and S. aureus"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9001,
      "preview": "--- page 371 ---"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9003,
      "preview": "364 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9004,
      "preview": "2. Peritonitis - may cause meningitis"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9005,
      "preview": "3. On rare occasion, infection can occur from a ruptured appendix or ruptured abdominal viscera"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9006,
      "preview": "E. Underdrainage or Overdrainage - Both can result in similar symptoms."
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9008,
      "preview": "1. Overdrainage - When too much CSF is drained compared with the amount of CSF being produced, the c"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9009,
      "preview": "2. Underdrainage - can cause recurrent hydrocephalus. Headaches are worse when flat and better uprig"
    },
    {
      "type": "text",
      "section": "V. Complications",
      "line": 9010,
      "preview": "3. Loculations - usually caused by infection or ventriculitis, causing catheter occlusion, and will "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Management of an Infected Shunt in the Neonate",
      "line": 9012
    },
    {
      "type": "text",
      "section": "VI. Management of an Infected Shunt in the Neonate",
      "line": 9014,
      "preview": "A. Obtain CSF culture (aerobic/anaerobic) and gram stain, serial blood cultures, urine culture, CBC "
    },
    {
      "type": "text",
      "section": "VI. Management of an Infected Shunt in the Neonate",
      "line": 9015,
      "preview": "B. Initiate broad spectrum antibiotics."
    },
    {
      "type": "text",
      "section": "VI. Management of an Infected Shunt in the Neonate",
      "line": 9016,
      "preview": "C. Once organism is isolated and antibiotic sensitivities are available, adjust antibiotics as indic"
    },
    {
      "type": "text",
      "section": "VI. Management of an Infected Shunt in the Neonate",
      "line": 9017,
      "preview": "D. Externalize shunt or remove shunt completely, monitoring head circumference and signs of increase"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. Tapping a Ventricular Reservoir",
      "line": 9019
    },
    {
      "type": "text",
      "section": "VII. Tapping a Ventricular Reservoir",
      "line": 9021,
      "preview": "A. Performed only by Neurosurgery Team"
    },
    {
      "type": "text",
      "section": "VII. Tapping a Ventricular Reservoir",
      "line": 9022,
      "preview": "B. Equipment: 25-gauge butterfly needles, syringe, sterile gloves, betadine prep, gauze and mask."
    },
    {
      "type": "text",
      "section": "VII. Tapping a Ventricular Reservoir",
      "line": 9023,
      "preview": "C. For patients requiring interval tapping: obtain surveillance head ultrasound every Monday and Thu"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9025
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9027,
      "preview": "A. Daily head circumference measurement."
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9028,
      "preview": "B. Assess fontanels routinely in an upright position and when infant is not irritable."
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9029,
      "preview": "C. Routine vital signs, including temperature."
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9030,
      "preview": "D. Monitor for signs and symptoms of increased ICP: nausea, vomiting, lethargy, irritability, discon"
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9031,
      "preview": "E. Assess entire shunt tract for fluid collection, erythema, and tenderness."
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9032,
      "preview": "F. Rotate head every 2-3 hours and avoid direct pressure to VP shunt to prevent skin breakdown."
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9033,
      "preview": "G. Typically a fast brain MRI without contrast is done after a VP shunt placement for baseline ventr"
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9035,
      "preview": "--- page 372 ---"
    },
    {
      "type": "text",
      "section": "VIII. Daily Nursing Considerations/Management",
      "line": 9037,
      "preview": "The fast MRI is only a few minutes long and can be done without sedation."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IX. General Follow-up Management",
      "line": 9039
    },
    {
      "type": "text",
      "section": "IX. General Follow-up Management",
      "line": 9041,
      "preview": "A. Consult with Neurosurgery Team prior to discharging patient."
    },
    {
      "type": "text",
      "section": "IX. General Follow-up Management",
      "line": 9042,
      "preview": "B. Family should have instructions on signs and symptoms to look for."
    },
    {
      "type": "text",
      "section": "IX. General Follow-up Management",
      "line": 9043,
      "preview": "C. Follow-up is often 2 weeks after hospital discharge for ETV/CPC or complicated patients and 3-4 w"
    },
    {
      "type": "text",
      "section": "IX. General Follow-up Management",
      "line": 9044,
      "preview": "D. VP shunt patients who live far away should be discharged with a copy of most recent neuroimaging "
    },
    {
      "type": "text",
      "section": "IX. General Follow-up Management",
      "line": 9046,
      "preview": "For any questions, during the day, please page the Neurosurgery resident on service/Fellow/or Attend"
    },
    {
      "type": "text",
      "section": "IX. General Follow-up Management",
      "line": 9048,
      "preview": "--- page 373 ---"
    },
    {
      "type": "text",
      "section": "IX. General Follow-up Management",
      "line": 9050,
      "preview": "366 Part II-I: Neurology"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 9052
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9054,
      "preview": "1. Hatlen, T.J., Shurtleff, D.B., Loeser, J.D., Ojemann, J.G., Avellino, A.M \\& Ellenbogen RG. (2012"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9055,
      "preview": "2. Jian, L., Hang-song, S., Zheng-lang, L., Li-sheng, Y., Heng, W., \\& Nu, Z. (2012). Implantation o"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9056,
      "preview": "3. Kahn, F, Shamim, M.S., Rehman, A. \\& Bari, M.E. (2013). Analysis of factors affecting ventriculop"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9057,
      "preview": "4. Kormanik, K. Praca, J., Garton, H.J.L., Sarkar, S. (2010). Repeated tapping of ventricular reserv"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9058,
      "preview": "5. Kulkarni, A., Drake, J., Mallucci, C., Sgouros, S., Roth, J. \\& Constantini, S. (2009) Endoscopic"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9059,
      "preview": "6. Kulkarni, A., Riva-Cambrin, J., Browd, S., Drake, J., Holubkov, R., Kestle, J., Limbrick, D., Roz"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9060,
      "preview": "7. Lavinio, A., Harding, S, Van Der Boogaard, F., Czosnyka, M., Smielewski, P., Richards, H.K., Pick"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9061,
      "preview": "8. Robinson, S. (2012). Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9062,
      "preview": "9. Shankaran, S. (2000). Complications of Neonatal Intracranial Hemorrhage. Neo Reviews, 1, e44 DOI:"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9063,
      "preview": "10. Sivaganesan. (2012) Neuroimaging of ventriculoperitoneal shunt complications in children. Pediat"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9064,
      "preview": "11. Stone, J, Walker, C, Jacobson, M., Philips, V, \\& Silberstein, H. (2013). Revision rate of pedia"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9065,
      "preview": "12. Tian, A., Hintz, S, Cohen, R. S., Edwards, M.S.B. (2012). Ventricular access devices are safe an"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9066,
      "preview": "13. Warf, B. (2007). Endoscopic Third Ventriculostomy and Choroid Plexus Cauterization for Pediatric"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9067,
      "preview": "14. Whitelaw, A. \\& Aquilina, K. (2012). Management of posthaemorrhagic ventriuclar dilatation. Arch"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9069,
      "preview": "--- page 374 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypothermia Therapy for Hypoxic-Ischemic Encephalopathy in Term and Near-Term Infants",
      "line": 9071
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Celia Shepherd Glennon, NNP-BC, Sonia Bonifacio, MD, Krisa Van Meurs, MD",
      "line": 9073
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. OVERVIEW",
      "line": 9075
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9077,
      "preview": "Therapeutic hypothermia is now the standard of care for newborns with moderate to severe HIE identif"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9079,
      "preview": "At LPCH more than $75 \\%$ of our neonates who undergo therapeutic hypothermia are transported to our"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9081,
      "preview": "The Late Hypothermia trial enrolled newborns with moderate to severe encephalopathy who had cooling "
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9082,
      "preview": "II. ACTIVE TRIALS FOR NEWBORNS WITH HIE AT LPCH. Please page research @15340 as soon as a potential "
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9083,
      "preview": "A. A Randomized Trial of Targeted Temperature Management with Whole Body Hypothermia for Moderate an"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9085,
      "preview": "Preemie Cooling will determine if whole body cooling will improve survival and reduce disability in "
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9086,
      "preview": "B. High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL)"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9088,
      "preview": "HEAL is a trial of high-dose erythropoietin vs. placebo in term babies with HIE who are being cooled"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9090,
      "preview": "--- page 375 ---"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9092,
      "preview": "The specific entry criteria are:"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9093,
      "preview": "A. Gestational age $\\geq 36$ weeks and chronologic age $<6$ hours (with the exception of Late Hypoth"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9094,
      "preview": "B. Clinical/biochemical data (must meet 1 or 2 below):"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9096,
      "preview": "1. Cord gas or postnatal gas $\\leq 1 \\mathrm{~h}$ with $\\mathrm{pH} \\leq 7.0$ or base deficit $\\geq "
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9097,
      "preview": "2. If no cord or postnatal gas within 1 hour OR if cord/postnatal gas within 1 h of birth with ph $7"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9098,
      "preview": "a. History of acute perinatal event AND"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9099,
      "preview": "b. Apgar $\\leq 5$ at 10 minutes OR need for assisted ventilation at birth and continued for 10 minut"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9100,
      "preview": "C. Infants meeting the following criteria are excluded:"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9101,
      "preview": "3. Gases at $\\leq 1 \\mathrm{~h}$ with $\\mathrm{pH}>7.15$ and base deficit $<10$"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9102,
      "preview": "4. Major congenital or chromosomal anomalies"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9103,
      "preview": "5. Severe IUGR ( $\\leq 1800 \\mathrm{~g}$ )"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9104,
      "preview": "D. Moderate or severe encephalopathy, based on a neurologic exam performed prior to cooling, or the "
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9105,
      "preview": "***A tutorial video of Neurologic Exam of Neonates with Suspected Encephalopathy by Dr. Courtney Wus"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9107,
      "preview": "THE MODIFIED SARNAT EXAM: (Smart Phrase. SARNAT in EPIC)"
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9109,
      "preview": "| CATEGORY | NORMAL | Mild HIE <br> (Stage 1) | Moderate HIE <br> (Stage 2) | Severe HIE <br> (Stage"
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9110,
      "preview": "| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9111,
      "preview": "| 1. Level of Consciousness | In Alert, responsive to external stimuli | 1= Hyperalert, apparent awa"
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9112,
      "preview": "| 2. Spontaneous Activity | In Changes position when quiet | 1= Normal or decreased | 2= Decreased a"
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9113,
      "preview": "| 3. Posture | In Predominantly flexed when quiet | 1=Mild flexion of distal joints (fingers, wrist "
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9114,
      "preview": "| 4. Tone | In Strong flexor tone in all extremities | 1= Normal or slightly increased | 2a= Hypoton"
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9115,
      "preview": "| 5. Primitive Reflexes: <br> a. Suck <br> b. Moro | In Suck strong, easily elicited <br> 3= Moro Co"
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9116,
      "preview": "| 6. Autonomic System: <br> a. Pupils <br> b. Heart Rate <br> c. Respirations | In Normal, reactive "
    },
    {
      "type": "table",
      "section": "I. OVERVIEW",
      "line": 9117,
      "preview": "| Summary of Encephalopathy Findings | \\# of Categories w/ Highest Score Normal: | \\# of Categories "
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9119,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "I. OVERVIEW",
      "line": 9121,
      "preview": "--- page 376 ---"
    },
    {
      "type": "image",
      "section": "I. OVERVIEW",
      "line": 9123,
      "content": "![img-64.jpeg](images/7182ddf121f550a9.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. PROCEDURES PRIOR TO THERAPY",
      "line": 9125
    },
    {
      "type": "text",
      "section": "V. PROCEDURES PRIOR TO THERAPY",
      "line": 9127,
      "preview": "A. Parental consent. We are developing 2 consent forms: one for those $<6$ hours age \\& one for infa"
    },
    {
      "type": "text",
      "section": "V. PROCEDURES PRIOR TO THERAPY",
      "line": 9128,
      "preview": "B. Attending approval."
    },
    {
      "type": "text",
      "section": "V. PROCEDURES PRIOR TO THERAPY",
      "line": 9129,
      "preview": "C. Review LPCH reference materials. The following documents are located in the binders in the side p"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9131
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9133,
      "preview": "A. After placement of the esophageal probe the infant is placed on the cooling blanket. Radiographic"
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9134,
      "preview": "B. Core body temperature is continuously monitored and servo-regulated using the esophageal temperat"
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9135,
      "preview": "C. During induction of cooling the entire baby's body (including the head) is placed directly on the"
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9137,
      "preview": "--- page 377 ---"
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9139,
      "preview": "370 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9140,
      "preview": "D. After the infant reaches target temperature the head should rest on a covered gel pillow and does"
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9141,
      "preview": "E. Core body temperature maintained for 72 hours for clinical hypothermia. If the infant's core temp"
    },
    {
      "type": "text",
      "section": "VI. THERAPEUTIC HYPOTHERMIA",
      "line": 9142,
      "preview": "F. At the conclusion of the cooling period, the patient is rewarmed slowly at a rate of $0.5^{\\circ}"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9144
    },
    {
      "type": "text",
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9146,
      "preview": "A. The infant bed is used for monitoring skin temp only. Expect skin temp to be 1-2\" cooler than eso"
    },
    {
      "type": "text",
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9147,
      "preview": "B. Infant is cared for in the supine position and log-rolled side to side during treatment."
    },
    {
      "type": "text",
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9148,
      "preview": "C. All blood gases are run on a special I-stat, which is calibrated to the core body temperature of "
    },
    {
      "type": "text",
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9149,
      "preview": "D. Ventilator gases are warmed normally."
    },
    {
      "type": "text",
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9150,
      "preview": "E. Expect lower heart rates. Monitor patient for skin alteration."
    },
    {
      "type": "text",
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9151,
      "preview": "F. Refer to the NICU Hypothermia Order Set in EPIC and the LPCH Intranet \"Nursing Policy and Procedu"
    },
    {
      "type": "text",
      "section": "VII. PATIENT CARE DURING COOLING",
      "line": 9152,
      "preview": "G. Order continuous video EEG and request a Neurology consult. NICU medical provider must page the o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9154
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9156,
      "preview": "A. Utilize Hypothermia Order Set in EPIC"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9158,
      "preview": "1. STAT head ultrasound with resistive indices on admission prior to vEEG placement"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9159,
      "preview": "2. Pre and post ductal saturations monitoring during the first 24 hours of admission"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9160,
      "preview": "3. vEEG"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9161,
      "preview": "4. Neurology consult"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9162,
      "preview": "B. Contact Neurology upon arrival of patient. Confirm start time for vEEG. If vEEG cannot be placed "
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9163,
      "preview": "C. Page Research Coordinator ASAP if eligible for study (i.e. Preemie Cooling, HEAL)"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9164,
      "preview": "D. Implement Seizure Management Protocol (on intranet) as clinically indicated."
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9165,
      "preview": "E. Include qualifying information for cooling in H\\&P. For all outborn infants utilize Transport HIE"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9167,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9169,
      "preview": "--- page 378 ---"
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9171,
      "preview": "F. Utilize Smart phrases where appropriate. \". Sarnat\" in H\\&P and in event notes for serial exams. "
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9172,
      "preview": "G. Complete MD/NNP aEEG Review and Interpretation Log at minimum q 3 hours during vEEG monitoring."
    },
    {
      "type": "text",
      "section": "VIII. STANDARDIZING WORKFLOW",
      "line": 9173,
      "preview": "H. Document outpatient Neurology follow up plans in Problem List or Discharge Summary."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IX. PATIENT CARE DURING AND AFTER REWARMING",
      "line": 9175
    },
    {
      "type": "text",
      "section": "IX. PATIENT CARE DURING AND AFTER REWARMING",
      "line": 9177,
      "preview": "A. Utilize Holding Algorithm to determine if infant is eligible for holding during maintenance phase"
    },
    {
      "type": "text",
      "section": "IX. PATIENT CARE DURING AND AFTER REWARMING",
      "line": 9178,
      "preview": "B. After 72 hours of cooling is complete, infant should be gradually rewarmed over at least 7 hours."
    },
    {
      "type": "text",
      "section": "IX. PATIENT CARE DURING AND AFTER REWARMING",
      "line": 9179,
      "preview": "C. Continuous vEEG should occur during induction phase, maintenance phase, and throughout rewarming "
    },
    {
      "type": "text",
      "section": "IX. PATIENT CARE DURING AND AFTER REWARMING",
      "line": 9180,
      "preview": "D. All patients undergoing therapeutic hypothermia need to have a brain MRI. Include \"therapeutic hy"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "X. OUTPATIENT FOLLOW UP",
      "line": 9182
    },
    {
      "type": "text",
      "section": "X. OUTPATIENT FOLLOW UP",
      "line": 9184,
      "preview": "A. All infants who are cooled should be referred to High Risk Infant Follow (HRIF) Clinic at 4 month"
    },
    {
      "type": "text",
      "section": "X. OUTPATIENT FOLLOW UP",
      "line": 9185,
      "preview": "B. All infant who are cooled (with and without seizures) should be offered outpatient Neurology foll"
    },
    {
      "type": "text",
      "section": "X. OUTPATIENT FOLLOW UP",
      "line": 9187,
      "preview": "--- page 379 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "REFERENCES",
      "line": 9189
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 9191,
      "preview": "1. Jacobs SE, Berg M, Hung R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with HIE (re"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 9192,
      "preview": "2. Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Arch Pediatr Adolesc Med (2012) 166:558-6"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 9193,
      "preview": "3. Shah PS. Hypothermia: a systematic review and meta-analysis of clinical trials. Seminars in Fetal"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 9194,
      "preview": "4. Akula VP, Joe P, Thusu K, et al. A randomized clinical trial of therapeutic hypothermia mode duri"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 9195,
      "preview": "5. Shankaran S, et al. Effect of depth and duration of cooling on death in the NICU among neonates w"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 9196,
      "preview": "6. ACOG/AAP Executive Summary: Neonatal encephalopathy and neurologic outcome, second edition. Repor"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 9198,
      "preview": "--- page 380 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Pain Assessment and Mangement in Neonates",
      "line": 9200
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Julie Good, M.D.",
      "line": 9202
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 9204
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 9206,
      "preview": "The goals of this chapter are: 1) to help you prevent, recognize and distinguish pain from other dis"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Background",
      "line": 9208
    },
    {
      "type": "text",
      "section": "II. Background",
      "line": 9210,
      "preview": "A. As recently as the late 1970s, it was commonplace to perform surgery on neonates without benefit "
    },
    {
      "type": "text",
      "section": "II. Background",
      "line": 9211,
      "preview": "B. We now have good evidence for the presence of a predictable stress response to painful interventi"
    },
    {
      "type": "text",
      "section": "II. Background",
      "line": 9212,
      "preview": "C. In the developing nervous system, nociceptive pathways are present by $24-26 \\mathrm{wks}$, but i"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Assessment of Pain",
      "line": 9214
    },
    {
      "type": "text",
      "section": "III. Assessment of Pain",
      "line": 9216,
      "preview": "A. Pain is defined as an unpleasant sensory and emotional experience, associated with actual or pote"
    },
    {
      "type": "text",
      "section": "III. Assessment of Pain",
      "line": 9217,
      "preview": "B. Pain is a subjective phenomenon. It is REAL regardless of whether tissue damage can be identified"
    },
    {
      "type": "text",
      "section": "III. Assessment of Pain",
      "line": 9218,
      "preview": "C. Most importantly for infants, the inability to communicate verbally does not negate the possibili"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Distinguishing Pain From Common Causes of Distress",
      "line": 9220
    },
    {
      "type": "text",
      "section": "IV. Distinguishing Pain From Common Causes of Distress",
      "line": 9222,
      "preview": "A. Common causes of non-painful distress are hunger, feeling too cold or hot, needing a diaper chang"
    },
    {
      "type": "text",
      "section": "IV. Distinguishing Pain From Common Causes of Distress",
      "line": 9223,
      "preview": "B. Behavior alone is an unreliable predictor of the cause of pain or distress. For example, a baby m"
    },
    {
      "type": "text",
      "section": "IV. Distinguishing Pain From Common Causes of Distress",
      "line": 9225,
      "preview": "--- page 381 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Measurement of the Pain",
      "line": 9227
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9229,
      "preview": "Across LPCH, pain is documented and communicated using standardized, validated pain measurement tool"
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9230,
      "preview": "A. Schedule for assessments: with every vital sign, 30 min after a pain management intervention (non"
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9231,
      "preview": "B. There are many tools available to systematically characterize the physiologic changes and/or beha"
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9232,
      "preview": "C. N-PASS scores are located in the chart under IView Critical Care Detailed, so that you can have a"
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9234,
      "preview": "1. The N-PASS pain is scored 0 (no pain) up to 10 (severe/highest pain). Note: negative points are a"
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9235,
      "preview": "2. Nurses will record pain regularly as described in A above, but if you want to score a baby yourse"
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9236,
      "preview": "3. Detailed information about the N-PASS tool can be found at http://www.ilemsc.org/PainMgt/NPASS.pd"
    },
    {
      "type": "text",
      "section": "V. Measurement of the Pain",
      "line": 9237,
      "preview": "D. Remember that the pain score is only one element of pain assessment. It is just as important to r"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Pain Management",
      "line": 9239
    },
    {
      "type": "text",
      "section": "VI. Pain Management",
      "line": 9241,
      "preview": "Management options for pain include prevention as well as treatment of the underlying process causin"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. General Guidelines",
      "line": 9243
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9245,
      "preview": "Multimodal therapy means using more than one strategy to prevent, treat, or manage pain. Using multi"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9246,
      "preview": "A. Non-pharmacologic pain management interventions are helpful alone, in conjunction with each other"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9248,
      "preview": "1. Prevention (do you REALLY need the information you will obtain from a particular test, or might t"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9250,
      "preview": "--- page 382 ---"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9252,
      "preview": "2. Encouraging parental physical contact/touch"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9253,
      "preview": "3. Providing adequate support for staff RNs so that baby has access to calm caregivers at bedside"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9254,
      "preview": "4. Decreasing bright lights and loud sounds"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9255,
      "preview": "5. Avoiding tactile over-stimulation, or cluster interventions to allow recovery and rest between th"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9256,
      "preview": "6. Choosing non-invasive monitoring over invasive monitoring techniques if possible"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9257,
      "preview": "7. Allow resting/sleeping periods for baby to establish and maintain circadian rhythm appropriate fo"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9258,
      "preview": "8. Limiting pain from tape removal by avoiding placement on hair, and remove gently with moistening/"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9259,
      "preview": "9. Lubricating NG/OG and urinary catheters before insertion"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9260,
      "preview": "10. Controling thermal stress by providing for comfortable stable ambient temperature"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9261,
      "preview": "11. Using skilled/trained personnel to obtain blood and place IV lines"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9262,
      "preview": "12. Use mechanical rather than manual lancets for heel sticks"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9263,
      "preview": "13. Comfort measures including: swaddling, containment, facilitated tucking, positioning, nesting, r"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9264,
      "preview": "14. Consulting pain service to provide acupuncture/acupressure and massage"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9265,
      "preview": "B. Pharmacologic interventions for pain management include opiates, non-opiate analgesics (acetamino"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9266,
      "preview": "15. Opiate medications are very effective for treatment and prevention of moderate to severe pain."
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9267,
      "preview": "a. They exhibit no ceiling analgesic effect, so may be increased as tolerance develops, to continue "
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9268,
      "preview": "b. Opiates may be administered by single dose or drip depending on length of time analgesia is neede"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9269,
      "preview": "c. The best routes to use in NICU population include PO, NG/OG, and IV. SC and rectal are not as use"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9270,
      "preview": "d. Opiate side effects most important to consider in the NICU include decreased GI motility (may man"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9272,
      "preview": "--- page 383 ---"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9274,
      "preview": "as vomiting or constipation), urinary retention, somnolence (is it the opiate? look for pinpoint pup"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9275,
      "preview": "e. Prolonged use leads to physical dependence (similar to that occurring with prolonged steroid use)"
    },
    {
      "type": "text",
      "section": "VII. General Guidelines",
      "line": 9276,
      "preview": "f. Morphine and fentanyl have been the most used and studied in the NICU population. Therefore, rese"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "i. Morphine",
      "line": 9278
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9280,
      "preview": "a) Morphine is a potent analgesic. Chest wall rigidity is less of a risk, and less tolerance develop"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9281,
      "preview": "b) Dosing guidelines to initiate therapy in opiate naive patients (usually safest to start low and g"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9282,
      "preview": "c) Future effects, a common parental and staff concern: Former preterm infants who had received morp"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9283,
      "preview": "ii. Fentanyl"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9284,
      "preview": "a) Fentanyl is a potent analgesic, that has quicker onset (1-2 min), is shorter acting (1-2 hrs), an"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9285,
      "preview": "b) It is lipophilic, so it distributes widely and quickly into fatty tissue and extravascular fluid."
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9287,
      "preview": "--- page 384 ---"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9289,
      "preview": "2. Non-opiate Analgesics are helpful for mild to moderate pain, alone or together with opiate medica"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9290,
      "preview": "a. Acetaminophen"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9292,
      "preview": "Acetaminophen has a mild to moderate analgesic effect by multiple central mechanisms (serotonin desc"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9293,
      "preview": "i. Analgesic ceiling: Doses beyond those recommended lead to more side effects but not better analge"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9294,
      "preview": "ii. Dose: Pharmacokinetics not established in preemies <28 wks. Usual dose modified in 2011 by recom"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9295,
      "preview": "iii. A systematic review of the literature (Ohlsson \\& Shaw, Cochrane 2015) supports efficacy in man"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9296,
      "preview": "b. NSAIDS (e.g. ibuprofen, ketorolac)"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9297,
      "preview": "i. NSAIDS are good mild/moderate analgesics especially in preventing inflammatory pain."
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9299,
      "preview": "Unfortunately, few studies have assessed risks/benefits in infants less than 6 mos of age, thus ther"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9300,
      "preview": "ii. Risks include displacement of bilirubin, renal toxicity and/or alteration of clearance of other "
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9301,
      "preview": "c. Sucrose"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9303,
      "preview": "Sucrose is an effective short acting (2-3 minute) analgesic for procedural pain. Thought to act by a"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9304,
      "preview": "i. Doses of $24 \\%$ solution found in multiple studies to decrease cry duration, lower heart rate va"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9305,
      "preview": "ii. Use along with non-nutritive sucking (i.e., pacifier) $\\pm$ other analgesics for heel stick, ven"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9306,
      "preview": "iii. No known side effects, but postulated could cause hyperglycemia or necrotizing enterocolitis. O"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9308,
      "preview": "--- page 385 ---"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9310,
      "preview": "intubated (only by MD or NNP order)."
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9311,
      "preview": "iv. Dose: Tootsweet\u00ae brand is $24 \\%$ solution, single dose based on weight: 2 drops ( 0.08 ml ) in "
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9312,
      "preview": "d. Local Anesthetics"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9314,
      "preview": "Local anesthetics such as lidocaine and bupivacaine/levo-bupivacaine provide local or regional anest"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9315,
      "preview": "i. Used in our NICU in various forms: topically in cream (LMX-4), for subcutaneous injection or into"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9316,
      "preview": "ii. Dose: LMX-41/4 inch thick to local area intact skin only, SQ/IM lidocaine injection varies, sugg"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9317,
      "preview": "e. Ketamine"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9319,
      "preview": "Ketamine is a dissociative anesthetic, with sedative, analgesic, and amnestic properties."
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9320,
      "preview": "i. Risk of deep sedation/anesthesia, hypoxemia, laryngospasm or apnea. Use at Packard is limited to "
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9321,
      "preview": "f. Alpha-2 Agonist therapy"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9323,
      "preview": "Clonidine and Dexmedetomidine are central alpha-2 agonist with analgesic properties."
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9324,
      "preview": "i. Limited data exist regarding pharmacokinetics, safety, and efficacy in infants. This currently li"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9325,
      "preview": "3. Non-analgesic adjuvants"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9327,
      "preview": "Sedatives and anxiolytic medications are often prescribed to induce sleep for diagnostic procedures,"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9329,
      "preview": "--- page 386 ---"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9331,
      "preview": "a. Remember, sedation is a continuum from mild sedation/anxiolysis, through moderate and deep sedati"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9332,
      "preview": "b. Benzodiazepines"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9334,
      "preview": "Midazolam is the benzodiazepine most studied in the NICU population."
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9335,
      "preview": "i. Risks include sedation (usually desired), respiratory depression, and hypotension. Short-term neu"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9336,
      "preview": "ii. Tolerance (needing a higher dose to achieve same effect over time) and dependency (withdrawal sy"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9337,
      "preview": "iii. Dose: $0.05-0.15 \\mathrm{mg} / \\mathrm{kg}$ IV, infusions $0.01-0.06 \\mathrm{mg} / \\mathrm{kg} "
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9338,
      "preview": "c. Chloral hydrate"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9340,
      "preview": "Chloral hydrate is a non-analgesic hypnotic primarily used for radiologic procedures. Although clini"
    },
    {
      "type": "text",
      "section": "i. Morphine",
      "line": 9341,
      "preview": "i. Dose: $25-50 \\mathrm{mg} / \\mathrm{kg}$ PO/PR."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9343
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9345,
      "preview": "Few realize that painful procedures occur with great regularity in the NICU. In one study, criticall"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9346,
      "preview": "A. Consider sucrose and non-nutritive sucking, swaddling, containment, facilitated tucking plus:"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9348,
      "preview": "1. Heel lance: venipuncture instead, skin to skin, mechanical lancet"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9349,
      "preview": "2. Venipuncture: LMX-4 to site"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9350,
      "preview": "3. Arterial puncture: LMX-4 to site, SubQ lidocaine locally"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9351,
      "preview": "4. Injections: choose IV over IM whenever possible"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9352,
      "preview": "5. Umbilical catheter: avoid sutures or hemostat clamps on the skin around the umbilicus"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9353,
      "preview": "6. Central line: LMX-4 to the site, SubQ lidocaine, opioid analgesic"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9355,
      "preview": "--- page 387 ---"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9357,
      "preview": "380 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9358,
      "preview": "7. Endotracheal suctioning: consider opioid analgesic"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9359,
      "preview": "8. Nasogastric tube placement: gentle technique, lubrication to tube"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9360,
      "preview": "9. For the following procedures, consider sucrose and pacifier with addition of options below:"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9361,
      "preview": "a. Lumbar puncture: LMX-4 at site, subQ lidocaine"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9362,
      "preview": "b. Chest tube: subQ lidocaine, opioid analgesic, or short acting anesthetic"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9363,
      "preview": "c. Circumcision: LMX-4 locally, dorsal penile nerve block or ring block with lidocaine, Mogen over G"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9364,
      "preview": "d. Eye examination: local anesthetic eye drops"
    },
    {
      "type": "text",
      "section": "VIII.Preventing Pain: What to do for Invasive Procedures",
      "line": 9365,
      "preview": "e. Post-operative pain: do not use sucrose. At least 48 hrs of around-the-clock analgesic such as op"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IX. For Further Information",
      "line": 9367
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9369,
      "preview": "A. Packard Pediatric Pain and Symptom Management Service Elliot Krane, M.D., Director"
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9371,
      "preview": "Julie Good, M.D., Director, Inpatient Pain Management Brenda Golianu, M.D."
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9372,
      "preview": "Genevieve D'Souza, M.D. Meredith Brooks, M.D., M.P.H"
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9373,
      "preview": "Srinivas Naidu, M.D."
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9374,
      "preview": "Rita Agrawal, M.D."
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9375,
      "preview": "Chris Almgren, R.N., P.N.P."
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9376,
      "preview": "In-patient office phone/VOALTE phone: 724-6000"
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9377,
      "preview": "Out-patient clinic phone: 724-5338"
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9378,
      "preview": "B. \"Curbside\" or formal consult: We are happy to help! Here's how to reach us:"
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9380,
      "preview": "M-F, 7 am-5 pm: pager\\# 18779 first. This is the advanced practice pager, held by our NP. We do not "
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9382,
      "preview": "Nights after 5 pm and weekends: call the page operator and ask for the pediatric pain management res"
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9384,
      "preview": "Text paging is fine too, but be sure the person you are calling is on (our schedule is available via"
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9386,
      "preview": "Non-urgent, non-clinical questions: e-mail me at julieg@stanford.edu."
    },
    {
      "type": "text",
      "section": "IX. For Further Information",
      "line": 9388,
      "preview": "--- page 388 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 9390
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9392,
      "preview": "1. Anand KJ, Brown MJ, Causon RC, Christofides ND, Bloom SR, Aynsley-Green A. Can the human neonate "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9393,
      "preview": "2. Anand KJ. Revisiting a dilemma: repetitive pain vs opioid expostures? Acta Pediatr 2016 Jul; 105("
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9394,
      "preview": "3. Watterberg KL et al. Prevention and management of procedural pain in the neonate: An update. Pedi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9395,
      "preview": "4. De Graaf et al. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9 years of "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9396,
      "preview": "5. Victoria NC, Murphy AZ. The long-term impact of early life pain on adult responses to anxiety and"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9397,
      "preview": "6. Cruz MD et al. Epidemiology of painful procedures performed in neonates: A systematic review of o"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9399,
      "preview": "--- page 389 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Brain Monitoring Using aEEG and NIRS",
      "line": 9401
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Alexis S. Davis, MD, MS Epi and Valerie Y. Chock, MD, MS Epi",
      "line": 9403
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Amplitude Integrated EEG (aEEG)",
      "line": 9405
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. What is aEEG?",
      "line": 9407
    },
    {
      "type": "text",
      "section": "A. What is aEEG?",
      "line": 9409,
      "preview": "aEEG is a simplified, bedside EEG device used to continuously monitor brain function. Brain wave act"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Indications for aEEG monitoring",
      "line": 9411
    },
    {
      "type": "text",
      "section": "B. Indications for aEEG monitoring",
      "line": 9413,
      "preview": "1. Confirmation of suspected clinical seizures, especially when formal continuous EEG is not availab"
    },
    {
      "type": "text",
      "section": "B. Indications for aEEG monitoring",
      "line": 9414,
      "preview": "2. Assessment for subclinical seizures in high risk infants (e.g. preterm with severe IVH)"
    },
    {
      "type": "text",
      "section": "B. Indications for aEEG monitoring",
      "line": 9415,
      "preview": "3. Continuous monitoring of therapeutic effects of anti-epileptic medication"
    },
    {
      "type": "text",
      "section": "B. Indications for aEEG monitoring",
      "line": 9416,
      "preview": "4. Prediction of outcomes in hypoxic-ischemic encephalopathy (HIE)"
    },
    {
      "type": "text",
      "section": "B. Indications for aEEG monitoring",
      "line": 9417,
      "preview": "5. Other potential, but not well-studied, uses for aEEG include: metabolic encephalopathy, patients "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Placement of aEEG",
      "line": 9419
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9421,
      "preview": "1. Types of electrodes"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9422,
      "preview": "a. Hydrogel: most commercial aEEG devices utilize these disposable electrodes which are similar to r"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9423,
      "preview": "b. Cup-disk or spider: reusable; requires EEG conductive paste (Ten20 paste)"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9424,
      "preview": "c. Needle: minimal skin preparation required and achieves low impedances; invasive, with theoretical"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9425,
      "preview": "2. Recording montages: Location of electrodes based on the 10-20 international classification system"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9426,
      "preview": "a. Single channel: traditionally, electrodes are positioned at P3 and P4, which is the area overlyin"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9427,
      "preview": "b. Three channel: electrodes positioned at C3, P3, C4, P4 create two bi-parietal channels (C3-P3, C4"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9428,
      "preview": "c. All devices require an additional ground electrode, usually placed on the upper back (preferred) "
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9429,
      "preview": "d. Other EEG recording systems may utilize additional channels"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9431,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9433,
      "preview": "--- page 390 ---"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9435,
      "preview": "Figure 1: One-channel aEEG typically utilizes the P3-P4 channel. Three channel aEEG utilizes electro"
    },
    {
      "type": "image",
      "section": "C. Placement of aEEG",
      "line": 9436,
      "content": "![img-65.jpeg](images/2ebdb5fc2fd95272.png)"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9437,
      "preview": "3. Skin preparation: when cup-disk or hydrogel electrodes are used, skin should be cleaned and exfol"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9438,
      "preview": "4. Data quality: Impedance is continuously measured during the aEEG recording. Impedances greater th"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9439,
      "preview": "5. Available aEEG equipment:"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9440,
      "preview": "a. BrainZ BRM3 monitor: 3-channel recording ability"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9441,
      "preview": "b. Moberg CNS monitor: can interface with the NIRS machine and Blanketrol; can expand beyond 3 aEEG/"
    },
    {
      "type": "text",
      "section": "C. Placement of aEEG",
      "line": 9442,
      "preview": "c. Natus OBM monitor: 3-channel recording ability, has seizure detection and background classificati"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Interpretation of aEEG recordings",
      "line": 9444
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9446,
      "preview": "1. Background pattern interpretation"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9447,
      "preview": "a. Continuous: minimum amplitude greater than $5 \\mu \\mathrm{~V}$ and maximum amplitude greater than"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9448,
      "preview": "b. Discontinuous: minimum amplitude less than $5 \\mu \\mathrm{~V}$ but demonstrating variability, max"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9449,
      "preview": "c. Burst Suppression: minimum amplitude less than 3-5 $\\mu \\mathrm{V}$ with minimal variability, bur"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9451,
      "preview": "--- page 391 ---"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9453,
      "preview": "d. Low Voltage: continuous background with both minimum and maximum amplitudes less than $10 \\mu \\ma"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9454,
      "preview": "e. Isoelectric/flat: primarily isoelectric tracing with amplitudes less than $5 \\mu \\mathrm{~V}$"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9455,
      "preview": "f. Recovery of a normal background pattern (either continuous or discontinuous) within 36-48 hours h"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9456,
      "preview": "g. Recovery of background pattern and SWCs may be delayed for infants treated with hypothermia."
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9457,
      "preview": "h. Preterm infants: In healthy preterm infants, the aEEG matures from a discontinuous pattern to a c"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9458,
      "preview": "2. Seizures"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9459,
      "preview": "a. On the compressed aEEG tracing an isolated seizure is reflected by an increase in the minimum amp"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9460,
      "preview": "b. It is important to confirm seizure activity on the raw EEG tracing (see Limitations)"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9462,
      "preview": "--- page 392 ---"
    },
    {
      "type": "image",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9464,
      "content": "![img-66.jpeg](images/8d567c6046ae5831.png)"
    },
    {
      "type": "text",
      "section": "D. Interpretation of aEEG recordings",
      "line": 9466,
      "preview": "Figure 3: Examples of seizure activity on compressed aEEG and raw EEG."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "3. Sleep-Wake Cycling",
      "line": 9468
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9470,
      "preview": "a. Immature SWCs may begin to appear as early as 25 to 27 weeks' gestational age as evidenced by sin"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9471,
      "preview": "b. More mature SWCs in healthy infants appear between 30 and 34 weeks' gestational age but are often"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9472,
      "preview": "c. In healthy preterm infants, SWCs may appear at earlier postmenstrual ages than would be expected "
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9474,
      "preview": "--- page 393 ---"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9476,
      "preview": "d. Shorter time to recovery of SWCs is associated with improved outcome in term HIE, while lack of S"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9477,
      "preview": "E. Limitations of aEEG monitoring"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9479,
      "preview": "1. Due to nature of the time-compressed recording, brief seizures (<30 seconds) may be missed"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9480,
      "preview": "2. As only one to three channels are recorded, seizures or abnormal background activity in the front"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9481,
      "preview": "3. Artifacts"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9482,
      "preview": "a. Mimics of seizures include any repetitive movement such as burping, patting, swinging"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9483,
      "preview": "b. High frequency ventilation, external electrical interference, EKG, and muscle movement can falsel"
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9484,
      "preview": "c. Contact between electrodes (either by physical contact or by a bridge created by paste/moisture) "
    },
    {
      "type": "text",
      "section": "3. Sleep-Wake Cycling",
      "line": 9485,
      "preview": "d. Sedative medications may depress the background pattern and/or suppress SWCs"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. Near-Infrared Spectroscopy (NIRS)",
      "line": 9487
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. What is NIRS?",
      "line": 9489
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9491,
      "preview": "NIRS is a non-invasive technique to continuously monitor regional tissue oxygenation. It has most co"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9492,
      "preview": "B. Indications for 2-site NIRS monitoring (and admission to NeuroNICU)"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9494,
      "preview": "1. Conditions with altered hemodynamic states causing cerebral hypoxemia"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9495,
      "preview": "a. Hypoxic ischemic encephalopathy"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9496,
      "preview": "b. Congenital heart disease- especially with decreased systemic outflow for peri-operative monitorin"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9497,
      "preview": "c. Prematurity with altered cerebral autoregulation. All preterm infants <29 weeks gestation undergo"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9498,
      "preview": "d. Hypoxic respiratory failure or pre-ECMO"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9499,
      "preview": "2. Conditions with altered hemodynamics affecting mesenteric or renal oxygenation"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9500,
      "preview": "a. Shock- Drop in somatic oxygenation may be an early potential indicator of low cardiac output befo"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9502,
      "preview": "--- page 394 ---"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9504,
      "preview": "b. Congenital heart disease"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9505,
      "preview": "c. Renal dysfunction"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9506,
      "preview": "d. Necrotizing enterocolitis"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9507,
      "preview": "e. Extracorporeal membrane oxygenation (ECMO)- to evaluate interventions while on ECMO or to assist "
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9508,
      "preview": "3. Other potential applications for NIRS include: assessment of IVH, intra-operative management, and"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9509,
      "preview": "C. Placement of NIRS"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9511,
      "preview": "Figure 2: Placement of NIRS sensors (cerebral and somatic- renal and/or mesenteric)"
    },
    {
      "type": "image",
      "section": "A. What is NIRS?",
      "line": 9512,
      "content": "![img-67.jpeg](images/55c66d025c7d7f86.png)"
    },
    {
      "type": "text",
      "section": "A. What is NIRS?",
      "line": 9514,
      "preview": "Cerebral"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Mesenteric Sensor Application",
      "line": 9516
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9518,
      "preview": "placement of the hydrocolloid adhesive-backed NIRS sensor directly onto a pitel (MoInlycke) or other"
    },
    {
      "type": "image",
      "section": "Mesenteric Sensor Application",
      "line": 9519,
      "content": "![img-68.jpeg](images/71c56eae084ed426.png)"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9521,
      "preview": "--- page 395 ---"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9523,
      "preview": "388 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9525,
      "preview": "1. Locations"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9526,
      "preview": "a. Cerebral sensor on lateral forehead"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9527,
      "preview": "b. Renal sensor on flank (below costal margin and above iliac crest)"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9528,
      "preview": "c. Mesenteric (splanchnic) sensor on abdomen, typically inferior to umbilicus in lower left quadrant"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9529,
      "preview": "2. Skin barrier (Mepitel) recommended under sensors for preterm infants"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9530,
      "preview": "3. Duration- Change sensors every 4 days. Avoid direct, prolonged pressure over sensors. Evaluate fo"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9531,
      "preview": "4. Data quality"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9532,
      "preview": "a. Excessive light may interfere with signal detection."
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9533,
      "preview": "b. Adhesion of sensor may interfere with signal detection. Consider use of light CPAP hat to secure "
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9534,
      "preview": "D. Interpretation of NIRS data - rSO2 (\\%). Normal values are controversial due to variability betwe"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9535,
      "preview": "5. Cerebral oxygenation"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9536,
      "preview": "a. Term infants: $60-80 \\%$, or approximately $30 \\%$ less than arterial saturation"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9537,
      "preview": "b. Preterm infants: Range is typically $60-85 \\%$, but values decrease over the first 1-2 weeks of l"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9538,
      "preview": "6. Somatic oxygenation"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9539,
      "preview": "a. Term infants: Typically, 5-15\\% above cerebral saturations"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9540,
      "preview": "b. Preterm infants: Renal rSO2 range typically $80 \\pm 10 \\%$ in first week of life, but decreases a"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9541,
      "preview": "7. Abnormal values and associations with outcomes"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9542,
      "preview": "a. Cerebral oxygenation"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9543,
      "preview": "i. Congenital heart disease: Values $<35-40 \\%$ for $>10$ minutes associated with neuronal injury af"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9544,
      "preview": "ii. Hypoxic Ischemic Encephalopathy: Values $>85-90 \\%$ after 24 hours of life in infants cooled for"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9545,
      "preview": "b. Somatic oxygenation"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9546,
      "preview": "i. Splanchnic (abdominal) saturations are lower in infants with feeding intolerance"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9547,
      "preview": "ii. Renal saturations $<66 \\%$ are associated with a hemodynamically significant PDA"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9549,
      "preview": "--- page 396 ---"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9551,
      "preview": "iii. Renal saturations $<50 \\%$ for $>2 \\mathrm{~h}$ associated with higher incidence of acute kidne"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9552,
      "preview": "E. Interventions to improve rSO2"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9554,
      "preview": "1. Improve blood pressure"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9555,
      "preview": "2. Avoid hypocarbia or hypercarbia"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9556,
      "preview": "3. Correct anemia with a red blood cell transfusion"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9557,
      "preview": "4. Increase FiO2"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9558,
      "preview": "5. Minimize metabolic demand (i.e. temperature regulation, sedation)"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9559,
      "preview": "F. Limitations of NIRS monitoring"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9560,
      "preview": "6. Depth of signal penetration limits measurement of deeper tissue structures: for cerebral monitori"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9561,
      "preview": "7. Better to trend rSO2 values over time or with interventions in an individual patient rather than "
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9562,
      "preview": "8. Risk of skin sensitivity due to sensor adhesive"
    },
    {
      "type": "text",
      "section": "Mesenteric Sensor Application",
      "line": 9563,
      "preview": "9. Interpretation must be made in the context of all factors that influence oxygen extraction and de"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 9565
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9567,
      "preview": "1. Hellstr\u00f6m-Westas L, Ros\u00e9n I, de Vries LS, et al. Amplitude-integrated EEG classification and inte"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9568,
      "preview": "2. Thoresen $M$ et al. Effect of hypothermia on amplitude-integrated electroencephalogram in infants"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9569,
      "preview": "3. Wolfberg AJ and du Plessis AJ. Near-infrared spectroscopy in the fetus and neonate. Clin Perinato"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9570,
      "preview": "4. Chock VY, Rose LA, Mante J, Punn R. Near Infrared Spectroscopy and Detection of a Hemodynamically"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9571,
      "preview": "5. Lemmers P, et al. Cerebral oxygenation and brain activity after perinatal asphyxia: does hypother"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9572,
      "preview": "6. NIRS Educational Module and aEEG Pattern Review available on Stanford Neonatology Division websit"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 9574,
      "preview": "--- page 397 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "The LPCH Neuro NICU",
      "line": 9576
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Celia Shepherd Glennon, N.N.P.-B.C. and Krisa Van Meurs, M.D.",
      "line": 9578
    },
    {
      "type": "text",
      "section": "Celia Shepherd Glennon, N.N.P.-B.C. and Krisa Van Meurs, M.D.",
      "line": 9580,
      "preview": "I. Over the last several decades, survival rates have improved across many diagnostic groups admitte"
    },
    {
      "type": "text",
      "section": "Celia Shepherd Glennon, N.N.P.-B.C. and Krisa Van Meurs, M.D.",
      "line": 9581,
      "preview": "A. The Johnson Center and LPCH generously provided funding for the development of a virtual unit wit"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "1. Nursing Staffing:",
      "line": 9583
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9585,
      "preview": "a. We are currently staffed with over 90 Neuro NICU trained RNs, and our goal is to ultimately train"
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9586,
      "preview": "b. Currently we can provide care for at least 2 Neuro NICU patients per shift. This number will incr"
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9587,
      "preview": "2. Neurodiagnostic equipment available in the LPCH NICU includes:"
    },
    {
      "type": "table",
      "section": "1. Nursing Staffing:",
      "line": 9589,
      "preview": "| Amplitude-integrated EEG (aEEG) | 6 Natus BRM3 <br> 1 OBM |"
    },
    {
      "type": "table",
      "section": "1. Nursing Staffing:",
      "line": 9590,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "1. Nursing Staffing:",
      "line": 9591,
      "preview": "| Near-Infrared Spectroscopy (NIRS) | 11 INVOS 5100 C Cerebral/Somatic oximeters |"
    },
    {
      "type": "table",
      "section": "1. Nursing Staffing:",
      "line": 9592,
      "preview": "| Cerebral auto-regulation trending | 2 Covidien Vital Sync - Paired with NIRS |"
    },
    {
      "type": "table",
      "section": "1. Nursing Staffing:",
      "line": 9593,
      "preview": "| Conventional video EEG (vEEG) | 2 Nihon Kohden EEG-1200 A |"
    },
    {
      "type": "table",
      "section": "1. Nursing Staffing:",
      "line": 9594,
      "preview": "| Therapeutic Hypothermia (Cooling) | 4 CSZ Blanketrol II and III |"
    },
    {
      "type": "table",
      "section": "1. Nursing Staffing:",
      "line": 9595,
      "preview": "| Multi-modal (Neuro+Physio) Monitors <br> - integration of EEG, aEEG, NIRS, HR/BP/Sats/Resp <br> Ra"
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9597,
      "preview": "a. The Neuro NICU (Staff, Office, Equipment, Supplies):"
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9598,
      "preview": "i. A Neuro NICU staff member (Celia Glennon, Laura Popovich, Rachael Small or Shannon Tinkler) is re"
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9599,
      "preview": "ii. Our office is located near the main entrance of the NICU across from NICU room 1. A monthly cale"
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9600,
      "preview": "iii. Equipment includes NIRS, Moberg, OBM, BRM and Vital Sync machines which are kept in the locked "
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9602,
      "preview": "--- page 398 ---"
    },
    {
      "type": "text",
      "section": "1. Nursing Staffing:",
      "line": 9604,
      "preview": "All Neuro NICU devices should remain in the NICU at all times. They should not travel off unit and a"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "b. Reference Binders:",
      "line": 9606
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9608,
      "preview": "i. Each Neuro NICU device has a reference binder containing information about the device and its use"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9609,
      "preview": "ii. Each binder contains a log where the name and MR number of each patient using the device is reco"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9610,
      "preview": "3. Neuro NICU eligible patients: The following table indicates Neuro NICU admission priority as well"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9612,
      "preview": "|  | Diagnosis | Expected LOS | Monitoring | Neuro Consult |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9613,
      "preview": "| :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9614,
      "preview": "| 1. | HIE/Cooling | 10 | aEEG/cEEG \\& NIRS | Yes |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9615,
      "preview": "| 2. | Seizures | 7 | aEEG/cEEG | Yes |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9616,
      "preview": "| 3. | ECMO/pre-ECMO | 7 | NIRS \\& aEEG | PRN |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9617,
      "preview": "| 4. | Grade III/IV or hydrocephalus | 10 | aEEG/cEEG | Yes |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9618,
      "preview": "| 5. | Critical/unstable | 7 | NIRS/aEEG | PRN |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9619,
      "preview": "| 6. | Premie $</=29$ weeks | 7 | NIRS | PRN |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9620,
      "preview": "| 7. | CNS anomalies | 7 | aEEG/cEEG | Yes |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9621,
      "preview": "| 8. | Metabolic disease | 7 | aEEG/cEEG | PRN |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9622,
      "preview": "| 9. | Cyanotic CHD | 7 | NIRS | PRN |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9623,
      "preview": "| 10. | CNS infection | 7 | aEEG/cEEG | Yes |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9624,
      "preview": "| 11. | Symptomatic PDA | 7 | NIRS | PRN |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9625,
      "preview": "| 12. | ALTE/BRUE | 3 | aEEG | PRN |"
    },
    {
      "type": "table",
      "section": "b. Reference Binders:",
      "line": 9626,
      "preview": "| 13. | Hyperbilirubinemia $>20$ or hemolytic process | 3 | aEEG; NIRS if exchange tx | PRN |"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9628,
      "preview": "a. Neuro NICU patients are identified on the patient magnet board (above the NICU printer/scanner be"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9629,
      "preview": "b. Neuro NICU patients are designated by the Neonatal fellow on midnight rounds so the resource RNs "
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9630,
      "preview": "c. Neuro NICU patients are cared for by residents/hospitalists/NNP's on both the Blue and Red teams."
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9631,
      "preview": "4. Joint Neurology-Neonatology Neuro NICU rounds: Rounds will occur weekdays at specified times with"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9632,
      "preview": "5. EPIC Modifications for the Neuro NICU"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9633,
      "preview": "a. Neuro NICU Tab: This tab includes data relevant for the Neuro NICU patient. The visible fields in"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9634,
      "preview": "i. the neurologic exam documented by the RN"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9636,
      "preview": "--- page 399 ---"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9638,
      "preview": "392 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9639,
      "preview": "ii. NIRS cerebral and renal/splanchnic saturations"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9640,
      "preview": "iii. aEEG impedance, margins, SWC, artifacts \\& suspicious Sz"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9641,
      "preview": "iv. temperatures for cooling patients"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9642,
      "preview": "v. sedative/analgesic and anticonvulsant medications"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9643,
      "preview": "vi. developmentally supportive cares, holding, positioning and related interventions"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9644,
      "preview": "b. Other pertinent neurologic information will be accessible in EPIC via the Comprehensive Flowsheet"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9645,
      "preview": "c. Order Sets available for Neuro NICU patients:"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9646,
      "preview": "i. Neuro NICU admission orders"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9647,
      "preview": "ii. Seizure order set (refer to \"Seizure Management Protocol\" on intranet)"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9648,
      "preview": "iii. Sedation/analgesia order set"
    },
    {
      "type": "text",
      "section": "b. Reference Binders:",
      "line": 9649,
      "preview": "iv. Hypothermia order set"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "d. Progress Notes:",
      "line": 9651
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9653,
      "preview": "i. All Neuro NICU patients should have a \"Problem\" identified in the note which specifically address"
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9654,
      "preview": "ii. Neuromonitoring trends pre-populate into the progress note, including cerebral and somatic satur"
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9655,
      "preview": "e. Smart Phrases in EPIC should be utilized to standardize documentation of infants in the daily pro"
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9656,
      "preview": "i. aEEG Interpretation: \". aEEG\" is a template for documenting Background Pattern, Symmetry, Sleep W"
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9657,
      "preview": "ii. Neonatal Encephalopathy: \". SARNAT\" is a template for documenting degree of encephalopathy for a"
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9658,
      "preview": "6. Outpatient Neurology Follow Up: All Neuro NICU patients who receive a formal Neurology consultati"
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9660,
      "preview": "Neuro NICU Database: With the goal of further improving care for this vulnerable population, we are "
    },
    {
      "type": "text",
      "section": "d. Progress Notes:",
      "line": 9662,
      "preview": "--- page 400 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "7. Education and Training",
      "line": 9664
    },
    {
      "type": "text",
      "section": "7. Education and Training",
      "line": 9666,
      "preview": "a. 5 Minute Friday - A collaborative and informal neuro-focused presentation is provided every Frida"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "b. Online Training",
      "line": 9668
    },
    {
      "type": "text",
      "section": "b. Online Training",
      "line": 9670,
      "preview": "i. NIRS - Online Review and Quiz: https://goo.gl/forms/g5UY1LOB6ITXHbfB2"
    },
    {
      "type": "text",
      "section": "b. Online Training",
      "line": 9671,
      "preview": "ii. aEEG Interpretation Webinar by Kathi Randall; https://www.anymeeting.com/892-131-257/EF54D788824"
    },
    {
      "type": "text",
      "section": "b. Online Training",
      "line": 9672,
      "preview": "iii. aEEG Interpretation with Pre-Test/Post-Test: https://nursekathi.wufoo.com/forms/aeeg-interpreta"
    },
    {
      "type": "text",
      "section": "b. Online Training",
      "line": 9673,
      "preview": "iv. 2017 aEEG Quiz: https://nursekathi.wufoo.com/forms/mgplhgo0qe5a5g/"
    },
    {
      "type": "text",
      "section": "b. Online Training",
      "line": 9674,
      "preview": "v. aEEG Sensor Application: http://www.aeegapplication.com"
    },
    {
      "type": "text",
      "section": "b. Online Training",
      "line": 9675,
      "preview": "c. Annual Didactic Training - Annually there is a two-day training course on NeuroNICU care. This co"
    },
    {
      "type": "text",
      "section": "b. Online Training",
      "line": 9676,
      "preview": "d. RN Skills Drills- Mandatory annual attendance for all Neuro NICU nurses. These \"hands on\" classes"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9678
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9680,
      "preview": "Krisa Van Meurs, MD, Neuro NICU Medical Director"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9681,
      "preview": "Alexis Davis, MD, NICU Medical Director"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9682,
      "preview": "Courtney Wusthoff, MD, Neurology Director Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9683,
      "preview": "Valerie Chock, MD MS Epi, Associate Medical Director Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9684,
      "preview": "Sonia Bonifacio, MD, Associate Medical Director Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9685,
      "preview": "Celia Shepherd Glennon, NNP, Lead Nurse Practitioner Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9686,
      "preview": "Rachel Small, NNP, Nurse Practitioner Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9687,
      "preview": "Laura Popovich, NNP, Nurse Practitioner Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9688,
      "preview": "Shannon Tinkler, RN, BSN, RNC-NICU, Nurse Educator Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9689,
      "preview": "Kathi Randall, RN, CNS, NNP, Consultant Neuro NICU"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9690,
      "preview": "Keithra Ortiz, Unit Secretary"
    },
    {
      "type": "text",
      "section": "8. The Neuro NICU Multidisciplinary Team:",
      "line": 9692,
      "preview": "--- page 401 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Moderate Sedation-Physician and Nurse Practitioner Responsibilities",
      "line": 9694
    },
    {
      "type": "text",
      "section": "Moderate Sedation-Physician and Nurse Practitioner Responsibilities",
      "line": 9696,
      "preview": "Arlene Sheehan, N.N.P.-B.C."
    },
    {
      "type": "text",
      "section": "Moderate Sedation-Physician and Nurse Practitioner Responsibilities",
      "line": 9698,
      "preview": "All neonatal patients who receive procedural sedation should be monitored by a provider who has LPCH"
    },
    {
      "type": "text",
      "section": "Moderate Sedation-Physician and Nurse Practitioner Responsibilities",
      "line": 9699,
      "preview": "https://intranet.lpch.org/pdf/formsPoliciesReferences/policies/hospitalWide/patientCare/sedationPoli"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition of Moderate Sedation:",
      "line": 9701
    },
    {
      "type": "text",
      "section": "I. Definition of Moderate Sedation:",
      "line": 9703,
      "preview": "A drug induced depression of consciousness during which patients respond purposefully to verbal comm"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. MD/AHP Credentialing and Competency Requirements",
      "line": 9705
    },
    {
      "type": "text",
      "section": "II. MD/AHP Credentialing and Competency Requirements",
      "line": 9707,
      "preview": "A. Completion of a sedation teaching module. The sedation module must be completed every 4 years."
    },
    {
      "type": "text",
      "section": "II. MD/AHP Credentialing and Competency Requirements",
      "line": 9708,
      "preview": "B. Successful completion of a written examination to test the knowledge of medications being given, "
    },
    {
      "type": "text",
      "section": "II. MD/AHP Credentialing and Competency Requirements",
      "line": 9709,
      "preview": "C. Must have PALS, ACLS, NRP or equivalent certification requiring training in airway management ski"
    },
    {
      "type": "text",
      "section": "II. MD/AHP Credentialing and Competency Requirements",
      "line": 9710,
      "preview": "D. Maintenance of privileges for moderate sedation will require a minimum volume of cases per medica"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Procedure/Process",
      "line": 9712
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9714
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9716,
      "preview": "1. Any procedure which requires neuromuscular blockade or breath-holding will require the procedure "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9717,
      "preview": "2. It is nearly impossible to delineate between 'minimal' and 'moderate' sedation in a neonate, so A"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9718,
      "preview": "a. Must be provided by an MD or NNP who can intubate independently"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9719,
      "preview": "b. Must be provided by an MD or NNP who has LPCH privileges for Moderate Sedation"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9720,
      "preview": "i. Exception: if an MD or NNP has not performed enough sedations to grant privileges, they should st"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9721,
      "preview": "ii. The proctor does not need to accompany the MD or NNP providing sedation but should be available "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9722,
      "preview": "3. Order sets for minimal or moderate sedation may be used (type in \"Sedation, Procedural\")"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9724,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9726,
      "preview": "--- page 402 ---"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9728,
      "preview": "a. Be aware, however, that the medications in these order sets (chloral hydrate, pentobarbital, mida"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9729,
      "preview": "b. The MD or NNP should use the medication(s) that he/she is most familiar with as a provider of sed"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9730,
      "preview": "4. For an intubated NICU patient:"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9731,
      "preview": "a. Sedation that is considered part of on-going critical care does not require separate sedation con"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9732,
      "preview": "b. If a deeper level of sedation is desired for a procedure, documentation must be completed accordi"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9733,
      "preview": "i. Separate consent for sedation is required"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9734,
      "preview": "ii. Documentation: A pre-procedure sedation assessment note and a sedation procedure note should be "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9735,
      "preview": "iii. NPO period is highly encouraged and will be ordered at the discretion of the primary team"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9736,
      "preview": "c. Off-unit procedures for intubated patients require the continuous presence of a NICU provider."
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9737,
      "preview": "d. Sedation may be initiated prior to leaving the NICU - this is the start of the procedure"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9738,
      "preview": "e. Extra doses of sedation may be brought to the procedure"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9739,
      "preview": "f. No more than 3 total doses of each sedation medication to be given during procedure - if this is "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9740,
      "preview": "5. For a non-intubated NICU/ICN patient:"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9741,
      "preview": "a. Informed consent is required"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9742,
      "preview": "b. Documentation for Moderate Sedation is required."
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9743,
      "preview": "c. NPO period in accordance with Moderate Sedation Policy is required"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9744,
      "preview": "d. No more than 3 total doses of each sedation medication to be given during procedure - if this is "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9745,
      "preview": "IV. Pre-Procedure Physician, Physician's Assistant, Nurse Practitioner responsibility (both ICU and "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9746,
      "preview": "A. Ensure there is a complete H \\& P exam documented as specified by hospital bylaws. Complete withi"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9747,
      "preview": "B. Establish and document a plan for sedation including level of sedation, NPO status, medications t"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9749,
      "preview": "--- page 403 ---"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9751,
      "preview": "396 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9752,
      "preview": "and reason for sedation. Enter orders in the Electronic Health Record for NPO status, sedative medic"
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9753,
      "preview": "C. Complete an examination of patient's airway and document this examination before sedation can be "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9754,
      "preview": "D. Assignment and documentation of the American Society of Anesthesiologists Physical Status Score ("
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9755,
      "preview": "E. For a patient with unstable or poorly controlled systemic disease or organ dysfunction, obtain a "
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9756,
      "preview": "F. Obtain informed consent for the sedation."
    },
    {
      "type": "text",
      "section": "A. Neonatal Intensive Care Units:",
      "line": 9757,
      "preview": "G. Immediately prior to administration of sedation, review the pre-sedation assessment and sedation "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. American Society of Anesthesiologists Physical Status (PS) Classifications",
      "line": 9759
    },
    {
      "type": "text",
      "section": "V. American Society of Anesthesiologists Physical Status (PS) Classifications",
      "line": 9761,
      "preview": "A. PS-1: A healthy patient without illness or disease"
    },
    {
      "type": "text",
      "section": "V. American Society of Anesthesiologists Physical Status (PS) Classifications",
      "line": 9762,
      "preview": "B. PS-2: A patient with localized disease or a systemic disease in good control (e.g., VSD without C"
    },
    {
      "type": "text",
      "section": "V. American Society of Anesthesiologists Physical Status (PS) Classifications",
      "line": 9763,
      "preview": "C. PS-3: A patient with systemic disease that is not controlled (e.g., VSD with CHF, cystic fibrosis"
    },
    {
      "type": "text",
      "section": "V. American Society of Anesthesiologists Physical Status (PS) Classifications",
      "line": 9764,
      "preview": "D. PS-4: A patient with a localized or systemic disease that represents an immediate threat to life;"
    },
    {
      "type": "text",
      "section": "V. American Society of Anesthesiologists Physical Status (PS) Classifications",
      "line": 9765,
      "preview": "E. PS-5: A moribund patient who is not expected to survive with or without the planned procedure"
    },
    {
      "type": "text",
      "section": "V. American Society of Anesthesiologists Physical Status (PS) Classifications",
      "line": 9766,
      "preview": "F. E: Added to above classifications to designate an unplanned emergency procedure (i.e., PS-2E)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. NPO Policy",
      "line": 9768
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9770,
      "preview": "A. All patients should be NPO prior to moderate sedation."
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9771,
      "preview": "B. Infants $>3 \\mathbf{k g}$ minimum NPO requirements:"
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9773,
      "preview": "1. $>6$ hrs for milk, formula, barium, contrast, etc."
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9774,
      "preview": "2. $>4$ hrs for breastmilk."
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9775,
      "preview": "3. $>2$ hrs for clear liquids."
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9776,
      "preview": "C. Infants $<3 \\mathrm{~kg}$ in weight minimum NPO requirements:"
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9777,
      "preview": "4. >than the usual duration between feedings for formula, breast milk, or barium contrast."
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9779,
      "preview": "--- page 404 ---"
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9781,
      "preview": "D. Example: A former premature infant weighing 2 kg is fed formula or breastmilk every 3 hrs , then "
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9783,
      "preview": "1. $>3$ hrs for infants on continuous gastric or jejunal feed."
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9784,
      "preview": "2. $>2$ hrs for clear liquids."
    },
    {
      "type": "text",
      "section": "VI. NPO Policy",
      "line": 9785,
      "preview": "E. NPO here indicates nothing by mouth, nasogastric tube or gastrostomy tube. Please note that the a"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9787
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9789,
      "preview": "A. Continuous observation and monitoring of ECG and Oximetry."
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9790,
      "preview": "B. Airway patency and respiratory rate, including $\\mathrm{ETCO}_{2}$ for moderate and deep sedation"
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9791,
      "preview": "C. Blood pressure every 15 min except for the following patients, for whom blood pressure will be re"
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9793,
      "preview": "1. Patients with a history of hypertension, whether treated or not at the time of the procedure"
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9794,
      "preview": "2. Patients who have had a renal transplant"
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9795,
      "preview": "3. Patients with acquired or congenital heart disease"
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9796,
      "preview": "4. Patients with a history of cardiac arrhythmias"
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9797,
      "preview": "5. Patients who have or are at risk for dehydration."
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9798,
      "preview": "6. Patients with a history of severe sleep apnea"
    },
    {
      "type": "text",
      "section": "VII. Intra-procedure Monitoring Requirements:",
      "line": 9799,
      "preview": "7. Deep sedation (e.g. ECMO cannulation)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. Post Procedure Monitoring",
      "line": 9801
    },
    {
      "type": "text",
      "section": "VIII. Post Procedure Monitoring",
      "line": 9803,
      "preview": "A. Practitioner credentialed in sedation must remain immediately available throughout the recovery p"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IX. Documentation",
      "line": 9805
    },
    {
      "type": "text",
      "section": "IX. Documentation",
      "line": 9807,
      "preview": "A. Procedure sedation note in clinical documents completed by the sedation trained provider. In EPIC"
    },
    {
      "type": "text",
      "section": "IX. Documentation",
      "line": 9809,
      "preview": "--- page 405 ---"
    },
    {
      "type": "image",
      "section": "IX. Documentation",
      "line": 9811,
      "content": "![img-69.jpeg](images/789be3b37d12af19.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Process for Moderate Sedation in NICU patients",
      "line": 9813
    },
    {
      "type": "text",
      "section": "Process for Moderate Sedation in NICU patients",
      "line": 9815,
      "preview": "Providers must have moderate sedation privileges"
    },
    {
      "type": "heading",
      "level": 3,
      "section": "Location of procedure/sedation",
      "line": 9817
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9819,
      "preview": "- **NICU-based sedation**"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9820,
      "preview": "- Patient intubated?"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9821,
      "preview": "- **No**"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9822,
      "preview": "- **Requires neuromuscular blockade or significantly deeper level of sedation?**"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9823,
      "preview": "- **No**"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9824,
      "preview": "- **Follow process for moderate sedation**"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9825,
      "preview": "- **No**"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9826,
      "preview": "- **Follow process for moderate sedation**"
    },
    {
      "type": "text",
      "section": "Location of procedure/sedation",
      "line": 9827,
      "preview": "- **Continuum of critical care, no need to follow process for moderate sedation**"
    },
    {
      "type": "heading",
      "level": 3,
      "section": "*Process for moderate sedation includes:",
      "line": 9829
    },
    {
      "type": "text",
      "section": "*Process for moderate sedation includes:",
      "line": 9831,
      "preview": "1. H&P or Progress note entered within the last 48h"
    },
    {
      "type": "text",
      "section": "*Process for moderate sedation includes:",
      "line": 9832,
      "preview": "2. Make NPO per policy ***"
    },
    {
      "type": "text",
      "section": "*Process for moderate sedation includes:",
      "line": 9833,
      "preview": "3. Consent family for sedation + procedure"
    },
    {
      "type": "text",
      "section": "*Process for moderate sedation includes:",
      "line": 9834,
      "preview": "4. Pre-sedation assessment note completed prior to procedure"
    },
    {
      "type": "text",
      "section": "*Process for moderate sedation includes:",
      "line": 9835,
      "preview": "5. Procedure sedation note completed after procedure"
    },
    {
      "type": "heading",
      "level": 3,
      "section": "Sedation/procedure outside NICU",
      "line": 9837
    },
    {
      "type": "text",
      "section": "Sedation/procedure outside NICU",
      "line": 9839,
      "preview": "- **Requires neuromuscular blockade or breath-holding?**"
    },
    {
      "type": "text",
      "section": "Sedation/procedure outside NICU",
      "line": 9840,
      "preview": "- **Consult anesthesia for procedural sedation**"
    },
    {
      "type": "text",
      "section": "Sedation/procedure outside NICU",
      "line": 9841,
      "preview": "- **The appropriate provider for procedural sedation for PS 4 and 5 patients outside the NICU should"
    },
    {
      "type": "text",
      "section": "Sedation/procedure outside NICU",
      "line": 9842,
      "preview": "- **PS-4: localized or systemic disease that presents an immediate threat to life**"
    },
    {
      "type": "text",
      "section": "Sedation/procedure outside NICU",
      "line": 9843,
      "preview": "- **PS-5: moribund patient not expected to survive with/without the planned procedure**"
    },
    {
      "type": "text",
      "section": "Sedation/procedure outside NICU",
      "line": 9844,
      "preview": "- **Follow process for moderate sedation*"
    },
    {
      "type": "text",
      "section": "Sedation/procedure outside NICU",
      "line": 9845,
      "preview": "- **Sedation may not be initiated until patient arrives at destination**"
    },
    {
      "type": "heading",
      "level": 3,
      "section": "*** NPO policy:",
      "line": 9847
    },
    {
      "type": "text",
      "section": "*** NPO policy:",
      "line": 9849,
      "preview": "- **Infant >3kg: >2h for clears, >3h for MBM, >6h for formula**"
    },
    {
      "type": "text",
      "section": "*** NPO policy:",
      "line": 9850,
      "preview": "- **Infant <3kg: > the usual time between feeds of any type**"
    },
    {
      "type": "text",
      "section": "*** NPO policy:",
      "line": 9852,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "*** NPO policy:",
      "line": 9854,
      "preview": "--- page 406 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Guidelines for Asymptomatic Subgaleal Hemorrhage",
      "line": 9856
    },
    {
      "type": "text",
      "section": "Guidelines for Asymptomatic Subgaleal Hemorrhage",
      "line": 9858,
      "preview": "Adam Frymoyer, M.D., Ronald S Cohen, M.D., and Arun Gupta, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Background",
      "line": 9860
    },
    {
      "type": "text",
      "section": "I. Background",
      "line": 9862,
      "preview": "A. Subgaleal hemorrhage ( SGH ) is caused by rupture of veins that run between the scalp aponeurosis"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Suggested Guidelines",
      "line": 9864
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Well-Baby Nursery",
      "line": 9866
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9868,
      "preview": "A. Close monitoring and evaluation in the well-baby nursery may be suitable for an asymptomatic newb"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9869,
      "preview": "B. A high index of suspicion and low threshold for admission to a higher level of care is warranted "
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9871,
      "preview": "1. Signs and symptoms may be present at birth or may not become clinically apparent until several ho"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9872,
      "preview": "C. Considerations for Investigations / Monitoring of Asymptomatic Newborns in WBN"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9873,
      "preview": "2. Inform the on-call Level II ICN Hospitalist about the newborn. This will allow for ICN team to be"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9874,
      "preview": "3. Vitals Signs - Measure vital signs every $30 \\mathrm{~min} \\times 2$ hrs then every 4 hrs for at "
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9875,
      "preview": "a. Frequency of further vitals signs can be adjusted based on clinical concern."
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9876,
      "preview": "b. Even mild tachycardia or tachypnea can be early sign of shock and should be reason for transfer t"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9877,
      "preview": "4. Check hematocrit and platelets on admit and then every $6-12 \\mathrm{hrs} \\times 24 \\mathrm{hrs}$"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9878,
      "preview": "a. Frequency of further monitoring of hematocrit can be adjusted based on clinical and laboratory pi"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9879,
      "preview": "b. Consider monitoring hematocrit for at least 48 hrs after birth based on clinical concern."
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9880,
      "preview": "5. Measure occipitofrontal circumference (OFC) on admit and then every $4-8$ hrs for at least 24 hrs"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9881,
      "preview": "a. Frequency of further OFC measurements can be adjusted based on clinical concern."
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9882,
      "preview": "6. If scalp appearance concerning, hematocrit dropping, or an increase in the OFC"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9883,
      "preview": "a. Reevaluate and adjust the level and frequency of investigations and monitoring as appropriate."
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9884,
      "preview": "b. Consider transfer to a higher level of care."
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9886,
      "preview": "--- page 407 ---"
    },
    {
      "type": "text",
      "section": "Well-Baby Nursery",
      "line": 9888,
      "preview": "6. Tailor monitoring and evaluation according to clinical concern and perceived risk as determined b"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9890
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9892,
      "preview": "A. Asymptomatic newborns with a SGH may be monitored and evaluated in the Level II NICU (i.e. ICN)."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9893,
      "preview": "B. Clinically symptomatic newborns, newborns with a rapidly evolving hemorrhage, or any other newbor"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9895,
      "preview": "1. Signs and symptoms may be present at birth or may not become clinically apparent until several ho"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9896,
      "preview": "C. Investigations / Monitoring for Asymptomatic Newborns in Level II/III"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9897,
      "preview": "2. Inform Level III NICU team that newborn was admitted to level II nursery. This will allow the Lev"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9898,
      "preview": "3. Place IV access."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9899,
      "preview": "4. Check hematocrit and platelets on admit and then every $4-6 \\mathrm{hrs} \\times 24 \\mathrm{hrs}$."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9900,
      "preview": "a. Frequency of further monitoring of hematocrit and platelets can be adjusted based on clinical and"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9901,
      "preview": "b. Hematocrit should be monitored for at least 48 hrs after birth."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9902,
      "preview": "5. Screening coagulation studies on admit should include fibrinogen (and platelets as defined above)"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9903,
      "preview": "a. Further coagulation studies (i.e. INR, PTT, PTT) and timing should be based on clinical and labor"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9904,
      "preview": "6. Vital Signs"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9905,
      "preview": "a. Measure vital signs every $30 \\mathrm{~min} \\times 2$ hrs then every 2 hrs $\\times 4$ hrs then ev"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9906,
      "preview": "b. BP should be monitored at least every 4-6 hrs $\\times 24$ hrs then every 8 hrs until 48 hrs after"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9907,
      "preview": "7. Assess appearance of scalp along with infant's color and perfusion with vital signs."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9908,
      "preview": "8. Monitor heart rate and respiratory rate continuously via cardio/respiratory monitor."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9909,
      "preview": "a. Even mild tachycardia or tachypnea can be early sign of shock and should be reason for transfer t"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9910,
      "preview": "9. Measure occipitofrontal circumference (OFC) on admit and then every 4 hrs $\\times 24$ hrs followe"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9911,
      "preview": "a. The OFC increases about 1 cm with each 40 ml of blood deposited in the subaponeurotic space."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9912,
      "preview": "10. If scalp appearance concerning, hematocrit dropping, or an increase in the OFC:"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9914,
      "preview": "--- page 408 ---"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9916,
      "preview": "a. Reevaluate and adjust the level and frequency of investigations and monitoring as appropriate."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9917,
      "preview": "b. Consider transfer to a higher level of care (if infant is in the ICN)."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9918,
      "preview": "10. Additional monitoring, laboratories, and treatments should be performed as determined by the tre"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9919,
      "preview": "D. Any clinical signs and symptoms consistent with subgaleal hemorrhage require transfer to a higher"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9921,
      "preview": "1. Concerning increase in size / progressive subgaleal hemorrhage noted on exam"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9922,
      "preview": "2. Poor feeding"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9923,
      "preview": "3. Pallor/poor perfusion"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9924,
      "preview": "4. Tachycardia"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9925,
      "preview": "5. Tachypnea"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9926,
      "preview": "6. Metabolic acidosis"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9927,
      "preview": "7. Hypotension"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9928,
      "preview": "8. Any bleeding, oozing, epistaxis, etc."
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9929,
      "preview": "9. Lethargy/hypotonia"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9930,
      "preview": "10. Seizures"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9931,
      "preview": "11. Irritable cry"
    },
    {
      "type": "text",
      "section": "Level II (ICN) or Level III Nursery (NICU)",
      "line": 9932,
      "preview": "12. Any other clinical concern"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 9934
    },
    {
      "type": "text",
      "section": "References",
      "line": 9936,
      "preview": "1. Plauch\u00e9 WC. Subgaleal hematoma. A complication of instrumental delivery. JAMA 1980; 244:1597."
    },
    {
      "type": "text",
      "section": "References",
      "line": 9937,
      "preview": "2. Rosenberg AA. Traumatic Birth Injury. Neoreviews 2003;4(10): e270-e276."
    },
    {
      "type": "text",
      "section": "References",
      "line": 9939,
      "preview": "--- page 409 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Approach to Neonatal Hypotonia",
      "line": 9941
    },
    {
      "type": "text",
      "section": "Approach to Neonatal Hypotonia",
      "line": 9943,
      "preview": "Anna-Kaisa Niemi, M.D., Ph.D., Caroline Tesi-Rocha, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Introduction",
      "line": 9945
    },
    {
      "type": "text",
      "section": "Introduction",
      "line": 9947,
      "preview": "Neonatal hypotonia is a relatively common yet often transient finding, especially in preterm infants"
    },
    {
      "type": "text",
      "section": "Introduction",
      "line": 9949,
      "preview": "Identification of the cause of hypotonia allows planning of supportive therapies (e.g. tracheostomy,"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9951
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9953,
      "preview": "Neonatal hypotonia can be classified several ways based on the etiology. The differential diagnosis "
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9955,
      "preview": "The differential diagnosis of neonatal hypotonia includes following:"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9956,
      "preview": "A. Prematurity (may be normal for gestational age or related to maternal magnesium therapy)"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9957,
      "preview": "B. Acute perinatal event"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9958,
      "preview": "C. Hypoxic ischemic encephalopathy (HIE)"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9959,
      "preview": "D. Intracranial hemorrhage (ICH)"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9960,
      "preview": "E. Maternal medications (e.g. magnesium, benzodiazepines)"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9961,
      "preview": "F. Maternal conditions (physiological effect or inherited) Myasthenia gravis, myotonic dystrophy"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9962,
      "preview": "G. Prenatal infection: TORCH infections (suspect if hepatomegaly, thrombocytopenia, intracranial cal"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9963,
      "preview": "H. Chromosomal disorders including (diagnosis often evident on physical examination): Trisomy 21 (hy"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9964,
      "preview": "I. Other genetic syndromes including: Prader-Willi syndrome, RASopathies (e.g. Noonan, Costello)"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9965,
      "preview": "J. Structural CNS malformations"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9966,
      "preview": "K. Anterior horn cell diseases: Spinal muscular atrophy (SMA)"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9967,
      "preview": "L. Congenital muscular dystrophies (very high CK typical): Walker-Warburg, Muscle-Eye-Brain Disease,"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9969,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9971,
      "preview": "--- page 410 ---"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9973,
      "preview": "M. Congenital myotonic dystrophy"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9974,
      "preview": "N. Disorders of neuromuscular junction: Congenital myasthenia (fluctuating symptoms), transient neon"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9975,
      "preview": "O. Congenital Myopathies"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9976,
      "preview": "P. Metabolic disorders (aka biochemical genetic disorders) including: Mitochondrial disorders, perox"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9977,
      "preview": "Q. Connective tissue disorders including: (e.g. Cutis laxa syndromes, neonatal Marfan, Ehlers-Danlos"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9978,
      "preview": "R. Endocrinological disorders: Hypothyroidism"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9979,
      "preview": "S. Infantile botulism (Affects neuromuscular junction)"
    },
    {
      "type": "text",
      "section": "I. Etiology of neonatal hypotonia:",
      "line": 9980,
      "preview": "T. Peripheral neuropathies (Congenital hypomyelination)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. Evaluation of neonatal hypotonia",
      "line": 9982
    },
    {
      "type": "text",
      "section": "II. Evaluation of neonatal hypotonia",
      "line": 9984,
      "preview": "Thoughtful and thorough evaluation of a neonate with hypotonia is essential given the availability o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. History - Clues to diagnosis",
      "line": 9986
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9988,
      "preview": "The following information may help in distinguishing if the cause of neonatal hypotonia was present "
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9990,
      "preview": "1. Family history of neuromuscular disorder"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9991,
      "preview": "a. Parental consanguinity: e.g. are parents from same small town in a remote area?"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9992,
      "preview": "2. Polyhydramnios (decreased fetal swallowing)"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9993,
      "preview": "3. Decreased fetal movements"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9994,
      "preview": "4. Fetal ultrasound results"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9995,
      "preview": "5. Malpresentation (often breech)"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9996,
      "preview": "6. Acute perinatal event? Condition of infant at the time of delivery? Fetal tracings and movements "
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9997,
      "preview": "7. Difficult delivery/extraction of infant? e.g. cervical spinal injury"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9998,
      "preview": "8. Maternal medications (magnesium, benzodiazepines)"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 9999,
      "preview": "9. Maternal handshake: if difficulty relaxing from handshake consider myotonic dystrophy"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 10001,
      "preview": "--- page 411 ---"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 10003,
      "preview": "10. Fluctuating symptoms? Think of congenital myasthenias (rare cause but fluctuation typical)"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 10004,
      "preview": "11. Infant discharged and readmitted with acute hypotonia?"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 10005,
      "preview": "a. Botulism? Ingestion of honey? Living in areas of construction/ground work?"
    },
    {
      "type": "text",
      "section": "A. History - Clues to diagnosis",
      "line": 10006,
      "preview": "b. Toxic ingestion? Non-accidental trauma?"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10008
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10010,
      "preview": "1. General appearance"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10011,
      "preview": "a. Alertness? In peripheral hypotonias infant typically alert and responds to surroundings."
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10012,
      "preview": "b. Typical position of a hypotonic infant: frog-leg position with hips abducted"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10013,
      "preview": "2. Measurements (weight, length, OFC - microcephaly? Macrocephaly?)"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10014,
      "preview": "3. Dysmorphic? Syndromic? Many syndromes evident in examination."
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10015,
      "preview": "4. Bruising, petechiae, evidence of trauma?"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10016,
      "preview": "5. Reflexes"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10017,
      "preview": "a. Brisk: central cause"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10018,
      "preview": "b. Decreased/absent: peripheral cause (neuropathy, myopathy)"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10019,
      "preview": "6. Antigravity movements? Often present in central hypotonias, absent in peripheral causes."
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10020,
      "preview": "7. Suck and cry? Strong or weak?"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10021,
      "preview": "8. Respiratory rate/pattern, diaphragmatic movement, paradoxical breathing?"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10022,
      "preview": "9. Apneas? Can happen in central causes as well as congenital myasthenias"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10023,
      "preview": "10. Ptosis? If present, consider myasthenias, congenital myopathies, congenital muscular dystrophies"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10024,
      "preview": "11. Tongue fasciculations? Present in anterior horn diseases (SMA) and other SMA-like syndromes."
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10025,
      "preview": "12. High arched palate?"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10026,
      "preview": "13. Joint laxity? May point to connective tissue disorders"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10027,
      "preview": "14. Joint contractures? Think of arthrogryposes, congenital Marfan syndrome?"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10028,
      "preview": "15. Hip dislocation"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10029,
      "preview": "16. Abnormal eye findings (e.g. optic nerve hypoplasia, retinal abnormalities, coloboma, cataracts)"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10031,
      "preview": "--- page 412 ---"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10033,
      "preview": "1. Electrolytes:"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10034,
      "preview": "a. Hypermagnesemia? Hypokalemia? Anion gap?"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10035,
      "preview": "2. Glucose:"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10036,
      "preview": "a. IEM, Endocrine etiology."
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10037,
      "preview": "3. Transaminases (AST, ALT):"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10038,
      "preview": "a. Liver involvement? May also be elevated in congenital muscular dystrophies and metabolic encephal"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10039,
      "preview": "4. CK:"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10040,
      "preview": "a. 2,000-10,000 or higher consider congenital muscular dystrophies"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10041,
      "preview": "b. Several hundred soon after birth may be related to birth process: repeat in a few days"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10042,
      "preview": "c. NOTE: Normal CK does NOT rule out muscular cause for hypotonia."
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10043,
      "preview": "5. TSH, FT4"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10044,
      "preview": "6. Ammonia:"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10045,
      "preview": "a. Especially if mental status changes, lethargy, emesis (concerning particularly when above 100)"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10046,
      "preview": "7. Lactate:"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10047,
      "preview": "a. If suspicion for mitochondrial disorders, glycogen storage disorders organic acidemias."
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10048,
      "preview": "8. Biochemical genetic screening labs"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10049,
      "preview": "a. Plasma amino acids, urine organic acids, plasma acylcarnitine profile, plasma total and free carn"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10050,
      "preview": "b. Rarely diagnostic in peripheral hypotonia. More diagnostic if other systemic symptoms (seizures, "
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10051,
      "preview": "9. Comparative genomic hybridization (CGH):"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10052,
      "preview": "a. If suspicion for chromosomal deletion syndrome for example in an infant with multiple anomalies a"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10053,
      "preview": "10. Karyotype:"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10054,
      "preview": "a. If suspicion of trisomies $(13,18,21)$"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10055,
      "preview": "11. Genetic testing for Prader-Willi syndrome:"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10056,
      "preview": "a. Hypotonic infant with feeding difficulties but often without respiratory distress"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10057,
      "preview": "12. Gene panels (sometimes)"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10059,
      "preview": "--- page 413 ---"
    },
    {
      "type": "text",
      "section": "B. Physical examination - clues to diagnosis",
      "line": 10061,
      "preview": "a. Based on suspected etiology (e.g. congental myopathies, congenial myasthenias, congenital muscula"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IMAGING and other diagnostic procedures",
      "line": 10063
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10065,
      "preview": "13. Chest x-ray:"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10066,
      "preview": "a. Lung volumes, cardiomegaly?"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10067,
      "preview": "14. Echocardiogram:"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10068,
      "preview": "a. Cardiomyopathy? Hypertrophic - think of Pompe disease (treatment available)."
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10069,
      "preview": "15. Abdominal ultrasound:"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10070,
      "preview": "a. Hepatomegaly? Splenomegaly?"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10071,
      "preview": "16. Head US"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10072,
      "preview": "17. Brain MRI +/- MRS (latter to look for lactate peaks when suspecting mitochondrial disease)"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10073,
      "preview": "18. EEG"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10074,
      "preview": "19. EMG/NCS- Repetitive stimulation if NMJ defect suspected."
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10075,
      "preview": "20. Muscle biopsy: if suspicion of myopathies"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10076,
      "preview": "21. Nerve biopsy: If suspected neuropathy"
    },
    {
      "type": "text",
      "section": "IMAGING and other diagnostic procedures",
      "line": 10077,
      "preview": "22. Placental pathology"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Consultants and ancillary services",
      "line": 10079
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10081,
      "preview": "A. Expertise to aid in diagnostic evaluation/work-up: Diagnostic evaluation is often coordinated wit"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10083,
      "preview": "1. Neurology (almost always)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10084,
      "preview": "2. Medical Genetics (almost always)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10085,
      "preview": "3. Ophthalmology (if suspecting specific syndromes, or if etiology has remained unclear)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10086,
      "preview": "B. Expertise for management/care:"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10087,
      "preview": "4. Neurology (almost always)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10088,
      "preview": "5. Biochemical Genetics (for metabolic disorders)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10089,
      "preview": "6. Pediatric General Surgery (e.g. gastrostomy)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10090,
      "preview": "7. Pulmonology (e.g. tracheostomy, long-term non-invasive ventilation)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10091,
      "preview": "8. Cardiology (if cardiomyopathy or other cardiac involvement)"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10093,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10095,
      "preview": "--- page 414 ---"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10097,
      "preview": "6. Palliative care"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10098,
      "preview": "7. Physical therapy"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10099,
      "preview": "8. Occupational therapy"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10100,
      "preview": "9. Social worker"
    },
    {
      "type": "text",
      "section": "III. Consultants and ancillary services",
      "line": 10101,
      "preview": "10. Genetic counselor/Medical Genetics team if genetic tests are ordered"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 10103
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10105,
      "preview": "1. Ahmed MI, Iqbal M, Hussain N. A structured approach to the assessment of a floppy neonate. J Pedi"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10106,
      "preview": "2. Birdi K, Prasad AN, Prasad C, Chodirker B, Chudley AE. The floppy infant: retrospective analysis "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10107,
      "preview": "3. Laugel V, Coss\u00e9e M, Matis J, et al. Diagnostic approach to neonatal hypotonia: retrospective stud"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10108,
      "preview": "4. Leyenaar J, Camfield P, Camfield C. A schematic approach to hypotonia in infancy. Paediatr Child "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10109,
      "preview": "5. Paro-Panjan D, Neubauer D. Congenital hypotonia: is there an algorithm? J Child Neurol. 2004 Jun;"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10110,
      "preview": "6. Peredo DE, Hannibal MC. The floppy infant: evaluation of hypotonia. Pediatr Rev. 2009 Sep;30(9): "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10112,
      "preview": "--- page 415 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Neonatal Abstinence Syndrome Due to In-Utero Opioid Exposure",
      "line": 10114
    },
    {
      "type": "text",
      "section": "Neonatal Abstinence Syndrome Due to In-Utero Opioid Exposure",
      "line": 10116,
      "preview": "Krista Birnie, M.D., Sarah Dubner, M.D., and Adam Frymoyer, M.D."
    },
    {
      "type": "text",
      "section": "Neonatal Abstinence Syndrome Due to In-Utero Opioid Exposure",
      "line": 10118,
      "preview": "Although Neonatal Abstinence Syndrome (NAS) can refer to neonatal drug withdrawal from other substan"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Definition",
      "line": 10120
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 10122,
      "preview": "A. A clinical diagnosis resulting from the abrupt discontinuation of prolonged fetal exposure to opi"
    },
    {
      "type": "text",
      "section": "I. Definition",
      "line": 10123,
      "preview": "B. A multisystem disorder, including disturbances of the central and autonomic nervous systems and g"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiology",
      "line": 10125
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10127,
      "preview": "A. Secondary to chronic maternal use of opiates"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10128,
      "preview": "B. Occurs in all communities and all ethnicities"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10129,
      "preview": "C. Methadone exposure"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10131,
      "preview": "1. Synthetic mu-opioid receptor agonist is a standard of care opioid addiction treatment for pregnan"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10132,
      "preview": "2. Buprenorphine is alternative to methadone treatment with comparable efficacy in pregnant and opio"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10133,
      "preview": "D. Abuse of prescription pain medications"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10134,
      "preview": "E. Psychotropic medications to treat depression and anxiety"
    },
    {
      "type": "text",
      "section": "II. Etiology",
      "line": 10135,
      "preview": "3. Intrauterine exposure to SSRIs, SNRIs, TCAs, and benzodiazepines has been associated with neonata"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Pathophysiology",
      "line": 10137
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10139,
      "preview": "A. Exact mechanism unknown, however a lack of opioids after chronic exposure causes an increased pro"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10140,
      "preview": "B. Opiate drugs have low molecular weight, are water soluble, and lipophilic; therefore, they easily"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10141,
      "preview": "C. The combination of methadone with heroin or cocaine increases the permeability of methadone"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10142,
      "preview": "D. Prolonged drug half-life in the fetus"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10143,
      "preview": "E. The locus coeruleus of the pons is the most important part of the brain related to opioid withdra"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10144,
      "preview": "F. Incidence and severity of withdrawal is less extensive in preterm neonates, proposed theories for"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10146,
      "preview": "--- page 416 ---"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10148,
      "preview": "1. CNS immaturity: fewer dendritic connections exist, which is key to the action of the opiates"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10149,
      "preview": "2. Immature livers: metabolites from maternal meds remain in body longer so effectively premature in"
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10150,
      "preview": "3. Exposure to lower doses for shorter time periods is possible (i.e. pregnant mothers in methadone "
    },
    {
      "type": "text",
      "section": "III. Pathophysiology",
      "line": 10151,
      "preview": "4. Decreased placental transfer rate of drug metabolites in premature infants"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Clinical Presentation",
      "line": 10153
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10155,
      "preview": "A. Symptoms of NAS following in-utero opioid exposure may vary depending on the type of substance us"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10156,
      "preview": "B. Timing"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10158,
      "preview": "1. Symptoms of withdrawal may begin as early as 24 to 48 hours after birth, or as late as 5 to 10 da"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10160,
      "preview": "TABLE 1 Onset, Duration, and Frequency of NAS Caused by Various Substances"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10162,
      "preview": "| Drug | Onset, h | Frequency, \\% | Duration, d |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10163,
      "preview": "| :-- | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10164,
      "preview": "| Opioids |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10165,
      "preview": "| Heroin | $24-48$ | $40-80^{27}$ | $8-10$ |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10166,
      "preview": "| Methadone | $48-72$ | $13-94^{37}$ | Up to 30 or more |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10167,
      "preview": "| Buprenorphine | $36-60$ | $22-67^{46,48}$ | Up to 28 or more |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10168,
      "preview": "| Prescription opioid medications | $36-72$ | $5-20^{56,60}$ | $10-30$ |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10169,
      "preview": "| Nonopioids |  |  |  |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10170,
      "preview": "| SSRIs | $24-48$ | $20-30^{64}$ | $2-6$ |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10171,
      "preview": "| TCAs | $24-48$ | $20-50^{64}$ | $2-6$ |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10172,
      "preview": "| Methamphetamines | 24 | $2-49^{101}$ | $7-10$ |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10173,
      "preview": "| Inhalants | $24-48$ | $48^{70}$ | $2-7$ |"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10175,
      "preview": "Reference: Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014;134: e547-61"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10177,
      "preview": "--- page 417 ---"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10179,
      "preview": "410 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10180,
      "preview": "C. Most common symptoms of NAS following in-utero opioid exposure are shown in Table 3."
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10182,
      "preview": "1. Each baby may experience symptoms differently"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10184,
      "preview": "TABLE 3 Clinical Features of the Neonatal Narcotic Abstinence Syndrome"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10186,
      "preview": "| Neurologic Excitability | Gastrointestinal Dysfunction |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10187,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10188,
      "preview": "| Tremors | Poor feeding |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10189,
      "preview": "| Irritability | Uncoordinated and constant sucking |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10190,
      "preview": "| Increased wakefulness | Vomiting |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10191,
      "preview": "| High-pitched crying | Diarrhea |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10192,
      "preview": "| Increased muscle tone | Dehydration |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10193,
      "preview": "| Hyperactive deep tendon reflexes | Poor wt gain |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10194,
      "preview": "| Exaggerated Moro reflex | Autonomic signs |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10195,
      "preview": "| Seizures | Increased sweating |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10196,
      "preview": "| Frequent yawning and sneezing | Nasal stuffiness |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10197,
      "preview": "|  | Fever |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10198,
      "preview": "|  | Mottling |"
    },
    {
      "type": "table",
      "section": "IV. Clinical Presentation",
      "line": 10199,
      "preview": "|  | Temperature instability |"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10201,
      "preview": "Reference: Hudak ML, et al. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-560"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10202,
      "preview": "D. Risk factors associated with increased risk of NAS"
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10204,
      "preview": "1. Definite: term, AGA, polydrug abuse, combination with benzodiazepines, mu-opioid receptor (OPRM1 "
    },
    {
      "type": "text",
      "section": "IV. Clinical Presentation",
      "line": 10205,
      "preview": "2. Probable: male gender, methadone, smoking, combination with SSRIs"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10207
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10209,
      "preview": "A. Patient Population: Newborns born at $>=35$ weeks at risk for neonatal abstinence syndrome admitt"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10211,
      "preview": "1. Infants may initially be admitted to newborn nursery unless prior Fetal Center consult noting oth"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10212,
      "preview": "B. Laboratory testing: Obtain urine drug screen and meconium drug screen if not done previously. Rev"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10213,
      "preview": "C. Optimize non-pharmacological measures at all times (e.g. to prevent or minimize onset of symptoms"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10215,
      "preview": "1. Room-in with mother. Prioritize these mother and infant dyads to single rooms, if possible."
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10216,
      "preview": "2. Minimal environmental stimulation: Low noise, low lights, swaddling, prefer to keep in low activi"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10217,
      "preview": "3. Holding by parents, as much as possible. If parents unavailable, use the help of volunteer cuddle"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10219,
      "preview": "--- page 418 ---"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10221,
      "preview": "4. Encourage prolonged skin to skin for optimizing neuro-behavioral aspects of the newborn"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10222,
      "preview": "5. Pacifier use to soothe the baby if mother ok with pacifier."
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10223,
      "preview": "6. Breastfeed ad lib frequently if no contraindications for breastfeeding."
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10224,
      "preview": "a. Mothers who received methadone maintenance during pregnancy and in a stable program should be enc"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10225,
      "preview": "D. NAS withdrawal scoring using the Modified Finnegan tool (see appendix A):"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10226,
      "preview": "7. Timing of Scoring:"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10227,
      "preview": "a. All scoring should be performed half to one hour after a feed."
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10228,
      "preview": "b. First score should occur within 2 to 4 hours after birth/admit to provide baseline"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10229,
      "preview": "c. Continue scoring every 3-4 hrs"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10230,
      "preview": "i. If all scores $<8$ for 24 hrs , may decrease frequency of scoring to every 8 hrs ."
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10231,
      "preview": "ii. Duration of scoring will depend on specific in-utero exposure $->$ see 'Duration of Scoring and "
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10232,
      "preview": "iii. If very low index of suspicion/concern for NAS, can start scoring at every 8 h in newborn nurse"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10233,
      "preview": "iv. If score $\\geq 8$, then increase frequency of scoring to every $3-4$ hrs"
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10234,
      "preview": "v. Note - newborn nursery cannot monitor more frequently than every 4 hrs ."
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10235,
      "preview": "8. If two scores are $\\geq 8$ within a 24 -hour period then the nurse is to inform the MD/NNP."
    },
    {
      "type": "text",
      "section": "V. Treatment Considerations for Newborns with In-utero Opioid Exposure",
      "line": 10236,
      "preview": "a. Ensure all non-pharmacological measures have been optimized."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "E. Duration of Scoring and Observation:",
      "line": 10238
    },
    {
      "type": "text",
      "section": "E. Duration of Scoring and Observation:",
      "line": 10240,
      "preview": "1. Consider half-life of in-utero exposure"
    },
    {
      "type": "text",
      "section": "E. Duration of Scoring and Observation:",
      "line": 10241,
      "preview": "a. If shorter-half life (heroin, most prescription opioids), consider 48-72 hrs of observation"
    },
    {
      "type": "text",
      "section": "E. Duration of Scoring and Observation:",
      "line": 10242,
      "preview": "b. If longer-half life (methadone), consider monitoring for up to 5 days"
    },
    {
      "type": "text",
      "section": "E. Duration of Scoring and Observation:",
      "line": 10243,
      "preview": "c. Earlier discharge may be appropriate if NAS scores stable, home situation stable, social worker a"
    },
    {
      "type": "text",
      "section": "E. Duration of Scoring and Observation:",
      "line": 10244,
      "preview": "2. If pharmacologic management (i.e. morphine) started in newborn"
    },
    {
      "type": "text",
      "section": "E. Duration of Scoring and Observation:",
      "line": 10245,
      "preview": "a. Observe 48 hours off of morphine with NAS scores $<8$, prior to discharge home"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "F. Medical Management:",
      "line": 10247
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10249,
      "preview": "1. Patients receiving medication to treat NAS will be cared for either in the ICN or NICU."
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10251,
      "preview": "--- page 419 ---"
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10253,
      "preview": "412 Part II-I: Neurology"
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10254,
      "preview": "2. Medical management of NAS with morphine should be reserved for infants with NAS due to opioids, n"
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10255,
      "preview": "3. Ensure all non-pharmacological measures have been optimized before starting pharmacologic managem"
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10257,
      "preview": "Opioid Pharmacologic Management Guidelines for NAS"
    },
    {
      "type": "table",
      "section": "F. Medical Management:",
      "line": 10259,
      "preview": "| Initiate | $\\square$ Consecutive NAS scores $\\geq 8$ three times or $\\geq 12$ two times <br> $\\squ"
    },
    {
      "type": "table",
      "section": "F. Medical Management:",
      "line": 10260,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "F. Medical Management:",
      "line": 10261,
      "preview": "| Escalate | Increase dose by $0.03 \\mathrm{mg} / \\mathrm{kg}$ every 3 hours until NAS score $\\leq 8"
    },
    {
      "type": "table",
      "section": "F. Medical Management:",
      "line": 10262,
      "preview": "| Stabilize | $\\square$ Stabilization dose $=$ dose which results in stable NAS scores of $<8$ in pr"
    },
    {
      "type": "table",
      "section": "F. Medical Management:",
      "line": 10263,
      "preview": "| Wean | $\\square$ Start initial wean after 48 hrs on stabilization dose <br> $\\square$ Wean dose da"
    },
    {
      "type": "table",
      "section": "F. Medical Management:",
      "line": 10264,
      "preview": "| Backslide / Rescue Dose | $\\square$ If single NAS score $>12$, give a higher \"rescue dose\" of morp"
    },
    {
      "type": "table",
      "section": "F. Medical Management:",
      "line": 10265,
      "preview": "| Discharge | $\\square 48$ hours off morphine with scores $<8$ |"
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10267,
      "preview": "a. Consult pharmacy if IV dosing needed."
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10268,
      "preview": "b. b If the dose needs to be escalated more than two times in a row, consider waiting and using the "
    },
    {
      "type": "text",
      "section": "F. Medical Management:",
      "line": 10269,
      "preview": "c. Some patients may require a higher dose than $0.2 \\mathrm{mg} / \\mathrm{kg} /$ dose (this dose is"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "d. Example wean from stabilization dose:",
      "line": 10271
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10273,
      "preview": "Infant weighing 3.2 kg has been on a dose of $0.32 \\mathrm{mg}(0.1 \\mathrm{mg} / \\mathrm{kg} /$ dose"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10275,
      "preview": "Day 1: 0.29 mg q3hr $(0.09 \\mathrm{mg} / \\mathrm{kg})$"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10276,
      "preview": "Day 2: 0.26 mg q3hr $(0.08 \\mathrm{mg} / \\mathrm{kg})$"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10278,
      "preview": "--- page 420 ---"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10280,
      "preview": "Day 3: 0.22 mg q3hr $(0.07 \\mathrm{mg} / \\mathrm{kg})$"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10281,
      "preview": "Day 4: 0.19 mg q3hr $(0.06 \\mathrm{mg} / \\mathrm{kg})$"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10282,
      "preview": "Day 5: 0.16 mg q3hr $(0.05 \\mathrm{mg} / \\mathrm{kg})$"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10283,
      "preview": "Day 6: 0.13 mg q3hr $(0.04 \\mathrm{mg} / \\mathrm{kg})$"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10284,
      "preview": "Day 7: 0.1 mg q3hr $(0.03 \\mathrm{mg} / \\mathrm{kg})$"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10285,
      "preview": "Day 8: 0.06 mg q3hr $(0.02 \\mathrm{mg} / \\mathrm{kg}) \\times 24 \\mathrm{hr}$ and then stop"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10286,
      "preview": "Day 9 and Day 10: Monitor in hospital for 48 hrs off morphine prior to discharge"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10288,
      "preview": "Appendix A. Modified Finnegan Scoring System"
    },
    {
      "type": "image",
      "section": "d. Example wean from stabilization dose:",
      "line": 10289,
      "content": "![img-70.jpeg](images/faabebffbb0d9bfd.png)"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10291,
      "preview": "--- page 421 ---"
    },
    {
      "type": "text",
      "section": "d. Example wean from stabilization dose:",
      "line": 10293,
      "preview": "414 Part II-I: Neurology"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 10295
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10297,
      "preview": "1. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infan"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10298,
      "preview": "2. Dysart K, Hsieh H, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mot"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10299,
      "preview": "3. Finnegan LP, Connaughton JF Jr., Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10300,
      "preview": "4. Jones HE, Fielder A. Neonatal abstinence syndrome: historical perspective, current focus, future "
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10301,
      "preview": "5. Hall ES, Wexelblatt SL, Crowley M, et al. A multicenter cohort study of treatment and hospital ou"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10302,
      "preview": "6. Hall ES, Wexelblatt SL, Crowley M, et al. Implementation of a Neonatal Abstinence Syndrome Weanin"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10303,
      "preview": "7. Holmes, A, Whalen B. Improved family-centered care at lower cost: Rooming-in to treat neonatal ab"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10304,
      "preview": "8. Hudak ML, Tan RC, COMMITTEE ON DRUGS, COMMITTEE ON FETUS AND NEWBORN, American Academy of Pediatr"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10305,
      "preview": "9. Jansson, Lauren M, et al. ABM Clinical Protocol \\#21: Guidelines for Breastfeeding and the Drug-D"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10306,
      "preview": "10. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014;134:e547-61."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10307,
      "preview": "11. Siu A, Robinson CA. Neonatal Abstinence Syndrome: Essentials for the Practitioner. J Pediatr Pha"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10308,
      "preview": "12. \"Neonatal Abstinence Syndrome\". Stanford Children's Health website. Available:"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10309,
      "preview": "http://www.stanfordchildrens.org/en/topic/default?id=neonatal-abstinence-syndrome-90-P02387."
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10311,
      "preview": "--- page 422 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part II-J: Genetics",
      "line": 10313
    },
    {
      "type": "text",
      "section": "Part II-J: Genetics",
      "line": 10315,
      "preview": "--- page 423 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Management of Hyperammonemia and Urea Cycle Defects",
      "line": 10317
    },
    {
      "type": "text",
      "section": "Management of Hyperammonemia and Urea Cycle Defects",
      "line": 10319,
      "preview": "Greg Enns, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Clinical presentation",
      "line": 10321
    },
    {
      "type": "text",
      "section": "I. Clinical presentation",
      "line": 10323,
      "preview": "Presentation of neonatal hyperammonemia due to urea cycle defects is stereotypical. In general, infa"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Etiologies",
      "line": 10325
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10327,
      "preview": "There are numerous disorders that can cause neonatal hyperammonemia."
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10328,
      "preview": "A. Urea cycle defects:"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10330,
      "preview": "1. Argininosuccinic acid lyase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10331,
      "preview": "2. Argininosuccinic acid synthetase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10332,
      "preview": "3. Carbamyl phosphate synthase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10333,
      "preview": "4. N-Acetylglutamate synthase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10334,
      "preview": "5. Ornithine transcarbamylase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10335,
      "preview": "6. Arginase deficiency (rarely - usually associated with later onset disease)"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10336,
      "preview": "B. Organic acidurias:"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10337,
      "preview": "7. 3-hydroxy-3methylglutaryl-CoA lyase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10338,
      "preview": "8. Isovaleric acidemia"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10339,
      "preview": "9. 3-Ketothiolase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10340,
      "preview": "10. Methylmalonic acidemia"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10341,
      "preview": "11. Multiple acyl-CoA dehydrogenase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10342,
      "preview": "12. Propionic acidemia"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10343,
      "preview": "C. Fatty acid oxidation defects:"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10344,
      "preview": "13. Carnitine uptake defect"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10345,
      "preview": "14. Carnitine palmitoyltransferase 1 deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10346,
      "preview": "15. Carnitine acylcarnitine translocase deficiecy"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10347,
      "preview": "16. Long-chain acyl-CoA dehydrogenase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10349,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10351,
      "preview": "--- page 424 ---"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10353,
      "preview": "5. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10354,
      "preview": "6. Very-long-chain acyl-CoA dehydrogenase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10355,
      "preview": "D. Amino acid defects:"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10356,
      "preview": "7. Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10357,
      "preview": "8. Lysinuric protein intolerance"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10358,
      "preview": "E. Disorders of Energy Metabolism:"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10359,
      "preview": "9. Pyruvate carboxylase deficiency"
    },
    {
      "type": "text",
      "section": "II. Etiologies",
      "line": 10360,
      "preview": "10. Mitochondrial disorders"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Diagnostic Studies",
      "line": 10362
    },
    {
      "type": "text",
      "section": "III. Diagnostic Studies",
      "line": 10364,
      "preview": "A. Blood: send a STAT ammonia level and glucoscan every 2 hrs. Check a CMP, Mg, phos, d bili, serum "
    },
    {
      "type": "text",
      "section": "III. Diagnostic Studies",
      "line": 10365,
      "preview": "B. Urine: send a routine urinalysis, urine for organic acids, urine for amino acids (quantitative), "
    },
    {
      "type": "text",
      "section": "III. Diagnostic Studies",
      "line": 10366,
      "preview": "C. CBC with manual differential and blood cultures."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Procedures and Consultations",
      "line": 10368
    },
    {
      "type": "text",
      "section": "IV. Procedures and Consultations",
      "line": 10370,
      "preview": "A. Place a urinary catheter."
    },
    {
      "type": "text",
      "section": "IV. Procedures and Consultations",
      "line": 10371,
      "preview": "B. Correct anemia, hypovolemia, and acidosis."
    },
    {
      "type": "text",
      "section": "IV. Procedures and Consultations",
      "line": 10372,
      "preview": "C. Intubate with a target PCO2 of 35-40."
    },
    {
      "type": "text",
      "section": "IV. Procedures and Consultations",
      "line": 10373,
      "preview": "D. Optimize glucose infusion: maintaining blood glucose $150-250 \\mathrm{mg} / \\mathrm{dL}$, advanci"
    },
    {
      "type": "text",
      "section": "IV. Procedures and Consultations",
      "line": 10374,
      "preview": "E. Consult Genetics, Nephrology, Surgery (if Nephrology and Neonatology have decided on dialysis), a"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10376
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10378,
      "preview": "A. Use \"Metabolic Admit < 20 kg \" order set in EPIC. Do not begin this treatment until discussed wit"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10379,
      "preview": "B. Sodium benzoate and sodium phenylacetate"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10381,
      "preview": "1. Loading dose: $250 \\mathrm{mg} / \\mathrm{kg}$ of each component in $25 \\mathrm{ml} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10382,
      "preview": "2. Continuous infusion: $250 \\mathrm{mg} / \\mathrm{kg}$ of each compound in $25 \\mathrm{ml} / \\mathr"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10383,
      "preview": "C. Arginine $\\mathrm{HCl} 10 \\%$"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10385,
      "preview": "--- page 425 ---"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10387,
      "preview": "418 Part II-J: Genetics"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10389,
      "preview": "1. Loading dose: $6 \\mathrm{ml} / \\mathrm{kg}(0.6 \\mathrm{~g} / \\mathrm{kg} /$ dose $)$ in D10W over"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10390,
      "preview": "2. Continuous infusion: $6 \\mathrm{ml} / \\mathrm{kg} / \\mathrm{d}(0.6 \\mathrm{~g} / \\mathrm{kg} /$ d"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10391,
      "preview": "D. Carnitine: $50 \\mathrm{mg} / \\mathrm{kg} /$ dose IV every 6 hrs ."
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10392,
      "preview": "E. Labs"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10393,
      "preview": "3. ABG and ammonia level at completion of loading dose"
    },
    {
      "type": "text",
      "section": "V. Medications for Acute Neonatal Management of Suspected Urea Cycle Defects",
      "line": 10394,
      "preview": "4. RFP, Mg panel 2 hrs after completion of loading dose and every 12-24 hrs while on therapy."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10396
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10398,
      "preview": "A. Acute management"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10400,
      "preview": "1. Sodium benzoate and sodium phenylacetate"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10401,
      "preview": "a. Loading dose: $250 \\mathrm{mg} / \\mathrm{kg}$ of each component over 90 min via central access."
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10402,
      "preview": "b. Continuous infusion: $250 \\mathrm{mg} / \\mathrm{kg}$ of each compound in $25 \\mathrm{ml} / \\mathr"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10403,
      "preview": "2. Arginine $\\mathrm{HCl} 10 \\%$"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10404,
      "preview": "a. Loading dose: $2 \\mathrm{ml} / \\mathrm{kg}(0.2 \\mathrm{~g} / \\mathrm{kg} /$ dose $)$ in D10W over"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10405,
      "preview": "b. Continuous infusion: $2 \\mathrm{ml} / \\mathrm{kg} / \\mathrm{d}(0.2 \\mathrm{~g} / \\mathrm{kg} /$ d"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10406,
      "preview": "B. Non-acute management"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10407,
      "preview": "3. Sodium phenylbutyrate: $450-600 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{d}$ in divided doses $4-6$ ti"
    },
    {
      "type": "text",
      "section": "VI. Medications for Carbamyl Phosphate Synthase or Ornithine Transcarbamylase deficiencies",
      "line": 10408,
      "preview": "4. Citrulline: $170 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{d}$ in divided doses given every 6 hrs ."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10410
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10412,
      "preview": "A. Acute management"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10414,
      "preview": "1. Sodium benzoate and sodium phenylacetate"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10415,
      "preview": "a. Loading dose: $250 \\mathrm{mg} / \\mathrm{kg}$ of each component over 90 min via central access."
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10416,
      "preview": "b. Continuous infusion: $250 \\mathrm{mg} / \\mathrm{kg}$ of each compound in $25 \\mathrm{ml} / \\mathr"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10417,
      "preview": "2. Arginine $\\mathrm{HCl} 10 \\%$"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10418,
      "preview": "a. Loading dose: $6 \\mathrm{ml} / \\mathrm{kg}(0.6 \\mathrm{~g} / \\mathrm{kg} /$ dose $)$ in D10W over"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10419,
      "preview": "b. Continuous infusion: $6 \\mathrm{ml} / \\mathrm{kg} / \\mathrm{d}(0.6 \\mathrm{~g} / \\mathrm{kg} /$ d"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10420,
      "preview": "B. Non-Acute Management"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10421,
      "preview": "3. Sodium phenylbutyrate: $450-600 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{d}$ in divided doses $4-6$ ti"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10423,
      "preview": "--- page 426 ---"
    },
    {
      "type": "text",
      "section": "VII. Medications for Argininosuccinic Acid Synthetase Deficiency",
      "line": 10425,
      "preview": "2. Arginine: $400-700 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{d}$ in divided doses every 6 hrs ."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VIII. Medication for Argininosuccinate Lyase Deficiency",
      "line": 10427
    },
    {
      "type": "text",
      "section": "VIII. Medication for Argininosuccinate Lyase Deficiency",
      "line": 10429,
      "preview": "A. Acute management"
    },
    {
      "type": "text",
      "section": "VIII. Medication for Argininosuccinate Lyase Deficiency",
      "line": 10431,
      "preview": "1. Arginine $\\mathrm{HCl} 10 \\%$"
    },
    {
      "type": "text",
      "section": "VIII. Medication for Argininosuccinate Lyase Deficiency",
      "line": 10432,
      "preview": "a. Loading dose: $6 \\mathrm{ml} / \\mathrm{kg}(0.6 \\mathrm{~g} / \\mathrm{kg} /$ dose $)$ in D10W over"
    },
    {
      "type": "text",
      "section": "VIII. Medication for Argininosuccinate Lyase Deficiency",
      "line": 10433,
      "preview": "b. Continuous infusion: $6 \\mathrm{ml} / \\mathrm{kg} / \\mathrm{d}(0.6 \\mathrm{~g} / \\mathrm{kg} /$ d"
    },
    {
      "type": "text",
      "section": "VIII. Medication for Argininosuccinate Lyase Deficiency",
      "line": 10434,
      "preview": "B. Non-Acute Management"
    },
    {
      "type": "text",
      "section": "VIII. Medication for Argininosuccinate Lyase Deficiency",
      "line": 10435,
      "preview": "2. Arginine: $400-700 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{d}$ in divided doses every 6 hrs ."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IX. Nutrition",
      "line": 10437
    },
    {
      "type": "text",
      "section": "IX. Nutrition",
      "line": 10439,
      "preview": "A. Start on TPN as soon as stable. Goal is to provide at least $100-120 \\mathrm{kcal} / \\mathrm{kg} "
    },
    {
      "type": "text",
      "section": "IX. Nutrition",
      "line": 10440,
      "preview": "B. After discussion with Genetics, introduce a low amount protein (e.g. 0.5 to $1.0 \\mathrm{~g} / \\m"
    },
    {
      "type": "image",
      "section": "IX. Nutrition",
      "line": 10441,
      "content": "![img-71.jpeg](images/4ced95e5f896817d.png)"
    },
    {
      "type": "text",
      "section": "IX. Nutrition",
      "line": 10442,
      "preview": "C. Monitor plasma amino acids at least $2 x / w k$ and ammonia levels every day until stable."
    },
    {
      "type": "text",
      "section": "IX. Nutrition",
      "line": 10444,
      "preview": "--- page 427 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Genetic Testing in the NICU",
      "line": 10446
    },
    {
      "type": "text",
      "section": "Genetic Testing in the NICU",
      "line": 10448,
      "preview": "Melanie Manning, M.D. and Athena Cherry, Ph.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 10450
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10452,
      "preview": "Chromosome abnormalities account for a significant portion of genetic disease and are important caus"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Indications for Chromosome Analysis",
      "line": 10454
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10456,
      "preview": "A. Chromosome analysis is indicated as a diagnostic procedure in a number of different general clini"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10458,
      "preview": "1. Problems with early growth and development including FTT, developmental delay, dysmorphic facies,"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10459,
      "preview": "2. Stillbirth and neonatal death"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10460,
      "preview": "3. Fertility problems"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10461,
      "preview": "4. Family history (known or suspected chromosome abnormality in $1^{\\circ}$ relative)"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10462,
      "preview": "5. Neoplasia"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10463,
      "preview": "6. Advanced maternal age"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10464,
      "preview": "B. For infants in the NICU, consider ordering a chromosome analysis if $\\geq 2$ of the following fea"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10465,
      "preview": "7. Abnormal growth parameters"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10466,
      "preview": "8. At least 1 major malformation"
    },
    {
      "type": "text",
      "section": "II. Indications for Chromosome Analysis",
      "line": 10467,
      "preview": "9. $\\geq 2$ minor anomalies"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10469
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10471,
      "preview": "A. Blood, routine: In most instances, a routine karyotype on peripheral whole blood is the appropria"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10472,
      "preview": "B. FISH: Fluorescence in-situ hybridization (FISH) studies are relatively new cytogenetic tests that"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10474,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10476,
      "preview": "--- page 428 ---"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10478,
      "preview": "1. 22q11.2 Deletion Syndrome: Velocardiofacial syndrome(VCF)/DiGeorge Syndrome(DGS). In the newborn "
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10479,
      "preview": "a. Tetralogy of Fallot (22\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10480,
      "preview": "b. Interrupted aortic arch (IAA - 15\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10481,
      "preview": "c. VSD (13\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10482,
      "preview": "d. Truncus arteriosus (7\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10483,
      "preview": "e. Vascular ring (5\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10484,
      "preview": "f. ASD (3\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10485,
      "preview": "g. Aortic arch anomaly (3\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10486,
      "preview": "h. VSD; ASD (4\\%)"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10487,
      "preview": "i. Other (4\\%). Includes hypoplastic L heart, pulmonary valve stenosis, double-outlet right ventricl"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10489,
      "preview": "VCF and DGS are 2 names for the same region on the chromosome that is deleted and identified by FISH"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10490,
      "preview": "2. Prader-Willi syndrome (PWS) is a multisystem disorder with mental retardation that can be difficu"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10491,
      "preview": "3. Williams syndrome (WMS) is due to a microdeletion of 7q11.23. It can be difficult to diagnose in "
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10492,
      "preview": "C. CGH: Comparative genomic hybridization is the latest test available for evaluation of a possible "
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10494,
      "preview": "--- page 429 ---"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10496,
      "preview": "422 Part II-J: Genetics"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10497,
      "preview": "prior cytogenetic testing (e.g. amniocentesis, routine chromosomes at $<550$ band level) and a subtl"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10499,
      "preview": "While CGH is a very effective tool for detecting submicroscopic chromosomal changes, there are limit"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10501,
      "preview": "Any questions regarding CGH should be directed to Dr. Athena Cherry (Cytogenetics Laboratory Directo"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10502,
      "preview": "D. If CGH is normal and/or a specific single gene disorder is not recognized, the next step to consi"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10504,
      "preview": "A positive result from WES would likely enhance medical decision-making, impact the treatment care p"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10506,
      "preview": "In addition to identifying genetic changes associated with a patient's features, WES may also identi"
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10508,
      "preview": "While WES is a very effective tool for detecting single gene changes, there are limitations. WES is "
    },
    {
      "type": "text",
      "section": "III. Determining the Appropriate Cytogenetic Test",
      "line": 10510,
      "preview": "The family will be contacted about the WES results, and an appointment will be offered to discuss th"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Specimen Requirements",
      "line": 10512
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10514,
      "preview": "A. Routine specimens"
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10516,
      "preview": "Specimens for routine chromosome analysis, FISH analysis, and CGH should be collected in the followi"
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10518,
      "preview": "1. Draw a minimum of 2 ml whole blood with routine venipuncture precautions."
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10519,
      "preview": "2. Place in green top, sodium heparin tube."
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10520,
      "preview": "3. Keep at room temperature."
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10521,
      "preview": "4. Transport sample, along with completed cytogenetic test requisition (ordering sheet) and EPIC ord"
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10523,
      "preview": "--- page 430 ---"
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10525,
      "preview": "5. All chromosome orders need an ICD-10 code on the Cytogenetics Laboratory requisition form"
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10527,
      "preview": "NOTE: As most neonatal transfusions use PRBCs and not whole blood, obtaining a blood sample for cyto"
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10528,
      "preview": "B. STAT specimens"
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10530,
      "preview": "1. STAT chromosome analysis is typically reserved for samples critical to urgent patient management "
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10531,
      "preview": "2. Inform the Cytogenetics Laboratory director or supervisor when STAT status is requested."
    },
    {
      "type": "text",
      "section": "IV. Specimen Requirements",
      "line": 10532,
      "preview": "3. Questions regarding ordering of appropriate tests or sample requirements may always be directed t"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 10534
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10536,
      "preview": "1. Manning MA, Hudgins L. 2010. Array-based technology and recommendations for utilization in medica"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10538,
      "preview": "--- page 431 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "22q11 Deletion Syndrome",
      "line": 10540
    },
    {
      "type": "text",
      "section": "22q11 Deletion Syndrome",
      "line": 10542,
      "preview": "Susan Hintz, M.D., M.S. Epi, Jon Bernstein, M.D., David Lewis, M.D., and Inger Olson, M.D."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Introduction",
      "line": 10544
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10546,
      "preview": "A. \"Named\" syndromes associated with 22q11 deletion include:"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10548,
      "preview": "1. Velocardiofacial syndrome (VCFS)"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10549,
      "preview": "2. DiGeorge Syndrome (DGS)"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10550,
      "preview": "3. Shprintzen Syndrome"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10551,
      "preview": "4. Conotruncal Anomaly Face Syndrome (CAFS)."
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10552,
      "preview": "B. More appropriate and general term 22q11 Deletion Syndrome should be used to encompass the broad c"
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10553,
      "preview": "C. Estimated prevalence is 1 in 4000-6000; the true frequency is unknown."
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10554,
      "preview": "D. The deletion can be inherited, but is more likely to be a new deletion ( $\\sim 90 \\%$ of cases)."
    },
    {
      "type": "text",
      "section": "I. Introduction",
      "line": 10555,
      "preview": "E. Among patients in the NICU, 22q11 deletion syndrome is most often recognized due to the presence "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Clinical Features",
      "line": 10557
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10559,
      "preview": "A. A wide range of clinical findings accompany 22 q 11 deletion syndrome; $>150$ features have been "
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10560,
      "preview": "B. Variability in clinical presentation is marked:"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10562,
      "preview": "1. \"Typical facial features\""
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10563,
      "preview": "a. Long narrow face, almond shaped eyes, small mouth, \"bulbous\" nose, \"simple\" ear."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10564,
      "preview": "b. These features may not be obvious in the neonatal period."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10565,
      "preview": "2. Congenital heart disease (prevalence $\\sim 70-80 \\%$ of patients presenting in infancy with 22q11"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10566,
      "preview": "a. TOF ( 15-20\\% reported to have deletion), IAA ( $\\sim 50-70 \\%$ reported to have deletion), trunc"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10567,
      "preview": "b. Conotruncal defects are most common, but virtually any congenital heart defect has been reported "
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10568,
      "preview": "3. Immune abnormalities $(70-80 \\%)$"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10569,
      "preview": "a. T-cell lymphopenia, usually mild to moderate, $<1 \\%$ with a severe combined immunodeficiency pic"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10570,
      "preview": "b. Humoral immune defect consisting of hypogammaglobulinemia without B-cell lymphopenia-this is rare"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10572,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10574,
      "preview": "--- page 432 ---"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10576,
      "preview": "in neonatal period."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10577,
      "preview": "c. Recurrent sinopulmonary infections - usually after 6 months of age."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10578,
      "preview": "d. Opportunistic infections, rare, usually only seen in those unusual cases of severe T-cell lymphop"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10579,
      "preview": "e. Higher risk for autoimmune disease (ITP, rheumatoid arthritis) in later life."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10580,
      "preview": "4. Endocrine problems"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10581,
      "preview": "a. Hypocalcemia (50-70\\%) due to hypoparathyroidism."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10582,
      "preview": "b. Short stature (10-40\\%) - in some cases associated with GH deficiency."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10583,
      "preview": "c. Higher risk for hypothyroidism."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10584,
      "preview": "5. Renal anomalies (35-40\\%) including single kidney, cortical cysts, dysplastic kidneys."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10585,
      "preview": "6. Pharyngeal/laryngeal/airway findings ( 70\\%)."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10586,
      "preview": "a. Velopharyngeal incompetence is common - may contribute to significant feeding problems, speech pr"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10587,
      "preview": "b. Cleft palate in $\\sim 5-8 \\%$."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10588,
      "preview": "7. Neurologic/brain structural anomalies."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10589,
      "preview": "a. Cerebellar hypoplasia/dysgenesis, periventricular cysts."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10590,
      "preview": "8. Vertebral anomalies"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10591,
      "preview": "9. Feeding problems (30\\%)"
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10592,
      "preview": "10. Speech and language problems (40-90\\%)."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10593,
      "preview": "11. Neurodevelopmental/learning difficulties/psychiatric disorders."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10594,
      "preview": "a. Cognitive disabilities in 40-50\\%."
    },
    {
      "type": "text",
      "section": "II. Clinical Features",
      "line": 10595,
      "preview": "b. Schizophrenia and bipolar disorder."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Diagnosis",
      "line": 10597
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10599,
      "preview": "A medical genetics consultation is indicated in cases in which 22q11 deletion has been diagnosed."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10600,
      "preview": "A. Diagnosis is made through FISH (fluorescent in-situ hybridization) or array CGH, per genetics rec"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10602,
      "preview": "1. The diagnosis may also be made prenatally by FISH or CGH (i.e., amniocentesis, CVS)."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10603,
      "preview": "2. Note that cffDNA non-invasive prenatal testing (NIPT) \"expanded panels\" for microdeletions that i"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10605,
      "preview": "--- page 433 ---"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10607,
      "preview": "diagnostic evaluation should be undertaken in the newborn if clinically indicated."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10608,
      "preview": "3. TUPLE1 probe for 22q11.2 region; ARSA probe for 22q13 region."
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10610,
      "preview": "If probes are \"seen\", the test is \"negative\" for genotypic evidence of the syndrome; however, it has"
    },
    {
      "type": "text",
      "section": "III. Diagnosis",
      "line": 10611,
      "preview": "4. Some other genetic causes have been identified, including deletions of 10p13-14 and deletions of "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. Recommendations",
      "line": 10613
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10615,
      "preview": "A. Complete basic evaluation for anomalies associated with 22q11 deletion syndrome."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10617,
      "preview": "1. Thorough physical exam"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10618,
      "preview": "a. Chest radiograph-evaluate for vertebral anomalies."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10619,
      "preview": "2. Echocardiography."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10620,
      "preview": "3. Renal ultrasound."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10621,
      "preview": "a. Referral to pediatric nephrology and/or pediatric urology for consultation is indicated depending"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10622,
      "preview": "4. Neuroimaging"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10623,
      "preview": "a. Cranial US in the immediate neonatal period"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10624,
      "preview": "B. Genetic - Consult with the medical genetics team IF the diagnosis of 22q11 deletion is made. Medi"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10625,
      "preview": "5. Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10626,
      "preview": "a. Rarely, additional genetic testing if recommended per genetics consultation (i.e., constellation "
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10627,
      "preview": "b. Genetics may recommend investigation of parental 22q11 status, and siblings if a parent is affect"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10628,
      "preview": "6. Beyond Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10629,
      "preview": "a. Follow-up with Genetics in 4 mos."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10630,
      "preview": "C. Cardiac"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10631,
      "preview": "7. Care/surgery and follow-up with cardiology as dictated by specific condition."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10632,
      "preview": "D. Immunologic - Consult with the immunology team IF the diagnosis of 22q11 deletion is made. Their "
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10633,
      "preview": "8. Neonatal Period/at diagnosis:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10634,
      "preview": "a. CBC and differential"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10636,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10638,
      "preview": "--- page 434 ---"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10640,
      "preview": "b. \"T and B cell subsets\" by flow cytometry (includes CD3, CD4, CD8, B cells marker, and a NK cell m"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10641,
      "preview": "c. Lymphocyte function (proliferation to mitogens)."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10642,
      "preview": "d. $\\lg G, \\lg M$, and $\\lg A$ levels"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10643,
      "preview": "e. Use only CMV negative, irradiated blood products."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10644,
      "preview": "2. Beyond Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10645,
      "preview": "a. Follow-up with Immunology is generally recommended at 3 mos, and q 3-6 mos until at least 2 yrs."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10646,
      "preview": "b. Routine follow-up with a pediatrician informed of the need for vigilance with respect to increase"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10647,
      "preview": "c. No live vaccines until approved by Immunology."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10648,
      "preview": "E. Endocrine"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10650,
      "preview": "1. Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10651,
      "preview": "a. Closely monitor iCa++ and phosphorus levels"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10653,
      "preview": "Random checks of intact PTH are NOT useful. (Only useful if iCa++ is low (<1.0)."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10654,
      "preview": "b. Newborn Screen."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10655,
      "preview": "c. Follow-up TSH and FT4 at 4-6 weeks or prior to discharge."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10656,
      "preview": "2. Beyond Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10657,
      "preview": "a. Follow-up with endocrinology if recommended."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10658,
      "preview": "b. Routine care with pediatrician aware of potential endocrine and growth impairment issues."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10659,
      "preview": "F. Feeding"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10661,
      "preview": "1. Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10662,
      "preview": "a. Occupational therapy consultation at initiation of oral feeds."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10663,
      "preview": "b. If feeding or airway difficulties present during initial hospitalization, obtain Pediatric ENT co"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10664,
      "preview": "2. Beyond Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10665,
      "preview": "a. Outpatient follow-up with OT and ENT as needed"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10666,
      "preview": "G. Neurodevelopment and behavior"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10667,
      "preview": "3. Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10668,
      "preview": "a. Developmental Team consultation and assessment."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10670,
      "preview": "--- page 435 ---"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10672,
      "preview": "b. Parent education."
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10673,
      "preview": "2. Beyond Neonatal Period:"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10675,
      "preview": "Follow-up in multidisciplinary neurodevelopmental clinic (OT, PT, speech and language, neuromotor an"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10676,
      "preview": "a. Routine care with a pediatrician aware of need for vigilance through young adulthood with respect"
    },
    {
      "type": "image",
      "section": "IV. Recommendations",
      "line": 10677,
      "content": "![img-72.jpeg](images/da156fb1330bd11c.png)"
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10678,
      "preview": "to psychiatric and behavioral disorders (anxiety, ADHD, depression, obsessions, schizophrenia), and "
    },
    {
      "type": "text",
      "section": "IV. Recommendations",
      "line": 10680,
      "preview": "Need for specialties by age. Figure 2 from Habel A, et al. Eur J Pediatr 2014; 173: page 759"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 10682
    },
    {
      "type": "text",
      "section": "References",
      "line": 10684,
      "preview": "1. Habel A, et al. Towards a safety net for management of 22q11.2 deletion syndrome: guideline for o"
    },
    {
      "type": "text",
      "section": "References",
      "line": 10685,
      "preview": "2. Gene Reviews: https://www.ncbi.nlm.nih.gov/books/NBK1523/"
    },
    {
      "type": "text",
      "section": "References",
      "line": 10686,
      "preview": "3. National Organization of Rare Diseases: https://rarediseases.org/rare-diseases/chromosome-22q11-2"
    },
    {
      "type": "text",
      "section": "References",
      "line": 10688,
      "preview": "--- page 436 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Trisomy 21 - Down Syndrome",
      "line": 10690
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Melanie Manning, M.D. and Gary Dahl, M.D.",
      "line": 10692
    },
    {
      "type": "text",
      "section": "Melanie Manning, M.D. and Gary Dahl, M.D.",
      "line": 10694,
      "preview": "The proper management and health supervision of children with trisomy 21 or Down Syndrome (DS) is cr"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10696
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10698,
      "preview": "The following recommendations are in keeping with the AAP and National DS Congress health supervisio"
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10699,
      "preview": "A. Routine blood karyotype. May be ordered STAT. Prenatal diagnosis by non-invasive prenatal testing"
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10700,
      "preview": "B. CBC with differential"
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10701,
      "preview": "C. Echocardiogram"
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10702,
      "preview": "D. Hearing screen (Routine, prior to discharge.)"
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10703,
      "preview": "E. Newborn screen (Will detect congenital hypothyroidism)."
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10704,
      "preview": "F. Monitor for intestinal obstruction"
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10705,
      "preview": "G. Genetics consult (This will assure the patient is scheduled in the Down Syndrome Clinic for their"
    },
    {
      "type": "text",
      "section": "I. General Health Supervision for Infants with DS",
      "line": 10707,
      "preview": "* Any questions regarding these recommendations may be directed to Melanie Manning, MD or the Medica"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Center for DS:",
      "line": 10710
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10712,
      "preview": "The Center for DS is a multi-disciplinary clinic devoted to the evaluation and care of children with"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10713,
      "preview": "A. Patient care"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10715,
      "preview": "The Clinic is staffed by a dedicated team of specialists that includes: clinical geneticists, geneti"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10717,
      "preview": "--- page 437 ---"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10719,
      "preview": "become strong advocates for their children, and assist them to locate resources in their community."
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10720,
      "preview": "B. Each patient will receive the following services:"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10722,
      "preview": "1. Comprehensive medical and genetics evaluation"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10723,
      "preview": "2. Speech and Language pathology consultation"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10724,
      "preview": "3. Physical therapy consultation"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10725,
      "preview": "4. Occupational therapy consultation"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10726,
      "preview": "5. Nutrition consultation"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10727,
      "preview": "6. Referrals as required to other sub-specialists and ancillary services"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10728,
      "preview": "7. Regular and/or continuing follow-up care (to be assessed and coordinated with primary care physic"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10729,
      "preview": "C. Referral information"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10731,
      "preview": "For neonatal inpatients with DS or suspected DS, an inpatient consultation is strongly recommended. "
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10733,
      "preview": "To make an outpatient referral, call the Medical Genetics office for referral instructions at 723-68"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10734,
      "preview": "D. Clinic Hours and Location"
    },
    {
      "type": "text",
      "section": "II. Center for DS:",
      "line": 10736,
      "preview": "Clinics are held 2 Friday afternoons per month from 1-5:00 pm at the Mary L. Johnson Pediatric Ambul"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "III. Transient Myeloproliferative Disorder (TMD) and DS",
      "line": 10738
    },
    {
      "type": "text",
      "section": "III. Transient Myeloproliferative Disorder (TMD) and DS",
      "line": 10740,
      "preview": "A. Background: TMD is an uncontrolled proliferation of myeloblasts occurring only in infants with DS"
    },
    {
      "type": "text",
      "section": "III. Transient Myeloproliferative Disorder (TMD) and DS",
      "line": 10741,
      "preview": "B. The incidence of TMD in DS has been estimated at $10 \\%$, based on a single small prospective obs"
    },
    {
      "type": "text",
      "section": "III. Transient Myeloproliferative Disorder (TMD) and DS",
      "line": 10742,
      "preview": "C. If TMD is diagnosed in a DS neonate, these infants are monitored inpatient with CBC with differen"
    },
    {
      "type": "text",
      "section": "III. Transient Myeloproliferative Disorder (TMD) and DS",
      "line": 10743,
      "preview": "D. All TMD patients, regardless of severity, are routinely followed in Pediatric Oncology Clinic mon"
    },
    {
      "type": "text",
      "section": "III. Transient Myeloproliferative Disorder (TMD) and DS",
      "line": 10745,
      "preview": "--- page 438 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References:",
      "line": 10747
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10749,
      "preview": "1. Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2"
    },
    {
      "type": "text",
      "section": "References:",
      "line": 10751,
      "preview": "--- page 439 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Newborn Screening",
      "line": 10753
    },
    {
      "type": "text",
      "section": "Newborn Screening",
      "line": 10755,
      "preview": "Janet Stolowitz, R.N., Parnaz Abidi, R.N."
    },
    {
      "type": "text",
      "section": "Newborn Screening",
      "line": 10757,
      "preview": "State regulations require newborn screening via blood testing for phenylketonuria, galactosemia, pri"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Timing of Specimen Collection",
      "line": 10759
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10761,
      "preview": "A. Regulations require testing prior to transfusion, on the 4th day of life, or as close to discharg"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10762,
      "preview": "B. In healthy term infants, testing should not be done prior to 12 hrs of age. The optimal age for t"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10763,
      "preview": "C. In infants who receive a red blood cell transfusion prior to 12 hrs of life, a newborn screen (NB"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10764,
      "preview": "D. If the baby was started on ECMO or received a complete exchange transfusion prior to 12 hrs of li"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10765,
      "preview": "E. If the baby receives an RBC transfusion after 12 hrs of life, the NBS collected prior to RBC tran"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10766,
      "preview": "F. If born at LPCH and NBS is pending or completed, do not resend NBS."
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10768,
      "preview": "1. Pending specimens can be identified by opening the patient's file in EPIC and clicking on the \"Re"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10769,
      "preview": "G. A newborn screen does not need to be done on infants who meet the following criteria:"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10770,
      "preview": "2. Admitted to LPCH at more than 48 hours of age and previously discharged home. Check with EPIC to "
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10771,
      "preview": "3. Newborn screen performed elsewhere (documented by a copy of NBS specimen submission form or resul"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10772,
      "preview": "4. The admitting MD/NNP must select the MD to RN Communication on EPIC admission labs that instruct "
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10773,
      "preview": "H. Newborn screens should be sent for any unscreened infant who is to be sent to the OR, Cath Lab or"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10775,
      "preview": "--- page 440 ---"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10777,
      "preview": "I. If a NBS was not obtained prior to an RBC transfusion the following testing should be performed:"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10779,
      "preview": "1. Hemoglobin pattern testing (DNA testing of the baby's white blood cells) is available through NBS"
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10780,
      "preview": "2. Galactosemia: the galactosemia results are invalid if the baby received a RBC transfusion prior ("
    },
    {
      "type": "text",
      "section": "I. Timing of Specimen Collection",
      "line": 10781,
      "preview": "J. If prior specimens have been resulted as \"inadequate for testing\", a repeat specimen must be sent"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. Results Notification",
      "line": 10783
    },
    {
      "type": "text",
      "section": "II. Results Notification",
      "line": 10785,
      "preview": "A. For babies in the NICU, nursery staff will be notified of recall results by telephone."
    },
    {
      "type": "text",
      "section": "II. Results Notification",
      "line": 10786,
      "preview": "B. Recall result letters are sent to the physician of record; the doctor whose name is written in on"
    },
    {
      "type": "text",
      "section": "II. Results Notification",
      "line": 10787,
      "preview": "C. Copies of the recall result letters are also sent to the Clinical Laboratory."
    },
    {
      "type": "text",
      "section": "II. Results Notification",
      "line": 10788,
      "preview": "D. Families are to be notified of the results by the NICU physician or their Primary Health Care pro"
    },
    {
      "type": "text",
      "section": "II. Results Notification",
      "line": 10789,
      "preview": "E. The primary Physician, Resident or Nurse Practitioner can call for results if not entered into th"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Transfusion",
      "line": 10791
    },
    {
      "type": "text",
      "section": "III. Transfusion",
      "line": 10793,
      "preview": "A. Blood transfusion with red blood cells, whole blood, and packed red blood cells, including proced"
    },
    {
      "type": "text",
      "section": "III. Transfusion",
      "line": 10794,
      "preview": "B. Transfusions with plasma, albumin or platelets will not invalidate newborn screening for hemoglob"
    },
    {
      "type": "text",
      "section": "III. Transfusion",
      "line": 10795,
      "preview": "C. Please see section I.I above for details about repeating the NBS if a PRBC transfusion given."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Galactosemia",
      "line": 10797
    },
    {
      "type": "text",
      "section": "IV. Galactosemia",
      "line": 10799,
      "preview": "A. Galactosemia should be suspected when signs and symptoms such as sepsis (often E. coli), vomiting"
    },
    {
      "type": "text",
      "section": "IV. Galactosemia",
      "line": 10801,
      "preview": "--- page 441 ---"
    },
    {
      "type": "text",
      "section": "IV. Galactosemia",
      "line": 10803,
      "preview": "434 Part II-J: Genetics"
    },
    {
      "type": "text",
      "section": "IV. Galactosemia",
      "line": 10804,
      "preview": "B. First check a urine specimen for reducing substances (Clinitest\u00ae), and, if positive, excluding gl"
    },
    {
      "type": "text",
      "section": "IV. Galactosemia",
      "line": 10805,
      "preview": "C. Galactosemia can also be ruled out by carrier testing of the parents. This is available from ARUP"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. Hemoglobinopathy",
      "line": 10807
    },
    {
      "type": "text",
      "section": "V. Hemoglobinopathy",
      "line": 10809,
      "preview": "Hemoglobinopathy can be ruled out by carrier testing of the parents. This is available from the Hemo"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. Thyroid",
      "line": 10811
    },
    {
      "type": "text",
      "section": "VI. Thyroid",
      "line": 10813,
      "preview": "If results for thyroid screening come back with an increased TSH level, the recommendations are to o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VII. SCID",
      "line": 10815
    },
    {
      "type": "text",
      "section": "VII. SCID",
      "line": 10817,
      "preview": "A. Specimen is tested for T-cell receptor excision circles (TRECs) in DNA extracted from dried blood"
    },
    {
      "type": "text",
      "section": "VII. SCID",
      "line": 10818,
      "preview": "B. An incomplete result must be followed up with a repeat NBS. If the repeat NBS is also incomplete "
    },
    {
      "type": "text",
      "section": "VII. SCID",
      "line": 10819,
      "preview": "C. A positive test followed up with confirmatory testing of CBC differential and lymphocyte subset a"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VIII. Tandem Mass Spectrometry (MS/MS) for inborn errors of metabolism",
      "line": 10821
    },
    {
      "type": "text",
      "section": "VIII. Tandem Mass Spectrometry (MS/MS) for inborn errors of metabolism",
      "line": 10823,
      "preview": "The NBS Nurse Coordinator will advise a NICU clinician of the abnormal results. Abnormal MS/MS resul"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IX. Cystic Fibrosis",
      "line": 10825
    },
    {
      "type": "text",
      "section": "IX. Cystic Fibrosis",
      "line": 10827,
      "preview": "The NBS nurse coordinator will advise the clinician in the NICU of abnormal CF results and then make"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "X. Biotinidase Deficiency",
      "line": 10829
    },
    {
      "type": "text",
      "section": "X. Biotinidase Deficiency",
      "line": 10831,
      "preview": "Based on the Newborn Screen biotinidase level, either a repeat NBS will be requested or an immediate"
    },
    {
      "type": "text",
      "section": "X. Biotinidase Deficiency",
      "line": 10833,
      "preview": "--- page 442 ---"
    },
    {
      "type": "text",
      "section": "X. Biotinidase Deficiency",
      "line": 10835,
      "preview": "A repeat NBS will be requested on PKU positives. If the phenylalanine level and phenylalanine/tyrosi"
    },
    {
      "type": "text",
      "section": "X. Biotinidase Deficiency",
      "line": 10837,
      "preview": "--- page 443 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Pierre Robin Syndrome/Sequence",
      "line": 10839
    },
    {
      "type": "text",
      "section": "Pierre Robin Syndrome/Sequence",
      "line": 10841,
      "preview": "Elena Hopkins, R.N., M.S., P.N.P."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10843
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10845,
      "preview": "A. Findings, Causes, Incidence and Risk factors"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10847,
      "preview": "1. Pierre Robin Sequence [PRS] is a condition present at birth, which involves the triad of microgna"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10848,
      "preview": "2. Incidence ranging from 1 in 8,500 to 1 in 14,000 live births."
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10849,
      "preview": "3. The exact cause of Pierre Robin sequence is unknown and may be isolated or a part of a genetic sy"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10850,
      "preview": "4. The lower jaw develops slowly before birth, but speeds up during the first year of life."
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10851,
      "preview": "5. PRS puts infant at risk for repeated ear infections, choking episodes, aspiration and hypoxia rel"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10852,
      "preview": "B. Most common associated genetic causes"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10853,
      "preview": "6. Stickler syndrome: (hereditary progressive arthro-ophthalmopathy). A group of genetic disorders a"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10854,
      "preview": "7. Velocardiofacial syndrome: The features of this syndrome vary widely, even among members of the s"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10855,
      "preview": "8. Fetal alcohol syndrome: A pattern of mental and physical defects that can develop in a fetus in a"
    },
    {
      "type": "text",
      "section": "I. Pierre Robin Syndrome/Sequence",
      "line": 10856,
      "preview": "9. Treacher Collins syndrome. An autosomal dominant congenital disorder characterized by craniofacia"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "C. Clinical management",
      "line": 10858
    },
    {
      "type": "text",
      "section": "C. Clinical management",
      "line": 10860,
      "preview": "1. Infants with this condition should NOT be put on their back. The goal is to prevent the tongue fr"
    },
    {
      "type": "text",
      "section": "C. Clinical management",
      "line": 10861,
      "preview": "2. Feeding must be done very carefully to avoid choking and aspiration. Many of these patients need "
    },
    {
      "type": "text",
      "section": "C. Clinical management",
      "line": 10862,
      "preview": "3. Infant must remain on a cardiorespiratory monitor and oxygen saturation monitor until defined sta"
    },
    {
      "type": "text",
      "section": "C. Clinical management",
      "line": 10864,
      "preview": "--- page 444 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. Pierre Robin Sequence LPCH Management Protocol",
      "line": 10866
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A. Stable airway",
      "line": 10868
    },
    {
      "type": "text",
      "section": "A. Stable airway",
      "line": 10870,
      "preview": "1. Secure airway in prone or lateral position."
    },
    {
      "type": "text",
      "section": "A. Stable airway",
      "line": 10871,
      "preview": "2. Consult Plastic Surgery, ENT, Pulmonary, Genetics and GI."
    },
    {
      "type": "text",
      "section": "A. Stable airway",
      "line": 10872,
      "preview": "3. SLP/Feeding evaluation. Begin gavage/oral feeds as deemed safe with continued oral stimulation wi"
    },
    {
      "type": "text",
      "section": "A. Stable airway",
      "line": 10873,
      "preview": "4. Monitor for hypoxemia."
    },
    {
      "type": "text",
      "section": "A. Stable airway",
      "line": 10874,
      "preview": "a. If no hypoxemia and cleared by Pulm, ENT and Plastics, consider discharge to home with specific r"
    },
    {
      "type": "text",
      "section": "A. Stable airway",
      "line": 10875,
      "preview": "b. If hypoxemia present, will need to discharge home with supplemental oxygen and an oxygen saturati"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Unstable airway",
      "line": 10877
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10879,
      "preview": "1. Secure airway in prone or lateral position."
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10880,
      "preview": "a. Nasopharyngeal airway, or"
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10881,
      "preview": "b. Intubation"
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10882,
      "preview": "2. Consult Plastic Surgery, ENT, Pulmonary, Genetics and GI."
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10883,
      "preview": "3. Glottic obstruction."
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10884,
      "preview": "a. If yes, then care conference with possible Neuro consult with MRI of brain and Genetics consult b"
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10885,
      "preview": "b. If no, then discuss with team, per attached algorithm."
    },
    {
      "type": "text",
      "section": "B. Unstable airway",
      "line": 10886,
      "preview": "4. SLP/Feeding evaluation once stable from a respiratory standpoint. Begin gavage/oral feeds as deem"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 10888
    },
    {
      "type": "text",
      "section": "References",
      "line": 10890,
      "preview": "1. Robert J. Shprintzen, (1992) The Implications of the Diagnosis of Robin Sequence. The Cleft Palat"
    },
    {
      "type": "text",
      "section": "References",
      "line": 10891,
      "preview": "2. Kelly N. Evans, MD, Kathleen C. Sie, MD, Richard A. Hopper, MD, MS, Robin P. Glass, MS, OTR, IBCL"
    },
    {
      "type": "text",
      "section": "References",
      "line": 10893,
      "preview": "--- page 445 ---"
    },
    {
      "type": "image",
      "section": "References",
      "line": 10895,
      "content": "![img-73.jpeg](images/bcc7482d5600e1a3.png)"
    },
    {
      "type": "text",
      "section": "References",
      "line": 10897,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "References",
      "line": 10899,
      "preview": "--- page 446 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Part III: Research",
      "line": 10901
    },
    {
      "type": "text",
      "section": "Part III: Research",
      "line": 10903,
      "preview": "--- page 447 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Neonatal/Perinatal Clinical Research",
      "line": 10905
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Bethany Ball, BSc, CCRC",
      "line": 10907
    },
    {
      "type": "text",
      "section": "Bethany Ball, BSc, CCRC",
      "line": 10909,
      "preview": "Two major sources of clinical research activity and funding in the Division of Neonatal and Developm"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10911
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10913,
      "preview": "Modern neonatal medicine is a rapidly developing, highly technical environment in which principles o"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10915,
      "preview": "- The efficacy of one exogenous surfactant versus another in the treatment of respiratory distress s"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10916,
      "preview": "- Antenatal use of phenobarbital in the prevention of intraventricular hemorrhage"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10917,
      "preview": "- Steroids for bronchopulmonary dysplasia"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10918,
      "preview": "- Prediction of jaundice in term infants"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10919,
      "preview": "- Accuracy of the revised Ballard exam in the assessment of gestational age"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10920,
      "preview": "- Vitamin A in the prevention of chronic lung disease"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10921,
      "preview": "- Indomethacin prophylaxis for IVH among pre-term infants"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10922,
      "preview": "- Whole body cooling for infants with hypoxic-ischemic encephalopathy"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10923,
      "preview": "- Neurodevelopmental outcomes of extremely low birth weight infants exposed to aggressive versus con"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10924,
      "preview": "- Efficacy of inhaled nitric oxide in the treatment of term infants and pre-term infants with hypoxi"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10925,
      "preview": "- Target ranges of oxygen saturation in extremely preterm infants"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10926,
      "preview": "- Early CPAP versus surfactant in extremely preterm infants"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10928,
      "preview": "The NICHD network grant has been competitively renewed four times and currently consists of 15 unive"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10930,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10932,
      "preview": "--- page 448 ---"
    },
    {
      "type": "text",
      "section": "I. National Institute of Child Health and Human Development Cooperative Multi-center Network of Neonatal Intensive Care Units",
      "line": 10934,
      "preview": "Question regarding the NRN should be directed to: Bethany Ball at 723-5363, 725-8342 or pager #15340"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Spectrum and Spectrum Child Health",
      "line": 10936
    },
    {
      "type": "text",
      "section": "II. Spectrum and Spectrum Child Health",
      "line": 10938,
      "preview": "Stanford University is the recipient of a Clinical Translational Science Award (CTSA) grant, a sourc"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Pediatric Trials Network (PTN)",
      "line": 10940
    },
    {
      "type": "text",
      "section": "III. Pediatric Trials Network (PTN)",
      "line": 10942,
      "preview": "Sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NI"
    },
    {
      "type": "text",
      "section": "III. Pediatric Trials Network (PTN)",
      "line": 10944,
      "preview": "To fill this troubling information gap, the PTN is studying the formulation, dosing, efficacy, and s"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IV. Other Funding",
      "line": 10946
    },
    {
      "type": "text",
      "section": "IV. Other Funding",
      "line": 10948,
      "preview": "In addition to the major funding provided by the NICHD and the CTSA, research may be funded by indus"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "V. Neonatal Research Protocols",
      "line": 10950
    },
    {
      "type": "heading",
      "level": 3,
      "section": "Survey of Morbidity and Mortality Among High Risk Pre-term Infants",
      "line": 10952
    },
    {
      "type": "text",
      "section": "Survey of Morbidity and Mortality Among High Risk Pre-term Infants",
      "line": 10954,
      "preview": "Krisa Van Meurs, MD and Valerie Chock, MD, MS Epi"
    },
    {
      "type": "text",
      "section": "Survey of Morbidity and Mortality Among High Risk Pre-term Infants",
      "line": 10956,
      "preview": "The purpose of the Generic Data Base (GDB) is to create a registry of baseline and outcome character"
    },
    {
      "type": "text",
      "section": "Survey of Morbidity and Mortality Among High Risk Pre-term Infants",
      "line": 10958,
      "preview": "--- page 449 ---"
    },
    {
      "type": "text",
      "section": "Survey of Morbidity and Mortality Among High Risk Pre-term Infants",
      "line": 10960,
      "preview": "data, although not representative of a regional sample, do represent a number of major academic tert"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Follow-up of High Risk Infants",
      "line": 10962
    },
    {
      "type": "text",
      "section": "Follow-up of High Risk Infants",
      "line": 10964,
      "preview": "Susan Hintz, MD, MS Epi and Krisa Van Meurs, MD"
    },
    {
      "type": "text",
      "section": "Follow-up of High Risk Infants",
      "line": 10966,
      "preview": "This study is a follow-up evaluation of all infants born before 27 weeks of gestation who are part o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A Randomized Trial of Targeted Temperature Management with Whole Body Hypothermia for Moderate and Severe Neonatal Encephalopathy in Premature Infants 33-35 Weeks Gestational Age-A Bayesian Study",
      "line": 10968
    },
    {
      "type": "text",
      "section": "A Randomized Trial of Targeted Temperature Management with Whole Body Hypothermia for Moderate and Severe Neonatal Encephalopathy in Premature Infants 33-35 Weeks Gestational Age-A Bayesian Study",
      "line": 10970,
      "preview": "Sonia Bonifacio, MD, Krisa Van Meurs, MD, Susan Hintz, MD, MS Epi and Valerie Chock, MD, M. Epi"
    },
    {
      "type": "text",
      "section": "A Randomized Trial of Targeted Temperature Management with Whole Body Hypothermia for Moderate and Severe Neonatal Encephalopathy in Premature Infants 33-35 Weeks Gestational Age-A Bayesian Study",
      "line": 10972,
      "preview": "The primary hypothesis of this trial is that the risk of death or moderate to severe disability at 1"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 18-22 Months of Age in Intubated Infants <30 Weeks Gestational Age",
      "line": 10974
    },
    {
      "type": "text",
      "section": "A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 18-22 Months of Age in Intubated Infants <30 Weeks Gestational Age",
      "line": 10976,
      "preview": "Krisa Van Meurs, MD and Valerie Chock, MD, MS Epi"
    },
    {
      "type": "text",
      "section": "A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 18-22 Months of Age in Intubated Infants <30 Weeks Gestational Age",
      "line": 10978,
      "preview": "Bronchopulmonary dysplasia (BPD) continues to be a leading morbidity of the extremely preterm infant"
    },
    {
      "type": "text",
      "section": "A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 18-22 Months of Age in Intubated Infants <30 Weeks Gestational Age",
      "line": 10980,
      "preview": "--- page 450 ---"
    },
    {
      "type": "text",
      "section": "A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 18-22 Months of Age in Intubated Infants <30 Weeks Gestational Age",
      "line": 10982,
      "preview": "Krisa Van Meurs, MD and Valerie Chock, MD, MS EPI"
    },
    {
      "type": "text",
      "section": "A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 18-22 Months of Age in Intubated Infants <30 Weeks Gestational Age",
      "line": 10984,
      "preview": "The research is a pilot trial to determine if milrinone infusion in neonates \u226536 weeks at birth with"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants",
      "line": 10986
    },
    {
      "type": "text",
      "section": "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants",
      "line": 10988,
      "preview": "Krisa Van Meurs, MD and Valerie Chock, MD, MS Epi"
    },
    {
      "type": "text",
      "section": "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants",
      "line": 10990,
      "preview": "This is a randomized, double-blind, controlled trial of darbepoetin alpha to test the hypothesis tha"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL)",
      "line": 10992
    },
    {
      "type": "text",
      "section": "High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL)",
      "line": 10994,
      "preview": "Krisa Van Meurs, MD and Sonia Bonifacio, MD"
    },
    {
      "type": "text",
      "section": "High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL)",
      "line": 10996,
      "preview": "The study is a Phase III randomized, double-blind, placebo-controlled, multicenter trial of erythrop"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Pharmacology of Aminophylline for Acute Kidney Injury in Neonates (PAANS)",
      "line": 10998
    },
    {
      "type": "text",
      "section": "Pharmacology of Aminophylline for Acute Kidney Injury in Neonates (PAANS)",
      "line": 11000,
      "preview": "Adam Frymoyer, MD; Krisa Van Meurs, MD; Paul Grimm, MD; Scott Sutherland, MD"
    },
    {
      "type": "text",
      "section": "Pharmacology of Aminophylline for Acute Kidney Injury in Neonates (PAANS)",
      "line": 11002,
      "preview": "This study will examine the medication aminophylline as a treatment approach for acute kidney injury"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Listening to Mom in the NICU: Neural, Clinical and Language Outcomes",
      "line": 11004
    },
    {
      "type": "text",
      "section": "Listening to Mom in the NICU: Neural, Clinical and Language Outcomes",
      "line": 11006,
      "preview": "Katherine Travis, PhD"
    },
    {
      "type": "text",
      "section": "Listening to Mom in the NICU: Neural, Clinical and Language Outcomes",
      "line": 11008,
      "preview": "Children born preterm are at-risk for developmental language delays. Language problems in preterm ch"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Congenital Diaphragmatic Hernia Registry",
      "line": 11010
    },
    {
      "type": "text",
      "section": "Congenital Diaphragmatic Hernia Registry",
      "line": 11012,
      "preview": "Krisa Van Meurs, MD"
    },
    {
      "type": "text",
      "section": "Congenital Diaphragmatic Hernia Registry",
      "line": 11014,
      "preview": "The purpose of this study is to provide a registry of baseline and outcome characteristics of infant"
    },
    {
      "type": "text",
      "section": "Congenital Diaphragmatic Hernia Registry",
      "line": 11016,
      "preview": "This document is intended for use by staff of Stanford Hospitals and Clinics and/or Lucile Packard C"
    },
    {
      "type": "text",
      "section": "Congenital Diaphragmatic Hernia Registry",
      "line": 11018,
      "preview": "--- page 451 ---"
    },
    {
      "type": "text",
      "section": "Congenital Diaphragmatic Hernia Registry",
      "line": 11020,
      "preview": "444 Part III: Research"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "NIRS Preemie Study",
      "line": 11022
    },
    {
      "type": "text",
      "section": "NIRS Preemie Study",
      "line": 11024,
      "preview": "Valerie Chock, MD, MS Epi"
    },
    {
      "type": "text",
      "section": "NIRS Preemie Study",
      "line": 11026,
      "preview": "The goal of this study is to use near-infrared spectroscopy (NIRS) in preterm infants (<1250 g birth"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Bilirubin binding capacity",
      "line": 11028
    },
    {
      "type": "text",
      "section": "Bilirubin binding capacity",
      "line": 11030,
      "preview": "Vinod K. Bhutani, MD, David Stevenson, MD and Angelo Lamola, PhD"
    },
    {
      "type": "text",
      "section": "Bilirubin binding capacity",
      "line": 11032,
      "preview": "BBC defines the dynamic relationship between an infant's level of unbound or \"free\" bilirubin and hi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Intermittent Phototherapy: A Safer Method to Treat Extremely Low Birth Weight Infants?",
      "line": 11034
    },
    {
      "type": "text",
      "section": "Intermittent Phototherapy: A Safer Method to Treat Extremely Low Birth Weight Infants?",
      "line": 11036,
      "preview": "David Stevenson, MD, Vinod Bhutani, MD, Ronald Cohen, MD"
    },
    {
      "type": "text",
      "section": "Intermittent Phototherapy: A Safer Method to Treat Extremely Low Birth Weight Infants?",
      "line": 11038,
      "preview": "Phototherapy with uninterrupted exposure to bright lights is used in treatment for almost all extrem"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Glucose-6-phosphate dehydrogenase (G6PD) Point-of-care testing",
      "line": 11040
    },
    {
      "type": "text",
      "section": "Glucose-6-phosphate dehydrogenase (G6PD) Point-of-care testing",
      "line": 11042,
      "preview": "Vinod K. Bhutani, MD, Bertil Glader, MD and David Stevenson, MD"
    },
    {
      "type": "text",
      "section": "Glucose-6-phosphate dehydrogenase (G6PD) Point-of-care testing",
      "line": 11044,
      "preview": "The traditional paradigm for newborn screening is through analysis of dried blood spots, which are s"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Neuro-humoral Biomakers for Kangaroo Mother Care (KMC)",
      "line": 11046
    },
    {
      "type": "text",
      "section": "Neuro-humoral Biomakers for Kangaroo Mother Care (KMC)",
      "line": 11048,
      "preview": "Vinod K. Bhutani, MD and Susan Crowe, MD"
    },
    {
      "type": "text",
      "section": "Neuro-humoral Biomakers for Kangaroo Mother Care (KMC)",
      "line": 11050,
      "preview": "The process of skin-to-skin holding of the infant by the mother immediately after birth triggers a l"
    },
    {
      "type": "text",
      "section": "Neuro-humoral Biomakers for Kangaroo Mother Care (KMC)",
      "line": 11052,
      "preview": "--- page 452 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Point-of Care Testing for Maternal-neonatal Rh status",
      "line": 11054
    },
    {
      "type": "text",
      "section": "Point-of Care Testing for Maternal-neonatal Rh status",
      "line": 11056,
      "preview": "Vinod K. Bhutani, MD"
    },
    {
      "type": "text",
      "section": "Point-of Care Testing for Maternal-neonatal Rh status",
      "line": 11058,
      "preview": "Usually blood groups are determined by obtaining a blood sample, testing in an immunohematology labo"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Neurodevelopmental Effects of Donor Human Milk vs. Preterm Formula in ELBW Infants: The MILK trial",
      "line": 11060
    },
    {
      "type": "text",
      "section": "Neurodevelopmental Effects of Donor Human Milk vs. Preterm Formula in ELBW Infants: The MILK trial",
      "line": 11062,
      "preview": "Krisa Van Meurs, MD, Valerie Chock, MD, MS Epi, and Susan Hintz, MD, MS Epi"
    },
    {
      "type": "text",
      "section": "Neurodevelopmental Effects of Donor Human Milk vs. Preterm Formula in ELBW Infants: The MILK trial",
      "line": 11064,
      "preview": "This is a randomized trial designed to test the hypothesis that among ELBW infants who receive no or"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Remodulin as an Adjunct to Nitric Oxide in PPHN (RAiN)",
      "line": 11066
    },
    {
      "type": "text",
      "section": "Remodulin as an Adjunct to Nitric Oxide in PPHN (RAiN)",
      "line": 11068,
      "preview": "Christine Johnson, MD and Jeffrey Feinstein, MD"
    },
    {
      "type": "text",
      "section": "Remodulin as an Adjunct to Nitric Oxide in PPHN (RAiN)",
      "line": 11070,
      "preview": "The study will explore the safety and treatment effect of IV Remodulin (treprostinil) as add-on ther"
    },
    {
      "type": "text",
      "section": "Remodulin as an Adjunct to Nitric Oxide in PPHN (RAiN)",
      "line": 11072,
      "preview": "Death"
    },
    {
      "type": "text",
      "section": "Remodulin as an Adjunct to Nitric Oxide in PPHN (RAiN)",
      "line": 11074,
      "preview": "- Initiation of ECMO per institutional policies"
    },
    {
      "type": "text",
      "section": "Remodulin as an Adjunct to Nitric Oxide in PPHN (RAiN)",
      "line": 11076,
      "preview": "Need for additional treatment (initiation of an additional targeted pulmonary vasodilator therapy [e"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Non-Contact Vital Sign Monitor for the NICU",
      "line": 11078
    },
    {
      "type": "text",
      "section": "Non-Contact Vital Sign Monitor for the NICU",
      "line": 11080,
      "preview": "Henry C. Lee, MD, MS Epi"
    },
    {
      "type": "text",
      "section": "Non-Contact Vital Sign Monitor for the NICU",
      "line": 11082,
      "preview": "Conventional vital sign monitors use mechanical or adhesive sensors that physically contact the infa"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Rainbow Acoustic Monitoring (RAM) Clinical Engineering Data Collection",
      "line": 11084
    },
    {
      "type": "text",
      "section": "Rainbow Acoustic Monitoring (RAM) Clinical Engineering Data Collection",
      "line": 11086,
      "preview": "David Drover, MD, Felice Su, MD, Adam Frymoyer, MD, Marianne Chen, MD, Brendan Carvalho, MBBCh, Pedr"
    },
    {
      "type": "text",
      "section": "Rainbow Acoustic Monitoring (RAM) Clinical Engineering Data Collection",
      "line": 11088,
      "preview": "--- page 453 ---"
    },
    {
      "type": "text",
      "section": "Rainbow Acoustic Monitoring (RAM) Clinical Engineering Data Collection",
      "line": 11090,
      "preview": "The purpose of this study is to collect high resolution RAM in neonates for the purpose of algorithm"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Optimizing safety of mother and neonate in a mixed methods learning laboratory",
      "line": 11092
    },
    {
      "type": "text",
      "section": "Optimizing safety of mother and neonate in a mixed methods learning laboratory",
      "line": 11094,
      "preview": "Louis P. Halamek, MD, Henry C. Lee, MD, et al"
    },
    {
      "type": "text",
      "section": "Optimizing safety of mother and neonate in a mixed methods learning laboratory",
      "line": 11096,
      "preview": "As the next phase of this ongoing study to develop the delivery room of the future, subjects will be"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Improvements in Neonatal Intubation Safety and Efficacy",
      "line": 11098
    },
    {
      "type": "text",
      "section": "Improvements in Neonatal Intubation Safety and Efficacy",
      "line": 11100,
      "preview": "Louis P. Halamek, MD, Paula McWilliam, EdD, MSN, Nicole Yamada, MD, Janene H. Fuerch, MD"
    },
    {
      "type": "text",
      "section": "Improvements in Neonatal Intubation Safety and Efficacy",
      "line": 11102,
      "preview": "We will be assessing the fidelity of various neonatal patient simulators in terms of intubation. Sub"
    },
    {
      "type": "text",
      "section": "Improvements in Neonatal Intubation Safety and Efficacy",
      "line": 11104,
      "preview": "--- page 454 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Informed Consent for Clinical Research",
      "line": 11106
    },
    {
      "type": "text",
      "section": "Informed Consent for Clinical Research",
      "line": 11108,
      "preview": "Bethany Ball, B.S., C.C.R.C."
    },
    {
      "type": "text",
      "section": "Informed Consent for Clinical Research",
      "line": 11110,
      "preview": "Informed consent is an essential element in the research process. Following is information regarding"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "I. Telephone Consent",
      "line": 11112
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11114,
      "preview": "Participation in a research study is not an emergency, thus the usual method of obtaining consent fo"
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11116,
      "preview": "If a child's parents are unable to be present to participate in the informed consent process for a r"
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11118,
      "preview": "- Fax or email the informed consent and HIPAA authorization documents to the parents"
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11119,
      "preview": "- Call the parents and explain the study (neonatologist, fellow or knowledgeable member of the resea"
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11120,
      "preview": "- Parents sign the consent and HIPAA documents (if they want child to participate)"
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11121,
      "preview": "- Parents send signed consent and HIPAA authorization back (fax or scan and email)"
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11122,
      "preview": "- Parents bring original documents to LPCH"
    },
    {
      "type": "text",
      "section": "I. Telephone Consent",
      "line": 11124,
      "preview": "If the child is being transported to LPCH, the transport team can be asked to provide the consent an"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "II. Foreign Language Consent",
      "line": 11126
    },
    {
      "type": "text",
      "section": "II. Foreign Language Consent",
      "line": 11128,
      "preview": "In general, the informed consent and HIPAA authorization documents should be available in the prefer"
    },
    {
      "type": "text",
      "section": "II. Foreign Language Consent",
      "line": 11129,
      "preview": "A. Short Form Consent - The short form is a generic document describing clinical research and contai"
    },
    {
      "type": "text",
      "section": "II. Foreign Language Consent",
      "line": 11130,
      "preview": "http://humansubjects.stanford.edu/new/resources/consent/short form consent process.html"
    },
    {
      "type": "text",
      "section": "II. Foreign Language Consent",
      "line": 11132,
      "preview": "--- page 455 ---"
    },
    {
      "type": "text",
      "section": "II. Foreign Language Consent",
      "line": 11134,
      "preview": "448 Part III: Research"
    },
    {
      "type": "text",
      "section": "II. Foreign Language Consent",
      "line": 11135,
      "preview": "An example of a Stanford short form in Spanish is included at the end of this section."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "1. Signature Requirements",
      "line": 11137
    },
    {
      "type": "text",
      "section": "1. Signature Requirements",
      "line": 11139,
      "preview": "If the parents agree to allow the child to participate in the study, the following signatures are re"
    },
    {
      "type": "text",
      "section": "1. Signature Requirements",
      "line": 11140,
      "preview": "a. Short Form (in appropriate language) must be signed and dated by:"
    },
    {
      "type": "text",
      "section": "1. Signature Requirements",
      "line": 11141,
      "preview": "i. Parent(s) or legally authorized representative"
    },
    {
      "type": "text",
      "section": "1. Signature Requirements",
      "line": 11142,
      "preview": "ii. Witness"
    },
    {
      "type": "image",
      "section": "1. Signature Requirements",
      "line": 11143,
      "content": "![img-74.jpeg](images/b0c591bc468846ed.png)"
    },
    {
      "type": "text",
      "section": "1. Signature Requirements",
      "line": 11144,
      "preview": "b. Summary Form (English consent) must be signed and dated by:"
    },
    {
      "type": "text",
      "section": "1. Signature Requirements",
      "line": 11145,
      "preview": "i. Person obtaining consent"
    },
    {
      "type": "text",
      "section": "1. Signature Requirements",
      "line": 11146,
      "preview": "ii. Witness"
    },
    {
      "type": "image",
      "section": "1. Signature Requirements",
      "line": 11147,
      "content": "![img-75.jpeg](images/e16fa24636d675fd.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. HIPAA Authorization",
      "line": 11149
    },
    {
      "type": "text",
      "section": "B. HIPAA Authorization",
      "line": 11151,
      "preview": "None. When using the Short Form Consent Process, the HIPAA authorization, either as a separate docum"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. Interpreters and Witnesses-Who are they and what do they do?",
      "line": 11153
    },
    {
      "type": "text",
      "section": "III. Interpreters and Witnesses-Who are they and what do they do?",
      "line": 11155,
      "preview": "An interpreter and a witness, both of whom speak the parents' language and English fluently, will be"
    },
    {
      "type": "text",
      "section": "III. Interpreters and Witnesses-Who are they and what do they do?",
      "line": 11157,
      "preview": "--- page 456 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "A. Who can be the interpreter?",
      "line": 11159
    },
    {
      "type": "text",
      "section": "A. Who can be the interpreter?",
      "line": 11161,
      "preview": "1. Hospital interpreter (preferred)"
    },
    {
      "type": "text",
      "section": "A. Who can be the interpreter?",
      "line": 11162,
      "preview": "2. Family member of the child can act as an interpreter but only if the parents have specifically de"
    },
    {
      "type": "text",
      "section": "A. Who can be the interpreter?",
      "line": 11163,
      "preview": "3. Member of study staff (can also function as Person Obtaining Consent)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "B. Who can be the witness?",
      "line": 11165
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11167,
      "preview": "1. A person who attests to the oral presentation and who is conversant in both English and the paren"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11168,
      "preview": "2. May be the interpreter (including the hospital interpreter), another family member, or other pers"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11169,
      "preview": "3. When the Person Obtaining Consent is assisted by an interpreter, the translator/interpreter may a"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11171,
      "preview": "Important:"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11173,
      "preview": "1. A member of study staff acting as interpreter and Person Obtaining Consent cannot also be the wit"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11174,
      "preview": "2. Before beginning the consent process, confirm that the interpreter will also act as a witness. If"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11176,
      "preview": "From: Stanford University Human Research Protection Program Policy Manual"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11177,
      "preview": "Se le invita a participar en un estudio de investigaci\u00f3n. El t\u00edtulo del estudio es: (Protocol Title)"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11178,
      "preview": "<enter Protocol Title>"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11180,
      "preview": "Antes de aceptar, el investigador debe informarle sobre (i) los objetivos, procedimientos y duraci\u00f3n"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11182,
      "preview": "Si es el caso, el investigador tambi\u00e9n debe informarle sobre (i) cualquier compensaci\u00f3n o tratamient"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11184,
      "preview": "Si usted acepta participar, debe recibir una copia firmada de este documento y un resumen escrito de"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11186,
      "preview": "Si tiene alguna pregunta, inquietud o queja sobre este estudio de investigaci\u00f3n, sus procedimientos,"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11188,
      "preview": "Director del protocolo, (Protocol Director): <PD name>"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11189,
      "preview": "Usted puede comunicarse ahora o m\u00e1s tarde al: (contact phone number) <phone number>"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11190,
      "preview": "Si no est\u00e1 satisfecho/a con la manera en la que el estudio se realiza o si tiene alguna inquietud, q"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11192,
      "preview": "--- page 457 ---"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11194,
      "preview": "revisi\u00f3n institucional, IRB) para hablar con alguna persona informada que no est\u00e1 relacionada con el"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11196,
      "preview": "Su participaci\u00f3n en esta investigaci\u00f3n es voluntaria y no sufrir\u00e1 ninguna penalidad ni perder\u00e1 benef"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11198,
      "preview": "Si firma este documento, quiere decir que se le ha explicado verbalmente el estudio de investigaci\u00f3n"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11200,
      "preview": "| Firma del participante | Fecha |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11201,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11202,
      "preview": "| Signature of Participant | Date |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11205,
      "preview": "| Firma del testigo (por ejemplo, | Fecha |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11206,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11207,
      "preview": "| miembro del equipo, in\u00e9rprete, | Date |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11208,
      "preview": "| familiar, etc.) |  |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11209,
      "preview": "| Signature of Witness (e.g. staff, |  |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11210,
      "preview": "| translator, family member or other |  |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11211,
      "preview": "| person who speaks both English |  |"
    },
    {
      "type": "table",
      "section": "B. Who can be the witness?",
      "line": 11212,
      "preview": "| and the participant's language) |  |"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11214,
      "preview": "Medical Research: Experimental Subject's Bill of Rights on next page is to be given to participant"
    },
    {
      "type": "text",
      "section": "B. Who can be the witness?",
      "line": 11216,
      "preview": "--- page 458 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Experimental Subject's Bill of Rights",
      "line": 11218
    },
    {
      "type": "heading",
      "level": 2,
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11220
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11222,
      "preview": "Toda persona a quien se le pida participar en un experimento medico tiene los siguientes derechos:"
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11224,
      "preview": "1) A ser informada del proposito del experimento medico."
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11225,
      "preview": "2) A ser informada de en que consistira el experimento y de si alguno de los procedimientos, drogas "
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11226,
      "preview": "3) A ser informada de la frecuencia y/o riesgos de importancia, efectos secundarios o malestares a q"
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11227,
      "preview": "4) A ser informada de si puede esperar algun beneficio por participar en el experimento medico y si "
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11228,
      "preview": "5) A ser informada de que otras alternativas tiene y de si serian mejores o peores que participar en"
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11229,
      "preview": "6) A que se la permita hacer cualquier pregunta relacionada con el experimento, ya sea antes o despu"
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11230,
      "preview": "7) A ser informada de que tratamientos medicos existen en el caso de que alguna complicacion surgier"
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11231,
      "preview": "8) A rehusar totalmente a participar en el experimento medico antes o durante el desarrollo de este."
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11232,
      "preview": "9) A recibir una copia del documento de consentimiento fechada y firmada."
    },
    {
      "type": "text",
      "section": "DERECHOS DE TODA PERSONA SUJETA A EXPERIMENTOS MEDICOS",
      "line": 11233,
      "preview": "10) A no ser presionada de ninguna forma respecto a la decision de participar o no en el experimento"
    }
  ],
  "images": [
    {
      "sha_name": "7fe048f8ec8c62bc.png",
      "original_ref": "img-0.jpeg",
      "page": 1,
      "relative_path": "images/7fe048f8ec8c62bc.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/7fe048f8ec8c62bc.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "7fe048f8ec8c62bc"
    },
    {
      "sha_name": "eb725fd5eb98b4b8.png",
      "original_ref": "img-1.jpeg",
      "page": 1,
      "relative_path": "images/eb725fd5eb98b4b8.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/eb725fd5eb98b4b8.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "eb725fd5eb98b4b8"
    },
    {
      "sha_name": "aa89b94622d7abfb.png",
      "original_ref": "img-2.jpeg",
      "page": 37,
      "relative_path": "images/aa89b94622d7abfb.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/aa89b94622d7abfb.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "aa89b94622d7abfb"
    },
    {
      "sha_name": "d89a1bb8f89ea8c0.png",
      "original_ref": "img-3.jpeg",
      "page": 40,
      "relative_path": "images/d89a1bb8f89ea8c0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/d89a1bb8f89ea8c0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d89a1bb8f89ea8c0"
    },
    {
      "sha_name": "3bad71b6cbbb0d64.png",
      "original_ref": "img-4.jpeg",
      "page": 46,
      "relative_path": "images/3bad71b6cbbb0d64.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/3bad71b6cbbb0d64.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "3bad71b6cbbb0d64"
    },
    {
      "sha_name": "12b7f39ee6b1af21.png",
      "original_ref": "img-5.jpeg",
      "page": 69,
      "relative_path": "images/12b7f39ee6b1af21.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/12b7f39ee6b1af21.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "12b7f39ee6b1af21"
    },
    {
      "sha_name": "dfe3081e1f15ca26.png",
      "original_ref": "img-6.jpeg",
      "page": 97,
      "relative_path": "images/dfe3081e1f15ca26.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/dfe3081e1f15ca26.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "dfe3081e1f15ca26"
    },
    {
      "sha_name": "56dbb7cdcb32694a.png",
      "original_ref": "img-7.jpeg",
      "page": 98,
      "relative_path": "images/56dbb7cdcb32694a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/56dbb7cdcb32694a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "56dbb7cdcb32694a"
    },
    {
      "sha_name": "f58fa3d1dfd1f01d.png",
      "original_ref": "img-8.jpeg",
      "page": 99,
      "relative_path": "images/f58fa3d1dfd1f01d.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/f58fa3d1dfd1f01d.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f58fa3d1dfd1f01d"
    },
    {
      "sha_name": "3e85841d5c9db5bf.png",
      "original_ref": "img-9.jpeg",
      "page": 120,
      "relative_path": "images/3e85841d5c9db5bf.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/3e85841d5c9db5bf.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "3e85841d5c9db5bf"
    },
    {
      "sha_name": "8ddee5e40012ee2c.png",
      "original_ref": "img-10.jpeg",
      "page": 123,
      "relative_path": "images/8ddee5e40012ee2c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/8ddee5e40012ee2c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "8ddee5e40012ee2c"
    },
    {
      "sha_name": "66e11eae536aebfd.png",
      "original_ref": "img-11.jpeg",
      "page": 130,
      "relative_path": "images/66e11eae536aebfd.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/66e11eae536aebfd.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "66e11eae536aebfd"
    },
    {
      "sha_name": "855df62a9e81b0bf.png",
      "original_ref": "img-12.jpeg",
      "page": 134,
      "relative_path": "images/855df62a9e81b0bf.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/855df62a9e81b0bf.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "855df62a9e81b0bf"
    },
    {
      "sha_name": "c700bad89c991d61.png",
      "original_ref": "img-13.jpeg",
      "page": 134,
      "relative_path": "images/c700bad89c991d61.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/c700bad89c991d61.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "c700bad89c991d61"
    },
    {
      "sha_name": "a37d624794826046.png",
      "original_ref": "img-14.jpeg",
      "page": 135,
      "relative_path": "images/a37d624794826046.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/a37d624794826046.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "a37d624794826046"
    },
    {
      "sha_name": "75be13901ce6d8c4.png",
      "original_ref": "img-15.jpeg",
      "page": 136,
      "relative_path": "images/75be13901ce6d8c4.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/75be13901ce6d8c4.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "75be13901ce6d8c4"
    },
    {
      "sha_name": "90edfcbb7142ff21.png",
      "original_ref": "img-16.jpeg",
      "page": 136,
      "relative_path": "images/90edfcbb7142ff21.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/90edfcbb7142ff21.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "90edfcbb7142ff21"
    },
    {
      "sha_name": "3b9dfc8e7b5f6c2c.png",
      "original_ref": "img-17.jpeg",
      "page": 137,
      "relative_path": "images/3b9dfc8e7b5f6c2c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/3b9dfc8e7b5f6c2c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "3b9dfc8e7b5f6c2c"
    },
    {
      "sha_name": "3f91a3158a1c5951.png",
      "original_ref": "img-18.jpeg",
      "page": 141,
      "relative_path": "images/3f91a3158a1c5951.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/3f91a3158a1c5951.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "3f91a3158a1c5951"
    },
    {
      "sha_name": "2e22abc6567f1825.png",
      "original_ref": "img-19.jpeg",
      "page": 142,
      "relative_path": "images/2e22abc6567f1825.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/2e22abc6567f1825.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2e22abc6567f1825"
    },
    {
      "sha_name": "7cb6920b7514df6a.png",
      "original_ref": "img-20.jpeg",
      "page": 156,
      "relative_path": "images/7cb6920b7514df6a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/7cb6920b7514df6a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "7cb6920b7514df6a"
    },
    {
      "sha_name": "6fa00f2306dcb1b7.png",
      "original_ref": "img-21.jpeg",
      "page": 188,
      "relative_path": "images/6fa00f2306dcb1b7.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/6fa00f2306dcb1b7.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "6fa00f2306dcb1b7"
    },
    {
      "sha_name": "c3c4ab497cabe80c.png",
      "original_ref": "img-22.jpeg",
      "page": 203,
      "relative_path": "images/c3c4ab497cabe80c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/c3c4ab497cabe80c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "c3c4ab497cabe80c"
    },
    {
      "sha_name": "ee52a06f5974bafc.png",
      "original_ref": "img-23.jpeg",
      "page": 218,
      "relative_path": "images/ee52a06f5974bafc.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/ee52a06f5974bafc.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "ee52a06f5974bafc"
    },
    {
      "sha_name": "f8a2243e19b6d940.png",
      "original_ref": "img-24.jpeg",
      "page": 218,
      "relative_path": "images/f8a2243e19b6d940.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/f8a2243e19b6d940.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f8a2243e19b6d940"
    },
    {
      "sha_name": "002e0c020d24e9f7.png",
      "original_ref": "img-25.jpeg",
      "page": 219,
      "relative_path": "images/002e0c020d24e9f7.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/002e0c020d24e9f7.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "002e0c020d24e9f7"
    },
    {
      "sha_name": "24a82a48c3e02b07.png",
      "original_ref": "img-26.jpeg",
      "page": 219,
      "relative_path": "images/24a82a48c3e02b07.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/24a82a48c3e02b07.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "24a82a48c3e02b07"
    },
    {
      "sha_name": "1ab5f5033c73f4d7.png",
      "original_ref": "img-27.jpeg",
      "page": 219,
      "relative_path": "images/1ab5f5033c73f4d7.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/1ab5f5033c73f4d7.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "1ab5f5033c73f4d7"
    },
    {
      "sha_name": "f4cdd2384747b9c1.png",
      "original_ref": "img-28.jpeg",
      "page": 219,
      "relative_path": "images/f4cdd2384747b9c1.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/f4cdd2384747b9c1.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f4cdd2384747b9c1"
    },
    {
      "sha_name": "042c88d26f6103d0.png",
      "original_ref": "img-29.jpeg",
      "page": 220,
      "relative_path": "images/042c88d26f6103d0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/042c88d26f6103d0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "042c88d26f6103d0"
    },
    {
      "sha_name": "6f7337dca3d1ddbb.png",
      "original_ref": "img-30.jpeg",
      "page": 220,
      "relative_path": "images/6f7337dca3d1ddbb.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/6f7337dca3d1ddbb.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "6f7337dca3d1ddbb"
    },
    {
      "sha_name": "e2f614b71d945801.png",
      "original_ref": "img-31.jpeg",
      "page": 220,
      "relative_path": "images/e2f614b71d945801.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/e2f614b71d945801.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "e2f614b71d945801"
    },
    {
      "sha_name": "13eaee84a52a0cff.png",
      "original_ref": "img-32.jpeg",
      "page": 221,
      "relative_path": "images/13eaee84a52a0cff.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/13eaee84a52a0cff.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "13eaee84a52a0cff"
    },
    {
      "sha_name": "62b1eeec0cc03856.png",
      "original_ref": "img-33.jpeg",
      "page": 221,
      "relative_path": "images/62b1eeec0cc03856.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/62b1eeec0cc03856.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "62b1eeec0cc03856"
    },
    {
      "sha_name": "70f882f1c93573a2.png",
      "original_ref": "img-34.jpeg",
      "page": 221,
      "relative_path": "images/70f882f1c93573a2.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/70f882f1c93573a2.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "70f882f1c93573a2"
    },
    {
      "sha_name": "abffab2d050e5581.png",
      "original_ref": "img-35.jpeg",
      "page": 221,
      "relative_path": "images/abffab2d050e5581.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/abffab2d050e5581.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "abffab2d050e5581"
    },
    {
      "sha_name": "f5b63c4a2d1e3f87.png",
      "original_ref": "img-36.jpeg",
      "page": 222,
      "relative_path": "images/f5b63c4a2d1e3f87.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/f5b63c4a2d1e3f87.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f5b63c4a2d1e3f87"
    },
    {
      "sha_name": "2b965f569cc44de0.png",
      "original_ref": "img-37.jpeg",
      "page": 222,
      "relative_path": "images/2b965f569cc44de0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/2b965f569cc44de0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2b965f569cc44de0"
    },
    {
      "sha_name": "f1db9dbcf154759c.png",
      "original_ref": "img-38.jpeg",
      "page": 222,
      "relative_path": "images/f1db9dbcf154759c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/f1db9dbcf154759c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f1db9dbcf154759c"
    },
    {
      "sha_name": "f652fad210d0d1cc.png",
      "original_ref": "img-39.jpeg",
      "page": 224,
      "relative_path": "images/f652fad210d0d1cc.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/f652fad210d0d1cc.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f652fad210d0d1cc"
    },
    {
      "sha_name": "be9ae7b0028d7b86.png",
      "original_ref": "img-40.jpeg",
      "page": 226,
      "relative_path": "images/be9ae7b0028d7b86.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/be9ae7b0028d7b86.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "be9ae7b0028d7b86"
    },
    {
      "sha_name": "0483b55a8f601c87.png",
      "original_ref": "img-41.jpeg",
      "page": 243,
      "relative_path": "images/0483b55a8f601c87.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/0483b55a8f601c87.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "0483b55a8f601c87"
    },
    {
      "sha_name": "5889c2bab708a745.png",
      "original_ref": "img-42.jpeg",
      "page": 246,
      "relative_path": "images/5889c2bab708a745.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/5889c2bab708a745.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "5889c2bab708a745"
    },
    {
      "sha_name": "a6f72b9f463fbd74.png",
      "original_ref": "img-43.jpeg",
      "page": 257,
      "relative_path": "images/a6f72b9f463fbd74.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/a6f72b9f463fbd74.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "a6f72b9f463fbd74"
    },
    {
      "sha_name": "4772ed0e030001cb.png",
      "original_ref": "img-44.jpeg",
      "page": 260,
      "relative_path": "images/4772ed0e030001cb.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/4772ed0e030001cb.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "4772ed0e030001cb"
    },
    {
      "sha_name": "d288713f5412a281.png",
      "original_ref": "img-45.jpeg",
      "page": 261,
      "relative_path": "images/d288713f5412a281.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/d288713f5412a281.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d288713f5412a281"
    },
    {
      "sha_name": "5c70c814a0970063.png",
      "original_ref": "img-46.jpeg",
      "page": 261,
      "relative_path": "images/5c70c814a0970063.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/5c70c814a0970063.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "5c70c814a0970063"
    },
    {
      "sha_name": "77e131f52d9bb115.png",
      "original_ref": "img-47.jpeg",
      "page": 262,
      "relative_path": "images/77e131f52d9bb115.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/77e131f52d9bb115.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "77e131f52d9bb115"
    },
    {
      "sha_name": "f7f02badf3396f62.png",
      "original_ref": "img-48.jpeg",
      "page": 264,
      "relative_path": "images/f7f02badf3396f62.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/f7f02badf3396f62.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f7f02badf3396f62"
    },
    {
      "sha_name": "39ebd4f284dcc5c3.png",
      "original_ref": "img-49.jpeg",
      "page": 265,
      "relative_path": "images/39ebd4f284dcc5c3.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/39ebd4f284dcc5c3.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "39ebd4f284dcc5c3"
    },
    {
      "sha_name": "c66094dbbf8fb840.png",
      "original_ref": "img-50.jpeg",
      "page": 267,
      "relative_path": "images/c66094dbbf8fb840.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/c66094dbbf8fb840.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "c66094dbbf8fb840"
    },
    {
      "sha_name": "6afb15b72f2e97ca.png",
      "original_ref": "img-51.jpeg",
      "page": 267,
      "relative_path": "images/6afb15b72f2e97ca.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/6afb15b72f2e97ca.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "6afb15b72f2e97ca"
    },
    {
      "sha_name": "c0cabee9acc3118d.png",
      "original_ref": "img-52.jpeg",
      "page": 270,
      "relative_path": "images/c0cabee9acc3118d.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/c0cabee9acc3118d.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "c0cabee9acc3118d"
    },
    {
      "sha_name": "8c578036276e2ca5.png",
      "original_ref": "img-53.jpeg",
      "page": 270,
      "relative_path": "images/8c578036276e2ca5.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/8c578036276e2ca5.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "8c578036276e2ca5"
    },
    {
      "sha_name": "12b268a68c68bb4c.png",
      "original_ref": "img-54.jpeg",
      "page": 271,
      "relative_path": "images/12b268a68c68bb4c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/12b268a68c68bb4c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "12b268a68c68bb4c"
    },
    {
      "sha_name": "3a87f9e55031bbe3.png",
      "original_ref": "img-55.jpeg",
      "page": 278,
      "relative_path": "images/3a87f9e55031bbe3.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/3a87f9e55031bbe3.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "3a87f9e55031bbe3"
    },
    {
      "sha_name": "1b5ab79eceec80dc.png",
      "original_ref": "img-56.jpeg",
      "page": 286,
      "relative_path": "images/1b5ab79eceec80dc.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/1b5ab79eceec80dc.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "1b5ab79eceec80dc"
    },
    {
      "sha_name": "1bf4b0d2541cfad1.png",
      "original_ref": "img-57.jpeg",
      "page": 287,
      "relative_path": "images/1bf4b0d2541cfad1.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/1bf4b0d2541cfad1.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "1bf4b0d2541cfad1"
    },
    {
      "sha_name": "47be11605044228c.png",
      "original_ref": "img-58.jpeg",
      "page": 287,
      "relative_path": "images/47be11605044228c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/47be11605044228c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "47be11605044228c"
    },
    {
      "sha_name": "c26995abd64cb5d9.png",
      "original_ref": "img-59.jpeg",
      "page": 315,
      "relative_path": "images/c26995abd64cb5d9.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/c26995abd64cb5d9.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "c26995abd64cb5d9"
    },
    {
      "sha_name": "ef487dad352af7cd.png",
      "original_ref": "img-60.jpeg",
      "page": 316,
      "relative_path": "images/ef487dad352af7cd.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/ef487dad352af7cd.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "ef487dad352af7cd"
    },
    {
      "sha_name": "ce56d017bdd3c9ba.png",
      "original_ref": "img-61.jpeg",
      "page": 350,
      "relative_path": "images/ce56d017bdd3c9ba.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/ce56d017bdd3c9ba.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "ce56d017bdd3c9ba"
    },
    {
      "sha_name": "39fce2a388790185.png",
      "original_ref": "img-62.jpeg",
      "page": 363,
      "relative_path": "images/39fce2a388790185.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/39fce2a388790185.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "39fce2a388790185"
    },
    {
      "sha_name": "191b2c9a58ff89f4.png",
      "original_ref": "img-63.jpeg",
      "page": 368,
      "relative_path": "images/191b2c9a58ff89f4.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/191b2c9a58ff89f4.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "191b2c9a58ff89f4"
    },
    {
      "sha_name": "7182ddf121f550a9.png",
      "original_ref": "img-64.jpeg",
      "page": 376,
      "relative_path": "images/7182ddf121f550a9.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/7182ddf121f550a9.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "7182ddf121f550a9"
    },
    {
      "sha_name": "2ebdb5fc2fd95272.png",
      "original_ref": "img-65.jpeg",
      "page": 390,
      "relative_path": "images/2ebdb5fc2fd95272.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/2ebdb5fc2fd95272.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2ebdb5fc2fd95272"
    },
    {
      "sha_name": "8d567c6046ae5831.png",
      "original_ref": "img-66.jpeg",
      "page": 392,
      "relative_path": "images/8d567c6046ae5831.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/8d567c6046ae5831.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "8d567c6046ae5831"
    },
    {
      "sha_name": "55c66d025c7d7f86.png",
      "original_ref": "img-67.jpeg",
      "page": 394,
      "relative_path": "images/55c66d025c7d7f86.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/55c66d025c7d7f86.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "55c66d025c7d7f86"
    },
    {
      "sha_name": "71c56eae084ed426.png",
      "original_ref": "img-68.jpeg",
      "page": 394,
      "relative_path": "images/71c56eae084ed426.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/71c56eae084ed426.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "71c56eae084ed426"
    },
    {
      "sha_name": "789be3b37d12af19.png",
      "original_ref": "img-69.jpeg",
      "page": 405,
      "relative_path": "images/789be3b37d12af19.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/789be3b37d12af19.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "789be3b37d12af19"
    },
    {
      "sha_name": "faabebffbb0d9bfd.png",
      "original_ref": "img-70.jpeg",
      "page": 420,
      "relative_path": "images/faabebffbb0d9bfd.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/faabebffbb0d9bfd.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "faabebffbb0d9bfd"
    },
    {
      "sha_name": "4ced95e5f896817d.png",
      "original_ref": "img-71.jpeg",
      "page": 426,
      "relative_path": "images/4ced95e5f896817d.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/4ced95e5f896817d.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "4ced95e5f896817d"
    },
    {
      "sha_name": "da156fb1330bd11c.png",
      "original_ref": "img-72.jpeg",
      "page": 435,
      "relative_path": "images/da156fb1330bd11c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/da156fb1330bd11c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "da156fb1330bd11c"
    },
    {
      "sha_name": "bcc7482d5600e1a3.png",
      "original_ref": "img-73.jpeg",
      "page": 445,
      "relative_path": "images/bcc7482d5600e1a3.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/bcc7482d5600e1a3.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "bcc7482d5600e1a3"
    },
    {
      "sha_name": "b0c591bc468846ed.png",
      "original_ref": "img-74.jpeg",
      "page": 455,
      "relative_path": "images/b0c591bc468846ed.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/b0c591bc468846ed.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "b0c591bc468846ed"
    },
    {
      "sha_name": "e16fa24636d675fd.png",
      "original_ref": "img-75.jpeg",
      "page": 455,
      "relative_path": "images/e16fa24636d675fd.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/2018 NICU Guide Full/images/e16fa24636d675fd.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "e16fa24636d675fd"
    }
  ],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754695831",
    "ts": "2025-08-08T23:30:31.199672+00:00"
  }
}